<SEC-DOCUMENT>0000950170-23-006377.txt : 20230307
<SEC-HEADER>0000950170-23-006377.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307073059
ACCESSION NUMBER:		0000950170-23-006377
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		23711040

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tcrt-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-06T18:31:26.8740+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:tcrt="http://alaunos.com/20221231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ff8881c2-6785-42ec-a5f4-f1592bc1297d" name="dei:EntityCentralIndexKey" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb">0001107421</ix:nonNumeric><ix:nonNumeric id="F_135f6a9b-d35b-4744-9bd0-7a49a3ff0c93" name="tcrt:OperatingLeasesExpirationMonthAndYear" contextRef="C_7b282fd7-92ce-4714-8d23-a789adb31804">2026-08</ix:nonNumeric><ix:nonNumeric id="F_6934d123-79b6-4d0e-9146-8913adc044ad" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771">http://fasb.org/us-gaap/2022#OperatingLeaseLiability</ix:nonNumeric><ix:nonNumeric id="F_81f602c7-d273-4d9b-b25a-6a46286cbc9c" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb">FY</ix:nonNumeric><ix:nonNumeric id="F_0f16ce4f-8d70-403f-b6b8-a51d4653179d" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_f8f70fa4-ffe5-4f49-b2ec-312c36fe67b2">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonFraction id="F_a5277795-d129-44d1-890a-5c034d8ecbb8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5e15993c-8126-4ed8-af04-1256b45c6355" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_ad073aa0-791f-4f8d-9041-a81168a4a320" name="dei:AmendmentFlag" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tcrt-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1812d480-8b71-4f59-be40-0442f1ffcd39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc6223b4-e9fb-47c2-a189-b5585700a3f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_514c2c0b-94bc-4b01-a4df-1fde50325832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9e1d219-2ee6-449a-8982-40603fb9f929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db9a000c-2293-40ba-a556-c8c4ee3dcd25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdb6cf3c-3394-4924-9e66-e2220477279d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e20012df-a692-4934-8738-dbd4679dcd32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_139d76d8-bc1c-4f22-909e-3ae5eccdbd1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d75e53ea-0702-44cf-9dd4-dc1d1548bebb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1450b5dd-88ba-4cc4-8794-083ce0aff494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d9edef7-64b4-4ce3-a9b2-3242785e4741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:EightScheduledPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2309968-f205-40c9-9241-713fc3396454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbb3baef-97e1-4ff6-93d5-c0d1469c37f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_614a96e6-084a-4999-9269-a5af0ea5ef99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdd40d07-247d-493f-b328-455e4e9594e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3008e586-4932-4ef5-a77c-b2171288e27c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b282fd7-92ce-4714-8d23-a789adb31804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-31</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f182bcec-cb46-49ba-8ea6-3294135323d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e818d17d-8abf-499d-ad41-5a7a4b414199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8cab28c-a6cf-4033-bee4-05aee3010971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:TenthScheduledPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cbfe56c-2a15-4444-a10e-cbfc6e942a3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_462e7c18-cbc4-47ba-a8c1-d1d50a7d313d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a6333ea-87fe-436f-953e-01fe64ba7678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0350ea77-ee99-48c3-9c29-b0c1a4050617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a58f3578-b2b0-43dd-bd56-4371d7c586c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3310b49c-90b3-469d-a382-9cd149d1f45d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0441e0c-ffba-4bb9-8a1f-155209670694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e5bc8db-02a5-46a2-8adb-1290a943c626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e079d01f-15d4-407c-9a4a-2730c6e26083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82b5c3f4-e428-4dc9-a489-d6da42ba15d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5031cbc2-7c7e-4564-8649-f11720d9f7a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af0771c8-7bb6-4d20-b747-7a3e0f9ad3c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c65c999f-7903-41c0-85f9-01dae5de02f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7117f1c3-b39a-4248-8ab6-f843b0bbb987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c21750f7-3aa5-4441-8546-e1bc5d4f21e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76510e7e-f84f-4555-b284-0b2f7facecaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-13</xbrli:startDate><xbrli:endDate>2015-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_345d7b2b-de3c-423d-87ef-dde286307576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f55809b-c104-4cd9-a7b8-c6170ba8dc7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9343419-8bf1-4057-a39a-08c499c72684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcrt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_221169cc-a657-4743-838c-9c8afe3317c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ce3d76b-39aa-4c2b-9bcd-7339fdd665a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b23a7cb-ebe0-4b57-95ac-66f47b3626a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1cdd995-a3b3-4a88-86cf-666181247c3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b91b4942-6a82-493e-af09-b7189d92ffaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a755066d-a762-4b1c-a9e5-da405de1577b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e116f993-9fc1-4e48-bcd6-42848abbc899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9f80da5-3640-4b51-b5d8-02726e56d225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:DueDateAxis">tcrt:PostMarketingApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2be3c3ac-efdc-402a-827b-95ce13fc11c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9a1def8-4beb-497b-91ba-095a8bfe834d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d61c456-2ac5-4ffa-a8f5-cec10246c86a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91867dd5-8c9c-41f9-a145-5e903aa8fc40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f0471b9-3122-450c-83f4-9876302a91e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-15</xbrli:startDate><xbrli:endDate>2019-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83b60ee4-931e-45fb-9e47-1b18baa0e863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70d3cfbc-3393-4744-8116-7ed62ae30d7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcb43152-91fe-48f4-aad0-514fa76c5e42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a9368e0-978e-4613-87fd-43031426e546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45066dfd-98ce-4ef8-a0f8-576b77666039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da30487a-eeaa-46ef-9c78-32283fba902d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df3febeb-1400-4046-ac65-31f7fc0f9f28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-05</xbrli:startDate><xbrli:endDate>2023-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c699063c-f010-42e1-bc84-c39f93a08ca4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_556eae28-eef9-4c0d-8fae-4a6281b6012c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c21c60ee-6599-4da6-a569-17713873c52b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c51598af-80b7-4a30-ab2d-b510980f50f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82dc65f6-769b-4678-a99c-19131c41570e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e843951-a185-415d-86e2-e4855f371dd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3be47963-40c3-4b80-8a99-5b3aa4d10c76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8339573a-0ca5-49ab-b505-6fdfb84cb410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_576d0b59-7299-4d46-925b-a9db2e440f2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8efabef4-accb-458c-ac37-ad97beec741c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bff7aa86-20fe-4134-91ba-5cfb0c6a91fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6b3f324-362c-44db-b937-baf10fb4ec1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6402fd7d-1a53-45aa-80c2-5f9871d2d458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da6bbf42-b6d9-4ce6-b86b-25c8cae6c071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8974b041-067c-4f6b-b5aa-fb9b4b13e7fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e10ba7f-a809-4a04-aaaa-74a531d68803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de82944d-045e-4494-962a-60bbd7316d2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c71e267-3b3d-41f1-9ee0-4e610cab53c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9646e1e-5226-419c-8438-aa3071058ea6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8f802e5-6966-41fa-9657-aae7124cdab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_426af431-5218-40c8-82c1-1b23c2d8f820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01541ff4-c565-4665-8fd3-c5b8b851f917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c270381e-43d4-46f3-b514-f780c08aa3f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-15</xbrli:startDate><xbrli:endDate>2019-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35eb5389-797d-41ed-9818-2a4c3978c31b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee038ec2-a0cc-48d1-b9ca-0fa12ba3bac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8f70fa4-ffe5-4f49-b2ec-312c36fe67b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_966e453b-8a58-437f-a91f-f254719ff9b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6e29649-519f-4d9c-9d10-a997f6d84271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8f1b252-50d6-4597-8b92-45eb247fae8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c7cceef-0908-4307-8356-9235dc9862fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb58e662-f444-4e56-ac22-b4f9e8e90c73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f707f4a5-a8e0-4111-bc42-c5d4a9d92abb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec21d5ba-40fd-4ef7-b050-7c8f6c9de41b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab1c56b6-303f-4a89-840a-261cdf06b4d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b3d36d4-5ca7-428a-aedc-04c2cb1c1e88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-19</xbrli:startDate><xbrli:endDate>2021-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_567da217-a1b9-4ef0-a65c-10a90ca9e5da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20b416e3-3907-4e97-9e9d-1fcba80f134c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:CARProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e31c15e4-38b9-4777-99d9-09e923ff1ef3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e220fa7c-9256-4e4c-9029-f93345c4f771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9245beb1-9103-47f9-b176-2c032568f730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3613417-09f3-43ff-8294-f0c33b77cc57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_735e4858-865a-4de6-850e-3aab57d7148b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0763068f-9bd4-45a0-98fc-aef5d8ca39a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80826595-228b-476d-8548-2b525f9d98c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56a01732-96e4-4efd-9e90-6e3312d5c45d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b05a99fe-7e2e-4148-b7f1-089978eb0f33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d2fdd28-ac94-4045-9dd8-0480c92e9cea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24124fdf-795d-467e-939d-a9e2516d8bd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c4f4916-db64-490f-8174-b66da79fd2dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c2387b7-8249-4b21-9502-83899b598473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_812ddf85-9537-4bc2-9318-da210de34991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7396adc0-9e69-4eb0-8a3e-8adda7c5d090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ef452a7-a519-46fd-b8a6-51b26e948a62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b37aa34-b800-43ee-8c0e-e716f02e6391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c4db62a-e3d4-421b-b8e8-3b6d5445b532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3167c98d-e838-42ca-8ff8-0935142120e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c676932d-8885-4601-9d56-bb66cbd31327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a975d4f-655a-404d-a576-8eb7fc9e24a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05d52965-6300-40e4-8bfd-1ef7d46d0bed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46e7fb2e-f1c9-4ccb-af6f-ca1ebbcc3b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78cf1452-7b74-4f09-9764-21fb4409a94d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ef2eeab-93c5-4783-a05f-f12f4779e164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-22</xbrli:startDate><xbrli:endDate>2019-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cf1d286-3ce3-4ffb-9230-67e0f5fc09ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_308754fb-dced-4d37-8887-7c93a07410c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_677a76fa-1b6a-49f5-9473-b720f11528d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0689a730-1379-4cf7-9841-565343bbdf44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d832fa54-4683-49e7-a755-64e9d019ea0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8ddf3ec-c36f-4b75-870a-25546c4e894f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d865232-5799-4e0f-9833-17a27353c527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08a67ddb-30d8-464e-a0ac-bdfb4a9ef7af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-12</xbrli:startDate><xbrli:endDate>2019-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_591e7f11-f18d-474b-89bb-898e7e2fecca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cf5e5f2-8735-40b8-b39f-efaad36c2475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67e87324-3985-420c-90be-d2e08d2df27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0e44d18-9dbf-45ad-95e4-6d8fae70e5de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_560b8551-11ec-45b0-8d0f-cb0f5a999523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa3e31b2-77fb-40fc-bedb-7d66b32336b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f70a1072-5f3c-4803-8752-dc98e3a0c142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75f173ba-c8dd-4b99-ad6d-2a5369c1267f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1081ead-241b-4b47-ab69-635932b5defa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1485eb13-1142-4bdb-a8fe-a487d8205fd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4418daac-e678-4e2c-be6e-3555ed9a312a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6286a83b-0f82-4d71-9785-6d19951b5c7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8ca27b4-bce0-411e-8807-6e790eaa7672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d61befa-1f31-42dc-852d-7c27952aa374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ee8d1b3-28cf-4ceb-8232-ccc388824044"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-04</xbrli:startDate><xbrli:endDate>2021-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f2cc6cf-873b-457d-a3f2-2aec2c6cc50f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_371756af-d614-4bb1-a82f-4dd701f5ea21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_951f87ae-ef91-4c42-a4b4-65ab2e55e723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9ae6604-f2d2-43d1-a9d1-f8a9f071c33f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2004-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19528722-40e7-41ed-a517-daad870351cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0afbd561-5066-4598-a3a2-7762df69e5a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb8415ef-ed42-43d3-bebe-c35459c15508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b10c21fd-e52b-4e2e-b88e-14eff7321012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf145b1e-8766-417b-b25d-39bde6bf3ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_019df9ac-fbae-4355-8668-11ee7fd04e38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e938d5a-7970-4180-afd9-341241ed6a9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_009c6c2d-9013-4f24-9a09-41485c023a44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9367da57-38ac-4d29-b5c8-316a4a7256ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-06-01</xbrli:startDate><xbrli:endDate>2012-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b83280a9-1359-4007-a613-0f63cf09a0cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:LicensedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28c42504-64db-4bbb-b58d-31b90866d765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64074300-aa0c-4f1a-858f-92fd5f911176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31452367-fd08-487e-a553-53625bcad801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff46e4b8-4535-4f61-bf4b-409c23561efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3245be1-2a56-4ce2-a313-9a3ec39aa110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d794ebc-1417-4c1e-9565-4410865a0c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdbd888b-893b-4b86-85b2-065fe730f06d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_074d1df4-7bc9-4dcb-b16c-ddf1bdf3643f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33682291-7fb7-4cab-a271-326647030806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80a96828-a458-4544-8958-01676a2b66a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d20ec984-e91b-4bbd-aeea-1e39b7a6c803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, DC 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_029ffade-f5dd-4bc4-b179-315c121961a8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dba865bf-8327-4b1d-b1eb-16c3e6d5b7f2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:DocumentAnnualReport" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2b279151-0072-499c-a64d-76e1917b18c1" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_65a61741-e566-4e37-a118-b9126ddc9169" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e453fe25-5937-41e0-a0e6-cc0b021cb379" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73f9b6e8-b115-4e8f-b863-33e1936d76cb" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:DocumentTransitionReport" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from _______ to _______</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f136aad5-f8c2-4398-b876-e9f04be68fe6" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-33038</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c16f4b4-ee1d-44a9-8414-a6d0793b9c14" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.495%;"></td>
    <td style="width:1.024%;"></td>
    <td style="width:48.481%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88ed7ba5-7ef5-46f0-bf2c-19cc9ffd4c36" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_554c722c-4624-4c62-8071-9bc61f3ef9c9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84-1475642</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction of<br />Incorporation or Organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_95e89de4-3aba-4d1d-bfc9-2c241f64e16e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8030 El Rio Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_83b59b58-e8cf-43fa-975e-9e54993dedcf" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Houston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82140785-efe0-4780-9850-d55883428659" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0b73482e-c34f-4215-bc80-ba3da099058f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77054</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34d1f9ae-f840-49b2-a649-d53df1b722f3" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">346</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4747f186-8a5a-4b7a-81f6-39109d123adb" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">355-4099</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Registrant&#x2019;s Telephone Number, Including Area Code)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.005%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:35.0%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:30.998%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which<br />registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a7fbdfe2-e700-478e-a981-22e3cbbc6f51" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54e2ccff-a376-4ad4-8232-70c9171f353c" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TCRT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8aa99b0d-6cab-4bc8-8ef8-b49c8d5e53f8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d840059a-8dc5-4739-8d04-bbe9c1e2201d" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9745;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_35801883-9183-440a-9169-cfc8188c27fe" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9745;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_146a8646-f585-4717-86d7-2e4a91740a04" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9745; No &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_982e51f2-18dc-47a0-ac04-77d31a03b9a2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9745; No &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerate filer&#x201d; and &#x201c;smaller reporting company&#x201d; in Rule 12b-2 of the Exchange Act. (Check one):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.988%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:58.021%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:1.997%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large Accelerated Filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated Filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57b1b45c-3dc3-4799-8b18-b3ad27cd483f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non- Accelerated Filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9745;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller Reporting Company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e45b81a-d7f6-4e21-a66e-18155be2bc06" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e93b507-5011-4a67-8b75-e266565ece3e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityEmergingGrowthCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b34bfd4c-73b9-4bf4-9ca1-f86d5e10a7f7" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_009974c6-295c-4920-bcd1-f5acb07a553e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the registrant&#x2019;s common stock held by non-affiliates was $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ce0361d-ad03-4594-9513-a225798be8d9" contextRef="C_8c7cceef-0908-4307-8356-9235dc9862fd" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">221,548,093</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of June 30, 2022 (the last business day of the registrant&#x2019;s most recently completed second fiscal quarter), based on a total of 178,667,817 shares of common stock held by non-affiliates and a closing price of $1.24 as reported on the Nasdaq Global Select on June 30, 2022. For purposes of this computation, all officers, directors, and 10% beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers, directors or 10% beneficial owners are, in fact, affiliates of the registrant.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 2, 2023, there were </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7130a68f-c92a-4373-8052-8285ef2f5d16" contextRef="C_da6bbf42-b6d9-4ce6-b86b-25c8cae6c071" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,627,055</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the registrant&#x2019;s common stock, $0.001 par value per share, outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Proxy Statement for the Registrant's 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Alaunos Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT ON FORM 10-K</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TAB</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LE OF CO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NTENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.009%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:78.22%;"></td>
    <td style="width:1.797%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:6.181%;"></td>
    <td style="width:1.797%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;border-bottom:1pt solid rgba(255,255,255,0.01);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_management_discussion_and_analys"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accountant"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Annual Report that are not historical fact, and in some cases can be identified by terms such as: &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;forecast,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;project,&#x201d; &#x201c;target,&#x201d; &#x201c;will&#x201d; and other words and terms of similar meaning.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These statements are based on management&#x2019;s current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to raise substantial additional capital to continue as a going concern, fund our planned operations and repay our existing indebtedness; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development of our product candidates, including statements regarding the initiation, timing, progress and results of our research and development, preclinical studies and clinical programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to advance our product candidates through various stages of development, especially through pivotal safety and efficacy trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that final trial data may not support interim analysis of the viability of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectation regarding the safety and efficacy of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, scope or likelihood of regulatory filings and approvals from the U.S. Food and Drug Administration, or FDA, or equivalent foreign regulatory agencies for our product candidates and for which indications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the results and potential benefits contemplated from relationships with collaborators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain and establish collaborations and licenses; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectation of developments and projections relating to competition from other pharmaceutical and biotechnology companies or our industry; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates regarding the potential market opportunity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the anticipated rate and degree of commercial scope and potential, as well as market acceptance of our product candidates for any indication, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our intellectual property position, including the strength and enforceability of our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain qualified employees and key personnel; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact on our business from a pandemic, epidemic or outbreak, including the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context requires otherwise, references in this Annual Report to &#x201c;Alaunos,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d; refer to Alaunos Therapeutics, Inc., and its subsidiaries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks Alaunos&#153;, Ziopharm&#174; and hunTR&#174; as well as the graphic trademark found on our website. Other trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K are listed without the &#174; and &#153; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this Annual Report. Some of the more significant risks include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional financial resources to continue as a going concern, continue ongoing development of our product candidates and pursue our business objectives; if we are unable to obtain these additional resources when needed, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our plans to develop and commercialize non-viral adoptive cellular therapies based on T-cell receptor, or TCR, therapies can be considered as new approaches to cancer treatment, the successful development of which is subject to significant challenges. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current product candidates are based on novel technologies and are supported by limited clinical data and we cannot assure you that our current and planned clinical trials will produce data that supports regulatory approval of one or more of these product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to attract, recruit and hire qualified personnel and we will continue to rely on key scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our existing indebtedness, together with our other financial obligations and contractual commitments, could adversely affect our financial condition and restrict our future operations. For instance, we were required to deposit a significant amount of cash into an account to be held as collateral.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain the necessary United States or worldwide regulatory approvals to commercialize any product candidate, our business will suffer. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are in various stages of clinical development, which is very expensive and time-consuming. We cannot be certain when we will be able to submit a Biologics License Application, or BLA, to the FDA and any failure or delay in completing clinical trials for our product candidates could harm our business. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cellular immuno-oncology product candidates rely on the availability of reagents, specialized equipment and other specialty materials and infrastructure, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be impaired. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price has been, and may continue to be, volatile. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1. Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our cancer hotspot mutation TCR library and our proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson, we are currently enrolling patients for a Phase 1/2 clinical trial evaluating 12 TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, solid tumors represent approximately 90% of new cancer diagnoses. Approximately 2.0 million people are expected to be diagnosed with cancer in the United States in 2023 and approximately 610,000 people are expected to die from cancer in the United States in 2023. Some of the cancers we are targeting in our TCR-T Library Phase 1/2 Trial are expected to be among the most prevalent cancers diagnosed in the United States in 2023. In 2023, it is estimated that 238,340 people will be diagnosed with lung and bronchus cancer, 153,020 will be diagnosed with colorectal cancer, 66,200 people will be diagnosed with endometrial cancer, 64,050 people will be diagnosed with pancreatic cancer, 19,710 people will be diagnosed with ovarian cancer and approximately 8,000 people will be diagnosed with bile duct cancer. Mutations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genes are commonly expressed across a wide variety of cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below sets forth our multiple solid tumor pipeline programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img159912857_0.jpg" alt="img159912857_0.jpg" style="width:634px;height:241px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T program targeting solid tumors consists of:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TCR Library</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We have built a TCR library that targets shared hotspot mutations known to be one of the key causes of cancer. These are non-inherited mutations. We have in-licensed from the National Cancer Institute, or the NCI, multiple TCRs derived from third parties that are reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our TCR library currently consists of 12 TCRs targeting six solid tumor indications. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty Gene Transfer Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Our proprietary non-viral genetic engineering technology utilizes a particular enzyme referred to as a transposase to cut and paste donor DNA referred to as a transposon into chromosomes of a T cell using a process called transposition. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">hunTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">man </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eoantigen </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cell </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eceptor) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Discovery Engine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Our robust and innovative TCR discovery engine enables us to rapidly identify new TCRs to add to our ever-expanding TCR library. Using our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">hunTR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">discovery engine, we are able to analyze thousands of single T cells simultaneously using state-of-the-art bioinformatics and next generation sequencing. We aim to maximize the breadth of our TCR library by evaluating both helper (CD4) and killer (CD8) T cells. The ability to continue discovering new TCRs has the potential to expand the applicable patient population for our ongoing and future clinical trials. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our TCR-T program has several potential advantages over other cell therapy approaches for solid tumors, including CAR-T and tumor-infiltrating lymphocytes, or TIL. As compared to CAR-T, these potential advantages include that our TCR-T program targets intracellular and extracellular neoantigens whereas CAR-T primarily targets extracellular antigens. As compared to TIL, these potential advantages include that our TCR-T program has defined target specificity from the genetic engineering employed in manufacturing whereas in TIL specificity typically arises from the endogenous TCR rather than an introduced immunoreceptor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background on TCRs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our strategy is to target the hallmark of genomic instability in cancer with TCRs. Genes in cancer cells can lead to the production of proteins, which are then processed by the cell into protein fragments known as peptides. These peptides are presented to T cells by a specialized set of molecules on the cancer cell surface called the human leukocyte antigen, or HLA, system. When peptide presentation occurs, and it results in T cell activation through the TCR, the peptides are known as antigens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When these immunogenic peptides are derived from proteins which are in turn expressed from genes that are mutated only in tumor cells (for example, within the cancer genome and not encoded in the germline), they are known as neoantigens. Tumor cells presenting neoantigens via HLA are targets for T cells. T cells can recognize and kill neoantigen-presenting cancer cells. This approach is different from traditional CARs, which directly recognize antigens, such as CD19, on the surface of malignant B cells, without presentation by HLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, the immune system avoids targeting the body&#x2019;s own healthy cells principally through processes known as immune tolerance by which T cells do not respond to HLA containing peptides from normal proteins. The recognition by the TCR of a peptide presented by the HLA system is a vital immune mechanism that allows the body both to respond against foreign threats, including cancer, as well as to avoid targeting the body&#x2019;s own healthy cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumors utilize a variety of strategies to evade and suppress the host immune system. This often renders T cells residing within the tumor, referred to as TILs, ineffective and, despite expressing tumor-specific TCRs, unable to recycle their effector functions to kill tumors. To overcome immune suppression, healthier T cells are likely needed, such as those found in the peripheral blood. However, these circulating T cells do not typically express tumor-specific TCRs in adequate numbers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neoantigens are encoded by tumor-specific mutated genes that are often unique to each patient. Targeting these unique neoantigens requires TCRs that are generated on a patient-by-patient basis. During cancer initiation and progression, tumor cells acquire mutations in naturally occurring genes that are responsible for transformation, known as driver mutations. Some of these driver mutations occur in common places called hotspots and are a class of mutations shared between tumor types and between individuals. Since driver mutations can be anticipated, it is possible to prepare TCRs in advance of a patient&#x2019;s need and form a library of banked TCRs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Approach to Targeting Neoantigens</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that to be successful in treating solid tumors, genetically modified T cells targeting one or more neoantigens will likely need to address the fact that (1) among a population of patients, not all tumors express the targeted neoantigen, referred to as inter-tumor heterogeneity, and (2) within a single patient, not all tumor cells express the targeted antigen, referred to as intra-tumor heterogeneity. Inter-tumor heterogeneity limits the number of recipients that are eligible to receive a treatment and intra-tumor heterogeneity creates the risk of antigen-escape variants, increasing the likelihood of cancer relapse. As a result, we believe companies developing T cell therapies targeting neoantigens must address both inter- and intra-tumor heterogeneity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We genetically modify peripheral blood-derived T cells to express TCRs with specificity to tumor-derived antigens, especially neoantigens, and propagate them to sufficient numbers prior to administration. We aim to overcome the key challenges of targeting neoantigens by using DNA plasmids to reprogram T cells to express introduced TCRs on a patient-by-patient basis. This is designed to help address tumor heterogeneity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T cells contain multiple different subsets of T cells, including effector and memory T cells. The effector T cells are associated with immediate anti-tumor activity. Memory T cells have greater growth potential relative to the effector T cells. Some of our TCR-T cells are T memory stem cells, which have been described to have the largest capacity for growth and renewal relative to other T-cell populations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our TCR-T Manufacturing Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The diagram below illustrates our manufacturing process for our current TCR-T product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img159912857_1.jpg" alt="img159912857_1.jpg" style="width:479px;height:335px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T approach focuses on what we believe to be the most critical and prevalent tumor-specific targets in cancer. These target mutations, called hotspots, are prevalent in genes including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which can be found in non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers in several different HLA alleles. These driver genes play a key role in regulating cell division, maturation and death, and mutations in these genes have been observed to play a critical role in the development of certain cancers. The advantage of our Library TCR-T approach is that subsets of patients with solid tumors may be rapidly treated by screening them for targeted neoantigens (e.g., </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), identifying patient HLA, and matching these results to the TCRs in the library. Patients with a variety of different cancers (e.g., non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers) can be screened for a match to our growing TCR library through tumor sequencing and identification of the patient&#x2019;s tumor mutation and HLA typing. Once a match to our TCR library is confirmed, a portion of the patient&#x2019;s white blood cells is collected through a peripheral blood leukapheresis and sent to our own current Good Manufacturing Practices, or cGMP, manufacturing facility in Houston, Texas.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once the desired pre-manufactured TCR transposon is selected from our TCR library, we utilize our proprietary non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genetic engineering technology to modify the patient&#x2019;s T cells (both CD4+ and CD8+). We use T cells from peripheral blood, which have a younger and healthier phenotype relative to tumor-resident T cells, to generate our TCR-T cells. Given initial clinical cellular kinetics of the TCR-T cells in the patients treated to date, we believe these modified TCR-T cells will persist in the recipient following infusion. We have observed in preclinical studies that genetic engineering of T cells by our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology resulted in the rapid and stable expression of the introduced neoantigen-specific TCR. The genetically modified T cells expressing high levels of the TCR are expanded to produce the patient-specific, or autologous, TCR-T cell product. The product candidate is then harvested from the manufacturing process, formulated, cryopreserved, transferred to the hospital facility and infused in the patient after thawing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Benefits of Our Non-Viral Sleeping Beauty Gene Transfer Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer platform provides several benefits, including those described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scalability and Reduction in Complexity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology is a straightforward means to manufacture a large number of autologous T-cell products. The technology requires only the synthesis of DNA plasmids as the starting material for genetic engineering of the T cells. In contrast, traditional viral gene transfer is more complex and requires specialized manufacturing of each viral vector(s) of interest. Production of a viral vector starts with the generation of plasmid DNA with the transgene of interest. This plasmid is then introduced into a packaging cell line and viruses are secreted into the media over a couple of days. This process is inherently more complex to scale with the numbers of cells and associated media required relative to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which only requires the plasmid DNA. Genetic modification of the patient cells using the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology is accomplished through electroporation with the DNA plasmids and subsequent culture, selection and growth of the T cells to large numbers using traditional manufacturing techniques. This simple process can be scaled through the addition of manufacturing lines.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customizable Therapies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We believe our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> platform provides us with the ability to manufacture more customizable therapies. The platform enables a library of TCRs to be assembled and used in cells to recognize diverse mutations within shared </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens and address a multitude of HLA types. We believe this can enable both our current Library TCR-T approach against shared cancer targets as well as personalized TCR therapies against unique, and potentially multiple, personal neoantigens. We believe multiplexing TCR-T cells, which involves infusing a patient with more than one TCR product, will be best enabled by our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> system and through our unique TCRs and expanding TCR library.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potential Clinical Benefits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We believe the anti-tumor activity of our TCR-T cells has the potential to last as long as the TCR-T cells persist and proliferate following the recognition of the neoantigen on the tumor cell surface. This may lead to durable and progressively greater clinical response in patients. In CAR-T cell products generated in human cells, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transposons were observed to integrate in a close-to-random distribution at thymine-adenine, or TA, dinucleotide sites, which increases the likelihood of insertion in a genomic safe harbor, thereby making them less likely to cause off-target effects when compared to other transposons and viral gene delivery methods. We also believe that including membrane-bound interleukin-15, or mbIL-15, in TCR-T cells can provide additional benefits. In particular, we have observed that T cells modified to express mbIL-15 as well as a TCR show increased potential for stemness corresponding with a potential ability to persist longer in the patient after infusion.  </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accommodation of Large Transgene Size</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Plasmids manufactured using our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> platform have a large enough payload size to allow for genetic engineering of both the TCR as well as insertion of a gene encoding for the expression of cytokines, such as mbIL-15. This facilitates uniformly high co-expression of both the TCR and cytokine on a single integrated gene.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical and Clinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Development of our TCR-T Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have independently evaluated all licensed TCRs using our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> platform. Candidate TCRs for clinical translation were selected based on conventional </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> immunological measurements. We presented these data at the 2021 American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC) annual meetings. We selected the TCRs based, in part, on their ability to express on the T cell surface and then specifically recognize the mutated target without also targeting healthy cells. For those TCRs that are destined for killer T cells, our preclinical data suggest that those TCR-T cells can kill the appropriate tumor cell lines expressing the target neoantigen. In our preclinical studies we observed TCR-T cells killed significantly more tumor cells when matched with the corresponding HLA and neoantigen relative to mismatched tumor cells and relative to mismatched T cells not expressing the relevant neoantigen-specific TCR.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selected licensed TCRs have also been co-expressed with mbIL-15 on T cells. This was accomplished with the transfer of a single transposon to deliver three independent genes (TCRalpha, TCRbeta, mbIL-15) to the T cell. We optimized the orientation order of these three genes and the growth conditions specific for the generation of mbIL-15 TCR-T cells. Using similar standard immunologic readouts described above, the mbIL-15 TCR-T cells were observed to display a similar specificity and potency profile to conventional TCR-T cells; however, we observed increased </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> survival of mbIL-15 TCR-T cells in the absence of all added support relative to TCR-T cells, especially in the T memory stem cell populations. We have filed an international patent application around these findings and presented preclinical data from this program at the American Society of Gene &amp; Cell Therapy conference in 2022. We believe mbIL-15 has the potential to increase the survival of TCR-T cells in the harsh tumor microenvironment and deepen clinical responses. We are working towards filing a related Investigational New Drug Application, or IND, in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TCR-T Library Phase 1/2 Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2021, we received FDA clearance for our company-sponsored IND to initiate a Phase 1/2 open-label, dose-escalation trial which is initially being conducted at MD Anderson. In January 2022, after screening patients, we opened enrollment in our TCR-T Library Phase 1/2 Trial and expect to enroll up to 180 adults during the course of the trial. We will only enroll patients who have a matched HLA and hotspot mutation that is targeted by one of the TCRs from our TCR library, who have progressive or recurrent solid tumors and who have failed at least one prior line of standard therapy. The trial is evaluating our 12 library TCRs targeting neoantigens arising from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mutations in patients across a broad range of solid tumors that include non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers, all in a single trial. We have used and anticipate continuing to use our hunTR discovery engine to add new TCRs to our library and clinical program as they are qualified by our laboratory. The patients are being enrolled in cohorts according to their cancer at three separate dose levels. The Phase 1 primary endpoint is to define dose limiting toxicity or the recommended maximum tolerated dose for a subsequent clinical trial. The primary endpoints for the Phase 2 portion of the trial are expected to determine the objective response rate and otherwise evaluate safety and tolerability. We are also monitoring TCR-T cell persistence and performing multiple conventional immune monitoring assays in the clinical trial to evaluate their persistence in patients. As of December 31, 2022, we have enrolled and dosed three patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We presented information on the first two patients treated in September 2022 at the CRI-ENCI-AACR International Cancer Immunotherapy Conference, or CICON. The first patient we treated had lung adenocarcinoma with multiple lines of prior therapy and was refractory to checkpoint inhibitors. The second patient we treated was diagnosed with colon cancer and had received multiple lines of standard prior therapies. We successfully dosed a third patient who was diagnosed with advanced pancreatic cancer refractory to multiple lines of standard therapy in our TCR-T Library Phase 1/2 Trial in December 2022. We continue to perform translational assessments to assess the biological activity of our TCR-T cells in order to guide next generation TCR-T therapy approaches including potential combination and multiplexed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TCR-T cell therapies. We believe that these data provide early clinical validation of the potential of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> TCR-T cell therapy in high value indications with significant unmet need.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients 1, 2 and 3 demonstrated manageable safety profiles with no dose limiting toxicities, or DLTs, or immune effector cell-associated neurotoxicity syndrome;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Persistence of the TCR-T cells has been observed. Patient 1 had persistence at 24 weeks with approximately 30% of the patient's total CD3+ T cells comprising TCR-T cells in peripheral blood after treatment with KRAS-G12D/HLA-A*11:01 mutation-specific TCR-T cells at dose level 1 (9x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cells). Patient 2 had persistence at 12 weeks with approximately 20% of the patient's total CD3+ T cells comprising TCR-T cells in peripheral blood after treatment with TP53-R175H/HLA-A*02:01 mutation-specific TCR-T cells at dose level 2 (64x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cells).</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Demonstrating six month progression-free survival, Patient 1 had best overall response of objective, partial response with regression of greater than 50% of target lesions at 12 weeks post-cell therapy. Patient 2 had best overall response of stable disease at six weeks with 12 week progression-free survival. Progressive disease was observed in Patient 1 and Patient 2 at weeks 24 and 12, respectively, and each patient subsequently went off study;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The targeted mutations, KRAS-G12D and TP53-R175H, were detected in progressing tumor biopsies suggesting no antigen loss; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor homing was observed in Patient 1 with infiltration of both CD4 and CD8 TCR-T cells six months post-TCR-T cell therapy.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To our knowledge, achievement of an objective clinical response resulting from treatment with KRAS-G12D and HLA-A*11:01 specific TCR-T cells has not been reported until Patient 1 in our TCR-T Library Phase 1/2 Trial. Patient 1&#x2019;s infusion product was high quality with 97.3% viability, 99.7% CD3+ purity and 95.2% TCR positivity. Patient 1&#x2019;s target lesions were reduced compared to baseline by 46% at six weeks, 51% at 12 weeks and 46% at 24 weeks. At six months following treatment, an elective tumor biopsy of non-measurable disease in the right lung showed continued presence of tumor cells, KRAS-G12D mutation and HLA-A*11:01 allele, and progressive disease was corroborated by another elective scan at seven months. Patient 1 is now off trial and is being monitored as part of our long-term follow-up protocol.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient 2's treatment was the first-in-human </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TCR-T cell therapy targeting TP53 hotspot mutations and was generally well tolerated. The same TCR used by the NCI to treat breast cancer, which resulted in a 6-month confirmed, objective partial response, was used to treat Patient 2. Patient 2 received highly pure TCR-T cells (92.5% viability, 99% CD3+ purity, and 92% TCR positivity). Reduction of target lesions by 15% from baseline was observed at six weeks post-infusion, but we observed 21.8% growth of lesions from the week six measurements and appearance of new liver and lung metastases at week 12 signaled progressive disease in Patient 2, who was removed from the trial as a result of such progression.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2022, we submitted an IND amendment to the FDA to add two new TCRs to our clinical trial targeting frequent mutations and HLAs, with the potential to double the addressable market of our TCR-T Library Phase 1/2 Trial. In over 700 patients screened at MD Anderson Cancer Center with gastrointestinal or lung tumors, we have improved our match rate from 5% ot over 10%, including roughly one in five patients matching two TCRs in the current library. The addition of these new TCRs highlights our strategy to add both more HLAs to existing mutations (KRAS-G12V and HLA-DRB1*07:01) and new mutations within our targeted gene families (TP53-R273C and HLA-DPB1*04:02). In 2023, we expect to further expand our library with exclusively owned TCRs targeting recurrent hotspot mutations in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to 15 TCRs. We continue to actively enroll patients in our TCR-T Library Phase 1/2 Trial targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hotspot mutations across six solid tumor indications. We expect to enroll multiple patients in the first half of 2023. The IND amendment also combined our treatment and screening protocols, streamlining enrollment and potentially making it easier for both patients and physicians. The amended IND also eliminated the requirement for retesting of the tumor mutation if six months had passed between screening and treatment. We anticipate providing an interim clinical data update in 2023 as we work toward advancing the TCR-T Library Phase 1/2 Trial into Phase 2 and we expect to be Phase 2 ready by the end of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IL-12 Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we announced in May 2021, we are winding down our existing Controlled IL-12 clinical program for the treatment of recurrent glioblastoma multiforme. We are actively seeking a partner for continued development of this program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cGMP facility in Houston, Texas is staffed by Alaunos personnel and is fully operational for manufacturing TCR T-cells genetically modified with our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer platform for our early-stage clinical trials. We continue to rely on third parties for the production of the DNA plasmids used in manufacturing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Library TCR-T approach allows us to streamline the T cell manufacturing process by pre-manufacturing DNA plasmids corresponding to each of our qualified library TCRs. These TCRs are then utilized in the manufacturing for the patient-specific, autologous TCR-T product candidates. Our in-house TCR-T manufacturing facility also allows us to integrate our research and development capabilities, potentially reducing the time from discovery to treating patients in a clinical trial. This integration is designed to minimize delays and reduce risks that can</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be encountered in drug development, including the failure of third parties to successfully produce the desired product, long technology transfer periods and long lead times for orders. We continue to execute on our multi-pronged strategy to expand manufacturing capacity and efficiency. We doubled our manufacturing capacity in 2022, allowing for production of two products simultaneously. We also filed an IND amendment to move from fresh to cryopreserved product and began implementing this change in the first half of 2023. The use of cryopreserved cell products is expected to reduce manufacturing process time from 30 days to 26 days, a 13% decrease, while increasing flexibility for patient scheduling and treatment. We have ongoing initiatives to optimize the process and further reduce the manufacturing time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We seek continuous improvement in our manufacturing and release workflow through process and analytical development. Our processes will continue to be optimized to increase efficiencies, incorporate new technologies and reduce time to treatment for the patient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to obtain, maintain and enforce patent and trade secret protection for our product candidates, formulations, processes, methods and other proprietary technologies. We strive to preserve our trade secrets and other confidential information and to operate without infringing the proprietary rights of other parties. Our policy is to actively seek the strongest possible intellectual property protection for our technology and product candidates through a combination of license agreements and owned patents, both in the United States and abroad.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Owned Patents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we have five families of pending patent applications that cover our TCR-T library, products and processes. We do not currently own any granted patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent terms extend for varying periods according to the date of patent filing or grant and the legal patent terms in the various countries where patent protection is obtained. The actual protection offering by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage, the issued claims and the availability of legal remedies in the country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, some of our patents, under certain conditions, may be eligible for limited patent term extension for a period of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. However, this extension period cannot be extended beyond 14 years from the drug&#x2019;s approval date. The patent term restoration period is generally one-half the period of time elapsed between the effective date of an IND application or the issue date of the patent, whichever is later. The submission date of a New Drug Application, or NDA, plus the period of time between the submission date of the NDA or the issue date of the patent, whichever is later, and FDA approval. The United States Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves applications for any patent term extension or restoration. We intend to seek the benefits of this statute, but there can be no assurance that we will be able to obtain any such benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also depend upon the skills, knowledge and experience of our scientific and technical employees, as well as those of our advisors, consultants, and other contractors, none of which may be patentable. To help protect unpatentable proprietary know-how, and for inventions for which patents may be difficult to enforce, we currently rely, and in the future, will continue to rely, on trade secret protection and confidentiality agreements to protect our interests. To this end, we generally require employees, consultants, advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent position and proprietary rights are subject to certain risks and uncertainties. Please read the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Related to Our Intellectual Property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> section for further information about certain risks and uncertainties that may affect our patent position and proprietary rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with PGEN Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, we entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the License Agreement, we have exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between us, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, we also have exclusive, worldwide rights for certain patents relating to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. We are required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products and TCR Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the licenses and other rights granted by PGEN, we pay PGEN an annual license fee of $0.1 million and reimbursed PGEN for certain historical costs of the licensed programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, we will pay PGEN tiered royalties ranging from low-single digit to high-single digit on the net sales derived from the sales of any approved IL-12 products and CAR products. We will also pay PGEN royalties ranging from low-single digit to mid-single digit on the net sales derived from the sales of any approved TCR products, up to a maximum royalty amount of $100.0 million in the aggregate. We will also pay PGEN 20% of any sublicensing income received by us relating to the licensed products. We are responsible for all development costs associated with each of the licensed products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PGEN will pay us royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $100.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#x2019;s obligations to provide transition assistance relating to the IL-12 products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement-The University of Texas MD Anderson Cancer Center</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 13, 2015, we, together with Precigen, entered into that certain license agreement, or the MD Anderson License, with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, we, together with PGEN, hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D. Dr. Cooper served as our Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the Research and Development Agreement, or the 2015 R&amp;D Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to us pursuant to the Fourth Amendment to the 2015 R&amp;D Agreement which was entered into on September 19, 2019, or the Fourth Amendment, with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from our company and one member from MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As provided under the MD Anderson License, we provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year. On November 14, 2017, we entered into an amendment to the 2015 R&amp;D Agreement extending its term until April 15, 2021 and on October 22, 2019, we entered into another amendment to the 2015 R&amp;D Agreement extending its term until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which we entered into on October 22, 2019, with MD Anderson, pursuant to which we agreed to collaborate with respect to the TCR program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, we, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if we and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if we and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both us and Precigen and may be terminated by the mutual written agreement of us, Precigen, and MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement-The University of Texas MD Anderson Cancer Center</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, we and MD Anderson will, among other things, collaborate on programs to expand our TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from our company and one member from MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and we will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. We have granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies, and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, we agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $20 million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, we will pay MD Anderson royalties on net sales of its TCR products at rates in the low single digits. We are required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $36.5 million, of which only $3.0 million will be due prior to the first marketing approval of our TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. We also agreed to sell our TCR products to MD Anderson at preferential prices and will sell our TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of our TCR products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, we issued MD Anderson a warrant to purchase 3,333,333 shares of our common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $0.001 per share, expires on December 31, 2026 and vests in four parts upon the occurrence of certain clinical milestones. As of December 31, 2022, the milestones have not been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The MD Anderson Warrant and the shares of our common stock to be issued upon exercise of the MD Anderson Warrant have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, we entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, we hold an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> neoantigens. In addition, pursuant to the Patent License, we hold an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021, and August 13, 2021 we amended the Patent License to expand our TCR library to include additional TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> neoantigens licensed from the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Patent License require us to pay the NCI minimum annual royalties in the amount of $0.3 million, which amount will be reduced to $0.1 million once the aggregate minimum annual royalties paid by us equals $1.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $4.3 million, of which aggregate payments of $3.0 million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. The first benchmark payment of $0.1 million was paid in 2022 upon the initiation of our TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $250.0 million to $1.0 billion. The aggregate potential amount of these benchmark payments is $12.0 million. We must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent we enter into a sublicensing agreement relating to a licensed product, we are required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. The NCI may terminate or modify the Patent License in the event of a material breach, including if we do not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event. We may terminate the Patent License, or any portion thereof, in our sole discretion at any time upon 60 days&#x2019; written notice to the NCI. In addition, the NCI has the right to: (i) require us to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if we are not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if we are not satisfying requirements for public use as specified by federal regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement with the NCI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 9, 2017, we entered into a Cooperative Research and Development Agreement, or CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with our researchers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, we will have the first opportunity to file a patent covering the invention. If we fail to provide timely notice of our decision to the NCI or decide not to file a patent covering the joint invention, NCI has the right to make the filing. For any invention solely owned by NCI or jointly made by NCI and us for which a patent application was filed, the U.S. Public Health service grants us an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by NCI or jointly owned by NCI and us, which are licensed according to the terms described above, we agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. We are also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of our solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI has a cleared IND that would permit them to begin this trial. To our knowledge, the trial has not yet enrolled. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2019, we extended the CRADA with the NCI until January 9, 2022, committing an additional $5.0 million to this program. In March 2022, we entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, we entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, we agreed to contribute $1.0 million per year, payable on a quarterly basis, beginning in the first quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TCR-T Platform Licenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2015, we in-licensed from MD Anderson a technology portfolio that includes intellectual property directed to certain non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technologies as well as TCR-T cell therapy and bioprocessing technology. Under the terms of the agreement, we have an exclusive license to certain of the intellectual property technology, a co-exclusive license to certain of the intellectual property technology and a non-exclusive license to certain of the intellectual property technology. Our rights to the MD Anderson intellectual property flow to us via our agreement with PGEN.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2019, we in-licensed from the NCI a patent portfolio that includes intellectual property related to our TCR-T cell library. Under the terms of the agreement, we hold an exclusive, worldwide license to certain intellectual property to develop, manufacture and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> neoantigens. In addition, we hold an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express certain TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governmental Regulation and Product Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a biopharmaceutical company, we are subject to extensive regulation. Our genetically engineered T-cell product candidates are regulated as biologics. With this classification, commercial production of our products will need to occur in registered and licensed facilities in compliance with cGMPs for biologics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human immunotherapy products are a new category of therapeutics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States (at the federal, state and local level) and in other countries and jurisdictions extensively regulate, among other things, the research, development, preclinical and clinical testing, manufacturing, quality control, labeling, packaging, storage, record-keeping, promotion, advertising, sale, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">although there can be important differences. The process for obtaining regulatory marketing approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Product Development Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates biological products under the Public Health Service Act, or PHSA, and the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations. Products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters and similar public notice of alleged non-compliance with laws, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be approved for marketing in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the FDA&#x2019;s regulations commonly referred to as Good Clinical Practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation and submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity and potency from results of nonclinical testing and clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP to assure that the facilities, methods and controls used in product manufacture are adequate to preserve the biological product&#x2019;s identity, strength, quality and purity and, if applicable, the FDA&#x2019;s current Good Tissue Practices, or GTPs, for the use of human cellular and tissue products; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payment of user fees for FDA review of the BLA; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA acceptance, review and approval, or licensure, of the BLA, which might include review by an advisory committee, a panel typically consisting of independent clinicians and other experts who provide recommendations as to whether the application should be approved and under what conditions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before testing any biological product candidate, including our product candidates, in humans, the product candidate must undergo rigorous preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations as well as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and animal studies to assess the potential safety and efficacy of the product candidate. The clinical trial sponsor must submit an IND to the FDA before clinical testing can begin in the United States. An IND must contain the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature, a proposed clinical protocol, an investigator&#x2019;s brochure, a sample informed consent form and other materials. Clinical trial protocols detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Some preclinical testing, such as toxicity studies, may continue even after the IND is submitted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials or places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Clinical trials involving recombinant or synthetic nucleic acid molecules also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control. Clinical trials must be conducted and monitored in accordance with the FDA&#x2019;s regulations comprising the GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population, generally at geographically dispersed clinical trial sites. These clinical trials are intended to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk to benefit profile of the product and to provide an adequate basis for product labeling.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board, an independent group of experts that evaluates study data for safety and makes recommendations concerning continuation, modification, or termination of clinical trials, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug or biologic products that meet certain criteria. Specifically, new drugs or biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for approved biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the biological product, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA GTP regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval. If the agency decides not to approve the BLA in its present form, the FDA will issue a Complete Response Letter, which generally outlines the specific deficiencies in the BLA identified by the FDA and may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the application. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Even with the submission of additional information, the FDA may ultimately decide that the application does not satisfy the regulatory criteria for approval. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may require that certain contraindications, warnings or precautions be included in the product labeling, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#x2019;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements and complying with FDA promotion and advertising requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, with manufacturing processes, or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, complete withdrawal from the market, product recalls, warning letters from the FDA, mandated corrective advertising or communications with doctors, product seizure or detention, injunctions and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could delay or prevent regulatory approval of our products under development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the FDA strictly regulates marketing, labeling, advertising and promotion of products. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act, or BPCIA, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. Biosimilars are approved pursuant to an abbreviated pathway whereby applicants need not submit the full slate of preclinical and clinical data, and approval is based in part on the FDA&#x2019;s findings of safety, purity, and potency for the original biologic (i.e., the reference product). Reference products are eligible to receive 12 years of exclusivity from the time of first licensure of the product, which prevents the FDA from approving any biosimilars to the reference product through the abbreviated pathway, but does not prevent approval of BLAs that are accompanied by a full data package and that do not rely on the reference product. A biosimilar may be approved if the product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and there are no clinically meaningful differences with the reference product in terms of the safety, purity and potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug or biologic product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a marketing application. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#x2019;s product for the same indication or disease. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Orphan drug status in the European Union, or EU, has similar but not identical benefits in that jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage, Pricing and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in significant part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. Third-party payors are increasingly challenging the price, examining the medical necessity of and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reimbursement may impact the demand for, and/or the price of, any product candidate that obtains marketing approval. Even if coverage and reimbursement is obtained for a given product candidate by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use a product, and physicians may be less likely to prescribe a product, unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of the product. Therefore, coverage and adequate reimbursement is critical to new drug product acceptance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The downward pressure on health care costs in general, particularly prescription drugs and biologics, has become very intense. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. As a result, increasingly high barriers are being erected to the entry of new products. The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide favorable coverage and adequate reimbursement. In addition, emphasis on managed care in the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health Care Laws Governing Interactions with Healthcare Providers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers and third-party payors in the United States play a primary role in the recommendation and prescription of drug products. Arrangements with healthcare providers, third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws, including false claims, privacy and security, price reporting and physician sunshine laws or regulations. Some of our pre-commercial activities are subject to some of these laws. The applicable federal, state and foreign healthcare laws and regulations laws that may affect a pharmaceutical manufacture&#x2019;s ability to operate include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute, which regulates our business activities, including our marketing practices, educational programs, pricing policies and relationships with healthcare providers or other entities, by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal civil and criminal false claims laws, including the False Claims Act which permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal civil and criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities and individuals subject to the law including certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, as well as individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates as well as their covered subcontractors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requirements to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, certain financial arrangements with physicians and teaching hospitals, as defined in the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, and its implementing regulations, including reporting any &#x201c;transfer of value&#x201d; made or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">distributed to prescribers and teaching hospitals, and reporting any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#x2019;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#x2019;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, it may be subject to the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, as well as additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. In addition, the approval and commercialization of drug products outside the United States may also subject a pharmaceutical manufacturer to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform Efforts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A primary trend in the United States healthcare industry and elsewhere is cost containment. Over the last several years, there have been federal and state proposals and legislation enacted regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products and making changes to healthcare financing and the delivery of care in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2010, President Obama signed into law the ACA, which included measures that have significantly changed the way healthcare is financed by both governmental and private insurers. The ACA, among other things, imposed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees on manufacturers and importers of certain branded prescription drugs and biologic agents, promoted a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#x2019; interactions with healthcare practitioners. The ACA also expanded eligibility for Medicaid programs and introduced a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research and a new Center for Medicare &amp; Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, legal and political challenges to certain aspects of the ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#x201c;Cadillac&#x201d; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201c;donut hole.&#x201d; Further, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act, or IRA, into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#34;donut hole&#34; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and implementing a newly established</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact ACA and our business. The ultimate content, timing or effect of any healthcare reform measures on the U.S. healthcare industry is unclear.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted. For example, as a result of the Budget Control Act of 2011, providers are subject to Medicare payment reductions of 2% per fiscal year, which went into effect on April 1, 2013. This 2% reduction was temporarily suspended during the COVID-19 pandemic, but has since been reinstated and, unless Congress and/or the Executive Branch take additional action, will begin to increase gradually starting in April 2030, reaching 4% in April 2031, until sequestration ends in October 2031. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. In November 2019, CMS issued a final rule finalizing the changes to the Medicare Quality Payment Program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#x2019;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 30, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The IRA delayed the implementation of the rule to January 1, 2032. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers; the implementation of these provisions has also been delayed by the IRA until January 1, 2032. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate price cap, currently set at 100% of a drug&#x2019;s average manufacturer price for single source and innovator multiple source products, beginning on January 1, 2024. Further, in July 2021, the Biden Administration released an executive order that included multiple provisions aimed at prescription drugs. In response to Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug price reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions by HHS. No legislative or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures have increasingly enacted legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Foreign Corrupt Practices Act, U.K. Bribery Act and Other Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Foreign Corrupt Practices Act, or the FCPA, prohibits any United States individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations are also subject to non-United States anti-corruption laws such as the U.K. Bribery Act 2010, or the Bribery Act. As with the FCPA, these laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States and authorities in the EU, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as trade control laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with the Bribery Act, the FCPA and other anti-corruption laws and trade control laws could subject us to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our novel hunTR discovery engine has a demonstrated ability to identify proprietary TCRs, allowing us to further expand and advance our pipeline with multiple solid tumor programs under development. In addition, our non-viral transposon method of expressing TCRs, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is less complex relative to many of our competitors&#x2019; viral approaches. Finally, our TCR-T Phase 1/2 Library Trial is designed to allow us to treat patients quickly and efficiently in many different indications with a tumor mutation and HLA matching one or more of the several TCRs in our library, which we believe gives us a distinct competitive advantage. However, the development and commercialization for new products to treat cancer, including the indications we are pursuing, is highly competitive and considerable competition exists from major pharmaceutical, biotechnology and specialty cancer companies. Many of these companies have more experience in preclinical and clinical development, manufacturing, regulatory, and global commercialization. Given the rapidly advancing and changing science and technologies in the industry, they may compete with us in hiring personnel, setting up clinical study sites, recruiting patients for clinical trials, and procuring technologies and licenses complementary to, or required for, our programs. We are also competing with academic institutions, governmental agencies and private organizations that are conducting research in the field of cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T cell therapies targeting solid tumors face significant competition from multiple companies, and their collaborators, in the TCR and CAR technology space. We face competition from several companies, including 2Seventy Bio, Achilles Therapeutics, Adaptimmune Therapeutics, Affini-T Therapeutics, Annoca, ArsenalBio, Athenex, BioNTech, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics, Kite (a Gilead company), Lion TCR, Lyell Immunopharma, Medigene, Nurix Therapeutics, Neogene Therapeutics (a member of the AstraZeneca group), NexImmune, PACT Pharma, Precigen, Tactiva Therapeutics, Takara Bio, TCR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Therapeutics, T-Cure BioScience, T-knife Therapeutics, Triumvira Immunologics, TScan Therapeutics, Turnstone Biologics, Zelluna Immunotherapy and others. Many of these companies are either investigating TCR-T cells against germline antigens or are utilizing tumor infiltrating lymphocytes. Some are pursuing CAR-T cells for solid tumors. In contrast, we are focused on developing TCR-T cell products against neoantigens arising from somatic mutations in solid tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companies in the T-cell therapy segment that have target discovery platforms like ours include Adaptive Biotechnologies, Affini-T Therapeutics, Enara Bio, Immatics, Neogene Therapeutics (a member of the AstraZeneca group), PACT Pharma, T-knife Therapeutics, TScan Therapeutics and 3T Biosciences. Several companies, including Advaxis, Amgen, BioNTech, Geneos Therapeutics, and Gritstone, are pursuing vaccine platforms to target neoantigens for solid tumors. Other companies are developing non-viral gene therapies, including Poseida Therapeutics and several companies developing CRISPR technology, including Captain T Cell and Crispr Therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several companies are pursuing the development of allogeneic CAR-T therapies, including Allogene Therapeutics, Atara Biotherapeutics and Precision Biosciences, which may compete with our product candidates. We also face competition from companies developing therapies using cells other than T cells, such as Athenex, Fate Therapeutics, ImmunityBio, IN8bio, Nkarta Therapeutics and Takeda Pharmaceutical. Other competitors are developing T cells with cytokines, such as Fate Therapeutics and Obsidian Therapeutics. Finally, we also face competition from non-cellular treatments offered by other companies, such as Amgen, AstraZeneca, Bristol-Myers Squibb, Immatics, Immunocore, Incyte, Merck, Mirati and Roche. Additionally, our ability to find partnerships relating to our IL-12 and CAR-T programs may be impacted by substantial competition from these and other biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition on a broader spectrum of the oncology market that is more common, cost-effective and reimbursable, such as surgery, radiation and other drug therapies like chemotherapy, hormone therapy, biologic therapy such as monoclonal and bispecific antibodies, or a combination of any of these therapies. If any of our TCR-T therapies are approved, they may not be as competitive as other therapies, to the extent they are used in combinations with these therapies. Insurers and other third-party payors may also encourage use of certain products; thus, gaining market acceptance or market share for any of our TCR-T therapies could pose difficulties. Finally, standard of care could evolve or change throughout the clinical development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, if our competitors develop and market a drug that is safer, more effective with fewer side effects, easier to administer, or less expensive, we could see a less favorable market opportunity for our TCR-T therapy candidates. Our competition may also receive FDA or other regulatory approval for their products more quickly than we do, which could give them a first mover advantage and a strong market position before we are able to commercialize our products. If approved, key competitive factors that may affect the success of our TCR-T candidates are likely their efficacy, safety, ease of administering, price and reimbursement from insurance or government.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 15, 2023, we had 34 full-time employees and no part-time employees, 28 of whom were engaged in research and development activities, and 6 of whom were engaged in administration. None of our employees are subject to a collective bargaining agreement and we believe our relations with our employees are good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our human capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recruit the best people for the position regardless of gender, ethnicity or other protected traits and it is our policy to fully comply with all laws applicable to discrimination in the workplace. Our diversity, equity and inclusion principles are also reflected in our employee training and policies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#x201c;EasyWeb, Inc.&#x201d; in February 1999. We re-incorporated in Delaware on May 16, 2005 under the same name. On September 13, 2005, we completed a &#x201c;reverse&#x201d; acquisition of privately held Ziopharm, Inc., a Delaware corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we caused Ziopharm, Inc. to merge with and into us and we changed our name to &#x201c;Ziopharm Oncology, Inc.&#x201d; As a result, Ziopharm, Inc. became the registrant with the Securities and Exchange Commission, or the SEC, and the historical financial statements of Ziopharm, Inc. became our historical financial statements. On January 25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to change our name to Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal executive offices are located at 8030 El Rio Street, Houston, Texas 77054, and our telephone number is (346) 355-4099.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our website address is www.alaunos.com. Our website and information included in or linked to our website are not part of this Annual Report on Form 10-K. We file reports with the SEC, which we make available on our website free of charge. These reports include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports, each of which is provided on our website as soon as reasonably practicable after we electronically file such materials with or furnish them to the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers, like us, that file electronically with the SEC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1A. Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An investment in our common stock is risky. In addition to the other information in this Annual Report on Form 10-K, you should carefully consider the following risk factors in evaluating us and our business. If any of the events described in the following risk factors were to occur, our business, financial condition, results of operation and future growth prospects would likely be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or a part of your investment in our common stock. Therefore, we urge you to carefully review this entire report and consider the risk factors discussed below. Moreover, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, financial condition, operating results or prospects. Additional risks that we currently do not know about, or that we currently believe to be immaterial, may also impair our business. Certain statements below are forward-looking statements. See &#x201c;Special Note Regarding Forward-Looking Statements&#x201d; in this Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional financial resources to continue as a going concern and to continue ongoing development of our product candidates and pursue our business objectives; if we are unable to obtain these additional resources when needed, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2022, we had a net loss of $37.7 million, and, as of December 31, 2022, our accumulated deficit since inception in 2003 was $880.6 million. We expect our operating expenditures and net losses to increase significantly in connection with our ongoing clinical trial and our internal research and development capabilities. Further development of our product candidates will require substantial increases in our expenses as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to undertake clinical trials for product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scale-up and scale-out the manufacturing of our TCR-T product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">work with regulatory authorities to identify and address program-related inquiries; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional internal systems and infrastructure; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel, including highly-skilled and experienced scientific staff. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we have approximately $53.0 million of cash and cash equivalents, including $13.9 million of restricted cash related to the Amended Loan and Security Agreement (as defined below).&#x202f;Given our current development plans and cash management efforts, we anticipate cash resources will be sufficient to fund operations into the fourth quarter of 2023. We have no committed sources of additional capital at this time. We follow the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The forecast of cash resources is forward-looking information that involves risks and uncertainties, and our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to, changes in the focus and direction of our development programs, slower and/or faster than expected progress of our research and development efforts, changes in governmental regulation, competitive and technical advances, rising costs associated with the development of our product candidates, our ability to secure partnering arrangements, and costs of filing, prosecuting, defending and enforcing our intellectual property rights. Global political and economic events, including the COVID-19 pandemic and increased inflation, have already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital or make the terms of any available financing less attractive, which could in the future negatively affect our operations. If we exhaust our capital reserves more quickly than anticipated, regardless of the reason, and we are unable to obtain additional financing on terms acceptable to us or at all, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We need to raise additional capital to fund our operations. The manner in which we raise any additional funds may affect the value of your investment in our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and collaboration agreements. We do not have any committed external source of funds. The unpredictability of the capital markets may severely hinder our ability to raise capital within the time periods needed or on terms we consider acceptable, if at all. In particular, a decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future at a time and price that we deem appropriate. Moreover, if we fail to advance one or more of our current product candidates into early or later-stage clinical trials, successfully commercialize one or more of our product candidates, or acquire new product candidates for development, we may have difficulty attracting investors that might otherwise be a source of additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, we entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and certain of its affiliates, or SVB. The Loan and Security Agreement provided for an initial term loan of $25.0 million funded at the closing, with an additional tranche of $25.0 million available if certain funding and clinical milestones were met by August 31, 2022, or the SVB Facility. In connection with the initial borrowing, we also issued warrants to SVB for the purchase of up to 432,844 shares of our common stock, in the aggregate, at an exercise price of $2.22 per share. The Loan and Security Agreement was subsequently amended, or the Amended Loan and Security Agreement, effective December 28, 2021, to, among other things, eliminate the additional tranche so that the $25.0 million we have drawn down is the full amount available under the SVB Facility. As a result, we do not have any other borrowings available under the SVB Facility. In connection with entering into the Amended Loan and Security Agreement we also amended and restated the warrants. These amended and restated warrants provide for the purchase of up to 649,615 shares of our common stock, in the aggregate, at an exercise price of $1.16 per share. The Amended Loan and Security Agreement also required us to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to 5.75% of the original principal amount of the SVB Facility in the event we failed to achieve certain equity raise and clinical milestones by August 31, 2022. We did not achieve these milestones and, as a result, deposited $13.9 million in a collateral account with SVB as required by the terms of the Amended Loan and Security Agreement. The collateralized cash represents a significant portion of our cash and cash equivalents that we are not able to access to fund our operations and is classified as restricted cash on our Balance Sheet.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#x2019; ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, creating liens, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred indebtedness that could adversely affect our business and place restrictions on our operating and financial flexibility.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Amended Loan and Security Agreement contains customary affirmative and negative covenants and events of default applicable to us and any subsidiaries. The affirmative covenants require us (and us to cause our subsidiaries, if any) to maintain governmental approvals, deliver certain financial reports, maintain insurance coverage and protect material intellectual property, among other things. The negative covenants restrict our and our subsidiaries&#x2019; ability to, among other things, transfer collateral, change our business, engage in mergers or acquisitions, incur additional indebtedness, pay cash dividends or make other distributions, make investments, create liens, sell assets and make any payment on subordinated debt. The restrictive covenants of the Amended Loan and Security Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial, including entering into certain licensing arrangements, maintaining flexible cash management arrangements and engaging in certain change in control transactions, among others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our debt combined with our other financial obligations and contractual commitments could have significant adverse consequences for our business, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requiring us to dedicate a substantial portion of cash flows to payment on our debt, which would reduce available funds for further research and development;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increasing the amount of interest that we must pay on debt with variable interest rates, if market rates of interest increase;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subjecting us to restrictive covenants that reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requiring us to pledge our non-intellectual property assets as collateral, which could limit our ability to obtain additional debt financing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to satisfy our debt service obligations with our existing cash and cash equivalents and any additional amounts we may raise through future debt and equity financings. Our ability to make payments due under the SVB Facility depends on our future performance, which is subject to economic, financial, competitive conditions and other factors beyond our control. We may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt. In addition, the Amended Loan and Security Agreement requires us to deposit unrestricted and unencumbered cash equal to 50% of the principal amount of the SVB Facility then outstanding and an amount equal to 5.75% of the original principal amount in a cash collateral account with SVB. As of December 31, 2022 we have $13.9 million in cash deposited in the cash collateral account pursuant to the terms of the Amended Loan and Security Agreement. Failure to pay any amount due under the SVB Facility, to comply with covenants under the Amended Loan and Security Agreement, or the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations or condition (financial or otherwise), would result in an event of default. The occurrence and continuation of an event of default could cause interest to be charged at the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rate that is otherwise applicable plus 3.00% (unless SVB elects to impose a smaller increase) and would provide SVB with the right to accelerate all obligations under the SVB Facility and exercise remedies against us and the collateral securing the SVB Facility and other obligations under the Amended Loan and Security Agreement, including foreclosure against assets securing the SVB Facility. In addition, the covenants under the Amended Loan and Security Agreement and the pledge of substantially all of our assets, excluding our intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement), as collateral on the loan may limit our ability to obtain additional debt financing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have previously identified material weaknesses in our internal control, all of which have been remediated. We may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Global Select Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. We may also be required to have our independent registered public accounting firm issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have identified material weaknesses in our internal control over financial reporting in the past. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the material weaknesses identified in the past have been remediated, we cannot assure you that any measures we have taken or may take in the future will be sufficient to avoid potential future material weaknesses. If we are unable to successfully remediate any future material weakness and maintain effective internal controls, we may not have adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by the requirements of the SEC, Nasdaq or the Sarbanes-Oxley Act. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in the identification of additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our plans to develop and commercialize non-viral adoptive TCR-T cell therapies can be considered a new approach to cancer treatment, the successful development of which is subject to significant challenges.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are employing technologies such as the technology licensed from MD Anderson pursuant to the MD Anderson License described above, from PGEN, pursuant to the License Agreement, and from the NCI, pursuant to the Patent License described above, to pursue the development and commercialization of non-viral cellular therapies based on T-cells and TCRs, targeting solid tumor malignancy. Because this is a new approach to cancer immunotherapy and cancer treatment generally, developing and commercializing product candidates subjects us to a number of challenges, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory approval from the FDA and other regulatory authorities that have very limited experience with the commercial development of genetically modified T-cell therapies for cancer; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designing and conducting our clinical trials using this new approach or selecting the appropriate TCRs in a way that may lead to optimal results; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying and manufacturing appropriate TCRs from either a patient or third parties that can be administered to the patient; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing and deploying consistent and reliable processes for engineering a patient&#x2019;s and/or donor&#x2019;s T cells ex vivo and infusing the T cells back into the patient; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditioning patients with chemotherapy in conjunction with delivery of the potential products, which may increase the risk of adverse side effects of the chemotherapy itself or of the potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of each of the potential products, such as the potential adverse side effects related to cytokine release; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing processes for the safe administration of these potential products, including long-term follow-up for all patients who receive the potential products; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process the potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing a manufacturing process with a cost of goods that allows for an attractive return on investment; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing therapies for types of cancers beyond those addressed by the current potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining and defending the intellectual property rights relating to any products we develop; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not infringing the intellectual property rights, in particular, the patent rights, of third parties, including competitors, such as those developing T-cell therapies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure you that we will be able to successfully address these challenges, which could prevent us from achieving our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current product candidates are based on novel technologies and are supported by limited clinical data and we cannot assure you that our current and planned clinical trials will produce data that supports regulatory approval of one or more of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our genetically modified TCR-T cell product candidates are supported by limited clinical data, some of which has been generated through trials conducted by MD Anderson and the NCI, rather than solely by us. We have assumed control of the overall clinical and regulatory development of our TCR-T cell product candidates, and any failure to obtain, or delays in obtaining, sponsorship of new INDs, or in filing INDs sponsored by us for these or any other product candidates we decide to advance could negatively affect the timing of our potential future clinical trials. Such an impact on timing could increase research and process development costs and could delay or prevent obtaining regulatory approval for our product candidates, either of which could have a material adverse effect on our business. We began enrolling patients in our TCR-T Library Phase 1/2 Trial in January 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we did not control the design or conduct of all of the previous trials. It is possible that the FDA will not accept these previous trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any of one or more reasons, including the safety, purity and potency of the product candidate, the degree of product characterization, elements of the design or execution of the previous trials or safety concerns or other trial results. We may also be subject to liabilities arising from any treatment-related injuries or adverse effects in patients enrolled in these previous trials. As a result, we may be subject to unforeseen third-party claims and delays in our potential future clinical trials. We may also be required to repeat in whole or in part clinical trials previously conducted by MD Anderson or other entities, which will be expensive and delay the submission and licensure or other regulatory approvals with respect to any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there are a number of regulatory requirements that we must continue to satisfy as we conduct our clinical trials of TCR-T cell product candidates in the United States. The criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products and change frequently. Satisfaction of these requirements will entail substantial time, effort and financial resources. To date, the FDA has approved only a few adoptive cell therapies for commercialization. Because adoptive cell therapies are relatively new and our product candidates employ novel gene expression and cell technologies, regulatory agencies may lack experience in evaluating product candidates like our Library TCR-T product candidates. This novelty may heighten regulatory scrutiny of our therapies or lengthen the regulatory review process, including the time it takes for the FDA to review our IND applications if and when submitted, increase our development costs and delay or prevent commercialization of our product candidates. These factors make it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates. Any time, effort and financial resources we expend on our clinical product candidates and other early-stage product development programs that are ultimately not successful may adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We report interim data on certain of our clinical trials and we cannot assure you that interim data will be predictive of either future interim results or final study results. In addition, the results ultimately obtained from our preclinical studies or other earlier clinical trials for our product candidates may not be predictive of future results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business, we provide updates related to the development of our product candidates, which may include updates related to interim clinical trial data. We anticipate that our clinical trials will involve small patient populations and because of the small sample size, the interim results of these, and all, clinical trials may be subject to substantial variability and may not be indicative of either future interim results or final results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We commenced enrollment in our TCR-T Library Phase 1/2 Trial in January 2022 and announced early clinical data for the first patient in September 2022 and for the first two patients in November 2022. The first two patients enrolled in our TCR-T Library Phase 1/2 Trial have been removed from the trial due to subsequent disease progression. We do not know at this stage whether patient response data from additional patients in this trial will be favorable, and initial success in clinical trials may not be indicative of results obtained when such trials are completed. Our product candidates may fail to show the desired safety and efficacy in clinical development, and we cannot assure you that the results of any future trials will demonstrate the value and efficacy of our product candidates. Even if our clinical trials are completed as planned, we cannot be certain that their results will support approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are no approved engineered TCR-T cell immunotherapies for solid tumors. We believe our product candidates may be effective against certain solid tumors and plan to develop product candidates for use in those certain solid tumors. We cannot guarantee that our product candidates will be able to access the solid tumor or show any functionality in the solid tumor microenvironment. The cellular environment in which solid tumor cells thrive is generally hostile to T cells due to factors such as the presence of immunosuppressive cells, humoral factors and limited access to nutrients. In addition, the safety profile of our product candidates may differ in a solid tumor setting. If we are unable to make our product candidates function in solid tumors, our development plans and business will be significantly harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. Negative differences between preliminary or interim data and final data could materially adversely affect the prospects of any product candidate that is impacted by such data updates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the results of any preclinical studies for our product candidates may not be predictive of the results of clinical trials. For example, preclinical models as applied to cell therapy in oncology do not adequately represent the clinical setting, and thus cannot predict clinical activity nor all potential risks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to recruit, hire and retain qualified personnel and we will continue to rely on key scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to attract or retain qualified management and commercial, scientific, manufacturing and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our principal scientific, regulatory and medical advisors. The loss of any of our key personnel could result in delays in product development, loss of key personnel or partnerships and diversion of management resources, which could adversely affect our operating results. We do not carry &#x201c;key person&#x201d; life insurance policies on any of our officers or key employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition from other biopharmaceutical companies, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T cell therapies targeting solid tumors face significant competition from multiple companies, and their collaborators, in the TCR and CAR technology space. We face competition from several companies, including 2Seventy Bio, Achilles Therapeutics, Annoca, Adaptimmune Therapeutics, Affini-T Therapeutics, ArsenalBio, Athenex, BioNTech, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics, Kite (a Gilead company), Lion TCR, Lyell Immunopharma, Medigene, Neogene Therapeutics (a member of the AstraZeneca group), NexImmune, Nurix Therapeutics, PACT Pharma, Precigen, Tactiva Therapeutics, Takara Bio, TCR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Therapeutics, T-Cure BioScience, T-knife Therapeutics, Triumvira Immunologics, TScan Therapeutics, Turnstone Biologics, Zelluna Immunotherapy and others. Many of these companies are either investigating TCR-T cells against germline antigens or are utilizing tumor infiltrating lymphocytes. Some are pursuing CAR-T cells for solid tumors. In contrast, we are focused on developing TCR-T cell products against neoantigens arising from somatic mutations in solid tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companies in the T-cell therapy segment that we believe to have target discovery platforms like ours include Adaptive Biotechnologies, Affini-T Therapeutics, Enara Bio, Immatics, Neogene Therapeutics (a member of the AstraZeneca group), PACT Pharma, T-knife Therapeutics, TScan Therapeutics and 3T Biosciences. Several companies, including Advaxis, Amgen, BioNTech, Geneos Therapeutics and Gritstone, are pursuing vaccine platforms to target neoantigens for solid tumors. Other companies are developing non-viral gene therapies, including Poseida Therapeutics and several companies developing CRISPR technology, including Captain T Cell and Crispr Therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several companies are pursuing the development of allogeneic CAR-T therapies, including Allogene Therapeutics, Atara Biotherapeutics and Precision Biosciences, which may compete with our product candidates. We also face competition from companies developing therapies using cells other than T cells, such as Athenex, Fate Therapeutics, ImmunityBio, IN8bio, Nkarta Therapeutics and Takeda Pharmaceutical. Other competitors are developing T cells with cytokines, such as Fate Therapeutics and Obsidian Therapeutics. Finally, we also face competition from non-cellular treatments offered by other companies, such as Amgen, AstraZeneca, Bristol-Myers Squibb, Immatics, Immunocore, Incyte, Merck, Mirati and Roche. Additionally, our ability to find partnerships relating to our IL-12 and CAR-T programs may be impacted by substantial competition from these and other biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain regulatory approval of potential TCR products, we may not be the first to market and that may affect the price or demand for our potential products. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication, or fewer side effects, than our potential products or may offer comparable performance at a lower cost. Additionally, the availability and price of our competitors&#x2019; products could limit the demand and the price we are able to charge for our potential products, thereby reducing or eliminating our commercial opportunity. We may not be able to implement our business plan if the acceptance of our potential products is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our potential products, or if physicians switch to other new drug or biologic products or choose to reserve our potential products. Additionally, a competitor could obtain orphan product exclusivity from the FDA with respect to such competitor&#x2019;s product. If such competitor product is determined to be the same product as one of our potential products, that may prevent us from obtaining approval from the FDA for such potential products for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the same indication for seven years, except in limited circumstances. If our potential products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors have products already approved or in development. In addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs or have substantially greater financial resources than we do, as well as significantly greater experience in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing drugs and biopharmaceuticals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undertaking preclinical testing and human clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining FDA and other regulatory approvals of drugs and biopharmaceuticals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">formulating and manufacturing drugs and biopharmaceuticals; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launching, marketing and selling drugs and biopharmaceuticals. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any termination of our licenses with PGEN, MD Anderson or the National Cancer Institute or our research and development agreements with MD Anderson and the National Cancer Institute could result in the loss of significant rights and could harm our ability to develop and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on patents, know-how and proprietary technology that are licensed from others, particularly MD Anderson, PGEN and the NCI, as well as the contributions by MD Anderson under our research and development agreements. Any termination of these licenses or research and development agreements could result in the loss of significant rights and could harm our ability to commercialize our product candidates. Disputes may also arise between us and these licensors regarding intellectual property subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the applicable license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes, and the technology and processes of PGEN, MD Anderson, the NCI and our other licensors, infringe intellectual property of the licensor that is not subject to the applicable license agreement; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties pursuant to our relationships with our licensors and partners; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are complying with our diligence and payment obligations with respect to the use of the licensed technology in relation to our development and commercialization of our potential products under the MD Anderson License, the License Agreement with PGEN and the Patent License with the NCI; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether or not our partners are complying with all of their obligations to support our programs under licenses and research and development agreements; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements, particularly with MD Anderson, PGEN and the NCI, on acceptable terms, we may be unable to successfully develop and commercialize the affected potential products. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize potential products under our applicable licenses could suffer. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. Recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review and post-grant review have been implemented, which adds uncertainty to the possibility of challenge to our or our licensors&#x2019; patents in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to retain the rights licensed to us and PGEN by MD Anderson or the rights licensed to us by the National Cancer Institute to technologies relating to TCR-T cell therapies and other related technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the MD Anderson License, we, together with PGEN, received an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR-T cell and TCR-T cell therapies as well as either co-exclusive or non-exclusive licenses under certain related technologies. These proprietary methods and technologies, along with others within PGEN&#x2019;s technology suite and licensed to us by PGEN, may help realize the promise of genetically modified TCR-T cell therapies by controlling cell expansion and activation in the body, minimizing off-target and unwanted on-target effects and toxicity while maximizing therapeutic efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term, we and PGEN shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After 10 years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if we and PGEN are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if we and PGEN are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us or PGEN, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both us or PGEN and may be terminated by the mutual written agreement of us, PGEN and MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Patent License, we received an exclusive, worldwide license to certain intellectual property and patents from NCI for TCRs we can introduce into T cells using transposon-based genetic engineering. These T cells may be used in our TCR-T Library Phase 1/2 Trial or in subsequent clinical trials, if initiated. The term of the Patent License shall expire with the last of the licensed patents. The NCI could terminate or modify the Patent License if it believes we have materially breached the Patent License, including by failing to meet the defined milestones by the required dates, and have not cured such breach within 90 days of receiving notice of such alleged breach. The NCI may also terminate the Patent License immediately upon our receipt of written notice of certain insolvency events. The Patent License is also subject to certain public use requirements wherein the NCI could require us to sublicense certain product candidates or terminate or modify the Patent License if we do not meet these public use requirements. The Patent License could also be terminated by the NCI if we are unable to pay the required benchmark payments or the annual minimum royalty payments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will be able to successfully perform under the MD Anderson License or the Patent License and if the MD Anderson License or the Patent License is terminated it may prevent us from achieving our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are partly reliant on the National Cancer Institute for research and development and early clinical testing of certain of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A portion of our research and development is being conducted by the NCI under the CRADA entered into in January 2017 and which was amended in March 2018, February 2019, March 2022 and June 2022. Under the CRADA, the NCI, with Dr. Steven A. Rosenberg as the principal investigator, is responsible for conducting a clinical trial using the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">system to express TCRs for the treatment of solid tumors. We have limited control over the nature or timing of the NCI&#x2019;s clinical trial and limited visibility into their day-to-day activities, including with respect to how they are providing and administering T-cell therapy. For example, the research we are funding constitutes only a small portion of the NCI&#x2019;s overall research. Additionally, other research being conducted by Dr. Rosenberg may at times receive higher priority than research on our program. The progress and timeline, including the timeline for dosing patients, for this trial are under the control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CRADA expired by its terms on January 9, 2022. In March 2022, we entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, we entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025.  In connection with the CRADA Fourth Amendment, we agreed to contribute $1.0 million per year, payable on a quarterly basis, beginning in the first quarter of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to commercialize any products, generate significant revenues, or attain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, none of our product candidates have been approved for commercial sale in any country. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. Unless and until we receive approval from the FDA and/or other foreign regulatory authorities for our product candidates, we cannot sell our products and will not have product revenues. Even if we obtain regulatory approval for one or more of our product candidates, if we are unable to successfully commercialize our products, we may not be able to generate sufficient revenues to achieve or maintain profitability or to continue our business without raising significant additional capital, which may not be available. Our failure to achieve or maintain profitability could negatively impact the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating history makes it difficult to evaluate our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not previously completed any pivotal clinical trials, submitted a BLA or demonstrated an ability to perform the functions necessary for the successful commercialization of any product candidates. The successful commercialization of any product candidates will require us to perform a variety of functions, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuing to undertake preclinical development and clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participating in regulatory approval processes; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Formulating and manufacturing products; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conducting sales and marketing activities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary product candidates and undertaking preclinical and clinical trials of our product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in establishing development and commercialization collaborations, which failure could adversely affect, and potentially prohibit, our ability to develop our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing biopharmaceutical products and complementary technologies, conducting clinical trials, obtaining marketing approval, establishing manufacturing capabilities and marketing approved products is expensive, and therefore, we anticipate exploring collaborations with third parties that have alternative technologies, more resources and more experience than we do. In situations where we enter into a development and commercial collaboration arrangement for a product candidate or complementary technology, we may also seek to establish additional collaborations for development and commercialization in territories outside of those addressed by the first collaboration arrangement for such product candidate or technology. There are a limited number of potential partners, and we expect to face competition in seeking appropriate partners. If we are unable to enter into any development and commercial collaborations and/or sales and marketing arrangements on reasonable and acceptable terms, if at all, we may be unable to successfully develop and seek regulatory approval for our product candidates and/or effectively market and sell future approved products, if any, in some or all of the territories outside of the United States where it may otherwise be valuable to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to successfully manage our growth as we expand our development and regulatory capabilities, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we advance our product candidates to the point of, and through, clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide for these capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To manage this growth, we must expand our facilities, augment our operational, financial and management systems and hire and train additional qualified personnel with expertise in preclinical and clinical research and testing, manufacturing, government regulation and eventually sales and marketing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business will subject us to the risk of liability claims associated with the use of hazardous materials and chemicals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our contract research and development activities may involve the controlled use of hazardous materials and chemicals. Although we believe that our safety procedures for using, storing, handling and disposing of these materials comply with federal, state and local laws and regulations, we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event of such an accident, we could be held liable for any resulting damages, and any liability could have a materially adverse effect on our business, financial condition, and results of operations. In addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require our contractors to incur substantial compliance costs that could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The testing and marketing of medical products entail an inherent risk of product liability, and we will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decreased demand for our product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injury to our reputation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of prior governmental approvals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs of related litigation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantial monetary awards to patients; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product recalls; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of revenue; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The inability to commercialize our product candidates; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A decline in our share price. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we currently carry clinical trial insurance and product liability insurance which we believe to be reasonable, it may not be adequate to cover all liability that we may incur. An inability to renew our policies or to obtain sufficient insurance at an acceptable cost could prevent or inhibit the commercialization of pharmaceutical products that we develop, alone or with collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our clinical investigators, contractors and consultants, are based primarily in Houston, Texas. These operations could be subject to power shortages, telecommunications failures, water shortages, hurricanes, floods, earthquakes, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we maintain customary insurance policies that we believe are appropriate. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to manufacture clinical supplies of our product candidates could be disrupted if our own operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption. We may have limited recourse against third parties if the non-compliance is due to factors outside of the manufacturer&#x2019;s control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to find appropriate partners to continue the development of the product candidates we de-prioritized in 2021, which may prevent us from ever deriving meaningful revenue from them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we elected to prioritize our Library TCR-T program and significantly reduced our activities in connection with our Controlled IL-12 and CAR-T programs to preserve our capital resources. The decision to significantly reduce activities for our Controlled IL-12 and CAR-T programs may negatively impact the potential for these programs, which could have a material adverse effect on our business. We are actively exploring partnership opportunities for our Controlled IL-12 and CAR-T programs to support their continued development. If we are unable to identify an appropriate strategic partner or to negotiate and consummate a license or sale agreement with such a partner, it will be difficult to advance the development of these two programs, increasing the likelihood that we may be unable to derive any meaningful revenue from these assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also mutually agreed with TriArm Therapeutics Ltd., or TriArm, to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity is in the process of being dissolved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our contract manufacturers, CROs, shippers and others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be adversely affected by health epidemics wherever we have clinical trial sites or other business operations. In addition, health epidemics could cause significant disruption in our manufacturing operations or the operations of third-party manufacturers, CROs and other third parties upon whom we rely or may rely on in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend on a worldwide supply chain to manufacture products used in our preclinical studies and clinical trials. Quarantines, shelter-in-place and similar government orders, or the expectation that such orders, shutdowns or other restrictions could occur, whether related to COVID-19 or other infectious diseases, could impact personnel at our own manufacturing facilities or third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our relationships with our suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Switching or adding additional suppliers or vendors involves substantial cost and requires management&#x2019;s time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our preclinical studies and our ongoing TCR-T Library Phase 1/2 Trial at MD Anderson have been, and may continue to be, affected by the COVID-19 pandemic. Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, have been, and may continue to be, delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, if we are unable to successfully recruit and retain patients, principal investigators, and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state, our clinical trial operations could be adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO THE CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have experienced, and may continue to experience, difficulties in patient enrollment in our ongoing TCR-T Library Phase 1/2 Trial and any future clinical trials, for a variety of reasons, including impacts that have resulted or may result from the COVID-19 pandemic. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the clinical trial until its conclusion. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patient eligibility criteria defined in the clinical trial protocol;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The size of the patient population required for analysis of the clinical trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The proximity of patients to clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The design of the clinical trial;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to recruit and retain clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reporting of the preliminary results of any of our clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient insurance approvals of trial participation; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk that patients enrolled in clinical trials will drop out of the clinical trials before the manufacturing and infusion of our product candidates or clinical trial completion.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some of our potential patients may instead opt to enroll in a clinical trial being conducted by one of our competitors. In addition, patients may be unwilling to participate in our studies because of negative publicity from adverse events in the biotechnology industry or for other reasons. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because our clinical trial is in, and our future clinical trials may be in, patients with relapsed/refractory cancer, the patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial, which would require additional patient enrollment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in completing patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these clinical trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. The process of obtaining regulatory approval is expensive and often takes many years following the commencement of clinical trials. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Regulatory approval is never guaranteed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective, or with respect to a biological product candidate, safe, pure and potent, for their intended uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may disagree with the design or implementation of our or our current or future collaborators&#x2019; clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs or biologics similar to our therapeutic product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, or any of our current or future collaborators, may be unable to demonstrate that a product candidate is safe and effective, and that the therapeutic product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of such authorities that our companion diagnostics are suitable to identify appropriate patient populations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, NDA, premarket approval, or PMA, or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may find deficiencies in the manufacturing processes, test procedures and specifications or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulations and approval policies of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#x2019; clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we obtain regulatory approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request and may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs or biologics based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are very early in our development efforts. Our most advanced product candidates are only in an early-stage clinical trial, which is very expensive and time-consuming. We cannot be certain when we will be able to submit a BLA to the FDA and any failure or delay in completing clinical trials for our product candidates could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are in various stages of development and require extensive clinical testing. Our most advanced product candidates are in our TCR-T Library Phase 1/2 Trial, which is currently enrolling and dosing patients. Human clinical trials are very expensive and difficult to design, initiate and implement, in part because they are subject to rigorous regulatory requirements. Notwithstanding our current clinical trial plans for each of our existing product candidates, which we estimate will take several years to complete, we may not be able to commence additional trials or see results from these trials within our anticipated timelines. Failure can occur at any stage of a clinical trial, and we can encounter problems that cause us to delay the start of, abandon or repeat clinical trials. Some factors which may lead to a delay in the commencement or completion of our clinical trials include: requests for additional nonclinical data from regulators, unforeseen safety issues, dosing issues, lack of effectiveness during clinical trials, difficulty recruiting or monitoring patients, or difficulty manufacturing clinical products, among other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As they enter later stages of development, our product candidates generally will become subject to more stringent regulatory requirements, including the FDA&#x2019;s requirements for chemistry, manufacturing and controls for product candidates entering Phase 3 clinical trials. There is no guarantee the FDA will allow us to commence Phase 3 clinical trials for product candidates studied in earlier clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA does not allow our product candidates to enter later stage clinical trials or requires changes to the formulation or manufacture of our product candidates before commencing Phase 3 clinical trials, our ability to further develop, or seek approval for, such product candidates may be materially impacted. As such, we cannot predict with any certainty if or when we might submit a BLA for regulatory approval of our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates or whether such a BLA will be accepted. Because we do not anticipate generating revenues unless and until we submit one or more BLAs and thereafter obtain requisite FDA approvals, the timing of our BLA submissions and FDA determinations regarding approval thereof will directly affect if and when we are able to generate revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with many pharmaceutical and biological products, treatment with our product candidates may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release. If our product candidates or similar products or product candidates under development by third parties demonstrate unacceptable adverse events, we may be required to halt or delay further clinical development of our product candidates. The FDA or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. If a serious adverse event were to occur in our TCR-T Library Phase 1/2 Trial, the FDA may place a hold on the clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidates to understand their side effect profiles, both for our planned clinical trials and upon any commercialization of any product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in adverse effects to patients, including death. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product candidates, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw approvals of such product; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the product&#x2019;s label; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our cellular therapy immuno-oncology product candidates rely on the availability of reagents, specialized equipment and other specialty materials and infrastructure, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing our product candidates requires many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates, including DNA plasmids, which are used as the vector to insert our TCRs into human T cells. Some of these suppliers may not have the capacity to support commercial products manufactured under current good manufacturing practices by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with some of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For some of these reagents, equipment, infrastructure and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, or source product on commercially reasonable terms, which could be due to, among other things, regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, supply chain issues or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our ability to conduct clinical trials, which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, some of the reagents and products used by us may be stored at a single vendor. The loss of materials located at a single vendor, or the failure of such a vendor to manufacture clinical product in accordance with our specifications, would impact our ability to conduct ongoing or planned clinical trials and continue the development of our products. Further, manufacturing replacement material may be expensive and require a significant amount of time, which may further impact our clinical programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain additional rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to maintain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical trials, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we are dependent, at least in part, upon clinical research institutions and other CROs for clinical testing and/or for research and development activities, the results of our clinical trials and such research activities are, to a certain extent, beyond our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We materially rely upon independent investigators and collaborators, such as universities and medical institutions, to conduct our clinical trials under agreements with us. In addition, we hire CROs to help us manage clinical trials, collect data and analyze clinical samples. These collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our product development programs, or if their performance is substandard, the approval of our FDA applications, if any, and our introduction of new products, if any, will be delayed. These institutions may also have, or implement in the future, policies and procedures that limit their ability to advance our programs. These collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors to our detriment, our competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have limited experience producing and supplying our product candidates. We may be unable to consistently manufacture our product candidates to the necessary specifications or in quantities necessary to treat patients in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited experience in biopharmaceutical manufacturing. In 2021, we began manufacturing our product candidates at our in-house current good manufacturing practices, or cGMP, manufacturing facility at our leased headquarters in Houston, Texas. Our ability to manufacture our product candidates depends on our finding and retaining personnel with the appropriate background and training to staff and operate the facility on a daily basis. Should we be unable to find or retain these individuals, we may need to train additional personnel to fill the needed roles or engage with external contractors. There are a small number of individuals with experience in cell therapy and the competition for these individuals is high.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifically, the operation of a cell-therapy manufacturing facility is a complex endeavor requiring knowledgeable individuals who have successful previous experience in cleanroom environments. Cell therapy facilities, like other biological agent manufacturing facilities, require appropriate commissioning and validation activities to demonstrate that they operate as designed. Additionally, each manufacturing process must be proven through the performance of process validation runs to guarantee that the facility, personnel, equipment, and process work as designed. Although we have developed our own manufacturing processes using an in-house team, there is timing risk associated with increased in-house product manufacture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacture of our product candidates is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in our manufacturing facilities, the manufacturing facilities may need to be closed for an extended period to investigate and remedy the contamination. It is possible that stability or other issues relating to the manufacture of our product candidates could occur in the future. We recently amended our clinical trial IND to use cryopreservation-based storage of clinical products. This process is new and we may experience manufacturing failures or difficulties producing sufficient quantities of our clinical products as a result of this change.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates currently are, and will continue to be, manufactured on a patient-by-patient basis. Delays in manufacturing could adversely impact the treatment of each patient and may discourage participation in our current or future clinical trials. We have not yet manufactured our clinical trial product candidates on a large scale and may not be able to achieve large scale clinical trial or commercial manufacturing and processing on our own to satisfy expected clinical trial or commercial demands for any of our product candidates. While we believe that our current manufacturing and processing approaches are appropriate to support our early-stage clinical product development, we have limited experience in managing the T cell engineering process, and our processes may be more difficult or more expensive than anticipated. The manufacturing processes employed by us may not result in product candidates that will be safe and effective. If we are unable to manufacture sufficient number of TCR-T cells for our product candidates, our development efforts would be delayed, which would adversely affect our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufacturing operations are subject to review and oversight by the FDA. We are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. Our license to manufacture product candidates is subject to continued regulatory review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of commercial manufacturing and processing of our product candidates. The actual cost to manufacture and process our product candidates at commercial scale could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also may fail to manage the logistics of collecting and shipping patient material to our manufacturing site and shipping the product candidate back to the patient. Logistical and shipment delays and problems, whether or not caused by us or our vendors, could prevent or delay the delivery of product candidates to patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may have difficulty validating our manufacturing process as we manufacture our product candidates from an increasingly diverse patient population for our clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During our development of the manufacturing process, our TCR-T cell product candidates have demonstrated consistency from lot to lot and from donor to donor. However, our sample size is small and the starting material used during our preclinical development work came from healthy donors. As we work with white blood cells taken from our patient population, we may encounter unforeseen difficulties due to starting with material from donors who are not healthy, including challenges inherent in harvesting white blood cells from unhealthy patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we believe our current manufacturing process is scalable for our clinical development and commercialization, if any of our product candidates are approved or commercialized, we may encounter challenges in validating our process due to the heterogeneity of the product starting material. However, we anticipate that during the early phases of our clinical trials we will be able to adapt our process to account for these differences, resulting in a more robust process. We cannot guarantee that any other issues relating to the heterogeneity of the starting material will not impact our ability to commercially manufacturing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The gene transfer vectors from our Sleeping Beauty system used to manufacture our product candidates may incorrectly modify the genetic material of a patient&#x2019;s T cells, potentially triggering the development of a new cancer or other adverse events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T cells are manufactured using our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> system, a non-viral vector to insert genetic information encoding the TCR construct into the patient&#x2019;s T cells. The TCR construct is then primarily integrated at thymine-adenine, or TA, dinucleotide sites throughout the patient&#x2019;s genome and, once expressed as protein, is transported to the surface of the patient&#x2019;s T cells. Because the gene transfer vector modifies the genetic information of the T cell, there is a theoretical risk that modification will occur in the wrong place in the T cell&#x2019;s genetic code, leading to vector-related insertional oncogenesis, and causing the T cell to become cancerous. If the cancerous T cell is then administered to the patient, the cancerous T cell could trigger the development of a new cancer in the patient. We use non-viral vectors to insert genetic information into T cells, which we believe have a lower risk of insertional oncogenesis as opposed to viral vectors. However, the risk of insertional oncogenesis remains a concern for gene therapy, and we cannot assure you that it will not occur in any of our ongoing or planned clinical trials. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of the vectors used to carry the genetic material. Although we use non-viral vectors, the FDA has stated that lentiviral vectors possess characteristics that may pose high risks of delayed adverse events. If any such adverse events occur from our non-viral vector, further advancement of our preclinical studies or clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a restricted distribution system. If any of our product candidates receives marketing approval, the accompanying label may limit the approved uses, which could limit sales of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. The FDA closely regulates the post-approval marketing and promotion of products to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Litigation involving patients taking our product; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warning letters; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recall of products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Damage to relationships with existing and potential collaborators; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product seizure; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncompliance with requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with U.S. and foreign regulatory requirements regarding the development of products for pediatric populations and the protection of personal health information can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate, our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to obtain the approvals necessary to commercialize our product candidates, or any product candidate that we may acquire or develop in the future for commercial sale. We will need FDA approval to commercialize our product candidates in the United States and approvals from regulatory authorities in foreign jurisdictions equivalent to the FDA to commercialize our product candidates in those jurisdictions. In order to obtain FDA approval of any product candidate, we must submit to the FDA a BLA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. Satisfaction of the FDA&#x2019;s regulatory requirements typically takes many years, depending upon the type, complexity and novelty of the product candidate, and will require substantial resources for research, development and testing. We cannot predict whether our research, development and clinical approaches will result in products that the FDA will consider safe for humans and effective for their intended uses. The FDA has substantial discretion in the approval process and may require us to conduct additional preclinical studies and clinical trials or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delay commercialization of, and our ability to derive product revenues from, our product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impose costly procedures on us; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diminish any competitive advantages that we may otherwise enjoy. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our BLAs. We cannot be sure that we will ever obtain regulatory approval for any of our product candidates. Failure to obtain FDA approval for our product candidates will severely undermine our business by leaving us without a marketable product, and therefore without any potential revenue source, until another product candidate can be developed. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will obtain FDA approval if we are able to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In foreign jurisdictions, we similarly must receive approval from applicable regulatory authorities before we can commercialize any of our product candidates. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no marketing, sales or distribution capabilities. If and when we become reasonably certain that we will be able to commercialize our current or future product candidates, we anticipate allocating resources to the marketing, sales and distribution of our proposed products in North America and in certain other geographies; however, we cannot assure that we will be able to market, sell, and distribute our products successfully. Our future success also may depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities and to encourage the collaborator&#x2019;s strategic interest in the product candidates under development, and such collaborator&#x2019;s ability to successfully market and sell any such products. Although we intend to pursue certain collaborative arrangements regarding the sale and marketing of certain of our product candidates, there are no assurances that we will be able to establish or maintain collaborative arrangements or, if we are able to do so, whether we would be able to conduct our own sales efforts. There can also be no assurance that we will be able to establish or maintain relationships with third-party collaborators or develop in-house sales and distribution capabilities. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful. In addition, there can also be no assurance that we will be able to market and sell our product candidates in the United States or overseas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to partner with a third party and are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our product candidates, which would harm our business. If we rely on pharmaceutical or biotechnology companies with established distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenues we receive will depend upon the efforts of third parties that may not be successful and that will be only partially in our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the FDA and/or foreign equivalents thereof approve our product candidates, physicians and patients may not accept and use them. The use of engineered T cells as potential cancer treatments is a relatively recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. Acceptance and use of our products will depend upon a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacological benefit and cost-effectiveness of our products relative to competing products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Availability of coverage and adequate reimbursement for our products from government or other third-party payors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The price at which we sell our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we expect sales of our current product candidates, if approved, to generate substantially all of our product revenues for the foreseeable future, the failure of a product to find market acceptance would harm our business and could require us to seek additional financing in order to fund the development of future product candidates. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to commercialize our product candidates, if approved, alone or with collaborators, will depend in part on the extent to which coverage and reimbursement will be available from third-party payors, including government and health administration authorities, private health maintenance organizations and health insurers and other payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Sufficient coverage and adequate reimbursement from third-party payors are critical to new product acceptance. Coverage decisions may depend upon clinical and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. It is difficult to predict the coverage and reimbursement decisions that will be made by third-party payors for novel gene and cell therapy products such as ours. Even if we obtain coverage for our product candidates, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#x2019; drug formularies or lists of medications for which third-party payors provide coverage and reimbursement, which might not include all of the FDA-approved drugs for a particular indication. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that would require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that approval will be obtained. If we are unable to obtain coverage of and adequate payment levels for our product candidates, if approved, from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer our products and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition and future success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in many foreign countries, particularly the countries of the EU, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, hormone therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates as a third line therapy for patients who have failed other approved treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Our market opportunities may also be limited by competitor treatments that may enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory enactments in recent years that change the healthcare system in ways that could impact our future ability to sell our product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, there have been and continue to be a number of initiatives at the federal and state level that seek to reduce healthcare costs. Most significantly, in March 2010, President Obama signed into law the ACA, which included measures that have significantly changed the way healthcare is financed by both governmental and private insurers. The ACA, among other things, imposed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees on manufacturers and importers of certain branded prescription drugs and biologic agents, promoted a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#x2019; interactions with healthcare practitioners. The ACA also expanded eligibility for Medicaid programs and introduced a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research and a new Center for Medicare &amp; Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, legal and political challenges to certain aspects of the ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. In December 2017, Congress repealed the tax penalty, effective January 1, 2019, for an individual&#x2019;s failure to maintain ACA-mandated health insurance as part of the Tax Act. Further, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. For example, on August 16, 2022, President Biden signed the IRA into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#34;donut hole&#34; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and implementing a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact ACA and our business. The ultimate content, timing or effect of any healthcare reform measures on the U.S. healthcare industry is unclear.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. As a result, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#x2019;s proposals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 30, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The IRA delayed the implementation of the rule to January 1, 2032. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2032. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate price cap, currently set at 100% of a drug's average manufacturer price for single source and innovator multiple source products, beginning on January 1, 2024. Further, in July 2021, the Biden Administration released an executive order that included multiple provisions aimed at prescription drugs. In response to Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug price reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions by HHS. No legislative or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Individual states in the United States also have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other healthcare reforms may prevent us from being able to generate revenue, attain profitability or, if we receive regulatory approval, commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#x2019; rights are and will be applicable to our business. For example, we could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute, which regulates our business activities, including our clinical research and relationships with healthcare providers or other entities as well as our future marketing practices, educational programs and pricing policies, and by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal civil and criminal false claims laws, including the False Claims Act, which permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which created new federal civil and criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HITECH, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities and individuals subject to the law including certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates and their subcontractors that use, disclose or otherwise process individually identifiable health information; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requirements under the Physician Payments Sunshine Act to report annually to CMS certain financial arrangements with prescribers and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any &#x201c;transfer of value&#x201d; made or distributed to teaching hospitals, and physicians, as defined by such law and reporting any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#x2019;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities, including any consulting agreements with physicians who may receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has further strengthened these laws. For example, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that any of our product candidates is ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that our business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, exclusion from participation in United States federal or state health care programs, such as Medicare and Medicaid, disgorgement, imprisonment, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. Although compliance programs can</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars and/or new technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, provides an abbreviated pathway for the approval of follow-on biological products. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. However, there is a risk that the U.S. Congress could amend the BPCIA to significantly shorten this exclusivity period, potentially creating the opportunity for generic competition sooner than anticipated. Further, this data exclusivity does not prevent another company from developing a product that is highly similar to the original branded product, generating its own data and seeking approval. Data exclusivity only assures that another company cannot rely upon the data within the innovator&#x2019;s application to support the biosimilar product&#x2019;s approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we, our CROs and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Although we have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates, we cannot guarantee that those measures will be successful in preventing any such security incident. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare Company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. If the technology supporting our hunTR discovery engine were to experience a cyber-incident resulting in the disclosure or theft of our proprietary screening software or library of TCRs our business may be materially and negatively impacted. While we are not aware of any such material system failure, accident or security breach to date, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research, development and commercialization efforts could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success, competitive position and future revenues will depend in part on our ability and the abilities of our licensors to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve confidential information, including trade secrets, to prevent third parties from infringing our proprietary rights, and to operate without infringing the proprietary rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have exclusive rights in the field of cancer treatment to certain U.S. and foreign intellectual property with respect to certain cell therapy and related technologies from MD Anderson and the NCI, as well as with respect to the PGEN technology, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the MD Anderson License, future patent applications require the agreement of each of MD Anderson, PGEN and us, and MD Anderson has the right to control the preparation, filing and prosecution of such patent applications unless the parties agree that we or PGEN instead may control such activities. Although under the MD Anderson License MD Anderson has agreed to review and incorporate any reasonable comments that we or PGEN may have regarding licensed patents and patent applications, we cannot guarantee that our comments will be solicited or implemented. Under the Patent License with the NCI for certain TCRs, the NCI is responsible for the preparation, filing, prosecution and maintenance of patent applications and patents licensed to us. Although under the Patent License the NCI is required to consult</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with us in the preparation, filing, prosecution and maintenance of all its patent applications and patents licensed to us, we cannot guarantee that our comments will be solicited or implemented. Under our License Agreement with PGEN, PGEN has the right, but not the obligation, to prepare, file, prosecute and maintain the patents and patent applications licensed to us and shall bear all related costs incurred by it in regard to those actions. PGEN is required to consult with us and keep us reasonably informed of the status of the patents and patent applications licensed to us, and to confer with us prior to submitting any related filings and correspondence. Although under the License Agreement PGEN has agreed to consider in good faith and consult with us regarding any comments we may have regarding these patents and patent applications, we cannot guarantee that our comments will be solicited or followed. Without direct control of the in-licensed patents and patent applications, we are dependent on MD Anderson, the NCI or PGEN, as applicable, to keep us advised of prosecution, particularly in foreign jurisdictions where prosecution information may not be publicly available. We anticipate that we, the NCI and PGEN will file additional patent applications both in the United States and in other jurisdictions. However, we cannot predict or guarantee for either our in-licensed patent portfolios or for Alaunos&#x2019; patent portfolio:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When, if at all, any patents will be granted on such applications;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope of protection that any patents, if obtained, will afford us against competitors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That third parties will not find ways to invalidate and/or circumvent our patents, if obtained; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That others will not obtain patents claiming subject matter related to or relevant to our product candidates; or </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That we will not need to initiate litigation and/or administrative proceedings that may be costly whether we win or lose. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of other jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, methods of therapeutic treatment, which are patent-eligible in the United States, may not be claimed in many other jurisdictions; some patent offices (such as the European Patent Office) may permit the redrafting of method of treatment claims into a &#34;medical use&#34; format that is patent-eligible, while other patent offices (such as the Indian Patent Office) may not accept any redrafted claiming format for such claims.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in patent laws or in interpretations of patent laws in the United States and other jurisdictions may diminish the value of our intellectual property or narrow the scope of our patent protection. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, resulting in a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In addition, the United States Supreme Court has ruled on several patent cases in recent years, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the value of patents, once obtained, and with regard to our ability to obtain patents in the future. As the USPTO continues to implement the Leahy-Smith Act, and as the federal courts have the opportunity to interpret the Leahy-Smith Act, the laws and regulations governing patents, and the rules regarding patent procurement could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain technologies utilized in our research and development programs are already in the public domain. Moreover, a number of our competitors have developed technologies, or filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and may cover or conflict with our owned or licensed patent applications, technologies or product candidates. Such conflicts could limit the scope of the patents, if any, that we may be able to obtain. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases at all, and because publications of discoveries in the scientific literature lag behind actual discoveries per se, neither we nor our licensors can be certain that others have not filed patent applications for technology used by us or covered by our pending patent applications. We cannot know with certainty whether we were the first to make and file for the inventions claimed in our owned patent portfolio, or whether our licensors were the first to make and file for the inventions claimed in our in-licensed patent portfolio. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in the issuance of patents that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. In addition, our own earlier filed patents and applications or those of MD Anderson, the NCI or PGEN may limit the scope of later patents we obtain, if any. If third parties file or have filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and that cover or conflict with our owned or licensed patent applications, technologies or product candidates, we may be required to challenge such protection, terminate or modify our programs impacted by such protection, or obtain licenses from such third parties, which might not be available on acceptable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our owned and licensed patent applications were to be issued as patents, they may not issue in a form that would provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity due to our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or even after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our confidential information, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors, as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, and to maintain our competitive position, we rely on trade secret protection and confidentiality agreements. To this end, it is our general policy to require our employees, consultants, advisors and contractors to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements may not provide adequate protection for our trade secrets, know-how, confidential information or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information. Moreover, we may not be able to obtain adequate remedies for any breaches of these agreements. Our trade secrets or other confidential information may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or other confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets or other confidential information were to be lawfully obtained or independently developed by competitors, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to protect or enforce patent rights, we may initiate patent infringement litigation against third parties. Similarly, we may be sued by others for patent infringement. We also may become subject to pre- and post-grant proceedings conducted in the USPTO, including interferences, derivations, post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review, or reexamination. In other jurisdictions, our patent estate may be subject to pre- and post-grant opposition, nullity, revocation proceedings and the like. Asserting and defending against intellectual property actions are costly and divert technical and management personnel away from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#x2019;s intellectual property rights, we cannot guarantee that our products or use of our products do not infringe or will not be asserted to infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications, or that as-yet unpublished third-party patent applications will later result in the grant of patents relevant to our business. Another possibility is for a third-party patent or patent application to first contain claims not relevant to our business but then to be reissued or amended in such a way that it does become relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be asserted to infringe patents or patent applications under which we do not hold licenses or other rights. Owning a patent does not confer on the patentee the right to practice the claimed invention and does not protect the patentee from being sued for infringement of another owner&#x2019;s patent. Our patent position cannot and does not provide any assurance that we are not infringing or will not be asserted to infringe the patent rights of another.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent landscape in the field of immuno-oncology is particularly complex. We are aware of numerous United States and foreign patents and pending patent applications of third parties directed to compositions, methods of use and methods of manufacture of immuno-oncology products. In addition, there may be patents and patent applications in the field of which we are not aware. The technology we license from MD Anderson, the NCI and PGEN is early-stage technology, and we are in the process of designing and developing products using this technology. Although we will seek to avoid pursuing the development of products that may infringe any third-party patent claims that we believe to be valid and enforceable, we may fail to do so. Moreover, given the breadth and number of claims in patents and pending patent applications in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the field of immuno-oncology and the complexities and uncertainties associated with them, third parties may allege that we are infringing patent claims even if we do not believe such claims have merit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a claim for patent infringement is asserted, there can be no assurance that the resolution of the claim would permit us to continue marketing the relevant product on commercially reasonable terms, if at all. We may not have sufficient resources to bring these actions to a successful conclusion. If we do not successfully defend any infringement actions to which we become a party or if we are unable to have any asserted third-party patents declared invalid or unenforceable, we may have to pay substantial monetary damages, which can be tripled if the infringement is deemed willful, and/or we may be required to discontinue or significantly delay commercialization and development of the affected products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any legal action against us or our collaborators claiming damages and seeking to enjoin developmental or marketing activities relating to affected products could, in addition to subjecting us to potential liability for damages, require us or our collaborators to obtain licenses to continue to develop, manufacture or market the affected products. Such licenses may not be available to us on commercially reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An adverse determination in a proceeding involving our owned or licensed intellectual property may allow entry in the market of substitutes, including biosimilar or generic substitutes, for our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annuities and other similar fees must be paid to the respective patent authority to maintain patents (or patents and patent applications) in most jurisdictions worldwide. Further, patent authorities in jurisdictions worldwide require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to submit documents with the necessary formal requirements, such as notarization and legalization. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We license rights to products and technology that are important to our business, and we expect to enter into additional licenses in the future. For instance, we have in-licensed patents and patent applications under the MD Anderson License, the Patent License, and the License Agreement. Under these agreements, we are subject to a range of obligations pertaining to commercialization and development, sublicensing, royalty, patent prosecution and maintenance, and insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure by us to obtain a needed license, comply with any of these obligations or any other breach by us of our license agreements could give the licensor the right to terminate the license in whole, terminate the exclusive nature of the license or bring a claim against us for damages. Any such termination or claim could have a material adverse effect on our financial condition, results of operations, liquidity or business. Even if we contest any such termination or claim and are ultimately successful, such dispute could lead to delays in the development or commercialization of potential products and result in time-consuming and expensive litigation or arbitration. On termination we may be required to license to the licensor any related intellectual property that we developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in certain cases, the rights licensed to us are rights of a third party licensed to our licensor. In such instances, if our licensors do not comply with their obligations under such licenses, our rights under our license agreements with our licensor may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#x2019;s former employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTHER RISKS RELATED TO OUR COMPANY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our stock price has been, and may continue to be, volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price for our common stock is volatile and may fluctuate significantly in response to a number of factors, most of which we cannot control, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price and volume fluctuations in the overall stock market; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating results and performance and stock market valuations of other biopharmaceutical companies generally, or those that develop and commercialize cancer drugs in particular; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market conditions or trends in our industry or the economy as a whole; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies or clinical trial results; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public statements by third parties like trial participants and clinical investigators regarding our current or future clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public concern as to the safety of drugs developed by us or others; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial or operational projections we may provide to the public, any changes in these projections or our failure to meet these projections; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comments by securities analysts or changes in financial estimates or ratings by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The public&#x2019;s response to press releases or other public announcements by us or third parties, including our filings with the SEC, as well as announcements of the status of development of our products, announcements of technological innovations or new therapeutic products by us or our competitors, announcements regarding collaborative agreements and other announcements relating to product development, litigation and intellectual property impacting us or our business; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government regulation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA determinations on the approval of a product candidate BLA submission; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The sustainability of an active trading market for our common stock; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future sales of our common stock by us, our executive officers, directors and significant stockholders; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements of mergers or acquisition transactions; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inclusion or deletion from certain stock indices; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developments in patent or other proprietary rights; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in reimbursement policies; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements of medical innovations or new products by our competitors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements of changes in our senior management or directors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General economic, industry, political and market conditions, including, but not limited to, the ongoing impact of global economic conditions; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other events or factors, including those resulting from war, incidents of terrorism, natural disasters, pandemics or responses to these events; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in accounting principles.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general and our stock in particular from time to time experiences significant price and volume fluctuations unrelated to the operating performance of particular companies, including in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Public debt and equity markets, and in particular the Nasdaq Global Select Market, have experienced extreme price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources, and the attention of management could be diverted from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public statements made by third parties such as trial participants and clinical investigators about our current or future clinical trials without our consent may adversely impact our stock price. We may not be aware of these third-party statements when made, may not be able to respond to these third-party statements and may not be able to defend our business or the public&#x2019;s legitimate interests due to restrictions on what we may say about our product candidates, which may cause the price of our stock to fluctuate. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to satisfy applicable listing standards, our common stock may be delisted from the Nasdaq Global Select Market. Delisting could prevent us from maintaining an active, liquid and orderly trading market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from the Nasdaq Global Select Market or if we are unable to transfer our listing to another stock market. On January 4, 2023, we were notified by The Nasdaq Stock Market LLC, or Nasdaq, that we were in breach of Listing Rule 5450(a)(1), or the Minimum Bid Price Rule, for continued listing on the Nasdaq Global Select Market because the minimum bid price of our listed securities for 30 consecutive business days had been less than $1 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), or the Compliance Period Rule, we have been provided a period of 180 calendar days, or until July 3, 2023, or the Compliance Date, to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, Nasdaq will provide us written notification that we have regained compliance with the Bid Price Requirement, unless Nasdaq exercises its discretion to extend this ten-day period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During this 180-day period, we anticipate reviewing our options to regain compliance with the Minimum Bid Price Rule, including conducting a reverse stock split. On March 2, 2023, the closing price of our common stock was $0.57 per share. If we are unable to continue to meet the requirements for listing on the Nasdaq Global Select Market we may apply to Nasdaq to list our common stock on the Nasdaq Capital Market, which may also provide us up to an additional 180 days to regain compliance with the Minimum Bid Price Rule. Nasdaq would have to accept our application to list on the Nasdaq Capital Market and we would need to show our compliance with the other listing standards and provide Nasdaq written notice of our intention to cure the Bid Price deficiency. Should Nasdaq determine that we are not eligible to list on the Nasdaq Capital Market or we elect not to submit an application to transfer to the Nasdaq Capital Market, we will receive written notice that our common stock will be delisted, at which point we will have the opportunity to appeal that decision. If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, deterring broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our common stock is delisted by Nasdaq, the price of our common stock may decline, and although our common stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. Further, if our common stock is delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our shareholders to sell our common stock in the secondary market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions authorize the issuance of &#x201c;blank check&#x201d; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover attempt, and limit who may call a special meeting of stockholders. In addition, Section 203 of the Delaware General Corporation Law, or Section 203, generally prohibits a publicly held Delaware corporation from engaging in a business combination with a party that owns at least 15% of its common stock unless the business combination is approved by our board of directors before the person acquires the 15% ownership</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stake or later by its board of directors and two-thirds of its stockholders. Section 203 could have the effect of delaying, deferring or preventing a change in control that our stockholders might consider to be in their best interests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the amended and restated certificate of incorporation or our bylaws; (v) any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware; or (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never paid dividends on our common stock, and we do not anticipate that we will pay any dividends for the foreseeable future. Accordingly, any return on an investment in us will be realized, if at all, only when you sell shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have generated significant net operating loss carryforwards, or NOLs, and research and development tax credits, or R&amp;D credits, as a result of our incurrence of losses and our conduct of research activities since inception. We generally are able to carry NOLs and R&amp;D credits forward to reduce our tax liability in future years. However, our ability to utilize the NOLs and R&amp;D credits is subject to the rules of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, respectively. Those sections generally restrict the use of NOLs and R&amp;D credits after an &#x201c;ownership change.&#x201d; An ownership change occurs if, among other things, the stockholders (or specified groups of stockholders) who own or have owned, directly or indirectly, 5% or more of a corporation&#x2019;s common stock or are otherwise treated as 5% stockholders under Section 382 of the Code and the U.S. Treasury Department regulations promulgated thereunder increase their aggregate percentage ownership of that corporation&#x2019;s stock by more than 50 percentage points over the lowest percentage of the stock owned by these stockholders over the applicable testing period. In the event of an ownership change, Section 382 of the Code imposes an annual limitation on the amount of taxable income a corporation may offset with NOL carry forwards and Section 383 of the Code imposes an annual limitation on the amount of tax a corporation may offset with business credit (including R&amp;D credits) carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may have experienced an &#x201c;ownership change&#x201d; within the meaning of Section 382 of the Code in the past and there can be no assurance that we will not experience additional ownership changes in the future. As a result, our NOLs and business credits (including R&amp;D credits) may be subject to limitations, and we may be required to pay taxes earlier and in larger amounts than would be the case if our NOLs or R&amp;D credits were freely usable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely or if our results of operations do not meet their expectations, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be negatively affected as a result of the actions of activist stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we were engaged in a consent solicitation led by WaterMill Asset Management Corp., or WaterMill, where three new directors were added to our board of directors. We could experience other stockholder activism in the future, including another consent solicitation or a proxy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contest. Activist shareholders may advocate for certain governance and strategic changes at our company. In the event of stockholder activism, particularly with respect to matters which our board of directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, our business could be adversely affected because responding to actions by activist stockholders can be costly and time-consuming, disrupting our operations and diverting the attention of management, and perceived uncertainties as to our future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if faced with a consent solicitation or proxy contest, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. If individuals are elected to our board of directors with a differing agenda, our ability to effectively and timely implement our strategic plan and create additional value for our stockholders may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively impact the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had warrants for 22,922,342 shares of our common stock outstanding at a weighted average exercise price of $5.62 per share. We are able to grant stock options, restricted stock, restricted stock units, stock appreciation rights, bonus stocks, and performance awards under our 2020 Equity Incentive Plan. As of December 31, 2022, under the 2020 Equity Incentive Plan and the 2012 Equity Incentive Plan, 10,408,622</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares were issuable upon the exercise of outstanding options at a weighted average exercise price of $1.84 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may harm the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our executive officers, directors and holders of five percent or more of our outstanding common stock beneficially owned, in the aggregate, 33.2% of our outstanding common stock. These stockholders may have interests that conflict with our other stockholders and, if acting together, have the ability to influence the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation or sale of all or substantially all of our assets. Accordingly, this concentration of ownership may harm the market price of our common stock by:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaying, deferring or preventing a change in control; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impeding a merger, consolidation, takeover or other business combination involving us; or </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, this significant concentration of stock ownership may adversely affect the trading price of our common stock should investors perceive disadvantages in owning shares of common stock in a company that has such concentrated ownership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes to corporate tax legislation, including the Tax Cuts and Jobs Act, signed into law in 2017, could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tax Act contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for NOLs to 80% of current year taxable income and elimination of NOL carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time and modifying or repealing many business deductions and credits. The Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, enacted in 2020, modified certain of these tax changes, and enacted other tax changes applicable to corporations. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act and the CARES Act is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. Currently, bills introduced in Congress, including the Build Back Better Act, contain additional changes to the taxation of corporations, which could adversely affect our business and financial condition. The impact of the Tax Act, the CARES Act and any other tax legislation on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are considered a &#x201c;smaller reporting company&#x201d; under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stock prices may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million as of the last business day of our most recently completed second quarter if our annual revenues are $100 million or more as of our most recently completed fiscal year, or until our public float exceeds $700 million as of the last business day of our most recently completed second quarter if our annual revenues are less than $100 million as of our most recently completed fiscal year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1B. Unresolved Staff Comments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 2. Properties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate office is located at 8030 El Rio Street, Houston, Texas 77054. Our Houston offices are leased pursuant to the 2019 Lease and the 2020 Lease, as described below, and comprise a total of approximately 17,265 square feet. In December 2021, we made the decision to close our former corporate office in Boston, Massachusetts. We are still party to the Boston lease and have subleased a portion of the space. We continue to seek an acceptable sublessee of the remaining portion of the Boston lease to become a subtenant and/or assume our obligations under the lease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, we entered into an agreement with MD Anderson to lease laboratory and office space on MD Anderson&#x2019;s campus, or, as amended, the 2019 Lease. We use this location to house our laboratory, cGMP clinical manufacturing facilities and office space on MD Anderson&#x2019;s campus. The 2019 Lease expires in February 2027. The monthly rent expense of the 2019 Lease with MD Anderson was being deducted from our prepayment at MD Anderson until the third quarter of 2021, since which time we pay MD Anderson monthly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we entered into a second agreement with MD Anderson to lease additional space on MD Anderson&#x2019;s campus, or, as amended, the 2020 Lease. The 2020 Lease expires in April 2028 and may be extended for one additional five-year term at our election. In April 2022, we modified the 2020 Lease, which reduced our leased space from 18,111 square feet to 3,228 square feet. See Note 8 to the accompanying financial statements, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our existing facilities are adequate to meet our current needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 3. Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our results of operations, cash flows or financial position. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management resources and other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results of operations, financial condition or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 4. Mine Safety Disclosures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_106"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#x201c;TCRT.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Record Holders</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 15, 2023, we had approximately 240 holders of record of our common stock, one of which was Cede &amp; Co., a nominee for Depository Trust Company, or DTC. Shares of common stock that are held by financial institutions as nominees for beneficial owners or in &#x201c;street name&#x201d; are deposited into participant accounts at DTC and are considered to be held of record by Cede &amp; Co. as one stockholder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid a cash dividend on our common stock and do not anticipate paying any cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We did not sell or issue any equity securities during the three months ended December 31, 2022 that were not registered under the Securities Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 6. [Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_19"><span id="item_7_management_discussion_and_analys"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 7. Management's Discussion and Analysis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> of Financial Condition and Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those under &#x201c;Risk Factors&#x201d; included in Part I, Item 1A and under &#x201c;Special Note Regarding Forward-Looking Statements&#x201d; or in other parts of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapy, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our cancer hotspot mutation TCR library and our proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In collaboration with MD Anderson, we are currently enrolling and treating patients for a Phase 1/2 clinical trial evaluating 12 TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately $53.0 million of cash, cash equivalents and restricted cash. Our restricted cash of $13.9 million relates to the Amended Loan and Security Agreement. Given our current development plans, we anticipate our cash resources will be sufficient to fund our operations into the fourth quarter of 2023, and we have no committed sources of additional capital at this time. See &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2022, we had a net loss of $37.7 million, and through December 31, 2022, we have incurred approximately $880.6 million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and net losses. Further development of our product candidates will likely require substantial increases in our expenses as we:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to undertake clinical trials for product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">work with regulatory authorities to identify and address program-related inquiries;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional internal systems and infrastructure;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scale up and scale out the manufacturing of our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to seek additional financial resources to fund the further development of our product candidates. If we are unable to obtain sufficient additional capital, one or more of these programs could be delayed, and we may be unable to continue our operations at planned levels and be forced to reduce our operations. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Developments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2022, we submitted an IND amendment to the FDA to add two new TCRs to our clinical trial targeting frequent mutations and HLAs, with the potential to double the addressable market of our TCR-T Library Phase 1/2 Trial. The addition of these new TCRs highlights our strategy to add both more HLAs to existing mutations (KRAS-G12V and HLA-DRB1*07:01) and new mutations within our targeted gene families (TP53-R273C and HLA-DPB1*04:02). In 2023, we expect to further expand our library with exclusively owned TCRs targeting recurrent hotspot mutations in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to include 15 TCRs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to actively enroll patients in our TCR-T Library Phase 1/2 Trial targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hotspot mutations across six solid tumor indications. In September 2022, we announced the first objective clinical response from a TCR-T cell therapy using non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> targeting solid tumors. We successfully dosed the third patient in the trial in December 2022 and expect to enroll multiple patients in the first half of 2023. The fourth quarter IND amendment also combined our treatment and screening protocols, streamlining enrollment and potentially making it easier for both patients and physicians. The amended IND also eliminated the requirement for retesting of the tumor mutation if six months had passed between screening and treatment. We anticipate providing an interim clinical data update in 2023 as we work toward advancing the TCR-T Library Phase 1/2 Trial into Phase 2 and we expect to be Phase 2 ready by the end of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to execute on our multi-pronged strategy to expand manufacturing capacity and efficiency. We doubled our manufacturing capacity in 2022 allowing for production of two products simultaneously. We also filed an IND amendment to move from fresh to cryopreserved product and expect to begin implementing this change in the first half of 2023. The use of cryopreserved cell products is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expected to reduce manufacturing process time from 30 days to 26 days, a 13% decrease, while increasing flexibility for patient scheduling and treatment. We have ongoing initiatives to optimize the process and further reduce the manufacturing time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are advancing our TCR-T cell therapy program towards an IND filing anticipated in the second half of 2023. We believe mbIL-15 has the potential to increase the survival of TCR-T cells in the harsh tumor microenvironment and deepen clinical responses. In addition, we continue to conduct translational assessments of treated patients to guide next generation &#x200b;TCR-T therapy approaches including potential combination and multiplexed TCR-T cell therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize research and development funding revenue over the estimated period of performance. To date we have not generated product revenue. Unless and until we receive approval from the FDA and/or other regulatory authorities for our product candidates, we cannot sell our products and will not have product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses consist primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities, reagents and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to contract research organizations in conjunction with clinical trials, fees paid to contract research organizations in conjunction with costs of materials used in research and development, consulting, license and milestone payments and sponsored research fees paid to third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future research and development expenses in support of our current and future programs will be subject to numerous uncertainties in timing and cost to completion. We test potential products in numerous preclinical studies for safety, toxicology and efficacy. We may conduct multiple clinical trials for each product. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products or indications. Completion of clinical trials may take several years or more, and the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product. It is not unusual for preclinical and clinical development of each of these types of products to require the expenditure of substantial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others, the following:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of clinical sites included in the trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The length of time required to enroll suitable patients;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of patients that ultimately participate in the trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The length of time and cost to develop and optimize manufacturing processes;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost to manufacture the clinical products for patients; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The duration of patient follow-up to ensure the absence of long-term product-related adverse events; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The efficacy and safety profile of the product.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our programs or when and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our programs in a timely manner or our failure to enter into appropriate collaborative agreements could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our product development strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries, benefits and stock-based compensation, consulting and professional fees, including patent related costs, general corporate costs and facility costs not otherwise included in research and development expenses or cost of product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense) consists primarily of interest expense associated with our Amended Loan and Security Agreement, as defined below, and sublease income, which started accruing on July 1, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations for the Fiscal Years ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.908%;"></td>
    <td style="width:1.689%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.696%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.689%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.017999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,922</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">398</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,018</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,643</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,142</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,564</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(133</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,027</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,947</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(35,105</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(77,549</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,154</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,189</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">529</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,625</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,202</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(37,730</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(78,751</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue during the years ended December 31, 2022 and 2021 were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.659%;"></td>
    <td style="width:1.222%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.877%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.231%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.314%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.231%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.069999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.392%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,922</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">398</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,524</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">634</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue during the year ended December 31, 2022 was $2.9 million compared to $0.4 during the year ended December 31, 2021. The increase was primarily due to $2.9 million we recognized under our license and collaboration agreement with Solasia Pharma K.K upon achievement of a milestone.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses during the years ended December 31, 2022 and 2021 were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.628%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.870000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.306000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.062000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.437%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,018</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,643</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24,625</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(50</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the year ended December 31, 2022 decreased by $24.6 million when compared to the year ended December 31, 2021 primarily due to a decrease in program-related costs of $9.7 million, mainly related to the winding down of our IL-12 and CAR-T programs, a $15.5 million decrease in employee-related expenses due to our reduced headcount, a $1.4 million decrease in consulting expenses due to our reduced use of outside service providers and a $0.5 million decrease in facilities and other expenses following the reduction of our real estate footprint in 2022. These decreases were partially offset by a one-time $2.5 million expense to MD Anderson under the terms of our License Agreement resulting from Solasia's achievement of a milestone.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our strategic restructuring event during the year ended December 31, 2021 resulted in the termination of approximately 60 full-time employees, which led to the decrease in employee-related expenses. We currently do not anticipate similar events in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses during the years ended December 31, 2022 and 2021 were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.628%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.870000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.306000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.062000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.437%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,142</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,564</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(14,422</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(52</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses for the year ended December 31, 2022 decreased by $14.4 million as compared to the year ended December 31, 2021, primarily due to a $12.4 million decrease in employee-related expenses as a result of our reduced headcount, a $1.7</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million decrease in consulting expenses due to lower legal costs and reduced use of consultants and a $0.3 million decrease in facilities and other expenses following the reduction of our real estate footprint in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our strategic restructuring event during the year ended December 31, 2021 resulted in the termination of approximately 60 full-time employees, which led to the decrease in employee-related expenses. We currently do not anticipate similar events in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gain on lease modification</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modifications during the years ended December 31, 2022 and 2021 was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.597%;"></td>
    <td style="width:1.052%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.127%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.052%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.163%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.052%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.892999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.828%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.235%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(133</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(133</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification during the year ended December 31, 2022 was $0.1 million as compared to $0 during the year ended December 31, 2021. As a result of a real estate lease modification during the second quarter of 2022, the associated lease liability and right-of-use asset were remeasured based on the revised lease payments, resulting in a gain of $0.1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairments during the years ended December 31, 2022 and 2021 were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.171%;"></td>
    <td style="width:1.105%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.029%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.105%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.286999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.105%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.931%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.748%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.519%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(740</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no impairments during the year ended December 31, 2022, compared to $0.7 during the year ended December 31, 2021. Due to a change in the intended use of our Boston office, an impairment charge of $0.6 million to the right-of-use asset and $0.1 million to leasehold improvements and other assets associated with the office was recognized during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense) during the years ended December 31, 2022 and 2021 was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.531%;"></td>
    <td style="width:1.228%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.042%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.228%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.284999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.228%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.040999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.415999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,154</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,189</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,965</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">529</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">542</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4169</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,625</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,202</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,423</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net for the year ended December 31, 2022 increased by $1.4 million as compared to the year ended December 31, 2021 due to additional interest expense associated with our Amended Loan and Security Agreement, as defined below, of $2.0 million, partially offset by increased interest income of $0.5 million recognized during the year ended December 31, 2022 as a result of higher interest rates earned on our cash balances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any revenue from product sales. Since inception, we have incurred net losses and negative cash flows from our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have financed our operations primarily through public offerings of our common stock, private placements of our convertible equity securities, term debt and collaborations. Through December 31, 2022, we have received an aggregate of $729.1 million from issuances of equity and $25.0 million from our Amended Loan and Security Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We follow the guidance of ASC Topic 205-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Given our current development plans and cash management efforts, we anticipate that our cash resources will be sufficient to fund operations into the fourth quarter of 2023. Our ability to continue operations after our current cash resources are exhausted depends on our ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in our focus and direction of our research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern. This forecast of cash resources and planned operations is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 29, 2022, we entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of 24,228,719 shares of our common stock, or the Firm Shares, to the Underwriter at a price of $0.6191 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our net proceeds from the Offering were $14.7 million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Underwriting Agreement, we granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 3,634,307 shares of common stock, or, together with the Firm Shares, the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase 216,294 shares of common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of the Shares sold in the Offering were sold by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2022, we entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which we can offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50 million through Piper Sandler as our sales agent in an &#x201c;at the market offering.&#x201d; Piper Sandler will receive a commission of 3.0% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the year ended December 31, 2022, there were no sales of our common stock under the Equity Distribution Agreement. In connection with entering into the Equity Distribution Agreement, we concurrently terminated, effective August 12, 2022, the Open Market Sale Agreement, dated June 21, 2019, governing our former &#x201c;at the market offering&#x201d; program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, we entered into the Loan and Security Agreement. The Loan and Security Agreement provided for an initial term loan of $25.0 million funded at the closing, with an additional tranche of $25.0 million available if certain funding and clinical milestones were met by August 31, 2022. Effective December 28, 2021, we entered into the Amended Loan and Security Agreement, or the Amended Loan and Security Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Amended Loan and Security Agreement, the SVB Facility was modified to eliminate the additional tranche, which remained unfunded, leaving only the initial $25.0 million as the full amount available under the SVB Facility. The SVB Facility bears interest at a floating rate per annum on the outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022. Commencing on September 1, 2022, aggregate outstanding borrowings became repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All outstanding obligations under the Amended Loan and Security Agreement are due and payable on August 1, 2023. We will also owe SVB 5.75% of the original principal amounts borrowed as a final payment. We are permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from 1.00% to 2.00%, of the SVB Facility, each such prepayment to be at least $5.0 million plus all accrued and unpaid interest on the portion being prepaid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of not achieving certain milestones specified in the Amended Loan and Security Agreement on or prior to August 31, 2022, we were required to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to 5.75% of the original principal amount of the SVB Facility. As of December 31, 2022, we have collateralized $13.9 million, which is classified as restricted cash on our Balance Sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">outstanding balance under the SVB Facility being satisfied, $2.5 million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $4.0 million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of our properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our entry into the Loan and Security Agreement, we issued to SVB warrants to purchase (i) up to 432,844 shares of our common stock, in the aggregate, and (ii) up to an additional 432,842 shares of Common Stock, in the aggregate, in the event we achieved certain clinical milestones, in each case at an exercise price per share of $2.22. In connection with our entry into the Amended Loan and Security Agreement, we amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to 649,615 shares of our common stock, in the aggregate, at an exercise price per share of $1.16, or the SVB Warrants. The SVB Warrants expire on August 6, 2031.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our net increase (decrease) in cash and cash equivalents for the years ended December 31, 2022 and 2021:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.066%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.721%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.964%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(29,232</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(61,468</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(193</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,323</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,367</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,776</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(23,058</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(39,015</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net loss for:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash operating items such as depreciation and stock-based compensation; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2022 was $29.2 million, as compared to $61.5 million for the year ended December 31, 2021. The decrease was primarily related to the reduction of our net loss by $41.1 million, partially offset by the extent of non-cash adjustments and working capital impacts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net cash used in operating activities for the year ended December 31, 2022 was primarily a result of our net loss of $37.7 million, adjusted for $9.6 million of non-cash items such as depreciation, stock-based compensation and a decrease in the carrying amount of right-of-use assets, a decrease in accounts receivable of $1.1 million and a decrease in prepaid expenses and other assets of $1.0 million, offset by a decrease in accrued expenses of $0.7 million and a decrease in lease liabilities of $2.5 million. The net cash used in operating activities for the year ended December 31, 2021 was primarily a result of our net loss of $78.8 million, adjusted for $14.5 million of non-cash items such as depreciation and stock-based compensation and a decrease in accrued expenses of $10.5 million, offset by a decrease in receivables of $3.6 million, a decrease in prepaid expenses and other assets of $9.4 million and an increase in accounts payable of $0.3 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the year ended December 31, 2022 as compared to $3.3 million for the year ended December 31, 2021. The decrease in net cash used in investing activities for the year ended December 31, 2022 compared to the year ended December 31, 2021 was primarily a result of the decision to use available cash to expand our internal cell therapy capabilities in our Houston, Texas facilities during the first half of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $6.4 million for the year ended December 31, 2022 compared to $25.8 million for the year ended December 31, 2021. The $6.4 million provided by financing activities during the year ended December 31, 2022 related primarily to $14.7 million in net proceeds from the issuance of common stock (before accounting for the partial exercise of the Underwriter's option), offset by $8.3 million of repayments of long-term debt. Net cash provided by financing activities was $25.8 million for the year ended December 31, 2021, related primarily to proceeds from our $25.0 million SVB Facility and the proceeds from the exercise of stock options equal to $1.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Capital and Capital Expenditure Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that losses will continue for the foreseeable future. As of December 31, 2022, our accumulated deficit was approximately $880.6 million. Our actual cash requirements may vary materially from those planned because of a number of factors, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the focus, direction and pace of our development programs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing technologies and market developments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, timing, costs and results of our TCR-T Library Phase 1/2 Trial for the treatment of certain solid tumors and costs associated with the development of our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth as we rebuild our workforce with a focus on our TCR program and scale our manufacturing capabilities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to secure partnering arrangements; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs of filing, prosecuting, defending and enforcing any patent claims and any other intellectual property rights, or other developments.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately $53.0 million of cash, cash equivalents and restricted cash. Our restricted cash of $13.9 million relates to the Amended Loan and Security Agreement. Given our current development plans, we anticipate our cash resources will be sufficient to fund our operations into the fourth quarter of 2023. In order to continue our operations beyond our forecasted runway we will need to raise additional capital, and we have no committed sources of additional capital at this time. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate. Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all. If adequate additional funds are not available when required, or if we are unsuccessful in entering into partnership agreements for further development of our product candidates, management may need to curtail its development efforts and planned operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Working capital, which excludes restricted cash, as of December 31, 2022 was $15.7 million, consisting of $39.9 million in current assets and $24.2 million in current liabilities. Working capital as of December 31, 2021 was $62.8 million, consisting of $78.8 million in current assets and $16.0 million in current liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commitments for operating leases relate to laboratory and office space in Houston, Texas and office space in Boston, Massachusetts. On December 21, 2015 and April 15, 2016, we renewed the sublease for our office space in Boston through August 31, 2021. On April 22, 2021, we extended our sublease for a portion of office space at our office in Boston through August 31, 2026.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2019, we entered into a lease agreement for office space in Houston at MD Anderson through April 2021. On October 15, 2019, we entered into another lease agreement for additional office and laboratory space in Houston through February 2027. On April 7, 2020, we entered into amendments to our existing lease to lease additional office and laboratory space in Houston through February 2027. In June and September 2020, we entered into short-term leases in Houston for additional office and laboratory space. On December 15, 2020, we entered into a second lease in Houston with MD Anderson which provided us additional office and laboratory space through April 2028.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we modified our real estate lease agreement executed on December 15, 2020 with MD Anderson. The modification reduced our leased space from 18,111 square feet to 3,228 square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $0.4 million based on revised lease payments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, we executed an agreement to sub-sublease 4,772 square feet of our subleased office space in Boston. The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026. For the year ended December 31, 2022, we recognized $0.1 million in lease income, which is classified within other income (expense), net in the Statement of Operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalty and License Fees</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, we entered into the Patent License with the NCI. The terms of the Patent License require us to pay the NCI minimum annual royalties in the amount of $0.3 million, which will be reduced to $0.1 million once the aggregate minimum annual royalties paid by us equals $1.5 million. For the year ended December 31, 2022, we recognized $0.3 million in royalty payments under the Patent License, and we recognized $0.3 million in royalty payments for the year ended December 31, 2021. As of December 31, 2022, we have paid a total of $0.5 million in minimum annual royalty payments under the Patent License.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Patent License, we are also required to make performance-based payments contingent upon the successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $4.3 million, of which aggregate payments of $3.0 million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. The first benchmark payment of $0.1 million was due upon the initiation of our TCR-T Library Phase 1/2 Trial. In addition, we are required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $250.0 million to $1.0 billion. The aggregate potential amount of these benchmark payments is $12.0 million. Payments of $0.1 million were made during the year ended December 31, 2022, and no payments were made during the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, we entered into the License Agreement with PGEN. Under the License Agreement, we are obligated to pay PGEN an annual licensing fee of $0.1 million expected to be paid through the term of the agreement and we have also agreed to reimburse certain historical costs of PGEN up to $1.0 million. For the years ended December 31, 2022 and 2021, we have made licensing fee payments in accordance with the terms of the agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the License Agreement, we are responsible for contingent milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, we will pay PGEN tiered royalties ranging from low-single digit to high-single digit on the net sales derived from the sales of any approved IL-12 products and CAR products. We will also pay PGEN royalties ranging from low-single digit to mid-single digit on the net sales derived from the sales of any approved TCR products, up to a maximum royalty amount of $100.0 million in the aggregate. We will also pay PGEN 20% of any sublicensing income received by us relating to the licensed products. We are responsible for all development costs associated with each of the licensed products. PGEN will pay us royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $100.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2022, the Company recorded $2.9 million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, compared to $0.4 million during the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Estimates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Management&#x2019;s Discussion and Analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the following are our more significant estimates and judgments used in the preparation of our financial statements:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs / Clinical Trial Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CROs in connection with performing research services on our behalf and clinical trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in changes to our previous</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates, which we considered reasonably reliable at the time. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We primarily generate revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, we recognized revenue in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 606&#x201d;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which replaced ASC 605, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Multiple Element Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as used in historical years. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize collaboration revenue under certain of our license or collaboration agreements that are within the scope of ASC 606. Our contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#x2019;s election.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of our arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. We measure the transaction price based on the amount of consideration to which we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of us or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we reevaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We allocate the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. We develop assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. We evaluate the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the employee&#x2019;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#x2019;s common stock price over the expected term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We review our valuation assumptions periodically and, as a result, we may change our valuation assumptions used to value share-based awards granted in future periods. Such changes may lead to a significant change in the expense we recognize in connection with share-based payments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our assumptions are estimated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the fair market value of our common stock is considered the quoted market price on Nasdaq;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expected volatility is based on the historical stock volatility of our common stock over a sufficient period of time equal to the expected term of the option;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expected term represents the period that our stock options are expected to be outstanding;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk-free interest rate is based on the yields of U.S. Treasury securities with maturities commensurate with the expected term of the award; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have not paid dividends on our common stock nor do we expect to pay dividends in the foreseeable future.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In preparing our financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which, prior to the consideration for the need for a valuation allowance, are included on our Balance Sheet. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. Our estimates of future taxable income include, among other items, our estimates of future income tax deductions related to the exercise of stock options. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on an annual basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#x201c;more-likely-than-not&#x201d; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews; we have no plans to appeal or litigate any aspect of the tax position; and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of new accounting standards, please read Note 3 to the accompanying financial statements, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Principles </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">included in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_20"><span id="item_7a_quantitative_and_qualitative"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 7A. Quantitative and Qualitative</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Disclosures About Market Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information under this Item 7A.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 8. Financial Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and Supplementary Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 8 is contained on pages F-1 through F-26 of this Annual Report and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 9. Changes in and Disagreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> with Accountants on Accounting and Financial Disclosures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 9A. Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer and our principal accounting officer, we have evaluated the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) or 15d-15(e) promulgated under the Exchange Act, as of December 31, 2022. Based on that evaluation, our principal executive officer and principal financial officer has concluded that as of December 31, 2022, our disclosure controls and procedures were effective as described below under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13(a)-15(f) and 15(d)-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and principal financial officer and our principal accounting officer and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer and our principal accounting officer, we assessed our internal control over financial reporting as of December 31, 2022, based on criteria for effective internal control over financial reporting established in Internal Control - Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management&#x2019;s assessment of the effectiveness of our internal control over financial reporting included testing and evaluating the design and operating effectiveness of our internal controls. In management&#x2019;s opinion, we have maintained effective internal control over financial reporting as of December 31, 2022, based on the criteria discussed above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inherent Limitations on Internal Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, and our principal accounting officer, do not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Controls over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rule 13(a)-15(f) of the Exchange Act) that occurred during the fiscal year ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 9B. Other Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 9C. Disclosure Regarding</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_134"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_25"><span id="item_10_directors_executive"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 10. Directors, Executive</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Officers and Corporate Governance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_26"><span id="item_11_executive_compensation"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 11. Executive Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_27"><span id="item_12_security_ownership"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 12. Security Ownership</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_28"><span id="item_13_certain_relationships"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 13. Certain Relationships</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and Related Transactions, and Director Independence</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_29"><span id="item_14_principal_accountant"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 14. Principal Accountant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Fees and Services</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;" id="bkmk_140"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_30"><span id="item_15_exhibits"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 15. Exhibits, Financial Statement Schedules</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(1) Financial Statements:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Financial Statements required to be filed by Item 8 of this Annual Report, and filed in this Item 15, are as follows:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:87.309%;"></td>
    <td style="width:2.023%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:8.464%;"></td>
    <td style="width:1.102%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.025in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.875pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Changes in Stockholders&#x2019; Equity for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(2) Financial Statement Schedules:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_147"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the financial statements and notes thereto.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(3) Exhibits:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.003%;"></td>
    <td style="width:1.997%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000112178105000194/exhibit10one.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger among the Registrant (formerly &#x201c;EasyWeb, Inc.&#x201d;), ZIO Acquisition Corp. and ZIOPHARM, Inc., dated August 3, 2005 (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Form 8-K, SEC File No. 000-32353, filed August 9, 2005).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex3_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation, and all amendments thereto (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420405029250/v025882_ex3-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Merger dated September 13, 2005, relating to the merger of ZIO Acquisition Corp. with and into ZIOPHARM, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Form 8-K, SEC File No. 000-32353, filed September 19, 2005).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420405029250/ex3-2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Ownership of the Registrant (formerly &#x201c;EasyWeb, Inc.&#x201d;) dated as of September 14, 2005, relating the merger of ZIOPHARM, Inc. with and into the Registrant, and changing the Registrant&#x2019;s corporate name from EasyWeb, Inc. to ZIOPHARM Oncology, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Form 8-K, SEC File No. 000-32353, filed September 19, 2005).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312516640603/d220092dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, as filed with the Delaware Secretary of State on July 1, 2016 (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K/A, SEC File No. 001-33038, filed July 1, 2016).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, dated as of September 21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed September 22, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420405031725/v026661_ex4-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Registration Statement on Form SB-2, SEC File No. 333-129020, filed October 14, 2005).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420406010771/v038061_ex4-6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option for the Purchase of Shares of common stock dated August 30, 2004 and issued to The University of Texas M. D. Anderson Cancer Center (incorporated by reference to Exhibit 4.6 to the Registrant&#x2019;s Annual Report on Form 10-KSB, SEC File No. 000-32353, filed March 20, 2006).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420406010771/v038061_ex4-7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule identifying Material Terms of Options for the Purchase of Shares of Common Stock (incorporated by reference to Exhibit 4.7 to the Registrant&#x2019;s Annual Report on Form 10-KSB, SEC File No. 000-32353, filed March 20, 2006).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312518324941/d601714dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038 filed November 13, 2018).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex47.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant to Purchase Common Stock issued to The University of Texas M. D. Anderson Cancer Center (incorporated by reference to Exhibit 4.7 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_6.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Warrant to Purchase Shares of Common Stock issued to SVB and certain of its Affiliates, dated December 28, 2021 (incorporated by reference to Exhibit 4.6 to the Registrant's Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.7 to the Registrant's Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312518281213/d627352dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038 filed September 24, 2018).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.003%;"></td>
    <td style="width:1.997%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420412036511/v316803_ex10-2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038 filed June 26, 2012).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420412036511/v316803_ex10-3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038 filed June 26, 2012).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.7+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520136509/d926789dex993.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Inducement Award Grant Notice and Inducement Award Grant Agreement (incorporated by reference to Exhibit 99.3 to the Registrant&#x2019;s Registration Statement on Form S-8, SEC File No. 333-238090, filed May 8, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.8+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520184639/d862521dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038 filed July 1, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.9+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021 ).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021 ).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.11+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420413005124/v333304_ex99-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnity Agreement for directors and executive officers (incorporated by reference to Exhibit 99.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed January 31, 2013).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.16+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/d11000dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement, dated August 24, 2021, by and between the Registrant and Kevin S. Boyle Sr. (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed August 30, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.23#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Retention Bonus Agreement (incorporated by reference to Exhibit 10.20 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.24#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312515023826/d862579dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement by and among the Registrant, Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as of January 13, 2015 (incorporated by reference to Exhibit 10.5 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed January 28, 2015).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.25&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312518323155/d623821dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive License Agreement by and between the Registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 9, 2018).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.26#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520286807/d82436dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020 (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Quarterly Report on Form 10-Q SEC File No. 001-33038, filed November 5, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.27&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312515117648/d902541dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and Collaboration Agreement by and among the Registrant, Intrexon Corporation and Ares Trading S.A. dated as of March 27, 2015 (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed April 2, 2015).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.28#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312515298126/d40873dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of August 17, 2015 (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed August 21, 2015).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of August 30, 2016 (incorporated by reference to Exhibit 10.21 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 5, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.30</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1022.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of January 17, 2017 (incorporated by reference to Exhibit 10.21 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 5, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.31</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1023.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of November 14, 2017 (incorporated by reference to Exhibit 10.23 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 5, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.32</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519287259/d786918dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to Research and Development Agreement, dated September 19, 2019 by and among the Registrant, The University of Texas MD Anderson Cancer Center and Precigen, Inc. (incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 7, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.33#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to Research and Development Agreement, dated October 22, 2019 by and among the Registrant and The University of Texas MD Anderson Cancer Center (incorporated by reference to Exhibit 10.20 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.34#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Research and Development Agreement, dated October 22, 2019, by and between the Registrant and The University of Texas MD Anderson Cancer Center (incorporated by reference to Exhibit 10.21 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.35#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519216056/d777738dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent License Agreement, dated as of May 28, 2019, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed August 8, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.36#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1023.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Patent License Agreement, dated as of January 8, 2020, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.23 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.003%;"></td>
    <td style="width:1.997%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.37#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520286807/d82436dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, SEC File No. 000-33038, filed November 5, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.38#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_38.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Patent License Agreement, dated as of April 16, 2021, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.38 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.39#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_39.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to Patent License Agreement, dated as of May 4, 2021, by and between the Registrant and the National Cancer Institute  (incorporated by reference to Exhibit 10.39 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.40#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_40.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to Patent License Agreement, dated as of August 13, 2021, by and between the Registrant and the National Cancer Institute  (incorporated by reference to Exhibit 10.40 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.41#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/d608895dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cooperative Research and Development Agreement, dated January 9, 2017, by and among the Registrant, the National Cancer Institute, and Intrexon Corporation (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038, filed September 26, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.42</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/d608895dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to the Cooperative Research and Development Agreement, dated March 23, 2018, by and among the Registrant, National Cancer Institute, Intrexon Corporation and Precigen, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038, filed September 26, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.43#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/d608895dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to the Cooperative Research and Development Agreement, dated February 1, 2019, by and among the National Cancer Institute, the Registrant and Precigen, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Current Report on Form 8-K SEC File No. 001-33038, filed September 26, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.44</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_44.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to the Cooperative Research and Development Agreement, dated March 15, 2022, by and among the National Cancer Institute and the Registrant (incorporated by reference to Exhibit 10.44 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.45</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022017225/tcrt-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to the Cooperative Research and Development Agreement, dated June 24, 2022, by and between the National Cancer Institute and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed August 15, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.46</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1039.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.39 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.47</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1040.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment, dated as of April 7, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.40 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.48</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1041.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment, dated as of April 7, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.41 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.49</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1042.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment, dated as of December 15, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.42 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.50</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1043.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement dated as of December 15, 2020, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.43 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.51</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521030026/d122203dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement dated February 4, 2021, by and among the Registrant, WaterMill Asset Management Corp. and Robert W. Postma (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed February 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.52</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017021003463/ziop-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement by and among the Registrant, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent, dated August 6, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 8, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.53</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_52.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to the Loan and Security Agreement by and among the Registrant, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent, dated December 28, 2021 (incorporated by reference to Exhibit 10.52 to the Registrant&#x2019;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.54</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022017225/tcrt-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Distribution Agreement, dated August 12, 2022, by and between Piper Sandler &amp; Co. and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed August 15, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.003%;"></td>
    <td style="width:1.997%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.55</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/d424988dex11.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Underwriting Agreement, dated as of November 29, 2022, by and between Cantor Fitzgerald &amp; Co. and the Registrant (incorporated by reference to Exhibit 1.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed November 30, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;24.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (incorporated by reference to the signature page of this Annual Report on Form 10-K).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File-the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furnished herewith.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicates management contract or compensatory plan.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions of this document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of this document (indicated by &#x201c;[***]&#x201d;) have been omitted because such information is not material and is the type of information that the Registrant treats as private or confidential.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGN</span><span id="power_of_attorney"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.002%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:3.003%;"></td>
    <td style="width:51.997%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 7, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer and Principal Financial Officer)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 7, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Wong</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Wong</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vice President, Finance</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin S. Boyle, Sr. and Michael Wong, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.002%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:34.002%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:20.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer and Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Wong</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Michael Wong</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vice President, Finance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Christopher Bowden</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Christopher Bowden</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ James Huang</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James Huang</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Robert W. Postma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robert W. Postma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mary Thistle</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mary Thistle</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jaime Vieser</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaime Vieser</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Holger Weis</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holger Weis</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:15.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;" id="financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:2.315%;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:89.149%;"></td>
    <td style="width:2.025%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:6.619%;"></td>
    <td style="width:1.103%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.025in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.875pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f46e094b-4809-40f2-a4bf-216d5e5fe085" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSM US LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_085df8a9-cd67-46ac-9eb9-a2198e846e7c" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, MA</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; PCAOB ID: </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4273c85-6ed3-4eda-a289-a58d39206009" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Changes in Stockholders&#x2019; Equity for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;" id="bkmk_180">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;" id="bkmk_141"><span id="report_of_independent"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying balance sheets of Alaunos Therapeutics, Inc. and its subsidiaries (the Company) as of December 31, 2022 and 2021, the related statements of operations, stockholders' equity and cash flows for the years then ended, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s Ability to Continue as a Going Concern</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred recurring operating losses since its inception and will be required to raise additional capital to fund operations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals for Clinical Trials and Other Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 3 to the financial statements, the Company accrues costs for clinical trials and other research and development expenses based on estimates of costs incurred through the balance sheet date that have not been invoiced by the clinical research organizations, clinical study sites, consultants, or other vendors. This process involves reviewing open contracts and purchase orders, communicating with vendors and internal personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The Company's accrual for clinical trial and preclinical study expenses totaled $2.4 million at December 31, 2022 as disclosed in Note 6.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified the accruals for clinical trials and other research and development expenses to be a critical audit matter because auditing the Company&#x2019;s accruals is complex as the information necessary to make an estimate is accumulated from multiple sources and there may be delays in invoicing from clinical study sites and other vendors, or payments may depend on factors such as the completion of clinical trial milestones. Additionally, in certain circumstances, it requires judgment, as the timing and pattern of vendor invoicing may not correspond to the level of services provided.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">How We Addressed the Matter in our Audit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit procedures to test the accruals for clinical trial and preclinical studies expenses included, among others:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We tested the accuracy and completeness of the underlying data used in the estimates and evaluated the reasonableness of assumptions used by management. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We inspected certain contracts with third parties and related information received by the Company to test proper recording of costs incurred to date.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We corroborated the progress of research and development activities through discussion with the Company&#x2019;s research and development personnel, specifically those who oversee the projects, and confirmations with the third parties.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We performed analytical procedures over fluctuations in accruals on a department level throughout the year.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We tested subsequent invoices received from third parties and cash disbursements to assess completeness of recorded accruals.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ RSM US LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company's auditor since 2010.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_188"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span id="bkmk_142"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.706%;"></td>
    <td style="width:1.615%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.032%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.615%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.032%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7172ff16-b021-48d4-8bc2-31a1f82f0f33" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_115586fd-69d6-4ca6-8ad5-19ef6eb965c5" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_097d29a3-87a5-41ed-82dd-e5735a2e661a" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe1ea8fa-229d-4b7e-8e63-0d3cea0dc663" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94c027fe-5dd2-4b78-b35d-920b70f5d48c" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1724197b-ac6c-42eb-bba3-0380bfd35094" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f27a910b-70d0-40eb-b0e2-d5f14089199c" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43e8c6b9-5b11-4c04-9675-25f49569e1b1" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,666</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dc78082-de66-439f-86c1-6e6e80ac79d4" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91ced3ff-3417-4f49-aa48-50ae1d2f6871" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,831</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_728befe4-9279-429e-889a-307471f0ac43" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87b0d8db-8523-4e94-9fd7-3f570bb68b44" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c0f597d-3375-4280-a26a-1194b1d185c7" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26b5a242-bbed-4967-982a-1b58adf47975" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33f49836-372d-4f37-834a-839b307901cc" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07275928-79f3-49c1-8af2-021d75867458" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79edff53-078a-479b-8ae8-fcdfbe8def4f" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6756ea8-6e66-431c-9a19-3b718cf6261b" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:50.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:50.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_416a7019-b89c-45f3-9185-e60d7c688af3" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b542b287-c32c-43a4-bac8-50bfe452e326" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b51b15e5-9eac-4a8e-834d-8de4b2a8fd64" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ea12b14-41b4-4957-9f93-5425df4560b7" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt, current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc740979-5ab0-4727-a43b-68ad993117cc" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a10a6a5d-645d-46db-8325-698ecc688dbc" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a5c761c-1fea-4041-ad95-b4c765370063" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f89e9ff-298a-4b65-93e5-8229a7b931a4" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,076</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b098bcd9-1c7a-44dd-9377-6ba66969a2f9" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">558</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e80b42f-1b2d-4a30-988a-03131675c52f" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbf22107-7cce-43cf-b47c-bf4496ad6ede" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_527f1334-054c-445b-a993-a356016cb6bf" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f236e868-b55a-445d-8f7b-f7a545cf950a" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a0dfc33-25cc-4341-8575-b62ed50e0444" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b8dd5ed-322a-4277-bb2b-0fdb5940cc41" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5586287b-e735-4249-ae4f-40f0c83082c4" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e802e36-4a15-469b-be6e-c410f9b806c6" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_595f234f-e0bd-4861-a590-e4905bac1fee" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4e9c3fc-e3da-4401-8a7a-72a83ef18f74" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_244d426f-d480-48b5-a5d7-a508b4495627" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5e15993c-8126-4ed8-af04-1256b45c6355;"><span style="-sec-ix-hidden:F_a5277795-d129-44d1-890a-5c034d8ecbb8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b6ce7f2-467a-4a3b-9692-4a40aa3d67a4" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal"><ix:nonFraction id="F_34fd6ac3-597a-4dbc-a3da-7c3868749c1b" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d75e44eb-d4c7-45d6-a360-89e37ad6e16d" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">420,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90fb4a78-cf71-4628-b155-e3df7a39ad02" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b61477bc-f1d1-4e45-8c7a-4330ff348670" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,410,761</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a14d5a99-e6c6-4e64-a81d-361f9f0ca7ab" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">350,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82ae12b3-195c-4e3c-87a6-82eaaba5399c" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d2c37c5c-1f50-4b30-8a19-3eeca2825134" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,127,443</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15fa9ed6-5e86-4f3e-9736-b73e22ee2b23" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62ce9d69-7e88-4f66-8083-42da88dbbf6d" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9822866-56bc-45fd-b54f-d93c3edb832c" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acb5f090-ea1f-467c-94d6-1be1112df5b0" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">900,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9332b3ad-e4af-49f9-8eae-9eae1b2e0cd7" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">880,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_013b1fe1-9167-4070-8a99-ce89727a2391" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">842,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64f4ea46-ce4c-4a53-b0f8-a045d016e716" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_131a8478-bcbd-4fbf-ba2b-3a0b9a20fef6" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_782d4d7d-9f3f-4850-9ccd-f271708778f5" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_043dc2c1-9f18-489a-afbc-bc6e146d22d2" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_191"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_143"><span id="statements_of_operations"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STATEMENTS OF OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.069%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.719%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.962%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cae47a70-28d2-4a23-a19f-d67bb3c450ef" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d89be63f-62af-4dbc-b972-d8407f53fb85" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">398</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0d6ff39-7da6-4811-ab66-abcb4c71b043" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_157a58b8-911a-4fde-939a-41dcc414baed" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d339aacd-5031-4d39-83f1-905859a88ed3" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d68c5c5b-508e-4c64-837f-ca32726dd97b" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f8c67a6-c46a-4e92-a51e-924a4c815de8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:GainLossOnOperatingLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_282e2442-d0b7-4771-b4e8-e7c9d6551cf7" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="tcrt:GainLossOnOperatingLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4234c4a5-18eb-4975-81b7-be6ecd0ea6e0" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_431b4101-c61b-46dd-a080-3dbf786895aa" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b0fdd58-be75-4ba0-ac0b-6910df2e9bc6" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f33fd6d-dd1a-4adf-82fa-56762947b828" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0175856-2e74-45d9-b4a0-ffb43036e0c4" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2329ae47-8d2d-45d9-a7d2-63ca4ead22cd" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">77,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26de8741-0816-4992-b2a8-0f3adf59b7dd" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e67ca8b3-b246-4bc4-9a5c-332eccd94fa4" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdb3b8ab-a8d6-42d3-bc56-ccd4d651f537" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f98a302-4206-48d4-9514-1c9c568a4ee0" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4176aabf-19d5-419c-b5bc-57f28dc1c715" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,625</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e26b2a63-93cc-4b01-a8fb-e515bf6faae7" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bc7508b-ec92-4d64-a0db-dd6947e57d1a" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f489ea1-7894-43ae-8041-6986448462d4" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78,751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03b37f7c-e3aa-45da-997c-0e5514307060" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_ad2fe704-1842-4fee-b9fd-0e7b244bedce" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6311d87e-2927-4aca-aa64-3e0b0a15f053" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_6daf60c0-b517-4bd5-a477-64d0923c9402" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.37</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e5c3057-6334-4052-9c14-adc27fb8a624" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_5adb9f87-e75e-4385-b0b7-089a5e59b14a" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">217,130,311</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93e2d04c-8a99-411e-a147-3fe0d3baa604" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_fe00872d-7623-464a-a072-06cc8292a3fb" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">214,399,074</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_193"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_144"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STATEMENTS OF CHANGES IN </span><span id="stockholders_equity"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STOCKHOLDERS&#x2019; EQUITY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.998%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.6530000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.097%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.981%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.097%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.981%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.097%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.988999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.104%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.997%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c091f84-b0fc-46de-ae2f-0d2b92f06dfd" contextRef="C_c51598af-80b7-4a30-ab2d-b510980f50f3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">214,591,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6237079-4570-4711-8588-cb3c874027d3" contextRef="C_c51598af-80b7-4a30-ab2d-b510980f50f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04a8c3ba-e55c-40d6-97fd-6fc47a675913" contextRef="C_45066dfd-98ce-4ef8-a0f8-576b77666039" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">887,868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02294eb6-311d-4f6e-8ee5-34b338e45746" contextRef="C_fc6223b4-e9fb-47c2-a189-b5585700a3f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">764,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_decba051-1cf2-4d88-80b2-0a1b1e2b84e5" contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,982</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bdf1b4b-2775-4765-9f18-8efb08d130aa" contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6e19fa2-a52e-4a7c-899f-e5629857287c" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of employee stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f892b32a-717a-4e41-901f-c05455246831" contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">363,109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e6f28ce-54f2-47c1-9b5b-93b9ea8aae3b" contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42497770-df3c-40c4-854c-b94a16d75cd2" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issuance</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b389925-9c23-4cb5-a9e2-e90b6b329071" contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,991</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ee7e818-54de-4d99-8337-acdad6745177" contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,601,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6d7d257-465b-42cd-9bd1-b1527f06e017" contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32e5fb54-725a-4e5c-b58f-9f66f57a9777" contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72a1a5d5-9712-44cd-98f1-acc1fea80aa4" contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">434,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44218142-5d21-46e4-90ba-776cf21ebb46" contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,016</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a44956d-f996-46a7-80db-353206634830" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,016</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daae6076-bf87-4ada-98db-8a82fab40749" contextRef="C_33682291-7fb7-4cab-a271-326647030806" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78,751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7baecac-e675-46ce-979f-abae3a3dde2e" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78,751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5516448b-e135-4abd-a17a-f8f26e75f6d6" contextRef="C_f182bcec-cb46-49ba-8ea6-3294135323d1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,127,443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff35aa78-d7d3-4a73-aecd-5d659ed50061" contextRef="C_f182bcec-cb46-49ba-8ea6-3294135323d1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a10f6aaa-04db-4c6a-a206-42661d4a8109" contextRef="C_c699063c-f010-42e1-bc84-c39f93a08ca4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">900,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c39333b-186c-487d-bd1b-a5d49cf99201" contextRef="C_5031cbc2-7c7e-4564-8649-f11720d9f7a5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">842,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f57df08e-797f-4a59-ae21-632bb2abb251" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85237a27-9a8d-4d45-a790-df8b98d99e6d" contextRef="C_308754fb-dced-4d37-8887-7c93a07410c3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cbafdfb-5fab-4f11-af75-c14d58b5a48b" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce47c504-3e99-48e9-b626-d7ec2d4b57e7" contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">280,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8412fead-a5e0-4017-9cf5-65084415d1cc" contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">232,901</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of employee stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72750edc-ebde-40e3-83f6-0b155d3221a0" contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7212c8b-1d0e-44f4-a729-3154c91ebace" contextRef="C_308754fb-dced-4d37-8887-7c93a07410c3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a7d4474-b169-4274-8b9d-3992e8bfd8c8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ded2cd9-be52-4ce1-8809-22af2cfaf7cb" contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d301b8a-f820-4d5a-8eab-f5acba539f56" contextRef="C_345d7b2b-de3c-423d-87ef-dde286307576" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cd0af24-4fff-47ea-93c6-a1d7768532d8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, net of expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52212570-890e-4f44-92d5-3ea46a5cb8ec" contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed" name="tcrt:IssuanceOfCommonStockNetOfExpensesInShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,228,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7abcb3b5-38d5-4412-9663-3b90b0a141c8" contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39c3619f-441e-4331-aaac-395377e888dd" contextRef="C_308754fb-dced-4d37-8887-7c93a07410c3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f03de41-d037-4b6f-9364-81ff76639006" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,724</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_904fde00-3381-4e1f-80d2-27044aee37dd" contextRef="C_345d7b2b-de3c-423d-87ef-dde286307576" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f83466b-7e51-4fe1-b2a7-92ec2e17279f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bc7bde8-2e98-4860-bc1b-1b8931c90d0e" contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,410,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_255e7ebe-fd05-42ff-bdcf-267898fc5ea3" contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b02af35-76db-4e6f-8dd8-a9fc2cd4c8cd" contextRef="C_951f87ae-ef91-4c42-a4b4-65ab2e55e723" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b4df150-ae33-4924-ba57-103f45c044e3" contextRef="C_2b37aa34-b800-43ee-8c0e-e716f02e6391" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">880,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a62749a5-5d8e-4d09-b52f-2bd3770f5efe" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;" id="bkmk_198"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_200"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_145"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STATEMENTS OF </span><span id="cash_flows"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.069%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.719%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.962%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15c81e95-e099-4774-a343-c2f31410168e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6bb6769-662c-426c-bfe5-ee70179ffe8b" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78,751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7caac82c-3f0b-45c7-9283-d047593c55a9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df9250b7-e224-4eb1-982a-82216dfcc021" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,597</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment and right-of-use asset impairment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bcd45fc-b93e-499a-8191-0faf7c2d10de" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86c0c5ec-1952-49b3-8f4d-fed93ff2f78f" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of financing costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c21e6b19-cee8-4034-94e7-0f5d6aaf551b" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">981</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_014d5602-b88d-42cb-b594-be66624a8ec1" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">383</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebc6b4c0-62da-4ee4-92d3-0531ea481190" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81581aae-6639-4839-ab1c-d2b88d22b5cc" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease (increase) in the carrying amount of right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b8fb767-4298-4007-90b7-dd9451760b5f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,417</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4801532c-9c2a-405b-b0f0-c695a8bf791e" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1faa86f1-a859-40da-992f-c98972b74331" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7880c24b-8c56-437e-a558-5deef5525097" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on sale of equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0750c978-b8c9-44a6-9386-de17f3a14b59" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fa74265-3f77-4995-8936-4a7914a0ef35" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Increase) decrease in:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ee25ad4-6e05-46f2-acd9-c4daca90ff9e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48319163-83fb-4f0c-a1cf-8d9cb13069d5" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edb77d69-9f59-4e66-badf-98f99a20b568" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76536071-3141-463d-9beb-5b65b429fba4" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d66911f-87c4-417f-a8a3-85130c8eb257" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76dd7505-7d1b-43ac-8c1d-689e402f7f20" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase (decrease) in:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5574057-e40d-43e8-bc42-fdb686e734a6" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf76da9f-1240-41b1-97a3-296d2e4134c1" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15e032df-21e8-4dfd-ad54-303bbf947bd4" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">668</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34d57191-5a62-435d-860b-a668f71ab115" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,512</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d51623ba-f523-46fb-892d-21f637e5d2e9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,501</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b5a9ca7-20cb-4bcf-94fb-351d07d81bf5" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5cd8038-07eb-4db5-8556-b1ffb9956692" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3a47637-7e6b-4d07-bdfe-d3625859a445" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc5413cc-5de9-4f80-b3f3-03df4f501e32" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5002a209-4a1e-4abe-aa0a-129b7aeb3425" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fa056c8-2489-4d4b-a9e7-ac482476d493" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9908431b-8890-4f24-9a27-16f4b833ff31" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the sale of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac0c0e10-6c96-479c-8433-c89808d5639e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5b8b880-7118-4cb1-a0eb-4d3a9915b7af" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d70887f-2d09-4daf-a55b-fa5ccda77035" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">193</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9395d774-e6b7-40ae-bb92-b10f8acf86cb" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from long-term debt borrowing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88b9bb23-e2fa-4eab-9ead-f62f05c17e3e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f8a7cd6-7754-4fba-ba15-707adc449f41" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa8f9b63-fc36-407f-a640-fe1077f77169" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de767859-23b1-4f18-a2fd-737664ff45ea" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6bd8e49-6a4f-4932-af4f-23d29c445aef" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0158cec-bcee-46bb-bc4a-984afee67b0f" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the issuance of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_282ecfc0-14fb-447b-a661-51a2e5785cf1" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,724</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_027c2d04-f91d-4a25-821a-77fa5d2f1de9" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5efdef02-edd1-4a65-b085-f71f16764470" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85b42966-4f27-4aec-b22d-276746e175a7" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repayment of long-term debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de3cf6f-46dc-4734-8bd2-f1d5a4f88772" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f310c9d0-b6f2-4a42-906a-9e385ab83c36" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37e7bf45-82a5-45f5-a3de-db8891fb63ba" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e4f1916-aded-418b-88ce-8c63458e1736" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2af2aa45-9496-42c2-84fa-f208c364c739" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_927abdbc-364b-4d1b-b37a-65d4a8ac8ea3" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,015</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_742d0170-9d8b-4621-a5c4-83fbdaf55c6d" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66665be7-2808-489c-b80f-9bbc47364ebe" contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50854357-7035-4223-8028-68df7edd8869" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb920257-32d8-403b-b316-c57e39d76067" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplementary disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_584572fe-3ff3-451e-ad3d-3d0c30e561a9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42f188e0-f2ac-442c-a89d-598d0b0a8127" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">630</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts included in accrued expenses and accounts payable related to property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff0c8402-b8cd-4a38-8759-bfa4a0e660a8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a0fe2f8-62f1-4d31-bb7c-1953e6a11292" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="bkmk_202"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:center;" id="notes_to_financial_statements"><span id="bkmk_146"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38ccb08e-2b3b-4751-8e28-33d515b5195d" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#x201c;Alaunos,&#x201d; or the &#x201c;Company,&#x201d; is a clinical-stage oncology-focused cell therapy company developing adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company is leveraging its proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts. In May 2021, the Company announced that it will be winding down its existing Controlled IL-12 clinical program for the treatment of recurrent glioblastoma multiforme. The Company continues to seek a partner for this program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s amended and restated certificate of incorporation authorizes it to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98f71493-6d89-4b5f-abd2-319d6cadc48d" contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">420,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. As of December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c638af63-9dce-4044-b261-9caad9dfafd3" contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,410,761</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding and an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54bb805a-6c7a-4eee-970e-e6ac13f32ec6" contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">33,330,964</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#x202f;The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae8ef4e4-9c51-44ef-b0d8-aacfe83a6366" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">53.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x202f;million of cash, cash equivalents and restricted cash. The restricted cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1949a9c0-6d67-4b6c-a348-91650cf78c25" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 is related to the Company's debt agreement (refer to Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The Company&#x2019;s accumulated deficit at December 31, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d325466-bd92-48b6-88c4-e37bf976d767" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">880.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x202f;million.&#x202f;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the fourth quarter of 2023.&#x202f;The Company&#x2019;s ability to continue operations after its current cash resources are exhausted depends on future events, including its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given, nor are within the Company's control. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba07c73c-039c-4071-a9d8-a0f6e4023bc9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:FinancingArrangementsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financings</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB.  The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51feb6de-1b4d-4ada-b243-443c5d567635" contextRef="C_46e7fb2e-f1c9-4ccb-af6f-ca1ebbcc3b72" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million funded at the closing, or the Term A Tranche, with an additional tranche of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cd39684-6166-444e-8580-85e1d9f3dd6d" contextRef="C_462e7c18-cbc4-47ba-a8c1-d1d50a7d313d" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective December 28, 2021, the Company, entered into a First Amendment to the Loan and Security Agreement. We refer to the Loan and Security Agreement, as so amended, as the Amended Loan and Security Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Amended Loan and Security Agreement extended the interest-only period through August 31, 2022. Certain milestones specified in the Amended Loan and Security Agreement were not met by the Company on or prior to August 31, 2022, and therefore, the interest-only period was not extended beyond August 31, 2022. The Amended Loan and Security Agreement also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the Amended Loan and Security Agreement, the SVB Facility will mature on August 1, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the Amended Loan and Security Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b8e6f7a-49cb-4420-b079-012a8d35bcb4" contextRef="C_bff7aa86-20fe-4134-91ba-5cfb0c6a91fb" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through Piper Sandler as its sales agent in an &#34;at the market offering.&#34; Piper Sandler will receive a commission of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3eef1be0-c551-4830-8a16-9c17ce3ae170" contextRef="C_bff7aa86-20fe-4134-91ba-5cfb0c6a91fb" name="tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the year ended December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3af91b24-b6af-4db5-aaa5-7aa430d5d04b" contextRef="C_c9a1def8-4beb-497b-91ba-095a8bfe834d" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80d4406e-65b3-4f89-ac87-4feb0a509a9d" contextRef="C_3310b49c-90b3-469d-a382-9cd149d1f45d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,228,719</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, or the Firm Shares, of the Company&#x2019;s common stock to the Underwriter at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00599fb0-f84a-4d98-951d-f552c84f4aba" contextRef="C_6402fd7d-1a53-45aa-80c2-5f9871d2d458" name="tcrt:UnderwriterParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.6191</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net proceeds to the Company from the Offering were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a837fc9-9299-447b-b798-9baf663041ec" contextRef="C_576d0b59-7299-4d46-925b-a9db2e440f2f" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_20d6a3b3-af53-4298-a98b-11415e41da73" contextRef="C_3310b49c-90b3-469d-a382-9cd149d1f45d" name="tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to purchase up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_609f7726-1b39-4d32-86d8-25bd31fb36b3" contextRef="C_e9343419-8bf1-4057-a39a-08c499c72684" name="tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,634,307</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8972755a-0fba-435a-bcb8-d46b9d0ae110" contextRef="C_df3febeb-1400-4046-ac65-31f7fc0f9f28" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,294</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of the Shares sold in the Offering were sold by the Company. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_8b5dc398-8218-4a9d-bb38-214dc9e538e9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2592a21d-e5d6-4827-9e36-dd08444adfdd" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_33abe69e-d9ea-471d-a47e-7ee27517b89c" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes.</span></div></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_26a83469-cd6c-4b98-b668-0bf8ee08d551" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. The Company did not have any material subsequent events that impacted its financial statements or disclosures.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df5e01b2-881c-47e1-83d0-d990118cff93" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1476391a-4c64-4371-b9cf-8afbc971ef15" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_810543e9-f23e-4c32-831c-fb333224d37e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.681%;"></td>
        <td style="width:5.562%;"></td>
        <td style="width:61.116%;"></td>
        <td style="width:5.562%;"></td>
        <td style="width:24.08%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x25cf;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ff43fc87-a092-45cb-bf60-73ea8d2f8480" contextRef="C_05d52965-6300-40e4-8bfd-1ef7d46d0bed" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x25cf;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d2b19bee-373e-4b17-8c63-05d9f58cb0ca" contextRef="C_614a96e6-084a-4999-9269-a5af0ea5ef99" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x25cf;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c8da568-ee6a-423e-aae6-a4fb8324ad06" contextRef="C_8e938d5a-7970-4180-afd9-341241ed6a9f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x25cf;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xfeff;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c7ff4c6-4a5f-4106-9d26-13336cba967d" contextRef="C_8974b041-067c-4f6b-b5aa-fb9b4b13e7fa" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life of the lease</span></ix:nonNumeric></span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the Statements of Operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f6038a7-177c-47e5-bb63-b4eef41ceba8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3fa181af-d6eb-4aaf-b953-a17d388f6aaf" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Segments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#x2019;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e60579e9-03de-4c15-af95-36239b4b94df" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:WarrantsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6020a32-b9de-4b87-a15b-96c61308d8b0" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6308a3e2-57b9-4f5d-ad1d-155e6621cd92" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"></td>
          <td style="width:1.201%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.45%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.212%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.215%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.212%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.215%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.212%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.472999999999999%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br />December 31,<br />2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br />Active Markets<br />for Identical<br />Assets/Liabilities<br />(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e17f05e1-0b88-47f0-85b0-522fc93dec8f" contextRef="C_f2309968-f205-40c9-9241-713fc3396454" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,058</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95ceb7ed-8010-4b69-90c5-044126373825" contextRef="C_ab1c56b6-303f-4a89-840a-261cdf06b4d5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,058</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"></td>
          <td style="width:1.201%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.45%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.212%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.215%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.212%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.215%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.212%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:9.472999999999999%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br />December 31,<br />2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br />Active Markets<br />for Identical<br />Assets/Liabilities<br />(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8c471b5-b663-484c-b0d1-9eadbfb36707" contextRef="C_514c2c0b-94bc-4b01-a4df-1fde50325832" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,222</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11304882-385d-4a4c-9e2c-0d3dd3aa4969" contextRef="C_1485eb13-1142-4bdb-a8fe-a487d8205fd0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,222</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2022 and 2021. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair value of non-financial instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2021, following the Company's strategic restructuring and further cost reduction initiatives, the Company determined that changes in the intended use of its Boston office represented an indicator of impairment, resulting in an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4f33e1c-c0c8-467d-97c3-0aac1628e017" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the right-of-use asset. In addition, the Company impaired approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c582359e-a733-457f-94da-ebeab62f8632" contextRef="C_9cf1d286-3ce3-4ffb-9230-67e0f5fc09ee" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of leasehold improvements and various other assets associated with its decision to close the Company's Boston office. Refer to Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b605ab71-14b5-4f3a-b29e-bbba538bd8da" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the year ended December 31, 2022 consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60233bac-95ea-455f-aaa5-79e717bb7ca9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and for the year ended December 31, 2021 consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17d8e908-3edf-4b1f-b5c9-54750657aa9a" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. For the years ended December 31, 2022 and 2021, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments and Contingencies.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. The Company&#x2019;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#x2019;s election.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Company&#x2019;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">using </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0041ca28-9af2-4055-a207-b4b3e8aab099" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to its prior estimates of accrued research and development expenses.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f380d88c-a008-4cff-8469-acb8be502c32" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f11ebff0-cf96-404f-b80f-ff10ee99c887" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#x2019;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#x2019;s common stock price over the expected term.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized the full impact of its share-based employee payment plans in the Statements of Operations for each of the years ended December 31, 2022 and 2021 and did not capitalize any such costs on the Balance Sheets. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bc68897-8c8e-410b-a244-598553b50a58" contextRef="C_c6b3f324-362c-44db-b937-baf10fb4ec1a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense related to stock options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9dc7371-1597-41ad-92de-f6533c766b22" contextRef="C_c676932d-8885-4601-9d56-bb66cbd31327" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense related to stock options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2021. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90a6ee60-9205-42bc-b793-3ddac652ab9e" contextRef="C_f0441e0c-ffba-4bb9-8a1f-155209670694" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense, related to restricted stock for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3e32c17-d75c-4f3f-bf02-efd298c71e98" contextRef="C_d832fa54-4683-49e7-a755-64e9d019ea0c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2021 (refer to Note 13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4ef57a1-b6b1-47df-8e9f-5751686d4907" contextRef="C_221169cc-a657-4743-838c-9c8afe3317c0" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_040f68ec-63c3-4ff4-a854-b9dc21501e59" contextRef="C_db9a000c-2293-40ba-a556-c8c4ee3dcd25" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. </span><span><ix:nonNumeric id="F_1bb722f9-95e7-468a-95a5-948f617323dd" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_1bb722f9-95e7-468a-95a5-948f617323dd_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#x2019;s Statements of Operations:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_1bb722f9-95e7-468a-95a5-948f617323dd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.914%;"></td>
          <td style="width:1.567%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.313%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.567%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:15.639%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5605fa2-03fc-4097-bcae-183140503395" contextRef="C_567da217-a1b9-4ef0-a65c-10a90ca9e5da" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">868</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69f07553-66b4-49d0-a550-607dc9dfc84d" contextRef="C_4c2387b7-8249-4b21-9502-83899b598473" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,598</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecdade76-da26-4a20-9b0e-f1e26b7d3c55" contextRef="C_560b8551-11ec-45b0-8d0f-cb0f5a999523" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,660</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_549cd227-8cd0-4c3e-9fb4-088dba9f04be" contextRef="C_426af431-5218-40c8-82c1-1b23c2d8f820" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,176</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c329ccf-d52f-4f91-828a-28e007e30828" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,528</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a637904-a522-4324-beb5-b192fd15eb33" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,774</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3395a167-d5f3-435e-9651-51d760f01b1b" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">0.77</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bff1385c-9687-4b4e-9d2c-c2c042d22462" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">2.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#x2019;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#x2019;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c3f0f43-735e-407b-9ca9-fda3a23ba419" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" escape="true" continuedAt="F_1c3f0f43-735e-407b-9ca9-fda3a23ba419_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_1c3f0f43-735e-407b-9ca9-fda3a23ba419_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.179%;"></td>
          <td style="width:1.623%;"></td>
          <td style="width:13.438%;"></td>
          <td style="width:1.623%;"></td>
          <td style="width:16.137%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_489ed37e-16fe-496c-a238-a985717b24c9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.63</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50e59563-1753-4b40-acad-919857c51d8b" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.21</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc9f95dc-e0af-483f-88e0-a184d9d4d013" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0570ce9-29a7-48a2-8791-04cbaae6fbf8" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.36</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c4a7b64-591f-427a-8f01-010854425105" contextRef="C_e116f993-9fc1-4e48-bcd6-42848abbc899" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9a14b123-c3fe-4bdd-aac3-306840b3c6ac" contextRef="C_82dc65f6-769b-4678-a99c-19131c41570e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_27bd2f83-0b14-4485-bae0-b6f79ca04a5d" contextRef="C_dbb3baef-97e1-4ff6-93d5-c0d1469c37f6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9de2f4ad-7e1e-4548-af4b-0404bc858bf9" contextRef="C_19528722-40e7-41ed-a517-daad870351cc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_414b26fa-3900-47fe-ade8-cc64c98d2b73" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">74.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ca3b562-218c-468f-8be2-cacd7f776398" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">88.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3a2a075-0f07-466c-b3bd-c9f300471b81" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce07846a-f351-47a2-9d7d-73f2abe519ae" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">74.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;%</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;%</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e01b2a13-dcfc-4f30-9e06-5c2737d19e23" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_220"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a53014d-0e27-41b5-aadb-889eabeb0745" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.797%;"></td>
          <td style="width:1.729%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.754999999999999%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.721%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.998%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a993f264-de26-422b-93e5-0fa34a8a18c6" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,730</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e45f26-8295-481f-80f5-d872584ee780" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78,751</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94c34ee5-a068-464b-9e73-58608753939e" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_bab83419-f73e-446b-ad96-7ff3ab4d340d" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">217,130,311</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63303800-81cf-420e-8aa9-bcdbc816b80e" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_818cb869-6c5e-43df-bebc-9c390c12dd53" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">214,399,074</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aabfc372-b600-4493-90b7-9d29229a2fbe" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_926d726c-cd94-4d41-898c-be18854132fe" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0083c092-b0f0-4792-92ca-ec8ff29455ed" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_e5bd5a51-6a38-4b07-8046-3d34f365c867" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.37</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain shares related to some of the Company&#x2019;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2022 and 2021 as the result would be antidilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ddd51864-b623-4902-ae94-73c0e2a5211b" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_ddd51864-b623-4902-ae94-73c0e2a5211b_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potential common shares on December 31, 2022 and 2021 consist of the following:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_ddd51864-b623-4902-ae94-73c0e2a5211b_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.845%;"></td>
          <td style="width:1.179%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.68%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.179%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.119%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fb21cc0-67a0-4164-b236-7e99ea49a8ff" contextRef="C_591e7f11-f18d-474b-89bb-898e7e2fecca" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,408,622</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ceff850-6185-47ee-b6ae-570ba424c033" contextRef="C_b10c21fd-e52b-4e2e-b88e-14eff7321012" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,665,869</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6cc4f9b-fa5a-4077-80ba-50007abcea38" contextRef="C_2a9368e0-978e-4613-87fd-43031426e546" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb50ae85-83e5-4ef8-853b-214d878ce742" contextRef="C_b91b4942-6a82-493e-af09-b7189d92ffaf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,500</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba58e3b9-4f8a-4572-97b4-611418e0c3b9" contextRef="C_9b23a7cb-ebe0-4b57-95ac-66f47b3626a5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">939,062</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13a1d650-0420-48e3-b3e1-313b7c43f8f4" contextRef="C_7c71e267-3b3d-41f1-9ee0-4e610cab53c4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,198,580</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddd74074-79ba-4598-8648-22ab0a06798f" contextRef="C_cb58e662-f444-4e56-ac22-b4f9e8e90c73" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,922,342</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22510aba-2fe2-4a4e-b13a-5526ea2e99cc" contextRef="C_8efabef4-accb-458c-ac37-ad97beec741c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,922,342</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f0a9bf1-1eec-410e-af70-7af958da183d" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">34,270,026</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be579284-8f29-4e95-b829-84f0a2c52023" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">34,819,291</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_30a07fe5-8747-419f-a6f1-faddf37fc05a" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the FASB issued Accounting Standards Update, or ASU, 2021-10, Government Assistance (Topic 832): Disclosures by Business entities about Government Assistance, which requires business entities to disclose information about certain government assistance that they receive. Entities must comply with the new disclosure requirements if they account for transactions with government entities under the (1) contribution model or (2) grant model by analogy. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842): Lessors &#x2013; Certain Leases with Variable Lease Payments, which requires lessors to classify as operating leases those leases with variable lease payments that do not depend on an index or rate if another classification (i.e. sales-type or direct financing) would result in a commencement date (&#x2018;day 1&#x2019;) selling loss. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation -  Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815- 40): Warrant modifications, which clarifies an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (e.g. warrants) that remain equity-classified after modification or exchange. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de6560d6-6d7a-45a3-88dc-ba89903cdaae" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Debt</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_027c4b2b-9303-46ec-90e1-3c10ca8ae3a1" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company's debt obligation were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.069%;"></td>
        <td style="width:1.625%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.719%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.625%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.962%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b78411ee-6784-4623-b4dd-0c18b8582e5e" contextRef="C_80a96828-a458-4544-8958-01676a2b66a9" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92e799f4-f8c6-43e5-8483-e0f86cb15250" contextRef="C_d6e29649-519f-4d9c-9d10-a997f6d84271" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c24eb30-22b6-48a8-bbc3-a94d964e4808" contextRef="C_80a96828-a458-4544-8958-01676a2b66a9" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">630</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35a88c76-a584-4ed9-a1f2-c44515c839d0" contextRef="C_d6e29649-519f-4d9c-9d10-a997f6d84271" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,091</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f46bd1a1-a53a-46c7-974c-874357cd6311" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,765</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3499082a-e831-4693-a197-103f9da6fac8" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,118</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: long-term debt, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e699edb9-54f3-4a41-a918-e2ec30d0f0b0" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,765</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7e902e1-70c8-40ad-bc33-f8d3af8f339b" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,868</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3e4a9c1-a50f-468b-9f85-907ff59f576a" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b41855d-bf74-4ef7-a7b8-9d50a4b8d851" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement. The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_751486f5-bceb-470f-9696-704f2fedc35f" contextRef="C_c21750f7-3aa5-4441-8546-e1bc5d4f21e6" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million funded at the closing, with an additional tranche of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a50ebae1-334b-4084-8492-00d1d5f7eb43" contextRef="C_c21750f7-3aa5-4441-8546-e1bc5d4f21e6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022. On December 28, 2021, the Company entered into the Amended Loan and Security Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Amended Loan and Security Agreement, the SVB Facility was modified to eliminate the additional $25.0 million tranche, which remained unfunded, leaving only the initial $25.0 million as the full amount available under the SVB Facility. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed8a42c1-bb56-41fb-9001-75b0552632b3" contextRef="C_70d3cfbc-3393-4744-8116-7ed62ae30d7e" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b50512a-5d99-4c31-aeb6-cc9d10b8d068" contextRef="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b741b889-b160-4c57-9e37-7c7f9efd3fd2" contextRef="C_3f2cc6cf-873b-457d-a3f2-2aec2c6cc50f" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, interest on the outstanding loans was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dfb90bb-eec9-48da-ac9e-f956ec78412d" contextRef="C_e20012df-a692-4934-8738-dbd4679dcd32" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">12.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022.  Commencing on September 1, 2022, aggregate outstanding borrowings became repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All outstanding obligations under the Amended Loan and Security Agreement are due and payable on</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de1f0b17-5dfd-4511-bd6c-9ca148ac3467" contextRef="C_70d3cfbc-3393-4744-8116-7ed62ae30d7e" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> August 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3061bab0-2e9c-4ed8-b086-70685a38c4e9" contextRef="C_0f55809b-c104-4cd9-a7b8-c6170ba8dc7d" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also owe SVB </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c064155-d18e-4cc2-aaa0-e4e072dc8c75" contextRef="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a" name="tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the original principal amounts borrowed as a final payment. The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00f5e902-dc38-4148-ae0d-121a77b59a00" contextRef="C_3167c98d-e838-42ca-8ff8-0935142120e8" name="tcrt:PercentageOfPrepaymentsPremium" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67937aef-e04a-40fa-8f7c-ee92012058dd" contextRef="C_91867dd5-8c9c-41f9-a145-5e903aa8fc40" name="tcrt:PercentageOfPrepaymentsPremium" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, of the SVB Facility, each such prepayment to be at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4703543f-fd8a-451e-8d45-33162d0eee56" contextRef="C_0f55809b-c104-4cd9-a7b8-c6170ba8dc7d" name="tcrt:DebtInstrumentPrepaymentPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million plus all accrued and unpaid interest on the portion being prepaid.</span></ix:nonNumeric></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of not achieving certain milestones specified in the Amended Loan and Security Agreement on or prior to August 31, 2022, the Company was required to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ae6c70e-dc66-4ec6-adb8-48f90817166f" contextRef="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a" name="tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the original principal amount of the SVB Facility. As of December 31, 2022, the Company has collateralized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_189a8273-367f-4e95-9d56-922dca010562" contextRef="C_b05a99fe-7e2e-4148-b7f1-089978eb0f33" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is classified as restricted cash on the Balance Sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94bd1b6f-779c-4ef2-b490-3199475ef602" contextRef="C_4d9edef7-64b4-4ce3-a9b2-3242785e4741" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78755d7e-b0a1-4cd5-a41e-fd88441a8881" contextRef="C_a8cab28c-a6cf-4033-bee4-05aee3010971" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of the Company&#x2019;s properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fa366a7-a691-4e9e-987d-dcd298201d51" contextRef="C_e9646e1e-5226-419c-8438-aa3071058ea6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">432,844</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20129aa3-424c-4011-8637-b3da73511990" contextRef="C_e9646e1e-5226-419c-8438-aa3071058ea6" name="tcrt:AdditionalNumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">432,842</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a85f03b-3cc2-4407-8c14-2eed6dd5ad67" contextRef="C_e9646e1e-5226-419c-8438-aa3071058ea6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Amended Loan and Security Agreement, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c4d8ca3-30f1-4998-8c74-97e52afa2dab" contextRef="C_35eb5389-797d-41ed-9818-2a4c3978c31b" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">649,615</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f480602-a57d-495d-978d-e49531469698" contextRef="C_31452367-fd08-487e-a553-53625bcad801" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_767ae0d7-29df-42ad-ad9c-13f8a7738be3" contextRef="C_35eb5389-797d-41ed-9818-2a4c3978c31b" name="tcrt:WarrantsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 6, 2031</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fbd75c6-7932-4b65-a406-cacb1dae974f" contextRef="C_1812d480-8b71-4f59-be40-0442f1ffcd39" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and primarily related to the warrants issued to SVB, which will be amortized into interest expense over the period to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2317d352-4544-49d9-9479-adfb64f245bc" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:InterestExpenseAmortizedDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Interest expense, including the amortization of issuance costs, was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_377ea848-6c1c-4689-80c1-3b8f23b8ed68" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab75f5dc-20b6-43d4-8ac2-5d3f9c53a4c4" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Amended Loan and Security Agreement as of December 31, 2022 approximates its face value.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ee4cc0a-c8e0-4edb-b6a1-248a896f23ba" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, net</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ae159a83-2578-4c98-a105-fc306089d006" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.417%;"></td>
        <td style="width:1.663%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.576%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.447%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.898%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f6154d7-31db-433d-8e61-ac475f2bbed3" contextRef="C_24124fdf-795d-467e-939d-a9e2516d8bd0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46e4b076-1abe-4ebf-9899-6a3cbe51cdc5" contextRef="C_b8ddf3ec-c36f-4b75-870a-25546c4e894f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aedefe6-f0fd-4ce3-a73c-365443840b92" contextRef="C_64074300-aa0c-4f1a-858f-92fd5f911176" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,291</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_965821cd-559c-47cd-b91f-6d7da25f280d" contextRef="C_0763068f-9bd4-45a0-98fc-aef5d8ca39a4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,236</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ba05a1a-d019-4ff5-a431-c8f70a6a0dc1" contextRef="C_812ddf85-9537-4bc2-9318-da210de34991" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09ad75a5-5eef-40a1-a408-bc40a3f54d74" contextRef="C_e818d17d-8abf-499d-ad41-5a7a4b414199" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df5672b-792f-49c8-8818-743949c2c4a8" contextRef="C_5cbfe56c-2a15-4444-a10e-cbfc6e942a3d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,232</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aff2753f-edf9-485a-aa7e-1c605a8c5828" contextRef="C_c21c60ee-6599-4da6-a569-17713873c52b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,110</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4d55cf3-3df4-41b5-9aae-b1e4833a619b" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,267</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df7e8586-cb3c-4a76-ac31-3e7ddde46115" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,354</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b9727ec-473d-4608-ad18-92556ceee89a" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_880d049c-560b-4312-880c-465b262611da" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,413</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf373849-879f-4309-8eb2-99bb5f53dcc2" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e59c5db-1eb7-46d9-8df8-63ec45f87419" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c47ad1d6-ff44-477d-8d2b-36224c88699f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e36cb2cc-4373-40d1-acdb-7d09c525af96" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. During the year ended December 31, 2021, the Company impaired property and equipment by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5042c63-fc7e-41f1-8a5e-7c1e03245145" contextRef="C_9cf1d286-3ce3-4ffb-9230-67e0f5fc09ee" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Refer to Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9bcce895-825d-4fd2-871d-4c7947d04e8f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d22648d-2a52-4723-93d0-cc91ef66dc1f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consist of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.696%;"></td>
        <td style="width:1.683%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.969%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.683%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.969%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4568c6b-44c4-41b1-88bd-c1461d4bfe96" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:AccruedClinicalExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96069e77-a461-44d2-be97-9a3d6d8bbe9b" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:AccruedClinicalExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0865073-4aaf-4d8d-882a-4f1649829002" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,160</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f673056a-bcff-4aa7-8027-b7bbbf3084ca" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84f2237e-1fb8-4abf-9fb2-455576ed556b" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95999147-2007-40c7-9428-070337a75dd3" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c493ea73-b87c-47fb-9249-78afa2923316" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:AccruedPreclinicalServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dec97e6-25d6-40b6-8728-daee25cb0c55" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:AccruedPreclinicalServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40d2798e-87bf-4166-8f00-5713b97a71d4" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:AccruedManufacturingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53c6e4e1-2aab-4a4e-a5bb-74a7b0088bb0" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:AccruedManufacturingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,056</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other consulting services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_388b467e-0ef5-443a-9d47-e6f149a88a3d" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:AccruedConsultingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00448718-1ac6-4bc6-b39d-17d16d7b4add" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:AccruedConsultingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97e967d9-8882-4d29-968f-4e30a3e929d5" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7f1ffff-3aa4-4b86-a2bd-d040259c4813" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55f3f908-8c32-4478-8b7c-c5c4382726c1" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,454</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68c0ace7-4105-4b90-9dbf-787a342c665c" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,076</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_45f7d390-2c4d-4d4e-8f90-7ea8e7259956" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration with Vineti Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc., or Vineti. Pursuant to the agreements, Vineti is developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#x2019;s T-cell therapy, or TCR-T, clinical programs. Heidi Hagen, who became a director of the Company in June 2019 and resigned November 2, 2021 and was appointed the Company's interim Chief Executive Officer on February 25, 2021 and resigned on August 30, 2021, is a co-founder and former officer, of Vineti. During the year ended December 31, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2284cafc-0d71-4175-a0b7-c33bdca58931" contextRef="C_1ce3d76b-39aa-4c2b-9bcd-7339fdd665a9" name="tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur expenses for services performed by Vineti, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c3bf61d-3173-4537-844b-653f0084c912" contextRef="C_f0e44d18-9dbf-45ad-95e4-6d8fae70e5de" name="tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">WaterMill Settlement Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 4, 2021, the Company entered into an agreement, or the Settlement Agreement, with WaterMill Asset Management Corp. and Robert W. Postma, or collectively, the WaterMill Parties. Pursuant to the Settlement Agreement, the Company increased the size of its board of directors from eight to nine directors and appointed Mr. Postma to fill the newly created directorship.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the Settlement Agreement, the Company agreed to reimburse the WaterMill Parties for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7f10ca6-89bd-4cc7-8445-5c31d107393c" contextRef="C_3ee8d1b3-28cf-4ceb-8232-ccc388824044" name="tcrt:PocketExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of their reasonable out-of-pocket expenses in connection with (i) the WaterMill Parties' solicitation of written consents from our stockholders to vote in favor of certain proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October 30, 2020, and (ii) the negotiation, execution, and effectuation of the Settlement Agreement. As of February 19, 2021, the Company has fully reimbursed the WaterMill Parties an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05e669c0-c288-46f1-a9cd-6044cc96b895" contextRef="C_8b3d36d4-5ca7-428a-aedc-04c2cb1c1e88" name="tcrt:RelatedPartyTransactionReimbursedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#x2019;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies in the People&#x2019;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm has contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ee4e500-1325-4e3c-814c-bb55b17109c8" contextRef="C_2e10ba7f-a809-4a04-aaaa-74a531d68803" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a91c71f4-d198-4a12-9d1c-96275e12c1cf" contextRef="C_0afbd561-5066-4598-a3a2-7762df69e5a3" name="tcrt:AdditionalLoansCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to this joint venture. TriArm also manages all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang is the Chair of the Company's board of directors and has been a director since July 2020. He also serves as a member of Eden BioCell&#x2019;s board of directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, Eden BioCell incurred a net loss and the Company continues to have no commitment to fund its operations. In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity is in the process of being dissolved. Refer to Note 15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further details.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0025754c-2859-4be1-b087-52437123b968" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2012, the Company entered into a master lease for the Company&#x2019;s office in Boston, Massachusetts, which was originally set to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b6138b52-7e09-44a0-8f30-670690f6d48c" contextRef="C_9367da57-38ac-4d29-b5c8-316a4a7256ab" name="tcrt:OperatingLeasesExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2016</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, but was renewed through August 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 22, 2021, the Company extended its lease for a portion of office space in Boston. The renewal of the portion of the Company's office space was originally set to expire on August 31, 2021, but was extended through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84bd0ed9-0c3b-40df-811d-b631d1e6d9ff" contextRef="C_a58f3578-b2b0-43dd-bd56-4371d7c586c7" name="tcrt:SubleaseTermCommencedEndDateAmendment" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_135f6a9b-d35b-4744-9bd0-7a49a3ff0c93;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></span></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, and December 31, 2021, a total security deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01231387-6f22-48dc-a835-a655108249cb" contextRef="C_556eae28-eef9-4c0d-8fae-4a6281b6012c" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_a82d5890-64d4-4f64-a1cb-5fa0483819a1" contextRef="C_074d1df4-7bc9-4dcb-b16c-ddf1bdf3643f" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is included in deposits on the Company&#x2019;s balance sheet. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company made the decision to move its operations away from its former corporate office in Boston. As described in Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company's change in the intended use of the Boston office represented an indicator of impairment. The Company determined the aggregate carrying value of the asset group (approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_816cee07-d1a9-47f6-8fe6-b750b5659fc5" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OperatingLeaseResidualValueOfLeasedAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2021) was in excess of the aggregate estimated fair value and recorded an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1154108-cf25-46e6-9db3-ee9511f06c64" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the right-of-use asset and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b59e5a86-d905-4a3c-8c19-40a5cd22d961" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OtherAssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to associated property and equipment during the year ended December 31, 2021. The fair value was determined based on the amount and timing of estimated net future cash flows, discounted at a risk-adjusted rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3d0230b-85d4-4c88-85c5-177954dfa749" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DiscountedRiskAdjustedRates" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2019, the Company entered into a lease agreement for office and lab space in Houston, Texas at MD Anderson through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54fbe2a1-24df-493e-90e8-0f0c4a93dc55" contextRef="C_08a67ddb-30d8-464e-a0ac-bdfb4a9ef7af" name="tcrt:OperatingLeasesExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the terms of the lease agreement, the Company leases approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25b13103-86f7-4e77-b91b-4709f66ed2f1" contextRef="C_c3245be1-2a56-4ce2-a313-9a3ec39aa110" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">1,038</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">feet and was required to make rental payments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an average monthly rate of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d4cc602-1ad7-40e6-9e96-ea1db2af5356" contextRef="C_08a67ddb-30d8-464e-a0ac-bdfb4a9ef7af" name="tcrt:LesseeOperatingLeaseMonthlyAverageRentalPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand through April 2021. On October 15, 2019, the Company entered into a lease agreement for additional office and laboratory space in Houston through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b4cc2c97-a944-43ab-bf43-877cbd06c33f" contextRef="C_c270381e-43d4-46f3-b514-f780c08aa3f9" name="tcrt:OperatingLeasesExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2027</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the terms of the lease, the Company leases from MD Anderson, approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96fb8b73-27f1-40b5-a5c6-5f85729b5ec0" contextRef="C_80826595-228b-476d-8548-2b525f9d98c5" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">8,443</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet and is initially required to make rental payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d47d89ae-cdde-492b-9b11-9f0f304e6dc5" contextRef="C_80826595-228b-476d-8548-2b525f9d98c5" name="tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through February 2027, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac349f90-c36c-4ffa-b2cb-05804cd063a9" contextRef="C_8f0471b9-3122-450c-83f4-9876302a91e0" name="tcrt:AnnualBaseRent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term. Effective April 7, 2020, the Company leased an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83545f87-5dff-40e1-a283-64477def8eff" contextRef="C_3be47963-40c3-4b80-8a99-5b3aa4d10c76" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">5,594</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet from MD Anderson. The Company is initially required to make rental payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07bea68f-5559-445a-aa07-ec894b8fe105" contextRef="C_3be47963-40c3-4b80-8a99-5b3aa4d10c76" name="tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_98ac2c19-6fa8-4924-935f-390c07f0f0d4" contextRef="C_3c4db62a-e3d4-421b-b8e8-3b6d5445b532" name="tcrt:OperatingLeasesExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2027</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_764b6e09-c1d0-4ee4-9874-b1708b0a796c" contextRef="C_a755066d-a762-4b1c-a9e5-da405de1577b" name="tcrt:AnnualBaseRent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 15, 2020, the Company entered into a second agreement with MD Anderson to lease additional space on MD Anderson&#x2019;s campus (the &#x201c;2020 Lease&#x201d;). The Company is initially required to make rental payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acccb3b4-28fb-4a02-9d29-d7268a862e71" contextRef="C_ff46e4b8-4535-4f61-bf4b-409c23561efb" name="tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through April 2028, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f502eac-07e0-4b8c-ae75-a51a5e8a3140" contextRef="C_3e843951-a185-415d-86e2-e4855f371dd3" name="tcrt:AnnualBaseRent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term beginning in April 2023. The 2020 Lease may be extended for one additional five-year term at the Company's election.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company modified the 2020 Lease, which reduced the Company's leased space from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d16d3811-a7ff-493e-ba1b-87fd78df1d03" contextRef="C_28c42504-64db-4bbb-b58d-31b90866d765" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">18,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a6b07c2-b570-4791-92ce-9f5a3d93f738" contextRef="C_677a76fa-1b6a-49f5-9473-b720f11528d4" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">3,228</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d27746f4-60e3-4c99-bda0-2215cfee600b" contextRef="C_677a76fa-1b6a-49f5-9473-b720f11528d4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million based on revised lease payments. A gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48ac62b1-8791-49db-8c44-30f2538c9aa0" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:GainLossOnModificationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the lease modification during the year ended December 31, 2022. The Company is initially required to make payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1c36134-22d7-42e3-b508-edac2a0abe29" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through April 2028, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4632833c-959e-4b85-9d9b-0e1626076aa2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:AnnualBaseRent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term. The 2020 Lease may be extended for one additional five-year term at the Company's election.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_746d5b8b-69a8-4cff-8220-1954036066da" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_231"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.343%;"></td>
        <td style="width:1.836%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.988000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.836%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.997%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04b01051-984c-44c8-a5d5-4880657e2e3a" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8adbfec9-132d-4965-9a6d-981b639e9629" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41bebbaa-0906-4d9e-b883-a40eece5b0e8" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b28da7c4-ddc1-4f60-aa93-767440f9dc6e" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8363d950-9c7e-4dac-8ceb-bec078faf2c3" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.13</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cfae845f-eeee-4a2e-a0c4-7dd868f0e5a4" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.58</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0e5c6e3-97fd-41b6-9832-e35acbcc74c4" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">8.26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17b78e0c-5072-4047-b562-fee8ed6975e0" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">8.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17fa1497-d249-48fa-b154-0808eb97abbe" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for amounts included in the measurement of the lease liabilities for the year-ended December 31, 2022. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2711dc6d-d8d3-4081-8b63-24ac7723905e" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize new operating lease assets obtained in exchange for operating lease liabilities for the year-ended December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1a93f7f-9e2c-4d63-a73d-a4572275f6d2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the maturities of the Company&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6934d123-79b6-4d0e-9146-8913adc044ad;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating lease liabilities</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.093%;"></td>
        <td style="width:13.477%;"></td>
        <td style="width:24.346%;"></td>
        <td style="width:11.972%;"></td>
        <td style="width:1.012%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.1%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of Lease Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7884d1c0-1a6d-455e-ae07-d69811b7b164" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">757</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1df7f784-6597-45ae-970c-00a8d25c024a" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82120970-9b15-43e0-bc41-c296b5824397" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4002add8-8768-4690-b8ab-b2f8c8ca4c3f" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">712</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c193c1a5-b444-4d61-89de-d1b1029cf158" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_180726c3-b93b-4e15-8950-b5acf712f523" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42690c03-00e0-446b-a2ff-f0b7f770bb2f" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dcdd84c-7fbc-49d5-a7b9-b556f4665e93" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">496</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edf16a94-54a2-43b7-8cb2-c180a3328055" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,746</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company executed an agreement to sub-sublease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4996f468-ca3c-4bcc-894c-23845d861e0f" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:SubleaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">4,772</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of subleased office space in Boston. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_60d83e28-c18e-4e16-87fd-c1beca5363a0" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> For the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_723b6362-33e7-46fd-a599-4c5f4de09bba" contextRef="C_cf145b1e-8766-417b-b25d-39bde6bf3ba7" name="us-gaap:LeaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in lease income, which is classified within other income (expense), net in the Statement of Operations. Under the current terms of the agreement, lease income for the remainder of the sub-sublease term is expected to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_202a9955-b3c8-4a68-b73c-abf5dfd42f82" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2023, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16f0d0b5-7f16-4174-82bf-4966741f219c" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2024 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9feb7273-356c-43b6-922e-cf44cc8dea7a" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2025.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_393a2b1c-df4d-46a8-b532-00022e83637b" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with PGEN Therapeutics</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement, the Company has exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between us, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also has exclusive, worldwide rights for certain patents relating to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products and TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the licenses and other rights granted by PGEN, the Company pays PGEN an annual license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9cee5e0-1a61-4e33-ac99-4e344363143f" contextRef="C_2be3c3ac-efdc-402a-827b-95ce13fc11c0" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the Company reimbursed PGEN for certain historical costs of the licensed programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will make milestone payments totaling up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4a7e553-9165-40c2-a447-45f25afa6da8" contextRef="C_2be3c3ac-efdc-402a-827b-95ce13fc11c0" name="tcrt:MaximumAmountOfAdditionalMilestonesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. The Company will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fcc35fa-a490-48f5-ac49-dee4ee496402" contextRef="C_966e453b-8a58-437f-a91f-f254719ff9b9" name="tcrt:MaximumAmountOfRoyaltyPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate. The Company will also pay PGEN </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db2753e2-9458-4e76-8f08-5f4c54362c4f" contextRef="C_966e453b-8a58-437f-a91f-f254719ff9b9" name="tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of any sublicensing income received by us relating to the licensed products. The Company is responsible for all development costs associated with each of the licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PGEN will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6c948c7-022d-4e01-9919-a0e24f14291c" contextRef="C_20b416e3-3907-4e97-9e9d-1fcba80f134c" name="tcrt:MaximumRoyaltyAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51461b5e-befb-4da2-833d-aee35fb3757b" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_31a22ac5-97d8-4617-b559-0649f89184a3" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> royalty amounts were incurred during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#x2019;s obligations to provide transition assistance relating to the IL-12 products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#x2014;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82dbd7bf-5e80-46d3-8be5-b72186cff76a" contextRef="C_76510e7e-f84f-4555-b284-0b2f7facecaa" name="tcrt:LicenseAgreementCommencingDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 13, 2015</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who served as the Company&#x2019;s Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#x201c;Fourth Amendment&#x201d;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69644363-e34b-4c53-a2db-df969569e143" contextRef="C_d20ec984-e91b-4bbd-aeea-1e39b7a6c803" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e200e7e5-aeda-461c-a936-1582f4cb8989" contextRef="C_de82944d-045e-4494-962a-60bbd7316d2d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which we entered into on October 22, 2019, with MD Anderson, pursuant to which we agreed to collaborate with respect to the TCR program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, PGEN, and MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#x2014;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to all, intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies, and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9db11396-c0f6-485e-912e-c3d9be21799d" contextRef="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d" name="tcrt:AggregateAmountPotentiallyReimburseableAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cae2656-fcb1-426a-b55b-efb6235ca388" contextRef="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d" name="tcrt:AggregatePotentialBenchmarkPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which only $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb7e3b53-8015-4ae8-86f8-b8c19737d32f" contextRef="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d" name="tcrt:AccrualsPriorToFirstMarketingApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the year ended December 31, 2022, the Company incurred clinical expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2884066e-56d9-4d39-9093-e07c7fc89d2c" contextRef="C_8339573a-0ca5-49ab-b505-6fdfb84cb410" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from MD Anderson related to this agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36c55898-41f8-4a40-96a9-a8f6e45e3575" contextRef="C_7396adc0-9e69-4eb0-8a3e-8adda7c5d090" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a39f632-23ca-4544-ac1a-49b5d4e6288e" contextRef="C_009c6c2d-9013-4f24-9a09-41485c023a44" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,333,333</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bf85192-ab20-4da2-87e0-b9b6537e2870" contextRef="C_009c6c2d-9013-4f24-9a09-41485c023a44" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1bff1169-a797-4dcd-8c33-15987391ff81" contextRef="C_009c6c2d-9013-4f24-9a09-41485c023a44" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and vests in four parts upon the occurrence of certain clinical milestones. As of December 31, 2022, the milestones have not been met.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Patent License require the Company to pay the NCI minimum annual royalties in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f324345d-06e7-4d77-b746-b27906b72385" contextRef="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b" name="tcrt:MinimumRoyaltiesAmountPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which amount will be reduced to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d35d281-c7c1-4afe-ba9e-1cbea0bba1da" contextRef="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b" name="tcrt:RoyaltiesAmountPayableThereafter" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million once the aggregate minimum annual royalties paid by the Company equals $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b58e4c9-e220-4c4d-8d47-e3e6f0b32eb7" contextRef="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b" name="tcrt:AggregateMinimumAnnualRoyaltiesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6e3aed4-2f6b-4c92-ab13-f5305793ecac" contextRef="C_735e4858-865a-4de6-850e-3aab57d7148b" name="tcrt:AggregateBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which aggregate payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a41638de-592d-46ea-81ed-d72bb2b47232" contextRef="C_f9f80da5-3640-4b51-b5d8-02726e56d225" name="tcrt:AggregateBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_404f7f82-a2a5-4817-8f86-15745f50e116" contextRef="C_eb8415ef-ed42-43d3-bebe-c35459c15508" name="tcrt:DescriptionOfFirstBenchmarkPayable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first benchmark payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c256b474-46b1-4267-9c89-a04679894a12" contextRef="C_d75e53ea-0702-44cf-9dd4-dc1d1548bebb" name="tcrt:InitialBenchmarkPaymentDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a6d7f97-7d64-4ec7-99f5-1036b22f4985" contextRef="C_b83280a9-1359-4007-a613-0f63cf09a0cd" name="tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1473c2e-c184-4a3b-a18a-4aa2f26fcc0f" contextRef="C_b83280a9-1359-4007-a613-0f63cf09a0cd" name="tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. The aggregate potential amount of these benchmark payments is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2f8b4d9-5235-4a24-ad3c-e346d1c56a49" contextRef="C_4418daac-e678-4e2c-be6e-3555ed9a312a" name="tcrt:PotentialBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d11d5055-2a5f-46a2-a8bc-5341de0772bd" contextRef="C_eb8415ef-ed42-43d3-bebe-c35459c15508" name="tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company may terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13bc18f3-0e8e-42ab-9688-0122fea8672b" contextRef="C_eb8415ef-ed42-43d3-bebe-c35459c15508" name="tcrt:AgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df9ece60-bf2c-4bfa-b416-1f83a4b0a9c8" contextRef="C_aa3e31b2-77fb-40fc-bedb-7d66b32336b4" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of expenses and incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50b7428f-f661-4af8-88e8-c32d1744389f" contextRef="C_a3613417-09f3-43ff-8294-f0c33b77cc57" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of expenses for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company will have the first opportunity to file a patent covering the invention. If the Company fails to provide timely notice of its decision to the NCI or decides not to file a patent covering the joint invention, the NCI has the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service grants the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which are licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company is also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI has a cleared Investigational New Drug Application, or IND, that would permit them to begin this trial. To the Company's knowledge, the trial has not yet enrolled. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a68fc504-43fa-4cfb-8dbd-b5724e254c05" contextRef="C_6286a83b-0f82-4d71-9785-6d19951b5c7d" name="tcrt:ObligationsDueUnderContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to this program; however, for the third and fourth quarters of 2021, the Company was not required to make payments toward the program as agreed with the NCI. Therefore, as of December 31, 2022, the Company made $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9d80d7c-cb10-4652-9b52-96296fc41592" contextRef="C_82b5c3f4-e428-4dc9-a489-d6da42ba15d5" name="tcrt:QuarterlyPaymentsUnderContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of payments under the February 2019 CRADA extension, and the NCI has agreed that this is full satisfaction of the agreement and no further payments are due under the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00b9e01a-b422-40da-90b4-a2b0b7a0ee1e" contextRef="C_6286a83b-0f82-4d71-9785-6d19951b5c7d" name="tcrt:ObligationsDueUnderContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commitment. In March 2022, the Company entered into an amendment to the CRADA that was retroactive, effective January 9, 2022 to extend the term of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRADA </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c34afac-a9e5-4798-a20d-d4f7055297e5" contextRef="C_c8f802e5-6966-41fa-9657-aae7124cdab0" name="tcrt:ContributionPayableOnPerAnnumBasis" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04288700-0d46-485a-8d47-35e8eef150e1" contextRef="C_82b5c3f4-e428-4dc9-a489-d6da42ba15d5" name="tcrt:AnnualExpenseIncurred" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur expenses under the CRADA for the year ended December 31, 2022, as compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50ac35ad-374a-484c-b526-9d56a6e120b7" contextRef="C_c65c999f-7903-41c0-85f9-01dae5de02f9" name="tcrt:AnnualExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#x2014;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bc57c33-ea8b-46df-8be5-63b99fb93196" contextRef="C_c9ae6604-f2d2-43d1-a9d1-f8a9f071c33f" name="tcrt:MilestonePaymentsMaximumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the year ended December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ade809e-fffc-4b24-b23b-f4df9ba788a5" contextRef="C_f1cdd995-a3b3-4a88-86cf-666181247c3f" name="tcrt:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was incurred as a one-time milestone payment under the terms of the agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fc9a6fa-c4b7-4fe5-8732-239ba2a9f72a" contextRef="C_1d2fdd28-ac94-4045-9dd8-0480c92e9cea" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_197912d0-38f5-42b0-9842-8973587baec4" contextRef="C_139d76d8-bc1c-4f22-909e-3ae5eccdbd1b" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand in royalty expenses on sales under this agreement during the year ended December 31, 2022, and did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03b3e964-9a0c-41d5-a8de-189f3ea866d0" contextRef="C_01541ff4-c565-4665-8fd3-c5b8b851f917" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur royalty expenses on sales under this agreement during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#x2019;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2022, the Company earned $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c14e67ed-37f2-449b-a464-7f7f510257b6" contextRef="C_e8f1b252-50d6-4597-8b92-45eb247fae8f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6033b57-6fd1-4f10-bd48-7076a933db0d" contextRef="C_9245beb1-9103-47f9-b176-2c032568f730" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_106f32b6-def8-41c8-814e-123091da91d9" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:WarrantTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company&#x2019;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4acd1f9-331f-4abb-8357-403bd08652e0" contextRef="C_ec21d5ba-40fd-4ef7-b050-7c8f6c9de41b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">47.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93b65f90-25dc-4322-94fe-fc654edb52dd" contextRef="C_af0771c8-7bb6-4d20-b747-7a3e0f9ad3c5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18,939,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def6fe3f-2f1e-45a6-8f58-9dfad04fed81" contextRef="C_af0771c8-7bb6-4d20-b747-7a3e0f9ad3c5" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6febefd-a480-407b-bfca-e6d7445d9a5e" contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13df2ada-cc13-4f61-86d7-92c1fe05b18c" contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">71</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b01d0eea-0c6f-4b28-9a06-91b15b9d93c7" contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a730ee79-dbd3-4eeb-a460-313998ceb4fb" contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70df2991-c736-4d43-9653-90cfcf95f2b9" contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78a15d3c-86f3-4b86-9cec-8deba56364e8" contextRef="C_019df9ac-fbae-4355-8668-11ee7fd04e38" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">17,803,031</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e1f5f3c-183c-4545-9046-221d368a9a3e" contextRef="C_019df9ac-fbae-4355-8668-11ee7fd04e38" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebbfcabb-4fff-40e4-ad6d-1e7433722f4a" contextRef="C_67e87324-3985-420c-90be-d2e08d2df27a" name="tcrt:PlacementAgentFeesAndOtherRelatedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_058aa26d-c870-4c21-836f-40b89df3274b" contextRef="C_7c4f4916-db64-490f-8174-b66da79fd2dd" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e36020e-8874-42d3-87aa-d516d4688d78" contextRef="C_f707f4a5-a8e0-4111-bc42-c5d4a9d92abb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">17,803,031</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock, or the 2019 Warrants, as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa9e229d-ab03-4bab-aabc-de6ca130d1cd" contextRef="C_f707f4a5-a8e0-4111-bc42-c5d4a9d92abb" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9aa8635-dc79-4569-94a9-686fcbdadd63" contextRef="C_9ef452a7-a519-46fd-b8a6-51b26e948a62" name="tcrt:NonOperatingIncomeExpenseInducementOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million non-cash charge in the Company&#x2019;s statement of operations in 2019.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ec3cd78-efd8-4eaa-914a-91634087498a" contextRef="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,333,333</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7abed2fa-0e3a-4d09-ad9c-44afda16c141" contextRef="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8bb3be5-a952-4140-a50e-c9e68ad7f3c6" contextRef="C_7ef2eeab-93c5-4783-a05f-f12f4779e164" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_367917d7-67cb-4bd1-b009-2dc161a31c63" contextRef="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the year ended December 31, 2022 and 2021, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e59de47-0590-4513-8b70-a4494218807f" contextRef="C_7117f1c3-b39a-4248-8ab6-f843b0bbb987" name="us-gaap:CommonStockSharesSubscribedButUnissued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">432,844</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_950eedac-2926-4a47-9b1e-1a53bca38c91" contextRef="C_83b60ee4-931e-45fb-9e47-1b18baa0e863" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The warrants have a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba7ca599-ee23-4c2a-90ed-8a92dec11083" contextRef="C_7117f1c3-b39a-4248-8ab6-f843b0bbb987" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5d5a7f6-0d03-4531-94a7-69d648124785" contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7a86b2a-5393-4f48-9241-feda28aad054" contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_149dc0c3-0518-40cf-ad03-c724c10aa58b" contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.31</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81b492fd-aaee-45cb-a292-d366c095f455" contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0144d4b9-a0de-45b9-9a91-7f09be4d49d2" contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the Amended Loan and Security Agreement, as described in Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ed3be69-2e3f-4388-949b-d0a664592f3f" contextRef="C_1cf5e5f2-8735-40b8-b39f-efaad36c2475" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">649,615</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f98986ea-592f-4f92-814b-ddb541fa81ed" contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.16</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. Using a Black-Scholes model with an expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97ec3a81-b599-43f8-a606-9a02da2cb32c" contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">81</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca8afacf-3939-4c44-816f-c14c7d80e473" contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16d1de80-f459-4b52-8a82-86ee50f32276" contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82e32e77-f066-4e0a-8d53-ca48003cf7b8" contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends, the Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4500275-26cc-4e94-bf15-90d38738e0c5" contextRef="C_f8f70fa4-ffe5-4f49-b2ec-312c36fe67b2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0f16ce4f-8d70-403f-b6b8-a51d4653179d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increase in the fair value</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the SVB Warrants due to the modification of the SVB Warrants during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed whether the SVB Warrants require accounting as derivatives. The Company determined that the SVB Warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the SVB Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7bb7c79-ed21-4a22-b5c9-c6880e7180c2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restructuring</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, in order to lower its existing cost structure in connection with the realignment of its business strategy, the Company announced a strategic reduction in force and notified approximately 60 full-time employees of its intention to terminate their services on or, in most cases, before November 30, 2021. Certain of the notified employees had employment agreements that provided for enhanced severance benefits. The severance benefits, apart from certain continuing Company-paid health care benefits for up to twelve months, were paid in 2021. The remaining benefits were paid in 2022, which reduced the severance benefits accrual to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baa53908-33c0-4bd9-8015-9cabf37d65b4" contextRef="C_fcb43152-91fe-48f4-aad0-514fa76c5e42" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6bb29e1b-20dc-4d16-964d-74a65c2b2fe2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred the following costs associated with termination benefit payments resulting from the strategic reduction in force:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.992%;"></td>
        <td style="width:1.713%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.528%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.767%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebd12dec-0baa-48c0-96b2-c727f9fa94c3" contextRef="C_4c2387b7-8249-4b21-9502-83899b598473" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db4bec9a-aa4c-4886-992d-cf97dd4285e5" contextRef="C_426af431-5218-40c8-82c1-1b23c2d8f820" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total severance expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9656765c-1930-41de-99b9-b7ba006111c2" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ba3490bb-b23e-4239-a929-b6cb04aac859" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is no provision for income taxes because the Company has incurred operating losses since inception. The reported amounts of income tax expense for the years ended December 31, 2022 and 2021 differ from the amounts that would result from applying domestic federal statutory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tax </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rates to pretax losses primarily because of the changes in the valuation allowance. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6cf2dff1-6913-4ac5-9524-52515feeee4c" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_6cf2dff1-6913-4ac5-9524-52515feeee4c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of the Company&#x2019;s deferred tax assets at December 31, 2022 and 2021 are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_6cf2dff1-6913-4ac5-9524-52515feeee4c_1"><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.201%;"></td>
        <td style="width:1.585%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.654%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.585%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.975999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8e062fe-e760-48ce-a481-feb1c72bd6cf" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,070</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dafaf6f0-50fe-424a-af16-74362f0d05f2" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,486</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Start-up and pre-clinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3782c04a-9e5c-41f0-88c9-4d80acf7ccc3" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe2b5ea5-bf36-4eca-b55b-b3a1cbce2a1a" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,705</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddf6437d-8546-4a4d-a146-0efacea0600d" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e7b56d5-30b7-4440-b8b9-b1108943f5eb" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7d20af2-fba4-40c2-b086-7930fd21544d" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dec9742-db33-46d7-91a8-48116c08240b" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">706</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized acquisition costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e4f90b3-2a7c-4338-8bb6-d241a7377038" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38ab4d2a-5dba-410b-9da7-0fd46de982e0" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,946</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3de89f1-2837-4ab3-aa83-d0e4ce4ddf3d" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_629d9e51-0467-4816-b6a9-8242a2c95f37" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bac2ab1-84f4-45b0-be72-9ad4cbab47da" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DeferredTaxAssetsDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36fc5831-cb24-43fe-929b-afd852517699" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:DeferredTaxAssetsDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d2c6fec-8c0c-4723-ab6b-d2a0150d1af1" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DeferredTaxAssetsResearchExpensesCapitalized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,156</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0716b52-1b4a-403e-addf-ba9ef52e7590" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:DeferredTaxAssetsResearchExpensesCapitalized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a15aa7-fccb-494a-a76e-321b44260359" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b377c9-2aa7-4d70-b440-53d0d0ecab35" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20d2af79-e803-4253-a453-77f767a5b57e" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">237,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03a27ca2-95fa-4d6f-8f80-de35a3ef66e1" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">231,196</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60958e36-a0e8-4fe8-ba67-e1397cd3b69f" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_281aa79b-d19c-4f5d-9af0-5151d29a4774" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">230,119</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a2812ff-9813-409b-be48-e14d18b6e3bb" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ad5a38f-36ac-4703-9fc1-a8d073e36a1c" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68bd760a-8db8-4fb8-ad50-d61b416dcad3" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="tcrt:DeferredTaxLiabilityRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f4f4f6a-0e2b-44c8-bff3-4bbb0968d0f6" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="tcrt:DeferredTaxLiabilityRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9403b5c-1f40-4e79-ab69-ea27db9c8451" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_380d6b47-849e-488e-8742-771ff08e7fd9" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba0e4286-4b84-44f2-9e2c-7514c9d818fa" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68d540f6-d40a-4384-9fe4-8b70188c9225" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2022, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_210aefe2-68e8-4f21-9c33-5e0b756df172" contextRef="C_bdb6cf3c-3394-4924-9e66-e2220477279d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">665.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dabef8dd-aafb-4014-b3e7-489fb0509d6a" contextRef="C_7a975d4f-655a-404d-a576-8eb7fc9e24a3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">341.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million expire at various dates through December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5ca69864-2ddf-4b9e-8d49-5beef70522ec" contextRef="C_3d61c456-2ac5-4ffa-a8f5-cec10246c86a" name="tcrt:OperatingLossCarryforwardsExpirationDatesState"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63f3abfa-531d-492b-875d-92cf7208d773" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">323.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million can be carried forward indefinitely. The Company also has approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d166f62-57bc-4ec1-a8c6-c1e7d5c6727d" contextRef="C_b9e1d219-2ee6-449a-8982-40603fb9f929" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">497.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating loss carryforwards available to offset future state taxable income, expiring at various dates through 2042. Additionally, the Company has approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_463192e2-faae-4e6f-bfe5-17e5a79993ea" contextRef="C_4d61befa-1f31-42dc-852d-7c27952aa374" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal and state research and development credits at December 31, 2022, expiring in varying amounts through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fbffa7e9-8eb4-493b-9d87-1d57260ff949" contextRef="C_ee038ec2-a0cc-48d1-b9ca-0fa12ba3bac8" name="tcrt:OperatingLossCarryforwardsResearchExpirationDates"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which may be available to reduce future taxes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has provided a valuation allowance for the full amount of its net deferred tax assets since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_097c0cc4-e222-4d31-9522-d7c23f5ca774" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2022 due primarily to net operating loss carryforwards and the increase in research and development credits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes using the federal statutory income tax rate differ from the Company&#x2019;s effective tax rate primarily due to non-deductible expenses related to the Company&#x2019;s issuance of warrants along with the change in the valuation allowance on deferred tax assets.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b3655759-29f1-420d-a3b5-8d3c32d7cf56" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.362%;"></td>
        <td style="width:1.112%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.258000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.112%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.156%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal income tax at statutory rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bb11d4b-f64f-47b0-a9cf-d25354557bb6" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_824fd970-9b7f-413a-929f-598f016a0fb9" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f77d6e98-9a18-40b0-9cd4-2aa6bc6ebac2" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb98cab7-e646-49d5-90cd-4107dec5ace3" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b6933fb-cb21-4d7f-b641-7037a5db2241" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a8cb29b-546e-4380-9a9f-e3f0944755e8" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development true-up</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cedaea5-f43c-4940-8f0b-2455d9765571" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26fbe0bc-3201-47f8-b36b-4a6b579d4600" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc1bc5ed-4bf4-4108-a19c-6581331de597" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0224014b-88d2-462b-827a-7c06f612064d" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal/state rate change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca829cce-c529-4c0a-ac0c-f261e75bc2ba" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6f2d7d7-fd59-457b-b820-91ef439da963" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41250db0-5c6e-49aa-9a6b-997b2f93a211" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68a9e81c-7fba-4737-a8e5-39704dee6331" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15836bec-f7ec-4a62-bb71-2a57c6fa5f80" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b16e310-6add-46c2-b7d2-c742d4f1d1cd" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Uncertain Tax Positions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements in accordance with FASB Statement No. 109, &#x201c;Accounting for Income Taxes.&#x201d; ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c8508c5-6ffe-424a-8392-a7b09c911559" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_544fdc1b-d15d-4d61-ac38-94a282e25cda" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> adjustments to its uncertain tax positions in the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized any interest and penalties in the statements of operations because of the Company&#x2019;s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2022 to the extent net operating losses continue to be carried forward to 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or the Tax Act, eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to capitalize and amortize them over five years pursuant to IRC Section 174. The mandatory capitalization requirement had no impact to the overall deferred tax assets due to the Company's loss position and full valuation allowance.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc5324ed-babe-4904-a5d2-f6b567750156" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option Plan</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, in May 2012. Including subsequent increases, the Company had reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b89e79a-8ff9-43d9-bfc3-0a61742aafaf" contextRef="C_fdbd888b-893b-4b86-85b2-065fe730f06d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">14,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares for issuance. On December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b94b2128-a1ac-4a5d-b58b-79602fea3cb5" contextRef="C_e079d01f-15d4-407c-9a4a-2730c6e26083" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,089,296</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for issuance and no shares available for future grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, in June 2020. The Company reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_955d642d-eec0-452c-8b84-a08aaf2e76b4" contextRef="C_56a01732-96e4-4efd-9e90-6e3312d5c45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">21,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares for issuance plus a carryover of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1c4f2a8-ac11-4a74-8e37-3545e5740a39" contextRef="C_8d865232-5799-4e0f-9833-17a27353c527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,066,275</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares from the 2012 Plan for a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_538177c4-0994-4303-ae33-79cff3b715e9" contextRef="C_56a01732-96e4-4efd-9e90-6e3312d5c45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,066,275</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, returning shares from the 2012 Plan are available for issuance under the 2020 Plan. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79184734-9617-4d6f-a4eb-c5dd9d1cf72b" contextRef="C_7d794ebc-1417-4c1e-9565-4410865a0c4a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,319,326</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for issuance and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cf5e5f1-c6d2-4ef6-9845-5be0c753ad5e" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,460,088</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for future grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options generally vest ratably in either quarterly or annual installments over three or four years, commencing on the first anniversary of the grant date and have contractual terms of ten years. Stock options to directors generally vest ratably over one or two years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation is recognized based on such fair value over the period of vesting on a straight-line basis.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the option exercises during the year ended December 31, 2022 amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec1e35a9-62a8-4901-ba68-d433b0db3731" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand and during the year ended December 31, 2021 amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b033efef-3169-4463-b25e-9de861f3b049" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The intrinsic value of these options amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e256fe8d-2534-46a5-a4a8-6a920e901002" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fa6b702-000f-4345-85f6-1e74759db691" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f5c24b49-5e7d-49ec-ad0d-1ceb8c82889d" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the Company's stock options plans for the years ending December 31, 2022 and 2021 were as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.426%;"></td>
        <td style="width:0.223%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.288%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.061%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.588999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.223%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.831999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.476%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.882%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_334c1d50-e086-4f7c-b727-7418d72900b1" contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,840,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a85a4504-508d-489f-a55d-bc68417aa719" contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e55a122-4bed-406f-9e77-93d35f726f49" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,380,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a51d3215-01b4-4a09-89d2-c922b329622e" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ebd414f-aa7b-4013-9ae3-c810bfd7b3ed" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">363,109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69a9dfa6-de79-49c3-8bb3-c4e40b3f6a9d" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec586387-59db-4992-a511-b283a28c873a" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,192,179</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d512be3a-a4fb-4388-9c89-30f0a452d581" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8f004f8-cf54-438d-b7c2-5a6b0087707d" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,665,869</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eff43236-ea71-40de-bbfb-e242adfd5cce" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_886e268a-a5ef-4f8b-9728-ad25b96f9c23" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,697,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3e523db-d061-4896-872b-01dc736af218" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0847764-32d2-4316-87e2-279211be7e60" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fcb9a18-37b7-4206-9c93-2daf67c7057f" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01559c7b-b20e-42f0-b7e9-3ef08992a655" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,928,497</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79a90639-44df-47b7-9c17-eb04221e3055" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec8ad833-1d6f-4866-9cd3-fd021e35f8b4" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,408,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3112f6fc-9eb6-4bf3-ba20-5e6bb3c9a477" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19519d77-8dcc-438e-b75f-fe88436447dc" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.69</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51a9023c-f7c8-41aa-9bf0-156d6954ff19" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bf5b6ab-affe-4c49-affb-836a78d1950f" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,891,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fd00e59-19e4-432a-abfb-fb1595736b36" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd444fc4-b195-47e2-b681-12dcc37f2848" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1feb74f5-456c-47c4-b0fc-4aa1cf4ec88c" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8dcd49c-055f-4495-9e8c-a069684df0c8" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,410,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e776e5a-1881-4cdc-a7bf-360b4b57e324" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.85</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e56a893-fe1d-4873-aa97-7f573960105c" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.53</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_485fe638-1c87-44ba-97a1-58ac2a93ff7f" contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grant, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfa774d2-891c-403d-a8e1-474fd73d688c" contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,460,088</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 31, 2022, total unrecognized compensation costs related to non-vested stock options outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9e553a3-3e45-47c9-ad12-addc08af8785" contextRef="C_75f173ba-c8dd-4b99-ad6d-2a5369c1267f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f7865f7-5ac5-4105-9056-6b1f05a3a34a" contextRef="C_78cf1452-7b74-4f09-9764-21fb4409a94d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.92</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30dbd877-845f-44ef-91cd-00596256199c" contextRef="C_e31c15e4-38b9-4777-99d9-09e923ff1ef3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">280,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c3871c8-b7c9-448c-9586-a5c6c1c3a8e7" contextRef="C_d1081ead-241b-4b47-ab69-635932b5defa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,601,224</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the year ended December 31, 2021 to employees and directors. During the year ended December 31, 2022, the Company repurchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08950821-65b2-4249-ac22-9cd3220e301f" contextRef="C_e31c15e4-38b9-4777-99d9-09e923ff1ef3" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c94a19d3-87af-4ceb-92f9-c392db8574f0" contextRef="C_fdd40d07-247d-493f-b328-455e4e9594e3" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.41</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share to cover payroll taxes for one employee exercise, which is in accordance with the original terms of the award. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9513c29-92ae-4f9e-bdf0-1e31934adbed" contextRef="C_d1081ead-241b-4b47-ab69-635932b5defa" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> repurchases by the Company for the year ended December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bf1729d1-3562-4efc-9c41-cf2460f162d0" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the status of restricted stock as of December 31, 2022 and 2021 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.19%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.988999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.034%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13dd6cfc-e04f-490c-acf9-0cdff7c1c774" contextRef="C_3008e586-4932-4ef5-a77c-b2171288e27c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">786,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4580fd9d-ed5b-4f27-ad80-06e33fb47d59" contextRef="C_3008e586-4932-4ef5-a77c-b2171288e27c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c18871ed-a704-4b58-9499-b4bcab05afbe" contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,601,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e331193-b0c1-42f2-b4d6-671a79b91e12" contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d61733a-9f67-45bc-8f4e-66e03c9591af" contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">754,137</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82233cc8-c253-4498-822e-9131e63e665a" contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa193eb3-6600-4314-8dae-93c76ed46f0d" contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">434,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e437114e-d371-4046-8ca9-419158d8a774" contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e82ce5e-5711-485b-89e3-fbeb8eddd6b1" contextRef="C_3a6333ea-87fe-436f-953e-01fe64ba7678" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,198,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bceb6e24-4dca-4ebd-80b1-8cf3556f5bc8" contextRef="C_3a6333ea-87fe-436f-953e-01fe64ba7678" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13e4b728-939f-4362-b4e1-ed6986a6dfe6" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">280,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90a8dfb7-e7b7-4c36-a57c-f8a1ee80808a" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbef8ab1-8476-459e-bcbb-0edc4ebe93ad" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">306,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6684e34-3ac1-4b4d-bfe4-f9de02260ccd" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.28</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa9b7cc6-f238-4f43-89bc-d228e269c614" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">232,901</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59acd749-216c-49d4-815b-321ea60c7865" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a7d6e74-aa82-4fe9-9f2a-f9f8cb4229fc" contextRef="C_f70a1072-5f3c-4803-8752-dc98e3a0c142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">939,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dd76bdd-33d7-4cf1-b827-8ea5def510f6" contextRef="C_f70a1072-5f3c-4803-8752-dc98e3a0c142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d800af1-786b-4ca1-bb49-39b079ecc701" contextRef="C_f70a1072-5f3c-4803-8752-dc98e3a0c142" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total unrecognized stock-based compensation expense related to non-vested restricted stock arrangements. The expense is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_003c9b1f-0051-4ad8-9c93-361298175418" contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.78</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6488cde8-4c90-4f5f-8606-be452c16cb26" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">14.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Benefit Plan</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IRC, or the 401(k) Plan. The Company may make contributions to the 401(k) Plan at its discretion. The Company contributed approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7ff7bc1-226c-4229-b02b-18ff910dbe67" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the 401(k) Plan during the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2eae1d99-5815-478a-a86f-85ef89fe63c7" contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c62a52c3-3f8c-454f-bc84-9e2e4ee6e276" contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">15.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joint Venture</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell to lead clinical development and commercialization of certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e21524-6d2a-48b1-ae1c-697208e0cfc0" contextRef="C_1450b5dd-88ba-4cc4-8794-083ce0aff494" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, Eden BioCell began treating patients in a clinical trial with the Company&#x2019;s investigational CD19 RPM CAR-T cell therapy, under the IND cleared by the Taiwan FDA in December 2020. In the first half of 2021, two patients were treated in this trial. The lead investigator at National Taiwan University in Taipei, has reported no serious adverse safety events in either of these patients. Laboratory results continue to support, as previously published, that non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer is effective in genetically modifying autologous T-cells. Patients were infused two days after gene transfer, thus shortening the turnaround time and demonstrating an advantage over viral methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc_page"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on laboratory data from the first two patients generated between March and May 2021, the TriArm/Eden team concluded, in concert with the investigator and the Company, that further process development work is required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, Eden BioCell incurred a net loss. In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity is in the process of being dissolved.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>tcrt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements (Nos. 333-129884, 333-134280, 333-142701, 333-160496, 333-167925, 333-185433, 333-199304, 333-220804, 333-228291, 333-238090, 333-241698 and 333-263983) on Form S-8 and Registration Statements (Nos. 333-134279, 333-141014, 333-161453, 333-162160, 333-163517, 333-166444, 333-174292, 333-177793, 333-201826, 333-229555, 333-232283 and 333-266841) on Form S-3 of Alaunos Therapeutics, Inc. of our report dated March 7, 2023, relating to the financial statements of Alaunos Therapeutics Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Alaunos Therapeutics, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ RSM US LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 7, 2023</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>tcrt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Kevin S. Boyle, Sr., certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Alaunos Therapeutics, Inc.&#x37e;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#x37e;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#x37e;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#x37e;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#x37e;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting&#x37e; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 7, 2023</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>tcrt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Kevin S. Boyle, Sr., Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#x37e; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:30.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:73.333%;"></td>
    <td style="width:26.667%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img159912857_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159912857_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 WP# 2(  A$! Q$!_\0
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MF\PC(3RSDCZ4?6:_\S#ZCA/Y$=/_ ,+$U?\ Y]['_OA__BJ/^%B:O_S[V/\
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MS;>5-HW'<A&!TS491PBN58*V=K$<''7%'UFM_,P6!PKV@CK/^%B:O_S[V/\
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MC*DC&1[4?6:W\S#ZAA?Y$=9_PL35_P#GWL?^^'_^*H_X6)J__/O8_P#?#_\
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MZ$]#C.*XNBM'B;WT[F2P-E;F[?K^#OL=3I]GJ$>HQW6MR2)#9HTP^T.6VG(
MXY(RQ';G%:$$'VW48]0MY5N6N;*:&1XU(W2JF.A .2,=JX:BI5=)6M^/]="Y
MX1R=^:SVVTM_P^NY/=V=S8S>3=0O#)C.UQ@XJ"BBN=^1V*]M0HHHH&=3H'_(
M,L/^PQ%_Z#4\DEK>V.LWT6V*Y\GR[B$<;CYBX<?7'/O]:X^BM_;^[RV_JUCC
MEA+S<^;K^M['?7*7T/B*>XNVD71C"!)YC?NV7RQP >ISZ=ZQO#"6W]J@6KW,
MDK6LN]=@0@[>B$$Y^N!7-44W7O+FMW_$4<&U3<.;=);=CL+:6XTPZI+=6UR5
M%O'^ZO7WLR&0 C.![T_^SK*1='\N8/IT;3W+NW58QM)5O?/%<910L1;I_5[@
M\&[W4K/_ (%NYWMMLU'6M*U2.XCN)!(\$[1*RC.UF3A@#T./PIUG'()--A9+
MF*0-< 0W;;I3F,\@\?+VQCK7 452Q-EM_6G^1G+ 7T4NEMO7_,Z.TL;JPT76
M(KN!X7*P,%<8)'F=:VYY+6^U_47.V*]M8YD(Z":/80#_ +P_E]*X&BI5>T5&
MVG_#FD\(YMR<M7Y=TEW\OZL=LMO=WMY:-97=Q!I0MU5)+9QMB./FWC(QSG.:
MXIAAB <X/6DHK.I4YW>QM1HNE?6_R_/N%%%%9FX4444 :OAG_D9=/_Z["M_2
M]2MY=2@L4>YG"//*TL^ PS&PVKR<"N+HK:%9P227]:?Y'+6PJJMMOI;\_P#,
MZFTMK?4/#\EKI\<Z&6]B4^<X;J&YX XJYJ!M]1@(L)X+B33ID:"(!EQ%\JD$
ML ",@'KW-<515*OI:W]+8AX2\N;F_KK^'H>A01S2:S:7,_VR":5YO]#EFWX_
M=GYD/8=JY'68KJ"\C\^&\C^7*+>/O8\_0<5ET4JE;G5K%4<*Z<N:]]+;>OGY
M^9T?B:.^>STNXO()$;R2C$Q[0IW,0N.W';TKG***SG+FDY&U&G[.'*%%%%0:
MA1110 4444 :OAG_ )&73_\ KL*WM+U*";6+"QB>YGV7,DIEG !&4(VJ,GC\
M:XRBMH5G!))=;_E_D<M;"JJVV]U;\]?Q.JTZVMM0T6_M=/CN$:6XMU;SI W5
MFY& .G-6]0-OJ,!%A/!<2:=,C01 ,N(OE4@E@ 1D ]>YKBJ*I5]+6_KH0\)>
M?-S>?Y)_EY'H$22OKNFW,YNX)I+B3-G--Y@'R'YD]!VKEM9M[R.\@$D%^F[_
M %:W;[V)SVX''3BLBBE.LI*UNM_R_P ATL*Z<N:_2VWKY^?F=3KT&IVFC"*_
M2>:66832S,/DC." B]L\\XX[5RU%%9U)\TKF]&E[.-G^5@HHHJ#4OZ'_ ,C!
MIO\ U]1?^ABO:Z\4T/\ Y&#3?^OJ+_T,5[77KY=\$CYO//XD/0\*^(6O?8O'
M.I6_V;?L\KYO,QG,2'T]ZYC_ (2C_IS_ /(O_P!:KWQ1_P"2C:K_ -L?_1*5
MR%=_U'#R]YQU?F_\SS(YIBX)0C/1:;+_ ".A_P"$H_Z<_P#R+_\ 6H_X2C_I
MS_\ (O\ ]:N>HH_L_#?R_B_\RO[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(Z'_A*/\ IS_\B_\ UJ/^$H_Z
M<_\ R+_]:N>HH_L_#?R_B_\ ,/[7QG\_X+_(ZQ-;WHK?9\9&?O\ _P!:G?VS
M_P!._P#X_P#_ %JQX?\ 41_[H_E3Z[5E.#M\'XO_ #.-YYC[_P 3\%_D:O\
M;/\ T[_^/_\ UJ/[9_Z=_P#Q_P#^M6511_9.#_D_%_YA_;F/_P"?GX1_R-7^
MV?\ IW_\?_\ K4?VS_T[_P#C_P#]:LJBC^R<'_)^+_S#^W,?_P _/PC_ )&K
M_;/_ $[_ /C_ /\ 6H_MG_IW_P#'_P#ZU95%']DX/^3\7_F']N8__GY^$?\
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MFNX^%G_(SW/_ %YM_P"AI45,LPL(.48:^K_S*AG.-G)1E/3T7^1T_P#PK_\
MZB?_ )+_ /V5'_"O_P#J)_\ DO\ _95VM107,-R91#('\J0QOC^%AU'ZUYWU
M*A_+^+._^U<7_/\ @O\ (X__ (5__P!1/_R7_P#LJ/\ A7__ %$__)?_ .RK
MM:*/J5#^7\6']JXO^?\ !?Y'%?\ "O\ _J)_^2__ -E1_P *_P#^HG_Y+_\
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M_P#^HG_Y+_\ V5<S_P +FN/^@)%_X$'_ .)H_P"%S7'_ $!(O_ @_P#Q-/\
ML^C_ "_B_P#,/[7Q7\_X+_(Z;_A7_P#U$_\ R7_^RH_X5_\ ]1/_ ,E__LJY
MG_A<UQ_T!(O_  (/_P 31_PN:X_Z D7_ ($'_P")H_L^C_+^+_S#^U\5_/\
M@O\ (Z;_ (5__P!1/_R7_P#LJ/\ A7__ %$__)?_ .RKF?\ A<UQ_P! 2+_P
M(/\ \31_PN:X_P"@)%_X$'_XFC^SZ/\ +^+_ ,P_M?%?S_@O\CIO^%?_ /43
M_P#)?_[*C_A7_P#U$_\ R7_^RKF?^%S7'_0$B_\  @__ !-'_"YKC_H"1?\
M@0?_ (FC^SZ/\OXO_,/[7Q7\_P""_P CIO\ A7__ %$__)?_ .RH_P"%?_\
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MO_ @_P#Q-'_"YKC_ * D7_@0?_B:/[/H_P OXO\ S#^U\5_/^"_R.F_X5_\
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M$'_XFC^SZ/\ +^+_ ,P_M?%?S_@O\CIO^%?_ /43_P#)?_[*C_A7_P#U$_\
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M_P#R7_\ LJW];^_I?_7]'_)JUJ?U&A_+^+#^U<7_ #_@O\CBO^%?_P#43_\
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M .OZ/^35K5DZW]_2_P#K^C_DU:U !1110 4444 %%%% !1110 4444 %%%%
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M<G^-/V3[BYSZE\M/[B_E1Y:?W%_*OEK_ (2;7_\ H.:E_P"!<G^-'_"3:_\
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M#RT_N+^5'EI_<7\J=14E#?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU%
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M1'_NC^5/ID/^HC_W1_*GUZ$=C@>X4444Q!1110 4444 %%%% !1110 4444
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MHU $U%0_:4]&H^TIZ-0!-14/VE/1J/M*>C4 345$+A&8 !N3BI: /G'XH_\
M)1M5_P"V/_HE*Y"NO^*/_)1M5_[8_P#HE*Y_1+!-4URQL)'9$N9TB9EZ@$XR
M*ZHZI&$MV4**W[;0K>3QL^B.US) MS)#F!09&"YQ@'C/%7KCP1>3Z'IE]I%K
M>7;W F,R[1A-C[1C'<@'C)I<RLF/E=[')45JP>&M:N; WT.FSO;!68R!> %.
M#^O:EN_#&N6 MS=Z9<0_:'$<6]<;F/1?8^QIW$9-%;-WX4UZPLY+N[TR>&"/
MEV< 8&=N<=<9[U2DT^6RDLWU"*6*WN%652N-S1D_> _/&:$TPLRG17;W.@>$
M8/#MOK/VS6S#<RO#&ODQ;@RCN-W3\:K2^&M#T>"UC\0:I=PWUS$LWDVMN'$"
MMTWDD9/L*7,AV.1HKK;/P_H2^&WUB_O;]H3?M:1FVB7YAMR&*L>/IFLGQ+HA
M\.Z[/IOGB=8PK+)MVDJP!&1V/-%U>P6,BBNVL-!\)WGAV[U9KS652R\M9U$,
M62S\?+\W(SZXKG]+T8Z]XB33=,=A%+(VR2< %8QD[FQQP!VIWUL*VES)HKH=
M3L/"\-K.NGZO?3WD) 7S+4".<YP=I#9'KS4<7A/5HI[!M0T^ZMK2YGCB,I3&
M-Q _ \\9H3N#5C"HKJ_$'A>TTG2KR[AFG=X-6DL5#D8**N03@=:Y2DFGL-IK
M<UH?]1'_ +H_E3Z9#_J(_P#='\J?7I1V//>X4444Q!1110 4444 /A5'F1))
M!&C, SD$A1ZX%=+?>%M.LM*BOSXA@>.X5S;J+60&4KP1TXYXYQ7+UU.MSVL]
MMX8L8[F%DBME\TK("(V=\L&/8COFHE>Z2?4J-K-M#KGP48FGMXM4@EOX+;[3
M):F-E.S:&.&Z$X/2J,V@VEII,-U=ZO%#=30>?':>0[,P).WYAP,X[UL^)_%4
M9US5(],M[-#./L[WZ,SL\> .#DJ!QU IUU?R6OAJ^M-5U>QU%7BCBL8K=UD*
M$$?-P 5P!CGDUDI3Y4WU->6%[?U_6YD6'A5KZUC(U&U2[FA:>&U.XLR+D\D#
M"G@X!KGJ[?3A9:'I.HG^U[&YL[NR(18R%N?-(&%P/F4 ]<G!%<16L&W)]C.2
M2BNX44459 4444 %%%% !7<?"S_D9[G_ *\V_P#0TKAZ[CX6?\C/<_\ 7FW_
M *&E95_X;-*/QH]<JL=1L1<?9S>VXGSM\KS5W9],9SFK-<7IEW!#K6JI)J&E
M1O\ ;I-L$JC[0QVC&TE_7_9->4CTV=I35EC:1XU=2Z8W*#RN>F1VKBQK.K6V
MF6MP;QKA[K3OM+;XDQ$P:,%@% R ')P<]*1+][>^U&6VU,S0R36J2WQ$9\M"
M&RV0-O7 SC SSTJN7^OG85SMZ*Y"/4]0N;M+:'4W,&ZX\NZ2.,F946,J?N[3
MAF89 P<5 =;U>.P$JW FDGL(;K+HH$!9PKD87[H!SSNQCO2M_7]>@7.VR!3'
MECB*"214+MM7<<;CZ#U-<;+<W,S:9-=:S!Y":@5%Q;S1N #"V S&,+G.0,#^
M+UJ>&[U"46ES/>>:LNJ/ L1A3"*K2 8.,YX'.?ZY+!?^OO\ \CKJ*X>7Q->?
MV3 8KU#>)I]Q)<J%4E)4"XW#'!!SQ5N>_P!3M;FZ_P")C)(EM/:@*T48WB5@
M&#87MGC&/?-'+_7X!<ZVBBBD,**** .9\8ZQ;Z NDZG=I*\,-X=RQ %CF&11
MC) ZGUK%_P"%O^'_ /GTU/\ [])_\73?C!_R*UI_U^K_ .@/7BM:1BFM2)2:
M9[9_PM_P_P#\^FI_]^D_^+H_X6_X?_Y]-3_[])_\77B=%5R(GG9[9_PM_P /
M_P#/IJ?_ 'Z3_P"+H_X6_P"'_P#GTU/_ +])_P#%UXG11R(.=GMG_"W_  __
M ,^FI_\ ?I/_ (NC_A;_ (?_ .?34_\ OTG_ ,77B=%'(@YV>V?\+?\ #_\
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M_P#SZ:G_ -^D_P#BZ/\ A;_A_P#Y]-3_ ._2?_%UXG11R(.=GMG_  M_P_\
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M_(NKDPN2R<#RI'X^7KE!^M7?^%/:'_S_ &H_]]I_\37<:S#&-1T'Y>M^>_\
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M>1'_ '?UH\B/^[^M%P*=%7/(C_N_K1Y$?]W]:+@4Z*N>1'_=_6CR(_[OZT7
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MPO7%*F@W;6R3226L!D3?'%/.J.Z^H!/0]LXSVK0B$.G:3J"O=6DRSP(()8I
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M- U'_P#"6^)/^@_JG_@9)_C1_P );XD_Z#^J?^!DG^-,_P"$9U__ * >I?\
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M)_["$?\ Z"U;%8^O??TG_L(1_P#H+5L4P"BBBD 4444 %%%% !1110 4444
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M-3_[])_\71R,.9'IGGQ_WOTH\^/^]^E>9_\ "W_#_P#SZ:G_ -^D_P#BZ/\
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M (4]H?\ S_:C_P!]I_\ $T?\*>T/_G^U'_OM/_B:.=!R,\6HKVG_ (4]H?\
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M?LR>K4?9D]6K/O/$ND6<#2MJ%LX25(G"3(2K,VWGGC')/L#6HCI+&LD;*Z,
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M^/\ O?I1Y\?][]*/:/L'(?+G_",Z_P#] /4O_ 23_"C_ (1G7_\ H!ZE_P"
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MZE_X"2?X5]1^?'_>_2CSX_[WZ4>T?8.0^7/^$9U__H!ZE_X"2?X4?\(SK_\
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M !1110 4444 %%%% !1110 4444 %>@?"#_D;+K_ *\7_P#1D=>?UZ!\(/\
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MGD'*CR?_ (4P_P#T'E_\!/\ [.C_ (4P_P#T'E_\!/\ [.O6**.>0<J/)_\
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M6_\ <;\J/+?^XWY4 -HIWEO_ '&_*CRW_N-^5 #:*=Y;_P!QORH\M_[C?E0
MVBG>6_\ <;\J/+?^XWY4 -HIWEO_ '&_*CRW_N-^5 &/J_\ R$-#_P"OX_\
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MDNGL+HW$$C387D@E67!W9QZ]ZU+OXC&Y:#&G3;(=1COQYU\TIRN<H"5X7GC
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M0 4444 %%%% 'R!\;?\ DKVN_P#;O_Z(CK@*[_XV$'XNZ[C_ *8?^B(ZX"@
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M54_M.R_Y^$H_M.R_Y^$HN@LRW153^T[+_GX2C^T[+_GX2BZ"S+=%5/[3LO\
MGX2C^T[+_GX2BZ"S+=%5/[3LO^?A*/[3LO\ GX2BZ"S+=>C_  5_Y'*\_P"P
M>_\ Z,CKRW^T[+_GX2N[^$_BC1-(\4W5QJ&HQ6\363H&?."V]#CIZ U,VN5E
M16I]'45RG_"RO!O_ $,%K_X]_A1_PLKP;_T,%K_X]_A7,:G5T5RG_"RO!O\
MT,%K_P"/?X4?\+*\&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K_P"/?X4?\+*\
M&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K_P"/?X4?\+*\&_\ 0P6O_CW^% '5
MT5RG_"RO!O\ T,%K_P"/?X4?\+*\&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K
M_P"/?X4?\+*\&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K_P"/?X4?\+*\&_\
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M65X-_P"A@M?_ ![_  I@=717*?\ "RO!O_0P6O\ X]_A1_PLKP;_ -#!:_\
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M_P +*\&_]#!:_P#CW^%'_"RO!O\ T,%K_P"/?X4 =717*?\ "RO!O_0P6O\
MX]_A1_PLKP;_ -#!:_\ CW^% &GKWW])_P"PA'_Z"U;%<#K/Q#\)3OIIBUVV
M;R[U'?&[A0&YZ>]:?_"RO!O_ $,%K_X]_A3 ZNBN4_X65X-_Z&"U_P#'O\*/
M^%E>#?\ H8+7_P >_P *0'5T5RG_  LKP;_T,%K_ ./?X4?\+*\&_P#0P6O_
M (]_A0!U=%<I_P +*\&_]#!:_P#CW^%'_"RO!O\ T,%K_P"/?X4 =717*?\
M"RO!O_0P6O\ X]_A1_PLKP;_ -#!:_\ CW^% '5T5RG_  LKP;_T,%K_ ./?
MX4?\+*\&_P#0P6O_ (]_A0!U=%<I_P +*\&_]#!:_P#CW^%'_"RO!O\ T,%K
M_P"/?X4 =717/Z;XY\,ZO?Q6.GZQ;W%U+G9$F<M@$GMZ UT% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img159912857_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159912857_1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :H"88# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445P?QF^,WASX&>"[GQ%XBN=D:Y2VLXR/.
MNY<9$<8[GU/0#)--)MV0F[:LG^+?Q;\._!7P7=^)/$EWY%K%\D,"8,UU*0=L
M4:]V./H "20 37Y%_'3XZ>)OVB/'1U;5BRP*QATW2+<EH[6,GA%'\3MQN;&6
M..@  ;\<?CIXI_:(\;+JNLL1&I\G3M)M=S16J$CY4'5F8XRW5CCH  /N/]B_
M]B]/AQ%9^.?'-FLOBN11)8:;* 5TT$<.X[S?^@?[W3T8QCAX\TMSCE)UGRQV
M(/V-_P!B2+P"MAXY\>6JS>)B!-8:1*H*:?GE9)!WF]!T3_>^[]GT45P3FYN[
M.J,5%604445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%>>?'#XX>'/@+X+FU_7YM\C9CLM/B8>=>2XX
M1!V'0ENBCWP"TFW9";MJR?XS?&;PY\#/!=SXB\17.R-<I;6<9'G7<N,B.,=S
MZGH!DFOR,^,WQF\4_M$>/CJVK&2621_L^G:3:[G2V1F^6*->K,3C)QEC^ $?
MQ8^+7B[]HCX@?VGJSS7U[<RB#3]*M0S1VZL0%AA3GDG'NQY.37WU^QK^QC#\
M);>W\8^,[:.X\9RKNMK-L.FEJ1Z]#,1U8<+T'<GT8QCAX\TMSC;E6=EL,_8U
M_8OM_A7:6OC'QI:177C*51):V4@#II:GD'T,WJW\/0=R?KRBBN"<W-W9UQBH
MJR"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*/OD?W4]""RFG&,INT4$I**NSZ0\5^+M%\#:'<:SX@U2UT?2[<9DNKN0(@]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HKPW]LKXN:M\&?@=J&L:"_D:Q=W,6GVUUM#?9VDW$R
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MSL82IS]W8^PJ***X3J"OD7]LS]C.'XKVMSXS\&6T=OXSA3=<V:85-44#\A,
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MK_V+6F?^DL==_7F2^)G='9!1114E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,RHU8R=D?45%%%<YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?*7_!2C_DW>V_[#EM_Z+FK\MJ_4G_@I1_R;O;?]ARV_
M]%S5^6U>KA?X9Y]?XS]M_P!GW_D@GPU_[%K3/_26.N_KSGX$WEOIW[//P\NK
MN>.VM8?"VG22S3.$2-1:1DLS'@ #N:I>&_VH/A5XM\21:!I/CC2[O599/)BA
MWL@E?. J.P"N2>@4G/;->:TVW9':FDE<]3HHHJ"PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHJ&ZNH;&VFN;F:.WMX4,DLTK!410,EF)X  Y)- $CNL:,[L%51DLQP
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MV]>R?\%0O^22^$_^PW_[0EK67^\(SC_!9\\_\$X?^3CX_P#L$77_ +)7O/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B_[7WQ0U?X1_ ;
M7]=T$M%J[-%9V]R%!^SF5PIDY[A<X_VBM?DYHOQ8\9>'_%$?B*P\3ZK#K22^
M<;PW;L[MG)WY)W@]PV0>A!K]J?B!X$TCXF^#=6\,:[!]HTO4H3#*H.&7D%74
M]F5@K ^H%?C-\;?@_K/P-^(>H^%M90LT)\RUNPN$NK=B=DJ_7!!'9@P[5Z.%
M<6G'J<==2NGT/K']HWX_:?\ M!?L8:=J\9C@UVTURTM]6L5/,,WE3?,!UV/@
MLI^HZJ:^$ZFAOKB"UN+:.9UM[C;YL0/RN5.5)'J.<'W/K4-=<(*FK(YI2<G=
MGUM^TC^TF)O@3\-_A7X=N\QIX:TN77IX6ZM]EB9+;/MPS^^T=F%?)D/F><GE
M;O-W#9LSNSGC'O3*^R/^"?/[-O\ PG/B8?$77[8-H.C3XTZ"5>+J\7G?[K%P
M?=\?W2*GW:,&RM:DK'Z%_#DZP?A[X7/B#=_;W]EVO]H[^OVGRE\W/OOW5T=%
M%>*>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"X2<M6-:BHKGAL:4JC;Y9;GU11117$=04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '@7[5G[*>D?M#>'?M5KY.F>,
M[&,BQU(C"RKR?(FQR4)S@]5)R,@D-^3WB?PWK7@/Q!J>@:U:3Z5JMHYM[NUD
M^4CD'!QPRGY6!&01@C/!K]WJ^?\ ]JG]D_1OV@]!>]M%ATOQM9Q8L]2QA9@,
MD0SXZH>S=5)R,C*GKHUN3W9;'-5I<VJW/S.^#/P_LO&FKS3:A/&;6SVLUF&^
M>;/3/^QZG\*^FH88[:%(H8UBBC4*D: !5 Z  =!7R)J&G^)/A)XVN+*]MY]%
MU_2YC'-!*,%3Z'LRD8.1D,"",@U]'_#KXBV7C[2]Z;;?480/M%KGD?[2^JG]
M.GU\?.*-9R56]X?E_P /W/UO@?,,#&F\'R\M9ZW_ )O^&[?/N=A4%]=06-K+
M/<R+%;QJ2[/T INH:A;Z79R75U*L$$8RSM_G]*\.\;>.;CQ5=&.,M#IT9_=P
M]V_VF]_Y?K7R-2JJ:\S]QR_+ZF.G9:16[_KJ<SXCTS0[SQ!->:79M:6I;<L)
M;Y2?[V.P_P!GH/TIE%%<%;$5<0TZLF['W.793@<IA*&!HJ"D[NRM=^84445S
M'KA0S!023@#DDT5D^)//^QJ(E8QYS)M&>/?VKKPF'^M5X4;VYCPL\S19+EM?
M,'!S]FKV77I\EKJ^BNS,UO6OMC&&$X@!Y/\ >_\ K5])_L;_ +'=Q\:+V#Q9
MXJBDM? ]O(?+BR5?5)%."BGJ(@00S#J057G)6G^Q]^Q_>?''5(_$?B2*:Q\"
MVDN#U234G'6.,]0@_B<?[J\Y*_J;I6E6>AZ;:Z=IUK#96-K&L,%M;H$CB11A
M551P !7ZC"%+!4E0H+;^OO/X6S3-,9G^,EC\?*\I=.B71)=$O^"]6R2QL;?3
M;."TM(([:TMXUBA@A4*D:*,*J@<    "IZ**YCB"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&D67B#2KO3=2M8;[3[N)
MH+BVG0/'+&PPRL#U!!J[10!\+_$K_@F'I>I:C+=^!_%+Z-!(V1INJ0F=(QCH
MLH.[ /9@QYZ\<^7P_P#!,/XGM*@E\0^$DC+#>R75TQ [D#[.,GVR/K7Z<45T
MK$5%U,71@^A\;_!W_@FWX5\':C!JGC75F\87,+;TT^.'R+($=-XR6EZ9P2JG
M."I'7[%CC2&-8XT5(U 5548  Z #TI]%8RG*;O)FD8J.B"BBBH*"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &30I<1/%*
MBR1.I5D<9# \$$=Q7":!\ _AQX6\0KKND>!]"T[5E;?'=6]C&K1-ZQC&$/NH
M'4^M=]13NUL*R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWJ'A97./M=O,+Z%/=\(C@?[JM7C^E_\ !,#X@7%JSW_B?PY9S;<K%"T\O..
MQ\M<>^,_C7C_ ,;OV1_B'\"+0ZCK5C!J.A;@IU;2I#+ A)P!("JLF20,LN"3
M@$T<E"6B%S58ZL_7GPSXHTCQEHEKK&A:E;:MIETN^&ZM9 Z,/J.XZ$'D'@UJ
MU^/O[)_[2VI_L_\ CJW6YN)I_!VH2K'J=@6+*@) ^T1KV=1@\?> VGL1^OMM
M<Q7EO%<02+-!*@DCDC;*NI&00>X(KCJTW3=NATTZBJ(EHHHK$U"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV7S/::*\0;]K+P_""]SX0\<6D(^]-/H$@1?J036MX<_:H^%GB:;R8?%]G8W
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MJXB%+1ZL^^Z*_,236+^20N]]<NS')9I6)/ZTG]JWO_/Y<?\ ?UO\:[_[+?\
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MZQ:B]L'2:1X&8J&*QLRYP0<9 _*OOW3=+M-'L8;.PM8;*TA&V."W0(B#T '
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_MW-J.#E\%[R_PK5_?MZL^2O$.O:IXX\37NK:A*]]JVI7#2RL 2SNQZ ?D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/EE9RZC>06L"[YYY%BC7U9B !^9KY;.ZC]RDO7_+]3^AO";!Q3Q>/GTM%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYZ_;0_P"1#T/_ +"7_M)Z^A:^>OVT/^1#T/\
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M-LPI*M1H^Z]FVE?TOK\]CZ_HKP+X=_M=^'_%5]#I^NV;>';J9@B3M*);<D]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KQ#]L[]W^SKXDN@?WEK-93Q^FX7<(Y]N37M]>(_MI?\FT>,O\ MS_]
M+(*Y<7_N]3T?Y'T?#?\ R.\%_P!?:?\ Z6CNOBY8>)=2\$7L7A6^-AJ:_O#)
M&/WKQJ"62+T=B !TZ]1UKB/@?\%SX>N(/%>NVBV.NO#LATZ%OW=HI4*SM_>E
M<#+'.,L< < >UT5E4P5*KB(XB>K6RZ>OK_71'+1S6OA\%/!4K)2>K6[79OM_
MPVS=_,/C1\/?!^I>%=<U_6-!AN;VSLY9Q<P9BF9E0[<LI&[G'WLUYS\!_AW\
M.O'3:MJ$7AJ21;.:#R5OYFD4!X(V(*;B&^?>?F!&&%>X_$33)M>\$:]I-I<1
M6][?6,T,)E?8,E=O)[#+ $^]<Q\$_A[KOP_L-7AUV_AOY;J6%HVA=F&$@2,]
M0,?=Q]%%$\1C(XNG"G)^SMKVZ^9=&A@'EE:I52]M=<O>UXWMIZ]2Q\5_A':?
M$3PO!8VDO]DWFG@FQ>&-?+4$ &)DX!1@ ".G ZXP>5_9YT_QAH]UJ]AJ6D_V
M%X8MV>.UTRX+L]M-N!(AD;/F0L&<[B3\W ]3[;7C/C3]HR/P?XOU/0SH4=W]
MB3<9SJUO$6^0-]QCD=<8Z]\=JX\73PV'KQQM23B]M+Z^MD_ZM?96[\NK8_&X
M2IE=""G'XE=I<NNK5VE^JN[:.5Z'QB^!-MJ4[:UI4JZ;IJR?;=8L('$/G; Q
M\^)C\JS*"V"V%^8Y/)SS_A_QG\1/C)#_ &5X3O5TCP_IY^S3>)+A&\^[V\!A
MG)#E=K$+SDY+#(%0_%KXT3>.OA-:VFGV!TZZUR\2R;;?03J$W'(RC[@254'*
M@8)Y]?H3PKX9L_!_AW3]%L$"6MG"L2X&-Q'5C[DY)]R:]7 T<+1B\;05W4V[
M:=;/^MV>3F>*QU3ER[&/^%Z-^EU?^K+HCQ2Z_9LUJSS?Q?$C76U/)=KO<X.X
M@*6QYF>BJ/O= !TKE?%GBSQMX+T\^&O'MU)J_A346\@ZSIX"7!7!/E%^ N2!
MNW!CMW8)[?5;*&4@C(/6N!\;>%K7Q9H&IZ)=J&AN(VC#,,[&_A<>X.#^%>A[
M2->+I5U>+WZ/\#R*?/AYQK47:4=5UV/G[XO?!^W\ _ "\O;N]AUB_DO[%;.:
M,9BM+=KI&$<!/.&W%B1C<3G&<D_8%?#^N>-I]4_9MTW1[F-I+G1M=@43/+%@
MI$XD5-N_S#PP7(4J .O!KZ!\#_M!)XT\96>@)HD=L;B$3?:%U:WFV_N@^-BG
M)ZXXY'4@8./FHRPF6XN6#B[?"EH]=^I^@8N&/SK)Z&-DN:TJLI.Z5E:GTNNS
MT6OWZ^OT445[9\">(?MG:L=)_9S\5;6VR77V>V7G&=T\>X?]\AJ_/C]G_1QK
MWQN\#6;+N1M7MI'7U5) Y'Y*:^WO^"@5]]E^!-O%NV_:M9MXL8SG$<KX]ON9
M_"OD[]C*Q^V_M(^$05+)$;J5L'&,6LN#_P!]8KY',/WF/IP]/S/Z8X)_V/@W
M&XE;_O9?=!+]#]2:***^N/YG"BBB@ HHHH **** $(##!Y%?D+\=/ X^'/Q=
M\4^'HT\NVM;UFMUQT@?$D0_!'6OU[K\\O^"AOAE=,^*^C:U&NU-4TP*_'WI8
MG92?^^&C'X5X&<T^:@I_RO\ /^D?LWA;CWA\XGA&]*L']\=5^',?2?[$WC(^
M+O@'I$,LGF7.CS2Z9(2>=J$/&/H(W0?A7O5?$7_!-_Q(WF>-= =_E(M[Z),]
M#\Z2'_T5^5?;M=^7U/:8:#\K?=H?'\:8%9?Q!BJ45HY<R_[>2E^;L%%%%>@?
M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?/7[:'_ "(>A_\ 82_]I/7T+7SU^VA_R(>A_P#82_\ :3UV8/\ WB!S
MXC^%(^/J***^Q/G@HHHH **** /T=^%?_)+_  ?_ -@>S_\ 1"5\/?';_DK_
M (K_ .OUOY"ON'X5_P#)+_!__8'L_P#T0E?#WQV_Y*_XK_Z_6_D*^?R_^//^
MNIZN*_A1.#HHHKZ \H**** "NI^%?_)4/!__ &&+/_T>E<M74_"O_DJ'@_\
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MK5S%I&HW.C:!&Y6WAM',4DJC@/(PP23UVYP.G.,GS'_A*];_ .@QJ'_@4_\
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MZ\R_(****^%/UX]B\-ZU>1_LQ^+K%92+?^V+=<>S!2P^F8U_7UKQVO5/#O\
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M(1%*KGV)<_\ ?-?+\0X>E4P;K3=I0V?K;0_0."L=B*&9QPM)7A5TDGV2;O\
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M %%%% !1110 4444 %%%% !7SU^VA_R(>A_]A+_VD]?0M?/7[:'_ "(>A_\
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M=1R+M*3*BE@/4'((/H?7(KN:X#X*_#"/X4>"(-+,@GOYG^TWLRGY3,0 0O\
ML@  >N">,XKOZ_=L'[;ZO#V_QVU/Y S+ZM]=J_4W>G=\OI_6WD%%%%=AYI^9
MWQ"_Y'[Q+_V$[G_T:U8%;_Q"_P"1^\2_]A.Y_P#1K5@5^!5OXLO5G]DX7_=Z
M?HOR"O5/@)_S4;_L3=2_]IUY77JGP$_YJ-_V)NI?^TZZ\O\ ]YA\_P F>=G/
M^X5/E_Z4CRNBBBO./;"OKW]B3_D5O$O_ %^1_P#HNOD*OKW]B3_D5O$O_7Y'
M_P"BZ^DX=_Y&,/1_D?"<;?\ (DJ^L?\ TI'TG1117Z^?S.%>%?MA>(7TGX6Q
M6$3[6U.^CAD&<$QJ&D/_ (\J?G7NM?.G[:UC)+X'T*[ S'#J)C;V+QL1_P"@
M'\Z\;.92CE]9Q[?\/^!]1PQ"%3.<,JFW-^*3:_&Q\=4445^*G]5A7J_[//CZ
M?P+K?B.2-N)M$NI$C[&:)#)&?_'6'_ C7E%=5\.]!FU[4]4$*LQM=(OKI@HS
MPMNX_FP_.NW!U)TL1"=/>YY6:4:.(P56G7^%K7^O4Y>21I'9W8N[')9CDD^I
MIM%%<1Z@5N^!?$4GA/QEHNL1L4-G=QS-CNH8;A]"N1^-856+"SDU*^M[2$;I
M9Y%B0?[3$ ?SJZ<I1FI1W1E6A"I3E"I\+33].I^I%%%%?T ?QD<K\6/^26^,
M?^P->?\ HAZ_-FOTF^+'_)+?&/\ V!KS_P!$/7YLU^;<5_QJ7H_S/W?PZ_W7
M$?XE^04445\*?KAZIX=_Y-S\7?\ 89M/_037E=>J>'?^3<_%W_89M/\ T$UY
M77H8KX*/^'_VZ1XF7?Q,5_U\_P#;(!1117GGMGZ#?LX_\D3\+?\ 7&3_ -'/
M7I5>:_LX_P#)$_"W_7&3_P!'/7I5?NN _P!TH_X8_DC^0\X_Y&6)_P <_P#T
MIA1117<>0?F=\0O^1^\2_P#83N?_ $:U8%;_ ,0O^1^\2_\ 83N?_1K5@5^!
M5OXLO5G]DX7_ '>GZ+\@HHHK$Z@HHHH *]?_ &4?^2UZ1_UQN/\ T2U>05Z_
M^RC_ ,EKTC_KC<?^B6KTLL_WZC_B7YG@Y]_R*<5_@E^3/O&BBBOW$_DH****
M &LP12S$!0,DG@5^=WB_7-5^./Q5DEME::XU*Z%M8PMP(XLX0'T 'S,?7<:^
M_P#Q-*T/AO59(SM=+25E/H0A(KX4_9EA6?XX^&%;D;KAOQ%O*1^HKXGB&]:M
MAL)?W9RU^]+]6?JW!7+A<-CLQ2O.G#3[I-_?9'W!X&\(VO@3PCI>@V?,-E"(
MR^,%VZNY]V8D_C6_117V<(1IQ4(JR6A^75:DZU256H[RD[M^;W"BBBK,CY"_
M;9TV&'Q1X;OU7$]Q:20N?4(X*_\ HPUV7P_\075C^Q_>W2N3-!8WL$3YY4&1
MU!^HW<?05R_[<'_(4\)?]<;G_P!"CK5\'?\ )E^J?]<;K_T>:_/K\F;8SET]
MQ_E$_:.55N',M537][%?+FFOR/-OV1]!AUKXO13S -_9ME->(K=VRL8_+S<_
MA7W/7Q9^Q;_R5+5/^P-+_P"CX*^TZ];AF*C@+KJV?.<>3E+..5O11C;\6%%%
M%?5GYT4-<T>V\0Z+?Z7>+OM;V![>51UVNI4X]\&OSW5M:^!/Q4/5=0T>ZQZ+
M/$?_ &5T/_CU?HO7PY^U]"T/Q@=F((EL('&/3YEY_(U\9Q-24:-/%1TG!Z/^
MO-'ZCP'B'+%5LOJ*].I%MI^6GXINY]KZ/JD&N:39:C:MOM;R!+B)O5'4,I_(
MU<KB/@G?-J'PD\(RO&8BNFPP[3GD(H0'\0N?QKMZ^MH5/:THU.Z3^]'YQBJ/
MU?$5*/\ +)K[G8****V.4**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?_P!I;7K'
M2?'WPC.J3_9M+M-8EU.ZFP6\L0Q@(2J@L<L^./?BOH"OG;X@>&8/BK^U!9>'
M;J>Y@T[1?#)OI9K.7RY4FDN-H0-@XRN"<=0/:O.Q_M/8\M&W,VK7VWN?5<-J
MG'&RK5FU"$)MVWLXN.GG>2MYGHUO\?/ U\NJ"SUQ+F;3HGEFC\F5.%SG:64!
MN1V)KBOV;_"Y\1_VC\2]<1;G6M9N9?LK/R+>)6*'9GIR"OLJ@=S70:M\"].T
M_0/%K:;?ZY=7^J65PBQ7&IRLAD9'VY (W\MT<MG//6D_9?URWU?X.Z3!$P\Z
MP>6UG3NK>87'YJZG\:]'!O$+"SE7MS-VT[:^NY\_F"P7UF,<$Y.%K^]:]].R
M1ZS7+>)M#L]3@N;"]MX[FQNDVR0R#*L#V_STKJ:Q=:<-<*H_A7FJBVGH<IX=
M\$_$D7PL\6^+/ FKW^W2[$_;]/FFR=L;8++QZAT.!W#'O7<3?M(?#*\LRDOB
M)9+>XW0E6LKG#<#(/[OIAA^=<'X5TV+Q[^T9XJECFN8[#3M-%G)<V5Q)"XE)
M08#HP(((D]ODZ5VB_LU^'5MX8!K7B3RXI3,J_P!IL!N(49QCC[HY'/O7+FKQ
MOM4\,HZI7O??[T>QD\<J]E+Z_*::>G+;;7NF;W@7X.^'? GB+4==TI)!-?1"
M&.,L/*MH<AO+C4#H2 23DY'USWM,5=JJHS@#'))/YFGU5&C3H1Y*<;+R.'$X
MFMBZGM*\W)[7?9;'S-X2UR_N_P!HM8CKWG6C:[J\1L_WF6\NUC7;RN,+M4=<
M?N^.V?IFN7L_AKX9T_Q NN6^DPPZJMQ/="X5FSYLRA97QG&6 ].Y]3745Q8'
M#5,-&:J._-)OKV7<]3-\=0QTZ4J$6E&"B[I+5-OIY->9XE\6OV>=#\2_\)+K
M\*M'=W.E7"M9*/W;7(A(BF7'W77 Z @]QR<]+^SCK USX$^!+D'=MTF"W)]3
M$OE']4KT9E#*589!X(->(?LAM_9OPUU7PNQ ?PQX@U#2"F<D!9C)^(_>'FG"
MA2P^(O3C;G3OZZ?\$]!XJOC\EJ0K3<G1G3M?I%J:?X\J_P"&1[C1117I'R)\
MT_\ !0"S^U? F&39N^SZQ;RY/\.4E3/_ (_C\:^2OV,[S['^TEX/8LP21KJ(
MA>^ZUF !]LX_*OM7]MG33?\ [./B60+N:UDM9P-N3_Q\1J2/3 8_AFO@C]F[
M4O[+^/7@2;=MW:M!!G)'^L;R\<?[U?(YA[F/IR_P_F?TQP5_M7!F-H+?]['[
MX)_J?K;1117UQ_,X4444 %%%% !1110 5\T?\% O^2$V_P#V&;?_ -%RU]+U
M\T?\% O^2$V__89M_P#T7+7#CO\ =JGH?7\(?\C_  ?^-'R=^Q;_ ,G,>#O^
MWS_TBGK]2*_+?]BW_DYCP=_V^?\ I%/7ZD5YV2_[O+_%^B/N/%;_ )'='_KU
M'_TN84445[Y^,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45G:E
MX@TW1P?MM]!;G^X[C=_WSUK!C^*OAY[H1?:954G'G-$P3_']*M0E+5(ER2W9
MU]%1PS)<1K)&RR1N RLIR"#T(->+_$GQ=>WVN7-A%,\-E;-Y?EH2N]AU+>O-
M53INH[(F<U!7/6[[Q!IFEY%W?V\##^%Y &_+K7/7WQ8\/VF?+EFNSZ0Q$?JV
M*\.HKL6&CU9S.O+HCU*\^-8Y%II9/HTTO] /ZUAW?Q>UVXSY?V:U';RXLG_Q
MXFN)HK94::Z&;J3?4WKKQUK]YGS-5N%S_P \F\O_ -!Q7DWQROKF]T*P-Q<2
MSG[3UD<M_ WK7>JK2,%52Q] ,UQGQFT&^;PA'>&TG6&WN49Y&C(4 @KUQZE?
MSKJHJ,:D3&IS2BSPVBBBO</-"BBB@ HHHH **** "BBB@ HHHH *ZCX6L$^)
MWA!F. -8LR?^_P E<O79?!O3'U;XH^&H44L4O$N#CL(_WA/_ ([6=72$K]BX
M:R2/L+XH>-;JVNH],T^=H$\L/-+$2&.2<*#V&!^M>>P:]J5JVZ'4+J)O5)F'
M]:[?QUX5N-3F2^LU\R15V21=R!T(KA)])O;7_76<\7^_&P_I7S='DY$D>O4Y
MN8V;7XB^(K7&W4Y''I*JO_,9K:M/C)J\.!/;6MPOJ%9&_/./TK@:*T=.#W1"
MG)=3UNR^-5G)@7>G30^IA</_ #VUOV/Q,\/7V!]M^SN?X;A"OZXQ^M>"T5D\
M/![&BK2/IJSU&TU!=UK<PW"]<PR!OY&K-?+T<C1.'1F1P<AE."*W=/\ 'FO:
M;@1:E,ZC^&8^8/I\V:Q>%?1FBKKJCZ$HKR/3?C1>1[5OK"*=>[0L4/UP<Y_2
MO3=%UFUU_3HKVT??"_8C!4CJ".QKFG3E3^(WC.,MB_1116184444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[VS@U*SGM;J%+
MBVG1HY89%W*ZD8*D'J"#5BBDU?1C3<7='Q5^U!\%M-^'<VEZOX?M8K#1;A1;
M/;^=)(_V@%VW?.2<%<#KQMZ<UX)7V5^VK"Q^'NBR 91=452<]"89"/Y&OF_X
M(>$=/\>?%#1="U59'L+KSO,$3[&^6"1Q@_517Y%F^#C',OJ]!)<UK+97?Z']
M*\-9I.60_7,9)RY%)M[MJ-WUW=CA:^@?V,='NKGXB:EJ21M]CM=/:.27'&]W
M3:OU(5C^%>T1_LD?#R.16:SOI #RK7C8/Y8->G^&?">D>#-)33=$T^'3K)#N
M$<(ZM_>8GECP.22>!7NY;P]B,/B8UZ\E:.NG7\#Y+/N-L'C<!4PF$A)RFK7:
M2277J[L^%/VC/"][X;^+FO-=1.L%_.;RWE(^61'Y.#['*GW%>95^G7B+PKH_
MBVR^R:UIEKJ=N#E4NH@^T^JDC@^XYKB9_P!GOX;VL<EPWA6W(B!D($LIZ<]-
M^/PJ,9PS5J5I5*,URMMZWT_!EY7Q[AJ&%IT,32ESQ27NV:=M+ZM6/S\K[V_9
MZ^%MAX'\"Z;=21VUYJEZ/MHO?LRK+&DJ+B,-R<!>O.,DU\$5^F'P^_Y$'PU_
MV#+;_P!%+7-PM2A/$5)R5W%*QZ'B%B*M+!T:4)6C)N_G9?\ !.@HHHK]-/P,
M**** /S.^(7_ "/WB7_L)W/_ *-:L"M_XA?\C]XE_P"PG<_^C6K K\"K?Q9>
MK/[)PO\ N]/T7Y!7JGP$_P":C?\ 8FZE_P"TZ\KKU3X"?\U&_P"Q-U+_ -IU
MUY?_ +S#Y_DSSLY_W"I\O_2D>5T445YQ[85]>_L2?\BMXE_Z_(__ $77R%7U
M[^Q)_P BMXE_Z_(__1=?2<._\C&'H_R/A.-O^1)5]8_^E(^DZ***_7S^9PKB
M_C!X%_X6-\/=6T1-HNY(_-M68XQ,AW(,]@2-I]F-=I1656G&M3E3GLU9G1AZ
M]3"UH5Z3M*+37JC\M;RSFT^ZFMKF)X+B%S')%(,,C X(([$&H:^Y/C7^S5IW
MQ,N'UC2IX](\0$8D9E_<7/H9 .0W^T,^X/&/DOQM\)_$?P_UVSTG5[6-+J]/
M^C&&9767YMN0<\<G^("OQS,,HQ. D[QO#HU^O9G]/9+Q+@<XIQ49J-2VL7OI
MO;NO3IO8X^OKG]C[X9O8Z'J?BC4K? U2,V=K'(/O6^<R,1Z,P '^X3W%9'PQ
M_8[N1?0WWC2YB6VC8-_9=HY9I/:20< >H7.?45]46MK%96\5O;Q)!;Q((XXH
MU"JB@8"@#H .U?3Y%DM6E56*Q,;6V77U9\#Q?Q5A\1AWE^ GS<WQ26UEK9/K
M?J]K:==/SC^*G@&Y^&OCC4=%G5O(C<R6LK#_ %L!)V-]<<'W!%<C7Z+?%?X1
M:-\6M%6TU$-;7L&3:W\0!DA)ZC'\2G RI].QYKXX^)W[/?B?X76<NHWIM;W2
M%D6,7EO*!RWW<HV&!^F1[UXF:Y+6P=252E&]/>ZZ>OIW/J^'>*L+F=&%#$3Y
M:^BL_M/NO7MO<\PKV3]EWX<R^-/B-;:G-$3I6BLMW+(1\K2@YB3Z[AN^BGU%
M3?"_]EWQ!\0+*PU>\NK?2=#NAYBR[O,FD3/54' SC^(C'H:^Q_!/@G2?A_X?
MM]&T:V^SVD7)9L%Y7/5W/=C_ ( 8  KKR7):U:K'$5XV@M5?KV^1YW%7%6&P
MV'J8+!SYJLKQ=MH]'KWZ66V[\]^BBBOU$_GTY7XL?\DM\8_]@:\_]$/7YLU^
MDWQ45I/AAXP15+,VCW@  R2?(?BOS9K\VXK_ (U+T?YG[MX=?[KB/\2_(***
M*^%/UT]4\._\FY^+O^PS:?\ H)KRNO5/#W_)N?BT]O[9M/\ T$UY77H8KX*/
M^'_VZ1XF6_Q,5_U\_P#;(!1117GGMGZ#?LX_\D3\+?\ 7&3_ -'/7I5>:_LX
M_P#)$_"W_7&3_P!'/7I5?NN _P!TH_X8_DC^0\X_Y&6)_P <_P#TIA1117<>
M0?F=\0O^1^\2_P#83N?_ $:U8%;_ ,0O^1^\2_\ 83N?_1K5@5^!5OXLO5G]
MDX7_ '>GZ+\@HHHK$Z@HHHH *]?_ &4?^2UZ1_UQN/\ T2U>05Z_^RC_ ,EK
MTC_KC<?^B6KTLL_WZC_B7YG@Y]_R*<5_@E^3/O&BBBOW$_DH**** ,'QW,T'
M@?Q%*APZ:=<,I]Q$QKXH_96A67XW:&QSF..Y9?KY#C^1-?:OQ!_Y$'Q+_P!@
MRY_]%-7Q=^RC_P EKTC_ *XW'_HEJ^)SG_D98/U_5'ZMPOID69M?RO\ ])D?
M>-%%%?;'Y2%%%% 'R'^VT['Q-X97<=@LY2%SP"7&3^@_*NAT-Q:?L2SR(HW2
M6\X;/?-ZRY_+^5<[^VY_R-/AK_KRD_\ 0ZW],_Y,??\ ZXS?^E[5^=R_Y&>-
M_P"O<ORB?MD?^1#E2_Z?0_.9R/[%<(;XC:S-GE=)9,?6:(_^RU]F5\;_ +$_
M_(_:[_V#/_:J5]D5[G#?_(OCZO\ ,^2XY=\ZG_AC^04445]0? !7G_Q$^!_A
M7XGZG9ZAK5M-]KMU\OS;:4QF2,$D(_J,D],'GK7H%?)_[9/B[6=,\2Z%I=EJ
M-Q967V,W+1V\K1[Y"[+EL'G 48],GUKR,UK4</A95*\.>.FA]+P[A<5C<PA1
MPE7V<VG[ROHK:['U18V,&EV-O9VD*V]K;QK#%$@PJ(H 51[  "K%<%\"=:O?
M$'PE\-7^HW$EY>26[+)/*<N^UV4$GN<*.>IZUWM>A0J*M2A4BK)I/[T>+BZ,
ML-B*E";NXR:;[M.P4445N<@4444 %%%% !1110 4444 %%%% !1110 4444
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MNK6DAV)=(&!$B-@^7*K#=N&-W.<Y(;U#PA8MH.AV6BW6LG6K^SBV27,Q FD
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M1\#].3;N\[78(\YZ8AG;/_COZU]/5\K?\%%)T7X-Z%"3^\;7HG QV%O< _\
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M7Z]G+\MP=3"4ISI1;<5T\CYC.L\S2CF6(I4\1-14Y))-Z*[/%O\ AD7X>_\
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M3UK.GE5%3E*--7>]_P#@CEQ5FW*DL3)+IRZ?E8^IE_8M^#>/^1.R?^PG>?\
MQZII/V-O@Z\"0GP;'M4Y!%_=AOQ82Y/XFOB]_P#@IY\4"[%?#_A%4SP&M+HD
M#Z_::DM_^"GOQ,63,_AWPG+'C[L=M<H<_4SG^5=7]F4_^?<?N1A_K5G#WQM7
M_P &3_S/L?\ X8M^#7_0F_\ E4O/_CU)_P ,=_#B,#[-;ZQ92+]R2WUBY#)]
M,N>W%?)EK_P5&\9(K?:?!NA2MG@Q2S(!^;-6]9_\%4KQ-WVKX;03<<>3K1C_
M )P-4_V93_Y]+[D5_K5F_7&U'ZSD_P V?2O_  R;X<CR+3Q7XVT]#U2VUZ0
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M#_A8'A?_ *&32/\ P.B_^*H_X6!X7_Z&32/_  .B_P#BJ.278.:/<WZ*P/\
MA8'A?_H9-(_\#HO_ (JC_A8'A?\ Z&32/_ Z+_XJCDEV#FCW-^BL#_A8'A?_
M *&32/\ P.B_^*K6LM0M=2A\ZTN8;J$\"2%PZ_F#2<6MT/F3V+-%%%2,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B1XJG\,Z/$+0[;NY8H
MDA&=@ Y/UY'YUTUQ?PV_#-EO[J\FN'^(6FS>*=.B%NJB:W8NBD_>!'(S^ _*
MM::7.N;8B=^5V/)+R]N-0G::YFDN)6ZO(Q8_K4%:4?AO599O*73[C?\ [49
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M'+&T4B]5<8(_"F54J<)[HF,Y1V/I32];L=<@\ZQNH[E.^P\K]1U'XU?KYO\
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MR_\ ;35HHHK]&/P\**** "OBS]M+_DJ6E_\ 8&B_]'SU]IU\6?MI?\E2TO\
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MG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3/[)U5H%N1;_ &B*;]VQ(5MT;,O53QG/%>Y? O\ Y/\ 8O\ L9M4_E<5H?\
M!2C_ ).(MO\ L!VW_HR:O14WSJ/D<7*N5R\QC?\ !-SXJM90W-M>^&KU)HA*
MJPWTJGD9"_/"O/Z>]86H?\$_/C99;O)\.6=_C&/L^J6XS]-[KTK]6?#_ /R
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MA8'RV)[D;67_ ("#WKY['X2-->UIK3J>MA<0Y/DF>U4445XAZ04444 %%%%
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M^KT,G_Y%]'T/$XG_ .1SB?\ $%?G'\:O^2M^+O\ L)S_ /H9K]'*_./XU?\
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M_<H?XE^4C]/\/?\ D:U/^O;_ /2H'T[^RC_R1/2/^NUQ_P"CFKU^O(/V4?\
MDB>D?]=KC_T<U>OU[^6?[E1_PK\CX[/O^1MBO\<OS85\K_MR?\R5_P!OO_MO
M7U17RO\ MR?\R5_V^_\ MO7!Q!_R+:OR_P#2D>OP;_R/</\ ]O?^D2*G[#__
M "%/%O\ UQMO_0I*^LZ^3/V'_P#D*>+?^N-M_P"A25]9U/#_ /R+J?S_ #9?
M&G_(\K_]N_\ I*"BBBOHSX<**** "O@O]I+X?W'@#XF75[;H\6G:K(;ZUF3(
M"N3F1 >Q5CGV#+7WI7.>// >D?$;P]-H^M6_G6[_ #)(F!)"_9T;'##\CR#D
M'%>'F^7_ -HX?DB[26J_KS/K.&\[_L/&^UFKTY*TEY=UYK_-'$? ?XZ:?\4=
M&@L;J9;;Q-;1 7%LW'GX&#+'Z@]2.JGVP3ZU7YZ_$CX9>(O@9XLMY//D$0D\
MW3]6MLJ'P<C_ '7'=?YCFOKSX _%AOBMX+^TW81-8LG^SWBQC"L<960#L&'Z
MANU<.4YI4JS>"Q:M5C^-OU_/<]CB3A^AAZ2S7+)<V'G_ .2W_2^G=/1GIU(3
MMY/ KS7XE?M >$_AC<-97UQ+?ZH!DV-BH=TSTWDD*OT)SCG%?+WQ4_::\2?$
M6.73K%?[!T63Y6M[>0F:8>CR<<'^Z !S@YKLQV=83 IQ<N::Z+]>W]:'F93P
MKF.;.,XPY*;^U+:WDMWY=/,R/VBO%4'C'XNZS<V4JW-I 4LX9(SN#;% 8@CJ
M-^[!'6OJ/XH>$9+7]F6]T-4/F:?I%OO"_P#3#RW8_P#D,DUX[^SU^S?J.IZM
M8>)_$]LUCIENZSVUC,N)+EARK,I^ZF<'G[V.F#FOKN[M8;^UFMKB-98)D:.2
M-NC*1@@_4&O'RG UJ\,1B,0N5UKV]'?\-=/0^FXDS;#82K@L%@I<ZPS3;7>-
MK+UT=_-GQC^QOX@@TSXDWNGSN$.HV+)%G^*1&5@O_?.\_A7VK7P-\8O@CK?P
M@UIK^S\Z?0C+OM-2@R&A.<JKD<JP[-T/4<Y [SX8_MA7VCPQ6'C"UDU6W4;5
MU&UP+@#_ &U. _U!!X[FN7*<RCEB> QJY6GH^FO]:/8[^(\CGGS6<93)5%)*
MZZZ?K;1K?U/KVBN7\"_$KPY\2+%[G0-2CO/+_P!; 04EB_WD/('OT/8USOQT
M^,$'PC\,)/'&ESK%Z6CLK=S\N0/FD;_97(X'4D#CJ/M9XNA3H/$N2Y%K?<_*
MZ.78NMBU@8TVJK=K/1_.^W?T+GQ>^+FE?"CP[+=7,L<NJS(196&?GF?H"1V0
M'JWX=<"OCCX)^#KOXI?%:R^U!KF!)SJ.HS-SE0VX[O\ ?8A?^!50\.>&?%WQ
MZ\:2E9)=1OIB'NK^Y.(H$SC+'HH'95'; '%?;OPI^%&D_"?P_P#V?I_[^[FP
M]W?.N'G<9Q]%&3A>V3U))/Q5-5N(,5&M./+0@]//_A^O1+S/U2M+"\&9?4PM
M.?/BJJUM]G_)*^E]6]=MNWHHHK] /QD**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K/\0?\@'4O^O:7_P! -:%5-4M7OM+N[:,@230O&I;IDJ0,TP/P
M4K]UOA]_R(/AK_L&6W_HI:_$N?X=>)K?QL?"#Z'>_P#"3"Y^R?V8(B9C)G&
M.X]^F.<XYK]O_"NFRZ+X8T?3IRIFM+.&WD*G(W(@4X]LBN_%-6B<>'W9JT44
M5YYV'Y3? O\ Y/\ 8O\ L9M4_E<5H?\ !2C_ ).(MO\ L!VW_HR:N%\-_$73
M?A-^V#J/BW6(+JYTW3/$6I23162*TS!GF0;0S*#RPZD57_:Z^-NA_'SXJQ>)
MO#]IJ%G8IIL-F8]2CC27>CR$G".XQAQW]>*]=1?M$^ECSKKD:\S]>_#_ /R
M=-_Z]HO_ $ 5H5G^'_\ D Z;_P!>T7_H K0KR#T0HHHH **** "N2^+FD?\
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M444 %%%% !1110 5[Q^QQ?2P?$V^ME;]S<:9(77ME9(R#_/\S7@]>X?L?_\
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M:GB#6[GQ)KNH:M>$&ZOIWN)=O3<S$D#VYKZL_;,\??V?H.G>$[:3$U^WVN[
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M4C(\Z0S(I([@$J3[+7MO[77_ "1NY_Z_8/YFOEOPA=+;_!GXB1L&)GNM*C7
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M_P #KYV&,Q']I>R<WR]K^1^^8C),L_U#680P\?;<L?>LN;^(D]?2Z/N( *
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M6</RE++H<WG;TN?G'&D:<<[K>S_NW]>5!1117T9\.%1S2I!$\LCK'&@+,S'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD-O&7;ZX':O7IX&E3UEKZGG3Q52>D="WX@\6:SXKN//U?4[G4)!ROG2$JO\
MNKT'X"LFO:?"/[+7B36@DVLW$&A6YY\L_OIO^^0=H_%L^U>S^%?V=_!GAD(\
ME@VL72\F;4&\P?\ ? PN/J#]:J>,H4E:.OH*.&JU-7IZGR-X?\'ZWXJF\K2-
M*NM0;."88B57_>;H/Q->K^&OV4_$>I;7UB^M=&C/6-?W\H_!2%_\>KZKM[>*
MUA2&&-(8D&U8XU"JH] !TJ3FO-J9C4E\"L=L,'!?$[GC^A_LS^"_#\)N-1%Q
MJS1J7=[N;9&,#D[4QQ]2:^6/%FI6FL>)-1N["UCLK"29OL]O"FU4C'"C [X
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M "BBB@ HHHH **** /G?]M5C_P *_P!$7)VG4P2/4^5)_P#7KQWPAXF7PO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFFKH.:.:.:.:D8<T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU+Q=J\VI:K=/=W<IY9NBCLJCH /05)X5\(ZKXUUB+3=(M6NKE^3CA(U[LQ[
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MEPJ@EHRQ4?O OS#C# -TP ? O#__  2\\<7-T5UOQ?X?TZVR/WFGK/=OCO\
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M16UO;>3$@Z*JI@#\@*_!FOWPNX3<6LT2D!G1E&>G(Q7YE_\ #L3XI?\ 0?\
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MP0RY).U@RY.<9YKXY\6_\$N?$EO<2MX8\::7?0%\QQZM!);,J\\%HQ)DCCG
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M)6] JY/N<#J17ZP?M36,&E_LO^.;.V016UOHYABC'157: /R%7_@/^S?X/\
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MBY9>UYK:'U'1117"=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(XR%R:^U/V&?V.]5\$ZQ#\0_'5D;#4XXV&E:1./WL!8$--*/X6VDA5/(W$D
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M%<;CS*O\$OX@8/N#ZBO3^:^.J0=.3A+='T<)*<5)!S1S1S1S698<T<T<T<T
M'-'-'-'- !S1S1S1S0 <TUE612K ,K#!!&013N:.: /)_&/ADZ#>^9$I-E,<
MH?[I_NG^E<[7M^IZ;#JUC+:SC,<@Z]P>Q'O7CNK:7-HM_+:SCYD/#=F'8BO1
MI5.96>YP5(<KNMCO?A3XR^RRKHMX_P"ZD/\ HSL?NL>J?0]O?ZUZS7S)8PSW
M%];Q6P8W#R*L>WKNSQ^M?3=<F(BHR374WHR;5F%%%%<AT!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MREVH\D;E"ZCMN #8Z DCM714HRII-F,*JF[(]8HK\9/'GQZ^)MGXZ\16]O\
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MF6SB@<-(S@@^6J@C"<<9Z\U]AU$XN$N5EQDI*Z"BBBH*"BBB@ HHHH ****
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MZ^BJSE%Q;BRHR4E=!1114E!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>I _&NNK\-?B)\+/%WPAUN/3?%FB76AWS+YD7F[660 XW)(A*L >ZDU]\_\
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M( ^S2*"?3YG7]*QOVU/^3H/'O_7U%_Z3Q5<:7)4Y8RZ$RJ<T+M'Z>?LZ^ _
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME%60<T<T<T<U(PYHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M2Y*,BJC?[.Z0,1W"X/!KZ?\ ^"H__)/?!/\ V%)?_15>+_\ !,[_ )."U/\
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M[H'A73P/LVE6B0;P,>8_620^[.68^[45?W5)4UU"G^\J.9U-%%%>>=A^??\
MP52_Y"'PV_ZY:A_Z%;5G_P#!+7_D<?'G_7A;?^C'K0_X*I?\A#X;?]<M0_\
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MX&_[!L__ *-%=KM]87H<R_@LYC_@G3\'= ^)'Q"U[7/$%I%J4?AR&"2ULKA
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MZG==6N=77XW?MB_\G->/_P#K_'_HI*_8]6$BAE(92,@CO7XX?MB_\G->/_\
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M7XZ_MJ?\G0>/?^OJ+_TGBK'"_&_0TQ'PH^\_^">/_)LND_\ 7_>?^C37Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115+5+G[/;[0<,
M_ ^G>@#,U"Y^TW!(/R+P/\:K<T<T<UJ <T<T<T<T '-'-'-'- !S1S1S1S0
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MPU:X@ACW,6;:B.%&6))P.22:_<BBN[ZTK6<3D]AK>Y^)'_#07Q2_Z*5XO_\
M!]=?_'*^_/\ @G'XX\1^./A]XLN?$>OZIX@N(=42.*;5+R2Y=%\I3M4NQ(&>
M<"OKNBLZE93C91L:0I.+O<_#?XO_ /)6O&W_ &&[[_T>]?KA^RC_ ,FX?#S_
M +!$/]:]8HI5*WM(J-MAPI\C;N?A=X^MY;KXD>(X((WFFDU:Y1(XU+,S&9@
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M"$/^X@1/JI]:]KJ*T^>;9=*/+$****P-3\^_^"J7_(0^&W_7+4/_ $*VK/\
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MH0<@\BO$?A9^P[\,_A+XVC\4Z9%J>H:C;N9+./5+E98K1B",HJHN2 >"Y8C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@#XD_P""FFFF31_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBWP8''"RQ/D'W&0/J*X,53]I!Q[G=AJG*T^Q^N/-'-<W\.O'%E\1_!.D>([
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MHYHYHYH .:.:.:.: #FCFCFCF@ YKSOX\^#_ /A,/ASJ"1)OO+'_ $V#CG*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(SSY289O_'M@_$U\DUZQ^TQXG_M[XDS6<;[K?2XEMEQTWGYG/URP7_@-<?\
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MF[MU=PO19,8=?P8$?A6[S7A'[)_B;[=X7U/0Y'S)83B:)3_SSD'0?1E8_P#
MJ]WYKP:]/V524#U:,_:04@YHYHYHYK V#FCFCFCF@ YHYHYHYH .:.:.:.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=S\K?2-QQ_WV:]Y^)G[._@;XK2-<:QI7D:DPQ_:5@WDS_B<%7_X$#7@.O?\
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M670]VC'EC=]0YHYHYHYKF.@.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-_LL ?:NIRJTM]3-1IU-C\XO#_[ ?Q;UB=$O=.TW0HV/S27VH1N%Y](2^?\
MZ]?4/P3_ &#_  E\-[R#5_$MP/%^LQ$/''/"$LX6]1$2=Y'JYQWV@U]/\T<U
ME*M.6AK&C&.H<T<T<T<U@;!S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0
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M[<:3*?\ EE?V$H/_ 'TBLOZU^8=%>C3S;$PW:?JO\K'PV,\-.'\4VZ<94O\
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MAF_[VD_M67,OR4EZZ^?0^6?V9OVVI5GM?"_Q'O-\38CM?$,I.Y3T"W![@_\
M/3M_%GEA]O(XD565@RL,A@>"/6OR-^-7P5UWX'^+GT?6$\ZUEW/8ZC&I$5U&
M#]X>C#(W+U!/<$$_2O[$_P"TTZS6GPY\4W6Z)L1Z+>S'E3VMF/<'^#/3[O\
M= QP./G3G]6Q.^R;_)GJ<8<'83%X3^WLALX-<THQV:ZRBNEOM1_)II_<%%%%
M?3G\_!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%17-Q':6\L\K;(HE+NV"<*!DGBO!O\
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M+KUKFO,Q<N:O)G=AX\M*(<T<T<T<UQG2'-'-'-'- !S1S1S1S0 <T<T<T<T
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MZG8YPK@>AP?]XU\S^'?$VL^"]634-$U2[TC4(C@7%E.T;]>F5/(XZ=#7U?\
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MKQ0R,]O#YWFP7@4$L(V(!#@ G:1T!()P<$J$XJ[01JQD[(^G**P?'FNS^%_
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M\&0?:O$EB!\RJWF9'L":]@YKY6_9J^)4>EZ\OA[4\,EX/+L[ICS&_P#SR/\
MLMV]\#OQ]4\UX&+A*G4Y6>QAI*4+H.:.:.:.:X3J#FCFCFCF@ YHYHYHYH .
M:.:.:.: /&/VJM4^Q_#FVM%/S7E]&A&?X55F/ZA:^2:^B_VOM1S-X:L ?NK/
M.P^I15_DWYU\^Z;9-J6I6MHF=]Q*D0^K$#^M?48%<M!,\+%.]5H^[?ACI?\
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MHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SO$G_(N
MZI_UZR_^@&OP:K]Y?$G_ "+NJ?\ 7K+_ .@&OP:KT<)M(X\1T/J'P3_P4.^(
MW@/P?HGAO3]%\+S6.DV<5C!)<VMRTK)&@52Q6X )P!G  ]JV_P#AYW\4O^@!
MX0_\ [K_ .2:^AO@G^QC\'/%WP>\%:YJW@_[7JFHZ/:75U/_ &G>)YDKQ*S-
MM68*,DG@ "NV_P"&#O@7_P!"/_Y5[[_X_4NI1N[Q!0JVT9MQ_'*XT_\ 9;A^
M*6K6]L-0.@IJ36UN&2%KAT&Q!N8D*9&4<DGGO7Y$M)K?Q.\<*9II-4\0Z]?J
MADD.6FN)G 'YLPK]1?VR?"EGX1_8U\1:#H%L;32M-AL((;<2,^R%+N  ;F)8
MX '))/%?G3^S)-;P?M#?#I[G B_MVT4;NFXR +_X\15X>RC*:)K7<E%GZ#_#
M_P#X)W_"GP[X=MK?Q)IUQXKU@HIN+V:]GMT\S^+RTB=<+D\;MQX'-?)'[:G[
M*MA^S[J>D:MX;GN)O#.K,\(ANG#R6LZ@';NXW*PR1QD;6!/2OU:KY#_X*<3V
MZ_ C1(I"OGOXAA,2]^+>XW'Z<C\Q6%&K-U%=[FU2G%0=D>5?\$S?B[>6WB76
M?AU>W#RZ;=6[:EI\;Y(AF0@2JOH'4[L=,QGNQS!_P5(_Y'KP-_V#9_\ T:*\
MK_X)_P ,TG[4GAAHPQ2.WO6EQV7[+(.?^!%:]4_X*D?\CUX&_P"P;/\ ^C17
M19+$*QC>]%GS#\$?@KXA^/7C>#PUX?6-&"&>ZO+@D0VL((!D;')Y(  Y)([9
M(^X_A5_P3?3X<_$3PYXJN/'_ /:@T>\CO?L2Z-Y7FLAW*-YG; W <[3T[5QO
M_!*U0=2^)#8&X0Z> >_+7'^ _*OT%K*O6FI.*V+I4XN*DS\J/^"C'_)R5U_V
M"[3^35T?[#?[)OA7XW:+JWBOQ?+<7MA8WIL(M)@D:%9&$:2%Y)%(;&' "J5Z
M$Y[5SG_!1C_DY*Z_[!=I_)J^DO\ @F#_ ,D5\2_]C#)_Z36]:RDXT$T1%*55
MIGCG[=G[*'A#X,^%]&\6^"[:?2[2XOAIUUISW$D\89HG=)$9RS#_ %3@Y8CY
MEQBOG[]GOX6S?'CXL>'?!US?SVVGOYC33*V6@MT#2N(P<@%CD#@C<^2#S7WK
M_P %,?\ DWW3/^QAM_\ T1<5\I_\$\/^3F=)_P"O"\_]%&G3G+V+D]Q3BO:)
M'U+\8OV OAA'\+]:G\+Z7<Z+X@T^QDN;>\^W33"=XT+;9%D9EPVW!VA<;LCI
MBOS=\%^*;OP3XNT7Q!8R/%=Z9>17<;(<'*,&Q]#C!]C7[?\ CW_D1?$7_8-N
M?_135^$]+#2<TU)W'6BHM-'[C?%QED^$7C1U.Y6T.](/J#;O7XE>'?\ D8=+
M_P"OJ+_T,5^UWQ._Y(KXL_[%Z[_])GK\4?#O_(PZ7_U]1?\ H8J<+LQXC='[
MRU^8O_!3O_DO>@?]BS;_ /I5=5^G5?F+_P %._\ DO>@?]BS;_\ I5=5AAOX
MAM6^ ]8_X):_\B=X\_Z_[;_T6]>'?\%'O^3CY/\ L$6O_L]>X_\ !+7_ )$[
MQY_U_P!M_P"BWKP[_@H]_P G'R?]@BU_]GKHC_O#,9?P4?1W_!,'_DBOB7_L
M89/_ $FMZW/VH/V&[7X]>-K/Q3I.N0^&]2DC2WU+S+4S+<*O"RC#+^\"X7!X
M(5>1CG#_ ."8/_)%?$O_ &,,G_I-;U-^U'^WI:_"37+SPEX-L8-:\26OR7E[
M=$FULY,?ZL*I!D<=^0%/!R<@8OG]L^3<T7+[-<YT7@[_ ()W_"#P[I:P:QIM
M]XIO2!ON[V_F@^;G.U(&0 '/0[CP.>N?AS]L;X"Z9^S_ /%2'2=#GGFT34+%
M+^V6Y;?)#EW1HRV!NP4R#Z,!R1FNNTGXG?M2_M!++<^'[WQ'<:?._E+/H\2:
M?:H=^=BSJ$&5)P27+8^\<5Y/\>/"7Q1\'^(=/MOBK/JD^L2VOF6K:IJJZ@X@
MWL.'$C[1N#<9'KBNFG&<9>]*_D83<7'W8GWA_P $U?&][XB^"^IZ'>2&5=!U
M)HK9F;)6&51($_!_,/\ P+':N"_X*1_#OPIX/\">%[[0?#&C:)>W6K2"XN=.
MT^*WDF!B8X=D4%N>>>]:O_!+7_D3O'G_ %_VW_HMZN_\%1?^2:^#?^PN_P#Z
M):L-L19&V]$^>_\ @GIX1T+QK\<M1L/$.BZ=KUBNA7$RVNIVD=S$'$T #!7!
M&0&(SUY-?HU_PS[\+?\ HFOA#_P0VO\ \;K\_/\ @F=_R<%J?_8O7'_H^WK]
M0JG$2:GHQT4N0_+S_@HUX)\.^!_B=X9M?#F@Z7X?M9M'\V2'2[..V1W\^0;B
MJ* 3@ 9]J]0_X)6_\@_XD_\ 773_ .5Q7$_\%0O^2M>$_P#L!_\ MQ+7;?\
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M1DO:S7H>5BJ[3]G$5F+L68EF)R23DGWI***]P\L**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#Q5I7F7<*%+;5+5_*N[<$YPKX((R3\K!ER<XS6]&K[-V>QC5I\^JW/FCX?\
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M?^DUO7YZ_%"QU#3?B3XJM=6#C4XM5NEN3(,,9/-;<3]3S^-?K9^R_P#L\_\
M#-_@G4_#_P#;_P#PD7VW4&O_ +1]B^R[,QQILV^8^?\ 5YSGOTKF/V@/V)/!
MGQWUB77_ +3<^&_$LJ!9;^S19([C"[5,L1QN(P!D%20,$],.-:,:DGT8I4Y2
M@EU1R_PM_;J^"^A_"WP_97.ISZ%>:?I\-L^CKIL[LKI&JD(R(8R"0<$L,]3B
MOB?]K/\ :"@_:*^(L&LZ?I<FF:1I]J+&T6X(,TJ;V??( 2JDEC\H)QCJ:^H_
M#O\ P2ST6UU!9-<\?WVIV0P3!8::EHYYY^=I)1_X[7K?Q0_8A\$>-/A3IG@K
MP\$\'C3;L7D&H0V_VF1W*['\W+*TFX8Y+#!5<<#%.,Z-.5T#C4E&S/*?^"6O
M_(G>//\ K_MO_1;UM_\ !3O1;J]^#_AS488R]M8ZR!.1_ 'B<*Q]LC'U85ZK
M^RU^S+_PS3H^O6'_  DG_"1_VI/'/YGV'[+Y6Q2,8\Q\YS[=*]9\8>$=(\>^
M&=1\/Z]91ZCI&H1&&XMY,X9<@@@CD$$ @CD$ CD5C*HO:\ZV-%!^SY6?D3^R
M;\<]._9]^*Q\2:O876H:9/82V$Z604S('9'#*&903NC P2.":_17]G7]KSPY
M^T7KWB#2=.TZXT6ZT[$UK#?2H9;NV. 9=J\(58@%06QN4[CG \2\2?\ !+71
MKS5))="\?7FE6#9*VU]IBW;KR>-ZRQY&,#[N>.M>N_ /]B/P=\"/$,7B*#4M
M4USQ!%&T<=S<2^3#&&&&VQ)C.03PY8=.,C-:UI4IKF6YG3C4B[=#Y@_X*A?\
ME:\)_P#8#_\ ;B6NV_X)6_\ (/\ B3_UUT_^5Q7KW[4/[&O_  TEXNTG6_\
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MHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH
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M(3/?O^"=M\;OX!W46XL+76[B'!'3,<+X_P#'_P!:^H>:^4?^";W_ "0W7/\
ML8I__2:UKZNYKBJ_&ST:?P(.:.:.:.:R-0YHYHYHYH .:.:.:.: #FCFCFCF
M@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YH
MYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FOS[\:VIL?&6O6Q
MR##?W$?)R>)&%?H)S7P?\7+?[+\3O$Z8"[K^5^/]IBW]:]G+7[\EY'FX[X8L
M]/\ V1;HKXDU^V_YZ6B2=/[KX_\ 9J^H>:^2OV4;CROB/>H<XETR1<#ID21'
M)_(_G7UKS7/CU^_?R-L(_P!T@YHYHYHYKSCL#FCFCFCF@#Y)_:NNGF^(UG$?
MN0Z=& /K)(2?\^E>,5[%^U1_R4R+_L'Q?^A/7CM?787^#'T/G:_\604445U&
M 4444 %%%% !1110 4444 %%%% 'T%^Q??/'\0-:M!_JY=,,I^J2Q@?^AFOL
M2OC/]C/_ )*AJG_8'E_]'P5]F5\KF/\ '?R/<P?\)!1117F':%%%% !1110
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M$UC*L<,9[L2N"S=2?H.@%>25^CW@WXF>%_B )/[ UBWU!XQN:$!HY57.,E'
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G_\ \%$_^2H>&_\
ML#C_ -'R5^@%?G__ ,%$_P#DJ'AO_L#C_P!'R5I3^(3/<?\ @F]_R0W7/^QB
MG_\ 2:UKZNYKY1_X)O?\D-US_L8I_P#TFM:^KN:XJOQL]&G\"#FCFCFCFLC4
M.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:
M.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
M #FCFCFCF@ YKX=^.D:P_%KQ&JC ,ZM^)C4G]37W%S7Q/^T,BQ_&+Q %  S
M>/4V\9/ZUZV6_P 5^G^1Y^-_AKU-7]E^1D^*404X#V<RM[C /\P*^P^:^,OV
M:V*_%O3 #@&&<'W_ ';5]F\U.8?QOD/!_P /YAS1S1S1S7EG>'-'-'-'- 'R
M)^U1_P E,B_[!\7_ *$]>.U[%^U1_P E,B_[!\7_ *$]>.U]?A?X,?0^=K_Q
M9!111728!3H89+B9(HD:25V"HB#+,3P !W--KT7X 7F@:7\3M.U#Q)>165C9
M*]Q&\X.TS 80< \@G</=145)<D7*U[%1CS22/=/A3^R9I5CI\&H>,E;4-1D
M?^STD*PP]PK%3EV]>=O;!ZUZ_#\(_!%O D2^$-$95& 7T^)V_%BI)_$UP_QB
M^/VA^'? MS+X;U^PU#6[H"*U6SG29HLXW2, 3MP,XW=\>]?%LNO:E-JIU.34
M+I]2+;S>-,QFW>N_.<_C7@TZ.(Q=YSFT>I.I2P]HQC<^P_B-^RAX9\1:?+-X
M;C&@:JJY15=FMY"!T923MSZKTZD&OCC5=+NM$U*ZT^^A:WO+61HI8FZJRG!'
MYU]__ SQ1?>,?A7H&JZD[27TD;QRRMUD*2,@8^Y"@GWS7RA^U-;P6_QGU?R
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M *^3SOXJ?S_0_I+PD_W?&-]X?E(_;*BBBOK#^;0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***P/'^N/X7\">)-9C.V33]-N;M3Z&.)G'\J
M /RS_;@^/%W\7?BW?Z3:W#?\(QX=GDL;.%6^2653MEG/J68$ _W5&.ISM_L;
M_L>)\=VG\3>)Y9[/P?:2F!(;<[);^4 $JK8^6-<C+#DG@8.2/EIW:1V=V+NQ
MR68Y)/J:_:[]G/PK!X+^!/@32H(UC\O2+>:4*.#+(@DE/XN['\:]2M+V--1B
M<%->TFW(@T7]F3X2Z#8)9VWPY\-RQ)C#7NFQ74G  YDE#,>G<^I[FO)?C+_P
M3W^'WC^SEN?"L0\$:YC*/:*7M)#Z/"3\OIE"N.N&Z5]445YZJ3B[IG8X1:LT
M>4_LX_ '2?V>? ":%8RB^U*X?[1J.I,FUKF;&.!V11PJY]3U)I/B-^U+\,/A
M+XD?0/%?B?\ LK5UB28V_P!@NIOD;[IW1Q,O./6O5Z_*C_@HQ_R<E=?]@NT_
MDU:4X^VG[S(G+V<?=/TGM?B]X,O/A_!XY7Q'8Q>$YX_-CU6XD\F(C)7'SX(;
M<"NPC=D8QGBO.H/VW_@I=33Q0^-1-) CR.L>EWK?*@RQ&(?F  ).,\ GH":_
M*IO%7BGQMX?\-^![7[7J%AIKS&PTFSC:0R32NSN^Q<EGYP.. ..IS[]^QS^S
MUXN_X7QI,GB[P)KNG^'EL[Z.[DU;2YK>!TEM98=A9U Y\W&.M;O#PBFY,R5:
M4FDD?:VF_MQ?!'5;^WLX/',0GN)%B3SM.O(DW$X&YWA"J/=B /6O=J_#CXO?
M#N[^$WQ+\0^$KS<TFF731)(PP9(CAHGZ?Q(RM^-?K#^R)\5/^%N? ?P[JD\P
MEU2RC_LS4/7SH0%W'W9-C_\  ZSK45"*E'8NG4<FXR/3?%_C#1O /AJ^\0>(
M+^+2]'L4$EQ=39*H"0HX )))(  !)) %>6^&/VR_@_XR\0Z=H6C>+7O]5U"=
M;>VMDTJ]!DD8X R80 /4D@ <G KP?_@IY\33IWA?PUX$M9@)=2F;4KU5//DQ
M_+$I]F<L?K%7GO\ P31^$O\ ;WCS5_'M[#NL]#B-I9,PX-U*N&8?[L1(/_74
M4HTH^S]I('4?/R1/TEKR+Q?^UK\(? UX]KJWCO31<1OY;Q6(DO61N<AA KXQ
M@YST/%?''[>G[5&K:YXNU+X;>&+^2QT#3&-OJLULY5[VXQ\\3,.?+3[I7NP;
M.0!7BOP1_9'^(/QZTZ34]!M;.PT97,0U/5IFAAD<=0FU69L'@D*0#QG@XN%!
M<O-4=A2JN_+!7/TS\'_M9?"+QW=):Z1X[TTW#OY:17WF63.W'"B=4SU&,=:]
M;K\;?CA^R;X_^ =G#J'B"UM+W1Y9!$-4TJ9I8%<C(5MRJRYY +* 2#@FO=_V
M!_VJ-5TWQ58?#3Q1?2W^CZA^YTBYN&+O:3 96'<>?+?& /X6V@8!.%.@N7FI
MNX1K._+-6/O3XB?$KPW\)_#,GB#Q5J/]E:1'(D+7'D2389CA1MC5FY/M7._"
MW]HSX=_&C4[S3O!OB2/5[ZSA%Q-;FUGMW$9.W<!*B[@"0#C.-PSC(KRW_@HI
M_P FTZA_V$K3_P!#-?F?\,YO%TWB8:/X*EO$UK7(FTKRK%MLD\4A!>/=V4[1
MN.1P#DXS2IT54AS7U"=5PE8_6;Q9^V'\'/!.L3:5JOCFS6^A)65+.WGO%1@<
M%2\,;J&!X(SD5TWPU^/GP^^+S/'X1\4V6K7"J7:T&Z&X"@X+>5(%?&>^W'(]
M17Q/IG_!+CQ#<>'1<7WCG3[/7&3(L([!Y8 V!\IGW@^O(C/2ODO5M-\3?!+X
MD7%F\TNC>*- O"HFMI.8Y%/#*W=2,$=B#[U<:-.>D):DNK..LEH?N77C/C#]
ML+X0^ _$VH>']=\7?8=7T^3R;FW_ +-O)/+; .-R0E3P1T)K:_9Q^+0^-GP=
M\/\ BJ15COYXS!?1H,*MS&2DF!V!(W =@PK\M?VO?^3EOB!_V$C_ .@+65*D
MIR<9=#2I4<8IQ/UH\3?%KP;X.\)VGB;6O$>GZ=H5Y&DMK>33#;<*ZAE,8'+D
MJ0<*"<<USWPR_:7^&WQBUR;1_"'B9=6U**$W#VYL[B!O+! +#S8U!P2.GJ*_
M(R^UKQG\9;O0M&@MM1\02Z/IT=AIVF:?!).88(U )6-03DGECCJ1V  ^N/\
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M<*F^2)5!)X&3R2!U(KIOB7^T%\//@_-';^+O%5GI-W(NY;0!Y[C:>C&*)6<
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MMYM&OF26-@0RL#!R""01[U\T?#?_ ()M_P#"POA_X;\3_P#"Q?L']L:?!?\
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M3QEX$N/&>E>)K.7PQ;.\<^HW!:W2%EQN5Q*%93\RX! R&4C.17Q#_P %2/\
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M:.:.:^>/9#FCFCFCF@ YHYHYHYH .:.:.:.: /SBKZ7_ &0?^0?XF_ZZP?\
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M^">/_)%M:_[&";_TFMJ^H:Z9[G %%%%0,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/_P#X*)_\E0\-_P#8''_H
M^2OT K\__P#@HG_R5#PW_P!@<?\ H^2M*?Q"9[C_ ,$WO^2&ZY_V,4__ *36
MM?5W-?*/_!-[_DANN?\ 8Q3_ /I-:U]7<UQ5?C9Z-/X$'-'-'-'-9&H<T<T<
MT<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T
M'-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-
M'-'- !S7Q3^T1_R6+Q!_V[_^D\5?:W-?$_[0TBR_&'Q"R'(!@7\1!&#^HKU<
MM_BOT_5'GXW^&O4M_LV_\E<TO_KE/_Z*:OLWFOC/]FN-F^+6G$#(6&<GV'EL
M/YD5]F<TLQ_C+T'@OX?S#FCFCFCFO+.\.:.:.:.: /D3]JC_ )*9%_V#XO\
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M[6]AQ=6,UF6_ZY2!P/\ R.?\YJW_ ,$W_$ BUKQKH;-EI[>WO8U]!&SHY_\
M(B?E7I'_  4&\,_VM\&[#5D3,NDZG&[-Z12*T;?^/F.OF']B7Q1_PC?[0FB1
M,^R'5(9]/D.<?>3>@_%XT'XU\-6_<9HI=[?BK']/Y;_PL>'U6@M94U+_ ,DE
MSK\+'Z?4445]:?S2%%%% !1110 4444 <G\69%B^%?C)W8(BZ+>%F8X 'D/R
M:_(305+:YIP4$DW,8 '?YA7ZV_'61(O@GX_9V"@Z!?KD\<FW< ?F17Y0> XV
ME\<>'412[MJ-N%51DDF5>!7R><ZU::_K<_I/PL]S+<;4\U^$6?LS1117UA_-
M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]\1-%?Q+\/\
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MW^,WQO\ $?B73V=M)=TMK NI4F") BM@\C<0SX/(WXK'"Q?.V:5VN6Q]I_\
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M1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0
M<T<T<T<T '-'-'-?,?[7_P"U5J_P&O=%T7PYI]G<ZM?P-=2W&H*SQQ1!BJA5
M5ERQ8-R3@!>ASQ<8N3LB9245=GT#<?\ 'Q+_ +Q_G4=>5?LV_&JX^.WP[;Q!
M>V,.GZC!>265U';[O*:151]R DD K(O!)YSS7JM==K:,\UZNX4444""BBB@
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MG:^8O^"BW_)M=[_V$[3_ -"-8TOC1K4^!G ?L"_\FC_$/_L)ZC_Z06]>0_\
M!,3_ )+WK_\ V+-Q_P"E5K7KW[ O_)H_Q#_[">H_^D%O7D/_  3$_P"2]Z__
M -BS<?\ I5:UV/:H<W6!^G5%%%><=H4444 %%%% !7Y5?M=:"/#_ .T1XQA1
M<1SW$=XI]?-B21C_ -],WY5^JM?G1_P4(TD6/QKTZ[4?+>Z-"['/\:RRH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%'@W0
M/&UC'9>(M#TW7[..02I;ZI:1W,:N 0&"N" <$C/N:H>&?A?X-\$WLEYX=\):
M%H-W(GEO<:9IL-M(R9SM+(H)&0./:NHHIW>PK+<****0PHHHH **** ,OQ'X
M7T;QAIK:=KVD6.MZ<S!VM-1MDN(BPZ$HX(R/7%86A_!OP!X8U6#4]&\#^&])
MU*W),-Y8Z1;PS1Y!4[75 1D$C@]"178T4[O85D%%%%(84444 %%%% !1110
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MPQ_6OH*>9P:_>*S/)G@I)^XSXAHK[6_X8_\  G_/;5__  *3_P"(H_X8_P#
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MECWPYHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@
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M760K"L<=E&_9F)WN/P 3_OH5]55ROPT\!VGPV\'6&AVA$AA7?//C!FE/+O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3:U9:5+IL^J7DT(N)!%($$498J.2#DDJW''0<\UZ1X?URV\2Z%I^K698VE[
MEQ%O&&VLH(!'KS64J<XQ4VM&:*<9-Q3U1HT445D6%%%% !1110!X+^V9_P D
MOTO_ +#$7_HB>JG[%_\ R(>N?]A+_P!I)5O]LS_DE^E_]AB+_P!$3U4_8O\
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MWWJ0H_[["5]L<UCF$>6M?N:X.5Z5NP<T<T<T<UYIVAS1S1S1S0 <T<T<T<T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ _:>T'P#IL6A>%%BUZ_M85MUN <6D6U0HY!^<\=%X_VNU=5:C.="E2@O/\
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M 4444 %%%% !7Y__ /!1/_DJ'AO_ + X_P#1\E?H!7Y__P#!1/\ Y*AX;_[
MX_\ 1\E:4_B$SW'_ ()O?\D-US_L8I__ $FM:^KN:^4?^";W_)#=<_[&*?\
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MO)=%\WK:Q1117LGY:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAX:_[>?_ $FEKV)?[J_\/Z'GK^/\_P!3LOVT/^1\T/\ [!O_ +5>OH7X#_\
M)'_"O_7F/YFOGK]M#_D?-#_[!O\ [5>OH7X#_P#)'_"O_7F/YFO'Q'^YT_Z[
MGH4O]XG_ %V.]HHHKQST HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" P((R*6B@#RG7O@[<
M27TDFE7,*VSG(BN"P*9/0$ Y _SFK'A7P:/#LDDT\BS7;#9\H^5!W _QKNO$
M.O6WAO2Y+ZZ)**0JHOWG8] /\]J\JD^*D\UZ\AL(U@8YV!SN'X__ %J[(RJU
M(VZ'.U3IRN>@<T<U4TS4H=6L8KJW.8I!T/4'N#[U;YK';0Z YHYHYHYI '-'
M-'-'- !S1S1S1S0 <U7O[&+4K&YL[A=\%Q&T4B^JL""/R-6.:.:8'YX:]I,N
M@:W?Z9/_ *ZSG>!^V2K$9_2O;?V2_$WV3Q#JVAR/A+R 7$0)XWQG! ]RK9_X
M!6%^T]X9_L7XB?VA&FV#5(%FR!@>8OR./R"G_@5<#\/_ !,W@_QIH^L D);7
M"F7'4QGY7'XJ6KZJ7^TX?U7X_P##GS\?W%;T9]^\T<TU'615=&#*PR&4Y!]Z
M=S7RA] '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T
M<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '
M-'-'-'- !S7S=^UI^U9>_ "ZT?2-#TFUU+6=0A:Z:2_+>3#$&VCY5(+%B&[C
M&WOGCZ1YKX*_X*/>!];OO%?A?Q%:Z=<76DBP:QDN((V<12B1G ? ^7<'XSUV
MMZ5M22E-)F55M1NCZ&_9V^-1^._P]/B&73UTV]ANY+*Z@C8M'YBJC[D)YVE9
M%.#T.1DXR?4*^=/V$O">K^%/@K<?VO8S:>^H:M->V\<Z%':$Q0H&*GD F-L>
MHP>]?1==4K)Z'GA1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?G_ /\ !1/_ )*AX;_[ X_]'R5^@%?G_P#\
M%$_^2H>&_P#L#C_T?)6E/XA,]Q_X)O?\D-US_L8I_P#TFM:^KN:^4?\ @F]_
MR0W7/^QBG_\ 2:UKZNYKBJ_&ST:?P(.:.:.:.:R-0YHYHYHYH .:.:.:.: #
MFCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFC
MFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH YWXBW7V'X?^))\X,>F
MW!7KU\ML?KBO@2ON+XYWGV'X3^(Y,XW0+%UQ]]U3_P!FKX=KZ'+5^[D_,\?&
MOWTCK_A7X!F^(WC"UTL;DLU_?7<R_P $0ZX]R<*/<U]QZ7I=KHNG6UA8P+;6
MEN@CBB0<*HKSSX _#G_A _!J3W46S5]2VSW&X?-&N/DC_ $D^[$=J].YKSL9
M7]M4LMD=F&H^SA=[L.:.:.:.:\\[ YHYHYHYH .:.:.:.: #FCFCFCF@#%\8
MWGV'PW>L#AG7RA_P+@_H37C]>B?$^X9;*Q@ ^221G)_W0 /_ $(_E7G=>A05
MH7."L_>L=Q\(=/\ M7BDW!'RVL+/G_:/RC]"?RKVNO._@SIWDZ/>7I&&GF"+
M_NJ/\6/Y5Z)7%7ES5&=-)6@%%%%<YL%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<MXK^%O@_QT2WB#PSI>K2$8\Z
MZM$:4?1\;A^!KJ:*F48R5I*YM1K5<//VE&3C+NG9_@>*W/[&_P ';J7S'\&1
MJ<8_=W]W&/R64"M+2?V5?A/HLBM;^"-.D*XQ]K,ER./42,V>O>O6**P6%H)W
M5-?<CV)9_G$X\DL94:[>TE_F9FB>&](\,V_V?1]*LM*M_P#GE96Z0I^2@"M.
MBBNA))61XDYRJ2<IN[?<****9 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTFKAJ=:'M<-\T.G6E3E[.M]Y]A44BL& (.0>012UY!Z 4444 %%%% !1110
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M_P#2:VKZAKY>_P"">/\ R1;6O^Q@F_\ 2:VKZAKIGN< 4445 PHHHH ****
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M^,T\,^(-+U^\OVM4O!)IMO \6QRP R\R'/R'MZ<U[[7Y:?\ !2C_ ).(@_[
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MNQG.,C/K7VQ7XH?LW?\ )P7PX_[&&Q_]'I7[7UOB(1@THHQHR<D[A1117*=
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M$WJK*&'Z&L,=1C&2JP^&1KA:CE%PENB[1117F':%%%% !1110 4444 %%%%
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MCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@
MYHYHYHYH .:.:.:.: #FCFCFCF@ YK\[O^"E$;#XI>%G*D(VC;0V."1/)D9_
M$?F*_1'FN(^*'P8\'_&33[6T\6Z,FIK:L6MYA(\4L)( .UT(.#@9&<' XX%:
MTY*$KLSJ1<HV1\[?\$\1_P 65UG_ +&"?_TFMJ^H:Q_"?@O1/A]HD.A^'M.B
MTO2[<MY=O%D\DY)+$DL3ZDDUL5U2=W<\X****0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y_\ _!1/_DJ'AO\
M[ X_]'R5^@%?G_\ \%$_^2H>&_\ L#C_ -'R5I3^(3/<?^";W_)#=<_[&*?_
M -)K6OJ[FOE'_@F]_P D-US_ +&*?_TFM:^KN:XJOQL]&G\"#FCFCFCFLC4.
M:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.
M:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M85F90%"EN.>&:JG_  5(_P"1Z\#?]@V?_P!&BOG[]F?]GG4OVB_'C:/;W/\
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MA&K!R2LT"E*$U%NZ9]*_M[?M#?$'X*^*_"EGX,\0?V-;7UE+-<)]BMY][+(
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MYDM>>NPXD4_3YR/^ U:_:JTM=0^#.J3$9:SG@N%^OF!#^CFO-_V)]283>++
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M3*JL=K8&5*R(>G&<=LUZ179:VAYK"BBB@04444 %%%% !1110 4444 %%%%
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MSI-+O'9/+?NT4@SL)P,Y# XZ9YK7FE.FG3>IG:,9M36A]#?\.JO^JH?^6_\
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M*;MKBUM-6\-,[[V31[T!#UR LRR!1ST7&,#&*^FZ*N,I1^%DN*ENCYB\)_\
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M_L&S_P#HT5]1:C^W#\$])U"ZL;OQIY5U:RM#+'_95ZVUU)5AD0X."#TKS/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC^ [U]?\UMF&(_Y<Q^9E@Z/_ "\?R#FCFCFCFO#/5#FCFCFCF@ YHYHYHYH
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M9]TUQWQBT_6=6^$_C*R\/EAKEQI%U%9>6<.96B8*%/9B> ?4BOG3X:_\%)O
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MC?0*'N-+O4$5W"#CDIDAAR!N0LN3C->GUDTXNS-$TU=!1112&%%%% !1110
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MX5>E^C?9?YGU]3AC&T\N68-;Z\O51LWS/MMMO^)]"4445[I\@%%%% !1110
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M-H8VB96B*@HRG((QP14E8,L****0!1110 4444 %%%% !1110 4444 %%%%
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MZ@?3=>94YN;W]SNAR\ON[!1116984444 %%%% !1110 4444 %%%% !1110
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MA/2Y-1UB_AT^RCX,LS8&?0#J3[#FO O%W[9NEV,KP>'-%FU+!P+J\?R8S[A
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M/$'$BQSE0R^\:4M97WG+35]EI:U[>04445].? !1110 4444 %%%% !1110
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M1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0
M<T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- $4EO'-]Y ??O5:
M32U/W'*^Q&:O<T<U2DUL1*$9;HR7TZ9>@#?0U$UO*O6-ORK;YHYK3VC,G1CT
M, J5ZC%%;_--VC/3FG[3R(]AYF%2A&;HI/X5N\#H*7FCVOD/V'F8BVLK=(V_
M+%3)ILS==J_4UJ\T<TO:,I48]2C'I:C[[D^PXJS';11_=0 ^O4U+S1S6;DWN
M:J$8[(.:.:.:.:DL.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFC
MF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ Y
MHYHYHYH .:.:.:.: #FCFCFN"^+WQ3M/AEX?,OR3ZM<@K9VI/4]W;_97]>GN
M+A"522C'=DRDH+FD<Q^T!\8AX*TUM#TF;_B>W:?/(AYM8S_%[.>WIU],_(Q)
M8DDY)ZFK6J:I=ZWJ5Q?WT[W-W<.9)97.2S&O0?@C\)9?B1KOVB\1DT"S8&YD
MSCS6ZB)3ZGN1T'H2*^HITX8.E=_,\&<Y8BIH=Q^S;\(?MTT7B[6(<V\39T^%
MQ]]P?]:1Z _=]^>PS]-<U%;V\5I;Q001K##$H1(XQA54#   Z "I>:^<KUI5
MI\S/:I4U2CRH.:.:.:.:YS8.:.:.:.: #FCFCFCF@ YHYHYHYH .:2EYKEO'
MGB#^R]/^RPMBYN!CCJJ=S^/3\ZJ,7)V1,I**NSC_ !IKW]M:H4B;-K;Y2/T8
M]V_SV%<]171>!?#+>)]=CA=3]DB_>3M_L_W?J3Q^?I7IZ4X^2/.UG(]>^'J3
MQ^#=+$X(D\LD;O[I8E?_ !W%='3558U554*JC 4#  ]*=7CR?,VSTDK*P444
M5(PHHHH **** "BBB@ HHHH **** "BBB@ KYP_X*"_\FO\ B'_KZL__ $H2
MOH^O)?VH_A+J_P ;O@WJOA+0[FRM-1NIK>1)=0=TA CE5SDHC'H#CBM*;M--
MD3UBTC\D?@[KUCX5^+G@C6M4G^RZ9INN6-Y=3[&?RXH[A'=MJ@L<*I. "3VK
M]2O^&\?@7_T/'_E(OO\ XQ7R'_P[$^*7_0?\(?\ @9=?_(U'_#L3XI?]!_PA
M_P"!EU_\C5WU/8U'=R..'M(;(^O/^&\?@7_T/'_E(OO_ (Q7S#_P4C^%<\FO
M:#\4-*C:YT75+2.SNY40_NY5!:)VSR Z$*,]#'@]16#_ ,.Q/BE_T'_"'_@9
M=?\ R-7Z,GP=8:MX%A\,Z]9VVJ6,EC'9W=M*N^*4! #U'J,@\$8!X-87A1DI
M0=S:TJB:FK'YH?L9?M>VOP#6_P##?B:UN+KPM?S_ &I+BT4/+9SE55CM)&Y&
M"KD Y!7(!R17U_KG_!0;X*Z3I;75IX@O=:N!TLK+3+A)3P3UE1$]OO=Z\=^)
MG_!,&&[O[B[\!>*EL8),M'IFM1LZQGDX$Z9;;G@90D#J6KA-)_X)?_$*:["Z
MGXH\,VEKCF2T>XG?/IM:)!Z\[JTE["H^9LB/M8+E2/:?@G_P4.TWXH?%6+PQ
MJ_AY?#FG:D_D:9>&Y\UO.)PB3?* -_0$=&('(.X5_P#@IYX3NM4^%OAG7H(V
MDATG4VBN-HSL29,!S[;HU7ZN*],_9Z_8Q\%_ .X35E>3Q)XH"[1JU]&$$&1A
MO(B!(CSZDLW)&[!(KVGQ=X3TKQUX:U'0-<M$O]*U"$PW%O)T93Z'L0<$$<@@
M$=*P<X1J*4%HC7EE*#4C\DOV/?CQ8? #XKMK&LPSS:)J%D]A=_9E#/$&='60
M+D9PR $>C'&3@5]L_$K_ (*+_#'PUX?FE\)W-SXOUEU(@MTM)K:%&YPTKRHI
MVC_9#$\#CJ/&?'W_  2^UZ/5Y7\%>*]-N-,=R4AUWS(98E[*7B1PY]]J_2NF
M^#W_  3-M]'U:VU+XB:];ZO%"P<Z/I(<0RD'H\S!6*],@*I]_7HFZ,WSMF,5
M5C[J1^>M?NA\,?\ DFOA/_L$6G_HE*^$OB=_P36\7ZU\0->U'PEJOAFQ\.WE
MW)<6=G=33PO;H[%O*VI"RA5SM&#T Z5]]>#M(F\/>$=#TJY:-[BQL8+:5HB2
MA9(U4E20#C([@5GB*D9I<K+HPE%NY^(GQ&_Y*%XG_P"PI=?^C6K]6/!_PMTO
MXS?L<^#_  GJPVPWOAFQ\FX RUO,($,<J^ZMCZC([U\J^+/^";/Q-UWQ3K&I
M0:YX32"\O9KB-9+NY#!7<L <6Y&<'U-??'PD\)WG@/X7>$O#>H20S7VDZ7;6
M,\ELQ:-I(XU5BI8 E<@XR ?:JKU$XQY7JA4H--\R/Q@US1_$?P7^(]Q8SM)I
M'B7P_?#;+$>8Y48,DB'N#\K ]""#WK]>?V;?CC9?'SX7V'B&'RX=5B_T;5+.
M,_ZBY4#=@==K##+[-C.0:\L_; _8UF_: U#3?$/AF]L-*\3V\?V:Y.H%TANH
M0<J69%8AUY .TY!QQ@5RG[*O[)_Q;_9V^()U*76O#%[X<U!!!JEA;WMSO=1D
MI(@:W +H2<9(R&89&<@J3A5A=O4(1E3G;H? /Q0O=1U'XD^*KG5V9M4DU6Z:
MZWDY$GFMN'/H<C\*_4GX%?&_X)^$_@WX>M])\6^&] M;>QC-Q8SW<5O="?RU
M\TO$Q#NY;.6 .X]":XC]I3]@.R^+GBJ^\6>%-8AT#7+X^9=V=W$6M;B7'^L#
M+\T;$XW<,#R<9SGQ?P[_ ,$O/&]QJ"KKWBWP_I]CQF33A/=2=><*Z1#I_M54
MITZL5=V)C&=.3LKGFO[;?QU\/_';XI6=]X9$\NE:79?84O)D,?VEO,=RZH1N
M5?F &[!..@KZ._X):_\ (G>//^O^V_\ 1;UL?$__ ()UZ!>?"C3=!\!2VUGX
MGL[L7$VK:R[9O5*%71V124 ^4J%4@8/=BU=W^QC^SCXE_9UT#Q-9>)+[2KZ7
M4[F&:%M+FED551&!#>9&F#DCIFIG4@Z7+$J,)JIS2/C?_@HQ_P G)77_ &"[
M3^35T_[#/[6'A#X(^']7\*^+UNK"UO;_ .WQ:K#&T\:DQQQE'106& @(*ALY
M(P,#/,?\%&/^3DKK_L%VG\FJQ^S7^Q_I_P"T=\&M6U>WUB30_$ECK,EK'-(G
MFV\L/DPL$=,@@@LQ# ]R"#QC;W?8KGV,O>]H^7<]D_:I_;Q\':]\-=5\*?#Z
M[N-:OM:@:TN-0:VDMX;>!QB0 2*K,[*2HXP,DYX /QM\ ?A7=?&3XM>'O#$$
M3/;7%PLM](H.(K5"&E8GM\N0/=@.]?1&C_\ !+[X@3:@B:IXJ\-V=C_%-9M<
M7$@Y[(T48/&?XJ^T_P!G[]FSPK^SOH,UIHBR7VJ7>#>ZO=@>=/CHHQPB YPH
M_$D\UG[2G1A:GJR^2=25YD?[6JA?V:_B" ,#^RG_ )K7Y._ [_DM7P__ .QA
MT_\ ]*8Z_83XY>!;_P")GPC\4^%M+FMH-0U2R:WADNV98E8D<L55B!QV!KXA
M^'/_  3G^)/@_P"(7A?7;S6_"LMGI>J6M],D%W<F1DBF5V"@VX!;"G&2!GN*
MBA.,8--EU8N4DTC]&:_)_P#X*'_\G,ZM_P!>%G_Z*%?K!7Q'^U3^Q'XY^.7Q
M@OO%>A:KX>M-/FMH(5BU&YG24,B;22$A88STYK+#R49WD76BY1LCJ/\ @F=_
MR;[J?_8PW'_HBWKX@_:T^#]Y\'?C5KU@\#+I.H3OJ.F3!?D>"1BVT'U0DH?]
MW/0BOTB_9!^!^N_L_P#PMO/#?B&[T^\OIM4EOEDTR21XMC1Q* 2Z(<YC/;'(
MYKMOC!\%?"OQR\+-H7BJQ-Q"K%[>Z@8)<6KXQOB?!P?4$$'N#5QK*%5OHR73
M<H)=3Y'_ &6_V_/#&@^ ]*\)_$1[G3+G28%M;;5X8'GAE@0802*@+APH"\*0
M<9R#7H_Q"_X*.?"[PSIKMX::_P#&.H,F8H8+:2TA#<\223*K*..JHW4>^/$O
M%_\ P2Y\36]VQ\+>,M)O[5GRJZQ%+:NB\\$QK(&(XYP,\G Z4GA/_@ESXHN+
MM#XG\9:186P?YETF*6Z=D]C(L8!/(Z''7GI6CCAV^:Y"=9+EL?2/[*'[75C^
MT9'J>FWVGQZ'XFL!YYLXY2\<]N2!YB$C.5) 8'U4@G) ^</^"I'_ "/7@;_L
M&S_^C17VG\%?@+X0^ OAUM+\+V)66;!N]1N"'NKMAG!=\#@9.%4!1DX&22?%
M/VS?V3_%W[17B3PWJ'AO4=%LH=-M)()EU2>:-F9G# KLB?(P.Y%8TY056ZT1
MI.,G3L]SRO\ X)6_\A#XD_\ 7+3_ /T*YK]!*^7/V+/V7/%7[.-UXNE\2ZAH
M]\NKI:K -*FED*^492V_?$F/]8,8ST/2OJ.HK24IMHNDG&"3/QL_:T^#]Y\'
M?C5KU@\#+I.H3OJ.F3!?D>"1BVT'U0DH?]W/0BOJ#]EO]OSPQH/@/2O"?Q$>
MYTRYTF!;6VU>&!YX98$&$$BH"X<* O"D'&<@U]<?&#X*^%?CEX6;0O%5B;B%
M6+V]U P2XM7QC?$^#@^H((/<&OB'Q?\ \$N?$UO=L?"WC+2;^U9\JNL12VKH
MO/!,:R!B..<#/)P.E=*J4ZL%&IHS!PG3E>![;\0O^"CGPN\,Z:[>&FO_ !CJ
M#)F*&"VDM(0W/$DDRJRCCJJ-U'OCH_V4/VNK']HR/4]-OM/CT/Q-8#SS9QRE
MXY[<D#S$)&<J2 P/JI!.2!\W>$_^"7/BBXNT/B?QEI%A;!_F728I;IV3V,BQ
M@$\CH<=>>E?:OP5^ OA#X"^'6TOPO8E99L&[U&X(>ZNV&<%WP.!DX50%&3@9
M))QJ*C&-HZLTA[1N\MC@_CE^VCX+^!/CJP\+ZI:WVJ7DD:S7K:>$862,?DW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC1R(T<BG!5A@@UVX=+5]3DKMZ((XVFD5$4N[$*JJ,DD]A7OW@?PPOA?1(X'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&M33NMM6?0XSBO,\=AYX:M*/++?W5ZA1117O'QX4444 %%%% !1110 4444
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M_$8>6'E9[=SV*-:-576Y;YHYHYHYKD.@.:.:.:.: #FCFCFCF@ YHYHYHYH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/U)ZGFO(Q6+=9\L=(_F>CA\.J:YI;AS1S1S1S7FG:'-'-'-'- !S1S1S1S0
M<T<T<T<T '-'-'-'- !S3)9D@C:21@D:C<S,<  =Z?S7G'COQ5]MD;3K5\VZ
M']ZZG[[#M]!6D(.;LB)R4%<K:YX]OKRZ=;&4VUJIPNT#<WN2?Y5T?PU\;3W>
ML+I^H$3/,"(9\ $$#.#CU ZUYE7;_"OP[-J6O1Z@5*VEF=S/_><@X4?GD_\
MUZ[*D(*#T..$I.9[91117E'>%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\^_M6:]XN^QZ?X=\/65W)I^H1LU]<6D+,2 <"-G
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M-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'-
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MY'TZ%?*CWRR(R(%8.J*2AR"/F SCBNNHG*G"R.>#2G*Y[U17B/\ PVM\$_\
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MR73_ .KBS^I]J\FN[N6^N9)YY#)+(<LQI^H:A/JEY)<W#[Y7//H/8>U5P"Q
M R:]*G3]FO,\^<W-CHXWFD2.-&>1R%55&22>@ KV_P"'_@=/#-G]INE#:E,O
MS'KY2_W1[^M9_P -_ /]DQIJ>H1_Z<PS%"P_U(]3_M']*]!KCKUN;W8['12I
MV]YA1117&=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM-'J0JPJ*\66^:.:.:.:P-0YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \O^,GQE3X=>'FO-'^P:UJ$%
MTL-U9?:07@C(8%V53D8?8O(_BJ[\'/C'IGQ<T-IX%%GJML +RQ+9*$]&4]T/
MKVZ'W\(^/7P-\2Z+XVN?%GAF&?5K;4)7FFBAC$DD#L"75EQAHV&>HQ@E6]^.
M;QE9_#VWL]:^%^I3PW,UNO\ ;MO-"LBQ,2I55$B9\O<67<"<?*"V2,_#U,UQ
M6%QDGB%:"^SW7\T=K^?9?A^M8?AW+\PRNG'!RYJTM>?5*+ZQGO;JHNVKM\_N
MNBN&^#OQ.A^+'@R/6$MFM+B.4VMU#U59E56.T]U(92/KCM76ZIJUEHED]YJ-
MY!8VL?WIKF01H/J3Q7V=&K#$0C4INZ>Q^78G#U<'6G0KJTHNS1'X@_Y .I?]
M>TO_ * :_+;_ ()T_P#)REE_V#+O_P!!%?>?C#]ISP!:6%]96^IS:E/)"\0^
MQV[%0Q! ^9L CGJ":^%OV1]//P2^,EIXE\13QOIBV<]NWV+=(ZLZ@#@@<?2O
M8HX>K[.7NO4\BI5ASQU/U/HKBO"?QE\&>-I4ATG7[:6Y;A;:;,,K'T"N 6_#
M-=K7G2C*#M)6.R,E)73N%>5?&#]H+1?A+<6UDUNVKZK+\SV<,H0PQXX9FP<$
M\8'7'/IFM\?/CM#\)["*QL$2Z\1W:"2&*528XH]Q'F/@C.2&  /4'TY^:O$5
MG;:UI/\ PG%]?V]]XUU2YW?\(XD0_=;L[)C'DLR[55@I&#N4G*\'Y3-,V='F
MH85KG6K?9?J_(_1.'N'(XKDQ>81?L9:12O>3\[;1W][38^X]!U0:YH>G:DL9
MA6\MH[@1DY*[U#8SWQFM"OG7]E3X>>)-(;4/%6ORW$2ZC#Y4%K=%C*X+AC*P
M/W<D<9Y.2>F,_15>U@<14Q.'C5J0Y6^C_/YGRN;8.E@,9/#T:BFH]5MZ==MK
MA1117>>.%4M4UBPT2W6?4;ZVL(&8(LEU*L:EL$X!8CG /'L:NUY]\</ABWQ8
M\#OI,-U]DO()UN[5F^XTBJRA7[[2'/(Z'!YQ@\^(E4ITI2I1YI):+N=F#IT:
MV(A3Q$^2#>KWLNYYUI7[5T5M\1+O0/$6FQ:;IB7#P1:C&[$ ;OW<C@_P,N#N
M''(/3FOH16#J&4@J1D$<BO@RQ\+VND1W>B?$R"\T2[AMG71;B2-@6?)&QG 8
M&$-@YZ#)P0"<^G_!+]H7Q''XTB\(^--UV]U(EO;3K#&CP.0 JG8 &1AC##/4
M')!X^2R[.)QG[+&OXGIIJGVEV\M-3]*SSABE.E[?*X_PXWEKI-?S0WOUYE?1
MZ*[W^IJ**XKQ9\9?!G@F5X=6U^VBN5X:VAS-*I]"J E?QQ7V\8RF[15S\GE)
M15V['PS_ ,%2/^1^\#_]@V;_ -&U]F?LP_\ )N_PZ_[ =K_Z+%?%'[;&J6O[
M0/BSP[?^%YO+M]-LY+>5K]3$69GW#: &XQZXKZ6_9]^._@SPS\*_"'A?5]4;
M3M3TW38+.8S0OY1D10IPX!&..IQ7HU,/5]C%<K..%6'M&[GTA15+2M8L-<LD
MO--O;>_M7^[-;2B1#]"#BF:]KEEX9T>\U349A;V-I&TLTI!.U1[#DGVKRY-0
M3<M+'H0C*I)1@KM[$?B+Q%IWA/1;K5=5NDL["V7?)*_;T '<D\ #DDUY[\(/
MCU:?%[6M5LK329M/CLHQ*LTTP8R*6P/E X/XFO"?$GQ>F_:!\0GPYJ$UMX9\
M%K.;DW\T>Z2W"(P1I&+!?F8A<>K 9/?D="^'NM>,O&7_  C'A4S)H<-S(G]K
MH&$,Z(Q4W+N.&R!\J@X&0!R2Q^)K9W5G7@\(N:G>UNLG^:7F?JV$X3P]+!U(
MYE+DK64KZ\L(_*R<GK>-]-'Z_?5%5=-L_P"SM/M;02&001+%O;JVT 9/Y5:K
M[97MJ?E$K)M(****8@HHHH **** "BBB@ HHHH **** (+RSAO[62WN(UFAD
M7:Z-R"*\3\>> 9O#,[7-JK3:8YX;J8C_ '6]O0U[G4<\$=U"\4J+)$X*LC#(
M(/8UK3J.F[HSG!31\P5J:#XAN?#]UYD)WQ-_K(6/RL/\?>NE\>?#F306>^T]
M6ETX\LO):'Z^J^_Y^M<-7JJ4:D=-C@:<&>UZ/K-MK=H)[9]PZ,A^\A]"*O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:Y#J#FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M-'$Y.;*=E93ZA=1VUM$TT\APJ*,DU[3X'^'L'AI5N[O;<:D1]X<K%[+[^_\
MDZ7A/P;9>$[7$0\Z[<8DN&'S-[#T'M70UP5:[E[L=CJITN75[A1117(= 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17A_Q_\
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MU,&\.S6VUCF(:-*0GMDYX_&OGO\ 6##6OR3_ / ?^"?;?ZF8^]O:T_\ P/\
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MZOK$1*332$_9[=O[IP<NP[@$ >N015S]J#XL3> O"\.D:7,T.LZL&43(<-!
M.&<'LQ)V@_[QZ@5\3<YR:]K X-55[6IMT/.Q.(<'R0W.\\0_';QYXEF9[GQ+
M?6Z-QY5C)]F3'IB/&1]<UR]QXJUN\D\RXUB_GDQC=)=.QQ]2:RZ*]^-.$=(I
M(\IRE+=FA_PD&J?]!*\_[_O_ (T^'Q1K-L^^'5[Z)\8W)<N#^AK,HJN5=B;L
MV_\ A./$?_0?U3_P-D_^*H_X3CQ'_P!!_5/_  -D_P#BJQ**.2/8?-+N;?\
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M VK;O.\.6D9//^B[H,?@A%=4<RC]J)SO!2Z2/AROI#]D&Q^3Q/>D=3;PJ?\
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M&_UBZ\F,G;'$HW22M_=1>Y_0=R*T-?URU\-Z+>ZI>OY=K:1-+(1UP!T'J3T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#Q']H#X"ZK\7-6TN^T[68;1;6 P-:W>[RQEB=Z
M[0?F.0#QT4<UYA'^Q;XC6SF!\2:<DK$8A5)#&_NS8[?0U]>T5X6(R3!8FK*M
M4B^9^;/K\'Q7FN P\,+0FE&.WNKO?L?+?@+]D?7O#?B>SU*Z\4QV"6Y)\S2"
MPN.5(PK.N!U[@\$\5QO[5'@*?PCXDT>^?5=1UF.^MFC^TZDZ/('C;E<HBC&'
M7'&>O-?:U><_'GX<GXE?#Z[LK:,-JEJ?M5EVS(H.4_X$I(^I![5Z^48/#975
M3I*R>^KZGBYUG&.SJ/\ M4DVMM$MOE<S/A'XDC\4_#G0KU&W2+;+!-[21C8W
MYD9^A%=C')Y<B,.JD&OD/]GWXIKX!UV?1-8=H-*O9,%I/E%M..-S9Z X /I@
M'L:^NE8.H(.X'D$5Z^*HNC4:Z/8\'#U%4@NZ.I5@R@CD'D4M9^DW0DA\IC\Z
M=/<5H5YYTA117%?%?XH:;\+/"\VHWCK)>R I9V>?FGDQ_P"@C()/8>Y +C%S
MDHQ6K)E)15V?-'[8?BI-6^(%CH\3[DTFU_>#^[+*0Q'_ 'R(_P Z]5L?V?\
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MK4XNZVU9[F+XLS7'8>>%K33C+?W5_D%%%%>\?'A1110 4444 %%%% !1110
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M6**^9?&G_!0WX0^$;][2VN]4\3.C['DT6T5HP?4/*\88>ZDCFKW@7]OKX/\
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M<R!)'RH)VY..01VKT*DTT[,:=U=!1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6]OJ]O$WV2]"'# %AAQ[<C(X)P#7N7@W]JO1M0ACA\26DNE771KBW4RP-ZG
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M@Q#FCFCFCFN$Z@YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M-Y;I.(..(DW @8SR1U/L!7 ?LH_!H[H_&^L0<<C3(9%_ S8_,+^)]#7N]O\
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M<]__ &&_V2+;QK_PC?Q5U'7O]%T[43-!H\-O\S30290O(6X 94; 4YZ9'?\
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MBUO+N=M3O(RTDD2N?E28*/O8P .E<7^U7^PW\/O"_P )]:\6>"[.X\/:CHL
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M/X5576M%$T]*<F?'?[%^CMKG[3W@. +N\N[DN3D<#RH9),_^.?G7[&5^5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S4<TT=O&9)9%B0=68@
M?B: ).:.:Y?5/B%IMCE8-U[(/^>?"_\ ?1_H#7'ZKXZU34@4206D1_AAX/\
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M8VS6,DKR&^D= 0P4#&U&_NGK7Q?XL\,W/@WQ)J&B7LD,MU8RF*1[<DH2/0D
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU[ZW6?PWX6N(6D4/#;VMTLCKGE5)G;!/8X//8T_JU07MH'Z9T5YQ\</C38_
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MX9Y)ILH&\P;)4 4[N!@\#.><#7ZO4O8S]M"US[OHK\Q?^'G?Q2_Z 'A#_P
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MN%5R:[6OROUS_@F_\7=)T4W]NV@:O.%#'3[&^<3],D?O(T0D=.'Z],U]#?\
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MK3]XL]4M]:M)"JMC<DB&4;TR <9!!'!&3GYM_P"'8GQ2_P"@_P"$/_ RZ_\
MD:O)_C[^ROXL_9SL]&N?$FH:->IJLDL< TJ>60J8PI.[?$F/OC&,]ZQA3AS+
MEGJ:2G.WO1T/NG]D'X#_  K^%FLW]UX;^(&D?$/Q?);,LEQ8W=NWV:WW+DI#
M'(Y3)V N6/8#&2#]4U^9W_!,'_DM7B7_ +%Z3_TIMZ^V/VE_CY8_L]?#:?7Y
M84OM5N)/LNF6+L0)IR"<MCG8H!8X] ,@L#6-6,O:<M[LTIR7)?8]-U35K'1;
M5KK4+RWL+93@S74JQH/^!,0*Y/3_ (Y?#?5+N.ULOB#X6O+J3.R"WUJV=VP,
MG"A\G@$_A7X^^*O&WCW]H;QQ =3N]1\4Z[>2&.TL85+A,\[(8EX1<#)"@="3
MW-=3X@_8Y^,GAC07UB_\"WBV$:>8YMYX+B5%VEB3%'(SC !SE>.]:_5HKXI:
MF?MF_AB?L>CK(BNC!U89#*<@CUIU?CM^SI^U9XL^ >O6J1WD^J^$VD'VS0YI
M"T>TGYFAS_JY,<Y& < ,#V_77POXDT[QEX=TW7=(N5O-,U&W2YMIU_C1@"#C
ML>>0>0<BN>K2=-ZFU.HJASJ?&[X=2:HNFIX^\+OJ+3?9Q9KK-L9C+NV[-F_.
M[=QMQG/%;_B3Q=H7@VQ^VZ_K6GZ'9YV_:-2NH[>/.0,;G('4C\Z_$'XB$K\0
MO$Y!P?[4NC_Y&:O2(?!_QH_:XURXU^+3M4\621_NA=S2)!:0@?\ +*-I&6-<
M?W5.><G).3TO#)6;EH8JNWI8_6'P]\6O _BZ^^Q:%XR\/ZU>8S]GT_5()Y/^
M^4<FNLK\,O'GPY\5_"+Q(NE>)])NM!U:,":-9".1D@/'(I*L,@_,I(R.M?H[
M_P $_P#]H/5/BUX)U/PYXCNY+_7?#YC\N]F8F2YM7R%+G^)D92"QY(9>IR3G
M4H<D>:+NBX5>9\K6I]84445R'0%9>O>)M'\+69O-:U6QTBU )-Q?W*01@#DG
M<Q X%>&_MC?M.#]GOP;;6^DI%<>+M8#I8K*-R6R+@/.Z]\$@*IX)/<*0?S%C
MC\>_M!>.6"_VKXS\370+G)::0(.OLB#/3A1D#BNJG0<US-V1A.KRNRU9^QVC
M?&;P!XBO!::5XZ\-ZG=D9%O9ZO;S2$9 SM5R>I _$5V5?C#X\_93^*_PRT.3
M6/$7@VZM-,A!:6ZMYX;I8E&,L_DN^P<CEL"O0_V4?VRM?^#_ (@T_0_$NHW&
MK>!9W6&2*X8R/IX)QYL1/(4=3'T(S@9ZW+#Z7@[D1K:VDK'Z>^*O'OAGP+';
MR>)/$>D^'DN2RP-JM]%;"4C&0ID8;L9&<>HK\8OCUXD_X2[XU^.M76\COX;G
M6KLP7,,@DC>$2LL11AP5V!<$=@*_3C]K;]FRY_::\,>'DT?7K73+G3)9)X7G
MC,D-PDJ+_$IR/NJ00#P37Y0>*O#MSX/\4:QH-X\4MYI=Y-8S/ 28V>)RC%20
M"5RIQD X["M,*HZN^I%=O;H?HE^S7X6_9P\-_"#PY)X@U#X?ZCXCO[**[U%O
M$%[9SSQS.NXQ[)F/E[<[=H ^[SS7V'H]Q87FDV-QI4MM/I<L$;VLMFRM"\)4
M%&C*_*5*XP1QC&*_+'X>_P#!/OXB?$GP3HWBC3-9\,0:?JMNMS!'=W5PLJJW
M0,%@8 _0FOTS^%OA>Z\$_#+PCX=OI(9;W2-(L]/GDMR6C:2*%(V*D@$J2IQD
M X["N>LHWNI79M2;MJK&MK_AS2?%FE3:9K>EV>L:;,5,MGJ%ND\+[2&7<C@@
MX(!&1U -<E_PS[\+?^B:^$/_  0VO_QNN_HKG3:V-K(_+7_@HMX,\/\ @?XN
M^'K/P[H6FZ!:2Z%'-);Z7:1VT;O]HG&XJ@ )P ,]< 5L_P#!-[P)X:\<^*_&
MD/B3P]I7B"*WLK=X8]5LHKE8V,C E0ZG!( Z4?\ !3[_ )+5X:_[%Z/_ -*;
MBMW_ ():_P#(X^//^O"V_P#1CUZ3;^KW.*W[ZQ]J_P##/OPM_P"B:^$/_!#:
M_P#QNI/B)XPT#X!_"?5=<6PM['1M$M<V^GV<:PQEB0L<2*H 7<[*O XSFN[K
MXP_X*?>*)M/^%OA;0HI"B:GJC3R@?QK#&?E/MNE4_517#!.I-19U2?)%M'Y^
M?$/X@:W\4_&6I>)=?NFO-4OY=['G:B]%C0=E48 'H*^U?V>_^"<MEJGA^SU[
MXFW5Y'<W4?FQ:#9.(O)4CY?.DP3NP<[%QMXR3R!\V_L<^";?Q]^T?X,T^]B6
M:R@N'OYD89!$$;2J".X+H@(]Z_8^NW$5'"T(Z'-1@I7E(^=-8_X)_P#P2U*Q
MDM[?PQ=:5*PXNK/5;II$X["61U_-3TKYXU7_ ()AZQ#\1-/@T[Q+;W/@B63?
M<W4XV7T$8Y*; -KL1P&! SDE1CG]$J*Y(UJD>IT.E!]#G/\ A'=-\)> 9=%T
MBTCL-,L=/>"WMH1A414( _\ K]3UK\+*_>7Q)_R+NJ?]>LO_ * :_!JNK"_:
M.?$=#]?_ (&_ WX;ZM\$_A_?7WP_\+7M[=>'M/GGN;C1;:2661K:-F=V*99B
M222>237B'[;7['_@W1OAIJ7CKP;I</A[4=)*2W=G:?+;W,+.%8B/HC*6##;@
M8##!.,?4_P"S[_R03X:_]BUIG_I+'7S[^WM^T5X7TCX5ZIX$TO5;75?$FL^7
M#-!:2"46D(=7=I"IPK$*%"GGYLXQ7/3E/VEEW-I*/)J?"'[.OC:\^'WQN\&:
MS9R/'LU.""=4./,@D<1RI^*,WXX-?MA7XM_LP?#V]^)GQV\(:3:Q-)#%?17U
MXZCB.WA<22,3VR!M&>[*.]?M)6N*MS(C#WLPHHHKA.H**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%<KP9E;R;<'V<@EOP7![&OTC#QEBDI45=,_$,0OJLY4ZVC3L_D<W_P %%O\
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M#FSU/X7:Q!;S6BS+-#KC6S"9 VUP5!)_=;@00O/+$9/!]&_9A\1>(/!>L_\
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M]_\ 2N:E6_@Q^0Z/\1G-?\%)+&"Y_9YBGDB5YK?6+9HI".4)613@^X-?'G[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?L\^!/%\,@DT2'3+ANESI8%NZGUP!M)^JFOE[XH? [Q)\%;Z+6M.NY;O3(I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1R&P[1P1JN[&_P"9AD#=SC-?=7[#W[*-_P# ^QOO%'BM(X_%>J0BW2SC</\
M8K?(8JS#@NS*I."0 H&>37U=153K.4>6*LA1I<KYF[L_//\ X*G?\C!\/?\
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M)HO^*QCO0(8QODM+C*?*/DY7HO3TXK\U?$TE?]RO_ U_D?L4> X2M_M4M?\
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M1110 4444 %%%% !1110 4444 %%%% #))%CC9W8(JC+,QP !W->.^,OVK/
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M/LN#7SYC/"O:K3G#TNKW_ ^NZ*PO ^M7'B+P9H6JW<7D7-]8PW$L?HSH&/\
M.MVOHH24XJ2V9\14IRI3E3ENG;[@HHHJS,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\5_:(^/#?"VWATC28Q)XBO(?.221,QV\18KO(/#,2
MK #V)/8'0_:.^*E_\+_!T,FE1*=2U&1K>&X?!$&%R7 [MZ=L\G.,'Y>TC7[3
M2K347\6PW6N^+[Z"/^R)KJ4S-IS?.5:0.V/F+JP4@X R1\U?)YOFGL6\)1ER
MRMK+MY>KZ?U;]&X:X>^LQCF.*AST[Z06\FG9M]HQW?>VVR?I6A^(M"\7>&[_
M /X3.VF\4_$?65%K;:2J;98H\ Q",A=D _Y:,W7J2#TKAO&/[/?CCX8_9=6L
MU?4$C19&NM)+&2V?'S @?-@<_,.,=<=*]A^!/[-^H>$?$C^*/%EPLVK0NQM8
M89C(-S AI7?^(G<<#W)/M]$U[60U\9AJ-ZZLG]E]?[SZ\S_I'@<51RZOB^7!
M2YK;R6R[1CTY(K;K>^I\1>%_VIO$VC1I#JUK;:W&O&]OW,Q^K*"/_'<UT,?[
M?GAS2=232I])E74795^S&YRH)Z#?LP"?0^HKZ1\2?"OPCXND:75O#UC=SL<M
M/Y6R5OJZX8_G7Y5?'SPGI6@_M=:IH%A:^1I,>L64*V_F.V$9(2PW$EN=Q[]Z
M^K53#5_^7=F?#N-:E]JZ/K7Q9^V%XHUF%X=%L+70488\W=]HF'T9@%'_ 'S6
M-X$^ _C3XNZK_:VLO<V-C.P>;4]2W-+*/]A6Y;V)POOVKZV\.?"7P=X3D272
M_#MC;SIRL[1>9*OT=\L/SKKJAXR%-6P\+>92PTIN]65SYFUR30?@CX9U#P#X
MITY+S1M1\RXTO5((@9)&SUN "&$D9*8=>JXP 1BN7^"?QT\4^'?'5EX<\47%
MSK-EJT\5O#+-)YCQ,[!8Y(W)^:,Y&><8Y'<'Z$^+WPCTOXM>'_LEV?LVHV^6
ML[Y5RT+'J".ZG R/8'J*^4O%T*_"W3]7^&FNV]O?/.T4]OK_ )9+6BML?;&I
M4ML+*0VT_P 3G!/!_+\TEC,+BEB7/W%L^_7EE^-F]C]NX?66YG@)8)4[U9?%
M&UN5:+VD.UE9RBK.36BM9'W517RQ^RKJWB_0?$#^&;ZTN)O#4T3W$%RR,\$;
M<$&*4?*5?/0'&>1@YS]3U]5@,8L=0591<7U3[GYUG&6/*<4\,YJ:W375/\GY
M!1117H'BA1110!GZ]K=KX;T6^U6^<QV=G"T\S*I8A5&3@#K7R7)\?M0^*/BZ
M:SUBZ;0OAT\@%ZD>%?R<':CR %B9" "J]1NQP":YCXD?%S7OBAXIO7EO)M(\
M+63&*2UBE8(8LX(< CS)'P<+_(!FK0LOAJ?CQKAE\#V2>'O"-G)'%+#=2?-%
M(PR\FT$ER0!U/8#('3\^QN:5<?45/![)[=9__:]^_P"7[3E7#^&R>@Z^9V4I
M+XM+4MK6_P"GCOI9.UO_  +I/%?P8MOC+?7NO?#W3;?2=%MXO*AED!ABU.93
MAC"F/D48*[C@,PZ#DUYOI/C3Q]\$-0.F3)<6**23I^HQ%H6]2OM[H>?6ON/P
M5X1L/ ?A;3]!TT/]CLT*HTK;F8EBS,3ZEF)].>*OZMHNGZ[:-:ZE8V^H6S=8
M;J)9$/X,"*_2\#BZM.A&GBES=_+R7DNG7S/Q?,*-"KB9U,'>,;Z=VN[\WN[:
M7V1\K:1^V T03[?X<Q*O66UNL#_OEE_K5[5/VUI?L[)IOA=!/VFN[LE?Q15'
M_H59'[;GP]\.?#7X,77B;PUI$&E:RM];PB:$MM",2&'ED[.<>E<[^P#X5T?X
MK^ _$&L^+--M]9U"TU;[/"\RD*D?DQMMV#"GECU!/->CS8-Q]IR/^OF>9;$<
MW)S?U]QCZUXV^(GQ\U(::@N-1CW!AI^GQ^7;ISPS]L#^\YX]:]8\)_LYZM\+
MM/M/&#/9ZQK^FN;J72)0/(,0!W!)#TE'WE;& 1CGK7TKI>DV.BVJVNG65O86
MR_=AMHEC0?0* *L21I-&\<B+)&X*LK#(8'J"/2N'%8J5:DZ-+W%Y;_U_3.W"
M4XT*T:U5<]NCV_K\MU9GQ9\2/C ;SQ(_BCX<W=YHT+"-]6MQ^[,DP8[99(P2
MK*00I;UX;[RY^G?@S\2?^%J>![?6GM?L=TLC6]Q&IRGF* 24[[2"#SR.G.,G
MP_XE_ 6'X4:I<^/]#>.XT;3Y([B30YE8[E:0(\8;G]V0QSD=,@YKR.;7]3US
MQN?%_@JR?3M1619&TO38]S6I"A<JJCYXF Y., L58<J6_+88S%97B9/$ZN6\
M5LU_-'_+=[OR_=*V5Y?Q!@(+ NR@M*DMT[+]W/9[-6EJELKO?]!J*Q/!>K7N
MO>$M'U'4;7[%?W5K'+/;[2OEN5!88/(Y[&MNOT*$E.*DMF?BE2FZ4Y4Y;IV^
MX***\E_:.^*E_P#"_P '0R:5$IU+49&MX;A\$087)<#NWIVSR<XP<<3B(86E
M*M4V1U8'!U<PQ,,+0^*3LC/_ &B/CPWPMMX=(TF,2>(KR'SDDD3,=O$6*[R#
MPS$JP ]B3V!\WT'Q'H7C#PUJ!\96\WBGXC:R!:6VE*NV6).L0C(79 /^6C'K
MU)!Z5YMH_B"TTNUU)_%L%WKOB^]@C&D374IF;3F^<JTF]OXBZL%(. ,X^:O<
MO@3^S?J'A'Q(_BCQ9<+-JT+L;6&&8R#<P(:5W_B)W' ]R3[?%4,9C<=C(U:.
MW;I#S?3FW:W_ $7ZOBLMRO)LLG1Q/Q?S=:KT?*NJIWLI;;77=^/>,?V>_''P
MQ^RZM9J^H)&BR-=:26,EL^/F! ^; Y^8<8ZXZ5=\+_M3>)M&C2'5K6VUN->-
M[?N9C]64$?\ CN:^W:Y3Q)\*_"/BZ5I=6\/6-W<,<M<>4$E;ZNN&/YU^IPQL
M9Q4<1'FMUZGX;+#M2<J+M?IT/![+]LRTM8>?#5PS9YC^UKM_!MO]*Y?Q9^V%
MXHUF%X=%L+70488\W=]HF'T9@%'_ 'S7S9\;]4G\'_M2:EX.T@K:>'H=5M+9
M+7&\B-UB++O;+<EFYSGGK7Z8>'/A+X.\)R)+I?AVQMYTY6=HO,E7Z.^6'YUM
M*>$I6DJ=VS*,:]1M.5K'R3X#^ _C/XN:L-6UI[FQL)V#S:GJ6XRS#_85N6XZ
M$X7W[5Z7KDF@_!'PSJ'@'Q3IR7FC:CYEQI>J01 R2-GK< $,)(R4PZ]5Q@ C
M%?3-<%\7OA'I?Q:\/_9+L_9M1M\M9WRKEH6/4$=U.!D>P/45\]F]7$XR@U0T
M:V71]T^^FWG\SZ;(7@\'BXO&7Y&]9+XHM;-/=6>^]UT;L?/?P3^.WBCP_P".
M[/PWXGN;C6K/5)XK>*6:7S'B>0A8Y$<GYHVR,\XQR.X/V#7PKXNA7X6Z?J_P
MTUVWM[YYVBGM]?\ +):T5MC[8U*EMA92&VG^)S@G@^A_LJZMXOT/7G\-7UI<
M2^&IH7N(+ED9X8VX(,4H^4JV>@.,\C!SGXO*<PJ8>HL%6O*[M?K%_P K[KSV
M_3]*XCR6CC*$LUPO+"RO9:*I&R]^/9]XVOIKNK_4]%%%?='Y"%%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&>UAN5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N(^+'Q4TOX3^&FU*^/GW<I*6EDK8>>3'Z*.[=N.Y
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M"#BV^X4445@:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLP^$P_\ ;.:K]TO@AUG+_P"1_/TWU_V;?@ ^A^5XP\4P,=8D/F6=G/R8 ?\
MEJX/_+0Y. ?N]>I^7Z/HHKV,'@Z6!HJC26GXM]V?,YIFF(S;$RQ.(>KV71+H
MD%%%%=QY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4455U'4K32+.2[O[J&RM8QEY[B0(BCW).!0
M!:HKPSQI^UQX2\/M)!I$5QXBN5R-T/[J#([;V&3]54CWKQ/Q3^UAXXUYG2PF
MMM!MSP%M(@\F/=WSS[@"O0IX&O4Z6]3DGBJ4.MS[=9EC5F9@JJ,EB< #UKG-
M4^)7A+1F*WWB;2;9QP8WO8]__?.<U^>FN>+=;\32%]6U>^U)B<_Z5</(!] 3
MQ637?'*U]J9RRQW\L3] +C]H;X=VI(?Q1:M@9_=QR/\ ^@J:J+^TU\-'8*/$
MHR3CFQN0/S,=?!5%;?V72[O\/\C/Z[4[(_0:T^/OP^O6Q'XJL5.<?OMT8_-@
M*Z72?&GA[7F5=-UW3=0=N MK=QR'Z8!-?FI14RRN'V9,I8V75'ZC45^;OA_X
ME>*O"I3^RO$&H6:+TA6=C%^*'*G\J]9\*?MB^*-+9(]<L;/7(1UD0?9YC[Y4
M%?\ QT5QU,MJQU@TSHCC(/XE8^M?$T\]KX;U::U.+J.TE>(@]'"$K^M?,7[$
M5C:2ZEXLO7 :_BBMXHV.,B-VD+X]<E$S]!ZUZ1I_[57@/5_#][<W,]Q87$4+
M,VGW,1WRG'W49<J<GCJ#SG YKS;]B.QN_P"U/%%[L86/DPPF3HK2;F( ]2!G
MZ;AZU\)F,7#-L+3ENN;3MIH_Z['Z9D]WP[F-1:1;II/O:6J_KN?65%%%?2'P
M0UF"*68@*!DD\"OD/XY_&34?BSXBB\">"O-N;"2;R99+<_\ '](#V/\ SR7!
M.>AQD\ 5H_M#?'2Y\5:@? 7@MFNUN)!;W=Q:_,UPY./(C(_ASU(Z].F<YLTN
MG_LL^$S!"T-[\3-6@!DDP'33XB>@[=O^!$9/R@ _$YGF"Q3E0IRY:4?CEW_N
MQ[M_UIO^KY#DSR]4\77I\^(J?PJ;Z?WY]DM_+U:M'XDUG3OV:_"LGAC0)HKW
MQ]J,0_M+5H>?L:GD(G<'T'!_B/\ "*[?]FWX -H*Q>+_ !1 9-9F'F6EI<+E
MK;//F/G_ ):'M_=SZGC(_9Q^!$^I7<?COQ?&]Q<S/]JL+>X)9G8G=]HDSU)/
M*@_4]J^HZURO+W7<<57CRQC\$.R[ONWO^/8YL_SE82-3+\)4YZD_XM3^9_RK
MM%;6733O<HHHK[$_,3POX^_L^Z!XNT[4/$MO<P^']6MXFGN+IP?L\ZJ"290.
M0?\ : )]0W&/ ?AQ\9/BC8Z3+H_AHWFM00J$119->/;9SMVG!('!P&R.#@5[
MO^V%XPCT;X<PZ)%.%O-6N5#0@_,8$^9C]-PC'ODUTO[,_@Z'PG\)M)D\G9>:
MHOVZX<CEM_\ J_P";>/<^M?#XC"+$9JZ>%E[-J-Y./5OH?K&#S&6"X=C7S""
MK*4^6G&:NDEN[[VW7X;'EOP@_9RUGQ#XD?Q;\1ED>1I//2QN7#2W$G4-*!T4
M<?)WQ@@ 8/U./EX' I:*^HP6!I8"GR4MWNWNWYGP.:YOB<WK*K7LDM(Q6BBN
MR04445Z!XH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEHW[%MTL:R:QXACR/O0:?"3^3OC_ -!KJ]-_9?\ !.G?+<V]]J##K]JN2O\
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M69)X9/[5O6V.K!E.#,0<$#J*Q=2A_*:<E7N>ZT445Q'4%%%% !1110 4444
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M<VX4445F6%%%% !1110 4444 %%%% $5Q<16L$D\\B0PQJ7>21@JJH&223P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1\<?^2*_$#_ +%[
M4/\ TFDK\0*_;_XX_P#)%?B!_P!B]J'_ *325^(%>EA=F<6(W1^[O@O_ )$[
M0O\ KP@_]%K4_B36H_#GAW5=6E&Z*PM9;IQG&51"QY_"H/!?_(G:%_UX0?\
MHM:R_BW8RZI\*?&=E"&,UQHM["@7KN:!P,?B:\[J=G0_$+6M8NO$&L7^J7TI
MFO;ZXDN9Y#U>1V+,?Q)-?L#^Q[\.K7X;_L]^$K:&!8[S4[1-5O),89Y9U#_-
M[JA1/^ 5^.5?M_\  _6(-?\ @WX&U"V96BGT2S;Y.BGR4#+^!!'X5Z.*^%(X
ML/\ $V=O1117FG<%?GG_ ,%3O^1@^'O_ %ZWO_H<-?H97YY_\%3O^1@^'O\
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M/P4^+FJ_ _XA6/BW2(UN;FVCEB:UE=EBG5XV7;)CJH8JV/5!R#@C]7_VMO\
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MLJG #\$D-G.,U\E_\%*/^3B(/^P';?\ HR6OU#L;^VU2SAO+*YBO+29!)%/
MX>.13T96'!'N*_+S_@I1_P G$0?]@.V_]&2US4)<U6]K&]56IVN>[?\ !+K_
M ))KXR_["Z?^B5KTG]K[]K"W_9YT6VTS288=0\9ZG&9+:"?)BM8<X\Z0 @G)
M!"KQD@DG"X/FW_!+K_DFOC+_ +"Z?^B5KXZ_:T\97/C?]HKQU>7$C2):ZE+I
MT )X6.W/DJ%] =A/U8GO5>S52L[[(GG<:2L8?B+XA_$KX[:\\&H:KKOBV_NF
MRNG6_F2H>1@1V\8VJ,XX50,U3DL?B)\%;^*XEM?$W@6\FVO'))%<:>\F,X(R
M%+8^;]:_2/\ X)[_  UTWPC\!-.\0I:Q?VSXBDEN;FZVCS/*61HXH]W]T!-V
M/5S7M_Q:^'.F_%CX>ZWX7U2WCGAOK=TB:0 F&;:?+E4]F5L$'VJI8A1ERVT$
MJ+DN:^I\D_L;_MPZCXTUZR\"?$*XCGU&ZQ%IFM[0C3R=H9@, LW16&,G .2<
MU]$_M;?\FV_$'_L%O_-:_&ZTN[G2-0AN;>1K>\M95DCD7AD=3D$>X(K]=OCY
MX@/B[]C?Q#KA4*=3\-17I51@#S$1^!V^]4U::A.,EU*IS<HM,_+7X/\ Q8UO
MX*>.+7Q3H#)]O@AFA\J;)BE5XV7$B@C<H)5L>J#TK4UZ#XK?'BXN?%-]IOB?
MQBBL[/?0V,UQ;P_W@NQ=D:C;T7 &.G%87PCTNTUSXK>"]-OX%N;&\UJRM[B!
M_NR1O.BLI]B"1^-?N'8V-MIEG#:6=O%:6L"".*"! B1J!@*JC@ #L*VK5%2:
M:6IE3A[1;Z'XG?"_XV^-O@MKD-YX;UJZL1#)F73Y'9K:;GYEDB)P<XQG&1V(
M-?L)\&OB=8_&3X9Z%XNL$\F/48-TMONW&"925DCSWVNK 'N,''-?F%^WKX?L
M?#_[3'B-;"W2VCO(K>\E2,8!E>)2[8]6(+'W)-?8?_!-2ZEN/V>;N.1RRP:[
M<QQC^ZIBA;'YL3^-9XA*4%46Y=%N,W ^KZ***\X[3PG]M;X8W?Q2_9]UVRTZ
M)KC4]-=-5MH5&3(8L[U'J3&TF!W.!WK\T?V:?C7+\ _BQIWB?R&NM/9&L]0M
MXSAI+=R-VW_:4JK =R@'>O7_ -K[]LS6/B9X@U'PIX0U&33O!5K(T#SVKE)-
M393AG9AR(L_=4=1RW4!>6U+]A_QYI_P,M/B(JK<3R(+N;0(HF-S#9E0RS$YY
M;')C RJX.<Y ].E'DARU.IP5'S2O#H?JMX2\6:3XZ\-Z?KVA7L6HZ3?Q":"Y
MA.0RGL?0@Y!!Y!!!Y%;%?D-^RC^U5JO[/?B06EZTVH>"KZ4&^T]3N:$GCSX0
M3PX&,CHP&#R 1]K?MM?%?2;G]DR\U'0=6BO+/Q1);6EE=6TG$J&022 =_N1.
MK \C)! /%<LJ+C-1Z,Z(U5*+?8^HZ*_,_P#X)A^'9;[XP^)-9V,;?3]%: MC
M@22S1E<G_=BD_*OTPK.I#V<N6Y<)<ZN%%%%9&@4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %5=2U*VTC3[F^O)UMK2WC:66:0X5%49)/X5:KY<_:
M\^*3*8O!.G38&%GU)D/XQQ']'/\ P#WKHH477J*",JM14H.3/&/C)\4KOXJ>
M+I;]B\6F09BL;5CQ''G[Q']YNI/T'0"LSX:_#W4OB;XJM]&TX; WSW%PPRL$
M0(W.?S  [D@5S=I:37]U#;6\337$SK''&@RSL3@ #U)(K[]^"/PJM_A5X1CM
M657U>Z"S7]PO\3XX0'^ZH) ]\GO7TF(K1P=)1AOT/&HTWB)WE\SI?!/@K2_A
M_P"';;1])@$-M",LY'SROCYI'/=C_@!P *WZ**^4E)R=WN>ZDDK(****0PHH
MHH **** "BBB@"&ZMUNH2C<=P?0U\Y_&+]G6/QEJTNJZ?<&TU!N)8\ JY]<9
M'\_SXKZ2K,UBUW*)U'(X:LJU"EBJ;HUX\T7T_K7[CLP>,Q&7UEB,+-PFNJ_R
M=TUY-'S-X$^%\?P]CD,D<LM_+Q)<RQE./[JCL/QY_*O0+/M7H?-,\I/[J_E7
M?A_986BJ%"'+%=$<.,EB,?B)8K%57.<MV_ZM\EH<Y8Q/)]U6;Z"MZVA,:@MP
M?2K'-'-*4^8B%-1#FO"_V@/C@?#,,OAKP_-NUN9=MQ<PG)M5/\*X_P"6A'_?
M(.>N,:GQX^-D?P_L6TG295D\17"=<;A:H?XS_M'L/Q/&,_.\3-\.85U6]/G^
M,KQ1/:QRMN;3T<;A<2#_ )[,""BG[H.XC.VOA\ZS?V?-A</*S^U+MY+^\_P_
M%?JO"_#GMN3'XR%T_@A_,_YGV@OQ\]$U);X:V[01AI?&]XH5W49;2T;JB_\
M3PP/)ZQ@X^\3MXV[TZYTN\FMKV"2VNX6*20S*59&'4$'O7TY^S_\#WT<Q>*_
M$D+-JTG[RUM9^3"#_P M'S_&<\ _=Z]>DG[2WPK&L::WBO3(?].M$Q>QH/\
M6PC^/ZKW_P!G_=KKX9RFG"K#%8R/^"+Z>;_O/\/NMCQCQ'.<)X# 3O?^)-?:
M_NQ[17XZ[ZN7+_LN_%Y?#>M1>%=9D#:3>S9LY)>1:W!Z 9Z*YX]FP>,DU]E5
M^7/.<BON_P#9S^*7_"R/ Z17DN_6]+VV]WN/S2+CY)?^! $'W4^HK] S'#*+
M]M'Y_P"9^182LVO9R^1ZO1117AGIA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4QR9(,^C\LO^T&')85K7@JD?:1(I2<)<DC]$:***\T[3\M/^"E'_ "<1!_V
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MX0^-&A#2O%VCQ:G!&2T$V3'/;L1]Z.12&7MD9P<#((XKXY^)W_!,$1V]S>>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]UD8$$>Q%7:*0SAK'X%_#;2[VWO+/X>^%;2[MY%FAN(-%MDDB=2"K*P3(8$
M@CD$5W-9WB#7].\*Z)?:QJ]W%8:98PM/<7,QPL:*,DG_ .MUKY_\$_M^?"GQ
MQXTA\.07&J:9)<2B"VO]2M5BM9G)PH#!RRY/0NJCGG%6HRGJM2;QCH>R>(OA
M'X&\7ZF^I:[X+\/:UJ#JJ-=ZCI4%Q*5 P 7="< =.:UO#/A#0O!>GM8>'M$T
M[0;%I#,UKIEK';1%R "Q5 !DA0,]>!6O14W>P[(****0PKB]6^"OP]UZ]>\U
M/P'X9U&[<8:XN]'MY9#]69":[2BFFUL+<S]%\/Z7X<LQ:Z3IMII=J, 0V4"0
MH,  ?*H X  _"K=Q;Q7EO+;W$23P2H8Y(I%#*ZD8*D'@@CM4M%(9P'_#/OPM
M_P"B:^$/_!#:_P#QNNPT30M-\,Z7!INCZ=:Z5IT (AL[*!888P3DA44 #DD\
M#O5^BFVWN*R04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD6/_ ,8K]<;*1IK."1SEVC5B?<BN'_X9]^%O_1-?"'_@AM?_ (W7>JHC4*H
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M="*]#--X?/\ 0Y,#M+Y#J***\(]0**** "BBB@ HHHH **** "BBB@ HHHH
M*Q];_P!;'_NUL5BZTW^DH!V3^IJH[@4.:.:.:.:L YHYHYHYH .:.:.:.: #
MFN(^-7_)*_$O_7H?YBNWYK@/CS<_9?A'XB?.,Q)'TS]Z5%_K6U'^)'U1G4^"
M7H?$-??W[.O_ "1?PQ_UQD_]&O7P#7Z#? .U^Q_!WPK'\PW6GF?-_M,S?UKV
MLT_A1]3RL%\;]#T"BBBOFCV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K.\2?\B[JG_7K+_Z :T:K:E9_P!H:?=6N_R_.B:+=C.-P(SC
M\: /P2K]#?A)_P %#OASX"^%WA+PWJ&B^*)K[2-+MK&>2VM+9HF>.-58J6N
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M#K'B'X-_$6TU&*"32_$F@7H8V]U&08Y4;#(Z\<'E2.X)K]SZ\:^.'[)_P_\
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MVG%D48N*=PHHHKE.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7&X_0#)_"OTJKMS27P1.3 Q^*04445X)Z@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q9^WM^SS\0/
MC5XK\*7G@SP__;-M8V4L-P_VVW@V,T@(&)9%)X]*T/V O@'X\^"=YXW?QIH7
M]C)J4=FMJ?MD$_F&,S;_ /52-C&]>N.M?8=%;>UER>SZ&7LUS<X4445B:A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*&!!&0>"#2T4 ?F
MY\1_"[>"_'>N:*R[5M+IUBSWC)W1G\4*G\:]B_8W\7#3?&&J>'YGQ'J4 FB!
M_P">L63@?5&8_P# !5O]LKP6;/7M)\40I^YO(_L=P0.DB9*$^Y4D?]LZ\%\(
M^)+GP?XFTS6K3_7V,ZS!<XW 'E3[$9!^M?6K_:\-YM?B> _W%?T_(_3"BJ.B
MZQ:^(='LM3LI/-L[R%9XG]58 C/OS5ZOD]M&>^%%%%( HHHH **** "BBB@
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MP8!9EVS0YRT,H^\A^A_,$'O6>88?V<_:1V?YE82KS1Y'NCIZ***\@] ****
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MVL[.'3[."UMHUAMX(UBBC7HJJ, #V %3T45\D>\%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>tcrt-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T18:31:26.4163+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheets" xlink:href="tcrt-20221231.xsd#BalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2" xlink:href="tcrt-20221231.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations" xlink:href="tcrt-20221231.xsd#StatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows" xlink:href="tcrt-20221231.xsd#StatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:href="tcrt-20221231.xsd#DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail" xlink:href="tcrt-20221231.xsd#DisclosureAccruedExpensesComponentOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20221231.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:href="tcrt-20221231.xsd#DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:href="tcrt-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/BalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_GainLossOnOperatingLeaseModification" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="14" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_ShareBasedCompensation" order="0" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedConsultingFeesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedClinicalExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedPreclinicalServicesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedManufacturingCostsCurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedConsultingFeesCurrent" xlink:label="tcrt_AccruedConsultingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedClinicalExpensesCurrent" xlink:label="tcrt_AccruedClinicalExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPreclinicalServicesCurrent" xlink:label="tcrt_AccruedPreclinicalServicesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedManufacturingCostsCurrent" xlink:label="tcrt_AccruedManufacturingCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsDepreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="9" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>tcrt-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T18:31:29.3570+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FederalAndStateMember" xlink:label="tcrt_FederalAndStateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncomeTaxesTable" xlink:label="tcrt_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfPaymentOfLicenseFee" xlink:label="tcrt_PercentageOfPaymentOfLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ExpectedCashPaymentPayable" xlink:label="tcrt_ExpectedCashPaymentPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsPolicyTextBlock" xlink:label="tcrt_WarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:label="tcrt_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ConditionalMilestoneAmountPayable" xlink:label="tcrt_ConditionalMilestoneAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfDaysOptionExerciable" xlink:label="tcrt_NumberOfDaysOptionExerciable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FairValueAssumptionsOfPreferredStock" xlink:label="tcrt_FairValueAssumptionsOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PerformanceBasedPaymentsMember" xlink:label="tcrt_PerformanceBasedPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePaymentMadeOne" xlink:label="tcrt_MilestonePaymentMadeOne"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_Covid19Member" xlink:label="tcrt_Covid19Member"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualBaseRent" xlink:label="tcrt_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" xlink:label="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="tcrt_StockIssuedDuringPeriodValueWarrantExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonCancerCenterMember" xlink:label="tcrt_MdAndersonCancerCenterMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_OperatingLeaseResidualValueOfLeasedAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PreferredStockRedemptionDiscountDerivatives" xlink:label="tcrt_PreferredStockRedemptionDiscountDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockIssuanceCost" xlink:label="tcrt_CommonStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPaymentsOfTcrProducts" xlink:label="tcrt_AccruedPaymentsOfTcrProducts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementWithJefferiesMember" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QualifiedImprovementPropertyMember" xlink:label="tcrt_QualifiedImprovementPropertyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumRoyaltiesAmountPayable" xlink:label="tcrt_MaximumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PublicOfferingMember" xlink:label="tcrt_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EligibilityOfBonusPercentage" xlink:label="tcrt_EligibilityOfBonusPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CostIncurredInAppointmentOfDirectors" xlink:label="tcrt_CostIncurredInAppointmentOfDirectors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockOptionsMember" xlink:label="tcrt_CommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MarketOfferingMember" xlink:label="tcrt_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ResearchAndDevelopmentServicesContractTerm" xlink:label="tcrt_ResearchAndDevelopmentServicesContractTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" xlink:label="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EarningPerShareBasicAndDilutedTable" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" xlink:label="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPreclinicalServicesCurrent" xlink:label="tcrt_AccruedPreclinicalServicesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SharesAuthorized" xlink:label="tcrt_SharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementCommencementDate" xlink:label="tcrt_LicenseAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" xlink:label="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfFirstAnnualRoyaltyPayable" xlink:label="tcrt_DescriptionOfFirstAnnualRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OrganizationalChangesPolicyTextBlock" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncomeTaxesLineItems" xlink:label="tcrt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonMember" xlink:label="tcrt_MdAndersonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfRoyaltiesReceivable" xlink:label="tcrt_MaximumAmountOfRoyaltiesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeDomain" xlink:label="tcrt_PeriodTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfSharesVested" xlink:label="tcrt_NumberOfSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentsUnderPatentLicense" xlink:label="tcrt_PaymentsUnderPatentLicense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GroupThreeMember" xlink:label="tcrt_GroupThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementMember" xlink:label="tcrt_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeAxis" xlink:label="tcrt_PeriodTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" xlink:label="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ScheduleOfEquityTable" xlink:label="tcrt_ScheduleOfEquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CharityCareDirectAndIndirectCostBasisAmount" xlink:label="us-gaap_CharityCareDirectAndIndirectCostBasisAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonLicenseMember" xlink:label="tcrt_MdAndersonLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AresTradingMember" xlink:label="tcrt_AresTradingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedManufacturingCostsCurrent" xlink:label="tcrt_AccruedManufacturingCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QuarterlyPaymentsUnderContract" xlink:label="tcrt_QuarterlyPaymentsUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TaxRelaxationOnTaxableIncome" xlink:label="tcrt_TaxRelaxationOnTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentForAnnualLicenseFees" xlink:label="tcrt_PaymentForAnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmbeddedDerivativeDividendAmount" xlink:label="tcrt_EmbeddedDerivativeDividendAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ConsultantsMember" xlink:label="tcrt_ConsultantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" xlink:label="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UncategorizedAbstract" xlink:label="tcrt_UncategorizedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMezzanineMember" xlink:label="tcrt_SeriesOnePreferredStockMezzanineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PublicOfferingNetPricePerShare" xlink:label="tcrt_PublicOfferingNetPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EquityLineItems" xlink:label="tcrt_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GeneralBusinessCreditsMember" xlink:label="tcrt_GeneralBusinessCreditsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ExpectedCashPaymentPayablePerInstallments" xlink:label="tcrt_ExpectedCashPaymentPayablePerInstallments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PreferredStockConversionFloorPrice" xlink:label="tcrt_PreferredStockConversionFloorPrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedClinicalExpensesCurrent" xlink:label="tcrt_AccruedClinicalExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeasesExpirationMonthAndYear" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TotalCompensationExpense" xlink:label="tcrt_TotalCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_BonusDepreciationEligibilityPercentage" xlink:label="tcrt_BonusDepreciationEligibilityPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedConsultingFeesCurrent" xlink:label="tcrt_AccruedConsultingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmployeesMember" xlink:label="tcrt_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SettlementOfRelatedPartyRelationshipTextBlock" xlink:label="tcrt_SettlementOfRelatedPartyRelationshipTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DiscountedRiskAdjustedRates" xlink:label="tcrt_DiscountedRiskAdjustedRates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DevelopmentCostsPaid" xlink:label="tcrt_DevelopmentCostsPaid"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:label="us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NetOperatingLossCarryforwardsMember" xlink:label="tcrt_NetOperatingLossCarryforwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Loans Committed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Loans Committed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional loans committed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FederalAndStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FederalAndStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal and State [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FederalAndStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and State [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPaymentOfLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upfront fee Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPaymentOfLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payment Of License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPaymentOfLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payment of license fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Annual License fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ExpectedCashPaymentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected Cash Payment Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ExpectedCashPaymentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Cash Payment Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ExpectedCashPaymentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Expected Cash Payment Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized acquisition costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Acquisition Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized acquisition costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts included in accrued expenses and accounts payable related to property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other income expense member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability statement of financial position [extensible list]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise, net of commissions and expenses of $1.1 million (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrant Exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrant exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConditionalMilestoneAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conditional milestone amount payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConditionalMilestoneAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conditional Milestone Amount Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConditionalMilestoneAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conditional milestone amount payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease income from sublease, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfDaysOptionExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days Option Exerciable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfDaysOptionExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NumberofDaysOptionExerciable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Royalty Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum royalty amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards without expire date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueAssumptionsOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueAssumptionsOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueAssumptionsOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Assumptions of Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-Vested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest and adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon valley bank.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of option To terminate Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">T-Cell Receptor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">T-Cell Receptor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity method investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentMadeOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment made</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentMadeOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Made One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentMadeOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment made One.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Watermill And Robert W Postma.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Watermill And Robert W Postma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Watermill And Robert W Postma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sub licensing income, attributable to related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Sub licensing Income Payable to Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of income payable to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock, shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, stated value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reimbursement of historical costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amount Potentially Reimburseable Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Amount Potentially Reimburseable Amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Banking and Thrift, Interest [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Research Expiration Dates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Research Expiration Dates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of additional milestones payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Additional Milestones Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected additional milestones payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease area.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Potential Benchmark Payments Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DeferredTaxAssetsLeaseLiability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type Axis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Date Fair Value of a warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of adjustment of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Boston, MA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_Covid19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Covid 19</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_Covid19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Covid 19 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term B Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development service agreement aggregate quarterly payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Service Agreement Quarterly Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development service agreement quarterly payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in contract liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodValueWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant exercise, net of commissions and expenses of $1.1 million</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodValueWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value warrant exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preferred stock dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Preferred Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (Loss) On Modification Of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Modification Of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on modification of lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds from sale of equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution payable on per annum basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution Payable on Per Annum Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution payable on per annum basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets depreciation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenth Scheduled Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenth Scheduled Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenth Scheduled Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Arrangements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">M.D. Anderson Cancer Center</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson Cancer Center [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">M.D. Anderson Cancer Center.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding used to compute basic net income (loss) per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cooperative Research and Development Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseResidualValueOfLeasedAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Residual Value of Leased Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseResidualValueOfLeasedAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Residual Value Of Leased Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreferredStockRedemptionDiscountDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of a related party relationship</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreferredStockRedemptionDiscountDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock Redemption Discount Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreferredStockRedemptionDiscountDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of decrease in currently redeemable preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-in-process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, commissions and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issuance cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due prior to the first marketing approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accruals Prior to First Marketing Approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due prior to the first marketing approval for TCR products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent and technology license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent And Technology License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent And Technology License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Biocell [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Biocell.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value of stock option granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPaymentsOfTcrProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPaymentsOfTcrProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payments Of Tcr Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPaymentsOfTcrProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Payments of TCR Products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement with Jefferies [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement with Jefferies [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QualifiedImprovementPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified Improvement Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QualifiedImprovementPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualified Improvement Property [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Jurisdiction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of First Benchmark Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of First Benchmark Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of First Benchmark Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">the "2020 Plan" [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Subscription Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Subscription Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash related to the Company's debt agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incurred expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, stated value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum royalties amount payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Royalties Amount Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum royalties amount payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal/state rate change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense federal rate change.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities into which the class of warrant converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrexon Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrexon Corporation/Precigen</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intrexon Corporation/Precigen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from bank debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EligibilityOfBonusPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible bonus percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EligibilityOfBonusPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eligibility Of Bonus Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EligibilityOfBonusPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eligibility of bonus percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settlement of a related party relationship (Note 7) (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity interest in affilated entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2014-09</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CostIncurredInAppointmentOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Incurred in appointment of directors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CostIncurredInAppointmentOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Incurred in Appointment of Directors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CostIncurredInAppointmentOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost Incurred in appointment of directors.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additonal tranche facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding used to compute diluted net income (loss) per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MarketOffering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Svb Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Svb Warrants [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Svb Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relaxation of Adjusted taxable income, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Limitation On Adjusted Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate limitation on adjusted taxable income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs related to non-vested restricted stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eighth Scheduled Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eighth Scheduled Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eight Scheduled Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ResearchAndDevelopmentServicesContractTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Services Contract Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ResearchAndDevelopmentServicesContractTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development services contract term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefit and Share-Based Payment Arrangement, Noncash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee Benefit and Share-based Payment Arrangement, Noncash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OfficeAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and computer equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OfficeAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OfficeAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Computer Equipment [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of a related party relationship (Note 7)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of Shares of Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Repurchase of shares of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum royalty amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Royalty Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson License and the Research and Development Agreement Member [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson License and the Research and Development Agreement Member [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction Expenses From Transactions With Related Party Advisory Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party Advisory Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction expenses from transactions with related party advisory fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson Agreement and Worldwide License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Agreement and Worldwide License.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Receivables, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with an at the market offering, net of commissions and expenses of $400 (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per share Basic and Diluted [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning Per share Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting for Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease income from sublease, 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Common Stock In Connection With Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Shares Issuance Of Common Stock In Connection With Public Offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a public offering, net of commissions and expenses of $5,900 (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPreclinicalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPreclinicalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical Services Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPreclinicalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued preclinical services current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series 1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series 1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of authorized capital stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tri Arm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tri Arm</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash inducement warrant expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash inducement warrant expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash inducement warrant expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Operating Income Expense Inducement Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Operating Income Expense Inducement Of Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Common Stock Issuable Upon Conversion Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock issuable upon conversion of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Severance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstAnnualRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of First Annual Royalty Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstAnnualRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of First Annual Royalty Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstAnnualRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of First Annual Royalty Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Restricted Stock Awards Text Block [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options and Restricted Stock Awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Benchmark Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts expensed for services incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pocket Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pocket Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pocket expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment and right-of-use asset impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for organizational changes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organizational Changes [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organizational Changes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock $0.001 par value; 420,000,000 shares authorized, 240,410,761 shares issued and outstanding at December 31, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of derivative liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Adoption [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of warrants, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise, net of commissions and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Warrants or Options Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Obligations due under contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligations Due Under Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligations due under contract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalties receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Royalties Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amount of royalties receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales commission as a percentage of gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on gross proceeds from sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument description of variable rate basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Monthly Rental Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Monthly Average Rental Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of Lessee Operating Lease Monthly Average Rental Payment .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone maximum payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments, Maximum Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments maximum amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition from Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PeriodTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PeriodTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PeriodTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Common Stock to Underwriters</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life in years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentsUnderPatentLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">payments under the Patent License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentsUnderPatentLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Under Patent License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentsUnderPatentLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments under patent license</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offered During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offered during period shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option And Restricted Stock Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock option and Restricted stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GroupThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upon enrollment of the first patient in a multi-center pivotal clinical trial</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GroupThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Group Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GroupThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Group Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Axis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right Axis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impact of Topic 606 Adoption on Financial Statements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Leases Future Minimum Monthly Payment Due Through Years February 2027 and April 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Monthly Payment Due Through Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum monthly payment due through year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) applicable to common shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recognition in exchange of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ZiopLicenseAgreementWithTheNationalCancerInstituteMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment under license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Under License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PeriodTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PeriodTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PeriodTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold period for exercise or conversion of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Commitment Period for Exercise of Rights to Participate in Future Offerings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold commitment period for exercise of rights to participate in future offerings.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized discount on Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized discount on Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of warrants, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value net On Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value ,Net On Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Subscribed but Unissued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development true-up</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Research and Development True Up</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense research and development true up.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock consideration received on transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a public offering, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential benchmark payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate potential benchmark payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential benchmark payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson License and the Research and Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson License and the Research and Development Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, reimbursed amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Reimbursed Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Reimbursed Amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vineti Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vineti Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vineti Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment and right-of-use assets impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment and right of use assets impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment And Right Of Use Assets Impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Distribution Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity distribution agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Operating Lease Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on operating lease modification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ScheduleOfEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ScheduleOfEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ScheduleOfEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CharityCareDirectAndIndirectCostBasisAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Charity Care, Direct and Indirect Cost Basis, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum royalties amount payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Royalties Amount Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Minimum Royalties Amount Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Md Anderson License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson License.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AresTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARES Trading License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AresTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ares Trading [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AresTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ares Trading [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Costs, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing costs, current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Bio Cell [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Bio Cell</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected recognition period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Aggregate Benchmark Payments Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity Under Stock Option Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement with Solasia Pharma K.K. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with solasia pharma K.K.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With Solasia Pharma KK [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Agreement termination, notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Md Anderson Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MDAndersonWarrantMember.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MD Anderson Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future termination benefit payments resulting from the strategic reduction in force</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to Fund Long-term Loans to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Fund Long-Term Loans to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Subscriptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyPaymentsUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Quarterly payments under contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyPaymentsUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Payments Under Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyPaymentsUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Quarterly payments under contract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from License Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per share Basic and Diluted [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning Per share Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">the "2012 Plan" [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twelve Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date Range, Start</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, initial maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziopharm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ziopharm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TaxRelaxationOnTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relaxation of taxable income, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TaxRelaxationOnTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Relaxation On Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TaxRelaxationOnTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax relaxation on taxable income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForAnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment For Annual License Fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForAnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Annual License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForAnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Annual Licensing fee paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties amount payable thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Amount Payable thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties amount payable thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmbeddedDerivativeDividendAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmbeddedDerivativeDividendAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative, Dividend Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmbeddedDerivativeDividendAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Embedded Derivative, Dividend Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Expiry date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payment and Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayments premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayments Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayments premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards with expire date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payments or receipts under collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payments Or Receipts Under Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payments or receipts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual expense incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Expense Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual expense incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UncategorizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncategorized [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UncategorizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncategorized [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMezzanineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 1 Preferred Stock - Mezzanine</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMezzanineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series One Preferred Stock Mezzanine [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMezzanineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series One Preferred Stock Mezzanine [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Dates State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Expiration Dates State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriter par or stated value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriter Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriter par or stated value per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease (increase) in the carrying amount of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research Expenses Capitalized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research expenses capitalized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of expenses (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Net Of Expenses In Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, net of expenses in shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on sale of equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingNetPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance &amp; sale of common stock in public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingNetPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public offering, net price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingNetPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering, net price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses, Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees and Expenses, Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cancelled restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal income tax at statutory rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GeneralBusinessCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Business Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GeneralBusinessCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Business Credits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GeneralBusinessCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General Business Credits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease income from sublease, 2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain Tax Positions Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease area.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement with the National Cancer Institute [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ExpectedCashPaymentPayablePerInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected cash payment payable per installments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ExpectedCashPaymentPayablePerInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Cash Payment Payable Per Installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ExpectedCashPaymentPayablePerInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected cash payment payable per installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility additional tranche amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CARProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C A R Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CARProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CAR Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate minimum annual royalties paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Minimum Annual Royalties Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate minimum annual royalties paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreferredStockConversionFloorPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred conversion floor price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreferredStockConversionFloorPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Floor Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreferredStockConversionFloorPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock conversion floor price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedClinicalExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedClinicalExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued clinical expenses current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedClinicalExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Expiration Month and Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issue costs paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TotalCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TotalCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TotalCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total compensation expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostMarketingApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Marketing Approval [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Increase) decrease in:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BonusDepreciationEligibilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonus Depreciation Eligibility, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BonusDepreciationEligibilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonus Depreciation Eligibility, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BonusDepreciationEligibilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligibility for bonus depreciation, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First benchmark payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Benchmark Payment Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first benchmark payment due upon the initiation of the Company's first sponsored phase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock dividends (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Houston, TX [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Houston Texas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Houston Texas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement commencing date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Commencing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement commencing date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number Of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of warrants issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Exercise Per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Call or Exercise Features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedConsultingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Consulting Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedConsultingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued consulting fees, current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedConsultingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other consulting services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Component of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sublease term amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Term Commenced End Date Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease term commenced end date amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net share based employee compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic advisory services fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit plan contributions by employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quarterly expense incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Expense Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Quarterly expense incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Proceeds from Underwriting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets and Liabilities Eliminated upon Consolidation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets and Liabilities Eliminated upon Consolidation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Earning Per share Basic and Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Earning Per share Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum sales revenue on which benchmark payments payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Sales Revenue On Which Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum sales revenue on which benchmark payments payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Amortized Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense amortized date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense amortized date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants fully vested upon issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Expense Included in Statements of Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SettlementOfRelatedPartyRelationshipTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of relatedparty relationship</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SettlementOfRelatedPartyRelationshipTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Related Party Relationship [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SettlementOfRelatedPartyRelationshipTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement Of Related Party Relationship</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for historical costs of the licensed programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Historical Costs of the Licensed Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for historical costs of the licensed programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liability Right of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liability Right of Use Asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liability Right of Use Asset, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in licensing agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DiscountedRiskAdjustedRates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounted risk adjusted rates.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DiscountedRiskAdjustedRates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounted Risk Adjusted Rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DiscountedRiskAdjustedRates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounted Risk-adjusted Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DevelopmentCostsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Costs Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DevelopmentCostsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development costs paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DevelopmentCostsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development costs paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional option available to the underwriter to purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Option Available To The Underwriter To Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional option available to the underwriter to purchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToAffiliateCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of expenses due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToAffiliateCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Affiliate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease Income, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NetOperatingLossCarryforwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NetOperatingLossCarryforwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NetOperatingLossCarryforwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carryforwards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Scholes Model [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black Scholes Model [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes Model [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of original principal due as a final payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Original Principal Due as a Final Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of original principal due as a final payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Placement agent fees and other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Fees And Other Related Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent fees and other related expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Revenue On Which Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Sales Revenue On Which Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CRADA Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CRADA Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure pertaining to the warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Domain [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense related to License payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment award granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options granted exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Start-up and pre-clinical studies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Start Up And Pre Clinical Studies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets start up and pre clinical studies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other noncurrent assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalLoansCommitted" xlink:to="tcrt_AdditionalLoansCommitted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FederalAndStateMember" xlink:to="tcrt_FederalAndStateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncomeTaxesTable" xlink:to="tcrt_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPaymentOfLicenseFee" xlink:to="tcrt_PercentageOfPaymentOfLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePayment" xlink:to="tcrt_MilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualLicenseFees" xlink:to="tcrt_AnnualLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ExpectedCashPaymentPayable" xlink:to="tcrt_ExpectedCashPaymentPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsPolicyTextBlock" xlink:to="tcrt_WarrantsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AtTheMarketOfferingMember" xlink:to="tcrt_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicensedProductsMember" xlink:to="tcrt_LicensedProductsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OtherIncomeExpenseMember" xlink:to="tcrt_OtherIncomeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="tcrt_StockIssuedDuringPeriodSharesWarrantExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ConditionalMilestoneAmountPayable" xlink:to="tcrt_ConditionalMilestoneAmountPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfDaysOptionExerciable" xlink:to="tcrt_NumberOfDaysOptionExerciable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfRoyaltyPayable" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FairValueAssumptionsOfPreferredStock" xlink:to="tcrt_FairValueAssumptionsOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankMember" xlink:to="tcrt_SiliconValleyBankMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TcellReceptorMember" xlink:to="tcrt_TcellReceptorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PerformanceBasedPaymentsMember" xlink:to="tcrt_PerformanceBasedPaymentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePaymentMadeOne" xlink:to="tcrt_MilestonePaymentMadeOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WatermillAndRobertWPostmaMember" xlink:to="tcrt_WatermillAndRobertWPostmaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwritingAgreementMember" xlink:to="tcrt_UnderwritingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:to="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SubleaseArea" xlink:to="tcrt_SubleaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PotentialBenchmarkPaymentsPayable" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsLeaseLiability" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeAxisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaMember" xlink:to="tcrt_MaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_Covid19Member" xlink:to="tcrt_Covid19Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualBaseRent" xlink:to="tcrt_AnnualBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" xlink:to="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockIssuedDuringPeriodValueWarrantExercise" xlink:to="tcrt_StockIssuedDuringPeriodValueWarrantExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnModificationOfLease" xlink:to="tcrt_GainLossOnModificationOfLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ContributionPayableOnPerAnnumBasis" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsDepreciation" xlink:to="tcrt_DeferredTaxAssetsDepreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TenthScheduledPaymentMember" xlink:to="tcrt_TenthScheduledPaymentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FinancingArrangementsDisclosureTextBlock" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonCancerCenterMember" xlink:to="tcrt_MdAndersonCancerCenterMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseResidualValueOfLeasedAsset" xlink:to="us-gaap_OperatingLeaseResidualValueOfLeasedAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PreferredStockRedemptionDiscountDerivatives" xlink:to="tcrt_PreferredStockRedemptionDiscountDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommonStockIssuanceCost" xlink:to="tcrt_CommonStockIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccrualsPriorToFirstMarketingApproval" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBiocellMember" xlink:to="tcrt_EdenBiocellMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedPaymentsOfTcrProducts" xlink:to="tcrt_AccruedPaymentsOfTcrProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwritingAgreementWithJefferiesMember" xlink:to="tcrt_UnderwritingAgreementWithJefferiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_QualifiedImprovementPropertyMember" xlink:to="tcrt_QualifiedImprovementPropertyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfFirstBenchmarkPayable" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareSubscriptionAgreementMember" xlink:to="tcrt_ShareSubscriptionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedStockMember" xlink:to="tcrt_NonVestedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumRoyaltiesAmountPayable" xlink:to="tcrt_MaximumRoyaltiesAmountPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PublicOfferingMember" xlink:to="tcrt_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PaymentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IntrexonCorporationMember" xlink:to="tcrt_IntrexonCorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EligibilityOfBonusPercentage" xlink:to="tcrt_EligibilityOfBonusPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SecuritiesPurchaseAgreementMember" xlink:to="tcrt_SecuritiesPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CostIncurredInAppointmentOfDirectors" xlink:to="tcrt_CostIncurredInAppointmentOfDirectors_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommonStockOptionsMember" xlink:to="tcrt_CommonStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MarketOfferingMember" xlink:to="tcrt_MarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SvbWarrantsMember" xlink:to="tcrt_SvbWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:to="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_DueDateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EightScheduledPaymentMember" xlink:to="tcrt_EightScheduledPaymentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ResearchAndDevelopmentServicesContractTerm" xlink:to="tcrt_ResearchAndDevelopmentServicesContractTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OfficeAndComputerEquipmentMember" xlink:to="tcrt_OfficeAndComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumRoyaltyAmount" xlink:to="tcrt_MaximumRoyaltyAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" xlink:to="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemDomain" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="tcrt_EarningPerShareBasicAndDilutedTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" xlink:to="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedPreclinicalServicesCurrent" xlink:to="tcrt_AccruedPreclinicalServicesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SeriesOnePreferredStockMember" xlink:to="tcrt_SeriesOnePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SharesAuthorized" xlink:to="tcrt_SharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementCommencementDate" xlink:to="tcrt_LicenseAgreementCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TriArmMember" xlink:to="tcrt_TriArmMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" xlink:to="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfFirstAnnualRoyaltyPayable" xlink:to="tcrt_DescriptionOfFirstAnnualRoyaltyPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OneTimeBenchmarkPaymentsMember" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PocketExpenses" xlink:to="tcrt_PocketExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OrganizationalChangesPolicyTextBlock" xlink:to="tcrt_OrganizationalChangesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ObligationsDueUnderContract" xlink:to="tcrt_ObligationsDueUnderContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonMember" xlink:to="tcrt_MdAndersonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfRoyaltiesReceivable" xlink:to="tcrt_MaximumAmountOfRoyaltiesReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:to="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePaymentsMaximumAmount" xlink:to="tcrt_MilestonePaymentsMaximumAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PeriodTypeDomain" xlink:to="tcrt_PeriodTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfSharesVested" xlink:to="tcrt_NumberOfSharesVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentsUnderPatentLicense" xlink:to="tcrt_PaymentsUnderPatentLicense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOfferedDuringPeriodShares" xlink:to="tcrt_StockOfferedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:to="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GroupThreeMember" xlink:to="tcrt_GroupThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:to="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementMember" xlink:to="tcrt_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentUnderLicenseAgreement" xlink:to="tcrt_PaymentUnderLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PeriodTypeAxis" xlink:to="tcrt_PeriodTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" xlink:to="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregatePotentialBenchmarkPayments" xlink:to="tcrt_AggregatePotentialBenchmarkPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RelatedPartyTransactionReimbursedAmount" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_VinetiIncMember" xlink:to="tcrt_VinetiIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DebtInstrumentPrepaymentPremium" xlink:to="tcrt_DebtInstrumentPrepaymentPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityDistributionAgreementMember" xlink:to="tcrt_EquityDistributionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnOperatingLeaseModification" xlink:to="tcrt_GainLossOnOperatingLeaseModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_ScheduleOfEquityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CharityCareDirectAndIndirectCostBasisAmount" xlink:to="us-gaap_CharityCareDirectAndIndirectCostBasisAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MinimumRoyaltiesAmountPayable" xlink:to="tcrt_MinimumRoyaltiesAmountPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonLicenseMember" xlink:to="tcrt_MdAndersonLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AresTradingMember" xlink:to="tcrt_AresTradingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedManufacturingCostsCurrent" xlink:to="tcrt_AccruedManufacturingCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBioCellMember" xlink:to="tcrt_EdenBioCellMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateBenchmarkPaymentsPayable" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FairValueOfWarrants" xlink:to="tcrt_FairValueOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTerminationNoticePeriod" xlink:to="tcrt_AgreementTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonWarrantMember" xlink:to="tcrt_MdAndersonWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="us-gaap_PrepaidRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_QuarterlyPaymentsUnderContract" xlink:to="tcrt_QuarterlyPaymentsUnderContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="tcrt_EarningPerShareBasicAndDilutedLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopharmMember" xlink:to="tcrt_ZiopharmMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TaxRelaxationOnTaxableIncome" xlink:to="tcrt_TaxRelaxationOnTaxableIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentForAnnualLicenseFees" xlink:to="tcrt_PaymentForAnnualLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RoyaltiesAmountPayableThereafter" xlink:to="tcrt_RoyaltiesAmountPayableThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EmbeddedDerivativeDividendAmount" xlink:to="tcrt_EmbeddedDerivativeDividendAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPrepaymentsPremium" xlink:to="tcrt_PercentageOfPrepaymentsPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ConsultantsMember" xlink:to="tcrt_ConsultantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NewWarrantsMember" xlink:to="tcrt_NewWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" xlink:to="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankLoanMember" xlink:to="tcrt_SiliconValleyBankLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualExpenseIncurred" xlink:to="tcrt_AnnualExpenseIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UncategorizedAbstract" xlink:to="tcrt_UncategorizedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SeriesOnePreferredStockMezzanineMember" xlink:to="tcrt_SeriesOnePreferredStockMezzanineMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermLoanMember" xlink:to="tcrt_TermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:to="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwriterParOrStatedValuePerShare" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:to="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PublicOfferingNetPricePerShare" xlink:to="tcrt_PublicOfferingNetPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_EquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedRestrictedStockMember" xlink:to="tcrt_NonVestedRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GeneralBusinessCreditsMember" xlink:to="tcrt_GeneralBusinessCreditsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeaseArea" xlink:to="tcrt_OperatingLeaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ExpectedCashPaymentPayablePerInstallments" xlink:to="tcrt_ExpectedCashPaymentPayablePerInstallments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_AgreementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CARProductsMember" xlink:to="tcrt_CARProductsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PreferredStockConversionFloorPrice" xlink:to="tcrt_PreferredStockConversionFloorPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedClinicalExpensesCurrent" xlink:to="tcrt_AccruedClinicalExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeasesExpirationMonthAndYear" xlink:to="tcrt_OperatingLeasesExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TotalCompensationExpense" xlink:to="tcrt_TotalCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PostMarketingApprovalMember" xlink:to="tcrt_PostMarketingApprovalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BonusDepreciationEligibilityPercentage" xlink:to="tcrt_BonusDepreciationEligibilityPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InitialBenchmarkPaymentDue" xlink:to="tcrt_InitialBenchmarkPaymentDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_HoustonTexasMember" xlink:to="tcrt_HoustonTexasMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementCommencingDate" xlink:to="tcrt_LicenseAgreementCommencingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalNumberOfWarrantsIssued" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCallOrExerciseFeatures" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedConsultingFeesCurrent" xlink:to="tcrt_AccruedConsultingFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LaboratoryEquipmentMember" xlink:to="tcrt_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SubleaseTermCommencedEndDateAmendment" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:to="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_QuarterlyExpenseIncurred" xlink:to="tcrt_QuarterlyExpenseIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:to="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:to="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_DeferredTaxAssetDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InterestExpenseAmortizedDate" xlink:to="tcrt_InterestExpenseAmortizedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EmployeesMember" xlink:to="tcrt_EmployeesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SettlementOfRelatedPartyRelationshipTextBlock" xlink:to="tcrt_SettlementOfRelatedPartyRelationshipTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:to="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DiscountedRiskAdjustedRates" xlink:to="tcrt_DiscountedRiskAdjustedRates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DevelopmentCostsPaid" xlink:to="tcrt_DevelopmentCostsPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:to="us-gaap_DueToAffiliateCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncome" xlink:to="us-gaap_LeaseIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsExpirationDate" xlink:to="tcrt_WarrantsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NetOperatingLossCarryforwardsMember" xlink:to="tcrt_NetOperatingLossCarryforwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BlackScholesModelMember" xlink:to="tcrt_BlackScholesModelMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CRADAAgreementMember" xlink:to="tcrt_CRADAAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantTextBlock" xlink:to="tcrt_WarrantTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseExpense" xlink:to="tcrt_LicenseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>tcrt-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T18:31:25.3680+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/CoverPage" xlink:href="tcrt-20221231.xsd#CoverPage" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheets" xlink:href="tcrt-20221231.xsd#BalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical" xlink:href="tcrt-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations" xlink:href="tcrt-20221231.xsd#StatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" xlink:href="tcrt-20221231.xsd#StatementStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="tcrt-20221231.xsd#StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows" xlink:href="tcrt-20221231.xsd#StatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/Organization" xlink:href="tcrt-20221231.xsd#Organization" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/Financings" xlink:href="tcrt-20221231.xsd#Financings" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="tcrt-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebt" xlink:href="tcrt-20221231.xsd#DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet" xlink:href="tcrt-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/AccruedExpenses" xlink:href="tcrt-20221231.xsd#AccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactions" xlink:href="tcrt-20221231.xsd#RelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/SettlementOfARelatedPartyRelationship" xlink:href="tcrt-20221231.xsd#SettlementOfARelatedPartyRelationship" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/Leases" xlink:href="tcrt-20221231.xsd#Leases" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingencies" xlink:href="tcrt-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/Warrants" xlink:href="tcrt-20221231.xsd#Warrants" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1" xlink:href="tcrt-20221231.xsd#DisclosureRestructuring1" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxes" xlink:href="tcrt-20221231.xsd#IncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficit" xlink:href="tcrt-20221231.xsd#PreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstruments" xlink:href="tcrt-20221231.xsd#DerivativeFinancialInstruments" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlan" xlink:href="tcrt-20221231.xsd#StockOptionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlan" xlink:href="tcrt-20221231.xsd#EmployeeBenefitPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/JointVenture" xlink:href="tcrt-20221231.xsd#JointVenture" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tcrt-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tcrt-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:href="tcrt-20221231.xsd#DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:href="tcrt-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/AccruedExpensesTables" xlink:href="tcrt-20221231.xsd#AccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/LeasesTables" xlink:href="tcrt-20221231.xsd#LeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringTables" xlink:href="tcrt-20221231.xsd#DisclosureRestructuringTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables" xlink:href="tcrt-20221231.xsd#IncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables" xlink:href="tcrt-20221231.xsd#DerivativeFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables" xlink:href="tcrt-20221231.xsd#StockOptionPlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#OrganizationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#FinancingsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfTopic606AdoptionOnFinancialStatementsDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpactOfTopic606AdoptionOnFinancialStatementsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="tcrt-20221231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="tcrt-20221231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:href="tcrt-20221231.xsd#DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail" xlink:href="tcrt-20221231.xsd#DisclosureAccruedExpensesComponentOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails" xlink:href="tcrt-20221231.xsd#LeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="tcrt-20221231.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20221231.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#WarrantsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail" xlink:href="tcrt-20221231.xsd#DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:href="tcrt-20221231.xsd#DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:href="tcrt-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail" xlink:href="tcrt-20221231.xsd#DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta" xlink:href="tcrt-20221231.xsd#DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#StockOptionPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" xlink:href="tcrt-20221231.xsd#DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:href="tcrt-20221231.xsd#DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#JointVentureAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/BalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_GainLossOnOperatingLeaseModification" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMezzanineMember" xlink:label="tcrt_SeriesOnePreferredStockMezzanineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" xlink:label="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" xlink:label="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="tcrt_StockIssuedDuringPeriodValueWarrantExercise"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:label="tcrt_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_27"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMezzanineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodValueWarrantExercise" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodSharesWarrantExercise" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockIssuanceCost" xlink:label="tcrt_CommonStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MarketOfferingMember" xlink:label="tcrt_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockIssuanceCost" xlink:label="tcrt_CommonStockIssuanceCost_1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PublicOfferingMember" xlink:label="tcrt_PublicOfferingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_CommonStockIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_MarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_CommonStockIssuanceCost_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_PublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/Organization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/Financings" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/AccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/SettlementOfARelatedPartyRelationship" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SettlementOfRelatedPartyRelationshipTextBlock" xlink:label="tcrt_SettlementOfRelatedPartyRelationshipTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="tcrt_SettlementOfRelatedPartyRelationshipTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/Leases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StockOptionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/JointVenture" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OrganizationalChangesPolicyTextBlock" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsPolicyTextBlock" xlink:label="tcrt_WarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tcrt_OrganizationalChangesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tcrt_WarrantsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/AccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/LeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tcrt_AgreementTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TotalCompensationExpense" xlink:label="tcrt_TotalCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ResearchAndDevelopmentServicesContractTerm" xlink:label="tcrt_ResearchAndDevelopmentServicesContractTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:label="us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CostIncurredInAppointmentOfDirectors" xlink:label="tcrt_CostIncurredInAppointmentOfDirectors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_TotalCompensationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EmployeeStockOptionAndRestrictedStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_ResearchAndDevelopmentServicesContractTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="tcrt_AgreementTypeAxisAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DueToAffiliateCurrentAndNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_CostIncurredInAppointmentOfDirectors" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfTopic606AdoptionOnFinancialStatementsDetail" xlink:title="presentationLink" xlink:type="extended"/>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EarningPerShareBasicAndDilutedTable" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:to="tcrt_EarningPerShareBasicAndDilutedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="tcrt_EarningPerShareBasicAndDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockOptionsMember" xlink:label="tcrt_CommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcrt_CommonStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_WarrantsExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_RestrictedCash" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_DebtInstrumentPrepaymentPremium" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_InterestExpenseAmortizedDate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedClinicalExpensesCurrent" xlink:label="tcrt_AccruedClinicalExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPreclinicalServicesCurrent" xlink:label="tcrt_AccruedPreclinicalServicesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedManufacturingCostsCurrent" xlink:label="tcrt_AccruedManufacturingCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedConsultingFeesCurrent" xlink:label="tcrt_AccruedConsultingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedClinicalExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedPreclinicalServicesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedManufacturingCostsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedConsultingFeesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonCancerCenterMember" xlink:label="tcrt_MdAndersonCancerCenterMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementMember" xlink:label="tcrt_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeAxis" xlink:label="tcrt_PeriodTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeDomain" xlink:label="tcrt_PeriodTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" xlink:label="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonMember" xlink:label="tcrt_MdAndersonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonCancerCenterMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PeriodTypeAxis" xlink:to="tcrt_PeriodTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_MdAndersonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_PocketExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="tcrt_PeriodTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_VinetiIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_WatermillAndRobertWPostmaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_OperatingLeaseResidualValueOfLeasedAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DiscountedRiskAdjustedRates" xlink:label="tcrt_DiscountedRiskAdjustedRates"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeasesExpirationMonthAndYear" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualBaseRent" xlink:label="tcrt_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_MaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tcrt_OtherIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_HoustonTexasMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseResidualValueOfLeasedAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_DiscountedRiskAdjustedRates" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesExpirationMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_GainLossOnModificationOfLease" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeaseArea" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_AnnualBaseRent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseArea" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncome" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PerformanceBasedPaymentsMember" xlink:label="tcrt_PerformanceBasedPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AresTradingMember" xlink:label="tcrt_AresTradingMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeAxis" xlink:label="tcrt_PeriodTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeDomain" xlink:label="tcrt_PeriodTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GroupThreeMember" xlink:label="tcrt_GroupThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonLicenseMember" xlink:label="tcrt_MdAndersonLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentForAnnualLicenseFees" xlink:label="tcrt_PaymentForAnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfRoyaltiesReceivable" xlink:label="tcrt_MaximumAmountOfRoyaltiesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CharityCareDirectAndIndirectCostBasisAmount" xlink:label="us-gaap_CharityCareDirectAndIndirectCostBasisAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" xlink:label="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfPaymentOfLicenseFee" xlink:label="tcrt_PercentageOfPaymentOfLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementCommencementDate" xlink:label="tcrt_LicenseAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfSharesVested" xlink:label="tcrt_NumberOfSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QuarterlyPaymentsUnderContract" xlink:label="tcrt_QuarterlyPaymentsUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ExpectedCashPaymentPayable" xlink:label="tcrt_ExpectedCashPaymentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ExpectedCashPaymentPayablePerInstallments" xlink:label="tcrt_ExpectedCashPaymentPayablePerInstallments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumRoyaltiesAmountPayable" xlink:label="tcrt_MaximumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfFirstAnnualRoyaltyPayable" xlink:label="tcrt_DescriptionOfFirstAnnualRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" xlink:label="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentsUnderPatentLicense" xlink:label="tcrt_PaymentsUnderPatentLicense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPaymentsOfTcrProducts" xlink:label="tcrt_AccruedPaymentsOfTcrProducts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DevelopmentCostsPaid" xlink:label="tcrt_DevelopmentCostsPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_AresTradingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PeriodTypeAxis" xlink:to="tcrt_PeriodTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tcrt_GroupThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_MdAndersonLicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentForAnnualLicenseFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_CARProductsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PeriodTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltiesReceivable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_CharityCareDirectAndIndirectCostBasisAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumRoyaltiesAmountPayable" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementScenarioAxis" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfPaymentOfLicenseFee" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_InitialBenchmarkPaymentDue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencementDate" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_NumberOfSharesVested" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ObligationsDueUnderContract" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyExpenseIncurred" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualExpenseIncurred" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyPaymentsUnderContract" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ExpectedCashPaymentPayable" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ExpectedCashPaymentPayablePerInstallments" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltiesAmountPayable" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_RoyaltiesAmountPayableThereafter" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstAnnualRoyaltyPayable" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationNoticePeriod" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentsUnderPatentLicense" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePayment" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccruedPaymentsOfTcrProducts" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DevelopmentCostsPaid" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" order="54" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="55" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PrepaidRoyalties" order="56" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="57" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsDepreciation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncomeTaxesTable" xlink:label="tcrt_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_Covid19Member" xlink:label="tcrt_Covid19Member"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncomeTaxesLineItems" xlink:label="tcrt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NetOperatingLossCarryforwardsMember" xlink:label="tcrt_NetOperatingLossCarryforwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QualifiedImprovementPropertyMember" xlink:label="tcrt_QualifiedImprovementPropertyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FederalAndStateMember" xlink:label="tcrt_FederalAndStateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GeneralBusinessCreditsMember" xlink:label="tcrt_GeneralBusinessCreditsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TaxRelaxationOnTaxableIncome" xlink:label="tcrt_TaxRelaxationOnTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EligibilityOfBonusPercentage" xlink:label="tcrt_EligibilityOfBonusPercentage"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_BonusDepreciationEligibilityPercentage" xlink:label="tcrt_BonusDepreciationEligibilityPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tcrt_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualOrInfrequentItemDomain" xlink:to="tcrt_Covid19Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="tcrt_NetOperatingLossCarryforwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_QualifiedImprovementPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tcrt_FederalAndStateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="tcrt_GeneralBusinessCreditsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_UnusualOrInfrequentItemAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsExpirationDatesState" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsResearchExpirationDates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="tcrt_IncomeTaxesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_TaxRelaxationOnTaxableIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EligibilityOfBonusPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_BonusDepreciationEligibilityPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ScheduleOfEquityTable" xlink:label="tcrt_ScheduleOfEquityTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UncategorizedAbstract" xlink:label="tcrt_UncategorizedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EquityLineItems" xlink:label="tcrt_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SharesAuthorized" xlink:label="tcrt_SharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementWithJefferiesMember" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfDaysOptionExerciable" xlink:label="tcrt_NumberOfDaysOptionExerciable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PublicOfferingNetPricePerShare" xlink:label="tcrt_PublicOfferingNetPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_UncategorizedAbstract" xlink:to="tcrt_ScheduleOfEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_SharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementWithJefferiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_AgreementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_NumberOfDaysOptionExerciable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_DividendsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_PublicOfferingNetPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_EquityLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmbeddedDerivativeDividendAmount" xlink:label="tcrt_EmbeddedDerivativeDividendAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PreferredStockRedemptionDiscountDerivatives" xlink:label="tcrt_PreferredStockRedemptionDiscountDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="tcrt_EmbeddedDerivativeDividendAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="tcrt_PreferredStockRedemptionDiscountDerivatives" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FairValueAssumptionsOfPreferredStock" xlink:label="tcrt_FairValueAssumptionsOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" xlink:label="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PreferredStockConversionFloorPrice" xlink:label="tcrt_PreferredStockConversionFloorPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="tcrt_FairValueAssumptionsOfPreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="tcrt_PreferredStockConversionFloorPrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmployeesMember" xlink:label="tcrt_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ConsultantsMember" xlink:label="tcrt_ConsultantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_EmployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_ConsultantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePaymentMadeOne" xlink:label="tcrt_MilestonePaymentMadeOne"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ConditionalMilestoneAmountPayable" xlink:label="tcrt_ConditionalMilestoneAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_MilestonePaymentMadeOne" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_ConditionalMilestoneAmountPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>tcrt-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T18:31:26.3011+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alaunos.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:tcrt="http://alaunos.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheets" id="BalanceSheets">
        <link:definition>100010 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2" id="DisclosureLeasesOperatingLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Leases - Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>100030 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>100040 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" id="StatementStatementsOfChangesInStockholdersEquity">
        <link:definition>100050 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" id="StatementStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>100070 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/Organization" id="Organization">
        <link:definition>100080 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/Financings" id="Financings">
        <link:definition>100090 - Disclosure - Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>100110 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>100140 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/SettlementOfARelatedPartyRelationship" id="SettlementOfARelatedPartyRelationship">
        <link:definition>100150 - Disclosure - Settlement of a Related Party Relationship</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/Leases" id="Leases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/Warrants" id="Warrants">
        <link:definition>100180 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1" id="DisclosureRestructuring1">
        <link:definition>100190 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficit" id="PreferredStockAndStockholdersEquityDeficit">
        <link:definition>100210 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstruments" id="DerivativeFinancialInstruments">
        <link:definition>100220 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlan" id="StockOptionPlan">
        <link:definition>100230 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>100240 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/JointVenture" id="JointVenture">
        <link:definition>100250 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>100280 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>100290 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>100300 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/LeasesTables" id="LeasesTables">
        <link:definition>100310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringTables" id="DisclosureRestructuringTables">
        <link:definition>100320 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>100330 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables" id="DerivativeFinancialInstrumentsTables">
        <link:definition>100340 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables" id="StockOptionPlansTables">
        <link:definition>100350 - Disclosure - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail" id="OrganizationAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail" id="FinancingsAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Financings - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfTopic606AdoptionOnFinancialStatementsDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesImpactOfTopic606AdoptionOnFinancialStatementsDetail">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Impact of Topic 606 Adoption on Financial Statements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail">
        <link:definition>100430 - Disclosure - Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail">
        <link:definition>100440 - Disclosure - Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" id="DisclosureDebtScheduleOfDebtDetails">
        <link:definition>100450 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="DisclosureDebtAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" id="DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
        <link:definition>100470 - Disclosure - Property and Equipment, net - Component of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Property and Equipment, net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail" id="DisclosureAccruedExpensesComponentOfAccruedExpensesDetail">
        <link:definition>100490 - Disclosure - Accrued Expenses - Component of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" id="DisclosureLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>100520 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesOperatingLeaseLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Leases - Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail" id="WarrantsAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" id="DisclosureRestructuringAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Restructuring - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail" id="DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail">
        <link:definition>100570 - Disclosure - Restructuring - Future termination benefit payments resulting from the strategic reduction in force (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" id="DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail">
        <link:definition>100580 - Disclosure - Income Taxes - Significant Component of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail">
        <link:definition>100590 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" id="PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail">
        <link:definition>100610 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail" id="DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail">
        <link:definition>100620 - Disclosure - Derivative Financial Instruments - Change in Derivative Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta" id="DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta">
        <link:definition>100630 - Disclosure - Derivative Financial Instruments - Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model for Derivatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" id="StockOptionPlanAdditionalInformationDetail">
        <link:definition>100640 - Disclosure - Stock Option Plan - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" id="DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail">
        <link:definition>100650 - Disclosure - Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" id="DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail">
        <link:definition>100660 - Disclosure - Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail" id="EmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>100670 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail" id="JointVentureAdditionalInformationDetail">
        <link:definition>100680 - Disclosure - Joint Venture  - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" name="AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" name="DisclosureOfEarningPerShareBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_UncategorizedAbstract" name="UncategorizedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WarrantsDisclosureAbstract" name="WarrantsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AgreementTypeAxis" name="AgreementTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AgreementTypeAxisAxis" name="AgreementTypeAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightAxisAxis" name="ClassOfWarrantOrRightAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateAxis" name="DueDateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeAxis" name="PaymentTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PeriodTypeAxis" name="PeriodTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccrualsPriorToFirstMarketingApproval" name="AccrualsPriorToFirstMarketingApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AccruedClinicalExpensesCurrent" name="AccruedClinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AccruedConsultingFeesCurrent" name="AccruedConsultingFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AccruedManufacturingCostsCurrent" name="AccruedManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AccruedPaymentsOfTcrProducts" name="AccruedPaymentsOfTcrProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" name="AccruedPaymentsOrReceiptsUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AccruedPreclinicalServicesCurrent" name="AccruedPreclinicalServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AdditionalLoansCommitted" name="AdditionalLoansCommitted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AdditionalNumberOfWarrantsIssued" name="AdditionalNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AggregateAmountPotentiallyReimburseableAmount" name="AggregateAmountPotentiallyReimburseableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AggregateBenchmarkPaymentsPayable" name="AggregateBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AggregateMinimumAnnualRoyaltiesPaid" name="AggregateMinimumAnnualRoyaltiesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AggregatePotentialBenchmarkPayments" name="AggregatePotentialBenchmarkPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AnnualBaseRent" name="AnnualBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AnnualExpenseIncurred" name="AnnualExpenseIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AnnualLicenseFees" name="AnnualLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_BonusDepreciationEligibilityPercentage" name="BonusDepreciationEligibilityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_CommonStockIssuanceCost" name="CommonStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ConditionalMilestoneAmountPayable" name="ConditionalMilestoneAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ContributionPayableOnPerAnnumBasis" name="ContributionPayableOnPerAnnumBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_CostIncurredInAppointmentOfDirectors" name="CostIncurredInAppointmentOfDirectors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DebtInstrumentPrepaymentPremium" name="DebtInstrumentPrepaymentPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" name="DeferredTaxAssetsCapitalizedAcquisitionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DeferredTaxAssetsDepreciation" name="DeferredTaxAssetsDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" name="DeferredTaxAssetsResearchExpensesCapitalized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" name="DeferredTaxAssetsStartUpAndPreClinicalStudies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DeferredTaxLiabilityRightOfUseAsset" name="DeferredTaxLiabilityRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_DescriptionOfFirstAnnualRoyaltyPayable" name="DescriptionOfFirstAnnualRoyaltyPayable" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DescriptionOfFirstBenchmarkPayable" name="DescriptionOfFirstBenchmarkPayable" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" name="DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DevelopmentCostsPaid" name="DevelopmentCostsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DiscountedRiskAdjustedRates" name="DiscountedRiskAdjustedRates" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" name="EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_EligibilityOfBonusPercentage" name="EligibilityOfBonusPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_EmbeddedDerivativeDividendAmount" name="EmbeddedDerivativeDividendAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ExpectedCashPaymentPayable" name="ExpectedCashPaymentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ExpectedCashPaymentPayablePerInstallments" name="ExpectedCashPaymentPayablePerInstallments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_FairValueAssumptionsOfPreferredStock" name="FairValueAssumptionsOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_GainLossOnModificationOfLease" name="GainLossOnModificationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_GainLossOnOperatingLeaseModification" name="GainLossOnOperatingLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_IncreaseDecreaseInRightOfUseAsset" name="IncreaseDecreaseInRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_InitialBenchmarkPaymentDue" name="InitialBenchmarkPaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_InterestExpenseAmortizedDate" name="InterestExpenseAmortizedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" name="IssuanceOfCommonStockNetOfExpensesInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" name="LesseeOperatingLeaseMonthlyAverageRentalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_LicenseAgreementCommencementDate" name="LicenseAgreementCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LicenseAgreementCommencingDate" name="LicenseAgreementCommencingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LicenseExpense" name="LicenseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MaximumAmountOfAdditionalMilestonesPayable" name="MaximumAmountOfAdditionalMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MaximumAmountOfRoyaltiesReceivable" name="MaximumAmountOfRoyaltiesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MaximumAmountOfRoyaltyPayable" name="MaximumAmountOfRoyaltyPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" name="MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_MaximumRoyaltiesAmountPayable" name="MaximumRoyaltiesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MaximumRoyaltyAmount" name="MaximumRoyaltyAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" name="MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MilestonePaymentMadeOne" name="MilestonePaymentMadeOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MilestonePaymentsMaximumAmount" name="MilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MinimumRoyaltiesAmountPayable" name="MinimumRoyaltiesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" name="MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" name="NonOperatingIncomeExpenseInducementOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" name="NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_NumberOfDaysOptionExerciable" name="NumberOfDaysOptionExerciable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_NumberOfSharesVested" name="NumberOfSharesVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ObligationsDueUnderContract" name="ObligationsDueUnderContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_OperatingLeaseArea" name="OperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLeasesExpirationMonthAndYear" name="OperatingLeasesExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" name="OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_OperatingLossCarryforwardsExpirationDatesState" name="OperatingLossCarryforwardsExpirationDatesState" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLossCarryforwardsResearchExpirationDates" name="OperatingLossCarryforwardsResearchExpirationDates" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PaymentForAnnualLicenseFees" name="PaymentForAnnualLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" name="PaymentForHistoricalCostsOfTheLicensedPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PaymentsUnderPatentLicense" name="PaymentsUnderPatentLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PaymentUnderLicenseAgreement" name="PaymentUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" name="PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" name="PercentageOfOriginalPrincipalDueAsAFinalPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfPaymentOfLicenseFee" name="PercentageOfPaymentOfLicenseFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfPrepaymentsPremium" name="PercentageOfPrepaymentsPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" name="PercentageOfSubLicensingIncomePayableToRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" name="PlacementAgentFeesAndOtherRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PocketExpenses" name="PocketExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PotentialBenchmarkPaymentsPayable" name="PotentialBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PreferredStockConversionFloorPrice" name="PreferredStockConversionFloorPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PreferredStockRedemptionDiscountDerivatives" name="PreferredStockRedemptionDiscountDerivatives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" name="PropertyAndEquipmentAndRightOfUseAssetsImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PublicOfferingNetPricePerShare" name="PublicOfferingNetPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_QuarterlyExpenseIncurred" name="QuarterlyExpenseIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_QuarterlyPaymentsUnderContract" name="QuarterlyPaymentsUnderContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_RelatedPartyTransactionReimbursedAmount" name="RelatedPartyTransactionReimbursedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" name="ResearchAndDevelopmentServiceAgreementQuarterlyPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ResearchAndDevelopmentServicesContractTerm" name="ResearchAndDevelopmentServicesContractTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_RoyaltiesAmountPayableThereafter" name="RoyaltiesAmountPayableThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_SharesAuthorized" name="SharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_StockIssuedDuringPeriodSharesWarrantExercise" name="StockIssuedDuringPeriodSharesWarrantExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" name="StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_StockIssuedDuringPeriodValueWarrantExercise" name="StockIssuedDuringPeriodValueWarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_StockOfferedDuringPeriodShares" name="StockOfferedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SubleaseArea" name="SubleaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SubleaseTermCommencedEndDateAmendment" name="SubleaseTermCommencedEndDateAmendment" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_TaxRelaxationOnTaxableIncome" name="TaxRelaxationOnTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" name="ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_TotalCompensationExpense" name="TotalCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_UnderwriterParOrStatedValuePerShare" name="UnderwriterParOrStatedValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AgreementTypeDomain" name="AgreementTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightDomainDomain" name="ClassOfWarrantOrRightDomainDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateDomain" name="DueDateDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeDomain" name="PaymentTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PeriodTypeDomain" name="PeriodTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EarningPerShareBasicAndDilutedLineItems" name="EarningPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EquityLineItems" name="EquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AdditionalPaidInCapitalCommonStockMember" name="AdditionalPaidInCapitalCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AresTradingMember" name="AresTradingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_BlackScholesModelMember" name="BlackScholesModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CARProductsMember" name="CARProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" name="CollaborationAgreementWithSolasiaPharmaKkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommonStockOptionsMember" name="CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ConsultantsMember" name="ConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_Covid19Member" name="Covid19Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CRADAAgreementMember" name="CRADAAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBiocellMember" name="EdenBiocellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBioCellMember" name="EdenBioCellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EightScheduledPaymentMember" name="EightScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EmployeeStockOptionAndRestrictedStockMember" name="EmployeeStockOptionAndRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_FederalAndStateMember" name="FederalAndStateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_GeneralBusinessCreditsMember" name="GeneralBusinessCreditsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_GroupThreeMember" name="GroupThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_HoustonTexasMember" name="HoustonTexasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IntrexonCorporationMember" name="IntrexonCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" name="LicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicensedProductsMember" name="LicensedProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaMember" name="MaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MarketOfferingMember" name="MarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" name="MdAndersonAgreementAndWorldwideLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonCancerCenterMember" name="MdAndersonCancerCenterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" name="MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" name="MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonLicenseMember" name="MdAndersonLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonMember" name="MdAndersonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonWarrantMember" name="MdAndersonWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NetOperatingLossCarryforwardsMember" name="NetOperatingLossCarryforwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NewWarrantsMember" name="NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonVestedRestrictedStockMember" name="NonVestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonVestedStockMember" name="NonVestedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OfficeAndComputerEquipmentMember" name="OfficeAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OneTimeBenchmarkPaymentsMember" name="OneTimeBenchmarkPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PatentAndTechnologyLicenseAgreementMember" name="PatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PerformanceBasedPaymentsMember" name="PerformanceBasedPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PostMarketingApprovalMember" name="PostMarketingApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_QualifiedImprovementPropertyMember" name="QualifiedImprovementPropertyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SeriesOnePreferredStockMember" name="SeriesOnePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SeriesOnePreferredStockMezzanineMember" name="SeriesOnePreferredStockMezzanineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareSubscriptionAgreementMember" name="ShareSubscriptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SiliconValleyBankLoanMember" name="SiliconValleyBankLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SvbWarrantsMember" name="SvbWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TcellReceptorMember" name="TcellReceptorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TenthScheduledPaymentMember" name="TenthScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" name="TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TriArmMember" name="TriArmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandTwelveEquityIncentivePlanMember" name="TwoThousandTwelveEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandTwelveStockOptionPlanMember" name="TwoThousandTwelveStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_UnderwritingAgreementMember" name="UnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_UnderwritingAgreementWithJefferiesMember" name="UnderwritingAgreementWithJefferiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_VinetiIncMember" name="VinetiIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WatermillAndRobertWPostmaMember" name="WatermillAndRobertWPostmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopharmMember" name="ZiopharmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" name="ZiopLicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EarningPerShareBasicAndDilutedTable" name="EarningPerShareBasicAndDilutedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ScheduleOfEquityTable" name="ScheduleOfEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_FinancingArrangementsDisclosureTextBlock" name="FinancingArrangementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OrganizationalChangesPolicyTextBlock" name="OrganizationalChangesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SettlementOfRelatedPartyRelationshipTextBlock" name="SettlementOfRelatedPartyRelationshipTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" name="StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantTextBlock" name="WarrantTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>tcrt-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T18:31:25.3821+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheets" xlink:href="tcrt-20221231.xsd#BalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical" xlink:href="tcrt-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" xlink:href="tcrt-20221231.xsd#StatementStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="tcrt-20221231.xsd#StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables" xlink:href="tcrt-20221231.xsd#DerivativeFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#OrganizationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#FinancingsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="tcrt-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="tcrt-20221231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="tcrt-20221231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:href="tcrt-20221231.xsd#DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails" xlink:href="tcrt-20221231.xsd#LeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="tcrt-20221231.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20221231.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#WarrantsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail" xlink:href="tcrt-20221231.xsd#DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:href="tcrt-20221231.xsd#DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta" xlink:href="tcrt-20221231.xsd#DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#StockOptionPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:href="tcrt-20221231.xsd#DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail" xlink:href="tcrt-20221231.xsd#JointVentureAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMezzanineMember" xlink:label="tcrt_SeriesOnePreferredStockMezzanineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" xlink:label="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" xlink:label="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="tcrt_StockIssuedDuringPeriodValueWarrantExercise"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:label="tcrt_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMezzanineMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodValueWarrantExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StockIssuedDuringPeriodSharesWarrantExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockIssuanceCost" xlink:label="tcrt_CommonStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MarketOfferingMember" xlink:label="tcrt_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PublicOfferingMember" xlink:label="tcrt_PublicOfferingMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_CommonStockIssuanceCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_MarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_PublicOfferingMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TotalCompensationExpense" xlink:label="tcrt_TotalCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ResearchAndDevelopmentServicesContractTerm" xlink:label="tcrt_ResearchAndDevelopmentServicesContractTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:label="us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CostIncurredInAppointmentOfDirectors" xlink:label="tcrt_CostIncurredInAppointmentOfDirectors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_TotalCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EmployeeStockOptionAndRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_ResearchAndDevelopmentServicesContractTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="tcrt_AgreementTypeAxisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DueToAffiliateCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_CostIncurredInAppointmentOfDirectors" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EarningPerShareBasicAndDilutedTable" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="tcrt_EarningPerShareBasicAndDilutedTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommonStockOptionsMember" xlink:label="tcrt_CommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcrt_CommonStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_WarrantsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_DebtInstrumentPrepaymentPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_InterestExpenseAmortizedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonCancerCenterMember" xlink:label="tcrt_MdAndersonCancerCenterMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementMember" xlink:label="tcrt_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeAxis" xlink:label="tcrt_PeriodTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeDomain" xlink:label="tcrt_PeriodTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeDomain" xlink:label="tcrt_PeriodTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" xlink:label="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonMember" xlink:label="tcrt_MdAndersonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonCancerCenterMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PeriodTypeAxis" xlink:to="tcrt_PeriodTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_PeriodTypeAxis" xlink:to="tcrt_PeriodTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_MdAndersonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_PocketExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="tcrt_PeriodTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_VinetiIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_WatermillAndRobertWPostmaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_OperatingLeaseResidualValueOfLeasedAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DiscountedRiskAdjustedRates" xlink:label="tcrt_DiscountedRiskAdjustedRates"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeasesExpirationMonthAndYear" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualBaseRent" xlink:label="tcrt_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_MaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tcrt_OtherIncomeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_HoustonTexasMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseResidualValueOfLeasedAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_DiscountedRiskAdjustedRates" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_GainLossOnModificationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_AnnualBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PerformanceBasedPaymentsMember" xlink:label="tcrt_PerformanceBasedPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AresTradingMember" xlink:label="tcrt_AresTradingMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeAxis" xlink:label="tcrt_PeriodTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PeriodTypeDomain" xlink:label="tcrt_PeriodTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GroupThreeMember" xlink:label="tcrt_GroupThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonLicenseMember" xlink:label="tcrt_MdAndersonLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentForAnnualLicenseFees" xlink:label="tcrt_PaymentForAnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumAmountOfRoyaltiesReceivable" xlink:label="tcrt_MaximumAmountOfRoyaltiesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CharityCareDirectAndIndirectCostBasisAmount" xlink:label="us-gaap_CharityCareDirectAndIndirectCostBasisAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" xlink:label="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PercentageOfPaymentOfLicenseFee" xlink:label="tcrt_PercentageOfPaymentOfLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementCommencementDate" xlink:label="tcrt_LicenseAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfSharesVested" xlink:label="tcrt_NumberOfSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QuarterlyPaymentsUnderContract" xlink:label="tcrt_QuarterlyPaymentsUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ExpectedCashPaymentPayable" xlink:label="tcrt_ExpectedCashPaymentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ExpectedCashPaymentPayablePerInstallments" xlink:label="tcrt_ExpectedCashPaymentPayablePerInstallments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumRoyaltiesAmountPayable" xlink:label="tcrt_MaximumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfFirstAnnualRoyaltyPayable" xlink:label="tcrt_DescriptionOfFirstAnnualRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" xlink:label="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentsUnderPatentLicense" xlink:label="tcrt_PaymentsUnderPatentLicense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AccruedPaymentsOfTcrProducts" xlink:label="tcrt_AccruedPaymentsOfTcrProducts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DevelopmentCostsPaid" xlink:label="tcrt_DevelopmentCostsPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_AresTradingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PeriodTypeAxis" xlink:to="tcrt_PeriodTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tcrt_GroupThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_MdAndersonLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentForAnnualLicenseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_CARProductsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PeriodTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltiesReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_CharityCareDirectAndIndirectCostBasisAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumRoyaltiesAmountPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfPaymentOfLicenseFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_InitialBenchmarkPaymentDue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_NumberOfSharesVested" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ObligationsDueUnderContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyExpenseIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualExpenseIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyPaymentsUnderContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ExpectedCashPaymentPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ExpectedCashPaymentPayablePerInstallments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltiesAmountPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_RoyaltiesAmountPayableThereafter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstAnnualRoyaltyPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentsUnderPatentLicense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccruedPaymentsOfTcrProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DevelopmentCostsPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="54" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="55" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="56" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PrepaidRoyalties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="57" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsDepreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncomeTaxesLineItems" xlink:label="tcrt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IncomeTaxesTable" xlink:label="tcrt_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_Covid19Member" xlink:label="tcrt_Covid19Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NetOperatingLossCarryforwardsMember" xlink:label="tcrt_NetOperatingLossCarryforwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_QualifiedImprovementPropertyMember" xlink:label="tcrt_QualifiedImprovementPropertyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FederalAndStateMember" xlink:label="tcrt_FederalAndStateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_GeneralBusinessCreditsMember" xlink:label="tcrt_GeneralBusinessCreditsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TaxRelaxationOnTaxableIncome" xlink:label="tcrt_TaxRelaxationOnTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EligibilityOfBonusPercentage" xlink:label="tcrt_EligibilityOfBonusPercentage"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_BonusDepreciationEligibilityPercentage" xlink:label="tcrt_BonusDepreciationEligibilityPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualOrInfrequentItemDomain" xlink:to="tcrt_Covid19Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="tcrt_NetOperatingLossCarryforwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_QualifiedImprovementPropertyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tcrt_FederalAndStateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="tcrt_GeneralBusinessCreditsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_UnusualOrInfrequentItemAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsExpirationDatesState" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsResearchExpirationDates" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_TaxRelaxationOnTaxableIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EligibilityOfBonusPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_BonusDepreciationEligibilityPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EquityLineItems" xlink:label="tcrt_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ScheduleOfEquityTable" xlink:label="tcrt_ScheduleOfEquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SharesAuthorized" xlink:label="tcrt_SharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementWithJefferiesMember" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NumberOfDaysOptionExerciable" xlink:label="tcrt_NumberOfDaysOptionExerciable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PublicOfferingNetPricePerShare" xlink:label="tcrt_PublicOfferingNetPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_ScheduleOfEquityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_SharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementWithJefferiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_NumberOfDaysOptionExerciable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_DividendsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_PublicOfferingNetPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_FairValueAssumptionsOfPreferredStock" xlink:label="tcrt_FairValueAssumptionsOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" xlink:label="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_PreferredStockConversionFloorPrice" xlink:label="tcrt_PreferredStockConversionFloorPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="tcrt_FairValueAssumptionsOfPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="tcrt_PreferredStockConversionFloorPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EmployeesMember" xlink:label="tcrt_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ConsultantsMember" xlink:label="tcrt_ConsultantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_EmployeesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_ConsultantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_MilestonePaymentMadeOne" xlink:label="tcrt_MilestonePaymentMadeOne"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20221231.xsd#tcrt_ConditionalMilestoneAmountPayable" xlink:label="tcrt_ConditionalMilestoneAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_MilestonePaymentMadeOne" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_ConditionalMilestoneAmountPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882362016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alaunos Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001107421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCRT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8030 El Rio Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1475642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-4099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,627,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,548,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880414800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,058<span></span>
</td>
<td class="nump">$ 76,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">53,799<span></span>
</td>
<td class="nump">78,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,460<span></span>
</td>
<td class="nump">10,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="nump">4,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">64,937<span></span>
</td>
<td class="nump">94,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current</a></td>
<td class="nump">16,765<span></span>
</td>
<td class="nump">7,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,454<span></span>
</td>
<td class="nump">6,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,166<span></span>
</td>
<td class="nump">16,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="nump">4,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,382<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value; 420,000,000 shares authorized, 240,410,761 shares issued and outstanding at December 31, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">918,942<span></span>
</td>
<td class="nump">900,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(880,627)<span></span>
</td>
<td class="num">(842,852)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">38,555<span></span>
</td>
<td class="nump">58,057<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 64,937<span></span>
</td>
<td class="nump">$ 94,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616969413552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">420,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">240,410,761<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">240,410,761<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880400576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 2,922<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">25,018<span></span>
</td>
<td class="nump">49,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,142<span></span>
</td>
<td class="nump">27,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_GainLossOnOperatingLeaseModification', window );">Gain on lease modification</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment', window );">Property and equipment and right-of-use assets impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,027<span></span>
</td>
<td class="nump">77,947<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(35,105)<span></span>
</td>
<td class="num">(77,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,154)<span></span>
</td>
<td class="num">(1,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">529<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(2,625)<span></span>
</td>
<td class="num">(1,202)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,730)<span></span>
</td>
<td class="num">$ (78,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, Basic</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, Diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">217,130,311<span></span>
</td>
<td class="nump">214,399,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">217,130,311<span></span>
</td>
<td class="nump">214,399,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_GainLossOnOperatingLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on operating lease modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_GainLossOnOperatingLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment and right of use assets impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616879966464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 123,982<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 887,868<span></span>
</td>
<td class="num">$ (764,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,591,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of employee stock options</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options (in shares)</a></td>
<td class="nump">363,109<span></span>
</td>
<td class="nump">363,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(434,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">$ 1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,751)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">58,057<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">900,693<span></span>
</td>
<td class="num">(842,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of employee stock options</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options (in shares)</a></td>
<td class="nump">26,250<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of expenses</a></td>
<td class="nump">14,724<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IssuanceOfCommonStockNetOfExpensesInShares', window );">Issuance of common stock, net of expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,228,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 38,555<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 918,942<span></span>
</td>
<td class="num">$ (880,627)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,410,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IssuanceOfCommonStockNetOfExpensesInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of expenses in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IssuanceOfCommonStockNetOfExpensesInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616876344608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,730)<span></span>
</td>
<td class="num">$ (78,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,759<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Property and equipment and right-of-use asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financing costs</a></td>
<td class="nump">981<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stock-based compensation</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="nump">10,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInRightOfUseAsset', window );">Decrease (increase) in the carrying amount of right-of-use assets</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease modification</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">3,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">867<span></span>
</td>
<td class="nump">9,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(10,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(2,501)<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,232)<span></span>
</td>
<td class="num">(61,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(3,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(3,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt borrowing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">14,724<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(8,333)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,367<span></span>
</td>
<td class="nump">25,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(23,058)<span></span>
</td>
<td class="num">(39,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">76,054<span></span>
</td>
<td class="nump">115,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">52,996<span></span>
</td>
<td class="nump">76,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts included in accrued expenses and accounts payable related to property and equipment</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881272784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#8220;Alaunos,&#8221; or the &#8220;Company,&#8221; is a clinical-stage oncology-focused cell therapy company developing adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company is leveraging its proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts. In May 2021, the Company announced that it will be winding down its existing Controlled IL-12 clinical program for the treatment of recurrent glioblastoma multiforme. The Company continues to seek a partner for this program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s amended and restated certificate of incorporation authorizes it to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">420,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. As of December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,410,761</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding and an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,330,964</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#8239;The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8239;million of cash, cash equivalents and restricted cash. The restricted cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 is related to the Company's debt agreement (refer to Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The Company&#8217;s accumulated deficit at December 31, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">880.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8239;million.&#8239;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the fourth quarter of 2023.&#8239;The Company&#8217;s ability to continue operations after its current cash resources are exhausted depends on future events, including its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given, nor are within the Company's control. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616967212080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FinancingArrangementsDisclosureTextBlock', window );">Financings</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financings</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB.  The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million funded at the closing, or the Term A Tranche, with an additional tranche of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective December 28, 2021, the Company, entered into a First Amendment to the Loan and Security Agreement. We refer to the Loan and Security Agreement, as so amended, as the Amended Loan and Security Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Amended Loan and Security Agreement extended the interest-only period through August 31, 2022. Certain milestones specified in the Amended Loan and Security Agreement were not met by the Company on or prior to August 31, 2022, and therefore, the interest-only period was not extended beyond August 31, 2022. The Amended Loan and Security Agreement also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the Amended Loan and Security Agreement, the SVB Facility will mature on August 1, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the Amended Loan and Security Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the year ended December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,228,719</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, or the Firm Shares, of the Company&#8217;s common stock to the Underwriter at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6191</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net proceeds to the Company from the Offering were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to purchase up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,634,307</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">216,294</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of the Shares sold in the Offering were sold by the Company. <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FinancingArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FinancingArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886745056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes.</span></div></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. The Company did not have any material subsequent events that impacted its financial statements or disclosures.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.681%;"/>
        <td style="width:5.562%;"/>
        <td style="width:61.116%;"/>
        <td style="width:5.562%;"/>
        <td style="width:24.08%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life of the lease</span></span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the Statements of Operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Segments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#8217;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"/>
          <td style="width:1.201%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.45%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.472999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,058</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,058</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"/>
          <td style="width:1.201%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.45%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.472999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2022 and 2021. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair value of non-financial instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2021, following the Company's strategic restructuring and further cost reduction initiatives, the Company determined that changes in the intended use of its Boston office represented an indicator of impairment, resulting in an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the right-of-use asset. In addition, the Company impaired approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of leasehold improvements and various other assets associated with its decision to close the Company's Boston office. Refer to Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the year ended December 31, 2022 consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and for the year ended December 31, 2021 consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. For the years ended December 31, 2022 and 2021, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments and Contingencies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. The Company&#8217;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#8217;s election.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Company&#8217;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">using </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to its prior estimates of accrued research and development expenses.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p></div><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#8217;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#8217;s common stock price over the expected term.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized the full impact of its share-based employee payment plans in the Statements of Operations for each of the years ended December 31, 2022 and 2021 and did not capitalize any such costs on the Balance Sheets. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense related to stock options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense related to stock options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2021. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense, related to restricted stock for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2021 (refer to Note 13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s Statements of Operations:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.914%;"/>
          <td style="width:1.567%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.313%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.567%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.639%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">868</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,598</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,660</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,176</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,528</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,774</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#8217;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#8217;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.179%;"/>
          <td style="width:1.623%;"/>
          <td style="width:13.438%;"/>
          <td style="width:1.623%;"/>
          <td style="width:16.137%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="bkmk_220" style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.797%;"/>
          <td style="width:1.729%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.754999999999999%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.721%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.998%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,730</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,751</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217,130,311</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214,399,074</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.17</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.37</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain shares related to some of the Company&#8217;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2022 and 2021 as the result would be antidilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potential common shares on December 31, 2022 and 2021 consist of the following:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.845%;"/>
          <td style="width:1.179%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.68%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.179%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.119%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,408,622</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,500</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939,062</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,270,026</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,819,291</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the FASB issued Accounting Standards Update, or ASU, 2021-10, Government Assistance (Topic 832): Disclosures by Business entities about Government Assistance, which requires business entities to disclose information about certain government assistance that they receive. Entities must comply with the new disclosure requirements if they account for transactions with government entities under the (1) contribution model or (2) grant model by analogy. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/>In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842): Lessors &#8211; Certain Leases with Variable Lease Payments, which requires lessors to classify as operating leases those leases with variable lease payments that do not depend on an index or rate if another classification (i.e. sales-type or direct financing) would result in a commencement date (&#8216;day 1&#8217;) selling loss. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation -  Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815- 40): Warrant modifications, which clarifies an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (e.g. warrants) that remain equity-classified after modification or exchange. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886439680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Debt</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company's debt obligation were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.069%;"/>
        <td style="width:1.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.719%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.962%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,209</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">630</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,765</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,118</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: long-term debt, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,765</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,868</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement. The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million funded at the closing, with an additional tranche of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022. On December 28, 2021, the Company entered into the Amended Loan and Security Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Amended Loan and Security Agreement, the SVB Facility was modified to eliminate the additional $25.0 million tranche, which remained unfunded, leaving only the initial $25.0 million as the full amount available under the SVB Facility. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, interest on the outstanding loans was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022.  Commencing on September 1, 2022, aggregate outstanding borrowings became repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All outstanding obligations under the Amended Loan and Security Agreement are due and payable on</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> August 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also owe SVB </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the original principal amounts borrowed as a final payment. The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, of the SVB Facility, each such prepayment to be at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million plus all accrued and unpaid interest on the portion being prepaid.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of not achieving certain milestones specified in the Amended Loan and Security Agreement on or prior to August 31, 2022, the Company was required to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the original principal amount of the SVB Facility. As of December 31, 2022, the Company has collateralized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is classified as restricted cash on the Balance Sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of the Company&#8217;s properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,844</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,842</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Amended Loan and Security Agreement, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">649,615</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 6, 2031</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and primarily related to the warrants issued to SVB, which will be amortized into interest expense over the period to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Interest expense, including the amortization of issuance costs, was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Amended Loan and Security Agreement as of December 31, 2022 approximates its face value.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881333936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, net</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.417%;"/>
        <td style="width:1.663%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.576%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.447%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.898%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,291</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,236</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,561</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,474</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,232</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,110</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,267</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,413</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,460</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. During the year ended December 31, 2021, the Company impaired property and equipment by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Refer to Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881248080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consist of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.696%;"/>
        <td style="width:1.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.969%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.969%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,160</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,922</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">198</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,056</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other consulting services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,454</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,076</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881336368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration with Vineti Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc., or Vineti. Pursuant to the agreements, Vineti is developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#8217;s T-cell therapy, or TCR-T, clinical programs. Heidi Hagen, who became a director of the Company in June 2019 and resigned November 2, 2021 and was appointed the Company's interim Chief Executive Officer on February 25, 2021 and resigned on August 30, 2021, is a co-founder and former officer, of Vineti. During the year ended December 31, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur expenses for services performed by Vineti, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">WaterMill Settlement Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 4, 2021, the Company entered into an agreement, or the Settlement Agreement, with WaterMill Asset Management Corp. and Robert W. Postma, or collectively, the WaterMill Parties. Pursuant to the Settlement Agreement, the Company increased the size of its board of directors from eight to nine directors and appointed Mr. Postma to fill the newly created directorship.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the Settlement Agreement, the Company agreed to reimburse the WaterMill Parties for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of their reasonable out-of-pocket expenses in connection with (i) the WaterMill Parties' solicitation of written consents from our stockholders to vote in favor of certain proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October 30, 2020, and (ii) the negotiation, execution, and effectuation of the Settlement Agreement. As of February 19, 2021, the Company has fully reimbursed the WaterMill Parties an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#8217;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies in the People&#8217;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm has contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to this joint venture. TriArm also manages all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang is the Chair of the Company's board of directors and has been a director since July 2020. He also serves as a member of Eden BioCell&#8217;s board of directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, Eden BioCell incurred a net loss and the Company continues to have no commitment to fund its operations. In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity is in the process of being dissolved. Refer to Note 15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further details.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886263696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2012, the Company entered into a master lease for the Company&#8217;s office in Boston, Massachusetts, which was originally set to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2016</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, but was renewed through August 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 22, 2021, the Company extended its lease for a portion of office space in Boston. The renewal of the portion of the Company's office space was originally set to expire on August 31, 2021, but was extended through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_135f6a9b-d35b-4744-9bd0-7a49a3ff0c93;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, and December 31, 2021, a total security deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is included in deposits on the Company&#8217;s balance sheet. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company made the decision to move its operations away from its former corporate office in Boston. As described in Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company's change in the intended use of the Boston office represented an indicator of impairment. The Company determined the aggregate carrying value of the asset group (approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2021) was in excess of the aggregate estimated fair value and recorded an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the right-of-use asset and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to associated property and equipment during the year ended December 31, 2021. The fair value was determined based on the amount and timing of estimated net future cash flows, discounted at a risk-adjusted rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2019, the Company entered into a lease agreement for office and lab space in Houston, Texas at MD Anderson through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the terms of the lease agreement, the Company leases approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,038</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">feet and was required to make rental payments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an average monthly rate of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand through April 2021. On October 15, 2019, the Company entered into a lease agreement for additional office and laboratory space in Houston through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the terms of the lease, the Company leases from MD Anderson, approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,443</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet and is initially required to make rental payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through February 2027, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term. Effective April 7, 2020, the Company leased an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,594</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet from MD Anderson. The Company is initially required to make rental payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 15, 2020, the Company entered into a second agreement with MD Anderson to lease additional space on MD Anderson&#8217;s campus (the &#8220;2020 Lease&#8221;). The Company is initially required to make rental payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through April 2028, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term beginning in April 2023. The 2020 Lease may be extended for one additional five-year term at the Company's election.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company modified the 2020 Lease, which reduced the Company's leased space from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,228</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million based on revised lease payments. A gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the lease modification during the year ended December 31, 2022. The Company is initially required to make payments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand per month through April 2028, subject to an annual base rent increase of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% throughout the term. The 2020 Lease may be extended for one additional five-year term at the Company's election.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="bkmk_231" style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.343%;"/>
        <td style="width:1.836%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.988000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.836%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.13</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.58</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.26</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for amounts included in the measurement of the lease liabilities for the year-ended December 31, 2022. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize new operating lease assets obtained in exchange for operating lease liabilities for the year-ended December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the maturities of the Company&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6934d123-79b6-4d0e-9146-8913adc044ad;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating lease liabilities</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.093%;"/>
        <td style="width:13.477%;"/>
        <td style="width:24.346%;"/>
        <td style="width:11.972%;"/>
        <td style="width:1.012%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.1%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of Lease Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">780</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">712</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,746</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company executed an agreement to sub-sublease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,772</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of subleased office space in Boston. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> For the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in lease income, which is classified within other income (expense), net in the Statement of Operations. Under the current terms of the agreement, lease income for the remainder of the sub-sublease term is expected to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2023, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2024 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881306480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with PGEN Therapeutics</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement, the Company has exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between us, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also has exclusive, worldwide rights for certain patents relating to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products and TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the licenses and other rights granted by PGEN, the Company pays PGEN an annual license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the Company reimbursed PGEN for certain historical costs of the licensed programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will make milestone payments totaling up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. The Company will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate. The Company will also pay PGEN </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of any sublicensing income received by us relating to the licensed products. The Company is responsible for all development costs associated with each of the licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PGEN will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#8217;s CAR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> royalty amounts were incurred during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#8217;s obligations to provide transition assistance relating to the IL-12 products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 13, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who served as the Company&#8217;s Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#8220;Fourth Amendment&#8221;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which we entered into on October 22, 2019, with MD Anderson, pursuant to which we agreed to collaborate with respect to the TCR program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, PGEN, and MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to all, intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies, and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which only $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the year ended December 31, 2022, the Company incurred clinical expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from MD Anderson related to this agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,333,333</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and vests in four parts upon the occurrence of certain clinical milestones. As of December 31, 2022, the milestones have not been met.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Patent License require the Company to pay the NCI minimum annual royalties in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which amount will be reduced to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million once the aggregate minimum annual royalties paid by the Company equals $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which aggregate payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first benchmark payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. The aggregate potential amount of these benchmark payments is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company may terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of expenses and incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of expenses for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology, the NCI would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company will have the first opportunity to file a patent covering the invention. If the Company fails to provide timely notice of its decision to the NCI or decides not to file a patent covering the joint invention, the NCI has the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service grants the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which are licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company is also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI has a cleared Investigational New Drug Application, or IND, that would permit them to begin this trial. To the Company's knowledge, the trial has not yet enrolled. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to this program; however, for the third and fourth quarters of 2021, the Company was not required to make payments toward the program as agreed with the NCI. Therefore, as of December 31, 2022, the Company made $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of payments under the February 2019 CRADA extension, and the NCI has agreed that this is full satisfaction of the agreement and no further payments are due under the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commitment. In March 2022, the Company entered into an amendment to the CRADA that was retroactive, effective January 9, 2022 to extend the term of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRADA </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur expenses under the CRADA for the year ended December 31, 2022, as compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#8212;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the year ended December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was incurred as a one-time milestone payment under the terms of the agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand in royalty expenses on sales under this agreement during the year ended December 31, 2022, and did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur royalty expenses on sales under this agreement during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#8217;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2022, the Company earned $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881248080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsDisclosureAbstract', window );"><strong>Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantTextBlock', window );">Warrants</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company&#8217;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,939,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,803,031</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,803,031</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock, or the 2019 Warrants, as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million non-cash charge in the Company&#8217;s statement of operations in 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,333,333</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the year ended December 31, 2022 and 2021, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,844</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The warrants have a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the Amended Loan and Security Agreement, as described in Note 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">649,615</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.16</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. Using a Black-Scholes model with an expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends, the Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0f16ce4f-8d70-403f-b6b8-a51d4653179d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increase in the fair value</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the SVB Warrants due to the modification of the SVB Warrants during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed whether the SVB Warrants require accounting as derivatives. The Company determined that the SVB Warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the SVB Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881235984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restructuring</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, in order to lower its existing cost structure in connection with the realignment of its business strategy, the Company announced a strategic reduction in force and notified approximately 60 full-time employees of its intention to terminate their services on or, in most cases, before November 30, 2021. Certain of the notified employees had employment agreements that provided for enhanced severance benefits. The severance benefits, apart from certain continuing Company-paid health care benefits for up to twelve months, were paid in 2021. The remaining benefits were paid in 2022, which reduced the severance benefits accrual to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred the following costs associated with termination benefit payments resulting from the strategic reduction in force:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.992%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.528%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.767%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total severance expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886373696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is no provision for income taxes because the Company has incurred operating losses since inception. The reported amounts of income tax expense for the years ended December 31, 2022 and 2021 differ from the amounts that would result from applying domestic federal statutory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tax </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rates to pretax losses primarily because of the changes in the valuation allowance. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at December 31, 2022 and 2021 are as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.201%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.654%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.975999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171,070</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Start-up and pre-clinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,705</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,116</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,817</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">706</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized acquisition costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,180</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,946</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,156</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">237,308</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231,196</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236,827</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">230,119</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,077</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2022, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">665.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">341.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million expire at various dates through December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">323.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million can be carried forward indefinitely. The Company also has approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">497.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating loss carryforwards available to offset future state taxable income, expiring at various dates through 2042. Additionally, the Company has approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal and state research and development credits at December 31, 2022, expiring in varying amounts through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which may be available to reduce future taxes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has provided a valuation allowance for the full amount of its net deferred tax assets since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2022 due primarily to net operating loss carryforwards and the increase in research and development credits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes using the federal statutory income tax rate differ from the Company&#8217;s effective tax rate primarily due to non-deductible expenses related to the Company&#8217;s issuance of warrants along with the change in the valuation allowance on deferred tax assets.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.362%;"/>
        <td style="width:1.112%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.258000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.112%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.156%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal income tax at statutory rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development true-up</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal/state rate change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Uncertain Tax Positions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements in accordance with FASB Statement No. 109, &#8220;Accounting for Income Taxes.&#8221; ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> adjustments to its uncertain tax positions in the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized any interest and penalties in the statements of operations because of the Company&#8217;s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2022 to the extent net operating losses continue to be carried forward to 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or the Tax Act, eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to capitalize and amortize them over five years pursuant to IRC Section 174. The mandatory capitalization requirement had no impact to the overall deferred tax assets due to the Company's loss position and full valuation allowance.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881304480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock', window );">Stock Option Plan</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option Plan</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, in May 2012. Including subsequent increases, the Company had reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares for issuance. On December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,089,296</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for issuance and no shares available for future grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, in June 2020. The Company reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares for issuance plus a carryover of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,066,275</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares from the 2012 Plan for a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,066,275</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, returning shares from the 2012 Plan are available for issuance under the 2020 Plan. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,319,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for issuance and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,460,088</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for future grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options generally vest ratably in either quarterly or annual installments over three or four years, commencing on the first anniversary of the grant date and have contractual terms of ten years. Stock options to directors generally vest ratably over one or two years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation is recognized based on such fair value over the period of vesting on a straight-line basis.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the option exercises during the year ended December 31, 2022 amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand and during the year ended December 31, 2021 amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The intrinsic value of these options amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the Company's stock options plans for the years ending December 31, 2022 and 2021 were as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.426%;"/>
        <td style="width:0.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.061%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.588999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.831999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.476%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.882%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,840,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,380,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,192,179</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,697,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.08</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,928,497</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,408,622</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.69</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,891,598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,410,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.53</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grant, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,460,088</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 31, 2022, total unrecognized compensation costs related to non-vested stock options outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.92</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,601,224</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the year ended December 31, 2021 to employees and directors. During the year ended December 31, 2022, the Company repurchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share to cover payroll taxes for one employee exercise, which is in accordance with the original terms of the award. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> repurchases by the Company for the year ended December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the status of restricted stock as of December 31, 2022 and 2021 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.19%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.988999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.623%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.034%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">786,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,601,224</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.60</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">754,137</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">434,787</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.82</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">306,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.28</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,901</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total unrecognized stock-based compensation expense related to non-vested restricted stock arrangements. The expense is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.78</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options and Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886310080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">14.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Benefit Plan</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IRC, or the 401(k) Plan. The Company may make contributions to the 401(k) Plan at its discretion. The Company contributed approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the 401(k) Plan during the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881277616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">15.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joint Venture</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell to lead clinical development and commercialization of certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, Eden BioCell began treating patients in a clinical trial with the Company&#8217;s investigational CD19 RPM CAR-T cell therapy, under the IND cleared by the Taiwan FDA in December 2020. In the first half of 2021, two patients were treated in this trial. The lead investigator at National Taiwan University in Taipei, has reported no serious adverse safety events in either of these patients. Laboratory results continue to support, as previously published, that non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer is effective in genetically modifying autologous T-cells. Patients were infused two days after gene transfer, thus shortening the turnaround time and demonstrating an advantage over viral methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on laboratory data from the first two patients generated between March and May 2021, the TriArm/Eden team concluded, in concert with the investigator and the Company, that further process development work is required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, Eden BioCell incurred a net loss. In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity is in the process of being dissolved.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882391424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. The Company did not have any material subsequent events that impacted its financial statements or disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.681%;"/>
        <td style="width:5.562%;"/>
        <td style="width:61.116%;"/>
        <td style="width:5.562%;"/>
        <td style="width:24.08%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9679;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life of the lease</span></span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the Statements of Operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Segments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#8217;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"/>
          <td style="width:1.201%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.45%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.472999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,058</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,058</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"/>
          <td style="width:1.201%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.45%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.472999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2022 and 2021. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair value of non-financial instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2021, following the Company's strategic restructuring and further cost reduction initiatives, the Company determined that changes in the intended use of its Boston office represented an indicator of impairment, resulting in an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the right-of-use asset. In addition, the Company impaired approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of leasehold improvements and various other assets associated with its decision to close the Company's Boston office. Refer to Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition from Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the year ended December 31, 2022 consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and for the year ended December 31, 2021 consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. For the years ended December 31, 2022 and 2021, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments and Contingencies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. The Company&#8217;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#8217;s election.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Company&#8217;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">using </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to its prior estimates of accrued research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#8217;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#8217;s common stock price over the expected term.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized the full impact of its share-based employee payment plans in the Statements of Operations for each of the years ended December 31, 2022 and 2021 and did not capitalize any such costs on the Balance Sheets. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense related to stock options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense related to stock options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2021. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of compensation expense, related to restricted stock for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2021 (refer to Note 13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s Statements of Operations:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.914%;"/>
          <td style="width:1.567%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.313%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.567%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.639%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">868</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,598</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,660</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,176</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,528</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,774</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#8217;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#8217;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.179%;"/>
          <td style="width:1.623%;"/>
          <td style="width:13.438%;"/>
          <td style="width:1.623%;"/>
          <td style="width:16.137%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="bkmk_220" style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.797%;"/>
          <td style="width:1.729%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.754999999999999%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.721%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.998%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,730</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,751</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217,130,311</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214,399,074</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.17</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.37</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain shares related to some of the Company&#8217;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2022 and 2021 as the result would be antidilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potential common shares on December 31, 2022 and 2021 consist of the following:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.845%;"/>
          <td style="width:1.179%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.68%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.179%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.119%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,408,622</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,500</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939,062</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,270,026</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,819,291</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the FASB issued Accounting Standards Update, or ASU, 2021-10, Government Assistance (Topic 832): Disclosures by Business entities about Government Assistance, which requires business entities to disclose information about certain government assistance that they receive. Entities must comply with the new disclosure requirements if they account for transactions with government entities under the (1) contribution model or (2) grant model by analogy. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/>In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842): Lessors &#8211; Certain Leases with Variable Lease Payments, which requires lessors to classify as operating leases those leases with variable lease payments that do not depend on an index or rate if another classification (i.e. sales-type or direct financing) would result in a commencement date (&#8216;day 1&#8217;) selling loss. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation -  Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815- 40): Warrant modifications, which clarifies an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (e.g. warrants) that remain equity-classified after modification or exchange. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881368400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"/>
          <td style="width:1.201%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.45%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.472999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,058</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,058</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.809%;"/>
          <td style="width:1.201%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.45%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.215%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.212%;"/>
          <td style="width:1.0%;"/>
          <td style="width:9.472999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Compensation Expense Included in Statements of Operations</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s Statements of Operations:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.914%;"/>
          <td style="width:1.567%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.313%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.567%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.639%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">868</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,598</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,660</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,176</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,528</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,774</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.179%;"/>
          <td style="width:1.623%;"/>
          <td style="width:13.438%;"/>
          <td style="width:1.623%;"/>
          <td style="width:16.137%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.797%;"/>
          <td style="width:1.729%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.754999999999999%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.721%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.998%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,730</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,751</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217,130,311</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214,399,074</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.17</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.37</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potential common shares on December 31, 2022 and 2021 consist of the following:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.845%;"/>
          <td style="width:1.179%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.68%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.179%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.119%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,408,622</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,500</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939,062</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,270,026</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,819,291</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886270896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company's debt obligation were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.069%;"/>
        <td style="width:1.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.719%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.962%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,209</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">630</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,765</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,118</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: long-term debt, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,765</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,868</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886259840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Component of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.417%;"/>
        <td style="width:1.663%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.576%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.447%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.898%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,291</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,236</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,561</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,474</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,232</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,110</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,267</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,413</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,460</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881277616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Component of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consist of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.696%;"/>
        <td style="width:1.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.969%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.969%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,160</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,922</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">198</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,056</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other consulting services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,454</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,076</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881316800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p id="bkmk_231" style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.343%;"/>
        <td style="width:1.836%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.988000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.836%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.13</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.58</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.26</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the maturities of the Company&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6934d123-79b6-4d0e-9146-8913adc044ad;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating lease liabilities</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.093%;"/>
        <td style="width:13.477%;"/>
        <td style="width:24.346%;"/>
        <td style="width:11.972%;"/>
        <td style="width:1.012%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.1%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of Lease Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">780</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">712</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,746</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881339792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Future termination benefit payments resulting from the strategic reduction in force</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred the following costs associated with termination benefit payments resulting from the strategic reduction in force:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.992%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.528%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.767%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total severance expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886341264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Component of Deferred Tax Assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at December 31, 2022 and 2021 are as follows:</span><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.201%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.654%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.975999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171,070</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Start-up and pre-clinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,705</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,116</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,817</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">706</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized acquisition costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,180</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,946</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,156</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">237,308</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231,196</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236,827</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">230,119</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,077</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.362%;"/>
        <td style="width:1.112%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.258000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.112%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.156%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal income tax at statutory rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development true-up</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal/state rate change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886448528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity Under Stock Option Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the Company's stock options plans for the years ending December 31, 2022 and 2021 were as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.426%;"/>
        <td style="width:0.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.061%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.588999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.831999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.476%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.882%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,840,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,380,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,192,179</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,697,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.08</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,928,497</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,408,622</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.69</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,891,598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,410,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.53</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grant, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,460,088</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Non-Vested Restricted Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the status of restricted stock as of December 31, 2022 and 2021 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.19%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.988999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.623%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.034%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">786,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,601,224</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.60</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">754,137</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">434,787</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.82</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">306,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.28</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,901</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880610880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 52,996<span></span>
</td>
<td class="nump">$ 76,054<span></span>
</td>
<td class="nump">$ 115,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(880,627)<span></span>
</td>
<td class="num">$ (842,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash related to the Company's debt agreement</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">420,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">240,410,761<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">240,410,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">33,330,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882121856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2023</div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember', window );">At The Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase', window );">Number of additional option available to the underwriter to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,634,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,228,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_UnderwriterParOrStatedValuePerShare', window );">Underwriter par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings', window );">Threshold period for exercise or conversion of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Stock Option [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Stock issued during period</a></td>
<td class="nump">216,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock', window );">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_SiliconValleyBankMember', window );">Silicon Valley Bank [Member] | Term A Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_SiliconValleyBankMember', window );">Silicon Valley Bank [Member] | Term B Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Additonal tranche facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional option available to the underwriter to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross proceeds from sale of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOfferedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offered during period shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOfferedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold commitment period for exercise of rights to participate in future offerings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_UnderwriterParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriter par or stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_UnderwriterParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881804032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 3,528<span></span>
</td>
<td class="nump">$ 10,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock option granted</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating Lease Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 2,922<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember', window );">Office and computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life</a></td>
<td class="text">Life of the lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_EmployeeStockOptionAndRestrictedStockMember', window );">Stock Options and Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_EmployeeStockOptionAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_EmployeeStockOptionAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882269392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 38,058<span></span>
</td>
<td class="nump">$ 75,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 38,058<span></span>
</td>
<td class="nump">$ 75,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616879978912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,528<span></span>
</td>
<td class="nump">$ 10,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,660<span></span>
</td>
<td class="nump">$ 8,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881975648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.63%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">74.49%<span></span>
</td>
<td class="nump">72.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">88.75%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882270480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,730)<span></span>
</td>
<td class="num">$ (78,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">217,130,311<span></span>
</td>
<td class="nump">214,399,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">217,130,311<span></span>
</td>
<td class="nump">214,399,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880382976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">34,270,026<span></span>
</td>
<td class="nump">34,819,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">22,922,342<span></span>
</td>
<td class="nump">22,922,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_CommonStockOptionsMember', window );">Common stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">10,408,622<span></span>
</td>
<td class="nump">10,665,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Two Thousand Twelve Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">939,062<span></span>
</td>
<td class="nump">1,198,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880600704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 16,765<span></span>
</td>
<td class="nump">$ 24,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="num">(16,765)<span></span>
</td>
<td class="num">(7,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan and Security Agreement</a></td>
<td class="nump">17,395<span></span>
</td>
<td class="nump">25,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount on Loan and Security Agreement</a></td>
<td class="num">$ (630)<span></span>
</td>
<td class="num">$ (1,091)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616877013184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash related to the Company's debt agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_InterestExpenseAmortizedDate', window );">Interest expense amortized date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Initial borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment', window );">Percentage of original principal due as a final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility additional tranche amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="nump">649,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Aug.  06,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms', window );">Description of payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company will also owe SVB 5.75% of the original principal amounts borrowed as a final payment. The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from 1.00% to 2.00%, of the SVB Facility, each such prepayment to be at least $5.0 million plus all accrued and unpaid interest on the portion being prepaid.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalNumberOfWarrantsIssued', window );">Additional number warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt instrument, initial maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Debt Instrument Redemption Period One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfPrepaymentsPremium', window );">Percentage of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Debt Instrument Redemption Period One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfPrepaymentsPremium', window );">Percentage of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash related to the Company's debt agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Term Loan [Member] | Tenth Scheduled Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from bank debt</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Term Loan [Member] | Eight Scheduled Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from bank debt</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance costs</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_InterestExpenseAmortizedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense amortized date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_InterestExpenseAmortizedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original principal due as a final payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfPrepaymentsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayments premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfPrepaymentsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=tcrt_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_TenthScheduledPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_TenthScheduledPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_EightScheduledPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_EightScheduledPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882111872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Component of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 18,267<span></span>
</td>
<td class="nump">$ 18,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(9,807)<span></span>
</td>
<td class="num">(7,413)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,460<span></span>
</td>
<td class="nump">10,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember', window );">Office and computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">9,561<span></span>
</td>
<td class="nump">9,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 5,232<span></span>
</td>
<td class="nump">$ 5,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616886734400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 2,759<span></span>
</td>
<td class="nump">$ 2,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616879939360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Component of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedClinicalExpensesCurrent', window );">Clinical</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 1,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Employee compensation</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedPreclinicalServicesCurrent', window );">Preclinical services</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedManufacturingCostsCurrent', window );">Manufacturing services</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedConsultingFeesCurrent', window );">Other consulting services</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,454<span></span>
</td>
<td class="nump">$ 6,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedConsultingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued consulting fees, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedConsultingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing costs, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedPreclinicalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedPreclinicalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616876330288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Feb. 04, 2021</div></th>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_VinetiIncMember', window );">Vineti Inc [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees', window );">Related Party Transaction Expenses From Transactions With Related Party Advisory Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember', window );">Eden Biocell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Payments to Fund Long-term Loans to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalLoansCommitted', window );">Additional Loans Committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_WatermillAndRobertWPostmaMember', window );">Watermill And Robert W Postma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PocketExpenses', window );">Pocket Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RelatedPartyTransactionReimbursedAmount', window );">Related party transaction, reimbursed amount</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalLoansCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional loans committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalLoansCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PocketExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pocket expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PocketExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction expenses from transactions with related party advisory fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RelatedPartyTransactionReimbursedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction Reimbursed Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RelatedPartyTransactionReimbursedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_VinetiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_VinetiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_WatermillAndRobertWPostmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_WatermillAndRobertWPostmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616876661520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th">
<div>Oct. 15, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 12, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jun. 30, 2012</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating Lease Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseResidualValueOfLeasedAsset', window );">Operating Lease Residual Value Of Leased Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Other Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DiscountedRiskAdjustedRates', window );">Discounted Risk-adjusted Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeasesExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027-02<span></span>
</td>
<td class="text">2027-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour', window );">Operating Leases Future Minimum Monthly Payment Due Through Years February 2027 and April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,136,000<span></span>
</td>
<td class="nump">4,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_GainLossOnModificationOfLease', window );">Gain (Loss) On Modification Of Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Recognition in exchange of Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualBaseRent', window );">Annual base rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SubleaseArea', window );">Sublease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">Lease income from sublease, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">Lease income from sublease, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">Lease income from sublease, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember', window );">Other Income Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_MaMember', window );">Boston, MA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SubleaseTermCommencedEndDateAmendment', window );">Sublease term amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeasesExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">2026-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember', window );">Houston, TX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment', window );">Operating Lease Monthly Rental Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeasesExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour', window );">Operating Leases Future Minimum Monthly Payment Due Through Years February 2027 and April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,443<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualBaseRent', window );">Annual base rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember', window );">Houston, TX [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DiscountedRiskAdjustedRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounted risk adjusted rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DiscountedRiskAdjustedRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_GainLossOnModificationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on modification of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_GainLossOnModificationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Lessee Operating Lease Monthly Average Rental Payment .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLeasesExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLeasesExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases future minimum monthly payment due through year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SubleaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SubleaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SubleaseTermCommencedEndDateAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease term commenced end date amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SubleaseTermCommencedEndDateAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseResidualValueOfLeasedAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of residual asset covered by residual value guarantee under operating lease. Excludes guarantee considered to be lease payments for lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseResidualValueOfLeasedAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tcrt_MaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tcrt_MaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tcrt_HoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616881365456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.26%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616885478480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest and adjustments</a></td>
<td class="num">(496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 2,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating lease liability statement of financial position [extensible list]</a></td>
<td class="text">Present value of lease payments<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616873311920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Aug. 17, 2015</div></th>
<th class="th"><div>Jan. 13, 2015</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Feb. 19, 2019</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Aug. 24, 2004</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,018,000<span></span>
</td>
<td class="nump">49,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922,000<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember', window );">Md Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember', window );">MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateAmountPotentiallyReimburseableAmount', window );">Reimbursement of historical costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccrualsPriorToFirstMarketingApproval', window );">Payments due prior to the first marketing approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_QuarterlyExpenseIncurred', window );">Quarterly expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregatePotentialBenchmarkPayments', window );">Aggregate potential benchmark payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember', window );">CRADA Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ContributionPayableOnPerAnnumBasis', window );">Contribution payable on per annum basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ObligationsDueUnderContract', window );">Obligations due under contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualExpenseIncurred', window );">Annual expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_QuarterlyPaymentsUnderContract', window );">Quarterly payments under contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember', window );">MD Anderson Agreement and Worldwide License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseAgreementCommencingDate', window );">License agreement commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcrt_CARProductsMember', window );">C A R Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumRoyaltyAmount', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePaymentsMaximumAmount', window );">Milestone maximum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePayment', window );">One time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentUnderLicenseAgreement', window );">Payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentUnderLicenseAgreement', window );">Payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement with Solasia Pharma K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseExpense', window );">License Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_InitialBenchmarkPaymentDue', window );">First benchmark payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MinimumRoyaltiesAmountPayable', window );">Minimum royalties amount payable</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateMinimumAnnualRoyaltiesPaid', window );">Aggregate minimum annual royalties paid</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RoyaltiesAmountPayableThereafter', window );">Royalties amount payable thereafter</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DescriptionOfFirstBenchmarkPayable', window );">Description Of First Benchmark Payable</a></td>
<td class="text">The first benchmark payment of $0.1 million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones', window );">Description Of option To terminate Agreement</a></td>
<td class="text">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTerminationNoticePeriod', window );">Agreement termination, notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Performance Based Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateBenchmarkPaymentsPayable', window );">Aggregate Benchmark Payments Payable</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PotentialBenchmarkPaymentsPayable', window );">Potential Benchmark Payments Payable</a></td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Post Marketing Approval [Member] | Performance Based Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateBenchmarkPaymentsPayable', window );">Aggregate Benchmark Payments Payable</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Licensed Products [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable', window );">Maximum Sales Revenue On Which Benchmark Payments Payable</a></td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable', window );">Minimum sales revenue on which benchmark payments payable</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualLicenseFees', window );">Annual License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable', window );">Expected additional milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation [Member] | T-Cell Receptor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfRoyaltyPayable', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty', window );">Portion of income payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccrualsPriorToFirstMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments due prior to the first marketing approval for TCR products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccrualsPriorToFirstMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateAmountPotentiallyReimburseableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Potentially Reimburseable Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateAmountPotentiallyReimburseableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Aggregate Benchmark Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateMinimumAnnualRoyaltiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate minimum annual royalties paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateMinimumAnnualRoyaltiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregatePotentialBenchmarkPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential benchmark payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregatePotentialBenchmarkPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualExpenseIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual expense incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualExpenseIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ContributionPayableOnPerAnnumBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution payable on per annum basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ContributionPayableOnPerAnnumBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DescriptionOfFirstBenchmarkPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Description Of First Benchmark Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DescriptionOfFirstBenchmarkPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_InitialBenchmarkPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first benchmark payment due upon the initiation of the Company's first sponsored phase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_InitialBenchmarkPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseAgreementCommencingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement commencing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseAgreementCommencingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to License payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional milestones payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfAdditionalMilestonesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumRoyaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumRoyaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Sales Revenue On Which Benchmark Payments Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments maximum amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MinimumRoyaltiesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Minimum Royalties Amount Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MinimumRoyaltiesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum sales revenue on which benchmark payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ObligationsDueUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations due under contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ObligationsDueUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sub licensing income, attributable to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PotentialBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Potential Benchmark Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PotentialBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_QuarterlyExpenseIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly expense incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_QuarterlyExpenseIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_QuarterlyPaymentsUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly payments under contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_QuarterlyPaymentsUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RoyaltiesAmountPayableThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties amount payable thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RoyaltiesAmountPayableThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_CARProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_CARProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_LicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_LicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_TcellReceptorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_TcellReceptorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616872875056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Sep. 12, 2019</div></th>
<th class="th"><div>Nov. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.75%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Per share</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember', window );">MD Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair Value of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember', window );">Svb Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants fully vested upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="nump">649,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | Svb Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair Value of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,803,031<span></span>
</td>
<td class="nump">18,939,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses', window );">Placement agent fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,803,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants', window );">Non-cash inducement warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Operating Income Expense Inducement Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NonOperatingIncomeExpenseInducementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and other related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PlacementAgentFeesAndOtherRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCallOrExerciseFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the call and/or exercise rights, prices and dates of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCallOrExerciseFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616885571408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882093040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Future termination benefit payments resulting from the strategic reduction in force (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 3,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">2,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 1,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882227264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Component of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 171,070<span></span>
</td>
<td class="nump">$ 164,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies', window );">Start-up and pre-clinical studies</a></td>
<td class="nump">17,204<span></span>
</td>
<td class="nump">21,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">40,116<span></span>
</td>
<td class="nump">39,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts', window );">Capitalized acquisition costs</a></td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">2,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsResearchExpensesCapitalized', window );">Capitalized research expenses</a></td>
<td class="nump">5,156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets Gross</a></td>
<td class="nump">237,308<span></span>
</td>
<td class="nump">231,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(236,827)<span></span>
</td>
<td class="num">(230,119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxLiabilityRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(1,077)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(1,077)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DeferredTaxAssetsLeaseLiability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsResearchExpensesCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research expenses capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsResearchExpensesCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets start up and pre clinical studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxLiabilityRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability Right of Use Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxLiabilityRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616885478496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal tax benefit</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp', window );">Research and development true-up</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange', window );">Federal/state rate change</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense federal rate change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense research and development true up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616872715344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 171,070<span></span>
</td>
<td class="nump">$ 164,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets operating loss carryforwards without expire date</a></td>
<td class="nump">323,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">40,116<span></span>
</td>
<td class="nump">39,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain Tax Positions Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 665,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLossCarryforwardsExpirationDatesState', window );">Net operating loss carryforwards, expiration date</a></td>
<td class="text">2037 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember', window );">Federal and State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets operating loss carryforwards with expire date</a></td>
<td class="nump">$ 341,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLossCarryforwardsResearchExpirationDates', window );">Net operating loss carryforwards, expiration date</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember', window );">Federal and State [Member] | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 497,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLossCarryforwardsExpirationDatesState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Dates State</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLossCarryforwardsExpirationDatesState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLossCarryforwardsResearchExpirationDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Research Expiration Dates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLossCarryforwardsResearchExpirationDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616879810480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Initial Public Offering of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,410,761<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,410,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,330,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="nump">$ 47,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880500672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Additional information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options issued</a></td>
<td class="nump">10,408,622<span></span>
</td>
<td class="nump">10,665,869<span></span>
</td>
<td class="nump">6,840,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">15,460,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based payment award granted</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">1,601,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of Shares of Restricted Stock</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember', window );">Unvested Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to non-vested restricted stock outstanding</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period</a></td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember', window );">Unvested Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based payment award granted</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">1,601,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember', window );">the "2012 Plan" [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">1,066,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember', window );">the "2012 Plan" [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,089,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember', window );">the "2020 Plan" [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,066,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember', window );">the "2020 Plan" [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">9,319,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tcrt_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tcrt_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882111328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance</a></td>
<td class="nump">10,665,869<span></span>
</td>
<td class="nump">6,840,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">4,697,500<span></span>
</td>
<td class="nump">9,380,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(26,250)<span></span>
</td>
<td class="num">(363,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(4,928,497)<span></span>
</td>
<td class="num">(5,192,179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance</a></td>
<td class="nump">10,408,622<span></span>
</td>
<td class="nump">10,665,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, at end of period</a></td>
<td class="nump">3,891,598<span></span>
</td>
<td class="nump">4,410,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">15,460,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">1.08<span></span>
</td>
<td class="nump">2.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="nump">2.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">3.34<span></span>
</td>
<td class="nump">3.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance</a></td>
<td class="nump">1.84<span></span>
</td>
<td class="nump">2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, at end of period</a></td>
<td class="text">8 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, at end of period</a></td>
<td class="text">8 years 29 days<span></span>
</td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, at end of period</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616882388592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail) - Unvested Restricted Common Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance</a></td>
<td class="nump">1,198,580<span></span>
</td>
<td class="nump">786,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">1,601,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(306,617)<span></span>
</td>
<td class="num">(754,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled</a></td>
<td class="num">(232,901)<span></span>
</td>
<td class="num">(434,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance</a></td>
<td class="nump">939,062<span></span>
</td>
<td class="nump">1,198,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">0.82<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="nump">3.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="nump">3.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616885603952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined benefit plan contributions by employer</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140616880639392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Joint Venture  - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jul. 05, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember', window );">Ziopharm [Member] | Eden Bio Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest in affilated entity</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>tcrt-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:tcrt="http://alaunos.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tcrt-20221231.xsd" xlink:type="simple"/>
    <context id="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_1812d480-8b71-4f59-be40-0442f1ffcd39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_fc6223b4-e9fb-47c2-a189-b5585700a3f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_514c2c0b-94bc-4b01-a4df-1fde50325832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b9e1d219-2ee6-449a-8982-40603fb9f929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_db9a000c-2293-40ba-a556-c8c4ee3dcd25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bdb6cf3c-3394-4924-9e66-e2220477279d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e20012df-a692-4934-8738-dbd4679dcd32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_139d76d8-bc1c-4f22-909e-3ae5eccdbd1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d75e53ea-0702-44cf-9dd4-dc1d1548bebb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1450b5dd-88ba-4cc4-8794-083ce0aff494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-05</instant>
        </period>
    </context>
    <context id="C_4d9edef7-64b4-4ce3-a9b2-3242785e4741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:EightScheduledPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_f2309968-f205-40c9-9241-713fc3396454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dbb3baef-97e1-4ff6-93d5-c0d1469c37f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_614a96e6-084a-4999-9269-a5af0ea5ef99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fdd40d07-247d-493f-b328-455e4e9594e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3008e586-4932-4ef5-a77c-b2171288e27c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7b282fd7-92ce-4714-8d23-a789adb31804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_f182bcec-cb46-49ba-8ea6-3294135323d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e818d17d-8abf-499d-ad41-5a7a4b414199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a8cab28c-a6cf-4033-bee4-05aee3010971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:TenthScheduledPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_5cbfe56c-2a15-4444-a10e-cbfc6e942a3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_462e7c18-cbc4-47ba-a8c1-d1d50a7d313d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_3a6333ea-87fe-436f-953e-01fe64ba7678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0350ea77-ee99-48c3-9c29-b0c1a4050617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_a58f3578-b2b0-43dd-bd56-4371d7c586c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3310b49c-90b3-469d-a382-9cd149d1f45d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_f0441e0c-ffba-4bb9-8a1f-155209670694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e5bc8db-02a5-46a2-8adb-1290a943c626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e079d01f-15d4-407c-9a4a-2730c6e26083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_82b5c3f4-e428-4dc9-a489-d6da42ba15d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5031cbc2-7c7e-4564-8649-f11720d9f7a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_af0771c8-7bb6-4d20-b747-7a3e0f9ad3c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-11</instant>
        </period>
    </context>
    <context id="C_c65c999f-7903-41c0-85f9-01dae5de02f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7117f1c3-b39a-4248-8ab6-f843b0bbb987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_c21750f7-3aa5-4441-8546-e1bc5d4f21e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_76510e7e-f84f-4555-b284-0b2f7facecaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-13</startDate>
            <endDate>2015-01-13</endDate>
        </period>
    </context>
    <context id="C_345d7b2b-de3c-423d-87ef-dde286307576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0f55809b-c104-4cd9-a7b8-c6170ba8dc7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_e9343419-8bf1-4057-a39a-08c499c72684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcrt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_221169cc-a657-4743-838c-9c8afe3317c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1ce3d76b-39aa-4c2b-9bcd-7339fdd665a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9b23a7cb-ebe0-4b57-95ac-66f47b3626a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f1cdd995-a3b3-4a88-86cf-666181247c3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b91b4942-6a82-493e-af09-b7189d92ffaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a755066d-a762-4b1c-a9e5-da405de1577b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="C_e116f993-9fc1-4e48-bcd6-42848abbc899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f9f80da5-3640-4b51-b5d8-02726e56d225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:DueDateAxis">tcrt:PostMarketingApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_2be3c3ac-efdc-402a-827b-95ce13fc11c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_c9a1def8-4beb-497b-91ba-095a8bfe834d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3d61c456-2ac5-4ffa-a8f5-cec10246c86a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91867dd5-8c9c-41f9-a145-5e903aa8fc40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8f0471b9-3122-450c-83f4-9876302a91e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-15</startDate>
            <endDate>2019-10-15</endDate>
        </period>
    </context>
    <context id="C_83b60ee4-931e-45fb-9e47-1b18baa0e863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_70d3cfbc-3393-4744-8116-7ed62ae30d7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fcb43152-91fe-48f4-aad0-514fa76c5e42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2a9368e0-978e-4613-87fd-43031426e546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_45066dfd-98ce-4ef8-a0f8-576b77666039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_da30487a-eeaa-46ef-9c78-32283fba902d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_df3febeb-1400-4046-ac65-31f7fc0f9f28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-05</startDate>
            <endDate>2023-01-05</endDate>
        </period>
    </context>
    <context id="C_c699063c-f010-42e1-bc84-c39f93a08ca4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_556eae28-eef9-4c0d-8fae-4a6281b6012c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c21c60ee-6599-4da6-a569-17713873c52b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c51598af-80b7-4a30-ab2d-b510980f50f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_82dc65f6-769b-4678-a99c-19131c41570e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3e843951-a185-415d-86e2-e4855f371dd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="C_3be47963-40c3-4b80-8a99-5b3aa4d10c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="C_8339573a-0ca5-49ab-b505-6fdfb84cb410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_576d0b59-7299-4d46-925b-a9db2e440f2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_8efabef4-accb-458c-ac37-ad97beec741c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bff7aa86-20fe-4134-91ba-5cfb0c6a91fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_c6b3f324-362c-44db-b937-baf10fb4ec1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6402fd7d-1a53-45aa-80c2-5f9871d2d458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="C_da6bbf42-b6d9-4ce6-b86b-25c8cae6c071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="C_8974b041-067c-4f6b-b5aa-fb9b4b13e7fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e10ba7f-a809-4a04-aaaa-74a531d68803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="C_de82944d-045e-4494-962a-60bbd7316d2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_7c71e267-3b3d-41f1-9ee0-4e610cab53c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e9646e1e-5226-419c-8438-aa3071058ea6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_c8f802e5-6966-41fa-9657-aae7124cdab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_426af431-5218-40c8-82c1-1b23c2d8f820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_01541ff4-c565-4665-8fd3-c5b8b851f917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c270381e-43d4-46f3-b514-f780c08aa3f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2019-10-15</startDate>
            <endDate>2019-10-15</endDate>
        </period>
    </context>
    <context id="C_35eb5389-797d-41ed-9818-2a4c3978c31b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_ee038ec2-a0cc-48d1-b9ca-0fa12ba3bac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f8f70fa4-ffe5-4f49-b2ec-312c36fe67b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_966e453b-8a58-437f-a91f-f254719ff9b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_d6e29649-519f-4d9c-9d10-a997f6d84271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e8f1b252-50d6-4597-8b92-45eb247fae8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8c7cceef-0908-4307-8356-9235dc9862fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_cb58e662-f444-4e56-ac22-b4f9e8e90c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f707f4a5-a8e0-4111-bc42-c5d4a9d92abb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_ec21d5ba-40fd-4ef7-b050-7c8f6c9de41b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_ab1c56b6-303f-4a89-840a-261cdf06b4d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8b3d36d4-5ca7-428a-aedc-04c2cb1c1e88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-19</startDate>
            <endDate>2021-02-19</endDate>
        </period>
    </context>
    <context id="C_567da217-a1b9-4ef0-a65c-10a90ca9e5da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20b416e3-3907-4e97-9e9d-1fcba80f134c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:CARProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_e31c15e4-38b9-4777-99d9-09e923ff1ef3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e220fa7c-9256-4e4c-9029-f93345c4f771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9245beb1-9103-47f9-b176-2c032568f730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a3613417-09f3-43ff-8294-f0c33b77cc57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_735e4858-865a-4de6-850e-3aab57d7148b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_0763068f-9bd4-45a0-98fc-aef5d8ca39a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_80826595-228b-476d-8548-2b525f9d98c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-15</instant>
        </period>
    </context>
    <context id="C_56a01732-96e4-4efd-9e90-6e3312d5c45d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_b05a99fe-7e2e-4148-b7f1-089978eb0f33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d2fdd28-ac94-4045-9dd8-0480c92e9cea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_24124fdf-795d-467e-939d-a9e2516d8bd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7c4f4916-db64-490f-8174-b66da79fd2dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_4c2387b7-8249-4b21-9502-83899b598473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_812ddf85-9537-4bc2-9318-da210de34991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7396adc0-9e69-4eb0-8a3e-8adda7c5d090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9ef452a7-a519-46fd-b8a6-51b26e948a62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_2b37aa34-b800-43ee-8c0e-e716f02e6391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c4db62a-e3d4-421b-b8e8-3b6d5445b532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="C_3167c98d-e838-42ca-8ff8-0935142120e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c676932d-8885-4601-9d56-bb66cbd31327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7a975d4f-655a-404d-a576-8eb7fc9e24a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_05d52965-6300-40e4-8bfd-1ef7d46d0bed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_46e7fb2e-f1c9-4ccb-af6f-ca1ebbcc3b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_78cf1452-7b74-4f09-9764-21fb4409a94d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7ef2eeab-93c5-4783-a05f-f12f4779e164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-22</startDate>
            <endDate>2019-10-22</endDate>
        </period>
    </context>
    <context id="C_9cf1d286-3ce3-4ffb-9230-67e0f5fc09ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_308754fb-dced-4d37-8887-7c93a07410c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_677a76fa-1b6a-49f5-9473-b720f11528d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0689a730-1379-4cf7-9841-565343bbdf44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d832fa54-4683-49e7-a755-64e9d019ea0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b8ddf3ec-c36f-4b75-870a-25546c4e894f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8d865232-5799-4e0f-9833-17a27353c527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_08a67ddb-30d8-464e-a0ac-bdfb4a9ef7af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-12</startDate>
            <endDate>2019-03-12</endDate>
        </period>
    </context>
    <context id="C_591e7f11-f18d-474b-89bb-898e7e2fecca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1cf5e5f2-8735-40b8-b39f-efaad36c2475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_67e87324-3985-420c-90be-d2e08d2df27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_f0e44d18-9dbf-45ad-95e4-6d8fae70e5de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_560b8551-11ec-45b0-8d0f-cb0f5a999523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa3e31b2-77fb-40fc-bedb-7d66b32336b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f70a1072-5f3c-4803-8752-dc98e3a0c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_75f173ba-c8dd-4b99-ad6d-2a5369c1267f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d1081ead-241b-4b47-ab69-635932b5defa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1485eb13-1142-4bdb-a8fe-a487d8205fd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4418daac-e678-4e2c-be6e-3555ed9a312a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_6286a83b-0f82-4d71-9785-6d19951b5c7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <context id="C_e8ca27b4-bce0-411e-8807-6e790eaa7672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_4d61befa-1f31-42dc-852d-7c27952aa374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3ee8d1b3-28cf-4ceb-8232-ccc388824044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-04</endDate>
        </period>
    </context>
    <context id="C_3f2cc6cf-873b-457d-a3f2-2aec2c6cc50f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_371756af-d614-4bb1-a82f-4dd701f5ea21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_951f87ae-ef91-4c42-a4b4-65ab2e55e723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c9ae6604-f2d2-43d1-a9d1-f8a9f071c33f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-08-24</instant>
        </period>
    </context>
    <context id="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_19528722-40e7-41ed-a517-daad870351cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0afbd561-5066-4598-a3a2-7762df69e5a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="C_eb8415ef-ed42-43d3-bebe-c35459c15508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="C_b10c21fd-e52b-4e2e-b88e-14eff7321012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cf145b1e-8766-417b-b25d-39bde6bf3ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_019df9ac-fbae-4355-8668-11ee7fd04e38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_8e938d5a-7970-4180-afd9-341241ed6a9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_009c6c2d-9013-4f24-9a09-41485c023a44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_9367da57-38ac-4d29-b5c8-316a4a7256ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-06-01</startDate>
            <endDate>2012-06-30</endDate>
        </period>
    </context>
    <context id="C_b83280a9-1359-4007-a613-0f63cf09a0cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:LicensedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="C_28c42504-64db-4bbb-b58d-31b90866d765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_64074300-aa0c-4f1a-858f-92fd5f911176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_31452367-fd08-487e-a553-53625bcad801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_ff46e4b8-4535-4f61-bf4b-409c23561efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="C_c3245be1-2a56-4ce2-a313-9a3ec39aa110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-12</instant>
        </period>
    </context>
    <context id="C_7d794ebc-1417-4c1e-9565-4410865a0c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fdbd888b-893b-4b86-85b2-065fe730f06d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-05-31</instant>
        </period>
    </context>
    <context id="C_074d1df4-7bc9-4dcb-b16c-ddf1bdf3643f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_33682291-7fb7-4cab-a271-326647030806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_80a96828-a458-4544-8958-01676a2b66a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d20ec984-e91b-4bbd-aeea-1e39b7a6c803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_ff8881c2-6785-42ec-a5f4-f1592bc1297d">0001107421</dei:EntityCentralIndexKey>
    <tcrt:OperatingLeasesExpirationMonthAndYear
      contextRef="C_7b282fd7-92ce-4714-8d23-a789adb31804"
      id="F_135f6a9b-d35b-4744-9bd0-7a49a3ff0c93">2026-08</tcrt:OperatingLeasesExpirationMonthAndYear>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      id="F_6934d123-79b6-4d0e-9146-8913adc044ad">http://fasb.org/us-gaap/2022#OperatingLeaseLiability</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_81f602c7-d273-4d9b-b25a-6a46286cbc9c">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_f8f70fa4-ffe5-4f49-b2ec-312c36fe67b2"
      id="F_0f16ce4f-8d70-403f-b6b8-a51d4653179d">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      id="F_a5277795-d129-44d1-890a-5c034d8ecbb8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      id="F_5e15993c-8126-4ed8-af04-1256b45c6355"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_ad073aa0-791f-4f8d-9041-a81168a4a320">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_029ffade-f5dd-4bc4-b179-315c121961a8">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_dba865bf-8327-4b1d-b1eb-16c3e6d5b7f2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_2b279151-0072-499c-a64d-76e1917b18c1">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_65a61741-e566-4e37-a118-b9126ddc9169">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_e453fe25-5937-41e0-a0e6-cc0b021cb379">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_73f9b6e8-b115-4e8f-b863-33e1936d76cb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_f136aad5-f8c2-4398-b876-e9f04be68fe6">001-33038</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_0c16f4b4-ee1d-44a9-8414-a6d0793b9c14">Alaunos Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_88ed7ba5-7ef5-46f0-bf2c-19cc9ffd4c36">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_554c722c-4624-4c62-8071-9bc61f3ef9c9">84-1475642</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_95e89de4-3aba-4d1d-bfc9-2c241f64e16e">8030 El Rio Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_83b59b58-e8cf-43fa-975e-9e54993dedcf">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_82140785-efe0-4780-9850-d55883428659">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_0b73482e-c34f-4215-bc80-ba3da099058f">77054</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_34d1f9ae-f840-49b2-a649-d53df1b722f3">346</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_4747f186-8a5a-4b7a-81f6-39109d123adb">355-4099</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_a7fbdfe2-e700-478e-a981-22e3cbbc6f51">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_54e2ccff-a376-4ad4-8232-70c9171f353c">TCRT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_8aa99b0d-6cab-4bc8-8ef8-b49c8d5e53f8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_d840059a-8dc5-4739-8d04-bbe9c1e2201d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_35801883-9183-440a-9169-cfc8188c27fe">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_146a8646-f585-4717-86d7-2e4a91740a04">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_982e51f2-18dc-47a0-ac04-77d31a03b9a2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_57b1b45c-3dc3-4799-8b18-b3ad27cd483f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_8e45b81a-d7f6-4e21-a66e-18155be2bc06">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_6e93b507-5011-4a67-8b75-e266565ece3e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_b34bfd4c-73b9-4bf4-9ca1-f86d5e10a7f7">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_009974c6-295c-4920-bcd1-f5acb07a553e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_8c7cceef-0908-4307-8356-9235dc9862fd"
      decimals="0"
      id="F_3ce0361d-ad03-4594-9513-a225798be8d9"
      unitRef="U_USD">221548093</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_da6bbf42-b6d9-4ce6-b86b-25c8cae6c071"
      decimals="INF"
      id="F_7130a68f-c92a-4373-8052-8285ef2f5d16"
      unitRef="U_shares">240627055</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_f46e094b-4809-40f2-a4bf-216d5e5fe085">RSM US LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_085df8a9-cd67-46ac-9eb9-a2198e846e7c">Boston, MA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_e4273c85-6ed3-4eda-a289-a58d39206009">49</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_7172ff16-b021-48d4-8bc2-31a1f82f0f33"
      unitRef="U_USD">39058000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_115586fd-69d6-4ca6-8ad5-19ef6eb965c5"
      unitRef="U_USD">76054000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_097d29a3-87a5-41ed-82dd-e5735a2e661a"
      unitRef="U_USD">13938000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_fe1ea8fa-229d-4b7e-8e63-0d3cea0dc663"
      unitRef="U_USD">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_94c027fe-5dd2-4b78-b35d-920b70f5d48c"
      unitRef="U_USD">4000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_1724197b-ac6c-42eb-bba3-0380bfd35094"
      unitRef="U_USD">1111000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f27a910b-70d0-40eb-b0e2-d5f14089199c"
      unitRef="U_USD">799000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_43e8c6b9-5b11-4c04-9675-25f49569e1b1"
      unitRef="U_USD">1666000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_3dc78082-de66-439f-86c1-6e6e80ac79d4"
      unitRef="U_USD">53799000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_91ced3ff-3417-4f49-aa48-50ae1d2f6871"
      unitRef="U_USD">78831000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_728befe4-9279-429e-889a-307471f0ac43"
      unitRef="U_USD">8460000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_87b0d8db-8523-4e94-9fd7-3f570bb68b44"
      unitRef="U_USD">10941000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_0c0f597d-3375-4280-a26a-1194b1d185c7"
      unitRef="U_USD">2136000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_26b5a242-bbed-4967-982a-1b58adf47975"
      unitRef="U_USD">4420000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_33f49836-372d-4f37-834a-839b307901cc"
      unitRef="U_USD">42000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_07275928-79f3-49c1-8af2-021d75867458"
      unitRef="U_USD">42000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_79edff53-078a-479b-8ae8-fcdfbe8def4f"
      unitRef="U_USD">500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_e6756ea8-6e66-431c-9a19-3b718cf6261b"
      unitRef="U_USD">631000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_416a7019-b89c-45f3-9185-e60d7c688af3"
      unitRef="U_USD">64937000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_b542b287-c32c-43a4-bac8-50bfe452e326"
      unitRef="U_USD">94865000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_b51b15e5-9eac-4a8e-834d-8de4b2a8fd64"
      unitRef="U_USD">1389000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_2ea12b14-41b4-4957-9f93-5425df4560b7"
      unitRef="U_USD">1368000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_dc740979-5ab0-4727-a43b-68ad993117cc"
      unitRef="U_USD">16765000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_a10a6a5d-645d-46db-8325-698ecc688dbc"
      unitRef="U_USD">7868000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_0a5c761c-1fea-4041-ad95-b4c765370063"
      unitRef="U_USD">5454000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_3f89e9ff-298a-4b65-93e5-8229a7b931a4"
      unitRef="U_USD">6076000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_b098bcd9-1c7a-44dd-9377-6ba66969a2f9"
      unitRef="U_USD">558000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_1e80b42f-1b2d-4a30-988a-03131675c52f"
      unitRef="U_USD">729000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_cbf22107-7cce-43cf-b47c-bf4496ad6ede"
      unitRef="U_USD">24166000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_527f1334-054c-445b-a993-a356016cb6bf"
      unitRef="U_USD">16041000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f236e868-b55a-445d-8f7b-f7a545cf950a"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_7a0dfc33-25cc-4341-8575-b62ed50e0444"
      unitRef="U_USD">16250000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_0b8dd5ed-322a-4277-bb2b-0fdb5940cc41"
      unitRef="U_USD">2188000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_5586287b-e735-4249-ae4f-40f0c83082c4"
      unitRef="U_USD">4518000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_3e802e36-4a15-469b-be6e-c410f9b806c6"
      unitRef="U_USD">28000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_595f234f-e0bd-4861-a590-e4905bac1fee"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_d4e9c3fc-e3da-4401-8a7a-72a83ef18f74"
      unitRef="U_USD">26382000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_244d426f-d480-48b5-a5d7-a508b4495627"
      unitRef="U_USD">36809000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="3"
      id="F_4b6ce7f2-467a-4a3b-9692-4a40aa3d67a4"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="3"
      id="F_34fd6ac3-597a-4dbc-a3da-7c3868749c1b"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="INF"
      id="F_d75e44eb-d4c7-45d6-a360-89e37ad6e16d"
      unitRef="U_shares">420000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="INF"
      id="F_90fb4a78-cf71-4628-b155-e3df7a39ad02"
      unitRef="U_shares">240410761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="INF"
      id="F_b61477bc-f1d1-4e45-8c7a-4330ff348670"
      unitRef="U_shares">240410761</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="INF"
      id="F_a14d5a99-e6c6-4e64-a81d-361f9f0ca7ab"
      unitRef="U_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="INF"
      id="F_82ae12b3-195c-4e3c-87a6-82eaaba5399c"
      unitRef="U_shares">216127443</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="INF"
      id="F_d2c37c5c-1f50-4b30-8a19-3eeca2825134"
      unitRef="U_shares">216127443</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_15fa9ed6-5e86-4f3e-9736-b73e22ee2b23"
      unitRef="U_USD">240000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_62ce9d69-7e88-4f66-8083-42da88dbbf6d"
      unitRef="U_USD">216000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f9822866-56bc-45fd-b54f-d93c3edb832c"
      unitRef="U_USD">918942000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_acb5f090-ea1f-467c-94d6-1be1112df5b0"
      unitRef="U_USD">900693000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_9332b3ad-e4af-49f9-8eae-9eae1b2e0cd7"
      unitRef="U_USD">-880627000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_013b1fe1-9167-4070-8a99-ce89727a2391"
      unitRef="U_USD">-842852000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_64f4ea46-ce4c-4a53-b0f8-a045d016e716"
      unitRef="U_USD">38555000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_131a8478-bcbd-4fbf-ba2b-3a0b9a20fef6"
      unitRef="U_USD">58057000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_782d4d7d-9f3f-4850-9ccd-f271708778f5"
      unitRef="U_USD">64937000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_043dc2c1-9f18-489a-afbc-bc6e146d22d2"
      unitRef="U_USD">94865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_cae47a70-28d2-4a23-a19f-d67bb3c450ef"
      unitRef="U_USD">2922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_d89be63f-62af-4dbc-b972-d8407f53fb85"
      unitRef="U_USD">398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_c0d6ff39-7da6-4811-ab66-abcb4c71b043"
      unitRef="U_USD">25018000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_157a58b8-911a-4fde-939a-41dcc414baed"
      unitRef="U_USD">49643000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_d339aacd-5031-4d39-83f1-905859a88ed3"
      unitRef="U_USD">13142000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_d68c5c5b-508e-4c64-837f-ca32726dd97b"
      unitRef="U_USD">27564000</us-gaap:GeneralAndAdministrativeExpense>
    <tcrt:GainLossOnOperatingLeaseModification
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_2f8c67a6-c46a-4e92-a51e-924a4c815de8"
      unitRef="U_USD">133000</tcrt:GainLossOnOperatingLeaseModification>
    <tcrt:GainLossOnOperatingLeaseModification
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_282e2442-d0b7-4771-b4e8-e7c9d6551cf7"
      unitRef="U_USD">0</tcrt:GainLossOnOperatingLeaseModification>
    <tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_4234c4a5-18eb-4975-81b7-be6ecd0ea6e0"
      unitRef="U_USD">0</tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment>
    <tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_431b4101-c61b-46dd-a080-3dbf786895aa"
      unitRef="U_USD">740000</tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment>
    <us-gaap:OperatingExpenses
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_7b0fdd58-be75-4ba0-ac0b-6910df2e9bc6"
      unitRef="U_USD">38027000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_3f33fd6d-dd1a-4adf-82fa-56762947b828"
      unitRef="U_USD">77947000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_e0175856-2e74-45d9-b4a0-ffb43036e0c4"
      unitRef="U_USD">-35105000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_2329ae47-8d2d-45d9-a7d2-63ca4ead22cd"
      unitRef="U_USD">-77549000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_26de8741-0816-4992-b2a8-0f3adf59b7dd"
      unitRef="U_USD">3154000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_e67ca8b3-b246-4bc4-9a5c-332eccd94fa4"
      unitRef="U_USD">1189000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_bdb3b8ab-a8d6-42d3-bc56-ccd4d651f537"
      unitRef="U_USD">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_0f98a302-4206-48d4-9514-1c9c568a4ee0"
      unitRef="U_USD">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_4176aabf-19d5-419c-b5bc-57f28dc1c715"
      unitRef="U_USD">-2625000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_e26b2a63-93cc-4b01-a8fb-e515bf6faae7"
      unitRef="U_USD">-1202000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_2bc7508b-ec92-4d64-a0db-dd6947e57d1a"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_2f489ea1-7894-43ae-8041-6986448462d4"
      unitRef="U_USD">-78751000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_03b37f7c-e3aa-45da-997c-0e5514307060"
      unitRef="U_USDollarShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_ad2fe704-1842-4fee-b9fd-0e7b244bedce"
      unitRef="U_USDollarShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_6311d87e-2927-4aca-aa64-3e0b0a15f053"
      unitRef="U_USDollarShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_6daf60c0-b517-4bd5-a477-64d0923c9402"
      unitRef="U_USDollarShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_3e5c3057-6334-4052-9c14-adc27fb8a624"
      unitRef="U_shares">217130311</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_5adb9f87-e75e-4385-b0b7-089a5e59b14a"
      unitRef="U_shares">217130311</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_93e2d04c-8a99-411e-a147-3fe0d3baa604"
      unitRef="U_shares">214399074</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_fe00872d-7623-464a-a072-06cc8292a3fb"
      unitRef="U_shares">214399074</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_c51598af-80b7-4a30-ab2d-b510980f50f3"
      decimals="INF"
      id="F_7c091f84-b0fc-46de-ae2f-0d2b92f06dfd"
      unitRef="U_shares">214591906</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c51598af-80b7-4a30-ab2d-b510980f50f3"
      decimals="-3"
      id="F_a6237079-4570-4711-8588-cb3c874027d3"
      unitRef="U_USD">215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45066dfd-98ce-4ef8-a0f8-576b77666039"
      decimals="-3"
      id="F_04a8c3ba-e55c-40d6-97fd-6fc47a675913"
      unitRef="U_USD">887868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc6223b4-e9fb-47c2-a189-b5585700a3f3"
      decimals="-3"
      id="F_02294eb6-311d-4f6e-8ee5-34b338e45746"
      unitRef="U_USD">-764101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626"
      decimals="-3"
      id="F_decba051-1cf2-4d88-80b2-0a1b1e2b84e5"
      unitRef="U_USD">123982000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18"
      decimals="-3"
      id="F_2bdf1b4b-2775-4765-9f18-8efb08d130aa"
      unitRef="U_USD">10774000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_b6e19fa2-a52e-4a7c-899f-e5629857287c"
      unitRef="U_USD">10774000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d"
      decimals="INF"
      id="F_f892b32a-717a-4e41-901f-c05455246831"
      unitRef="U_shares">363109</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18"
      decimals="-3"
      id="F_2e6f28ce-54f2-47c1-9b5b-93b9ea8aae3b"
      unitRef="U_USD">1036000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_42497770-df3c-40c4-854c-b94a16d75cd2"
      unitRef="U_USD">1036000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d"
      decimals="INF"
      id="F_5b389925-9c23-4cb5-a9e2-e90b6b329071"
      unitRef="U_shares">5991</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d"
      decimals="INF"
      id="F_3ee7e818-54de-4d99-8337-acdad6745177"
      unitRef="U_shares">1601224</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d"
      decimals="-3"
      id="F_b6d7d257-465b-42cd-9bd1-b1527f06e017"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18"
      decimals="-3"
      id="F_32e5fb54-725a-4e5c-b58f-9f66f57a9777"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_da30487a-eeaa-46ef-9c78-32283fba902d"
      decimals="INF"
      id="F_72a1a5d5-9712-44cd-98f1-acc1fea80aa4"
      unitRef="U_shares">434787</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_b6130cc4-b0f4-4212-8c5e-aaea3b984c18"
      decimals="-3"
      id="F_44218142-5d21-46e4-90ba-776cf21ebb46"
      unitRef="U_USD">1016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_4a44956d-f996-46a7-80db-353206634830"
      unitRef="U_USD">1016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_33682291-7fb7-4cab-a271-326647030806"
      decimals="-3"
      id="F_daae6076-bf87-4ada-98db-8a82fab40749"
      unitRef="U_USD">-78751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_f7baecac-e675-46ce-979f-abae3a3dde2e"
      unitRef="U_USD">-78751000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_f182bcec-cb46-49ba-8ea6-3294135323d1"
      decimals="INF"
      id="F_5516448b-e135-4abd-a17a-f8f26e75f6d6"
      unitRef="U_shares">216127443</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f182bcec-cb46-49ba-8ea6-3294135323d1"
      decimals="-3"
      id="F_ff35aa78-d7d3-4a73-aecd-5d659ed50061"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c699063c-f010-42e1-bc84-c39f93a08ca4"
      decimals="-3"
      id="F_a10f6aaa-04db-4c6a-a206-42661d4a8109"
      unitRef="U_USD">900693000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5031cbc2-7c7e-4564-8649-f11720d9f7a5"
      decimals="-3"
      id="F_5c39333b-186c-487d-bd1b-a5d49cf99201"
      unitRef="U_USD">-842852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_f57df08e-797f-4a59-ae21-632bb2abb251"
      unitRef="U_USD">58057000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_308754fb-dced-4d37-8887-7c93a07410c3"
      decimals="-3"
      id="F_85237a27-9a8d-4d45-a790-df8b98d99e6d"
      unitRef="U_USD">3528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_4cbafdfb-5fab-4f11-af75-c14d58b5a48b"
      unitRef="U_USD">3528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"
      decimals="INF"
      id="F_ce47c504-3e99-48e9-b626-d7ec2d4b57e7"
      unitRef="U_shares">280000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"
      decimals="INF"
      id="F_8412fead-a5e0-4017-9cf5-65084415d1cc"
      unitRef="U_shares">232901</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"
      decimals="INF"
      id="F_72750edc-ebde-40e3-83f6-0b155d3221a0"
      unitRef="U_shares">26250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_308754fb-dced-4d37-8887-7c93a07410c3"
      decimals="-3"
      id="F_c7212c8b-1d0e-44f4-a729-3154c91ebace"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_0a7d4474-b169-4274-8b9d-3992e8bfd8c8"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"
      decimals="INF"
      id="F_9ded2cd9-be52-4ce1-8809-22af2cfaf7cb"
      unitRef="U_shares">18750</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_345d7b2b-de3c-423d-87ef-dde286307576"
      decimals="-3"
      id="F_1d301b8a-f820-4d5a-8eab-f5acba539f56"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_8cd0af24-4fff-47ea-93c6-a1d7768532d8"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <tcrt:IssuanceOfCommonStockNetOfExpensesInShares
      contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"
      decimals="INF"
      id="F_52212570-890e-4f44-92d5-3ea46a5cb8ec"
      unitRef="U_shares">24228719</tcrt:IssuanceOfCommonStockNetOfExpensesInShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a94c213d-3ded-4218-9c42-a1ad23dc05ed"
      decimals="-3"
      id="F_7abcb3b5-38d5-4412-9663-3b90b0a141c8"
      unitRef="U_USD">24000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_308754fb-dced-4d37-8887-7c93a07410c3"
      decimals="-3"
      id="F_39c3619f-441e-4331-aaac-395377e888dd"
      unitRef="U_USD">14700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_1f03de41-d037-4b6f-9364-81ff76639006"
      unitRef="U_USD">14724000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_345d7b2b-de3c-423d-87ef-dde286307576"
      decimals="-3"
      id="F_904fde00-3381-4e1f-80d2-27044aee37dd"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_8f83466b-7e51-4fe1-b2a7-92ec2e17279f"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44"
      decimals="INF"
      id="F_4bc7bde8-2e98-4860-bc1b-1b8931c90d0e"
      unitRef="U_shares">240410761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44"
      decimals="-3"
      id="F_255e7ebe-fd05-42ff-bdcf-267898fc5ea3"
      unitRef="U_USD">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_951f87ae-ef91-4c42-a4b4-65ab2e55e723"
      decimals="-3"
      id="F_1b02af35-76db-4e6f-8dd8-a9fc2cd4c8cd"
      unitRef="U_USD">918942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2b37aa34-b800-43ee-8c0e-e716f02e6391"
      decimals="-3"
      id="F_3b4df150-ae33-4924-ba57-103f45c044e3"
      unitRef="U_USD">-880627000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_a62749a5-5d8e-4d09-b52f-2bd3770f5efe"
      unitRef="U_USD">38555000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_15c81e95-e099-4774-a343-c2f31410168e"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_b6bb6769-662c-426c-bfe5-ee70179ffe8b"
      unitRef="U_USD">-78751000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_7caac82c-3f0b-45c7-9283-d047593c55a9"
      unitRef="U_USD">2759000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_df9250b7-e224-4eb1-982a-82216dfcc021"
      unitRef="U_USD">2597000</us-gaap:Depreciation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_8bcd45fc-b93e-499a-8191-0faf7c2d10de"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_86c0c5ec-1952-49b3-8f4d-fed93ff2f78f"
      unitRef="U_USD">740000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_c21e6b19-cee8-4034-94e7-0f5d6aaf551b"
      unitRef="U_USD">981000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_014d5602-b88d-42cb-b594-be66624a8ec1"
      unitRef="U_USD">383000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_ebc6b4c0-62da-4ee4-92d3-0531ea481190"
      unitRef="U_USD">3528000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_81581aae-6639-4839-ab1c-d2b88d22b5cc"
      unitRef="U_USD">10774000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_3b8fb767-4298-4007-90b7-dd9451760b5f"
      unitRef="U_USD">-2417000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_4801532c-9c2a-405b-b0f0-c695a8bf791e"
      unitRef="U_USD">352000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_1faa86f1-a859-40da-992f-c98972b74331"
      unitRef="U_USD">133000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_7880c24b-8c56-437e-a558-5deef5525097"
      unitRef="U_USD">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_0750c978-b8c9-44a6-9386-de17f3a14b59"
      unitRef="U_USD">-7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_6fa74265-3f77-4995-8936-4a7914a0ef35"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_8ee25ad4-6e05-46f2-acd9-c4daca90ff9e"
      unitRef="U_USD">-1107000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_48319163-83fb-4f0c-a1cf-8d9cb13069d5"
      unitRef="U_USD">-3555000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_edb77d69-9f59-4e66-badf-98f99a20b568"
      unitRef="U_USD">-867000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_76536071-3141-463d-9beb-5b65b429fba4"
      unitRef="U_USD">-9189000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_0d66911f-87c4-417f-a8a3-85130c8eb257"
      unitRef="U_USD">-131000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_76dd7505-7d1b-43ac-8c1d-689e402f7f20"
      unitRef="U_USD">-201000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_b5574057-e40d-43e8-bc42-fdb686e734a6"
      unitRef="U_USD">-25000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_cf76da9f-1240-41b1-97a3-296d2e4134c1"
      unitRef="U_USD">274000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_15e032df-21e8-4dfd-ad54-303bbf947bd4"
      unitRef="U_USD">-668000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_34d57191-5a62-435d-860b-a668f71ab115"
      unitRef="U_USD">-10512000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_d51623ba-f523-46fb-892d-21f637e5d2e9"
      unitRef="U_USD">-2501000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_0b5a9ca7-20cb-4bcf-94fb-351d07d81bf5"
      unitRef="U_USD">434000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_d5cd8038-07eb-4db5-8556-b1ffb9956692"
      unitRef="U_USD">28000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_b3a47637-7e6b-4d07-bdfe-d3625859a445"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_cc5413cc-5de9-4f80-b3f3-03df4f501e32"
      unitRef="U_USD">-29232000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_5002a209-4a1e-4abe-aa0a-129b7aeb3425"
      unitRef="U_USD">-61468000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_4fa056c8-2489-4d4b-a9e7-ac482476d493"
      unitRef="U_USD">216000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_9908431b-8890-4f24-9a27-16f4b833ff31"
      unitRef="U_USD">3323000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_ac0c0e10-6c96-479c-8433-c89808d5639e"
      unitRef="U_USD">23000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_f5b8b880-7118-4cb1-a0eb-4d3a9915b7af"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_7d70887f-2d09-4daf-a55b-fa5ccda77035"
      unitRef="U_USD">-193000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_9395d774-e6b7-40ae-bb92-b10f8acf86cb"
      unitRef="U_USD">-3323000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_88b9bb23-e2fa-4eab-9ead-f62f05c17e3e"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_2f8a7cd6-7754-4fba-ba15-707adc449f41"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_aa8f9b63-fc36-407f-a640-fe1077f77169"
      unitRef="U_USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_de767859-23b1-4f18-a2fd-737664ff45ea"
      unitRef="U_USD">260000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_d6bd8e49-6a4f-4932-af4f-23d29c445aef"
      unitRef="U_USD">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_e0158cec-bcee-46bb-bc4a-984afee67b0f"
      unitRef="U_USD">1036000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_282ecfc0-14fb-447b-a661-51a2e5785cf1"
      unitRef="U_USD">14724000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_027c2d04-f91d-4a25-821a-77fa5d2f1de9"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_5efdef02-edd1-4a65-b085-f71f16764470"
      unitRef="U_USD">45000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_85b42966-4f27-4aec-b22d-276746e175a7"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_5de3cf6f-46dc-4734-8bd2-f1d5a4f88772"
      unitRef="U_USD">8333000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_f310c9d0-b6f2-4a42-906a-9e385ab83c36"
      unitRef="U_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_37e7bf45-82a5-45f5-a3de-db8891fb63ba"
      unitRef="U_USD">6367000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_0e4f1916-aded-418b-88ce-8c63458e1736"
      unitRef="U_USD">25776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_2af2aa45-9496-42c2-84fa-f208c364c739"
      unitRef="U_USD">-23058000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_927abdbc-364b-4d1b-b37a-65d4a8ac8ea3"
      unitRef="U_USD">-39015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_742d0170-9d8b-4621-a5c4-83fbdaf55c6d"
      unitRef="U_USD">76054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626"
      decimals="-3"
      id="F_66665be7-2808-489c-b80f-9bbc47364ebe"
      unitRef="U_USD">115069000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_50854357-7035-4223-8028-68df7edd8869"
      unitRef="U_USD">52996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_cb920257-32d8-403b-b316-c57e39d76067"
      unitRef="U_USD">76054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_584572fe-3ff3-451e-ad3d-3d0c30e561a9"
      unitRef="U_USD">2171000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_42f188e0-f2ac-442c-a89d-598d0b0a8127"
      unitRef="U_USD">630000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_ff0c8402-b8cd-4a38-8759-bfa4a0e660a8"
      unitRef="U_USD">91000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_5a0fe2f8-62f1-4d31-bb7c-1953e6a11292"
      unitRef="U_USD">134000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_38ccb08e-2b3b-4751-8e28-33d515b5195d">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Alaunos Therapeutics, Inc., which is referred to herein as &#x201c;Alaunos,&#x201d; or the &#x201c;Company,&#x201d; is a clinical-stage oncology-focused cell therapy company developing adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company is leveraging its proprietary, non-viral &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;EGFR.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts. In May 2021, the Company announced that it will be winding down its existing Controlled IL-12 clinical program for the treatment of recurrent glioblastoma multiforme. The Company continues to seek a partner for this program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s amended and restated certificate of incorporation authorizes it to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;420,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. As of December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,410,761&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock outstanding and an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,330,964&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#x202f;The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x202f;million of cash, cash equivalents and restricted cash. The restricted cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022 is related to the Company's debt agreement (refer to Note 4, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). The Company&#x2019;s accumulated deficit at December 31, 2022 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;880.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x202f;million.&#x202f;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the fourth quarter of 2023.&#x202f;The Company&#x2019;s ability to continue operations after its current cash resources are exhausted depends on future events, including its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given, nor are within the Company's control. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44"
      decimals="INF"
      id="F_98f71493-6d89-4b5f-abd2-319d6cadc48d"
      unitRef="U_shares">420000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44"
      decimals="INF"
      id="F_c638af63-9dce-4044-b261-9caad9dfafd3"
      unitRef="U_shares">240410761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0689a730-1379-4cf7-9841-565343bbdf44"
      decimals="INF"
      id="F_54bb805a-6c7a-4eee-970e-e6ac13f32ec6"
      unitRef="U_shares">33330964</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_ae8ef4e4-9c51-44ef-b0d8-aacfe83a6366"
      unitRef="U_USD">53000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_1949a9c0-6d67-4b6c-a348-91650cf78c25"
      unitRef="U_USD">13900000</us-gaap:RestrictedCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_4d325466-bd92-48b6-88c4-e37bf976d767"
      unitRef="U_USD">-880600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <tcrt:FinancingArrangementsDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_ba07c73c-039c-4071-a9d8-a0f6e4023bc9">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2021 Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB.  The Loan and Security Agreement provided for an initial term loan of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million funded at the closing, or the Term A Tranche, with an additional tranche of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective December 28, 2021, the Company, entered into a First Amendment to the Loan and Security Agreement. We refer to the Loan and Security Agreement, as so amended, as the Amended Loan and Security Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Amended Loan and Security Agreement extended the interest-only period through August 31, 2022. Certain milestones specified in the Amended Loan and Security Agreement were not met by the Company on or prior to August 31, 2022, and therefore, the interest-only period was not extended beyond August 31, 2022. The Amended Loan and Security Agreement also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the Amended Loan and Security Agreement, the SVB Facility will mature on August 1, 2023.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Refer to Note 4, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further discussion of the Loan and Security Agreement and the Amended Loan and Security Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2022 Equity Distribution Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp;amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the year ended December 31, 2022, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; sales of the Company's common stock under the Equity Distribution Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2022 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp;amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,228,719&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, or the Firm Shares, of the Company&#x2019;s common stock to the Underwriter at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6191&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The net proceeds to the Company from the Offering were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,634,307&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;216,294&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All of the Shares sold in the Offering were sold by the Company. &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</tcrt:FinancingArrangementsDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_46e7fb2e-f1c9-4ccb-af6f-ca1ebbcc3b72"
      decimals="-5"
      id="F_51feb6de-1b4d-4ada-b243-443c5d567635"
      unitRef="U_USD">25000000.0</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_462e7c18-cbc4-47ba-a8c1-d1d50a7d313d"
      decimals="-5"
      id="F_0cd39684-6166-444e-8580-85e1d9f3dd6d"
      unitRef="U_USD">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bff7aa86-20fe-4134-91ba-5cfb0c6a91fb"
      decimals="-5"
      id="F_1b8e6f7a-49cb-4420-b079-012a8d35bcb4"
      unitRef="U_USD">50000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock
      contextRef="C_bff7aa86-20fe-4134-91ba-5cfb0c6a91fb"
      decimals="3"
      id="F_3eef1be0-c551-4830-8a16-9c17ce3ae170"
      unitRef="U_pure">0.030</tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_c9a1def8-4beb-497b-91ba-095a8bfe834d"
      decimals="INF"
      id="F_3af91b24-b6af-4db5-aaa5-7aa430d5d04b"
      unitRef="U_shares">0</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3310b49c-90b3-469d-a382-9cd149d1f45d"
      decimals="INF"
      id="F_80d4406e-65b3-4f89-ac87-4feb0a509a9d"
      unitRef="U_shares">24228719</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <tcrt:UnderwriterParOrStatedValuePerShare
      contextRef="C_6402fd7d-1a53-45aa-80c2-5f9871d2d458"
      decimals="4"
      id="F_00599fb0-f84a-4d98-951d-f552c84f4aba"
      unitRef="U_USDollarShare">0.6191</tcrt:UnderwriterParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_576d0b59-7299-4d46-925b-a9db2e440f2f"
      decimals="-5"
      id="F_1a837fc9-9299-447b-b798-9baf663041ec"
      unitRef="U_USD">14700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings
      contextRef="C_3310b49c-90b3-469d-a382-9cd149d1f45d"
      id="F_20d6a3b3-af53-4298-a98b-11415e41da73">30 days</tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings>
    <tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase
      contextRef="C_e9343419-8bf1-4057-a39a-08c499c72684"
      decimals="INF"
      id="F_609f7726-1b39-4d32-86d8-25bd31fb36b3"
      unitRef="U_shares">3634307</tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_df3febeb-1400-4046-ac65-31f7fc0f9f28"
      decimals="INF"
      id="F_8972755a-0fba-435a-bcb8-d46b9d0ae110"
      unitRef="U_shares">216294</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_8b5dc398-8218-4a9d-bb38-214dc9e538e9">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;3.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s most significant estimates and judgments used in the preparation of the financial statements are:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical trial expenses and other research and development expenses;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration agreements;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements of stock-based compensation; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. The Company did not have any material subsequent events that impacted its financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:3.681%;"/&gt;
        &lt;td style="width:5.562%;"/&gt;
        &lt;td style="width:61.116%;"/&gt;
        &lt;td style="width:5.562%;"/&gt;
        &lt;td style="width:24.08%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Life of the lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#x2019;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.809%;"/&gt;
          &lt;td style="width:1.201%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.45%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.472999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.809%;"/&gt;
          &lt;td style="width:1.201%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.45%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.472999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2022 and 2021. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair value of non-financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During 2021, following the Company's strategic restructuring and further cost reduction initiatives, the Company determined that changes in the intended use of its Boston office represented an indicator of impairment, resulting in an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the right-of-use asset. In addition, the Company impaired approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of leasehold improvements and various other assets associated with its decision to close the Company's Boston office. Refer to Note 8, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further details.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition from Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue for the year ended December 31, 2022 consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and for the year ended December 31, 2021 consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. For the years ended December 31, 2022 and 2021, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes collaboration revenue under certain of the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. The Company&#x2019;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#x2019;s election.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The terms of the Company&#x2019;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;using &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;investigative sites or other providers in connection with clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;vendors in connection with preclinical and clinical development activities; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to its prior estimates of accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#x2019;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#x2019;s common stock price over the expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized the full impact of its share-based employee payment plans in the Statements of Operations for each of the years ended December 31, 2022 and 2021 and did not capitalize any such costs on the Balance Sheets. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of compensation expense related to stock options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of compensation expense related to stock options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2021. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of compensation expense, related to restricted stock for&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2021 (refer to Note 13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents share-based compensation expense included in the Company&#x2019;s Statements of Operations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.914%;"/&gt;
          &lt;td style="width:1.567%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.313%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.567%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.639%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2022 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#x2019;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#x2019;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.179%;"/&gt;
          &lt;td style="width:1.623%;"/&gt;
          &lt;td style="width:13.438%;"/&gt;
          &lt;td style="width:1.623%;"/&gt;
          &lt;td style="width:16.137%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="bkmk_220" style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The computation of basic and diluted net loss per share consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.797%;"/&gt;
          &lt;td style="width:1.729%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.754999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.721%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.998%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;217,130,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214,399,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain shares related to some of the Company&#x2019;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2022 and 2021 as the result would be antidilutive. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Such potential common shares on December 31, 2022 and 2021 consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.845%;"/&gt;
          &lt;td style="width:1.179%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.68%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.179%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.119%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,408,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inducement stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,270,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,819,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the FASB issued Accounting Standards Update, or ASU, 2021-10, Government Assistance (Topic 832): Disclosures by Business entities about Government Assistance, which requires business entities to disclose information about certain government assistance that they receive. Entities must comply with the new disclosure requirements if they account for transactions with government entities under the (1) contribution model or (2) grant model by analogy. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842): Lessors &#x2013; Certain Leases with Variable Lease Payments, which requires lessors to classify as operating leases those leases with variable lease payments that do not depend on an index or rate if another classification (i.e. sales-type or direct financing) would result in a commencement date (&#x2018;day 1&#x2019;) selling loss. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation -  Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815- 40): Warrant modifications, which clarifies an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (e.g. warrants) that remain equity-classified after modification or exchange. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_2592a21d-e5d6-4827-9e36-dd08444adfdd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_33abe69e-d9ea-471d-a47e-7ee27517b89c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s most significant estimates and judgments used in the preparation of the financial statements are:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical trial expenses and other research and development expenses;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration agreements;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements of stock-based compensation; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_26a83469-cd6c-4b98-b668-0bf8ee08d551">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. The Company did not have any material subsequent events that impacted its financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_df5e01b2-881c-47e1-83d0-d990118cff93">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_1476391a-4c64-4371-b9cf-8afbc971ef15">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_810543e9-f23e-4c32-831c-fb333224d37e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:3.681%;"/&gt;
        &lt;td style="width:5.562%;"/&gt;
        &lt;td style="width:61.116%;"/&gt;
        &lt;td style="width:5.562%;"/&gt;
        &lt;td style="width:24.08%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Life of the lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_05d52965-6300-40e4-8bfd-1ef7d46d0bed"
      id="F_ff43fc87-a092-45cb-bf60-73ea8d2f8480">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_614a96e6-084a-4999-9269-a5af0ea5ef99"
      id="F_d2b19bee-373e-4b17-8c63-05d9f58cb0ca">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8e938d5a-7970-4180-afd9-341241ed6a9f"
      id="F_1c8da568-ee6a-423e-aae6-a4fb8324ad06">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_8974b041-067c-4f6b-b5aa-fb9b4b13e7fa"
      id="F_2c7ff4c6-4a5f-4106-9d26-13336cba967d">Life of the lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_8f6038a7-177c-47e5-bb63-b4eef41ceba8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_3fa181af-d6eb-4aaf-b953-a17d388f6aaf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#x2019;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <tcrt:WarrantsPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_e60579e9-03de-4c15-af95-36239b4b94df">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</tcrt:WarrantsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_e6020a32-b9de-4b87-a15b-96c61308d8b0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.809%;"/&gt;
          &lt;td style="width:1.201%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.45%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.472999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.809%;"/&gt;
          &lt;td style="width:1.201%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.45%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.472999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2022 and 2021. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair value of non-financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During 2021, following the Company's strategic restructuring and further cost reduction initiatives, the Company determined that changes in the intended use of its Boston office represented an indicator of impairment, resulting in an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the right-of-use asset. In addition, the Company impaired approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of leasehold improvements and various other assets associated with its decision to close the Company's Boston office. Refer to Note 8, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further details.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_6308a3e2-57b9-4f5d-ad1d-155e6621cd92">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.809%;"/&gt;
          &lt;td style="width:1.201%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.45%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.472999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.809%;"/&gt;
          &lt;td style="width:1.201%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.45%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.215%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.212%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:9.472999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f2309968-f205-40c9-9241-713fc3396454"
      decimals="-3"
      id="F_e17f05e1-0b88-47f0-85b0-522fc93dec8f"
      unitRef="U_USD">38058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ab1c56b6-303f-4a89-840a-261cdf06b4d5"
      decimals="-3"
      id="F_95ceb7ed-8010-4b69-90c5-044126373825"
      unitRef="U_USD">38058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_514c2c0b-94bc-4b01-a4df-1fde50325832"
      decimals="-3"
      id="F_e8c471b5-b663-484c-b0d1-9eadbfb36707"
      unitRef="U_USD">75222000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1485eb13-1142-4bdb-a8fe-a487d8205fd0"
      decimals="-3"
      id="F_11304882-385d-4a4c-9e2c-0d3dd3aa4969"
      unitRef="U_USD">75222000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_b4f33e1c-c0c8-467d-97c3-0aac1628e017"
      unitRef="U_USD">600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_9cf1d286-3ce3-4ffb-9230-67e0f5fc09ee"
      decimals="-5"
      id="F_c582359e-a733-457f-94da-ebeab62f8632"
      unitRef="U_USD">100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_b605ab71-14b5-4f3a-b29e-bbba538bd8da">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition from Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue for the year ended December 31, 2022 consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and for the year ended December 31, 2021 consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. For the years ended December 31, 2022 and 2021, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes collaboration revenue under certain of the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. The Company&#x2019;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#x2019;s election.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The terms of the Company&#x2019;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;using &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_60233bac-95ea-455f-aaa5-79e717bb7ca9"
      unitRef="U_USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_17d8e908-3edf-4b1f-b5c9-54750657aa9a"
      unitRef="U_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_0041ca28-9af2-4055-a207-b4b3e8aab099">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;investigative sites or other providers in connection with clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;vendors in connection with preclinical and clinical development activities; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to its prior estimates of accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_f380d88c-a008-4cff-8469-acb8be502c32">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_f11ebff0-cf96-404f-b80f-ff10ee99c887">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#x2019;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#x2019;s common stock price over the expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized the full impact of its share-based employee payment plans in the Statements of Operations for each of the years ended December 31, 2022 and 2021 and did not capitalize any such costs on the Balance Sheets. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of compensation expense related to stock options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of compensation expense related to stock options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2021. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of compensation expense, related to restricted stock for&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2021 (refer to Note 13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents share-based compensation expense included in the Company&#x2019;s Statements of Operations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.914%;"/&gt;
          &lt;td style="width:1.567%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.313%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.567%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.639%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2022 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#x2019;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#x2019;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.179%;"/&gt;
          &lt;td style="width:1.623%;"/&gt;
          &lt;td style="width:13.438%;"/&gt;
          &lt;td style="width:1.623%;"/&gt;
          &lt;td style="width:16.137%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c6b3f324-362c-44db-b937-baf10fb4ec1a"
      decimals="-5"
      id="F_3bc68897-8c8e-410b-a244-598553b50a58"
      unitRef="U_USD">3000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c676932d-8885-4601-9d56-bb66cbd31327"
      decimals="-5"
      id="F_d9dc7371-1597-41ad-92de-f6533c766b22"
      unitRef="U_USD">7400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f0441e0c-ffba-4bb9-8a1f-155209670694"
      decimals="-5"
      id="F_90a6ee60-9205-42bc-b793-3ddac652ab9e"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d832fa54-4683-49e7-a755-64e9d019ea0c"
      decimals="-5"
      id="F_e3e32c17-d75c-4f3f-bf02-efd298c71e98"
      unitRef="U_USD">3400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_221169cc-a657-4743-838c-9c8afe3317c0"
      decimals="-5"
      id="F_e4ef57a1-b6b1-47df-8e9f-5751686d4907"
      unitRef="U_USD">3500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_db9a000c-2293-40ba-a556-c8c4ee3dcd25"
      decimals="-5"
      id="F_040f68ec-63c3-4ff4-a854-b9dc21501e59"
      unitRef="U_USD">10800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_1bb722f9-95e7-468a-95a5-948f617323dd">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents share-based compensation expense included in the Company&#x2019;s Statements of Operations:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.914%;"/&gt;
          &lt;td style="width:1.567%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.313%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.567%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.639%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_567da217-a1b9-4ef0-a65c-10a90ca9e5da"
      decimals="-3"
      id="F_d5605fa2-03fc-4097-bcae-183140503395"
      unitRef="U_USD">868000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4c2387b7-8249-4b21-9502-83899b598473"
      decimals="-3"
      id="F_69f07553-66b4-49d0-a550-607dc9dfc84d"
      unitRef="U_USD">2598000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_560b8551-11ec-45b0-8d0f-cb0f5a999523"
      decimals="-3"
      id="F_ecdade76-da26-4a20-9b0e-f1e26b7d3c55"
      unitRef="U_USD">2660000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_426af431-5218-40c8-82c1-1b23c2d8f820"
      decimals="-3"
      id="F_549cd227-8cd0-4c3e-9fb4-088dba9f04be"
      unitRef="U_USD">8176000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_5c329ccf-d52f-4f91-828a-28e007e30828"
      unitRef="U_USD">3528000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_7a637904-a522-4324-beb5-b192fd15eb33"
      unitRef="U_USD">10774000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="INF"
      id="F_3395a167-d5f3-435e-9651-51d760f01b1b"
      unitRef="U_USDollarShare">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="INF"
      id="F_bff1385c-9687-4b4e-9d2c-c2c042d22462"
      unitRef="U_USDollarShare">2.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_1c3f0f43-735e-407b-9ca9-fda3a23ba419">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.179%;"/&gt;
          &lt;td style="width:1.623%;"/&gt;
          &lt;td style="width:13.438%;"/&gt;
          &lt;td style="width:1.623%;"/&gt;
          &lt;td style="width:16.137%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="4"
      id="F_489ed37e-16fe-496c-a238-a985717b24c9"
      unitRef="U_pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="4"
      id="F_50e59563-1753-4b40-acad-919857c51d8b"
      unitRef="U_pure">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="4"
      id="F_cc9f95dc-e0af-483f-88e0-a184d9d4d013"
      unitRef="U_pure">0.0050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="4"
      id="F_d0570ce9-29a7-48a2-8791-04cbaae6fbf8"
      unitRef="U_pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e116f993-9fc1-4e48-bcd6-42848abbc899"
      id="F_0c4a7b64-591f-427a-8f01-010854425105">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_82dc65f6-769b-4678-a99c-19131c41570e"
      id="F_9a14b123-c3fe-4bdd-aac3-306840b3c6ac">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_dbb3baef-97e1-4ff6-93d5-c0d1469c37f6"
      id="F_27bd2f83-0b14-4485-bae0-b6f79ca04a5d">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_19528722-40e7-41ed-a517-daad870351cc"
      id="F_9de2f4ad-7e1e-4548-af4b-0404bc858bf9">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="4"
      id="F_414b26fa-3900-47fe-ade8-cc64c98d2b73"
      unitRef="U_pure">0.7449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="4"
      id="F_0ca3b562-218c-468f-8be2-cacd7f776398"
      unitRef="U_pure">0.8875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="4"
      id="F_b3a2a075-0f07-466c-b3bd-c9f300471b81"
      unitRef="U_pure">0.7253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="4"
      id="F_ce07846a-f351-47a2-9d7d-73f2abe519ae"
      unitRef="U_pure">0.7480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_e01b2a13-dcfc-4f30-9e06-5c2737d19e23">&lt;p id="bkmk_220" style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The computation of basic and diluted net loss per share consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.797%;"/&gt;
          &lt;td style="width:1.729%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.754999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.721%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.998%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;217,130,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214,399,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain shares related to some of the Company&#x2019;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2022 and 2021 as the result would be antidilutive. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Such potential common shares on December 31, 2022 and 2021 consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.845%;"/&gt;
          &lt;td style="width:1.179%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.68%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.179%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.119%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,408,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inducement stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,270,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,819,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_2a53014d-0e27-41b5-aadb-889eabeb0745">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The computation of basic and diluted net loss per share consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.797%;"/&gt;
          &lt;td style="width:1.729%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.754999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.721%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.998%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;217,130,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214,399,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_a993f264-de26-422b-93e5-0fa34a8a18c6"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_a9e45f26-8295-481f-80f5-d872584ee780"
      unitRef="U_USD">-78751000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_94c34ee5-a068-464b-9e73-58608753939e"
      unitRef="U_shares">217130311</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_bab83419-f73e-446b-ad96-7ff3ab4d340d"
      unitRef="U_shares">217130311</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_63303800-81cf-420e-8aa9-bcdbc816b80e"
      unitRef="U_shares">214399074</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_818cb869-6c5e-43df-bebc-9c390c12dd53"
      unitRef="U_shares">214399074</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_aabfc372-b600-4493-90b7-9d29229a2fbe"
      unitRef="U_USDollarShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_926d726c-cd94-4d41-898c-be18854132fe"
      unitRef="U_USDollarShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_0083c092-b0f0-4792-92ca-ec8ff29455ed"
      unitRef="U_USDollarShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_e5bd5a51-6a38-4b07-8046-3d34f365c867"
      unitRef="U_USDollarShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_ddd51864-b623-4902-ae94-73c0e2a5211b">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Such potential common shares on December 31, 2022 and 2021 consist of the following:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.845%;"/&gt;
          &lt;td style="width:1.179%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.68%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.179%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.119%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,408,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inducement stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,270,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,819,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_591e7f11-f18d-474b-89bb-898e7e2fecca"
      decimals="0"
      id="F_6fb21cc0-67a0-4164-b236-7e99ea49a8ff"
      unitRef="U_shares">10408622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b10c21fd-e52b-4e2e-b88e-14eff7321012"
      decimals="0"
      id="F_5ceff850-6185-47ee-b6ae-570ba424c033"
      unitRef="U_shares">10665869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2a9368e0-978e-4613-87fd-43031426e546"
      decimals="0"
      id="F_f6cc4f9b-fa5a-4077-80ba-50007abcea38"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b91b4942-6a82-493e-af09-b7189d92ffaf"
      decimals="0"
      id="F_eb50ae85-83e5-4ef8-853b-214d878ce742"
      unitRef="U_shares">32500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9b23a7cb-ebe0-4b57-95ac-66f47b3626a5"
      decimals="0"
      id="F_ba58e3b9-4f8a-4572-97b4-611418e0c3b9"
      unitRef="U_shares">939062</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7c71e267-3b3d-41f1-9ee0-4e610cab53c4"
      decimals="0"
      id="F_13a1d650-0420-48e3-b3e1-313b7c43f8f4"
      unitRef="U_shares">1198580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cb58e662-f444-4e56-ac22-b4f9e8e90c73"
      decimals="0"
      id="F_ddd74074-79ba-4598-8648-22ab0a06798f"
      unitRef="U_shares">22922342</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8efabef4-accb-458c-ac37-ad97beec741c"
      decimals="0"
      id="F_22510aba-2fe2-4a4e-b13a-5526ea2e99cc"
      unitRef="U_shares">22922342</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_5f0a9bf1-1eec-410e-af70-7af958da183d"
      unitRef="U_shares">34270026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_be579284-8f29-4e95-b829-84f0a2c52023"
      unitRef="U_shares">34819291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_30a07fe5-8747-419f-a6f1-faddf37fc05a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the FASB issued Accounting Standards Update, or ASU, 2021-10, Government Assistance (Topic 832): Disclosures by Business entities about Government Assistance, which requires business entities to disclose information about certain government assistance that they receive. Entities must comply with the new disclosure requirements if they account for transactions with government entities under the (1) contribution model or (2) grant model by analogy. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842): Lessors &#x2013; Certain Leases with Variable Lease Payments, which requires lessors to classify as operating leases those leases with variable lease payments that do not depend on an index or rate if another classification (i.e. sales-type or direct financing) would result in a commencement date (&#x2018;day 1&#x2019;) selling loss. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation -  Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815- 40): Warrant modifications, which clarifies an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (e.g. warrants) that remain equity-classified after modification or exchange. The Company adopted this standard effective January 1, 2022, with no material impact upon adoption.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_de6560d6-6d7a-45a3-88dc-ba89903cdaae">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Debt&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying values of the Company's debt obligation were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.069%;"/&gt;
        &lt;td style="width:1.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.719%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.962%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized discount on Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: long-term debt, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement. The Loan and Security Agreement provided for an initial term loan of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million funded at the closing, with an additional tranche of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million available if certain funding and clinical milestones were met by August 31, 2022. On December 28, 2021, the Company entered into the Amended Loan and Security Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the Amended Loan and Security Agreement, the SVB Facility was modified to eliminate the additional $25.0 million tranche, which remained unfunded, leaving only the initial $25.0 million as the full amount available under the SVB Facility. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and (b) the current published U.S. prime rate, plus a margin of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, interest on the outstanding loans was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022.  Commencing on September 1, 2022, aggregate outstanding borrowings became repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All outstanding obligations under the Amended Loan and Security Agreement are due and payable on&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; August 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will also owe SVB &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the original principal amounts borrowed as a final payment. The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, of the SVB Facility, each such prepayment to be at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million plus all accrued and unpaid interest on the portion being prepaid.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of not achieving certain milestones specified in the Amended Loan and Security Agreement on or prior to August 31, 2022, the Company was required to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the original principal amount of the SVB Facility. As of December 31, 2022, the Company has collateralized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is classified as restricted cash on the Balance Sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of the Company&#x2019;s properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with its entry into the Loan and Security Agreement, the Company issued to SVB warrants to purchase (i) up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,844&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, in the aggregate, and (ii) up to an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,842&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with its entry into the Amended Loan and Security Agreement, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;649,615&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, in the aggregate, at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, or the SVB Warrants. The SVB Warrants expire on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 6, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and primarily related to the warrants issued to SVB, which will be amortized into interest expense over the period to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Interest expense, including the amortization of issuance costs, was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of the Amended Loan and Security Agreement as of December 31, 2022 approximates its face value.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_027c4b2b-9303-46ec-90e1-3c10ca8ae3a1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying values of the Company's debt obligation were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.069%;"/&gt;
        &lt;td style="width:1.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.719%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.962%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized discount on Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: long-term debt, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_80a96828-a458-4544-8958-01676a2b66a9"
      decimals="-3"
      id="F_b78411ee-6784-4623-b4dd-0c18b8582e5e"
      unitRef="U_USD">17395000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_d6e29649-519f-4d9c-9d10-a997f6d84271"
      decimals="-3"
      id="F_92e799f4-f8c6-43e5-8483-e0f86cb15250"
      unitRef="U_USD">25209000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_80a96828-a458-4544-8958-01676a2b66a9"
      decimals="-3"
      id="F_2c24eb30-22b6-48a8-bbc3-a94d964e4808"
      unitRef="U_USD">630000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_d6e29649-519f-4d9c-9d10-a997f6d84271"
      decimals="-3"
      id="F_35a88c76-a584-4ed9-a1f2-c44515c839d0"
      unitRef="U_USD">1091000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f46bd1a1-a53a-46c7-974c-874357cd6311"
      unitRef="U_USD">16765000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_3499082a-e831-4693-a197-103f9da6fac8"
      unitRef="U_USD">24118000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_e699edb9-54f3-4a41-a918-e2ec30d0f0b0"
      unitRef="U_USD">16765000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_a7e902e1-70c8-40ad-bc33-f8d3af8f339b"
      unitRef="U_USD">7868000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_b3e4a9c1-a50f-468b-9f85-907ff59f576a"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_1b41855d-bf74-4ef7-a7b8-9d50a4b8d851"
      unitRef="U_USD">16250000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_c21750f7-3aa5-4441-8546-e1bc5d4f21e6"
      decimals="-5"
      id="F_751486f5-bceb-470f-9696-704f2fedc35f"
      unitRef="U_USD">25000000.0</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_c21750f7-3aa5-4441-8546-e1bc5d4f21e6"
      decimals="-5"
      id="F_a50ebae1-334b-4084-8492-00d1d5f7eb43"
      unitRef="U_USD">25000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_70d3cfbc-3393-4744-8116-7ed62ae30d7e"
      id="F_ed8a42c1-bb56-41fb-9001-75b0552632b3">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a"
      decimals="4"
      id="F_0b50512a-5d99-4c31-aeb6-cc9d10b8d068"
      unitRef="U_pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_3f2cc6cf-873b-457d-a3f2-2aec2c6cc50f"
      decimals="3"
      id="F_b741b889-b160-4c57-9e37-7c7f9efd3fd2"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_e20012df-a692-4934-8738-dbd4679dcd32"
      decimals="4"
      id="F_7dfb90bb-eec9-48da-ac9e-f956ec78412d"
      unitRef="U_pure">0.1200</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="C_70d3cfbc-3393-4744-8116-7ed62ae30d7e"
      id="F_de1f0b17-5dfd-4511-bd6c-9ca148ac3467">2023-08-01</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
      contextRef="C_0f55809b-c104-4cd9-a7b8-c6170ba8dc7d"
      id="F_3061bab0-2e9c-4ed8-b086-70685a38c4e9">The Company will also owe SVB 5.75% of the original principal amounts borrowed as a final payment. The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from 1.00% to 2.00%, of the SVB Facility, each such prepayment to be at least $5.0 million plus all accrued and unpaid interest on the portion being prepaid.</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment
      contextRef="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a"
      decimals="4"
      id="F_9c064155-d18e-4cc2-aaa0-e4e072dc8c75"
      unitRef="U_pure">0.0575</tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment>
    <tcrt:PercentageOfPrepaymentsPremium
      contextRef="C_3167c98d-e838-42ca-8ff8-0935142120e8"
      decimals="4"
      id="F_00f5e902-dc38-4148-ae0d-121a77b59a00"
      unitRef="U_pure">0.0100</tcrt:PercentageOfPrepaymentsPremium>
    <tcrt:PercentageOfPrepaymentsPremium
      contextRef="C_91867dd5-8c9c-41f9-a145-5e903aa8fc40"
      decimals="4"
      id="F_67937aef-e04a-40fa-8f7c-ee92012058dd"
      unitRef="U_pure">0.0200</tcrt:PercentageOfPrepaymentsPremium>
    <tcrt:DebtInstrumentPrepaymentPremium
      contextRef="C_0f55809b-c104-4cd9-a7b8-c6170ba8dc7d"
      decimals="-5"
      id="F_4703543f-fd8a-451e-8d45-33162d0eee56"
      unitRef="U_USD">5000000.0</tcrt:DebtInstrumentPrepaymentPremium>
    <tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment
      contextRef="C_918479d5-af10-42c7-bdc8-c0f0ec819c3a"
      decimals="4"
      id="F_2ae6c70e-dc66-4ec6-adb8-48f90817166f"
      unitRef="U_pure">0.0575</tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment>
    <us-gaap:RestrictedCash
      contextRef="C_b05a99fe-7e2e-4148-b7f1-089978eb0f33"
      decimals="-5"
      id="F_189a8273-367f-4e95-9d56-922dca010562"
      unitRef="U_USD">13900000</us-gaap:RestrictedCash>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_4d9edef7-64b4-4ce3-a9b2-3242785e4741"
      decimals="-5"
      id="F_94bd1b6f-779c-4ef2-b490-3199475ef602"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_a8cab28c-a6cf-4033-bee4-05aee3010971"
      decimals="-5"
      id="F_78755d7e-b0a1-4cd5-a41e-fd88441a8881"
      unitRef="U_USD">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_e9646e1e-5226-419c-8438-aa3071058ea6"
      decimals="INF"
      id="F_3fa366a7-a691-4e9e-987d-dcd298201d51"
      unitRef="U_shares">432844</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <tcrt:AdditionalNumberOfWarrantsIssued
      contextRef="C_e9646e1e-5226-419c-8438-aa3071058ea6"
      decimals="INF"
      id="F_20129aa3-424c-4011-8637-b3da73511990"
      unitRef="U_shares">432842</tcrt:AdditionalNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e9646e1e-5226-419c-8438-aa3071058ea6"
      decimals="2"
      id="F_1a85f03b-3cc2-4407-8c14-2eed6dd5ad67"
      unitRef="U_USDollarShare">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="C_35eb5389-797d-41ed-9818-2a4c3978c31b"
      decimals="INF"
      id="F_9c4d8ca3-30f1-4998-8c74-97e52afa2dab"
      unitRef="U_shares">649615</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_31452367-fd08-487e-a553-53625bcad801"
      decimals="2"
      id="F_8f480602-a57d-495d-978d-e49531469698"
      unitRef="U_USDollarShare">1.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:WarrantsExpirationDate
      contextRef="C_35eb5389-797d-41ed-9818-2a4c3978c31b"
      id="F_767ae0d7-29df-42ad-ad9c-13f8a7738be3">2031-08-06</tcrt:WarrantsExpirationDate>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_1812d480-8b71-4f59-be40-0442f1ffcd39"
      decimals="-5"
      id="F_1fbd75c6-7932-4b65-a406-cacb1dae974f"
      unitRef="U_USD">1200000</us-gaap:DeferredFinanceCostsNet>
    <tcrt:InterestExpenseAmortizedDate
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_2317d352-4544-49d9-9479-adfb64f245bc">2023-08-01</tcrt:InterestExpenseAmortizedDate>
    <us-gaap:InterestExpenseDebt
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_377ea848-6c1c-4689-80c1-3b8f23b8ed68"
      unitRef="U_USD">3200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_ab75f5dc-20b6-43d4-8ac2-5d3f9c53a4c4"
      unitRef="U_USD">1200000</us-gaap:InterestExpenseDebt>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_7ee4cc0a-c8e0-4edb-b6a1-248a896f23ba">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;5.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net, consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.417%;"/&gt;
        &lt;td style="width:1.663%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.576%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.447%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.898%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense for the year ended December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021. During the year ended December 31, 2021, the Company impaired property and equipment by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Refer to Note 3, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for further details.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_ae159a83-2578-4c98-a105-fc306089d006">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net, consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.417%;"/&gt;
        &lt;td style="width:1.663%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.576%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.447%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.898%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_24124fdf-795d-467e-939d-a9e2516d8bd0"
      decimals="-3"
      id="F_6f6154d7-31db-433d-8e61-ac475f2bbed3"
      unitRef="U_USD">2183000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b8ddf3ec-c36f-4b75-870a-25546c4e894f"
      decimals="-3"
      id="F_46e4b076-1abe-4ebf-9899-6a3cbe51cdc5"
      unitRef="U_USD">2534000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_64074300-aa0c-4f1a-858f-92fd5f911176"
      decimals="-3"
      id="F_2aedefe6-f0fd-4ce3-a73c-365443840b92"
      unitRef="U_USD">1291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0763068f-9bd4-45a0-98fc-aef5d8ca39a4"
      decimals="-3"
      id="F_965821cd-559c-47cd-b91f-6d7da25f280d"
      unitRef="U_USD">1236000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_812ddf85-9537-4bc2-9318-da210de34991"
      decimals="-3"
      id="F_9ba05a1a-d019-4ff5-a431-c8f70a6a0dc1"
      unitRef="U_USD">9561000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e818d17d-8abf-499d-ad41-5a7a4b414199"
      decimals="-3"
      id="F_09ad75a5-5eef-40a1-a408-bc40a3f54d74"
      unitRef="U_USD">9474000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5cbfe56c-2a15-4444-a10e-cbfc6e942a3d"
      decimals="-3"
      id="F_9df5672b-792f-49c8-8818-743949c2c4a8"
      unitRef="U_USD">5232000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c21c60ee-6599-4da6-a569-17713873c52b"
      decimals="-3"
      id="F_aff2753f-edf9-485a-aa7e-1c605a8c5828"
      unitRef="U_USD">5110000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f4d55cf3-3df4-41b5-9aae-b1e4833a619b"
      unitRef="U_USD">18267000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_df7e8586-cb3c-4a76-ac31-3e7ddde46115"
      unitRef="U_USD">18354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_8b9727ec-473d-4608-ad18-92556ceee89a"
      unitRef="U_USD">9807000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_880d049c-560b-4312-880c-465b262611da"
      unitRef="U_USD">7413000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_cf373849-879f-4309-8eb2-99bb5f53dcc2"
      unitRef="U_USD">8460000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_6e59c5db-1eb7-46d9-8df8-63ec45f87419"
      unitRef="U_USD">10941000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_c47ad1d6-ff44-477d-8d2b-36224c88699f"
      unitRef="U_USD">2800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_e36cb2cc-4373-40d1-acdb-7d09c525af96"
      unitRef="U_USD">2600000</us-gaap:Depreciation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_9cf1d286-3ce3-4ffb-9230-67e0f5fc09ee"
      decimals="-5"
      id="F_a5042c63-fc7e-41f1-8a5e-7c1e03245145"
      unitRef="U_USD">100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_9bcce895-825d-4fd2-871d-4c7947d04e8f">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;6.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.696%;"/&gt;
        &lt;td style="width:1.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.969%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.969%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Preclinical services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Manufacturing services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_7d22648d-2a52-4723-93d0-cc91ef66dc1f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.696%;"/&gt;
        &lt;td style="width:1.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.969%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.969%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Preclinical services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Manufacturing services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <tcrt:AccruedClinicalExpensesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_a4568c6b-44c4-41b1-88bd-c1461d4bfe96"
      unitRef="U_USD">2200000</tcrt:AccruedClinicalExpensesCurrent>
    <tcrt:AccruedClinicalExpensesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_96069e77-a461-44d2-be97-9a3d6d8bbe9b"
      unitRef="U_USD">1677000</tcrt:AccruedClinicalExpensesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_d0865073-4aaf-4d8d-882a-4f1649829002"
      unitRef="U_USD">1160000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_f673056a-bcff-4aa7-8027-b7bbbf3084ca"
      unitRef="U_USD">1922000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_84f2237e-1fb8-4abf-9fb2-455576ed556b"
      unitRef="U_USD">534000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_95999147-2007-40c7-9428-070337a75dd3"
      unitRef="U_USD">825000</us-gaap:AccruedProfessionalFeesCurrent>
    <tcrt:AccruedPreclinicalServicesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_c493ea73-b87c-47fb-9249-78afa2923316"
      unitRef="U_USD">198000</tcrt:AccruedPreclinicalServicesCurrent>
    <tcrt:AccruedPreclinicalServicesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_8dec97e6-25d6-40b6-8728-daee25cb0c55"
      unitRef="U_USD">363000</tcrt:AccruedPreclinicalServicesCurrent>
    <tcrt:AccruedManufacturingCostsCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_40d2798e-87bf-4166-8f00-5713b97a71d4"
      unitRef="U_USD">1177000</tcrt:AccruedManufacturingCostsCurrent>
    <tcrt:AccruedManufacturingCostsCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_53c6e4e1-2aab-4a4e-a5bb-74a7b0088bb0"
      unitRef="U_USD">1056000</tcrt:AccruedManufacturingCostsCurrent>
    <tcrt:AccruedConsultingFeesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_388b467e-0ef5-443a-9d47-e6f149a88a3d"
      unitRef="U_USD">16000</tcrt:AccruedConsultingFeesCurrent>
    <tcrt:AccruedConsultingFeesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_00448718-1ac6-4bc6-b39d-17d16d7b4add"
      unitRef="U_USD">66000</tcrt:AccruedConsultingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_97e967d9-8882-4d29-968f-4e30a3e929d5"
      unitRef="U_USD">169000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_e7f1ffff-3aa4-4b86-a2bd-d040259c4813"
      unitRef="U_USD">167000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_55f3f908-8c32-4478-8b7c-c5c4382726c1"
      unitRef="U_USD">5454000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_68c0ace7-4105-4b90-9dbf-787a342c665c"
      unitRef="U_USD">6076000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_45f7d390-2c4d-4d4e-8f90-7ea8e7259956">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;7.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration with Vineti Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc., or Vineti. Pursuant to the agreements, Vineti is developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#x2019;s T-cell therapy, or TCR-T, clinical programs. Heidi Hagen, who became a director of the Company in June 2019 and resigned November 2, 2021 and was appointed the Company's interim Chief Executive Officer on February 25, 2021 and resigned on August 30, 2021, is a co-founder and former officer, of Vineti. During the year ended December 31, 2022, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t incur expenses for services performed by Vineti, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;WaterMill Settlement Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 4, 2021, the Company entered into an agreement, or the Settlement Agreement, with WaterMill Asset Management Corp. and Robert W. Postma, or collectively, the WaterMill Parties. Pursuant to the Settlement Agreement, the Company increased the size of its board of directors from eight to nine directors and appointed Mr. Postma to fill the newly created directorship.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with the Settlement Agreement, the Company agreed to reimburse the WaterMill Parties for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of their reasonable out-of-pocket expenses in connection with (i) the WaterMill Parties' solicitation of written consents from our stockholders to vote in favor of certain proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October 30, 2020, and (ii) the negotiation, execution, and effectuation of the Settlement Agreement. As of February 19, 2021, the Company has fully reimbursed the WaterMill Parties an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Joint Venture with TriArm Therapeutics/Eden BioCell&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies in the People&#x2019;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm has contributed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to Eden BioCell and has committed up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to this joint venture. TriArm also manages all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang is the Chair of the Company's board of directors and has been a director since July 2020. He also serves as a member of Eden BioCell&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021, Eden BioCell incurred a net loss and the Company continues to have no commitment to fund its operations. In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity is in the process of being dissolved. Refer to Note 15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
      contextRef="C_1ce3d76b-39aa-4c2b-9bcd-7339fdd665a9"
      decimals="0"
      id="F_2284cafc-0d71-4175-a0b7-c33bdca58931"
      unitRef="U_USD">0</tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees>
    <tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
      contextRef="C_f0e44d18-9dbf-45ad-95e4-6d8fae70e5de"
      decimals="-5"
      id="F_4c3bf61d-3173-4537-844b-653f0084c912"
      unitRef="U_USD">400000</tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees>
    <tcrt:PocketExpenses
      contextRef="C_3ee8d1b3-28cf-4ceb-8232-ccc388824044"
      decimals="-5"
      id="F_e7f10ca6-89bd-4cc7-8445-5c31d107393c"
      unitRef="U_USD">400000</tcrt:PocketExpenses>
    <tcrt:RelatedPartyTransactionReimbursedAmount
      contextRef="C_8b3d36d4-5ca7-428a-aedc-04c2cb1c1e88"
      decimals="-5"
      id="F_05e669c0-c288-46f1-a9cd-6044cc96b895"
      unitRef="U_USD">400000</tcrt:RelatedPartyTransactionReimbursedAmount>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="C_2e10ba7f-a809-4a04-aaaa-74a531d68803"
      decimals="-5"
      id="F_3ee4e500-1325-4e3c-814c-bb55b17109c8"
      unitRef="U_USD">10000000.0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <tcrt:AdditionalLoansCommitted
      contextRef="C_0afbd561-5066-4598-a3a2-7762df69e5a3"
      decimals="-5"
      id="F_a91c71f4-d198-4a12-9d1c-96275e12c1cf"
      unitRef="U_USD">25000000.0</tcrt:AdditionalLoansCommitted>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_0025754c-2859-4be1-b087-52437123b968">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;8.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2012, the Company entered into a master lease for the Company&#x2019;s office in Boston, Massachusetts, which was originally set to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2016&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, but was renewed through August 31, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 22, 2021, the Company extended its lease for a portion of office space in Boston. The renewal of the portion of the Company's office space was originally set to expire on August 31, 2021, but was extended through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_135f6a9b-d35b-4744-9bd0-7a49a3ff0c93;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, and December 31, 2021, a total security deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million is included in deposits on the Company&#x2019;s balance sheet. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2021, the Company made the decision to move its operations away from its former corporate office in Boston. As described in Note 3, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company's change in the intended use of the Boston office represented an indicator of impairment. The Company determined the aggregate carrying value of the asset group (approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2021) was in excess of the aggregate estimated fair value and recorded an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the right-of-use asset and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to associated property and equipment during the year ended December 31, 2021. The fair value was determined based on the amount and timing of estimated net future cash flows, discounted at a risk-adjusted rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 12, 2019, the Company entered into a lease agreement for office and lab space in Houston, Texas at MD Anderson through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under the terms of the lease agreement, the Company leases approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,038&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;feet and was required to make rental payments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;an average monthly rate of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand through April 2021. On October 15, 2019, the Company entered into a lease agreement for additional office and laboratory space in Houston through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under the terms of the lease, the Company leases from MD Anderson, approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,443&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet and is initially required to make rental payments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand per month through February 2027, subject to an annual base rent increase of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% throughout the term. Effective April 7, 2020, the Company leased an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,594&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet from MD Anderson. The Company is initially required to make rental payments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand per month through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, subject to an annual base rent increase of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% throughout the term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 15, 2020, the Company entered into a second agreement with MD Anderson to lease additional space on MD Anderson&#x2019;s campus (the &#x201c;2020 Lease&#x201d;). The Company is initially required to make rental payments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand per month through April 2028, subject to an annual base rent increase of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% throughout the term beginning in April 2023. The 2020 Lease may be extended for one additional five-year term at the Company's election.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2022, the Company modified the 2020 Lease, which reduced the Company's leased space from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,228&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million based on revised lease payments. A gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded on the lease modification during the year ended December 31, 2022. The Company is initially required to make payments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand per month through April 2028, subject to an annual base rent increase of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% throughout the term. The 2020 Lease may be extended for one additional five-year term at the Company's election.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="bkmk_231" style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.343%;"/&gt;
        &lt;td style="width:1.836%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.988000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.836%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for amounts included in the measurement of the lease liabilities for the year-ended December 31, 2022. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize new operating lease assets obtained in exchange for operating lease liabilities for the year-ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the maturities of the Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_6934d123-79b6-4d0e-9146-8913adc044ad;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.093%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:24.346%;"/&gt;
        &lt;td style="width:11.972%;"/&gt;
        &lt;td style="width:1.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.1%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2022, the Company executed an agreement to sub-sublease &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,772&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of subleased office space in Boston. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; For the year ended December 31, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in lease income, which is classified within other income (expense), net in the Statement of Operations. Under the current terms of the agreement, lease income for the remainder of the sub-sublease term is expected to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2023, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2024 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <tcrt:OperatingLeasesExpirationMonthAndYear
      contextRef="C_9367da57-38ac-4d29-b5c8-316a4a7256ab"
      id="F_b6138b52-7e09-44a0-8f30-670690f6d48c">2016-08</tcrt:OperatingLeasesExpirationMonthAndYear>
    <tcrt:SubleaseTermCommencedEndDateAmendment
      contextRef="C_a58f3578-b2b0-43dd-bd56-4371d7c586c7"
      id="F_84bd0ed9-0c3b-40df-811d-b631d1e6d9ff">2026-08-31</tcrt:SubleaseTermCommencedEndDateAmendment>
    <us-gaap:SecurityDeposit
      contextRef="C_556eae28-eef9-4c0d-8fae-4a6281b6012c"
      decimals="-5"
      id="F_01231387-6f22-48dc-a835-a655108249cb"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_074d1df4-7bc9-4dcb-b16c-ddf1bdf3643f"
      decimals="-5"
      id="F_a82d5890-64d4-4f64-a1cb-5fa0483819a1"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseResidualValueOfLeasedAsset
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-5"
      id="F_816cee07-d1a9-47f6-8fe6-b750b5659fc5"
      unitRef="U_USD">1400000</us-gaap:OperatingLeaseResidualValueOfLeasedAsset>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_c1154108-cf25-46e6-9db3-ee9511f06c64"
      unitRef="U_USD">600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_b59e5a86-d905-4a3c-8c19-40a5cd22d961"
      unitRef="U_USD">100000</us-gaap:OtherAssetImpairmentCharges>
    <tcrt:DiscountedRiskAdjustedRates
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="2"
      id="F_d3d0230b-85d4-4c88-85c5-177954dfa749"
      unitRef="U_pure">0.10</tcrt:DiscountedRiskAdjustedRates>
    <tcrt:OperatingLeasesExpirationMonthAndYear
      contextRef="C_08a67ddb-30d8-464e-a0ac-bdfb4a9ef7af"
      id="F_54fbe2a1-24df-493e-90e8-0f0c4a93dc55">2021-04</tcrt:OperatingLeasesExpirationMonthAndYear>
    <tcrt:OperatingLeaseArea
      contextRef="C_c3245be1-2a56-4ce2-a313-9a3ec39aa110"
      decimals="0"
      id="F_25b13103-86f7-4e77-b91b-4709f66ed2f1"
      unitRef="U_sqft">1038</tcrt:OperatingLeaseArea>
    <tcrt:LesseeOperatingLeaseMonthlyAverageRentalPayment
      contextRef="C_08a67ddb-30d8-464e-a0ac-bdfb4a9ef7af"
      decimals="-3"
      id="F_7d4cc602-1ad7-40e6-9e96-ea1db2af5356"
      unitRef="U_USD">2000</tcrt:LesseeOperatingLeaseMonthlyAverageRentalPayment>
    <tcrt:OperatingLeasesExpirationMonthAndYear
      contextRef="C_c270381e-43d4-46f3-b514-f780c08aa3f9"
      id="F_b4cc2c97-a944-43ab-bf43-877cbd06c33f">2027-02</tcrt:OperatingLeasesExpirationMonthAndYear>
    <tcrt:OperatingLeaseArea
      contextRef="C_80826595-228b-476d-8548-2b525f9d98c5"
      decimals="0"
      id="F_96fb8b73-27f1-40b5-a5c6-5f85729b5ec0"
      unitRef="U_sqft">8443</tcrt:OperatingLeaseArea>
    <tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour
      contextRef="C_80826595-228b-476d-8548-2b525f9d98c5"
      decimals="-3"
      id="F_d47d89ae-cdde-492b-9b11-9f0f304e6dc5"
      unitRef="U_USD">17000</tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour>
    <tcrt:AnnualBaseRent
      contextRef="C_8f0471b9-3122-450c-83f4-9876302a91e0"
      decimals="3"
      id="F_ac349f90-c36c-4ffa-b2cb-05804cd063a9"
      unitRef="U_pure">0.030</tcrt:AnnualBaseRent>
    <tcrt:OperatingLeaseArea
      contextRef="C_3be47963-40c3-4b80-8a99-5b3aa4d10c76"
      decimals="0"
      id="F_83545f87-5dff-40e1-a283-64477def8eff"
      unitRef="U_sqft">5594</tcrt:OperatingLeaseArea>
    <tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour
      contextRef="C_3be47963-40c3-4b80-8a99-5b3aa4d10c76"
      decimals="-3"
      id="F_07bea68f-5559-445a-aa07-ec894b8fe105"
      unitRef="U_USD">12000</tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour>
    <tcrt:OperatingLeasesExpirationMonthAndYear
      contextRef="C_3c4db62a-e3d4-421b-b8e8-3b6d5445b532"
      id="F_98ac2c19-6fa8-4924-935f-390c07f0f0d4">2027-02</tcrt:OperatingLeasesExpirationMonthAndYear>
    <tcrt:AnnualBaseRent
      contextRef="C_a755066d-a762-4b1c-a9e5-da405de1577b"
      decimals="3"
      id="F_764b6e09-c1d0-4ee4-9874-b1708b0a796c"
      unitRef="U_pure">0.030</tcrt:AnnualBaseRent>
    <tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour
      contextRef="C_ff46e4b8-4535-4f61-bf4b-409c23561efb"
      decimals="-3"
      id="F_acccb3b4-28fb-4a02-9d29-d7268a862e71"
      unitRef="U_USD">37000</tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour>
    <tcrt:AnnualBaseRent
      contextRef="C_3e843951-a185-415d-86e2-e4855f371dd3"
      decimals="3"
      id="F_5f502eac-07e0-4b8c-ae75-a51a5e8a3140"
      unitRef="U_pure">0.030</tcrt:AnnualBaseRent>
    <tcrt:OperatingLeaseArea
      contextRef="C_28c42504-64db-4bbb-b58d-31b90866d765"
      decimals="INF"
      id="F_d16d3811-a7ff-493e-ba1b-87fd78df1d03"
      unitRef="U_sqft">18111</tcrt:OperatingLeaseArea>
    <tcrt:OperatingLeaseArea
      contextRef="C_677a76fa-1b6a-49f5-9473-b720f11528d4"
      decimals="INF"
      id="F_1a6b07c2-b570-4791-92ce-9f5a3d93f738"
      unitRef="U_sqft">3228</tcrt:OperatingLeaseArea>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_677a76fa-1b6a-49f5-9473-b720f11528d4"
      decimals="-5"
      id="F_d27746f4-60e3-4c99-bda0-2215cfee600b"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tcrt:GainLossOnModificationOfLease
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_48ac62b1-8791-49db-8c44-30f2538c9aa0"
      unitRef="U_USD">100000</tcrt:GainLossOnModificationOfLease>
    <tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f1c36134-22d7-42e3-b508-edac2a0abe29"
      unitRef="U_USD">7000</tcrt:OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour>
    <tcrt:AnnualBaseRent
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="3"
      id="F_4632833c-959e-4b85-9d9b-0e1626076aa2"
      unitRef="U_pure">0.030</tcrt:AnnualBaseRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_746d5b8b-69a8-4cff-8220-1954036066da">&lt;p id="bkmk_231" style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.343%;"/&gt;
        &lt;td style="width:1.836%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.988000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.836%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_04b01051-984c-44c8-a5d5-4880657e2e3a"
      unitRef="U_USD">756000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_8adbfec9-132d-4965-9a6d-981b639e9629"
      unitRef="U_USD">1394000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_41bebbaa-0906-4d9e-b883-a40eece5b0e8"
      unitRef="U_USD">756000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_b28da7c4-ddc1-4f60-aa93-767440f9dc6e"
      unitRef="U_USD">1394000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      id="F_8363d950-9c7e-4dac-8ceb-bec078faf2c3">P4Y1M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      id="F_cfae845f-eeee-4a2e-a0c4-7dd868f0e5a4">P5Y6M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="4"
      id="F_f0e5c6e3-97fd-41b6-9832-e35acbcc74c4"
      unitRef="U_pure">0.0826</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="4"
      id="F_17b78e0c-5072-4047-b562-fee8ed6975e0"
      unitRef="U_pure">0.0800</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_17fa1497-d249-48fa-b154-0808eb97abbe"
      unitRef="U_USD">800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="0"
      id="F_2711dc6d-d8d3-4081-8b63-24ac7723905e"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_f1a93f7f-9e2c-4d63-a73d-a4572275f6d2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the maturities of the Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_6934d123-79b6-4d0e-9146-8913adc044ad;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.093%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:24.346%;"/&gt;
        &lt;td style="width:11.972%;"/&gt;
        &lt;td style="width:1.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.1%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_7884d1c0-1a6d-455e-ae07-d69811b7b164"
      unitRef="U_USD">757000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_1df7f784-6597-45ae-970c-00a8d25c024a"
      unitRef="U_USD">780000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_82120970-9b15-43e0-bc41-c296b5824397"
      unitRef="U_USD">804000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_4002add8-8768-4690-b8ab-b2f8c8ca4c3f"
      unitRef="U_USD">712000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_c193c1a5-b444-4d61-89de-d1b1029cf158"
      unitRef="U_USD">158000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_180726c3-b93b-4e15-8950-b5acf712f523"
      unitRef="U_USD">31000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_42690c03-00e0-446b-a2ff-f0b7f770bb2f"
      unitRef="U_USD">3242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_3dcdd84c-7fbc-49d5-a7b9-b556f4665e93"
      unitRef="U_USD">496000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_edf16a94-54a2-43b7-8cb2-c180a3328055"
      unitRef="U_USD">2746000</us-gaap:OperatingLeaseLiability>
    <tcrt:SubleaseArea
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="0"
      id="F_4996f468-ca3c-4bcc-894c-23845d861e0f"
      unitRef="U_sqft">4772</tcrt:SubleaseArea>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_60d83e28-c18e-4e16-87fd-c1beca5363a0">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LeaseIncome
      contextRef="C_cf145b1e-8766-417b-b25d-39bde6bf3ba7"
      decimals="-5"
      id="F_723b6362-33e7-46fd-a599-4c5f4de09bba"
      unitRef="U_USD">100000</us-gaap:LeaseIncome>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_202a9955-b3c8-4a68-b73c-abf5dfd42f82"
      unitRef="U_USD">200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_16f0d0b5-7f16-4174-82bf-4966741f219c"
      unitRef="U_USD">200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_9feb7273-356c-43b6-922e-cf44cc8dea7a"
      unitRef="U_USD">100000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_393a2b1c-df4d-46a8-b532-00022e83637b">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;9.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreement with PGEN Therapeutics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License Agreement, the Company has exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between us, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also has exclusive, worldwide rights for certain patents relating to the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products and TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In consideration of the licenses and other rights granted by PGEN, the Company pays PGEN an annual license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the Company reimbursed PGEN for certain historical costs of the licensed programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will make milestone payments totaling up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. The Company will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate. The Company will also pay PGEN &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of any sublicensing income received by us relating to the licensed products. The Company is responsible for all development costs associated with each of the licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;PGEN will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; royalty amounts were incurred during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#x2019;s obligations to provide transition assistance relating to the IL-12 products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement and 2015 Research and Development Agreement &#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 13, 2015&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who served as the Company&#x2019;s Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;amp;D Agreement which was entered into on September 19, 2019 (the &#x201c;Fourth Amendment&#x201d;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;amp;D Agreement for a period of three years and in an amount of no less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and no greater than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;amp;D Agreement to extend the term of the 2015 R&amp;amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;amp;D Agreement, which we entered into on October 22, 2019, with MD Anderson, pursuant to which we agreed to collaborate with respect to the TCR program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, PGEN, and MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Research and Development Agreement&#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will own all inventions and intellectual property developed under the 2019 R&amp;amp;D Agreement and the Company will retain all rights to all, intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;amp;D Agreement, including the Company's&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies, and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for development costs under the 2019 R&amp;amp;D Agreement, after the funds from the 2015 R&amp;amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, of which only $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the year ended December 31, 2022, the Company incurred clinical expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from MD Anderson related to this agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2019 R&amp;amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;amp;D Agreement following written notice of a material breach. The 2019 R&amp;amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the execution of the 2019 R&amp;amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,333,333&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and vests in four parts upon the occurrence of certain clinical milestones. As of December 31, 2022, the milestones have not been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;EGFR &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;neoantigens. In addition, pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;KRAS &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;neoantigens licensed from the NCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The terms of the Patent License require the Company to pay the NCI minimum annual royalties in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which amount will be reduced to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million once the aggregate minimum annual royalties paid by the Company equals $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, of which aggregate payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The first benchmark payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, the Company is required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion. The aggregate potential amount of these benchmark payments is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company may terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022 the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of expenses and incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of expenses for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cooperative Research and Development Agreement (CRADA) with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company will have the first opportunity to file a patent covering the invention. If the Company fails to provide timely notice of its decision to the NCI or decides not to file a patent covering the joint invention, the NCI has the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service grants the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which are licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company is also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The NCI has a cleared Investigational New Drug Application, or IND, that would permit them to begin this trial. To the Company's knowledge, the trial has not yet enrolled. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to this program; however, for the third and fourth quarters of 2021, the Company was not required to make payments toward the program as agreed with the NCI. Therefore, as of December 31, 2022, the Company made $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of payments under the February 2019 CRADA extension, and the NCI has agreed that this is full satisfaction of the agreement and no further payments are due under the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;commitment. In March 2022, the Company entered into an amendment to the CRADA that was retroactive, effective January 9, 2022 to extend the term of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CRADA &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t incur expenses under the CRADA for the year ended December 31, 2022, as compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Patent and Technology License Agreement&#x2014;The University of Texas MD Anderson Cancer Center and the Texas A&amp;amp;M University System&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the year ended December 31, 2022, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was incurred as a one-time milestone payment under the terms of the agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand in royalty expenses on sales under this agreement during the year ended December 31, 2022, and did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t incur royalty expenses on sales under this agreement during the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreement with Solasia Pharma K.K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#x2019;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2022, the Company earned $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tcrt:AnnualLicenseFees
      contextRef="C_2be3c3ac-efdc-402a-827b-95ce13fc11c0"
      decimals="-5"
      id="F_c9cee5e0-1a61-4e33-ac99-4e344363143f"
      unitRef="U_USD">100000</tcrt:AnnualLicenseFees>
    <tcrt:MaximumAmountOfAdditionalMilestonesPayable
      contextRef="C_2be3c3ac-efdc-402a-827b-95ce13fc11c0"
      decimals="-5"
      id="F_e4a7e553-9165-40c2-a447-45f25afa6da8"
      unitRef="U_USD">52500000</tcrt:MaximumAmountOfAdditionalMilestonesPayable>
    <tcrt:MaximumAmountOfRoyaltyPayable
      contextRef="C_966e453b-8a58-437f-a91f-f254719ff9b9"
      decimals="-5"
      id="F_8fcc35fa-a490-48f5-ac49-dee4ee496402"
      unitRef="U_USD">100000000.0</tcrt:MaximumAmountOfRoyaltyPayable>
    <tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty
      contextRef="C_966e453b-8a58-437f-a91f-f254719ff9b9"
      decimals="2"
      id="F_db2753e2-9458-4e76-8f08-5f4c54362c4f"
      unitRef="U_pure">0.20</tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty>
    <tcrt:MaximumRoyaltyAmount
      contextRef="C_20b416e3-3907-4e97-9e9d-1fcba80f134c"
      decimals="-5"
      id="F_f6c948c7-022d-4e01-9919-a0e24f14291c"
      unitRef="U_USD">100000000.0</tcrt:MaximumRoyaltyAmount>
    <us-gaap:RoyaltyExpense
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_51461b5e-befb-4da2-833d-aee35fb3757b"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_31a22ac5-97d8-4617-b559-0649f89184a3"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <tcrt:LicenseAgreementCommencingDate
      contextRef="C_76510e7e-f84f-4555-b284-0b2f7facecaa"
      id="F_82dbd7bf-5e80-46d3-8be5-b72186cff76a">2015-01-13</tcrt:LicenseAgreementCommencingDate>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d20ec984-e91b-4bbd-aeea-1e39b7a6c803"
      decimals="-5"
      id="F_69644363-e34b-4c53-a2db-df969569e143"
      unitRef="U_USD">15000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_de82944d-045e-4494-962a-60bbd7316d2d"
      decimals="-5"
      id="F_e200e7e5-aeda-461c-a936-1582f4cb8989"
      unitRef="U_USD">20000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <tcrt:AggregateAmountPotentiallyReimburseableAmount
      contextRef="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d"
      decimals="-5"
      id="F_9db11396-c0f6-485e-912e-c3d9be21799d"
      unitRef="U_USD">20000000.0</tcrt:AggregateAmountPotentiallyReimburseableAmount>
    <tcrt:AggregatePotentialBenchmarkPayments
      contextRef="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d"
      decimals="-5"
      id="F_0cae2656-fcb1-426a-b55b-efb6235ca388"
      unitRef="U_USD">36500000</tcrt:AggregatePotentialBenchmarkPayments>
    <tcrt:AccrualsPriorToFirstMarketingApproval
      contextRef="C_2ccf70e2-2ad3-4b7f-bb44-2ad967b6198d"
      decimals="-5"
      id="F_eb7e3b53-8015-4ae8-86f8-b8c19737d32f"
      unitRef="U_USD">3000000.0</tcrt:AccrualsPriorToFirstMarketingApproval>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_8339573a-0ca5-49ab-b505-6fdfb84cb410"
      decimals="-5"
      id="F_2884066e-56d9-4d39-9093-e07c7fc89d2c"
      unitRef="U_USD">800000</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_7396adc0-9e69-4eb0-8a3e-8adda7c5d090"
      decimals="-5"
      id="F_36c55898-41f8-4a40-96a9-a8f6e45e3575"
      unitRef="U_USD">300000</tcrt:QuarterlyExpenseIncurred>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_009c6c2d-9013-4f24-9a09-41485c023a44"
      decimals="0"
      id="F_6a39f632-23ca-4544-ac1a-49b5d4e6288e"
      unitRef="U_shares">3333333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_009c6c2d-9013-4f24-9a09-41485c023a44"
      decimals="3"
      id="F_1bf85192-ab20-4da2-87e0-b9b6537e2870"
      unitRef="U_USDollarShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_009c6c2d-9013-4f24-9a09-41485c023a44"
      id="F_1bff1169-a797-4dcd-8c33-15987391ff81">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <tcrt:MinimumRoyaltiesAmountPayable
      contextRef="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b"
      decimals="-5"
      id="F_f324345d-06e7-4d77-b746-b27906b72385"
      unitRef="U_USD">300000</tcrt:MinimumRoyaltiesAmountPayable>
    <tcrt:RoyaltiesAmountPayableThereafter
      contextRef="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b"
      decimals="-5"
      id="F_4d35d281-c7c1-4afe-ba9e-1cbea0bba1da"
      unitRef="U_USD">100000</tcrt:RoyaltiesAmountPayableThereafter>
    <tcrt:AggregateMinimumAnnualRoyaltiesPaid
      contextRef="C_2bd274ff-2bfe-4831-9d50-b73ab0801f4b"
      decimals="-5"
      id="F_3b58e4c9-e220-4c4d-8d47-e3e6f0b32eb7"
      unitRef="U_USD">1500000</tcrt:AggregateMinimumAnnualRoyaltiesPaid>
    <tcrt:AggregateBenchmarkPaymentsPayable
      contextRef="C_735e4858-865a-4de6-850e-3aab57d7148b"
      decimals="-5"
      id="F_e6e3aed4-2f6b-4c92-ab13-f5305793ecac"
      unitRef="U_USD">4300000</tcrt:AggregateBenchmarkPaymentsPayable>
    <tcrt:AggregateBenchmarkPaymentsPayable
      contextRef="C_f9f80da5-3640-4b51-b5d8-02726e56d225"
      decimals="-5"
      id="F_a41638de-592d-46ea-81ed-d72bb2b47232"
      unitRef="U_USD">3000000.0</tcrt:AggregateBenchmarkPaymentsPayable>
    <tcrt:DescriptionOfFirstBenchmarkPayable
      contextRef="C_eb8415ef-ed42-43d3-bebe-c35459c15508"
      id="F_404f7f82-a2a5-4817-8f86-15745f50e116">The first benchmark payment of $0.1 million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</tcrt:DescriptionOfFirstBenchmarkPayable>
    <tcrt:InitialBenchmarkPaymentDue
      contextRef="C_d75e53ea-0702-44cf-9dd4-dc1d1548bebb"
      decimals="-5"
      id="F_c256b474-46b1-4267-9c89-a04679894a12"
      unitRef="U_USD">100000</tcrt:InitialBenchmarkPaymentDue>
    <tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable
      contextRef="C_b83280a9-1359-4007-a613-0f63cf09a0cd"
      decimals="-5"
      id="F_7a6d7f97-7d64-4ec7-99f5-1036b22f4985"
      unitRef="U_USD">250000000.0</tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable>
    <tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable
      contextRef="C_b83280a9-1359-4007-a613-0f63cf09a0cd"
      decimals="-8"
      id="F_f1473c2e-c184-4a3b-a18a-4aa2f26fcc0f"
      unitRef="U_USD">1000000000.0</tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable>
    <tcrt:PotentialBenchmarkPaymentsPayable
      contextRef="C_4418daac-e678-4e2c-be6e-3555ed9a312a"
      decimals="-5"
      id="F_b2f8b4d9-5235-4a24-ad3c-e346d1c56a49"
      unitRef="U_USD">12000000.0</tcrt:PotentialBenchmarkPaymentsPayable>
    <tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones
      contextRef="C_eb8415ef-ed42-43d3-bebe-c35459c15508"
      id="F_d11d5055-2a5f-46a2-a8bc-5341de0772bd">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones>
    <tcrt:AgreementTerminationNoticePeriod
      contextRef="C_eb8415ef-ed42-43d3-bebe-c35459c15508"
      id="F_13bc18f3-0e8e-42ab-9688-0122fea8672b">P60D</tcrt:AgreementTerminationNoticePeriod>
    <tcrt:LicenseExpense
      contextRef="C_aa3e31b2-77fb-40fc-bedb-7d66b32336b4"
      decimals="-5"
      id="F_df9ece60-bf2c-4bfa-b416-1f83a4b0a9c8"
      unitRef="U_USD">700000</tcrt:LicenseExpense>
    <tcrt:LicenseExpense
      contextRef="C_a3613417-09f3-43ff-8294-f0c33b77cc57"
      decimals="-5"
      id="F_50b7428f-f661-4af8-88e8-c32d1744389f"
      unitRef="U_USD">500000</tcrt:LicenseExpense>
    <tcrt:ObligationsDueUnderContract
      contextRef="C_6286a83b-0f82-4d71-9785-6d19951b5c7d"
      decimals="-5"
      id="F_a68fc504-43fa-4cfb-8dbd-b5724e254c05"
      unitRef="U_USD">5000000.0</tcrt:ObligationsDueUnderContract>
    <tcrt:QuarterlyPaymentsUnderContract
      contextRef="C_82b5c3f4-e428-4dc9-a489-d6da42ba15d5"
      decimals="-5"
      id="F_e9d80d7c-cb10-4652-9b52-96296fc41592"
      unitRef="U_USD">3800000</tcrt:QuarterlyPaymentsUnderContract>
    <tcrt:ObligationsDueUnderContract
      contextRef="C_6286a83b-0f82-4d71-9785-6d19951b5c7d"
      decimals="-5"
      id="F_00b9e01a-b422-40da-90b4-a2b0b7a0ee1e"
      unitRef="U_USD">5000000.0</tcrt:ObligationsDueUnderContract>
    <tcrt:ContributionPayableOnPerAnnumBasis
      contextRef="C_c8f802e5-6966-41fa-9657-aae7124cdab0"
      decimals="-5"
      id="F_1c34afac-a9e5-4798-a20d-d4f7055297e5"
      unitRef="U_USD">1000000.0</tcrt:ContributionPayableOnPerAnnumBasis>
    <tcrt:AnnualExpenseIncurred
      contextRef="C_82b5c3f4-e428-4dc9-a489-d6da42ba15d5"
      decimals="-6"
      id="F_04288700-0d46-485a-8d47-35e8eef150e1"
      unitRef="U_USD">0</tcrt:AnnualExpenseIncurred>
    <tcrt:AnnualExpenseIncurred
      contextRef="C_c65c999f-7903-41c0-85f9-01dae5de02f9"
      decimals="-5"
      id="F_50ac35ad-374a-484c-b526-9d56a6e120b7"
      unitRef="U_USD">1300000</tcrt:AnnualExpenseIncurred>
    <tcrt:MilestonePaymentsMaximumAmount
      contextRef="C_c9ae6604-f2d2-43d1-a9d1-f8a9f071c33f"
      decimals="-5"
      id="F_3bc57c33-ea8b-46df-8be5-63b99fb93196"
      unitRef="U_USD">4500000</tcrt:MilestonePaymentsMaximumAmount>
    <tcrt:MilestonePayment
      contextRef="C_f1cdd995-a3b3-4a88-86cf-666181247c3f"
      decimals="-5"
      id="F_6ade809e-fffc-4b24-b23b-f4df9ba788a5"
      unitRef="U_USD">2500000</tcrt:MilestonePayment>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_1d2fdd28-ac94-4045-9dd8-0480c92e9cea"
      decimals="-5"
      id="F_5fc9a6fa-c4b7-4fe5-8732-239ba2a9f72a"
      unitRef="U_USD">100000</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_139d76d8-bc1c-4f22-909e-3ae5eccdbd1b"
      decimals="-3"
      id="F_197912d0-38f5-42b0-9842-8973587baec4"
      unitRef="U_USD">2000</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_01541ff4-c565-4665-8fd3-c5b8b851f917"
      decimals="-6"
      id="F_03b3e964-9a0c-41d5-a8de-189f3ea866d0"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e8f1b252-50d6-4597-8b92-45eb247fae8f"
      decimals="-5"
      id="F_c14e67ed-37f2-449b-a464-7f7f510257b6"
      unitRef="U_USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9245beb1-9103-47f9-b176-2c032568f730"
      decimals="-5"
      id="F_d6033b57-6fd1-4f10-bd48-7076a933db0d"
      unitRef="U_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tcrt:WarrantTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_106f32b6-def8-41c8-814e-123091da91d9">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;10.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the Company&#x2019;s November 2018 private placement that provided net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, the Company issued warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,939,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,803,031&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company issued participating investors new warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,803,031&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of common stock, or the 2019 Warrants, as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million non-cash charge in the Company&#x2019;s statement of operations in 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 22, 2019, the Company entered into the 2019 R&amp;amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;amp;D Agreement, the Company issued the MD Anderson Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,333,333&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The MD Anderson Warrant expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the year ended December 31, 2022 and 2021, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,844&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.22&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The warrants have a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; life and were fully vested upon issuance. The fair value of the warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends. On December 28, 2021, the Company entered into the Amended Loan and Security Agreement, as described in Note 4, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;649,615&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, in the aggregate, at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. Using a Black-Scholes model with an expected volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends, the Company recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_0f16ce4f-8d70-403f-b6b8-a51d4653179d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;increase in the fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the SVB Warrants due to the modification of the SVB Warrants during the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed whether the SVB Warrants require accounting as derivatives. The Company determined that the SVB Warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As such, the Company has concluded the SVB Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tcrt:WarrantTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ec21d5ba-40fd-4ef7-b050-7c8f6c9de41b"
      decimals="-5"
      id="F_a4acd1f9-331f-4abb-8357-403bd08652e0"
      unitRef="U_USD">47100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_af0771c8-7bb6-4d20-b747-7a3e0f9ad3c5"
      decimals="0"
      id="F_93b65f90-25dc-4322-94fe-fc654edb52dd"
      unitRef="U_shares">18939394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_af0771c8-7bb6-4d20-b747-7a3e0f9ad3c5"
      decimals="2"
      id="F_def6fe3f-2f1e-45a6-8f58-9dfad04fed81"
      unitRef="U_USDollarShare">3.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617"
      decimals="-5"
      id="F_c6febefd-a480-407b-bfca-e6d7445d9a5e"
      unitRef="U_USD">18400000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617"
      decimals="2"
      id="F_13df2ada-cc13-4f61-86d7-92c1fe05b18c"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617"
      decimals="4"
      id="F_b01d0eea-0c6f-4b28-9a06-91b15b9d93c7"
      unitRef="U_pure">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617"
      id="F_a730ee79-dbd3-4eeb-a460-313998ceb4fb">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_0350ea77-ee99-48c3-9c29-b0c1a4050617"
      decimals="-3"
      id="F_70df2991-c736-4d43-9653-90cfcf95f2b9"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_019df9ac-fbae-4355-8668-11ee7fd04e38"
      decimals="0"
      id="F_78a15d3c-86f3-4b86-9cec-8deba56364e8"
      unitRef="U_shares">17803031</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_019df9ac-fbae-4355-8668-11ee7fd04e38"
      decimals="2"
      id="F_2e1f5f3c-183c-4545-9046-221d368a9a3e"
      unitRef="U_USDollarShare">3.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:PlacementAgentFeesAndOtherRelatedExpenses
      contextRef="C_67e87324-3985-420c-90be-d2e08d2df27a"
      decimals="-5"
      id="F_ebbfcabb-4fff-40e4-ad6d-1e7433722f4a"
      unitRef="U_USD">1100000</tcrt:PlacementAgentFeesAndOtherRelatedExpenses>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_7c4f4916-db64-490f-8174-b66da79fd2dd"
      decimals="-5"
      id="F_058aa26d-c870-4c21-836f-40b89df3274b"
      unitRef="U_USD">52500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f707f4a5-a8e0-4111-bc42-c5d4a9d92abb"
      decimals="0"
      id="F_9e36020e-8874-42d3-87aa-d516d4688d78"
      unitRef="U_shares">17803031</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f707f4a5-a8e0-4111-bc42-c5d4a9d92abb"
      decimals="2"
      id="F_fa9e229d-ab03-4bab-aabc-de6ca130d1cd"
      unitRef="U_USDollarShare">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:NonOperatingIncomeExpenseInducementOfWarrants
      contextRef="C_9ef452a7-a519-46fd-b8a6-51b26e948a62"
      decimals="-5"
      id="F_c9aa8635-dc79-4569-94a9-686fcbdadd63"
      unitRef="U_USD">60800000</tcrt:NonOperatingIncomeExpenseInducementOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972"
      decimals="INF"
      id="F_5ec3cd78-efd8-4eaa-914a-91634087498a"
      unitRef="U_shares">3333333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972"
      decimals="3"
      id="F_7abed2fa-0e3a-4d09-ad9c-44afda16c141"
      unitRef="U_USDollarShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_7ef2eeab-93c5-4783-a05f-f12f4779e164"
      decimals="-5"
      id="F_b8bb3be5-a952-4140-a50e-c9e68ad7f3c6"
      unitRef="U_USD">14500000</tcrt:FairValueOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_fff2de8f-883a-4071-a9fa-cfe80ce5d972"
      id="F_367917d7-67cb-4bd1-b009-2dc161a31c63">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="C_7117f1c3-b39a-4248-8ab6-f843b0bbb987"
      decimals="0"
      id="F_0e59de47-0590-4513-8b70-a4494218807f"
      unitRef="U_shares">432844</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_83b60ee4-931e-45fb-9e47-1b18baa0e863"
      id="F_950eedac-2926-4a47-9b1e-1a53bca38c91">2.22</us-gaap:CommonStockCallOrExerciseFeatures>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_7117f1c3-b39a-4248-8ab6-f843b0bbb987"
      id="F_ba7ca599-ee23-4c2a-90ed-8a92dec11083">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <tcrt:FairValueOfWarrants
      contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f"
      decimals="-5"
      id="F_a5d5a7f6-0d03-4531-94a7-69d648124785"
      unitRef="U_USD">800000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f"
      decimals="2"
      id="F_a7a86b2a-5393-4f48-9241-feda28aad054"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f"
      decimals="4"
      id="F_149dc0c3-0518-40cf-ad03-c724c10aa58b"
      unitRef="U_pure">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f"
      id="F_81b492fd-aaee-45cb-a292-d366c095f455">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_20f7049d-0ec6-4e04-9bf6-9c3ccf17492f"
      decimals="-3"
      id="F_0144d4b9-a0de-45b9-9a91-7f09be4d49d2"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_1cf5e5f2-8735-40b8-b39f-efaad36c2475"
      decimals="0"
      id="F_9ed3be69-2e3f-4388-949b-d0a664592f3f"
      unitRef="U_shares">649615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672"
      id="F_f98986ea-592f-4f92-814b-ddb541fa81ed">1.16</us-gaap:CommonStockCallOrExerciseFeatures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672"
      decimals="2"
      id="F_97ec3a81-b599-43f8-a606-9a02da2cb32c"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672"
      decimals="4"
      id="F_ca8afacf-3939-4c44-816f-c14c7d80e473"
      unitRef="U_pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672"
      id="F_16d1de80-f459-4b52-8a82-86ee50f32276">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_e8ca27b4-bce0-411e-8807-6e790eaa7672"
      decimals="-3"
      id="F_82e32e77-f066-4e0a-8d53-ca48003cf7b8"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_f8f70fa4-ffe5-4f49-b2ec-312c36fe67b2"
      decimals="-5"
      id="F_f4500275-26cc-4e94-bf15-90d38738e0c5"
      unitRef="U_USD">200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_b7bb7c79-ed21-4a22-b5c9-c6880e7180c2">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;11.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 27, 2021, in order to lower its existing cost structure in connection with the realignment of its business strategy, the Company announced a strategic reduction in force and notified approximately 60 full-time employees of its intention to terminate their services on or, in most cases, before November 30, 2021. Certain of the notified employees had employment agreements that provided for enhanced severance benefits. The severance benefits, apart from certain continuing Company-paid health care benefits for up to twelve months, were paid in 2021. The remaining benefits were paid in 2022, which reduced the severance benefits accrual to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurred the following costs associated with termination benefit payments resulting from the strategic reduction in force:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.992%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.528%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.767%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total severance expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_fcb43152-91fe-48f4-aad0-514fa76c5e42"
      decimals="-3"
      id="F_baa53908-33c0-4bd9-8015-9cabf37d65b4"
      unitRef="U_USD">0</us-gaap:SeveranceCosts1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_6bb29e1b-20dc-4d16-964d-74a65c2b2fe2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurred the following costs associated with termination benefit payments resulting from the strategic reduction in force:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.992%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.528%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.767%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total severance expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_4c2387b7-8249-4b21-9502-83899b598473"
      decimals="-3"
      id="F_ebd12dec-0baa-48c0-96b2-c727f9fa94c3"
      unitRef="U_USD">2368000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_426af431-5218-40c8-82c1-1b23c2d8f820"
      decimals="-3"
      id="F_db4bec9a-aa4c-4886-992d-cf97dd4285e5"
      unitRef="U_USD">1289000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_9656765c-1930-41de-99b9-b7ba006111c2"
      unitRef="U_USD">3657000</us-gaap:SeveranceCosts1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_ba3490bb-b23e-4239-a929-b6cb04aac859">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;12.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;is no provision for income taxes because the Company has incurred operating losses since inception. The reported amounts of income tax expense for the years ended December 31, 2022 and 2021 differ from the amounts that would result from applying domestic federal statutory&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;tax &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;rates to pretax losses primarily because of the changes in the valuation allowance. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets at December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.201%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.654%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.975999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;171,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Start-up and pre-clinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;237,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;231,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;236,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;230,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2022, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;665.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, of which approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;341.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million expire at various dates through December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;323.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million can be carried forward indefinitely. The Company also has approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;497.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of state net operating loss carryforwards available to offset future state taxable income, expiring at various dates through 2042. Additionally, the Company has approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal and state research and development credits at December 31, 2022, expiring in varying amounts through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which may be available to reduce future taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has provided a valuation allowance for the full amount of its net deferred tax assets since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2022 due primarily to net operating loss carryforwards and the increase in research and development credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes using the federal statutory income tax rate differ from the Company&#x2019;s effective tax rate primarily due to non-deductible expenses related to the Company&#x2019;s issuance of warrants along with the change in the valuation allowance on deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.362%;"/&gt;
        &lt;td style="width:1.112%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.258000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.112%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal income tax at statutory rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal/state rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company adopted ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Uncertain Tax Positions&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements in accordance with FASB Statement No. 109, &#x201c;Accounting for Income Taxes.&#x201d; ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; adjustments to its uncertain tax positions in the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not recognized any interest and penalties in the statements of operations because of the Company&#x2019;s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2022 to the extent net operating losses continue to be carried forward to 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or the Tax Act, eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to capitalize and amortize them over five years pursuant to IRC Section 174. The mandatory capitalization requirement had no impact to the overall deferred tax assets due to the Company's loss position and full valuation allowance.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_6cf2dff1-6913-4ac5-9524-52515feeee4c">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets at December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.201%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.654%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.975999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;171,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Start-up and pre-clinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;237,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;231,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;236,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;230,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_e8e062fe-e760-48ce-a481-feb1c72bd6cf"
      unitRef="U_USD">171070000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_dafaf6f0-50fe-424a-af16-74362f0d05f2"
      unitRef="U_USD">164486000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_3782c04a-9e5c-41f0-88c9-4d80acf7ccc3"
      unitRef="U_USD">17204000</tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies>
    <tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_fe2b5ea5-bf36-4eca-b55b-b3a1cbce2a1a"
      unitRef="U_USD">21705000</tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_ddf6437d-8546-4a4d-a146-0efacea0600d"
      unitRef="U_USD">40116000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_1e7b56d5-30b7-4440-b8b9-b1108943f5eb"
      unitRef="U_USD">39817000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_d7d20af2-fba4-40c2-b086-7930fd21544d"
      unitRef="U_USD">698000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_9dec9742-db33-46d7-91a8-48116c08240b"
      unitRef="U_USD">706000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_8e4f90b3-2a7c-4338-8bb6-d241a7377038"
      unitRef="U_USD">2180000</tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts>
    <tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_38ab4d2a-5dba-410b-9da7-0fd46de982e0"
      unitRef="U_USD">2946000</tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts>
    <tcrt:DeferredTaxAssetsLeaseLiability
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_d3de89f1-2837-4ab3-aa83-d0e4ce4ddf3d"
      unitRef="U_USD">618000</tcrt:DeferredTaxAssetsLeaseLiability>
    <tcrt:DeferredTaxAssetsLeaseLiability
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_629d9e51-0467-4816-b6a9-8242a2c95f37"
      unitRef="U_USD">1278000</tcrt:DeferredTaxAssetsLeaseLiability>
    <tcrt:DeferredTaxAssetsDepreciation
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_1bac2ab1-84f4-45b0-be72-9ad4cbab47da"
      unitRef="U_USD">239000</tcrt:DeferredTaxAssetsDepreciation>
    <tcrt:DeferredTaxAssetsDepreciation
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_36fc5831-cb24-43fe-929b-afd852517699"
      unitRef="U_USD">102000</tcrt:DeferredTaxAssetsDepreciation>
    <tcrt:DeferredTaxAssetsResearchExpensesCapitalized
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_9d2c6fec-8c0c-4723-ab6b-d2a0150d1af1"
      unitRef="U_USD">5156000</tcrt:DeferredTaxAssetsResearchExpensesCapitalized>
    <tcrt:DeferredTaxAssetsResearchExpensesCapitalized
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_f0716b52-1b4a-403e-addf-ba9ef52e7590"
      unitRef="U_USD">0</tcrt:DeferredTaxAssetsResearchExpensesCapitalized>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_15a15aa7-fccb-494a-a76e-321b44260359"
      unitRef="U_USD">27000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_82b377c9-2aa7-4d70-b440-53d0d0ecab35"
      unitRef="U_USD">156000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_20d2af79-e803-4253-a453-77f767a5b57e"
      unitRef="U_USD">237308000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_03a27ca2-95fa-4d6f-8f80-de35a3ef66e1"
      unitRef="U_USD">231196000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_60958e36-a0e8-4fe8-ba67-e1397cd3b69f"
      unitRef="U_USD">236827000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_281aa79b-d19c-4f5d-9af0-5151d29a4774"
      unitRef="U_USD">230119000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_6a2812ff-9813-409b-be48-e14d18b6e3bb"
      unitRef="U_USD">481000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_8ad5a38f-36ac-4703-9fc1-a8d073e36a1c"
      unitRef="U_USD">1077000</us-gaap:DeferredTaxAssetsNet>
    <tcrt:DeferredTaxLiabilityRightOfUseAsset
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_68bd760a-8db8-4fb8-ad50-d61b416dcad3"
      unitRef="U_USD">481000</tcrt:DeferredTaxLiabilityRightOfUseAsset>
    <tcrt:DeferredTaxLiabilityRightOfUseAsset
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_6f4f4f6a-0e2b-44c8-bff3-4bbb0968d0f6"
      unitRef="U_USD">1077000</tcrt:DeferredTaxLiabilityRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_f9403b5c-1f40-4e79-ab69-ea27db9c8451"
      unitRef="U_USD">481000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_380d6b47-849e-488e-8742-771ff08e7fd9"
      unitRef="U_USD">1077000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_ba0e4286-4b84-44f2-9e2c-7514c9d818fa"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_68d540f6-d40a-4384-9fe4-8b70188c9225"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_bdb6cf3c-3394-4924-9e66-e2220477279d"
      decimals="-5"
      id="F_210aefe2-68e8-4f21-9c33-5e0b756df172"
      unitRef="U_USD">665500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_7a975d4f-655a-404d-a576-8eb7fc9e24a3"
      decimals="-5"
      id="F_dabef8dd-aafb-4014-b3e7-489fb0509d6a"
      unitRef="U_USD">341700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <tcrt:OperatingLossCarryforwardsExpirationDatesState
      contextRef="C_3d61c456-2ac5-4ffa-a8f5-cec10246c86a"
      id="F_5ca69864-2ddf-4b9e-8d49-5beef70522ec">2037</tcrt:OperatingLossCarryforwardsExpirationDatesState>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-5"
      id="F_63f3abfa-531d-492b-875d-92cf7208d773"
      unitRef="U_USD">323800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b9e1d219-2ee6-449a-8982-40603fb9f929"
      decimals="-5"
      id="F_9d166f62-57bc-4ec1-a8c6-c1e7d5c6727d"
      unitRef="U_USD">497900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4d61befa-1f31-42dc-852d-7c27952aa374"
      decimals="-5"
      id="F_463192e2-faae-4e6f-bfe5-17e5a79993ea"
      unitRef="U_USD">40100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <tcrt:OperatingLossCarryforwardsResearchExpirationDates
      contextRef="C_ee038ec2-a0cc-48d1-b9ca-0fa12ba3bac8"
      id="F_fbffa7e9-8eb4-493b-9d87-1d57260ff949">2042</tcrt:OperatingLossCarryforwardsResearchExpirationDates>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_097c0cc4-e222-4d31-9522-d7c23f5ca774"
      unitRef="U_USD">6700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_b3655759-29f1-420d-a3b5-8d3c32d7cf56">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.362%;"/&gt;
        &lt;td style="width:1.112%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.258000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.112%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal income tax at statutory rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal/state rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_1bb11d4b-f64f-47b0-a9cf-d25354557bb6"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_824fd970-9b7f-413a-929f-598f016a0fb9"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_f77d6e98-9a18-40b0-9cd4-2aa6bc6ebac2"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_eb98cab7-e646-49d5-90cd-4107dec5ace3"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_7b6933fb-cb21-4d7f-b641-7037a5db2241"
      unitRef="U_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_8a8cb29b-546e-4380-9a9f-e3f0944755e8"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_6cedaea5-f43c-4940-8f0b-2455d9765571"
      unitRef="U_pure">-0.02</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_26fbe0bc-3201-47f8-b36b-4a6b579d4600"
      unitRef="U_pure">0</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_dc1bc5ed-4bf4-4108-a19c-6581331de597"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_0224014b-88d2-462b-827a-7c06f612064d"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_ca829cce-c529-4c0a-ac0c-f261e75bc2ba"
      unitRef="U_pure">-0.05</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_b6f2d7d7-fd59-457b-b820-91ef439da963"
      unitRef="U_pure">-0.02</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_41250db0-5c6e-49aa-9a6b-997b2f93a211"
      unitRef="U_pure">-0.18</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_68a9e81c-7fba-4737-a8e5-39704dee6331"
      unitRef="U_pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_15836bec-f7ec-4a62-bb71-2a57c6fa5f80"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_1b16e310-6add-46c2-b7d2-c742d4f1d1cd"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_9c8508c5-6ffe-424a-8392-a7b09c911559"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-3"
      id="F_544fdc1b-d15d-4d61-ac38-94a282e25cda"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_dc5324ed-babe-4904-a5d2-f6b567750156">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;13.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, in May 2012. Including subsequent increases, the Company had reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares for issuance. On December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,089,296&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares reserved for issuance and no shares available for future grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, in June 2020. The Company reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares for issuance plus a carryover of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,066,275&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares from the 2012 Plan for a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,066,275&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, returning shares from the 2012 Plan are available for issuance under the 2020 Plan. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,319,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares reserved for issuance and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,460,088&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares available for future grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options generally vest ratably in either quarterly or annual installments over three or four years, commencing on the first anniversary of the grant date and have contractual terms of ten years. Stock options to directors generally vest ratably over one or two years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation is recognized based on such fair value over the period of vesting on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Proceeds from the option exercises during the year ended December 31, 2022 amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand and during the year ended December 31, 2021 amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The intrinsic value of these options amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under the Company's stock options plans for the years ending December 31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.426%;"/&gt;
        &lt;td style="width:0.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.061%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.588999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.831999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.476%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.882%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,840,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,380,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;363,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,192,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,697,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,928,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,408,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,891,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,410,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options available for future grant, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,460,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 31, 2022, total unrecognized compensation costs related to non-vested stock options outstanding amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022 the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of restricted stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,601,224&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the year ended December 31, 2021 to employees and directors. During the year ended December 31, 2022, the Company repurchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share to cover payroll taxes for one employee exercise, which is in accordance with the original terms of the award. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; repurchases by the Company for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the status of restricted stock as of December 31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.19%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.988999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.623%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.034%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;786,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,601,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;754,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;434,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;306,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of total unrecognized stock-based compensation expense related to non-vested restricted stock arrangements. The expense is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fdbd888b-893b-4b86-85b2-065fe730f06d"
      decimals="0"
      id="F_1b89e79a-8ff9-43d9-bfc3-0a61742aafaf"
      unitRef="U_shares">14000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e079d01f-15d4-407c-9a4a-2730c6e26083"
      decimals="0"
      id="F_b94b2128-a1ac-4a5d-b58b-79602fea3cb5"
      unitRef="U_shares">1089296</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_56a01732-96e4-4efd-9e90-6e3312d5c45d"
      decimals="0"
      id="F_955d642d-eec0-452c-8b84-a08aaf2e76b4"
      unitRef="U_shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_8d865232-5799-4e0f-9833-17a27353c527"
      decimals="0"
      id="F_c1c4f2a8-ac11-4a74-8e37-3545e5740a39"
      unitRef="U_shares">1066275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_56a01732-96e4-4efd-9e90-6e3312d5c45d"
      decimals="0"
      id="F_538177c4-0994-4303-ae33-79cff3b715e9"
      unitRef="U_shares">22066275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7d794ebc-1417-4c1e-9565-4410865a0c4a"
      decimals="0"
      id="F_79184734-9617-4d6f-a4eb-c5dd9d1cf72b"
      unitRef="U_shares">9319326</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="0"
      id="F_1cf5e5f1-c6d2-4ef6-9845-5be0c753ad5e"
      unitRef="U_shares">15460088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_ec1e35a9-62a8-4901-ba68-d433b0db3731"
      unitRef="U_USD">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_b033efef-3169-4463-b25e-9de861f3b049"
      unitRef="U_USD">1000000.0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-3"
      id="F_e256fe8d-2534-46a5-a4a8-6a920e901002"
      unitRef="U_USD">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_5fa6b702-000f-4345-85f6-1e74759db691"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_f5c24b49-5e7d-49ec-ad0d-1ceb8c82889d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under the Company's stock options plans for the years ending December 31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.426%;"/&gt;
        &lt;td style="width:0.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.061%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.588999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.831999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.476%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.882%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,840,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,380,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;363,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,192,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,697,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,928,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,408,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,891,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,410,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options available for future grant, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,460,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626"
      decimals="0"
      id="F_334c1d50-e086-4f7c-b727-7418d72900b1"
      unitRef="U_shares">6840719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1e5bc8db-02a5-46a2-8adb-1290a943c626"
      decimals="2"
      id="F_a85a4504-508d-489f-a55d-bc68417aa719"
      unitRef="U_USDollarShare">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_7e55a122-4bed-406f-9e77-93d35f726f49"
      unitRef="U_shares">9380438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_a51d3215-01b4-4a09-89d2-c922b329622e"
      unitRef="U_USDollarShare">2.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_5ebd414f-aa7b-4013-9ae3-c810bfd7b3ed"
      unitRef="U_shares">363109</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_69a9dfa6-de79-49c3-8bb3-c4e40b3f6a9d"
      unitRef="U_USDollarShare">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="0"
      id="F_ec586387-59db-4992-a511-b283a28c873a"
      unitRef="U_shares">5192179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="2"
      id="F_d512be3a-a4fb-4388-9c89-30f0a452d581"
      unitRef="U_USDollarShare">3.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="0"
      id="F_c8f004f8-cf54-438d-b7c2-5a6b0087707d"
      unitRef="U_shares">10665869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="2"
      id="F_eff43236-ea71-40de-bbfb-e242adfd5cce"
      unitRef="U_USDollarShare">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_886e268a-a5ef-4f8b-9728-ad25b96f9c23"
      unitRef="U_shares">4697500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_d3e523db-d061-4896-872b-01dc736af218"
      unitRef="U_USDollarShare">1.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_b0847764-32d2-4316-87e2-279211be7e60"
      unitRef="U_shares">26250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_9fcb9a18-37b7-4206-9c93-2daf67c7057f"
      unitRef="U_USDollarShare">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="0"
      id="F_01559c7b-b20e-42f0-b7e9-3ef08992a655"
      unitRef="U_shares">4928497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="2"
      id="F_79a90639-44df-47b7-9c17-eb04221e3055"
      unitRef="U_USDollarShare">3.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="0"
      id="F_ec8ad833-1d6f-4866-9cd3-fd021e35f8b4"
      unitRef="U_shares">10408622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="2"
      id="F_3112f6fc-9eb6-4bf3-ba20-5e6bb3c9a477"
      unitRef="U_USDollarShare">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_19519d77-8dcc-438e-b75f-fe88436447dc">P8Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_51a9023c-f7c8-41aa-9bf0-156d6954ff19"
      unitRef="U_USD">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="0"
      id="F_2bf5b6ab-affe-4c49-affb-836a78d1950f"
      unitRef="U_shares">3891598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="2"
      id="F_2fd00e59-19e4-432a-abfb-fb1595736b36"
      unitRef="U_USDollarShare">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_fd444fc4-b195-47e2-b681-12dcc37f2848">P8Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="-3"
      id="F_1feb74f5-456c-47c4-b0fc-4aa1cf4ec88c"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="0"
      id="F_f8dcd49c-055f-4495-9e8c-a069684df0c8"
      unitRef="U_shares">4410312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="2"
      id="F_2e776e5a-1881-4cdc-a7bf-360b4b57e324"
      unitRef="U_USDollarShare">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      id="F_8e56a893-fe1d-4873-aa97-7f573960105c">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b18519ea-5ad5-4c53-b674-b8ef326ea73f"
      decimals="-3"
      id="F_485fe638-1c87-44ba-97a1-58ac2a93ff7f"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e220fa7c-9256-4e4c-9029-f93345c4f771"
      decimals="0"
      id="F_dfa774d2-891c-403d-a8e1-474fd73d688c"
      unitRef="U_shares">15460088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_75f173ba-c8dd-4b99-ad6d-2a5369c1267f"
      decimals="-5"
      id="F_c9e553a3-3e45-47c9-ad12-addc08af8785"
      unitRef="U_USD">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_78cf1452-7b74-4f09-9764-21fb4409a94d"
      id="F_6f7865f7-5ac5-4105-9056-6b1f05a3a34a">P1Y11M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_e31c15e4-38b9-4777-99d9-09e923ff1ef3"
      decimals="0"
      id="F_30dbd877-845f-44ef-91cd-00596256199c"
      unitRef="U_shares">280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_d1081ead-241b-4b47-ab69-635932b5defa"
      decimals="0"
      id="F_6c3871c8-b7c9-448c-9586-a5c6c1c3a8e7"
      unitRef="U_shares">1601224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_e31c15e4-38b9-4777-99d9-09e923ff1ef3"
      decimals="0"
      id="F_08950821-65b2-4249-ac22-9cd3220e301f"
      unitRef="U_shares">18750</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="C_fdd40d07-247d-493f-b328-455e4e9594e3"
      decimals="2"
      id="F_c94a19d3-87af-4ceb-92f9-c392db8574f0"
      unitRef="U_USDollarShare">2.41</us-gaap:SharePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_d1081ead-241b-4b47-ab69-635932b5defa"
      decimals="0"
      id="F_d9513c29-92ae-4f9e-bdf0-1e31934adbed"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_bf1729d1-3562-4efc-9c41-cf2460f162d0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the status of restricted stock as of December 31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.19%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.988999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.623%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.034%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;786,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,601,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;754,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;434,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;306,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_3008e586-4932-4ef5-a77c-b2171288e27c"
      decimals="0"
      id="F_13dd6cfc-e04f-490c-acf9-0cdff7c1c774"
      unitRef="U_shares">786280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3008e586-4932-4ef5-a77c-b2171288e27c"
      decimals="2"
      id="F_4580fd9d-ed5b-4f27-ad80-06e33fb47d59"
      unitRef="U_USDollarShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"
      decimals="0"
      id="F_c18871ed-a704-4b58-9499-b4bcab05afbe"
      unitRef="U_shares">1601224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"
      decimals="2"
      id="F_2e331193-b0c1-42f2-b4d6-671a79b91e12"
      unitRef="U_USDollarShare">2.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"
      decimals="0"
      id="F_4d61733a-9f67-45bc-8f4e-66e03c9591af"
      unitRef="U_shares">754137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"
      decimals="2"
      id="F_82233cc8-c253-4498-822e-9131e63e665a"
      unitRef="U_USDollarShare">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"
      decimals="0"
      id="F_fa193eb3-6600-4314-8dae-93c76ed46f0d"
      unitRef="U_shares">434787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_2c69de33-7c67-4de6-b3b1-2149fb1cd536"
      decimals="2"
      id="F_e437114e-d371-4046-8ca9-419158d8a774"
      unitRef="U_USDollarShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_3a6333ea-87fe-436f-953e-01fe64ba7678"
      decimals="0"
      id="F_3e82ce5e-5711-485b-89e3-fbeb8eddd6b1"
      unitRef="U_shares">1198580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3a6333ea-87fe-436f-953e-01fe64ba7678"
      decimals="2"
      id="F_bceb6e24-4dca-4ebd-80b1-8cf3556f5bc8"
      unitRef="U_USDollarShare">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      decimals="0"
      id="F_13e4b728-939f-4362-b4e1-ed6986a6dfe6"
      unitRef="U_shares">280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      decimals="2"
      id="F_90a8dfb7-e7b7-4c36-a57c-f8a1ee80808a"
      unitRef="U_USDollarShare">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      decimals="0"
      id="F_dbef8ab1-8476-459e-bcbb-0edc4ebe93ad"
      unitRef="U_shares">306617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      decimals="2"
      id="F_a6684e34-3ac1-4b4d-bfe4-f9de02260ccd"
      unitRef="U_USDollarShare">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      decimals="0"
      id="F_fa9b7cc6-f238-4f43-89bc-d228e269c614"
      unitRef="U_shares">232901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      decimals="2"
      id="F_59acd749-216c-49d4-815b-321ea60c7865"
      unitRef="U_USDollarShare">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f70a1072-5f3c-4803-8752-dc98e3a0c142"
      decimals="0"
      id="F_3a7d6e74-aa82-4fe9-9f2a-f9f8cb4229fc"
      unitRef="U_shares">939062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f70a1072-5f3c-4803-8752-dc98e3a0c142"
      decimals="2"
      id="F_2dd76bdd-33d7-4cf1-b827-8ea5def510f6"
      unitRef="U_USDollarShare">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f70a1072-5f3c-4803-8752-dc98e3a0c142"
      decimals="-5"
      id="F_8d800af1-786b-4ca1-bb49-39b079ecc701"
      unitRef="U_USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_4408d8c9-bb09-497d-a18f-ad941f11ff5a"
      id="F_003c9b1f-0051-4ad8-9c93-361298175418">P1Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_6488cde8-4c90-4f5f-8606-be452c16cb26">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;14.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IRC, or the 401(k) Plan. The Company may make contributions to the 401(k) Plan at its discretion. The Company contributed approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the 401(k) Plan during the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      decimals="-5"
      id="F_c7ff7bc1-226c-4229-b02b-18ff910dbe67"
      unitRef="U_USD">500000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_371756af-d614-4bb1-a82f-4dd701f5ea21"
      decimals="-5"
      id="F_2eae1d99-5815-478a-a86f-85ef89fe63c7"
      unitRef="U_USD">700000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb"
      id="F_c62a52c3-3f8c-454f-bc84-9e2e4ee6e276">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;15.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell to lead clinical development and commercialization of certain &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies as set forth in a separate license agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% equity interest in the joint venture in exchange for their contributions to Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2021, Eden BioCell began treating patients in a clinical trial with the Company&#x2019;s investigational CD19 RPM CAR-T cell therapy, under the IND cleared by the Taiwan FDA in December 2020. In the first half of 2021, two patients were treated in this trial. The lead investigator at National Taiwan University in Taipei, has reported no serious adverse safety events in either of these patients. Laboratory results continue to support, as previously published, that non-viral &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; gene transfer is effective in genetically modifying autologous T-cells. Patients were infused two days after gene transfer, thus shortening the turnaround time and demonstrating an advantage over viral methods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on laboratory data from the first two patients generated between March and May 2021, the TriArm/Eden team concluded, in concert with the investigator and the Company, that further process development work is required.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021, Eden BioCell incurred a net loss. In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity is in the process of being dissolved.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_1450b5dd-88ba-4cc4-8794-083ce0aff494"
      decimals="2"
      id="F_c3e21524-6d2a-48b1-ae1c-697208e0cfc0"
      unitRef="U_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'N6;*T9])K(3X/B"<[G=R2Y0_D^#T?]02P,$%     @ VCMG5LUV M2.!0
M@!<  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RMF'UOVS80A[\*X05;
M"]@Q2;VGCH'42=$!71<D[?8W+=,Q44ET22II]NE'RHIDBY3L; V01++OCK_C
MV\/C[(F+;W)#J0(_\JR0EZ.-4MN+Z52F&YH3><ZWM-#?K+G(B=*OXF$JMX*2
M5>649U,,83C-"2M&\UGUV:V8SWBI,E;06P%DF>=$/+^G&7^Z'*'1RP=W[&&C
MS ?3^6Q+'N@]55^WMT*_39LH*Y;30C)> $'7EZ,K=+' B7&H+/YB]$GN/0.3
MRI+S;^;E]]7E"!I%-*.I,B&(_O=(%S3+3"2MXWL==-2T:1SWGU^B?ZB2U\DL
MB:0+GOW-5FIS.8I'8$77I,S4'7_Z2.N$ A,OY9FL_H*GVA:.0%I*Q?/:62O(
M6;'[3W[4';'G@/P>!UP[X%,=O-K!JQ+=*:O2NB:*S&>"/P%AK'4T\U#U3>6M
MLV&%&<9[)?2W3/NI^?NK3U>?%S?@_N/-S9=[, %?[Z_!F[.WX RP GS9\%*2
M8B5G4Z4;,R[3M [\?A<8]P2^INDY\- 88(BQPWUQNCLZ=)_J%)L\<9,GKN)Y
M/?$6I1"T4(!(296\<.6S"^"[ YCE="&W)*67([U>)!6/=#3_]1<4PG>N['Y2
ML(-<O297;RCZ?$'D!NA1 ZEYH-]+]D@RG;QS%'>APBJ46?./<R^!03R;/NZG
M8UM%(0S\QNI I]_H] =UWE&I!$L5W2EUJ=L%"/;:15[B==795M"M+&B4!4>4
MI51WVC*CSCX+K/;\CB+; ND?MZBP$14.BKH5=$O8"M ?>@^75%9#S-6&"KU1
M[,]NE^30$A0E24>T;8/",'2+CAK1T:#H+UR1[ 1]D=5VX-D*;:LHCKV>?HT;
MB?&1?M50%.JYZD^S6K8:4VH,"JI<2F-+0^R'L"/4-D(P\7N$)HW09'A6&B1-
M^'I22KKK2I>^Q&H:(R_LZ+.-?!_W+!H$6Y; 08'7=,LE<P]P[7K0).ZH&K8Y
M%+4'.#0HZL]JA12\F!R?A76H@VD(NV/K, K[YB!J^80&D5 OE %IV&[53[RH
M*\XV2_PX#'KDM4A!WDG\S!A9LHPI1MT018-H>BU%?U:TPZ1;/J%A0%VE*2\U
M-\&6/!L8.!-V(2KN;EQ.JS#N&9464VB84Y]X\3!15.3ZY+K46U8]PYTZ'4@*
MH[V)40NUS:*X5VB++C3,+MV3HJ0MNYP*;?X$?M EJ\,JA%$/I5"+*33,J4]4
MUP+-['X>[DH'K*P3D\,HPDF/S!95:)A5ASC=6XQ.G3:%L(_"+@L<9GH%]<$*
MM;1"P[@ZG)Q.@3:&K,W6-D$A#GI0A5M4X6%46>.]!PAG<6"C":.X.^@.*S]
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M-V"_+_*\>C[@[\/LW[ :_0=02P,$%     @ VCMG5ASC?NM.!P  UB   !@
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MM#])>H2&8!Z=+@>9S\#,GNRI%Z \+34O3NKBG%'G?, C-H2TXU#Z_#&P;>G
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M685IB0>J-C^8/.?)&YP\P">:$IH(AUB*Y+U=QKR!#F\+_QIY01#/)F$#=H;
M7F35%V-QL<GV*2E;\&KAH?J:*T#84A5BOF"R#IFZU&!.>LNM,T.LB%+<: 7[
M*H@C@9$,:S;3Y1Z,^.6%*C6P*0P#%G7SU"BZ@"4<$2JO$$<@&X_@XV,#P4$#
ME@]_1MYE31,]5N[Q$). _38(=+<!M8^_ &N"4M:BDBJR,<#(_Z 'D^0]*C&
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MV59X))ACOR@'&BC3PX,JE,^B>FF41,V<6R_9*IP'?+)ZKY1K5Z)P%AV?,%M
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MNDRNIE?0]6%G,2S]X;NK=)2^(>.G27HQ%+^6XKY:(._$E+D(1G:P%- ,['(
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M=MO3?NEU ^K_5VNI!5 4,4\AB!0,FAG0 Z@X[,[P/*9>OO'4U% +@U:H=8[
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M498ZM5_NZ&M$[03HOE+DZG'C#/2?[?(?4$L#!!0    ( -H[9U:$&D\(J0(
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MSR&K^!7@;GO\EG(!IM)XH:M4@:/SY/FS263&_B;8AK\)I#8$6_-EB;:@'&W
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MQM'DA1-F/M>)PA;QTH"315>\E\[)9%DZY3U07B]ULA1KB:56+W0AL^Q)X)W
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M*@DL: '>SXWQ]0\ZH/G_B9O_ %!+ P04    " #:.V=63_9EH/8:  !Z7
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MAWWMIV3B55,6BFB'#)8U:P99CZ4IV$#O%(ERS\:(1E=>UUCUJE#!8\:^*3
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MV'4-/.@1X$/.0YF*RHE0V+R$K8TJFP&RT]2XH)E/%!L2'JQ*R-;QA@MRN#P
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MC"# ]X6U=-P$ _U_C=7?4$L#!!0    ( -H[9U:%&R\"9@D  '08   9
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M0(?^-(]WWF]47"_=6QR#IB QMJ\ZAM7A1=%U^WYDN[U]R_21:2PR R5?X-'
MGTY&H-LW-^V-5;5[6S)7UJK*7:XXPQF(-N#SA5*VOR$!P^NSJ_\#4$L#!!0
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MA!9":G/9R)ZI/>NAJ^%.4 N&V_NK$] VCKN=X&OPPIADX;?&9T%$Y';'[<&
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M4-=A/O0C"4F696QW=P)]\LO!8O[J+2_F\X1:AGK PB#LZZO+5O]IZ(&A")#
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M9X&60987X'ENC.\N>(/^?P?'_P)02P,$%     @ VCMG5MC258AT(@  DG,
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M\O[6%2O&8&>"M6+^&L=ZHUXFN-3\XE5R"ZP+2Y1)V^!K#M.X3 U3-(@6E34
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M#A[ ?*\W"B6_1\E9!4(S*8B"8N$MP]EJ9.V=P0\&>WUT)C:3K92/5OB2+[S
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M"@J-3L_/ F:ZN=-M4->^UU.--#G\LJ11#<8YD+W0&G<;EZ ?_LEO4$L#!!0
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M-""+U63%CA;[?/736F@MXGQSQUG 97:"^7TCA'[9R0JHUO0M_P502P,$%
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M79',(<?B@I50J#L9XSF6:LIGKB@YX-2 <NH&GA>[.2:%,QJ8M0<^&K"EI*2
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M+;B^$\M?L/+C&[Y8<%7^DF45ZX<6B0NE1;H"HX*49=4_?5GMPQK [>P!>"N
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M0<K/IOF1R#;<=VOWW:/6=_>8QH]$MF&\5QOOO9./>,3XB29CP%IB^I6<SR2
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MTTW4J!;*KH6R2SSG?X2Z(LN$H2 M$<CG.PPG[Q6D\DM7J3MLMQM;+]4;F;,
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M%,;5W^"];HB= 'UP)(#6 70O@-(C 48=8)Q;PJ .&.R7,#H2,*P#AN<&C.J
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MH%9,U$1",?$^A%?7H178-[XQV*J=,3&I+(1X,I//^<0+C"/@L-0F!,7'!FZ
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MP>310$9K$% P\X&,[L!0QC\L0X-<+&*8=?NNVWV3,_O&"?DJA2DUN1<YY*<
M(8KHE22O2M;)(.(=9&,RB3^2)$H2#Z'-][O' W0F?6 G#F]R,;#DCNF,2]TH
M('_?;K51F+O_^$+6(D[]B/9"W^B:9K *\,9J4'L(TE]^BN?1KSZY_Q/8B?AI
M+WXZA)Y^AAP4Y82U03 8!&J(-M0T1JIO1%$#VA>!%C:.'*XM0?LT&MOSV!]+
MNV1UPGG6<YX-<GY"=G#$^",16$7Q!A2=&*MBVV:^C_K,1RJ:O*-^R>J$^KRG
M/A^D_H@'2%56$BIRK&%[+,XUEEI#,@4Y,]Y(S[U$DG=T_59GZ"YZNHL?HVM4
M U=-[:,[C#A*QE'TLZ\,;18>!7[ZUSW]ZPN)(K/G*_MVY 23Q=9$5RU]M(>1
M1O%9VC_@>"+F4R_FT_?<U%"[[+?WDF0E%3OPJ1F&&LW.JKG@Z#N]$S5Q]/:<
M18-8&T<>KS'94]ZTKQCEV*Q0D7DU7< ;Q==G55UR3:87=1T]T_$@V'U1@.MX
M7!FRY^05$P]E>\=ZT*:E%QXU%!6HG>NS-&9[(TS[(O>K?2]WZSJ8=^MKV^.Y
M1N4-IFT0OU*U8T(3#@5"1N,%5D;5]ESMQ,C:M2U;:; )<L,2^U10U@"_%U*:
MUXG=H.]\T_\ 4$L#!!0    ( -L[9U9$C^Q&A00  *@6   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;+58;5/C-A#^*QKWI@,S5VPIB1UHDAD(O2F=
MH\/ T7ZXZ0=A;Q+W;"LG*01F^N.[LHV=8",NP7Q)_*)]M,]J=_58H[60W]0"
M0).'-,G4V%EHO3QQ714N(.7J2"PAPS<S(5.N\5;.7;64P*/<*$U<YGF^F_(X
M<R:C_-F5G(S$2B=Q!E>2J%6:<OEX!HE8CQWJ/#VXCN<+;1ZXD]&2S^$&].WR
M2N*=6Z%$<0J9BD5&),S&SBD]F3)F#/(1?\6P5AO7Q%"Y$^*;N;F(QHYG/(($
M0FT@./[=PQ22Q""A']]+4*>:TQAN7C^A?\K)(YD[KF JDK_C2"_&SM A$<SX
M*M'78OT[E(0&!B\4B<I_R;H8&S"'A"NE15H:HP=IG!7__*$,Q(8!]5\P8*4!
M>V[0?\&@5QKT<J*%9SFM<Z[Y9"3%FD@S&M',11Z;W!K9Q)E9QALM\6V,=GIR
MD84B!?*%/X BOY#3*(I->'E"+K(B24RP#\Y!\S@YQ!&W-^?DX,,A^4#BC'Q9
MB)7B6:1&KD9G#*0;EA.?%1.S%R:FC%R*3"\4^2V+(-H&<)%%184]43EC5L1S
M"(](CWXDS&.LQ:'ICYM3BSN]*K*]'*_W(Y']^AG?D@L-J?JG+58%5+\=RI3R
MB5KR$,8.UJH">0_.Y.>?J._]VL:S([ MUOV*==^&/OD3.P_V&(EYD\U)(I0B
M(9?R$7-IS65[HA2(?HYHVL[]A ;4"[R1>[])JV68W^\/_6K8EL.#RN&!U>%S
MF(&4$!'-'PA7"K2R$L#ZU)CUFL##,I9 (JZAC50QZV##VQ[K#;WGI*S.[;E6
M?D7=MU*_1D0NPP7!"L;6=X\]?8D=6I,0XQ'KUQ?.;W#L>Y3ZSR@V1_6.AS1H
M7[:@\CVP^GZ;A2"Q)V6FP,B54'G;4MC _L6F:5BT.1PT7'F^'D$CR;QV1X>5
MHT.KH]@&<'M50 XB**X.3>>,FFG7YO"PX; ?-'+(ZL">.71<T3NVEP_V.*7C
M,%^&TQ66AHSU(_EZ">D=R-9>9P7<M==U!+;%G7KUYNEUU^-+K(Z(=X6VS7Q#
M-M#.^WP)N5E<OC\8-/+9/O6^U%A-C;V)VL>B]1?*Z*7V;Y^CG0/S>@%I7>L]
MP%X/2"UDJ%4Q3#Y!A-%(\FWB1B-A:WG;P79.\_<0,[16,[3?88%;I='.S#M"
MVV9>RR+Z#KKH-5%4SKG9 7I]VMS1[+[MR[W61=0NC+KI /8YF-=O_4BQF^U+
MO995U*ZK7JYU\A^I!*/9[*>%2)QN!*8U#-;Y=BZ*CM"VHU-K.3KLL!UTI,M*
MYN^A\F@M\ZA=Y[WY6Z'$WRQ]_%AH5OY["#I6"SIFE4V3(N4-Q\\BQ#+X8R5C
M%<7%D9-MU[/C[KK87:%M1Z$6=XQVE^:L([56,G\/[<=J[<?>IOU: \":F7T<
M'#=2VS[UKM3<C3._%.0\/PI%;\4JT\696?6T.FX]S0\9GST_HR?3XM"TABG.
M<"^YG,?X39W #"&]HP!W95D<BQ8W6BSSD\4[H;5(\\L%<-Q S !\/Q-"/]V8
M":K#Z<G_4$L#!!0    ( -L[9U8#NK;2* 0  /(4   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;+6848_B-A#'OXJ5GMH[:4OB$&!W"T@LN:HK=5MT
M=-N'4Q],,A!KDYBS';CKIZ^=A$ @I$1R>0#'\?SM^=D>#Q[O&7\3$8!$7Y,X
M%1,KDG+[:-LBB" AHL>VD*HW:\83(M4CW]ABRX&$N5$2VZ[C#.V$T-2:CO.Z
M!9^.629CFL*"(Y$E">'?GB!F^XF%K4/%)[J)I*ZPI^,MV< 2Y.MVP=637:F$
M-(%44)8B#NN)-<.//AYJ@[S%GQ3VXJ2,M"LKQM[TPW,XL1P](H@AD%J"J)\=
MS"&.M9(:QY=2U*KZU(:GY8/ZS[GSRID5$3!G\5\TE-'$NK=0"&N2Q?(3V_\"
MI4,#K1>P6.3?:%^V=2P49$*RI#16(TAH6OR2KR6($P/L73%P2P/WW&!XQ:!?
M&O1O[<$K#;R<3.%*SL$GDDS'G.T1UZV5FB[D,'-KY3Y-];PO)5=OJ;*3TX7"
M#)Q#B):2!6^(I&4I8G$(7/R /G[)J/R&WONPI@&5']"/:!:&5,\:B=%S6JP]
M/8>JB20TUBU>ESYZ_^X#>H=L)"+"02":HM>42G&G*E7YCXAE0O4FQK94?NC1
MV$$YYGDQ9O?*F+&+7E@J(X$^IB&$=0%; :@HN <*3VZKXF]LUT,8WR'7P?=-
M VHW]R'HH7YN[KH-YO[MYKC%FWXUI_U<KW]%KYRQS[^J>O0L(1%_-PSJJ1#Q
MFD5TO'D46Q+ Q%(!10#?@37]_CL\='YJ F12S#<D5H/G5?"\-O7IG"6)6LM"
M[X&[P]HEF8P8I_^<+[8"9*M@5Y"%V" 7TT%[-_54#,\_8WMW2NFR97]PWK*&
M8% A&+0B>%;;E*J]O<A6,0W0[VL5(6BZ06R-2CIYA&A"T2K<%44A-CIQT.DY
M#C[#\%^M:@B&%8)A*X+99L-A0R0HITOOMYP&T.1SJU)7GPNQX8DWV!NYWIG/
MAKJLH1E5:$;=-XC**(14T5R!:D+4JM@5T>ABW;N>XV%G-#Q?&@TM\1"[(\_K
M-R^/^XK!_2T,BB/S\PLD*^"-,;95IJOC)L5\0V(U? \5O@<3!]2#27@FQ7Q#
M8C5XV#FF;([I(ZI=L2O+4NV60\I4QW54)]DM-A;'VZ4Z,\(7D?PBC)OJL0['
M/<)QC4?R=LG.D-R;8[FICNNLCBDU;DTZ:Q&_8E5V%"+U'PBM,YEQ0%2(C*17
M5IC1E+M4JR6 ZN,\#"_6V?^14.-C1HW;4^HE!!E7*:4BMLAX$*F_Z6BF]B4D
MD,K6X[-=N#,PDVJ^*;4ZU&..C@<FSE!L-",WJN:;4JL3/*;XV%R.CR_S<F^$
MST^[>7N/G?D83?/MDTNB!/@FOVP3*&!9*HO[HJJVNM";Y==8]K%Y<1OX0OB&
MI@+%L%:F3F^D)I(7%VS%@V3;_,IIQ:1D25Z,@(3 =0/U?LV8/#SH#JIKSNF_
M4$L#!!0    ( -L[9U:A,9^-N@<  &=#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;,6<:W.;.!2&_XK&V]EI9]H8A*_=Q#.)0;/=V6PS3;/[H=,/
M"I9MIH"\0N2RTQ^_XA*# *NF/9U\23#6>1!ZQ9%X+3B]Y^)+LF5,HH<HC).S
MP5;*W=OA,/&W+*+)"=^Q6'VSYB*B4GT4FV&R$XRN\J H'&++F@PC&L2#Q6F^
M[THL3GDJPR!F5P(E:111\7C!0GY_-K '3SL^!)NMS'8,%Z<[NF'73-[LKH3Z
M--Q35D'$XB3@,1)L?38XM]\29YP%Y"7^#MA]4MM&V:G<<OXE^_!N=3:PLAJQ
MD/DR0U#U[XXM61AF)%6/?TOH8'_,++"^_40G^<FKD[FE"5OR\)]@);=G@]D
MK=B:IJ'\P.]_9^4)Y17T>9CD?]%]6=8:(#]-)(_*8%6#*(B+__2A;(A: !X=
M",!E &X$V(<"G#+ .39@5 :,C@T8EP'C9H!S(&!2!DSRMB\:*V]IETJZ.!7\
M'HFLM*)E&[E<>;1JX"#.>M:U%.K;0,7)Q;7D_A?T?I?+?!72&+U!YZM5D'VF
M(0KBHO-FW[YTF:1!^$J5N+EVT<L7K] +-$3)E@J6J)+H)@YD\EKM5-L?MSQ-
M:+Q*3H=253,[V- OJW115 D?J)*-T26/Y39!7KQB*QTP5.>W/TG\=)(7V$AT
MF7^"'/LUPA;&'15:'A]N=X2[QX=;'>&>.?R/-%;AUL%P8@Z_I(_EP6UL:$IG
MWU^<'.<<ZB^9VF^R:WF%ECQ2"2XI>L>Y$#3>,)5T)+I]1/5R5_0QWWU^3\4*
M??I3(=$[R:+D<U?G*(X_ZCY^EFC?)COJL[.!RJ0)$W=LL/CU%WMB_=8E+"3,
MA81YD# "!--ZQ&C?(T8F^N)]*A.IKO0@WB">YQ&5#)(D;5ZYA;H%:YRSLE'O
M;F%;(VLVR:[+N[IR704GD_%L,M<+NNV"D]G(FMJ-<I[Q+/HV.!!,:_#QOL''
MQ@:_$MQG;)6@M> 12O($_M3P[($)/TBZV[[ 3FHME:4SK=7;16S+F31:W%B]
MOM<!)(P P319)GM9)D99/G*9#YA2!&K>Y:,[&J8,\?63-EV*3-J*-!I[V2XR
MLZR&(,:*]14$$D: 8)H@T[T@4W-B*J\)>J=F+?0V9$C-9= ZE:E@:*-&*]DE
MR;2==\:CB67-9@UAC ?O.[1 PCQ(& &":0K.]@K.C I^8(FZFGRIYA#%//73
M)8MNF?B,OB(OVH7\D:F9Y]/.+C6-_+Z3"4B8"PGS(&$$"*8I/M\K/G_FZ>4<
MLD= PEQ(F <)(T PK4?85G6':AFS0%WK7:DUS;7.DWCW7*=DUO,X5@-G<^A<
M=I13%;<Q'C7&6',E^\H#2B-0-%V@FH5@?R--[U+A;Y5 V73GNO #U%8S?7?J
M9+?;?S8=MV1J%VM.@LR5["T0)(U T72!<"40_L8=0^ SM&.B$*=3AX(PJU\O
M)Z/F[8'Y.'T3'BC- Z41*)JN6.6RV,9;]L5-?*<NGM:\IU,Y4,,$E.:"TCQ0
M&H&BZ0I7KHD]>N:9C@WI>"Q!:2XHS0.E$2B:WC$J=\<VVSLWL6 ^W\3!?TIQ
MO]XS?)[(! D6TBPS2(YB'K\I\X2HQMK2$:ILN<[.T79Z)K@].X)T9UQ0F@=*
M(U T7?3*.[+-YI'WL&-^H6.N?:ZW&K #WCV[-=-L],BH0+:-HN*'%!NMZ&/G
M50WI]KB@- ^41J!HNL"5%V6;S:C]@%Z;%*NTK_0Y9HB'='26H#07E.:!T@@4
M3=>\<J_LV7,/\:#^%BC-!:5YH#0"1=,[1F5RV4;'I'>V-]/*;#_?)WLKR_9=
MOS<LS:3>"H,Z5J T D73UQM4GA7^"9X5/M*SZBC7[5F9*]E7(% :@:+I E6>
M%39[5MHL.Y\QEVII,V[VD&VS8^?<M,KKG3_WE772?EZUV_)"6D\N*,T#I1$H
MFMX'*EL,FVTQN65HD*V+R1<^#8Q3,#.J[T@+2G-!:1XHC4#1=(DK'PT_]W(E
M#&J_@=)<4)H'2B-0-+UC5/8;-J]:*N^]BKQ='F!57R"0+6&BL=]IEIO9O34'
M==9 :1XHC>".15TCR]*F.+J>E6N&S:[9]RWV**'-569X.FZ.R:!&&"C- Z41
M*)JN8V6$8;-U=6A,1E_1)7T(HC0R#].0GM$2E.:"TCQ0&H&BZ:I7[AB>/O<P
M#6JA@=)<4)H'2B-0-+UC5!8:-J\ ^[%A>M:1W6=S/&^NL317HK><H,87*(U
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M5!J(YZL\YX<;.4%S0+CX#U!+ P04    " #;.V=6;88-"9 #  !;#   &0
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MH<I1O*QDRXYD>U,,/C&I2DO3W*GJ'[@V4.\WC,F7CIZ@_CT1_P=02P,$%
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M*$G<"&!N!U&$(7 WX@CF #Q@2!29]^#.^RA8O:>"]2^XPV=02P,$%     @
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M_R>IGL[GYNOE+\NOG7B_:"\X)_AWY_$O4$L#!!0    ( -L[9U9TTL9BW@$
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M;TS5'O-9_TO-[ U02P$"% ,4    " #:.V=6!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -H[9U;S
M(*:B[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( -H[9U:97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ VCMG5AG^X&],!P
M=3   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( -H[9U;-=@+4C@4  ( 7   8              " @8\/
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #:.V=6,YA(
MT#\"   =!@  &               @(%3%0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ VCMG5J%Q%&J<!   &Q$  !@
M ("!R!<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -H[
M9U;:ZM\2#P8  &TE   8              " @9H<  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " #:.V=6'.-^ZTX'  #6(   &
M        @('?(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ VCMG5HAM 7O%"0  .Q@  !@              ("!8RH  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -H[9U9V[K/FB 8  '41   8
M              " @5XT  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " #:.V=6LH6KJF<A  !3:P  &               @($<.P  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ VCMG5HN*/[MI"
MJ18  !D              ("!N5P  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " #:.V=6[X0 !DP#  !X!P  &0              @(%9
M90  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -H[9U:$
M&D\(J0(  -4%   9              " @=QH  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ VCMG5I+NAQV7!P  ,!(  !D
M     ("!O&L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -H[9U:%&R\"9@D  '08   9              "
M@5RC  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ VCMG
M5O5XRUM1!P  2A,  !D              ("!^:P  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " #:.V=6<QEK5-("  " !@  &0
M        @(&!M   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( -H[9U96N8W^# <  $<0   9              " @8JW  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ VCMG5MC258AT(@  DG,
M !D              ("!S;X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " #:.V=6/GU4A;$&  !.$@  &0              @(%XX0
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -H[9U8S266<
MS@(  .L%   9              " @6#H  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ VCMG5BI#<7_: @  +08  !D
M ("!9>L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #:
M.V=6<FYN"[8"  #7!0  &0              @(%V[@  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -H[9U92BM$T2P,  )P'   9
M          " @6/Q  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#
M%     @ VCMG5F#E*;RX @  " 8  !D              ("!Y?0  'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #:.V=6X$R(EGH$  ![
M"@  &0              @('4]P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;%!+ 0(4 Q0    ( -H[9U;N%3-X7P0  %@*   9              " @87\
M  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ VCMG5D!E
M"L=\ P  N0T  !D              ("!&P$! 'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"% ,4    " #:.V=6_//'G]@&  #?-P  &0
M    @('.! $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M -H[9U:6T(KV,P4  !P>   9              " @=T+ 0!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ VCMG5N(<TMC? @  RP@  !D
M             ("!1Q$! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " #:.V=6SC2]2$<#  #P"P  &0              @(%=% $ >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -H[9U8I?>AX,@,
M ,@*   9              " @=L7 0!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ VCMG5N]=Y',( P  T @  !D              ("!
M1!L! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #:.V=6
MTY%?0NP#  #F$@  &0              @(&#'@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( -H[9U:[W6?#]P(  *L)   9
M      " @:8B 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ VCMG5JN0Q9LZ"0  H$8  !D              ("!U"4! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #:.V=6I%N[/Z4#  !J$0
M&0              @(%%+P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( -H[9U;YJE\.I0(  "H'   9              " @2$S 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ VCMG5ASN R/^
M @  7@D  !D              ("!_34! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " #:.V=6&2VNQCX$  #.&0  &0
M@($R.0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( -H[
M9U8&TB:+F@D  "MD   9              " @:<] 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ VCMG5H0!<8ZG @  % <  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( -L[9U8V*XWMW (  ,L(   9
M  " @7AO 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
MVSMG5MW L[<K!   1P\  !D              ("!BW(! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " #;.V=6%"](6EH#   %"P  &0
M            @('M=@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( -L[9U9$C^Q&A00  *@6   9              " @7YZ 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ VSMG5@.ZMM(H!
M\A0  !D              ("!.G\! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6Q02P$"% ,4    " #;.V=6H3&?C;H'  !G0P  &0              @(&9
M@P$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( -L[9U8B
MS522O00  "P4   9              " @8J+ 0!X;"]W;W)K<VAE971S+W-H
M965T-3<N>&UL4$L! A0#%     @ VSMG5FV&#0F0 P  6PP  !D
M     ("!?I ! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
M" #;.V=6TCX*77$"  #7!0  &0              @(%%E $ >&PO=V]R:W-H
M965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -L[9U;D-;*N/@(  /,$   9
M              " @>V6 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L!
M A0#%     @ VSMG5C)H8D12 P  SA4   T              ( !8ID! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #;.V=6EXJ[',     3 @  "P
M        @ '?G $ 7W)E;',O+G)E;'-02P$"% ,4    " #;.V=67R_,D^\$
M  !9)P  #P              @ '(G0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ VSMG5I@;6I[[ 0  RR,  !H              ( !Y*(! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ VSMG5G32QF+> 0
M6B,  !,              ( !%Z4! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $0 1 "3$@  )J<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>180</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/Financings</Role>
      <ShortName>Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/JointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/AccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables</Role>
      <ShortName>Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20221231/taxonomy/role/StockOptionPlan</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Financings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail</Role>
      <ShortName>Financings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment, net - Component of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, net - Component of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment, net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Accrued Expenses - Component of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Component of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Leases - Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Restructuring - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail</Role>
      <ShortName>Restructuring - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Restructuring - Future termination benefit payments resulting from the strategic reduction in force (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail</Role>
      <ShortName>Restructuring - Future termination benefit payments resulting from the strategic reduction in force (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Significant Component of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Significant Component of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail</Role>
      <ShortName>Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock Option Plan - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail</Role>
      <ShortName>Stock Option Plan - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail</Role>
      <ShortName>Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail</Role>
      <ShortName>Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tcrt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Joint Venture  - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail</Role>
      <ShortName>Joint Venture  - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: tcrt:OperatingLeasesExpirationMonthAndYear -  tcrt-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tcrt-20221231.htm">tcrt-20221231.htm</File>
    <File>tcrt-20221231.xsd</File>
    <File>tcrt-20221231_cal.xml</File>
    <File>tcrt-20221231_def.xml</File>
    <File>tcrt-20221231_lab.xml</File>
    <File>tcrt-20221231_pre.xml</File>
    <File>tcrt-ex23_1.htm</File>
    <File>tcrt-ex31_1.htm</File>
    <File>tcrt-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img159912857_0.jpg</File>
    <File>img159912857_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="534">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tcrt-20221231.htm": {
   "axisCustom": 4,
   "axisStandard": 30,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 534,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 180,
   "dts": {
    "calculationLink": {
     "local": [
      "tcrt-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tcrt-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tcrt-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tcrt-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tcrt-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tcrt-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 728,
   "entityCount": 1,
   "hidden": {
    "http://alaunos.com/20221231": 1,
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 8
   },
   "keyCustom": 79,
   "keyStandard": 284,
   "memberCustom": 47,
   "memberStandard": 26,
   "nsprefix": "tcrt",
   "nsuri": "http://alaunos.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://alaunos.com/20221231/taxonomy/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://alaunos.com/20221231/taxonomy/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://alaunos.com/20221231/taxonomy/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:WarrantTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Warrants",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://alaunos.com/20221231/taxonomy/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:WarrantTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://alaunos.com/20221231/taxonomy/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Stock Option Plan",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://alaunos.com/20221231/taxonomy/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Joint Venture",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://alaunos.com/20221231/taxonomy/role/JointVenture",
     "shortName": "Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://alaunos.com/20221231/taxonomy/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://alaunos.com/20221231/taxonomy/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stock Option Plans (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables",
     "shortName": "Stock Option Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Organization - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Financings - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
     "shortName": "Financings - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:FinancingArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e9343419-8bf1-4057-a39a-08c499c72684",
      "decimals": "INF",
      "lang": null,
      "name": "tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_f2309968-f205-40c9-9241-713fc3396454",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_f2309968-f205-40c9-9241-713fc3396454",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
     "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_567da217-a1b9-4ef0-a65c-10a90ca9e5da",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
     "shortName": "Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
     "shortName": "Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
     "shortName": "Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Debt - Schedule of Debt (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
     "shortName": "Debt - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_3f2cc6cf-873b-457d-a3f2-2aec2c6cc50f",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_3f2cc6cf-873b-457d-a3f2-2aec2c6cc50f",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment, net - Component of Property and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
     "shortName": "Property and Equipment, net - Component of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Property and Equipment, net - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tcrt:AccruedClinicalExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Accrued Expenses - Component of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Component of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tcrt:AccruedClinicalExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_1ce3d76b-39aa-4c2b-9bcd-7339fdd665a9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_1ce3d76b-39aa-4c2b-9bcd-7339fdd665a9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Leases - Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RoyaltyExpense",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RoyaltyExpense",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Warrants - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail",
     "shortName": "Warrants - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_7c4f4916-db64-490f-8174-b66da79fd2dd",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_1e5bc8db-02a5-46a2-8adb-1290a943c626",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
     "shortName": "STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_1e5bc8db-02a5-46a2-8adb-1290a943c626",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_371756af-d614-4bb1-a82f-4dd701f5ea21",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Restructuring - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
     "shortName": "Restructuring - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_fcb43152-91fe-48f4-aad0-514fa76c5e42",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_371756af-d614-4bb1-a82f-4dd701f5ea21",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Restructuring - Future termination benefit payments resulting from the strategic reduction in force (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail",
     "shortName": "Restructuring - Future termination benefit payments resulting from the strategic reduction in force (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_4c2387b7-8249-4b21-9502-83899b598473",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes - Significant Component of Deferred Tax Assets (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Significant Component of Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "lang": null,
      "name": "tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
     "shortName": "Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_e220fa7c-9256-4e4c-9029-f93345c4f771",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Stock Option Plan - Additional information (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
     "shortName": "Stock Option Plan - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_b18519ea-5ad5-4c53-b674-b8ef326ea73f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
     "shortName": "Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_3a6333ea-87fe-436f-953e-01fe64ba7678",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
     "shortName": "Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_3008e586-4932-4ef5-a77c-b2171288e27c",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_1450b5dd-88ba-4cc4-8794-083ce0aff494",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Joint Venture  - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail",
     "shortName": "Joint Venture  - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_1450b5dd-88ba-4cc4-8794-083ce0aff494",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://alaunos.com/20221231/taxonomy/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Financings",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://alaunos.com/20221231/taxonomy/role/Financings",
     "shortName": "Financings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20221231.htm",
      "contextRef": "C_0f9697de-19cb-43d0-ba43-ad3a65ec7eeb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r207",
      "r434",
      "r435",
      "r436",
      "r437",
      "r513",
      "r595",
      "r676",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r207",
      "r434",
      "r435",
      "r436",
      "r437",
      "r513",
      "r595",
      "r676",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r368",
      "r546",
      "r567",
      "r596",
      "r597",
      "r614",
      "r621",
      "r627",
      "r681",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r368",
      "r546",
      "r567",
      "r596",
      "r597",
      "r614",
      "r621",
      "r627",
      "r681",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r263",
      "r548",
      "r615",
      "r625",
      "r673",
      "r674",
      "r683",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r263",
      "r548",
      "r615",
      "r625",
      "r673",
      "r674",
      "r683",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r358",
      "r368",
      "r398",
      "r399",
      "r400",
      "r522",
      "r546",
      "r567",
      "r596",
      "r597",
      "r614",
      "r621",
      "r627",
      "r672",
      "r681",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r358",
      "r368",
      "r398",
      "r399",
      "r400",
      "r522",
      "r546",
      "r567",
      "r596",
      "r597",
      "r614",
      "r621",
      "r627",
      "r672",
      "r681",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r175",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r235",
      "r278",
      "r279",
      "r423",
      "r443",
      "r447",
      "r448",
      "r449",
      "r484",
      "r505",
      "r506",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r175",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r235",
      "r278",
      "r279",
      "r423",
      "r443",
      "r447",
      "r448",
      "r449",
      "r484",
      "r505",
      "r506",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r175",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r224",
      "r235",
      "r423",
      "r443",
      "r447",
      "r448",
      "r484",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r668",
      "r669",
      "r720",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r225",
      "r369",
      "r638",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r616",
      "r626",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r580",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r616",
      "r626",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r225",
      "r369",
      "r638",
      "r639",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r663",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AccrualsPriorToFirstMarketingApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due prior to the first marketing approval for TCR products.",
        "label": "Accruals Prior to First Marketing Approval",
        "terseLabel": "Payments due prior to the first marketing approval"
       }
      }
     },
     "localname": "AccrualsPriorToFirstMarketingApproval",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical expenses current.",
        "label": "Accrued clinical expenses current",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccruedConsultingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued consulting fees, current.",
        "label": "Accrued Consulting Fees, Current",
        "terseLabel": "Other consulting services"
       }
      }
     },
     "localname": "AccruedConsultingFeesCurrent",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccruedManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing costs, current.",
        "label": "Accrued Manufacturing Costs, Current",
        "terseLabel": "Manufacturing services"
       }
      }
     },
     "localname": "AccruedManufacturingCostsCurrent",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccruedPaymentsOfTcrProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Payments of TCR Products.",
        "label": "Accrued Payments Of Tcr Products",
        "terseLabel": "Accrued Payments"
       }
      }
     },
     "localname": "AccruedPaymentsOfTcrProducts",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccruedPaymentsOrReceiptsUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payments or receipts under collaboration agreement.",
        "label": "Accrued Payments Or Receipts Under Collaboration Agreement",
        "terseLabel": "Accrued payments or receipts"
       }
      }
     },
     "localname": "AccruedPaymentsOrReceiptsUnderCollaborationAgreement",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccruedPreclinicalServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical services current.",
        "label": "Accrued Preclinical Services Current",
        "terseLabel": "Preclinical services"
       }
      }
     },
     "localname": "AccruedPreclinicalServicesCurrent",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AdditionalLoansCommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional loans committed.",
        "label": "Additional Loans Committed",
        "terseLabel": "Additional Loans Committed"
       }
      }
     },
     "localname": "AdditionalLoansCommitted",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AdditionalNumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of warrants issued.",
        "label": "Additional Number Of Warrants Issued",
        "terseLabel": "Additional number warrants issued"
       }
      }
     },
     "localname": "AdditionalNumberOfWarrantsIssued",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_AdditionalPaidInCapitalCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock [Member]",
        "terseLabel": "Additional Paid In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStockMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AggregateAmountPotentiallyReimburseableAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Amount Potentially Reimburseable Amount.",
        "label": "Aggregate Amount Potentially Reimburseable Amount",
        "verboseLabel": "Reimbursement of historical costs"
       }
      }
     },
     "localname": "AggregateAmountPotentiallyReimburseableAmount",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AggregateBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Aggregate Benchmark Payments Payable.",
        "label": "Aggregate Benchmark Payments Payable",
        "verboseLabel": "Aggregate Benchmark Payments Payable"
       }
      }
     },
     "localname": "AggregateBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AggregateMinimumAnnualRoyaltiesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate minimum annual royalties paid.",
        "label": "Aggregate Minimum Annual Royalties Paid",
        "terseLabel": "Aggregate minimum annual royalties paid"
       }
      }
     },
     "localname": "AggregateMinimumAnnualRoyaltiesPaid",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AggregatePotentialBenchmarkPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential benchmark payments.",
        "label": "Aggregate potential benchmark payments",
        "terseLabel": "Aggregate potential benchmark payments"
       }
      }
     },
     "localname": "AggregatePotentialBenchmarkPayments",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period.",
        "label": "Agreement Termination Notice Period",
        "verboseLabel": "Agreement termination, notice period"
       }
      }
     },
     "localname": "AgreementTerminationNoticePeriod",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "tcrt_AgreementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Type [Axis]"
       }
      }
     },
     "localname": "AgreementTypeAxis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_AgreementTypeAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Type Axis [Axis]"
       }
      }
     },
     "localname": "AgreementTypeAxisAxis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_AgreementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Type [Domain]"
       }
      }
     },
     "localname": "AgreementTypeDomain",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AnnualBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent.",
        "label": "Annual Base Rent",
        "terseLabel": "Annual base rent increase"
       }
      }
     },
     "localname": "AnnualBaseRent",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_AnnualExpenseIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual expense incurred.",
        "label": "Annual Expense Incurred",
        "terseLabel": "Annual expense incurred"
       }
      }
     },
     "localname": "AnnualExpenseIncurred",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AnnualLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual License Fees",
        "label": "Annual License Fees",
        "verboseLabel": "Annual License fee"
       }
      }
     },
     "localname": "AnnualLicenseFees",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AresTradingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares Trading [Member]",
        "label": "Ares Trading [Member]",
        "terseLabel": "ARES Trading License"
       }
      }
     },
     "localname": "AresTradingMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities Eliminated upon Consolidation [Abstract]",
        "label": "Assets and Liabilities Eliminated upon Consolidation [Abstract]",
        "verboseLabel": "Net Proceeds from Underwriting"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesEliminatedUponConsolidationAbstract",
     "nsuri": "http://alaunos.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tcrt_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering [Member]",
        "terseLabel": "Market Offering [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_BlackScholesModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Model [Member].",
        "label": "Black Scholes Model [Member]",
        "terseLabel": "Black-Scholes Model [Member]"
       }
      }
     },
     "localname": "BlackScholesModelMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_BonusDepreciationEligibilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus Depreciation Eligibility, Percentage",
        "label": "Bonus Depreciation Eligibility, Percentage",
        "terseLabel": "Eligibility for bonus depreciation, percentage"
       }
      }
     },
     "localname": "BonusDepreciationEligibilityPercentage",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_CARProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAR Products [Member]",
        "terseLabel": "C A R Products [Member]"
       }
      }
     },
     "localname": "CARProductsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CRADAAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRADA Agreement",
        "label": "CRADA Agreement [Member]"
       }
      }
     },
     "localname": "CRADAAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ClassOfWarrantOrRightAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Axis.",
        "label": "Class Of Warrant Or Right Axis [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxisAxis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ClassOfWarrantOrRightDomainDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right.",
        "label": "Class Of Warrant Or Right Domain [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomainDomain",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CollaborationAgreementWithSolasiaPharmaKkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with solasia pharma K.K.",
        "label": "Collaboration Agreement With Solasia Pharma KK [Member]",
        "terseLabel": "Collaboration Agreement with Solasia Pharma K.K. [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementWithSolasiaPharmaKkMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "terseLabel": "Accrued Payments",
        "verboseLabel": "Accrued Payments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments and Contingencies Disclosure [Table]",
        "terseLabel": "Commitments and Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_CommonStockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuance cost.",
        "label": "Common Stock Issuance Cost",
        "terseLabel": "Issuance of common stock, commissions and expenses"
       }
      }
     },
     "localname": "CommonStockIssuanceCost",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_CommonStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options.",
        "label": "Common stock options [Member]",
        "terseLabel": "Common stock options [Member]"
       }
      }
     },
     "localname": "CommonStockOptionsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ConditionalMilestoneAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional milestone amount payable.",
        "label": "Conditional Milestone Amount Payable",
        "terseLabel": "Conditional milestone amount payable"
       }
      }
     },
     "localname": "ConditionalMilestoneAmountPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]",
        "terseLabel": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ContributionPayableOnPerAnnumBasis": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution payable on per annum basis.",
        "label": "Contribution Payable on Per Annum Basis",
        "terseLabel": "Contribution payable on per annum basis"
       }
      }
     },
     "localname": "ContributionPayableOnPerAnnumBasis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_CostIncurredInAppointmentOfDirectors": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Incurred in appointment of directors.",
        "label": "Cost Incurred in Appointment of Directors",
        "terseLabel": "Cost Incurred in appointment of directors"
       }
      }
     },
     "localname": "CostIncurredInAppointmentOfDirectors",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_Covid19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Covid 19 [Member]",
        "terseLabel": "Covid 19"
       }
      }
     },
     "localname": "Covid19Member",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_DebtInstrumentPrepaymentPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment premium.",
        "label": "Debt Instrument Prepayment Premium",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremium",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized acquisition costs.",
        "label": "Deferred Tax Assets, Capitalized Acquisition Costs",
        "terseLabel": "Capitalized acquisition costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedAcquisitionCosts",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DeferredTaxAssetsDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets depreciation.",
        "label": "Deferred Tax Assets, Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciation",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DeferredTaxAssetsLeaseLiability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DeferredTaxAssetsResearchExpensesCapitalized": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets research expenses capitalized.",
        "label": "Deferred Tax Assets Research Expenses Capitalized",
        "terseLabel": "Capitalized research expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchExpensesCapitalized",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets start up and pre clinical studies.",
        "label": "Deferred Tax Assets Start Up And Pre Clinical Studies",
        "terseLabel": "Start-up and pre-clinical studies"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartUpAndPreClinicalStudies",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DeferredTaxLiabilityRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability Right of Use Asset.",
        "label": "Deferred Tax Liability Right of Use Asset",
        "negatedLabel": "Right of use asset",
        "totalLabel": "Deferred Tax Liability Right of Use Asset, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilityRightOfUseAsset",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DescriptionOfFirstAnnualRoyaltyPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of First Annual Royalty Payable.",
        "label": "Description Of First Annual Royalty Payable",
        "verboseLabel": "Description Of First Annual Royalty Payable"
       }
      }
     },
     "localname": "DescriptionOfFirstAnnualRoyaltyPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DescriptionOfFirstBenchmarkPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of First Benchmark Payable.",
        "label": "Description Of First Benchmark Payable",
        "verboseLabel": "Description Of First Benchmark Payable"
       }
      }
     },
     "localname": "DescriptionOfFirstBenchmarkPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.",
        "label": "Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones",
        "verboseLabel": "Description Of option To terminate Agreement"
       }
      }
     },
     "localname": "DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DevelopmentCostsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development costs paid.",
        "label": "Development Costs Paid",
        "terseLabel": "Development costs paid"
       }
      }
     },
     "localname": "DevelopmentCostsPaid",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Earning Per share Basic and Diluted",
        "label": "Disclosure Of Earning Per share Basic and Diluted [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEarningPerShareBasicAndDilutedAbstract",
     "nsuri": "http://alaunos.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tcrt_DiscountedRiskAdjustedRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted risk adjusted rates.",
        "label": "Discounted Risk Adjusted Rates",
        "terseLabel": "Discounted Risk-adjusted Rate"
       }
      }
     },
     "localname": "DiscountedRiskAdjustedRates",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_DueDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date [Axis]"
       }
      }
     },
     "localname": "DueDateAxis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DueDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date [Domain]"
       }
      }
     },
     "localname": "DueDateDomain",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EarningPerShareBasicAndDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earning Per share Basic and Diluted",
        "label": "Earning Per share Basic and Diluted [Line Items]"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDilutedLineItems",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_EarningPerShareBasicAndDilutedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earning Per share Basic and Diluted",
        "label": "Earning Per share Basic and Diluted [Table]"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDilutedTable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_EdenBioCellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Bio Cell",
        "label": "Eden Bio Cell [Member]"
       }
      }
     },
     "localname": "EdenBioCellMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EdenBiocellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Biocell.",
        "label": "Eden Biocell [Member]"
       }
      }
     },
     "localname": "EdenBiocellMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate limitation on adjusted taxable income.",
        "label": "Effective Income Tax Rate Limitation On Adjusted Taxable Income",
        "terseLabel": "Relaxation of Adjusted taxable income, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible expense federal rate change.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change",
        "terseLabel": "Federal/state rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible expense research and development true up.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Research and Development True Up",
        "terseLabel": "Research and development true-up"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_EightScheduledPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eighth Scheduled Payment.",
        "label": "Eighth Scheduled Payment [Member]",
        "terseLabel": "Eight Scheduled Payment"
       }
      }
     },
     "localname": "EightScheduledPaymentMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EligibilityOfBonusPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligibility of bonus percentage.",
        "label": "Eligibility Of Bonus Percentage",
        "terseLabel": "Eligible bonus percentage"
       }
      }
     },
     "localname": "EligibilityOfBonusPercentage",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_EmbeddedDerivativeDividendAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Embedded Derivative, Dividend Amount",
        "label": "Embedded Derivative, Dividend Amount",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "EmbeddedDerivativeDividendAmount",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_EmployeeStockOptionAndRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock option and Restricted stock.",
        "label": "Employee Stock Option And Restricted Stock Member",
        "terseLabel": "Stock Options and Restricted Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionAndRestrictedStockMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity distribution agreement.",
        "label": "Equity Distribution Agreement [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity [Line Items]",
        "label": "Equity [Line Items]",
        "terseLabel": "Equity [Line Items]"
       }
      }
     },
     "localname": "EquityLineItems",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ExpectedCashPaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Expected Cash Payment Payable.",
        "label": "Expected Cash Payment Payable",
        "verboseLabel": "Expected Cash Payment Payable"
       }
      }
     },
     "localname": "ExpectedCashPaymentPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_ExpectedCashPaymentPayablePerInstallments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected cash payment payable per installments.",
        "label": "Expected Cash Payment Payable Per Installments",
        "terseLabel": "Expected cash payment payable per installments"
       }
      }
     },
     "localname": "ExpectedCashPaymentPayablePerInstallments",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_FairValueAssumptionsOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Assumptions of Preferred Stock.",
        "label": "Fair Value Assumptions Of Preferred Stock",
        "verboseLabel": "Fair Value Assumptions of Preferred Stock"
       }
      }
     },
     "localname": "FairValueAssumptionsOfPreferredStock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_FairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Warrants",
        "label": "Fair Value of Warrants"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and State [Member]",
        "label": "Federal and State [Member]",
        "terseLabel": "Federal and State"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_FinancingArrangementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.",
        "label": "Financing Arrangements Disclosure [Text Block]",
        "terseLabel": "Financings"
       }
      }
     },
     "localname": "FinancingArrangementsDisclosureTextBlock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/Financings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_GainLossOnModificationOfLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on modification of lease.",
        "label": "Gain (Loss) On Modification Of Lease",
        "terseLabel": "Gain (Loss) On Modification Of Lease"
       }
      }
     },
     "localname": "GainLossOnModificationOfLease",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_GainLossOnOperatingLeaseModification": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on operating lease modification.",
        "label": "Gain (Loss) On Operating Lease Modification",
        "negatedLabel": "Gain on lease modification",
        "terseLabel": "Gain on lease modification"
       }
      }
     },
     "localname": "GainLossOnOperatingLeaseModification",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_GeneralBusinessCreditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General Business Credits [Member]",
        "label": "General Business Credits [Member]",
        "terseLabel": "General Business Credits"
       }
      }
     },
     "localname": "GeneralBusinessCreditsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_GroupThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group Three",
        "label": "Group Three [Member]",
        "terseLabel": "Upon enrollment of the first patient in a multi-center pivotal clinical trial"
       }
      }
     },
     "localname": "GroupThreeMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_HoustonTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Houston Texas [Member]",
        "label": "Houston Texas [Member]",
        "verboseLabel": "Houston, TX [Member]"
       }
      }
     },
     "localname": "HoustonTexasMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_IncreaseDecreaseInRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of right of use asset reported as assets.",
        "label": "Increase Decrease In Right Of Use Asset",
        "negatedLabel": "Decrease (increase) in the carrying amount of right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAsset",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_InitialBenchmarkPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first benchmark payment due upon the initiation of the Company's first sponsored phase.",
        "label": "Initial Benchmark Payment Due",
        "terseLabel": "First benchmark payment"
       }
      }
     },
     "localname": "InitialBenchmarkPaymentDue",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_InterestExpenseAmortizedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense amortized date.",
        "label": "Interest Expense Amortized Date",
        "terseLabel": "Interest expense amortized date"
       }
      }
     },
     "localname": "InterestExpenseAmortizedDate",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_IntrexonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrexon Corporation/Precigen [Member]",
        "terseLabel": "Intrexon Corporation/Precigen",
        "verboseLabel": "Intrexon Corporation [Member]"
       }
      }
     },
     "localname": "IntrexonCorporationMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_IssuanceOfCommonStockNetOfExpensesInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock, net of expenses in shares.",
        "label": "Issuance Of Common Stock Net Of Expenses In Shares",
        "terseLabel": "Issuance of common stock, net of expenses (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockNetOfExpensesInShares",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Lessee Operating Lease Monthly Average Rental Payment .",
        "label": "Lessee Operating Lease Monthly Average Rental Payment",
        "terseLabel": "Operating Lease Monthly Rental Payment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyAverageRentalPayment",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LicenseAgreementCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement commencement date.",
        "label": "License Agreement Commencement Date",
        "terseLabel": "Agreement commencement date"
       }
      }
     },
     "localname": "LicenseAgreementCommencementDate",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "tcrt_LicenseAgreementCommencingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement commencing date.",
        "label": "License Agreement Commencing Date",
        "terseLabel": "License agreement commencing date"
       }
      }
     },
     "localname": "LicenseAgreementCommencingDate",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_LicenseAgreementWithTheNationalCancerInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement with the National Cancer Institute [Member]"
       }
      }
     },
     "localname": "LicenseAgreementWithTheNationalCancerInstituteMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_LicenseExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to License payments.",
        "label": "License Expense",
        "terseLabel": "License Expense"
       }
      }
     },
     "localname": "LicenseExpense",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LicensedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Products [Member]"
       }
      }
     },
     "localname": "LicensedProductsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MD Anderson License and the Research and Development Agreement Member [Member]",
        "terseLabel": "MD Anderson License and the Research and Development Agreement Member [Member]"
       }
      }
     },
     "localname": "MDAndersonLicenseAndTheResearchAndDevelopmentAgreementMemberMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MA",
        "label": "MA [Member]",
        "verboseLabel": "Boston, MA [Member]"
       }
      }
     },
     "localname": "MaMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MarketOffering",
        "label": "Market Offering [Member]"
       }
      }
     },
     "localname": "MarketOfferingMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MaximumAmountOfAdditionalMilestonesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of additional milestones payable.",
        "label": "Maximum Amount of Additional Milestones Payable",
        "verboseLabel": "Expected additional milestones payable"
       }
      }
     },
     "localname": "MaximumAmountOfAdditionalMilestonesPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumAmountOfRoyaltiesReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalties receivable.",
        "label": "Maximum Amount of Royalties Receivable",
        "verboseLabel": "Amount of royalties receivable"
       }
      }
     },
     "localname": "MaximumAmountOfRoyaltiesReceivable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumAmountOfRoyaltyPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalty payable.",
        "label": "Maximum Amount of Royalty Payable",
        "verboseLabel": "Maximum royalty amount"
       }
      }
     },
     "localname": "MaximumAmountOfRoyaltyPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of common stock issuable upon conversion of preferred stock.",
        "label": "Maximum Percentage Of Common Stock Issuable Upon Conversion Of Preferred Stock"
       }
      }
     },
     "localname": "MaximumPercentageOfCommonStockIssuableUponConversionOfPreferredStock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_MaximumRoyaltiesAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum royalties amount payable.",
        "label": "Maximum Royalties Amount Payable",
        "terseLabel": "Maximum royalties amount payable"
       }
      }
     },
     "localname": "MaximumRoyaltiesAmountPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumRoyaltyAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalty.",
        "label": "Maximum Royalty Amount",
        "terseLabel": "Maximum royalty amount"
       }
      }
     },
     "localname": "MaximumRoyaltyAmount",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Sales Revenue On Which Benchmark Payments Payable",
        "label": "Maximum Sales Revenue On Which Benchmark Payments Payable"
       }
      }
     },
     "localname": "MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MdAndersonAgreementAndWorldwideLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Agreement and Worldwide License.",
        "label": "MD Anderson Agreement and Worldwide License [Member]"
       }
      }
     },
     "localname": "MdAndersonAgreementAndWorldwideLicenseMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "M.D. Anderson Cancer Center.",
        "label": "MD Anderson Cancer Center [Member]",
        "verboseLabel": "M.D. Anderson Cancer Center"
       }
      }
     },
     "localname": "MdAndersonCancerCenterMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson License and the Research and Development Agreement.",
        "label": "MD Anderson License and the Research and Development Agreement [Member]"
       }
      }
     },
     "localname": "MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson License.",
        "label": "Md Anderson License [Member]",
        "terseLabel": "MD Anderson License"
       }
      }
     },
     "localname": "MdAndersonLicenseMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson [Member]",
        "label": "MD Anderson [Member]"
       }
      }
     },
     "localname": "MdAndersonMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MDAndersonWarrantMember.",
        "label": "Md Anderson Warrant [Member]",
        "terseLabel": "MD Anderson Warrant [Member]",
        "verboseLabel": "MD Anderson Warrant [Member]"
       }
      }
     },
     "localname": "MdAndersonWarrantMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "One time milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MilestonePaymentMadeOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment made One.",
        "label": "Milestone Payment Made One",
        "terseLabel": "Milestone payment made"
       }
      }
     },
     "localname": "MilestonePaymentMadeOne",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MilestonePaymentsMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments maximum amount.",
        "label": "Milestone Payments, Maximum Amount",
        "terseLabel": "Milestone maximum payment"
       }
      }
     },
     "localname": "MilestonePaymentsMaximumAmount",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MinimumRoyaltiesAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Minimum Royalties Amount Payable.",
        "label": "Minimum Royalties Amount Payable",
        "verboseLabel": "Minimum royalties amount payable"
       }
      }
     },
     "localname": "MinimumRoyaltiesAmountPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum sales revenue on which benchmark payments payable.",
        "label": "Minimum Sales Revenue On Which Benchmark Payments Payable",
        "terseLabel": "Minimum sales revenue on which benchmark payments payable"
       }
      }
     },
     "localname": "MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_NetOperatingLossCarryforwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryforwards [Member]",
        "label": "Net Operating Loss Carryforwards [Member]",
        "terseLabel": "Net Operating Loss Carryforwards"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_NewWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Warrants [Member]"
       }
      }
     },
     "localname": "NewWarrantsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_NonOperatingIncomeExpenseInducementOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Operating Income Expense Inducement Of Warrants.",
        "label": "Non Operating Income Expense Inducement Of Warrants",
        "negatedLabel": "Non-cash inducement warrant expense",
        "terseLabel": "Non-cash inducement warrant expense",
        "verboseLabel": "Non-cash inducement warrant expense"
       }
      }
     },
     "localname": "NonOperatingIncomeExpenseInducementOfWarrants",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_NonVestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Restricted Stock",
        "label": "Non Vested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Common Stock [Member]"
       }
      }
     },
     "localname": "NonVestedRestrictedStockMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_NonVestedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Stock [Member]",
        "label": "Non Vested Stock [Member]",
        "terseLabel": "Unvested Stock [Member]"
       }
      }
     },
     "localname": "NonVestedStockMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional option available to the underwriter to purchase.",
        "label": "Number Of Additional Option Available To The Underwriter To Purchase",
        "terseLabel": "Number of additional option available to the underwriter to purchase"
       }
      }
     },
     "localname": "NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_NumberOfDaysOptionExerciable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NumberofDaysOptionExerciable",
        "label": "Number of Days Option Exerciable"
       }
      }
     },
     "localname": "NumberOfDaysOptionExerciable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "tcrt_NumberOfSharesVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares vested.",
        "label": "Number Of Shares Vested",
        "terseLabel": "Shares vested"
       }
      }
     },
     "localname": "NumberOfSharesVested",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_ObligationsDueUnderContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations due under contract.",
        "label": "Obligations Due Under Contract",
        "verboseLabel": "Obligations due under contract"
       }
      }
     },
     "localname": "ObligationsDueUnderContract",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_OfficeAndComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Computer Equipment [Member].",
        "label": "Office And Computer Equipment [Member]",
        "terseLabel": "Office and computer equipment [Member]"
       }
      }
     },
     "localname": "OfficeAndComputerEquipmentMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_OneTimeBenchmarkPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Time Benchmark Payments [Member]"
       }
      }
     },
     "localname": "OneTimeBenchmarkPaymentsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_OperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease area.",
        "label": "Operating Lease Area",
        "terseLabel": "Operating Lease Area"
       }
      }
     },
     "localname": "OperatingLeaseArea",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "tcrt_OperatingLeasesExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases expiration month and year.",
        "label": "Operating Leases Expiration Month and Year",
        "verboseLabel": "Operating lease expiration month and year"
       }
      }
     },
     "localname": "OperatingLeasesExpirationMonthAndYear",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases future minimum monthly payment due through year four.",
        "label": "Operating Leases Future Minimum Monthly Payment Due Through Year Four",
        "verboseLabel": "Operating Leases Future Minimum Monthly Payment Due Through Years February 2027 and April 2028"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_OperatingLossCarryforwardsExpirationDatesState": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Expiration Dates State",
        "label": "Operating Loss Carryforwards Expiration Dates State",
        "terseLabel": "Net operating loss carryforwards, expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDatesState",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "tcrt_OperatingLossCarryforwardsResearchExpirationDates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Research Expiration Dates",
        "label": "Operating Loss Carryforwards Research Expiration Dates",
        "terseLabel": "Net operating loss carryforwards, expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsResearchExpirationDates",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "tcrt_OrganizationalChangesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for organizational changes.",
        "label": "Organizational Changes [Policy Text Block]",
        "terseLabel": "Organizational Changes"
       }
      }
     },
     "localname": "OrganizationalChangesPolicyTextBlock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_OtherIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income expense member.",
        "label": "Other Income Expense [Member]",
        "terseLabel": "Other Income Expense [Member]"
       }
      }
     },
     "localname": "OtherIncomeExpenseMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PatentAndTechnologyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and technology license agreement.",
        "label": "Patent And Technology License Agreement [Member]",
        "terseLabel": "Patent And Technology License Agreement [Member]"
       }
      }
     },
     "localname": "PatentAndTechnologyLicenseAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PaymentForAnnualLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Annual License Fees.",
        "label": "Payment For Annual License Fees",
        "verboseLabel": "Annual Licensing fee paid"
       }
      }
     },
     "localname": "PaymentForAnnualLicenseFees",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for historical costs of the licensed programs.",
        "label": "Payment for Historical Costs of the Licensed Programs",
        "terseLabel": "Payment for historical costs of the licensed programs"
       }
      }
     },
     "localname": "PaymentForHistoricalCostsOfTheLicensedPrograms",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PaymentTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Type [Axis]"
       }
      }
     },
     "localname": "PaymentTypeAxis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_PaymentTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Type [Domain]"
       }
      }
     },
     "localname": "PaymentTypeDomain",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PaymentUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment under license agreement.",
        "label": "Payment Under License Agreement",
        "terseLabel": "Payment under license agreement"
       }
      }
     },
     "localname": "PaymentUnderLicenseAgreement",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PaymentsUnderPatentLicense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments under patent license",
        "label": "Payments Under Patent License",
        "verboseLabel": "payments under the Patent License"
       }
      }
     },
     "localname": "PaymentsUnderPatentLicense",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on gross proceeds from sale of common stock",
        "label": "Percentage Of Commission On Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Sales commission as a percentage of gross proceeds"
       }
      }
     },
     "localname": "PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original principal due as a final payment.",
        "label": "Percentage of Original Principal Due as a Final Payment",
        "terseLabel": "Percentage of original principal due as a final payment"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalDueAsAFinalPayment",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfPaymentOfLicenseFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payment of license fee.",
        "label": "Percentage Of Payment Of License Fee",
        "terseLabel": "Percentage of upfront fee Payable"
       }
      }
     },
     "localname": "PercentageOfPaymentOfLicenseFee",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfPrepaymentsPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayments premium.",
        "label": "Percentage Of Prepayments Premium",
        "terseLabel": "Percentage of prepayments premium"
       }
      }
     },
     "localname": "PercentageOfPrepaymentsPremium",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sub licensing income, attributable to related party.",
        "label": "Percentage of Sub licensing Income Payable to Related Party",
        "verboseLabel": "Portion of income payable to related party"
       }
      }
     },
     "localname": "PercentageOfSubLicensingIncomePayableToRelatedParty",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PerformanceBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based payments.",
        "label": "Performance Based Payments [Member]"
       }
      }
     },
     "localname": "PerformanceBasedPaymentsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PeriodTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Type [Axis]",
        "label": "Period Type [Axis]",
        "terseLabel": "Period Type [Axis]"
       }
      }
     },
     "localname": "PeriodTypeAxis",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_PeriodTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Type [Domain]",
        "label": "Period Type [Domain]",
        "terseLabel": "Period Type [Domain]"
       }
      }
     },
     "localname": "PeriodTypeDomain",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PlacementAgentFeesAndOtherRelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent fees and other related expenses.",
        "label": "Placement Agent Fees And Other Related Expenses",
        "verboseLabel": "Placement agent fees and other expenses"
       }
      }
     },
     "localname": "PlacementAgentFeesAndOtherRelatedExpenses",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PocketExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pocket expenses.",
        "label": "Pocket Expenses",
        "terseLabel": "Pocket Expenses"
       }
      }
     },
     "localname": "PocketExpenses",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PostMarketingApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Marketing Approval [Member]"
       }
      }
     },
     "localname": "PostMarketingApprovalMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PotentialBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Potential Benchmark Payments Payable.",
        "label": "Potential Benchmark Payments Payable",
        "verboseLabel": "Potential Benchmark Payments Payable"
       }
      }
     },
     "localname": "PotentialBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PreferredStockConversionFloorPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock conversion floor price.",
        "label": "Preferred Stock Conversion Floor Price",
        "terseLabel": "Preferred conversion floor price"
       }
      }
     },
     "localname": "PreferredStockConversionFloorPrice",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "perShareItemType"
    },
    "tcrt_PreferredStockRedemptionDiscountDerivatives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in currently redeemable preferred stock.",
        "label": "Preferred stock Redemption Discount Derivatives",
        "verboseLabel": "Settlement of a related party relationship"
       }
      }
     },
     "localname": "PreferredStockRedemptionDiscountDerivatives",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment and right of use assets impairment",
        "label": "Property And Equipment And Right Of Use Assets Impairment",
        "terseLabel": "Property and equipment and right-of-use assets impairment"
       }
      }
     },
     "localname": "PropertyAndEquipmentAndRightOfUseAssetsImpairment",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PublicOfferingNetPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering, net price per share",
        "label": "Public offering, net price per share",
        "terseLabel": "Issuance &amp; sale of common stock in public offering price per share"
       }
      }
     },
     "localname": "PublicOfferingNetPricePerShare",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "tcrt_QualifiedImprovementPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualified Improvement Property [Member]",
        "terseLabel": "Qualified Improvement Property"
       }
      }
     },
     "localname": "QualifiedImprovementPropertyMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_QuarterlyExpenseIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly expense incurred.",
        "label": "Quarterly Expense Incurred",
        "terseLabel": "Quarterly expense incurred"
       }
      }
     },
     "localname": "QuarterlyExpenseIncurred",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_QuarterlyPaymentsUnderContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly payments under contract.",
        "label": "Quarterly Payments Under Contract",
        "verboseLabel": "Quarterly payments under contract"
       }
      }
     },
     "localname": "QuarterlyPaymentsUnderContract",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction expenses from transactions with related party advisory fees.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party Advisory Fees",
        "terseLabel": "Related Party Transaction Expenses From Transactions With Related Party Advisory Fees",
        "verboseLabel": "Expenses From Transactions With Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_RelatedPartyTransactionReimbursedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction Reimbursed Amount.",
        "label": "Related Party Transaction Reimbursed Amount",
        "terseLabel": "Related party transaction, reimbursed amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionReimbursedAmount",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_ResearchAndDevelopmentServiceAgreementQuarterlyPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development service agreement quarterly payment.",
        "label": "Research And Development Service Agreement Quarterly Payment",
        "terseLabel": "Research and development service agreement aggregate quarterly payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServiceAgreementQuarterlyPayment",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_ResearchAndDevelopmentServicesContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development services contract term.",
        "label": "Research and Development Services Contract Term"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesContractTerm",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "tcrt_RoyaltiesAmountPayableThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties amount payable thereafter.",
        "label": "Royalties Amount Payable thereafter",
        "terseLabel": "Royalties amount payable thereafter"
       }
      }
     },
     "localname": "RoyaltiesAmountPayableThereafter",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_ScheduleOfEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Equity [Table]",
        "label": "Schedule Of Equity [Table]",
        "terseLabel": "Schedule Of Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityTable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SeriesOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 1 Preferred Stock [Member]",
        "label": "Series 1 Preferred Stock [Member]",
        "terseLabel": "Series 1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesOnePreferredStockMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SeriesOnePreferredStockMezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series One Preferred Stock Mezzanine [Member]",
        "label": "Series One Preferred Stock Mezzanine [Member]",
        "terseLabel": "Series 1 Preferred Stock - Mezzanine"
       }
      }
     },
     "localname": "SeriesOnePreferredStockMezzanineMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SettlementOfRelatedPartyRelationshipTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Of Related Party Relationship",
        "label": "Settlement Of Related Party Relationship [Text Block]",
        "verboseLabel": "Settlement of relatedparty relationship"
       }
      }
     },
     "localname": "SettlementOfRelatedPartyRelationshipTextBlock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SettlementOfARelatedPartyRelationship"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ShareSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Subscription Agreement",
        "label": "Share Subscription Agreement [Member]"
       }
      }
     },
     "localname": "ShareSubscriptionAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Shares Authorized",
        "terseLabel": "Shares of authorized capital stock"
       }
      }
     },
     "localname": "SharesAuthorized",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_SiliconValleyBankLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank loan.",
        "label": "Silicon Valley Bank Loan [Member]",
        "terseLabel": "Silicon Valley Bank Loan [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankLoanMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon valley bank.",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Issuance Of Common Stock In Connection With Public Offering.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock In Connection With Public Offering",
        "terseLabel": "Issuance of common stock in connection with a public offering, net of commissions and expenses of $5,900 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPublicOffering",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_StockIssuedDuringPeriodSharesWarrantExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares warrant exercise.",
        "label": "Stock Issued During Period Shares Warrant Exercise",
        "terseLabel": "Warrant exercise, net of commissions and expenses of $1.1 million (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_StockIssuedDuringPeriodValueNetOnExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value ,Net On Exercise Of Warrants",
        "label": "Stock Issued During Period Value net On Exercise Of Warrants",
        "verboseLabel": "Issuance of common stock upon exercise of warrants, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNetOnExerciseOfWarrants",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_StockIssuedDuringPeriodValueWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value warrant exercise.",
        "label": "Warrant exercise, net of commissions and expenses of $1.1 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantExercise",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_StockOfferedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock offered during period shares.",
        "label": "Stock Offered During Period Shares",
        "terseLabel": "Stock issued during period",
        "verboseLabel": "Stock issued during period"
       }
      }
     },
     "localname": "StockOfferedDuringPeriodShares",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and Restricted Stock Awards.",
        "label": "Stock Options And Restricted Stock Awards Text Block [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_SubleaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease area.",
        "label": "Sublease Area",
        "terseLabel": "Sublease Area"
       }
      }
     },
     "localname": "SubleaseArea",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "tcrt_SubleaseTermCommencedEndDateAmendment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease term commenced end date amendment.",
        "label": "Sublease Term Commenced End Date Amendment",
        "verboseLabel": "Sublease term amendment"
       }
      }
     },
     "localname": "SubleaseTermCommencedEndDateAmendment",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_SvbWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Svb Warrants [Member].",
        "label": "Svb Warrants [Member]",
        "terseLabel": "Svb Warrants [Member]"
       }
      }
     },
     "localname": "SvbWarrantsMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TaxRelaxationOnTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax relaxation on taxable income.",
        "label": "Tax Relaxation On Taxable Income",
        "terseLabel": "Relaxation of taxable income, percentage"
       }
      }
     },
     "localname": "TaxRelaxationOnTaxableIncome",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_TcellReceptorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "T-Cell Receptor [Member]",
        "verboseLabel": "T-Cell Receptor [Member]"
       }
      }
     },
     "localname": "TcellReceptorMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TenthScheduledPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenth Scheduled Payment.",
        "label": "Tenth Scheduled Payment [Member]",
        "terseLabel": "Tenth Scheduled Payment"
       }
      }
     },
     "localname": "TenthScheduledPaymentMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan member",
        "label": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System",
        "label": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]",
        "terseLabel": "The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]"
       }
      }
     },
     "localname": "TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold commitment period for exercise of rights to participate in future offerings.",
        "label": "Threshold Commitment Period for Exercise of Rights to Participate in Future Offerings",
        "terseLabel": "Threshold period for exercise or conversion of stock"
       }
      }
     },
     "localname": "ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_TotalCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total compensation expense.",
        "label": "Total Compensation Expense",
        "terseLabel": "Total compensation expense"
       }
      }
     },
     "localname": "TotalCompensationExpense",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_TriArmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tri Arm",
        "label": "Tri Arm [Member]"
       }
      }
     },
     "localname": "TriArmMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandTwelveEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twelve Equity Incentive Plan [Member]",
        "label": "Two Thousand Twelve Equity Incentive Plan [Member]",
        "terseLabel": "the \"2012 Plan\" [Member]"
       }
      }
     },
     "localname": "TwoThousandTwelveEquityIncentivePlanMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandTwelveStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twelve Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwelveStockOptionPlanMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "verboseLabel": "the \"2020 Plan\" [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_UncategorizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncategorized [Abstract]",
        "label": "Uncategorized [Abstract]"
       }
      }
     },
     "localname": "UncategorizedAbstract",
     "nsuri": "http://alaunos.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tcrt_UnderwriterParOrStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriter par or stated value per share.",
        "label": "Underwriter Par or Stated Value Per Share",
        "terseLabel": "Underwriter par or stated value per share"
       }
      }
     },
     "localname": "UnderwriterParOrStatedValuePerShare",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "tcrt_UnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement",
        "label": "Underwriting Agreement [Member]",
        "terseLabel": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_UnderwritingAgreementWithJefferiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement with Jefferies [Member]",
        "terseLabel": "Underwriting Agreement with Jefferies [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementWithJefferiesMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_VinetiIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vineti Inc.",
        "label": "Vineti Inc [Member]",
        "terseLabel": "Vineti Inc [Member]"
       }
      }
     },
     "localname": "VinetiIncMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_WarrantTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to the warrant.",
        "label": "Warrant [Text Block]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantTextBlock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_WarrantsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsDisclosureAbstract",
     "nsuri": "http://alaunos.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tcrt_WarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiration Date",
        "label": "Warrants Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "WarrantsExpirationDate",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_WarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrants.",
        "label": "Warrants [Policy Text Block]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsPolicyTextBlock",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_WatermillAndRobertWPostmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Watermill And Robert W Postma.",
        "label": "Watermill And Robert W Postma [Member]",
        "terseLabel": "Watermill And Robert W Postma [Member]"
       }
      }
     },
     "localname": "WatermillAndRobertWPostmaMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
        "label": "Ziop License Agreement With The National Cancer Institute [Member]",
        "terseLabel": "Ziop License Agreement With The National Cancer Institute [Member]"
       }
      }
     },
     "localname": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ZiopharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ziopharm [Member]",
        "label": "Ziopharm [Member]"
       }
      }
     },
     "localname": "ZiopharmMember",
     "nsuri": "http://alaunos.com/20221231",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASU 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r624"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r150",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued Liabilities, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79",
      "r182"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r211",
      "r212",
      "r213",
      "r214",
      "r225",
      "r267",
      "r268",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r403",
      "r404",
      "r405",
      "r420",
      "r421",
      "r422",
      "r423",
      "r430",
      "r431",
      "r432",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r476",
      "r477",
      "r481",
      "r482",
      "r483",
      "r484",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r549",
      "r550",
      "r551",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r117",
      "r118",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r87",
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Net share based employee compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r29",
      "r337",
      "r479",
      "r648"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r50",
      "r76"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Property and equipment and right-of-use asset impairment",
        "totalLabel": "Asset Impairment Charges, Total"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r145",
      "r160",
      "r184",
      "r205",
      "r247",
      "r257",
      "r261",
      "r272",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r434",
      "r436",
      "r460",
      "r624",
      "r677",
      "r678",
      "r732"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r178",
      "r189",
      "r205",
      "r272",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r434",
      "r436",
      "r460",
      "r624",
      "r677",
      "r678",
      "r732"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "localname": "BankingAndThriftInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r58",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts included in accrued expenses and accounts payable related to property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r180",
      "r599"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash balance"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r52",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r136"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CharityCareDirectAndIndirectCostBasisAmount": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of charity care provided during the period based on the provider's direct and indirect costs of providing charity care services.",
        "label": "Charity Care, Direct and Indirect Cost Basis, Amount"
       }
      }
     },
     "localname": "CharityCareDirectAndIndirectCostBasisAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r205",
      "r228",
      "r229",
      "r231",
      "r233",
      "r237",
      "r238",
      "r272",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r460",
      "r598",
      "r637",
      "r650",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r102",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise per share",
        "verboseLabel": "Warrant Exercise Per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of Warrants",
        "verboseLabel": "Number of securities into which the class of warrant converted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r151",
      "r165"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r300",
      "r301",
      "r581",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCallOrExerciseFeatures": {
     "auth_ref": [
      "r7",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe the call and/or exercise rights, prices and dates of common stock.",
        "label": "Common Stock, Call or Exercise Features",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "CommonStockCallOrExerciseFeatures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Common Stock, shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r653",
      "r654",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Initial Public Offering of Common Stock",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r7",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Common stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r624"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock $0.001 par value; 420,000,000 shares authorized, 240,410,761 shares issued and outstanding at December 31, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r158",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r30",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Licensing fee",
        "totalLabel": "Cost of Goods and Services Sold, Total"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Fees and Expenses, Related Party"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r204",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r331",
      "r338",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r146",
      "r147",
      "r159",
      "r207",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r480",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Line of credit facility, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r147",
      "r159",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Loan and Security Agreement",
        "totalLabel": "Total debt",
        "verboseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Debt instrument description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r138",
      "r140",
      "r315",
      "r480",
      "r610",
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Loan and Security Agreement"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date Range, Start",
        "terseLabel": "Debt instrument, initial maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r207",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r480",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Third anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Second anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r95",
      "r98",
      "r99",
      "r100",
      "r137",
      "r138",
      "r140",
      "r157",
      "r207",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r480",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r137",
      "r140",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized discount on Loan and Security Agreement",
        "terseLabel": "Unamortized discount on Loan and Security Agreement",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r139",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Issuance costs",
        "totalLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "terseLabel": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]",
        "terseLabel": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r714"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r714"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r130",
      "r715"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Deferred tax assets operating loss carryforwards without expire date"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Deferred tax assets operating loss carryforwards with expire date"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r130",
      "r715"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r128",
      "r130",
      "r715"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r130",
      "r715"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r123",
      "r714"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r357",
      "r359",
      "r367",
      "r617",
      "r618",
      "r619",
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Defined benefit plan contributions by employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r50",
      "r77"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r26",
      "r132",
      "r144",
      "r190",
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "negatedTerseLabel": "Change in fair value",
        "terseLabel": "Change in fair value of derivative liabilities",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total",
        "verboseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsChangeInDerivativeLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r101",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends",
        "totalLabel": "Dividends, Total"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.",
        "label": "Dividends [Axis]",
        "terseLabel": "Dividends [Axis]"
       }
      }
     },
     "localname": "DividendsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.",
        "label": "Dividends [Domain]",
        "terseLabel": "Dividends [Domain]"
       }
      }
     },
     "localname": "DividendsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r101",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedLabel": "Preferred stock dividends",
        "totalLabel": "Dividends, Preferred Stock, Total"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToAffiliateCurrentAndNoncurrent": {
     "auth_ref": [
      "r141",
      "r149",
      "r167",
      "r169",
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due to Affiliate",
        "terseLabel": "Reimbursement of expenses due"
       }
      }
     },
     "localname": "DueToAffiliateCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r198",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r226",
      "r228",
      "r231",
      "r232",
      "r233",
      "r235",
      "r448",
      "r449",
      "r564",
      "r566",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share, basic",
        "terseLabel": "Earnings per share, Basic",
        "totalLabel": "Net loss per share, basic",
        "verboseLabel": "Net income (loss) per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r198",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r228",
      "r231",
      "r232",
      "r233",
      "r235",
      "r448",
      "r449",
      "r564",
      "r566",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, diluted",
        "terseLabel": "Earnings per share, Diluted",
        "totalLabel": "Net loss per share, diluted",
        "verboseLabel": "Net income (loss) per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r206",
      "r410",
      "r425"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal income tax at statutory rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r712",
      "r716"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r712",
      "r716"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r712",
      "r716"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r712",
      "r716"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.",
        "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash",
        "totalLabel": "Employee Benefit and Share-based Payment Arrangement, Noncash, Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to non-vested restricted stock outstanding"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r174",
      "r194",
      "r195",
      "r196",
      "r208",
      "r209",
      "r210",
      "r212",
      "r221",
      "r224",
      "r236",
      "r277",
      "r352",
      "r403",
      "r404",
      "r405",
      "r422",
      "r423",
      "r447",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r506",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity interest in affilated entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r72",
      "r248",
      "r641"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "verboseLabel": "Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r50",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Grant Date Fair Value of a warrant",
        "verboseLabel": "Fair value of adjustment of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r451",
      "r452",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r329",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r452",
      "r519",
      "r520",
      "r521",
      "r610",
      "r611",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r451",
      "r452",
      "r454",
      "r455",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r329",
      "r359",
      "r364",
      "r452",
      "r519",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r329",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r519",
      "r520",
      "r521",
      "r610",
      "r611",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "verboseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liability, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r340",
      "r349",
      "r438",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r607",
      "r664",
      "r665",
      "r666",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on sale of equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Gain on lease modification",
        "terseLabel": "Gain on lease modification"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r288",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r411",
      "r412",
      "r418",
      "r424",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r193",
      "r408",
      "r409",
      "r412",
      "r413",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r547",
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Changes in contract liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase (decrease) in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r647"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables",
        "totalLabel": "Increase (Decrease) in Receivables, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r139",
      "r154",
      "r197",
      "r246",
      "r478"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r35",
      "r335",
      "r343",
      "r612",
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r199",
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees.",
        "label": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions",
        "terseLabel": "Strategic advisory services fee",
        "totalLabel": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total"
       }
      }
     },
     "localname": "InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r495",
      "r623"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Lease, Cost, Total",
        "verboseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseIncome": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.",
        "label": "Lease Income",
        "terseLabel": "Lease income",
        "totalLabel": "Lease Income, Total"
       }
      }
     },
     "localname": "LeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest and adjustments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "Lease income from sublease, 2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "Lease income from sublease, 2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "Lease income from sublease, 2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r205",
      "r272",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r435",
      "r436",
      "r437",
      "r460",
      "r605",
      "r677",
      "r732",
      "r733"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r148",
      "r162",
      "r624",
      "r652",
      "r667",
      "r723"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r179",
      "r205",
      "r272",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r435",
      "r436",
      "r437",
      "r460",
      "r624",
      "r677",
      "r732",
      "r733"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Loan and Security Agreement",
        "verboseLabel": "Initial borrowing"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.",
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "terseLabel": "Description of payment terms"
       }
      }
     },
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Additonal tranche facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility additional tranche amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r15",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Less: current portion of long-term debt",
        "terseLabel": "Long-term debt, current",
        "totalLabel": "Long-term Debt, Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r51",
      "r152",
      "r168",
      "r177",
      "r191",
      "r192",
      "r196",
      "r205",
      "r211",
      "r215",
      "r216",
      "r218",
      "r219",
      "r223",
      "r224",
      "r230",
      "r247",
      "r256",
      "r260",
      "r262",
      "r272",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r449",
      "r460",
      "r606",
      "r677"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) applicable to common shareholders",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Amounts expensed for services incurred",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r247",
      "r256",
      "r260",
      "r262",
      "r606"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r491",
      "r623"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating Lease Impairment Loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Recognition in exchange of Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "verboseLabel": "Operating lease liability statement of financial position [extensible list]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r489",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseResidualValueOfLeasedAsset": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of residual asset covered by residual value guarantee under operating lease. Excludes guarantee considered to be lease payments for lessor.",
        "label": "Operating Lease, Residual Value of Leased Asset",
        "terseLabel": "Operating Lease Residual Value Of Leased Asset"
       }
      }
     },
     "localname": "OperatingLeaseResidualValueOfLeasedAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r486"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r494",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r493",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r150",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Incurred expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r648",
      "r671"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Other Asset Impairment Charges"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Payments for Royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt issuance costs",
        "terseLabel": "Debt issue costs paid"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r644",
      "r729"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "terseLabel": "Payments to Fund Long-term Loans to Related Parties"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockDividendsShares": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Preferred Stock Dividends, Shares",
        "terseLabel": "Preferred stock dividends (in shares)"
       }
      }
     },
     "localname": "PreferredStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, stated value",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r600",
      "r608",
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid Royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r646"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from bank debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt borrowing",
        "totalLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement",
        "verboseLabel": "Proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Cash proceeds from sale of equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r115"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercise, net of commissions and expenses",
        "verboseLabel": "Issuance of common stock upon exercise of warrants, net"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r78",
      "r181"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, Gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r80",
      "r164",
      "r565",
      "r624"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Component of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r163",
      "r170",
      "r624"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "totalLabel": "Receivables, Net, Current, Total"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r366",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r366",
      "r509",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r507",
      "r508",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "totalLabel": "Repayments of Long-Term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "verboseLabel": "Cooperative Research and Development Agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r120",
      "r171",
      "r740"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r640",
      "r649",
      "r741",
      "r742"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash related to the Company's debt agreement",
        "totalLabel": "Restricted Cash, Total",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r640",
      "r649"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]",
        "verboseLabel": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r289",
      "r291",
      "r294",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuring1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r101",
      "r161",
      "r574",
      "r579",
      "r624"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r174",
      "r208",
      "r209",
      "r210",
      "r212",
      "r221",
      "r224",
      "r277",
      "r403",
      "r404",
      "r405",
      "r422",
      "r423",
      "r447",
      "r570",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r244",
      "r245",
      "r255",
      "r258",
      "r259",
      "r263",
      "r264",
      "r266",
      "r354",
      "r355",
      "r548"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition from Collaboration Agreements"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction Price",
        "verboseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty fee",
        "verboseLabel": "Royalty amount"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Issuance of common stock in connection with a public offering, net",
        "verboseLabel": "Sale of stock consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Component of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Component of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Change in Derivative Liability"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "auth_ref": [
      "r61",
      "r64",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "verboseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r113",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-Based Compensation Expense Included in Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r59",
      "r60",
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "verboseLabel": "Impact of Topic 606 Adoption on Financial Statements"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of Non-Vested Restricted Stock"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Future termination benefit payments resulting from the strategic reduction in force"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r108",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity Under Stock Option Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r90",
      "r92",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r186",
      "r187",
      "r188",
      "r237",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r614",
      "r637",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "verboseLabel": "Issuance of Common Stock to Underwriters"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Remaining benefits",
        "verboseLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringFutureTerminationBenefitPaymentsResultingFromTheStrategicReductionInForceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation expenses",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Share-based payment award granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate",
        "verboseLabel": "Fair Value Assumptions Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "verboseLabel": "Fair Value Assumptions Expected volatility Rate Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "verboseLabel": "Fair Value Assumptions Risk Free Interest Rate Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Options available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "verboseLabel": "Stock options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of stock option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Outstanding options issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Stock options granted exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Term A Tranche [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Term B Tranche [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r376",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per Share",
        "verboseLabel": "Par value per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years",
        "verboseLabel": "Fair Value Assumptions Expected Term1"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r205",
      "r228",
      "r229",
      "r231",
      "r233",
      "r237",
      "r238",
      "r272",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r460",
      "r598",
      "r637",
      "r650",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsFairValueAssumptionsUsedInProbabilityWeightedApproachAndMonteCarloSimulationModelForDerivativesDeta",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r94",
      "r174",
      "r194",
      "r195",
      "r196",
      "r208",
      "r209",
      "r210",
      "r212",
      "r221",
      "r224",
      "r236",
      "r277",
      "r352",
      "r403",
      "r404",
      "r405",
      "r422",
      "r423",
      "r447",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r506",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r236",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/DerivativeFinancialInstrumentsTables",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20221231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock in licensing agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in connection with an at the market offering, net of commissions and expenses of $400 (Shares)",
        "verboseLabel": "Common stock issuance"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Cancelled restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted common stock (in shares)",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of employee stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Aggregate offering price",
        "verboseLabel": "Issuance of common stock, net of expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "verboseLabel": "Cancelled restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted common stock",
        "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of employee stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Settlement of a related party relationship (Note 7) (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "verboseLabel": "Settlement of a related party relationship (Note 7)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Repurchase of Shares of Restricted Stock",
        "verboseLabel": "Repurchase of shares of restricted common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r6",
      "r7",
      "r94",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r71",
      "r624",
      "r652",
      "r667",
      "r723"
     ],
     "calculation": {
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r475",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r475",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r475",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "At The Market Offering [Member]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, stated value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r340",
      "r349",
      "r438",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r664",
      "r665",
      "r666",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/JointVentureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r7",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r211",
      "r212",
      "r213",
      "r214",
      "r225",
      "r267",
      "r268",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r403",
      "r404",
      "r405",
      "r420",
      "r421",
      "r422",
      "r423",
      "r430",
      "r431",
      "r432",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r476",
      "r477",
      "r481",
      "r482",
      "r483",
      "r484",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r549",
      "r550",
      "r551",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "totalLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total",
        "verboseLabel": "Uncertain Tax Positions Adjustment"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r239",
      "r240",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrant Expiry date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants fully vested upon issuance"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r227",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted average common shares outstanding used to compute diluted net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average common shares outstanding used to compute basic net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20221231/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(b))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126943290&loc=d3e8255-115641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r632": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r633": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0000950170-23-006377-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-006377-xbrl.zip
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MVFH8#S$:(+N_>M2C* M1RT2T",6]1-ZUA:UE<\'V=[-10 4$!?C$(0EO9J(
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M*T8]N9:8S14U^&B-6#G5@S_S%PQ,3^<5NR>'C#YLMHSYZGM$3SAH%U:5)6E
M+G]C&(HEE*NS'U81]W(LF%SNU)S)/])O#;^8W3Q]VSP'9OONQ;Y2E%[)YET=
MPP\M5#=NYP8*O7,UK-QD/?"_NH_7A0)^JO9<1Q]='F;VK_"<";R=B *P+/I7
M7B92F?&$G9^(5&L3M));)#C,=I7!0"3/HX!?X$*%<=XG"A3FX\K_6ODHUD\>
M*2\GOAT:,.">G#*?/5J89&B!KD_:H@  :6M9TV.A9H_P7?AFV<0CKY'92L[R
M"VPYE8Z5G11F-%X90&[_B\;&UYK&J<3M!0G$I1+8)+'.^O+X9DB,'CAU';1:
MS#P^>$6TC]?S"QFPAJA:GZ<WY3A'\_!UXQ=RD>27Y@H15 2*:-R\$/7O.N$J
M<0'D^T<[^P'_X"<W'[Y,Q_?@Z&B*@-3!*37%79*.9H?WY5JWMN,6N5# >Z]N
MR\H&_]2?RR6I:U5/J]W8,NZZ?IW$5G+GH"/UDTX2DKY5AAAJ5S%HFNI*[?8M
MJKY?JZB;1K AYM"#53+7L?1SY,IJP1Z%(]26;N^.?8/7]D66#:JT7XM=1ST=
M4?U_P3F$R\B$Q5V1LF"X,=?R$FWO-VDY7&0XQ%SX!<RA(9TSYRXQE65_FM/"
M/!^BP9A\U:6W2_PCSVU]W-ZH7D;03Q-U9T4U^4?]G 0;8VLL- LZ=M?/\H@Q
M.74_O8!=,W&!\QIH*_ ',M_%!5_@E9N24/NEN\T,8 FGW(AJ$;QJW(B@OZAX
MZ;U?W?J[4W)G!>6>^7-ZU*Z'TZ-;WYV;C<UY*S<N$< 3UK$O-\,LP]P5X%^,
M[VI8>.Q1CK7Y%W%4C 5T ;HHX%^R'DZ%[92Q%LC GL6_$E=B[]SR(:&T.U=P
M%C^B,*GWK<2-L9=Z60990JM]G5&]IC 0^&-&<W_.J./3%5W9C:%64LB$_O4'
ME*_4QO05RN!'W=^#M;,-R.65OBD)U5]24Q82RCK;6AC,[5=OC?>\BXM$ C-#
MV:/ +IN,S+;V>YPEQ,#:\>!O_U5,J&B'1MS8T-^4NSMH[Z:4;FP=^#I\5/FM
MKR>="-4_(C]N\C@TF%SB%VB:7LOA2&%3KIO 0!/DN+]!LZD.I4?4MJD:-]1K
MTQUKN.YWLTOYE=DI,\T$W@RX$1"GG8;_%DKJ#T_K11I"Y*LJLWYI5_3?\X3_
M"Y&_@T+B FDNWS<&WR!%KH0F22I31Q51=OP8='@"-*T/:4C[O"J=#Z_[Y\IY
MD\J&Y"T5/L:Y[,]0=0IZ/.6/)'=\/U&14'3_IM_'WKKWYT.P[ A\G(LR^F#C
MF]QO73W4^X&KK'>)T$'_=:2P+6-4&_R8%HA"E2"?PB\,Y69'R;E;OC&OE )\
MX29FD&,_]WW^7^6IW^WK_^]\219ORC(@E2/R;'(C%Y6Z9GSJ58VF')Z[=")0
MSS^D\>U7F2H;J*XO'[_Q:SE6USNUE RY<716P=1Z5(._*QP*H/RU^2 ;;<JO
M+FVLN,D_Y;-(2J?N[1IZ2_M*TGN^7'IV\X_ ]\$Z[M.ON%(8#Z%1":05LPJ^
M%8^VE:BP'3[64I=%K)KW=X0BX,I3'YXP\\G8E)I0]^9[JL?) T 6!H2GW(G<
M(1%4?*KS'U" C@)L[G%Y1OGM2U+=;ZSM;]\:]>3G\$E,CYF*Y$0! 06'R $4
M,)>?AC6VGH3P*QS;:4<!8NF/5(-U]G*VC;Z.0T?F#U@:Z&)]&N:PYCB)_ 6)
MU(P-P_&Q<;3Q0B!0<XG-##>?(KF X;9TJ#&%Q@Z"O&WBDG0OLFEB0BW#+(9'
M7F(F#IC%%)\1VIN)+2-]N:Y3^_@5N5BF3#L^KM>3'40\Q05MA--,41.CT6MK
M];C@1TH&#I7570>'_F.M?!LN4\C10YQV#H>12ON1D:.C"*<./3,K4ZZRT#[5
M5P],K4KH/\S L=A5@[XL;V50^@AE]U8=A(0HCC5O+)7Y]XN1%3JY;C9HW,_-
M9T]HJ<FV&ZDJP)"ON6CS.4ETKYNJ=WG&?SR\23E$3!&_R7OX,BX5)-UR2V';
MO[E]!A<-EC]=*+<'V]/+S0VZ7RC3TS6@E6EF&.R^B(7."U\LA;H3U"F(&2@F
M">;E^_MPNGXPWRU2$"-X#_[ !TY>RF_H$SQ6N%^I^KT!I-G0?;<F4CONLP0G
MTC.F<F2_)2DS@-G8\Q$6X'3.B$I_^D97#ZWUCPPV/.=O)LVDS(S>S/0NN_V6
M,'R4TEI<^'K "TTF@I), U,8J.359'+G;->?%8Q Q[<%GM.QF)LEW%+_TEFW
M8'1M4'2 0<Z0[#EB/VE>Q3Y;RKPOE*C=LN-^I5$P4G?#]KZ<]OOMC"L^F6F,
M(YDU<NA+$PF5H9GO>XT3#_IJ=Q1D=O8417%#;>@-=5_T)8K;#+Z/;G>U*U1@
MUVHE"XPV?<W,W4S(X5^N&I5@W:TDGE\)J:L+K/I$FU(J93:(-'@SA;= 1$>[
M6=54W8I$ 8(PTDPQ@N?=P<$>/G31NF+X\F=4P) -OY:YA[&9TF,(V5LO00'N
M,/X29T34E('&N';JII@)76QT]\!:)L*W *:" K[*/HT/*62=*W%MZQ]KE#*;
M%8QR-I#+_GQ .ODD?;YO"LY4$I&?-=KILENXA0):ELUCNF>Z5E! +CKR\4)7
M"&LV,9DMY^(G,W7&G>" 'H-<HJ<1J;QMR(^FKV-3%PGGA]94.!ZRK+I1&.]N
M\']4:=<NK2Q2#I'(CI3/#G[G>,_SU=?SELZ6#&VI.Z;E_!.]31M\$-G!M5LF
M7X+QS[E)HF5<>Z%I1B TH)9J,;N+GY4YTF?>O+EO_'4AL;08MB?>LT*C>UWQ
M6[$ _,-8;]I8^G:-HEC<;0^E\H@1:I;\QK&-H&%?51(QJ(7SB)M0U!1$22HQ
MLF\^26=3P)LEID!67$V1,81PIV/4701GZBW"_XAOFP ^07R]L"LOOB!,]HR4
M.L^JQSYPZ/^J^(#^?B5_KD[/"OZ:3\2[(&2ZQ>(*%EULEL!9$/FSI9=,%3U:
M5VZPV-S*'1 C>B>,=U/Y_DI9U&=5B)@QJ3^;E1;L&^B__-2QXH-<H=]@ 2.+
MS"1<3Y9'U0S/0OB)+(*O8ME'K_9#[G6'OS,C\J&*7&&LR3D4;@EJ#.,HG+ZN
MYV\U6H3%:.1=6N[_\-NMP)EYL]+XTGURNRB<8L)*?5MZ6M;\KU0MH0RM[0P<
M#8N=J8/&NW;0(:A)82"$O4GT0QT[3[H-IXI;CWKO:E])H9Y.JO1AQ@?FMJ,V
M)#V3Q6T)XXNECTOS_6]Z@ZXQA?@+@^L7:GA=BGK!C:R'(XKK6P4:*H_/0QSG
MY.[X3A25,$IXEV^MZ&=QJ\PL'R!Q#LGO1QDE2R37VZ8W4MXQ]&,]O!,R: U,
M!K+7V,T2Q*!#S+KUNIFF-4**<\))*+BHGJ6$S0GS49&GOHI-4)52'X-O?RT>
M)_NXG[8S) .K7BP6'/G8ZCLJV\UR,:RMCY@WF2ZV>"R@/]-,%,39Z$$TK(&]
M&EF-!YOCNAVH/MJ_R--AYC/;N+%R@\Q<Z/%X?1_9X9$I/+9P![G*5)GZ<#+D
MRJ;-S.+!:+VK=>C7/1_G-P4!S_0PKSCZ'1;HW+(\LV S/YI=QAHR-ABM7MX2
MF)]6VO=(%&?TM0C?P3=5+C$>[8V90EB-PI=\V>H/ST)&_*L&-?Q8%P)'-#2#
M"=>1"]N[N3?>GN5XOBJ';,L)> 9C?G3PS$RPN=3V85VG<OEFK=4[^6S"^2/M
M;VOFNXJY*."Y^:RS6:Y";UZZHL#K%>HKMZ_F23=QY+_G?81[!U[UT8C,0Y:;
M4"8L_I(E.H]9R8.P]NOK&SMU_'UGQ!1K!LR.C)'BUI]UQ)A#AOH0;?Z@,ZH6
MZZ4L?3YNG<6J2DSM^-'4W)')(O](K V$2^\]YMQ-N"Z  LJ@H9U%I S*SF+B
M@[#J<#G,F>&(?#>M3BU$92IYSM#(Z*@Z5_!(#:E\H;(44X39Z\F947:V-IOP
MB3#=UQB\@L9T:0M*L_;9^:3,P=N5S9LK^ IBAN;@#\!DSP@IK@5%EF*-=6XS
M.MK2W5)8,<+<;.IL=Z]FRQHLB\":F$N/4?M"';J=M$^6GY62:E81@@!]R((9
M4_HV+FZC:5(]/XG%XP>SO.8QQ=]P&&:BS;:),;,BL;TYYP.B7Y_7%-OXA)X%
M^+H[[7+5*BBESIO"9!Y37-F8F4&6("F\8D3(.DVY0SF.<BXD.%9^G?[@!K5S
MTQ?T,IFR#<N(+H.WO]J AM(5PLOA4)%:@P[I!'-;4P()K/GF\-W.(:?]_?V/
M$.^X"F=!YHF-"WAE@;[WG$4_MHA.%I*7,T;$^K19SP0%Y).ZM9'%B.$KD7KB
M*PB? R_2"A(PL(?*H8",JL*\<ND+^6^PB2-G7$/9I0TB '%YOQ1V!X2I;VR!
MIQ%ZH);%/BR@60,KI6!H1&.S;YT_G7]P2+[#8OG9W@I>0E&ARF;\I9X/ >[\
M-BK;:!;)G\5>KFE*)=WS0Q=FGV )EJ1Q1]='ZRO.8/!)T)'1.)B[4Z7M,CP*
M"X2%!LSA46=FS!=R?"BZ&3AQ;Z"5)PRCP4U_BSPUI-=LE:K,7>K<@3D*4"FT
M*/=N-\<@YTWSH;^?$YA?,K:! FYT5I58SU3*F"W.SL[8\F^1?DSTI:R4F@E1
M>]G94CWE^\W]S=#M37\!528Q@H]2F](S6\;.O -(%:SCP%$9@P(:OB2B@+YN
MG0/B3--,_*\H8.I1%VQQ@>7HHFI^7V:HRQ4AB]M(:D%<K#W/3-<W]?S!E0.%
M2QL5%APD+9*N@HMA*.!E'#("!6RPH #U3!<P%0ST XN9(<C1E> &55BWY<9N
MA*V;!:*=G2^1^8(H1X=Q#IAOQ9SJ!M^3ALZ#V10E"MA.C8R%'^>[2!9$$[*O
M#@;]5MDP!QNG0P%)4,0;%- ;A[P"/[ !":\\,IE-CCLN:RK!W[/^O\;_4>/%
MJQJC/F-&=>)N*-!]J'\\ CW7?3!%__Z4#2;K"I##N/T'B_D&O (N$+ GA]]L
MV"$*N+JF,P46BD]10%<E$GH\T:$1\B-8,*  9+Z!@L3.?=Q]*!%2]Z@8#N;]
M42]A#3W'Z7$2# %# >D2.^U' BA@$@4<F32!\HR ;+BQ(*H/;<"4'@K%!(TN
M]10A\.6H WL44(\"#GJ"Q2 #O- IA,Z^U\X,%.GFA@?JB^J)V2%#T*U5,#$Z
M5A8&'VB.):QQKW(3=[D%AD @J)#BF2<FAQ; YL=0 #CMHHHR/DP?#-Q!Z[ 9
MR!"HM_O[>Q((/YT_I^Z&_<EN6@H=LO$+"J"= 'T<M) -K)DWU^#[I)5_3IY\
M@F$U)86CH!=(N5H4$ 8S!XOKV=EQR 87[,_I%4XQG .*BA8#$?5=5,/@Y.WM
M5=!_ W MW)==R"L"S>D"4*.C]@\SKBB@Y+,>&<RI*'Q%B!#6T ZJB+89"HA)
M$+N7BXW))TYZ4+G)0-+&;:WP;FM+9^H9"E@#J\(%6M!\0=R"(:>>[/+QB5B'
MW]]EQ]B(9ZN >GHI'/1]W&: -._E5AZJ$H%AP .4$4B7)TB+ A01B@*6DD\]
MI>;'PC_)(W5JO78R6/91P#FD! $*P )YBX7M@RY@0.'4DZJI&$0Q!M1DW&5-
MG4TD-L*?$0FV/[H+.@P=%) 3=^HIH]='*.'./HP0,EA4.8L@VB=313""\@0S
MH*E*%& @<>I)*QW?5=IK WD+FF\%:]]CV>#-W -KU^VK** 1AFR"GWPH5:<[
M",:=1CR$F8!Z$ 7:A)7.SW#*4_B.2A:R!U2$8_/[QEQ&S&2>%LW_7,^6[36$
M:F6"V^5H=8=MK^?4I&D.N^H6N&KS3K'"M$\LH#TA@SAS\=J5?M;0M>(,Z-P%
M(B0Z!'GSTR.Z\CA0U6EF^A/*OF,H^S,,.<"J/'P2Z1X ^R:" B:>@ )IM4(!
MPI*5:]=!O0)KVMPY%,#R7<'SUW6.H>"W^*=0%$?M:?9!MM!!C3T+UM=7)1#,
MIO"#LV)@(H2! KSC#H7@QSZ[^E"'X!_ZD/@S?7C_(S6PJIDB%!!-K;-W&;87
M#OU?2YKUZA>/WHDFJF3"0Z69RRZ^9OODF[N5_?63*I7CH+)W@\D*#0HX9)A<
M0=YJM[4RH.^DTLEI,T1KI[5?&6';=3C<1S#T_4\&X/^1]I]2F\TO'IT:=_F?
M6^2UW<!HJ!L+_@!U/HKJ38=5@4XO.0HI@P)VE.M'7=0B5S0D^.^:[AC7?':<
M6ME7L]J%#1[]=U*9G&<Z;T)V2R+L!H-]!K[0GK5B_I8^9(^&-I;O)'_#_;H'
M[G7_;98S(A:0XV#;:_H&9G'LEV$_]<N*O[EQ%/!?X/,G3ALJ]-33\I.X!25H
MZ+KN4>H;).P++."S]AZKVH='MF='718Q:XCK1/@.1WM,3\6W]".+U7G8]A%D
MPZ0W:9OT[TR6\&_15GM2>91.:=)@AT1W,HQEHOK/^._SWR?^1T9]@^68J!1"
M!P40[P-E*\0Y/' X2DJ;XB 'M0<^Y>I=<5C27U7X4B=,^HR[[;,WX;60?;K!
MS*-L%-!!K^EIBP+P85-Q)I4[8&9V-\&:8(@\H&87+)F218Z7Y?[)=3X/ND"%
M I[!&%S9(=M@UEH"#18JQURR%*SRH4N\'NM#!X#7V1T_$Q;;TFLJ6LU,53<H
MHK-:;4<I.]-<!'8.&V_%!FH,Q/O47><10S>QU)ST&WU1Z#25IW77F+0U,?JK
MX\2H,%)[N?3U[I?Z:=6^FD19YIVJC:YEO%:;G3"Y]WE5^XWU&-?]V6J->!L;
M-?0D>>-7C\SM^/V]]/30/SG'JXLDBB5].K08"<[@7L.?#91[JB+QZADC"6>"
M/_*<\XB:@0;3B![FRU6(RF<$@V>?;\603=I18K5K1ORG0[C ^9OR9[/,RK:V
M/D''H=VQ/4PS>2,624-+2MFJ34ORYSO[5Q?]MP,][ZN4H@"=J&]O9CR,=VC7
M9D+/M7ELJCWL7U!/#O-.-X^_\5(8=G9*?WNF:/XU1\/=Q]<?(I>,IF>3;J]K
M,57ZY!W*1!4,.;C1K7:,Q$0M7Q1=H?9K]F4CV3E095_I%! @RR4+6C!]2&_#
MW1#*E/:J0XP@)NSWY6-5J[5<I+ASU,&FQ=$E1J^,R7$CA.\N='MF[(!411D%
MO&JE0SS9;IJ:"']BMKU(-U[AO^'L/3@2,B@?_^Z:Y%OFCH;%\$6Z3+JM-OX%
M,^D#W1W;[LG7M4]\[:1(1F:0FR3 K,6#>=D*YT5Q4V73 4KD5TJZEIS50!;J
MJYL9FLEZ0T+! ]U$*BJ%#9]L+<B:DAC+;5XL"-(/JS#,W4J/'7H\(Q.(G]I\
M\UO+Y[<#EQJF\%ZH<S;H^HP2^!!W\G[553@/4%1%W;%_5 !JV=NJXV7(?URX
M@GM@&4*9GW3DEHETWY[(WS+RWAJ257<E;3K X\H+]2N_0,7KH<A'MGTV%054
ME:XE'9V]BD0!4BB@5B4@4-+K6NYL">.<W)ZJ&S[HD$5A8_/0XXU3K;T'R.<7
M4  L'LP-/QW>919WV15S!7^!M5H5M84I=WA$^WU[D+$2"_;U!G1U*PJA3-&!
M027D'%OQ$K1M^W&Y W3:(V30]V-*!&.>T+G+4;L'<D@&^),7 5&"'3JBL-/4
M*/PX=IY(0WOD7&;,#\0D_SCZX/4IH_9GJE^CUC(0]&", :>O[(0=;UV='G_Y
MLC4'R.L(%\N9/4/L5AJJS@X5YURR%ZVP]R[OKT&<>T00C'=^(-7S7R3AQ@;'
MKV%,WGG-1[(Y0K!%>PHVR ]T.]\E\]U?\3FX>IJ6TT,+QN+\GY:(]GR* VXU
M]^;\&\(0GYNE> VW^_9#]2)<5^7_+5CVKH?,.'SSX Y4(V:@] VAS2+8@GIL
M^4G<71LF= KN"-=MN!]+L.2^"_K2AY8,9BQ5I#A^]CNEE[AYC8!DUY8:M+YK
MWK5FW4VJ#&Q9"F($Y\[]8W7N^"+A'QOK!*OG ^A43[K:R0?AD\U.7CCPH\='
M8MHI8,F>II.<VAT&X47\L"JELRZ!E.8&S>4I;$M:]886W@!Q.6AS*9=_W)(Z
M<9U)QSUXC0)&($U1][R.[L)6X--RF:("9+B6L3[TKQE,98Q96&[DOZ'0[[QE
M&J5HR4 :,NK(9/ZXR+.@\:K7G3F1AL3SK=VDFCJF^05=F<QN;5CYWT(AK$C*
M4DGL@*^;_MOX._Q.#NJ,#>&JI<Y13 -%\MQ3R>3KP;.(]P9]Z=RCC::)940\
MR8V,KG'/]*R:S62CX341AJFRG]2DXC2,YPTL$TGNI=\H1F=[%%,T4(]=?]NH
M_/&[]%U2GFM'TU'9\S9SH8I?+E4U KXT+?":G.QK;V\*LDOP34;FNYFQ2'[0
MCA)]U?G02+B9O"&L<)6 W9Z>_ *Z56=NYO9'_BGU-Z[\,^<*# ;P2E5\ >MA
MQT=3N]3A@8LUW.GVCLYZ2<WGE@=<NV2MJ3>J9^T^XUE:2C:VW@35!=)9?9]&
M#G<>-ABZ(:X;:.!/%*3O8O%(2+G]:01N9XI._&/;0&SC]/$ D;OO9B/]7@R;
MGT^;'TRSL[,9;+>@#FBDE"8E*4M2N3?Y,<E?SL2N/ T%F&O7/^N=N("N2Z*\
MD11H?9ZWS7$Q*&@T;[<8\;HKM*6<ZU54T@AW^('MR%'WDTLU 3*%>I<O8,7(
MH?$V+BXKFSU]MG^;!^;0RC%Z5P^+G]+\*>RS-W $#0Z8>"@T<!3_; ?9Q;9L
M'#*)EVLV5)0X/%LY6N>L3)S/*+E%OP7F&?<-W_>*?UA&(]'Z[%+*[S):Z2>6
M8%&*O* ];W0_KS,C[]#3(>-BML;M'"VBP>RBP]=$9!Z6_+.1_$IC_05^*1I2
MFXGAO<:.;",-\JR?(8K?D@]\TFU3YKN,\?JKDT:$]4@:2A7AM/8&&QMR"&S_
M'K+P)?AX?UX II:OO6QIZ+V0"_Z?V6@WMA*["T7O<^>R#Z=*UJJ:!$IJSJ)U
M?@ #X?<T1&NU2OY:K:JP.^RK3N;AO":!_1@F"I@R+4$!F40HX.MD&JCUE\(5
M]CJ6(M5A5C"&VWG(":320M6;!SVV)"L068\6=1$.D0]>CSIS(KA9A10B_/?K
MI3<(DQ+-]HV/:A')&UV';_95G$T+($],;</>WR'^LC&F^_;B.UR_A*+YB!X9
MEJL#!<$&5LZTH9R]V</2V35+V>?)'[K;9=@TXWWMRGUT:ACKO1?WG,=R;BT9
M;+KX[K/DMM39K=8-3Q:8A.1G##],6%2OQV;*#/2<;KO=2':1C.*Y).T"72Z:
M<[/<"LNT1$C4L$Y3UE,7L5>E<(4G%PJ#J:2>5DOF<EQ<5@8^5I,]CU(O&T1&
M9%=-&),UESZ60/=' ?35!F=#B&^3/7\A%I;QQ/$$);<I:'(#5W8NJ#P1*Z_2
M2,UCUQWPT/M8A,'BZV33F12ETV4V\T3;GCWM%:4W=JD%%K$[/ADBGH*NVQ#^
MG0PX$[2H,E@ANW?K2%J'N=.&BAA1V_(TIHMW.-Z=V,C7M]>3U'WL>QN*[ZC;
MXKO7]71 \[=P@V&3VX>PKK*>S.FD7:*-3*&]+[961N,?2):-0BZ$[-LU7@W6
M#1LFPVN77J_<D\I' 0<X)CI[1+1[O0%>[,7,*D;=%7_*47FC#T$]"&;&&%PL
M".P@Q!,4\/(#F"%'SR2 =9TUS ^J?_@FXB#T!( 5ZC^V@:P%F:* +;+NRC5F
MN?6X :'Q-E>9[\3%?>^GPP2KD@4KH*\VBBC@<S&T#GZ*KHZE*,M9H83OL"K\
MQE-(Y?C-/A0PQ_<)]DTS:E+B-(T[<D4V48HGU$*U6><T"<@K9C#DB_!0Y+E&
M)*<S[3!?^R>7[VK[78*ITYFG"4 !%[C!2D6D%2Q4SDZA %+!H!6RV8[!3MH=
M_^<;F8B7N!8']N'YB-\0*]WST@@(B'K831)GUJ ^W?C @YWOV[> O7#8#V0^
M_4]-^[?$0]&XBV.SH'-"4?9-3S'_(_+ZAUY\VRPG5- E_R]D0$^#G^-:_5^B
M ?Y]>$(]L0C0W=PX,X1\+Z6._(TA+<2=] ;YBNQD-O%ASPS-9=XZB=MD5_>[
M4,!I.G-U_UVU^_ ,0K$XR/R)?&AL>%24-Q#;^WU/7Z6BI2LN"DBI\/B:/X2+
M9VRU0.I2.N%&(C?J5YJ*4Q>K8$4:W(I[TE0):"Z=&#5)0?CGC\2#&S>/:*=U
M]C$EAHY"TF'?A])?'(.!*6K62]@!MDHMZ[43?-V/??NWQO_%8[_[% /HS\&Z
M(<*-#@4TBO? EN%(;^DIQLR].+#.OP960@70 QK&MQEA2[[:XV+XRIATL3[
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M93TC4?>,^%*Y:N=#+>^DFWRZ&9,@C@+,@YY>23Z\0QYW30JFLR/K*+DU,/A
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M^OJ=;U$<M*_;69\[U+U%;]K5FC)U>Z Q-:V5VDT/81.&.J(?TO#VD.VT"9X
MF (G3S:0 *QO2[*(.C!4ERXQ<&FT28<AH0DOZ;-F?3=A?-:+)@ZKAB?H>TLU
M1*W/5@>AU#2PD8]?NPF;H4XQ=C53S^[%D$97C#D;4CK0;B=:=#FZY\IN:*RM
M-;:/373=<MD(KC6)PH?YU[?O+:1;ND2V$EE49H1G:4[&,Y=,\K*EZK/O:+"'
M]1DF3L%-0_N7-FLW1#<WX)8.U'=&!!\F0V^&!; )4ND+I<<+028R8Q3M=C@P
MY;X68&XZ+1!/FB%N%$;*P7+EOFJSR&$NRTCO6\E;ML(2* O>W6M8<;LYQ\5!
M;>KVI6B-/\P[_\[(TE-I!PYZ*>WMD"6"V;H9J"Q6,S1(^XEH>8"\+J/<H$2\
M/7 7*-M>,47Q[=@^R8-@QL]=?>O($@G0!$D!1P>MCPP3M0D1W/'J!0/L8$Y-
M36_Q+S&;?46L-E0!9'3DBXZ?D0#E$8<LX9MF7K1A#8D4I+&C]II2=2\] W-X
M67>7190LOEAS^$9.L;U+'&F5)H\8ZM&Z'=D8^;J*NCQ?H)<(#JZ?L/:O;2M>
M5U.:\DSM[H'#RQ:"W18'3DGVX.PTYJB%C.<5R)1!5UZ !+QSA,#M%!996M1^
M+#BQ!9,=/3);P# B 82UUE"TZER#5(YNM 58C? N)JA//?9Y8UQO-=.IL@SC
M6B8HZR#>_IA&J:;@N) O76IE<%"/(S9\@[Z09!:"$^SSNN=AC\! ]!XDZ3S9
MD^GL-H<?9U5=(;N_H3\V9\>FCE(%#[6R%?UI@F..\ W8E]M6P@>P)_:X\.BI
M()RVC_[W'@D>]G))M+7.&LGQ,P[Z%FB^Z#)\0/YF-^*Q-.WKG:2>S* V&TTJ
M(38':Q8<5O<WA"*E)/2R4Q$UDM"-9T-Y [MPT-R-N$JOI,PSPH$C"VE(&2P-
M-OV$:WHOJ)+<X%W:\3L\=T -]M;S30^*&\5=KO8YZF9]W5G=9I0&C+3\98!G
M#_V6ZV32K>?'#(OZ%N*?/M!:)0P(-"YGH>+98E$S6RZS/U(=JF7I7X1M5!_&
MX#C;.:IOMB17,!E,B6*\$]:?3#YC^;BU"XJ#7]$$:7\@<A&V_SHT$#.!CF(I
M0*[,CZ$Y=+TS4$B-X9%/ X2?)#%VUG1WXVSK5@<D@A <#*/$K9_;81D[\O&X
MVL,6N6&HS!_PH>H;GURBSI1#F\>(3D7^V%KXY9)!^A+#6^'C6]3Z>\\> >PW
M/5?9K:']H ::*KA;W1%FU S5@'+]"3 3GA(^,]4#C0V!C4UPV]9/=C!2#E(T
MW!$;7"H:IJTLJZS6Y(XV<-A9! 9<P_S69JMHAF#U'I0H**@8B%A=9P]I)N0<
MTY%B4+=Q-J&N@2IMS=^O,+V?*5=$)2&PO:S+F<F:D,S@HN-2OT"U"@4E'8,:
M2&+.PPGFB!E@@MP[,ZZ5\'?^S6BN+!*;M^TFG]_#E%Z R+B="5;SYW_+G/SD
MDK<@S1A'9AR)DB$J/UW:-) 4M!$R/_1U[!(%S>.LWH% *FML^IN$NAYSQ]X=
M>W?I >]<J#GJ9"=</5$MSFJP6%ISNNFK&%\ G+1Y;Q\5"Y3"JJ <FM&\OYK_
MUJKZBHD)7@E7T'Y(_H9AW!4,)8^<]?NWM-#7JA1H1Z@SORJFFY8=[JXINL82
MW.UKO!6)%^S2M !<MY-PR<[W4#.Q$DX+D#0IJ'VM[X*[$$LA_\35EQI>@#40
MB2!L-X!UMX:894I?+Q>7OBE;%G/?YV,7.9FJ<$7FUJ5"S.BO6> ]:2[W?%4<
MBA>;XE7D=,Y\K.&ODI=*YH_LL^!%"($@O]"9_F'!E4\1UO<*IJJ>H_$V8"0.
M35.H#; )8MF:94T&=5 HJ8MG)32W/#9T>B1H$M8:?>;)L#CAO:8!^FCB?%NJ
MH,&FKX2!U'S#!A\&L^/+V'*VAEH?W58MJMLO#X(A7.13'*F4!EI9KT3PT;^[
M?XW*F9G2))&W#62^, 9H1G^'CS4"V124O5')G9G1E'E\?T9+\D&D3>\W7[*V
M+U<L3Q8]69-2>*!P4[SI2S4T<^"S4+6D WP0G)S*M<5-I$'WF!(LLDZ-DHL>
M\#/""K[+5O8';F>C&L/#N37!!)I2:["N6^H'3"@&$^JGL+,U42$7ZAW84+LM
ME&/&H\;-L21WX[:1=(H#7MKK<B"ZW>Z0[4#FS8V2!PI4S6L[;$TME$ZP]JV=
MG AL0(3$N3^*!%TGL+%L:)\""<"96'-*&6:,X. :$3<H;^ EX\LTG2AM/N F
M6K/3I(_SSM5,PX;+D-)&*.BY+J0+"'GXV0,#.R*;)\2>L#F,-16RXGS,"7[^
MMA&&1D:_K:![?37D6E%0P"5N<19]FT7(],1_>:7ZU3GFM>_<)X$&S+(6T1M<
MP=G4 EYVVOS-+07L4BX=<HY7/7=+-?[NEEJOAXC?4#I'G:/3J*$.U[H ) "Z
M?QXL8CX&%CZJ<G?,/+)K7.N9EW7WK:4P>AM8\ 6(AWUPI]H'021"!.IS5T0"
MZOV1@)NE>,9V6GF]64S@6"3@Z\-M'CA6*<T9MO5VZB\5P48M/6%_7TTH$L_!
M4U3<HPX)N)+TMFY%* NU1Y^<YT7X<!2/\)D(0V#P'/6OO[=/7;O*N@0GG6=\
M4Y(OSYI=2A$T)MK\3DM&7=M]?\43U_W [_.82Y!LV+/!;[-$L$ZO/:OI%TY<
MA#YOAB(YLU("(\XMX=<\+1"/-;#@OO@7HO0O\O%[E PK]4=@IVN>]@CA$MU3
M;'PX,8,E:CN=6X$XX+Y8B,"(,N97*)GY#S6*MI_3PO]2U$.)][1_EIE5^-$O
M.@OQ[!E*!8FH0?'CR3K$F]#RJ]^'V-@0I/NTFD@UN!]&8@Z)F9W0C^L9:)PV
M>M>*)]AZMQXMT2<[K[R:SC7?'/+N2(FBQJ#STGT[MB\>!/6TB?B*P;N!*[K*
ML-Y@0=84=0O^+W%W,E,;K<1"3'=;;$GLRL<["P[G2QP4"(X,FIH@,Q20X>1
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M.%INXJ\Y4^7W*K2V=61W$OO0I4?H[H:N??EOG5/_Z1<(.?Z_ %!+ P04
M" #;.V=6]MQS9+"8! "?@@4 $@   &EM9S$U.3DQ,C@U-U\Q+FIP9^R\=UQ3
MS[__>2@*TGMO2E,!41"0&D6E"DAO0D2:]-Y#(B @74! J=*+=*0WZ0+2F]1
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M-:J;L@HY7QB3DQQ![^#T;6#L8XB*7%&)W8Q/EK)A8^W4ONZG5WH_U:YKNTM
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M-=*3(.<ON5&-"U[7Y(WL8)SVV7^(1TPJ#O.X3S:OT04EAYS/?494N$9F%XK
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M>>6?MH9T7WM/OQEF*8O;8R^F7+_NJ\QR+G*6++#O5](I>.932=1FD]_H%"4
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M;ULXZO+K)BVM:&F$W0/2V'UN8%>[TS!EWPODQOGBPBFO0_,B7$G(T0LZQB.
MLD]HTPV".5B5+=D_G[V3[1N]S!>>,+I1P_D)*;L5L@.6PUUVTM!W_HO]<N5H
M*&DRGIZ7MA\3[\'1OO^-[%#^[HV[_O+/;3PIZ4W+)#YD&BLOFY04G><43QNO
M_\B6N\B'@%YU"#3/= B8[41AX8V6BJBZKC&!SH/OO^?B1;8[Y\W1^!F?*@8'
M/#TF351&^=RPL0Y%K%(CH=%+JC[ST*( U484=EI[[49A9)*Q]D9_K>O8X\.6
MFU7A,$<PYB8S/-SG-P&X!KG/,N9G]XNSD^Y9C$1!6(0:W:9)Z6HKL00YA;]C
M/].F[H)0;5)HJ])N7B>/*/X&= ),]SG-;+(^YUUZQ4>VH"SV0Z71IE'8]!K9
MXYS<RJ-5^/X%BG%MI9,Y)\Y5"&7WMC; ^.Z*2FF06UB$33)01P,UE<RT%IEM
M]'<P5_5BMO!1W;5@3EF#,3IT2"(/,BJW3S4#"G>E=[S<Y(YMK!('K'=I^4*I
MH2!,#_HM)B</HC*[,(;@C5J/'S/,["%Q/*4EOR;IHL_N6>A/XL VP-9GKYU<
MLK#G(!?-8K]7P7PFB2I&[V'B4/)ZWA-2\CE77CN$,%<FRC^57PUK49^C35)]
MRD?43RN A+)?E"F)8?3UX\_G$#3MOKLJ5M.'EF@A8.N*D*@LFOVTPHC%M_W'
M19LK=,+X![QA:V^P##_.PSE1U28C"D(FOHZ[&3^+T!&[DY?LND'E;WR%*7;5
M<YX_^C?,5GSA#AP=C8$)Y2K0_\3$:"6ZG,BK>57?8U?75WCKS@EDAI;+?A,>
M(0"K^9;2*-H0/!O&[K G'5W\V4*K/$!/JW!%W?D@^TFD@\U+M>]D/#,I#X:D
M&,PDU9N&6+<#!O:"L/3^ Y?"CU&TS6%]^+6WR7'<H7VQJA?7GQ')6\]_6-L9
M/J7261GD\XB=@_N<56")<2:HSM@.D&JQ$UX"=;6YF #8+@VB+30-LA%B/7:<
MULWL[ KK[4'&.*:@ 1X!I$P(Y+K'6B>=8S9O=K"&R6::9GO2?($NBW*-"FDL
M6JI";<C'P.;'SM"]\$FESKQ.02@+?@E.K\2!T>E-]UXHA$?[*#Y".%'N!^X<
M=-9]IQ*PO30G[J.>;VASUX9,EB/X:TY?L-FY4S.>'Y,K^&$S==$HFWR [<PZ
M+L4829S>/82-G.5W^6N=XT@>;7W1UF:\1@!8'5IH>[EUZP^I+8<:MG1;@:6?
M=71?KGL,?P8%^6K+DL7R3L8]?MXPZ8W-^#V8M#*Y()3N4/# X"EI'>,V(-2\
MJY\B8^=TK?1+W@CS63AJ$4_!N@YF_9WFJT323 #>FO=XJ!EQ?D08M;4\]_>U
M(QLF _:?DV^;S&6,K(,70#T-(@B1"F.$8=$GMJ..Y<!3N,U"( /XU!;:9C1,
M+>*X9_?[3O36GACSF7SA9?BKC)?868!(3SHNN&#[6Z$3/L7]-C#E1=_0(._]
M,86YG[S5AP-NO!#?*9PI;/VF%8NTBV.ZSTA[8JBL9L"*._4$>B_AP4Y.8-3X
M!U;)VU+6PC;!3Y\R&<M6ZSYE OZ+0?0G#<>4C]=:6<3WI,+/[SCB&JJF<S"W
M5'$9[8T7D6*=QR]FSEPL*UDQ]CG@=="E8+"'G_'E4,/VS*9 QZERA[]'H:0K
MYCOPNK&>X2_-ZPWUD=T+WDDCDF_5ILU4-"5Y )+F,DO.BQ(E9O_&WL37'#KQ
M]UO;C4P5/N:N?!>$K-Z6!RK5MYDRT2,!%=++B0OIZB].Y&[F?:[^]V[?^/\?
M$;N[G)P.E:YV\2LK3!*:]\N9Z1\.V@F_ 3:2'S+(E[\>W6,VL*GC A2=CM+0
MPQ>-@BB;],@0)5[+LT#:D:N%%0_A4H=VT2S<-W8I8;R/_ES@W!8YT3]S$%Z6
M_N+?C@8=UNY[<?_*>UN>GDV[;/F;)L@'*AG2=7:Z!NMNK>*R$)OY[N3"(MTS
M,E'(7U9\HMA1_S.?2D&QWMXF,K)G[H=3^1T&A4G8#"[M$W@MIX>SB@=\EN36
M,'G=6<N=3!36E%V!Z^2#YDP<!VF1:8=V=U]IK _W+7#"C96>EMZ_4%I4KXV8
M'&5J; A7+O"(!6Z/0")DN!5>M#YU3MA6B.3+3=*M/2T#18/S]CJ5.@REM.[,
MF4YMU;:'N(K9651QQI,3 -[ LQB$:G?K(>GN54W_S;9)0=GH-8.DG#TE.=Z_
MM JOON05O1_*)>P"Q\1MD0C:7NNR@!;7CYO.^+U&REFP%7[LZ-QGF/;CL#AD
MV."<)Q7T=@>E;)#3>O.BU;E5Z?<P_MK@-E1IEO$;^EQ^^$:*:)$=")2"NTEK
M-8?\MF/*I N6?U>)8K8U_&*Q!QW\8/OA#X19E%M6UE.@.?M@&7SRV7@BI[9S
M7]\'&?0\I@?/EV0^=O6%^L%A<2N/S:/I7(5:VM.TS(BST>ATJ6)EQT(9NY@1
MB;8[7N&IM.PTKS4/=?)U\L&SD?MV624+OSF"ZT_B>HU]C>G+J\<H(]3I8O])
MGE0@=!@<LFG'W>HK[-!B\IHU[T8\O.1=#'0O@HBFDX"J4;=Y-W1Y$^:>?SKK
MNU])O[OT.S0]QXKO*7P/*U4.L.'5'7T<<+COAC5Q!/.V/1)**1P43 @I%P+9
MU&^:[8?PZ=P\ 747'X3]3@;GV9ZD6M&\WG$90XS>7CO'B<>>U]N/L#M=\[-T
MNA1"R[GB^]S8U_Z-B-,87CS]LKX>LC'<^6=%2F'*<)<H_'C63EEBH':+X@&[
MK/6IZM[4&@QC"B>%,"/$HSHXIT[@S*J4'Z6XW;3CG3KY-/I95W9-&%I->"1[
M?&2K/H%>@7Y.X$P5TWIYN7<( .KZ,ZU"!QF1R_:OF+%+U,'5\G87'YZ Q.$7
MG,!-@(KB1$3CG@;=-L3VYB!V<E>,2?>%O=J_YAKU+5B>V/C0E-\UC'C$\V$W
M&H$0D0]PO2.HQA=%E:3)?\7@N81)\C? [S-M" %XS8L1OK+\JRJ@$B?>4J\9
M\'-HA;L=)C+\*H!. VK1K,"_WT_[PY]D/8<7QXH:ZYZ/]O_2O9 :&Q(=$_59
M:/G=@^X?S2H;\;&!"687E4AX]%<PNT.^[KA4#+5G3T"LA4/C+0^6M1F_7'Y^
M_MC3+Z=&[\%F(RY>5'XL1]?CU6R??]]5H7COSQ??W[(>E>F=6GR_I-\L'WFT
MEM:7P SA17&9S87[!!RW%HK\ZH]])D-!NY2J%-^63?MLX^41N(*7%O;:B9<7
M.MH(9K1J-.$9T&II;J\=?2*YV#\B$'!P[44\UC1H[E?:?LRJ(LG:P/XUA MC
MCX>J0Y%XLKLH MLP)JK.?^.<JN'A-@G10D?610)$!E:.[\EA%K56$2]5*FMP
M2.CH[Q=@0XLVX:B]C6+MF25O:_5K"W?)G,[A;\]5BM\I2#HUF'8U,Q6P/M(4
MC4N"%B;\!M?!B/"D&*]5<*CWOHC&U'Y$F=B,#[6N-4_P4B_Q1N?*8I-[\S?
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MJ)/)7YMIH&)F.S=&S<'4*TO.MRYR%=^&OE+KWQ/XPJ,*;DYP7+NO$P?G4I*
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MR&R<1N%D*OQI>SFR0RK,= H=&^)=#O9MSM0VN+C<AZ!&I#;TH9)=5<N[9P0
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MK)9R5V[2Y/GH+87_QMU[AC45=>NBL2)*4:K4J* @H0I()Z+21(C42(V 2(F
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M+]6JN4OL;\83QYCQ3Y_G^8\,L_.(DWTG.E>[M:N$H&9JAO!Y[J381_9P";1
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M1<4]&L#)2W^'<??O*76*K]+,_WZ6GX,:9/!:X)ET1JQMQ#TS0G@'9]BW$IT
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MPI!WR$DO]IMHUAG3CF-=J0#(803-(=(8J25"!;AF4ZY3U,,S%%9K"A&#W53
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MT859^6'^OO-Y$BO&* Y-!0"-[3D'LEZ+Y/0*";:9B:_UT ]K<JS-GHL'[?+
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M,,A_!@CL_,R:C+TH],DHQJR7LO $EOI3]Y1. IG^,Q=OLQY,[F12 ;=XPZD
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M/MEWR&OLTC]_$&1GLE6MTKZD)^,H.V0Q_S4MK@J^$9&:1/.Z#8OL]"X*.(&
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M+Z#>VN<+QK%0R_9*&G@J1(_K!K]RZJ6\2M69!!=\,7Z8U7H4<OB1'8JJ2:+
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M"0/&G:1D)O#P&7HWF$!,"[:D.L$[C??3Q,<$&8CT>NNWX#D[%G\5/,@$.A;
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M&NU]_^'+E<4O<3I61X.%HK<Y2YE T7G6(HZJA-JD#??U9%597X>J,B:4+Y'
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M%FL%F'<S:F182(D@@%8L0Y(YQN#8)ZS;PF 9V$8/9+,UXP\=,DK3(VVAB4R
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M;FJ;-,W]6DZ[]J@9UP5"U<$3P OB#7Z^%!9D!"_#H.<;]7VH6W1I^.,M%BH
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MJ;S*E4(GB,H69/2A[0)!/"M=O>!/[UN>YPMY$L6 H[=JRQ:MD"1>.MQ4*?;
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M@<TZH9SM387V?EIJIG:ODEA/_YC,4'Q3=?J5R*E/:E86B50 <^(\Y.C,"H@
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ML."GT\V-Z3!$E'N&%6*%2ON+@O(?KDUGS.\5!;;CZ[]ZU6*[7!#E9V;-X&>
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M=Y"-A8Q:?OS2E]KLRLHFG7C#TK6D7;7/)&8"JPWV0\^2MR-8=WAK4 "CF6S
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M,$FB+XDQ?OJ93@BG4I6O]P?3=98VY?EW['*4 $M@&B-Y'@)*L?RJ:5_@&;4
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MJ"CW 4^N8?C,#\;?(1K^D1W6\AAM[':MNS=/@L876,Y%%;@!1,/;"MQUY[*
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M6;X  &!?L';20".PIOA>')>R:\^SX&UA#C,N4Y,-G=WDQC_ZHO"OL@M["EM
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M8MXJK9)ZO930??@6Z''@67B-=#5:Y^8,PL$ PNH/I3"EYEC//D,WG2IR\9T
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MV</WO[[8N)K"Z&.P,GV#"DA+:I'9#%@ZGG_RQ,RXD$79(&9T-<[!8J8:!^N
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MH?E_B[1_J^+$NIRE')Z/K[M9.KXGK"'R3$; _$G8IIJ<W/D3!!SQ(:6O19C
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MIT1-LV4*PL<XXH=*:>BRFB#D&N$F(0BZ,B%'RE$LW*!')4ZMI!D7!^VI(8V
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MY6@EDNOA1N>SR\7LR%I*S&5;9",#7_&):V<B"DR4'&MHVLBOMNUYR5W: .P
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M0O2CYY-+7?M<DU!S W]$,%&NS% ,"S)I_0H4Z54''=WT.86/F/+C&&=A;W#
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M]N0X""-;!(5W9L-//%)D7T.EDU%7^<$#8(MP^/HIA!:]SO&A(NGA5H'U+ 5
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M\&;B$/"HQ_IY1><=@Q- 0Z?:16CSH"G98>T3_,L>B$%1>C[^*LD.=R5$8^C
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M=V91=M)B] 00GCQ1YM/KK]7*'S!?Q\'4+%]B_:E373IA?FH@&G2Y]#H6%G;
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M#M!^^FQ3")Z*/I-L<2< LC\CF3-YLTK_D1]<*5JO*D"W@W&B@:)#C^XBQ\B
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MNA>SBPS%3JGD0M#+>";_C*[ @7"I6$.,-G8Y0W*"O711/"-5I4;-E^MKR@7
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MJ]-^ORBHJOMG(F+(];\_H?WO'X&[!%-?HU_5HT1UYL#1\HIOY40AT8@-1@J
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M2KV*1LNJGF"@)Q"OV12PU,SNBOWA:(C+M594+"HX$FR.478SE?Z DED<'O!
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M)Q3 C1PR5\\BA 0$G3ZEBL\RJ^40K+]KF'<=J6/I@:G%?<##L$4'9%1;.@6
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M4-><^![:35AUXNG/B4?@.[&],[>._A#,E(,C_$F&926UK,?IRB>=57;#[Q:
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MEJ;VEL/)Z"'ZR-5PP5>EMRN?+Z\.[;#*T:ES]'[12WXRZ\^HIU-AM['*>DK
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ML[B7D*1XP#OS+>XM>-HZWO]L81&Y<\DZA4$/+37V\X95UI^!3T'Y2;"-NQ1
MD#="-X[Q&\C?M#(D_[:!I"G?.@7P'ED)CX3*;:OL_)B&17S_1#]H:J# GJ_[
M@.AN7?NH^VGO\";B?=/%[$!)3'-F\'>3TDRXLRR/I1K87]T-;3U+Y@9<=-PX
M4XJ/.!IP47A>%=[>/G7A[8Q9-Q.?SI]SK<7)XW?EN+-4K^M?'4(IRN7BTT>F
MMSDM,DNI+H*B6^D8E;VW&#-94DW8G]HER,<+\;Q1HJ'N%,#!PM,Z^_*CV%HU
M\$6$9W:ZBS-M&^@:<C&SY?:8=<IZV]E<2_.-56<W?3/M^(>G=WIFDU@/7=;@
MZ.$/RO<?O6/+6W*[9E*#GUD+L=VM-_;2&[[Y*6@;)UBO';E 3Y3"FCT*$NIL
M</89N?9<S]IY1.8D!UH$4QD)D2UE?8$N/T3LC!-\\IL]G);@4>(=3O[XN)E.
MP&5T<N/]Q;<?J+Y:8-,!>R'A^;76:^["!T*X4!+\&!;,*V3F,(6H$FX?+-AZ
M]&[MSE8<. S%IQ2OLZ'\DQ0*MN\CFA3 (Z"W&R0<_0,5CHK3S$24&N+3F;4-
M'X6 IX9/Y-I+!5Q]OWD6-1[T$D#_O+E#HN1_;/0.!CX]\^R0>"O'$6!;BG@.
M>;BA0;)F/>@**B2H.""G(5>\2JXV(Y/EJ3;>ALKME_.*T0UGSBU&.:Z_L \2
MJI^=@!\%<A7!7'V?J4Y<F74MR4J+;[PIA!URLDX_1+[G3,6EMEM<C!KH_/QP
M?L;F%1@[5[WQ%36L'W]_E?<7[FZ+O> _38/-?YR@;%!]6?EWP6Q'S&F"./15
M=#>6ME.,P==@6LG(K++RB[N5PZ-$,I[#;:R^GFHW(D;K]="L_##O,7?P QX7
M3@.!DM<+O?T&-ZM<N"T\%QCVH /+6K(X;_MA="X0Q;I6"V9I$L&E!3;K/=A7
MT)Y:Y>!8QM^;#\9ZM)^YUA?,*1?6R+KR^8#MDHA9X;#0<:DMS:15MGJ3=;5W
M6@IP2QU+,RK?D,.,D\,AQ$_UU)?B">MX$2A) 62E4GU641A^S@]D5$J,W[/+
M^?LR1''"L&YV4RV9TV.I@'05>7K+@P+HWJ!RF*]X!PI 18S\E/IBL0W*"+-3
MT&S'C![9]B0S3]7/C2BYWJ%]Q@$[>$Q5U]CQ+%*^,N>O)?;.HBMDTK?V^%\]
MT9!__(K5__F1E]GU2 :B&J8GYH9ZCM.D_(=.N]XXJ[5EE-4I4G-3^*YJU[1F
M=U1!$=V=[%RK?QM3,T=T/0/M:H>1Q2JZ]ZOL3SXMRPYM<'L1G8I*]IG4$O$P
MO3C5.:[I_I*"NCON]P01;'%?)>?DC]8:J$=FP3JV5%(](R\'-A2$N4GCQ].,
M/1')<N[[L(C XKKX0$'E#ZB^Y#U8^4*7DW88[(8(7/^+V<99D]"+^K0X-L$W
MAG$J.QP/A7Z^=CJ<O;I\];F 4AG,]9TK9XO8[:[1#N'!'MO)0>D6!TEHUNC3
MRU8)O7F(4>VE[XB>A5A3'F0X6<QW^'G5RY24AN:)M]]O7,YT<H&TOH*RGK5A
M:7I,C3H@M%M0ODF[:W_^=-KPR3IPX:TAAM;O:0NI^YF=:GGO8-F*2^:6=_UC
M9VL3K?-/N1NAN:B!=8_8+,:"(Z$/=8Y;9<(L3GI5UBNK 63Z0PE[*@M7.5,4
MW@7A!>?>)^IA=S=I'JC87I9=7W>(HE)AVDT(N]'< D:+\+KE!K:Z>R=*3"1G
M)BY#9PB&W1]K-B^%L /A*U /-*NV78=QAM<*Y%11N^).=C1A&=]+?0"(^]17
M&>:;2'B&7DO,Y4MD2\W+LCU*,7KC1O14MPRC "XL8>KBU;#QD7/B;^HBM*.P
MXZ_3N&GVU]1/Z4Z7<0V_ARH)JK[]NNX_AWDJXK5%;XR<'.O". G/<*RCJ&>D
M3,_BY)>,.7Y>GCT34<]-B-F@Y, 4]I.II+4S"#%^T_(V;"KP8GB'NK9]8<$6
M!>!+ 5P?_KZ1'7TV?OKC[W_O[W4OKCIGVO>C>LO8\66VM78<>VTFVP:V(=F6
M^$C*/UH+HJ9O>T=#4W00%+O ',CBA5GH2=\/=^USJ)HI>/^T@_>UEWI/SEU#
MHM/1#,X$'[G 3+Z,A^ED0F1>5L5LGGSXFGC?^&7/7*(U_*1X%8Z_$Q&,TL"2
M0]&1UO2\"/O)\62>-Q_BOQ"2/$$8NAGJNW+W'<WY'6BR)&?3KW75_UL#RVA2
MY"HXTA>YGWYZ'T3@5=:75P+KPYZ_4ZW+"/VQU@<]^)9+)FL@GFT?**]1':OM
M^+67_R^N OOO7C0*G? #T2WX\;88^;T3QA'I]W=OT^T]JJ);5E  &Y>0EXI'
MVUWXXIE&SB+:P)B7^Y'S-!AHU%(S6!73-"FO]=7P+PT/)_>Q"K5@_7*S]U=:
M.5IIIFLH@*5UV'7DQKDE()&F@0)823_C6H3O6&,\NA9HFUC+'.>!!,O"'QNX
M5",]"L!A7BA-N+-DL/H-G;C&(D"8NCV<\>^BI\=@LL$^$D]Z5JBVA[U(5S.:
M\8[H7C=. =C60>\Z3N(Z7LK3.6JYN'+<<HIX5'YIC?]N0I*[QGHS]$E5^D+G
M/O?== <I[6O;J*UP#493IZBOYTXKZ4BJI(K NW9+H#^H3E/&8&<7R5)IKLNW
M:IDE=L)$%P&NKXT7S_7Q8R'?P)7\DQCHR )CYOIYL=T95:X&5W$ $H]E]0VX
MTV^?CG+7L=L =U#=42%8.YP1[SV]T)GNU1-]'!+M*O:F.7-.<1A],"9D+JK-
M5<M+*W6@OEM(N/<'.MR0F5#LZQH0U211+-%^J^'M@>G0=Y[&NMD2<74.+F.6
M,:1A\0H8?[<3MXWA>Q+]N"4 '\["?(*>7WYW1K4YQCK%,CH6_Q=S[QW55-CT
MBT81$4%0BG2BTD1$I E*B8J @( @O46E2Q.0'A(%!>D"(DJ+%*43JH! 0N]%
M>F\)O2:4$$B[\7V_==9WWN\]=ZVS[KG?O7_LM5FP$_9^YC<SOYD]S\R.FV&:
MD4#\,AC[9#ZJ^LN<R!A4P&9&^;?;:-TK"XA'PM5OY]@*3AB>U0G(\NQTW(8U
M&8*6 K$*Y%!'*F PJQY!8:0"F(>@(QG<3BT<L7.'/SKLB3=#X81+%H?ZA!N:
MI#B;LU1 J2L5<")GJI[0*L$]=V"^S]H$#$%>)1QB_)7E%P]CN*]F;.PMQ%\H
MNO+6SM4KX K@KG#LI- .Z ,8JWM \,:QMV3<J/D[BNK[X*Y0 Y%M;<XTI=/O
M^IRCZX5&[\J#;2L/$EO5@Q&D\)VSBRP9IW9[K&!O284'E\L1%J_T)%ZN/XN*
M3 3= "UD _>\3,%XIDJ*KC5P2X$H2C#%^$85^B/:]F9L)LSF4L]5?A5V,M&X
ME/-A*?ZQZXO&\S\"V3-&^V%-&J"EI1+4%I<S*0690%/AYU1 %R=.BAPM UN7
M;W 15_RC>XGCA_%/_]7M2>)U?[6%@0\''I<)MZ:";PVA"<[C%MXS6LHO4L3>
MQ//TW*8"C!:6/QXG<R/@*$?4APJ(/Z%L<9[!:G[ +1?U=?A)\9>063IM]&VO
M4[:?%(6\ET+[@C>I 'II*B Q>!BT]:*:MO)<G'MP$GL+1<^1IF,(I@$RA_-P
M6D-4XLRS2'P$T)#TDOP6R:V)15G FT^L^Z/0%U3;=5*#!JIU;Z=C'D[;F?,D
M7ZAF<+)R[UR/),UBP9'N)';T-E?K91EETT#[)5//<G[^[+,=?S ,$^/;5$ <
M;$D=QT4.=8<=/#-=5+DIES9LZ"?@E%<Y2(S!>7[1?V\CYZ.45*DTQ)IW9Q<<
M82- !<2'Z]!N+ ]U( VNFF='+442*BAMFRBR:"#) +M+BKX')@>KT]A'9-JM
M7O^806(/^"L*^PQU+!7(0(ZZ0X.+L0\XU_B8%I/1*U$!"4??81,5'E3 #U/C
M,#Y"V"B2;@RT\ 6U)^:_3T%MHPXLQ\-A_U-FW@9#<SQ5M/M0ZH ?4@%N5$#6
M7+T2Y;P*%2 &%".'2,+P@6MQQ!;I9*S!@1^)G8'R&!$!VWJ12 5H%6]Z_^TH
MM0U5\9\::+NG5\L:=B@NI!.LTULE*]F,8+K>(K5[>O&U_U73^-C75,#"5]">
M.H3VN+;,\!-=CV?0$5CU#T2SKM=^L\V%LE +G BB*R#HC59512)PHSG_K*;
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MFJI!)^*%V Q4P.&V%-%#;:1R5Z&+:%_YA>(P.ZV0;X414AQX,MX,PVX@3@J
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MMLJ_PMYRFG'[1(+(38+",0/-*"73>'#KE%S6@(']4Z2OAFTJW;M:+U;BXPG
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M*A:X'I#M:*X1E;\*$ZZ,F\(/\64X.CD47]^Z,>X9]W*OQ2/T(*A6MQ%>BD9
M95WL',]GNWC:V+/=XBSL^NI[X@+@JI&$X"D-/%S0,8:=MS_4R#(R]'HV%['9
M;<V%BY"M2Q">,:UKSYB:-#-M$O(?ZS[_[(8*CT@+AUT^>W+J^T2"8G/JY1I<
M?(@\LS,IM[KV4\<L;!7/J/X6P)KI=X#-;NV#/L)*97T?RG<1J9ZIK!!]36_%
M?6;OX37OO68HG'@7"BHE^.*$7L@M-_$Z[4KXTHEKF%:<-]%<Y]&A_?9$XE?G
MA/5#H_G:G1*.Y"_97)NI%EH<X!IOZ__,N1-KW/&Q3T6_.:QKNUG0P])AZ%M[
M#S9BB]0+;H9\BT2ZY) 'ZY@MHK_>PE?V\1$FG6PE$*]@+@1F6!!L%$;S@Q!"
M5":4-W0HQ)'[10:?1)S2Y7ZL*B;0?F.&]:'$=M+,?I,.F1VJCYT.*\3(IES=
M>!Y]]I7M!__O7]3#A*_1ESOVIVT]=+5(-GZ3DP1RS9]#C'7B'^&0S=(?T-A/
MA&<C4^.=]AQLYEVN\QV1"?S.?/>B(MV2ER+W]L#^4*=TTFUL<_ '-1#\?&:F
M58M(D!=BL4 EG[;^4=N% (LRS--KO4V-HX,:)<(],F:GI-=^J+J9%1H/&&QN
M3)":*( @ 4(M!7"##T+BIEJWYM^=H!$0IG9H6J'U?DE[_0ZJ=VYB?1*2N0N.
M/XH(VB13ES3]\D.<@;I#!\?P4;4T^2YIL_@O.DFWD=8_AJ"*#MG*D%+]31 -
M"\A\N(+Z%U="6L8CQ;#2#].$."7;5QKOWR$[Z@[32\WT.=_ O>M!;#]"+8Q"
M=_V/G*%2% #+^"!ZV9>*U>H=X;B.R#DR0VV!I'= "_XZ:/_9-W?@9S=2_N:8
M. 7P_1NRDX#>41[^4*-+ 6@R40#'136$H"?=J'AJ 6>>0P2%[MH;N(J\SMY^
M9*8(P1JP?N@]"!*P:?1D1+O#!E1*8*?X6;O1MY=SO/4Y=^'> ZS4)U$=#-OS
M/Y*$.4[ ?E( '#,?Q;4S)L[8O?$< 1HD:.;*;8VP8P(7)EP?PVU&&@RZU"HR
M_1'IN:+;J/Y[XJ!B[!3<FXH+S]T"E152C1@-?/$)@;UA;09!MRPH:!%78RG>
MPG?QU=PI ZD3FRWZLI$)<YG>BAO->7I?R9U6RG%3LX4+<1*.?AVOS)Y5!0K
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M(Z!G02P6#0-2BVE<8]=DRT\Z[<@<"A63Q!I73DW56YB)(/I9"6+9I"3]- K
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M3#/!^ AN#7%)YNKBW4J"M_EU+LL*4P _DTO@/_,+TRORS09U9,7?_%8W7*(
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MAVT"I!'F) 'L!;<O"N(UHH^%K^ Z6-"FER+P$;D.794,;SLR/"YBQ+KX\W]
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M.GI4*?Q%ERY1=?9JT9?932LQ+J09=4V[ZT$M(5IQ+8,3-3U\O$>["*H-L+4
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MJH(9SVZ[%;&M_HXT9Y!IVZ<OWE3?/M7]J38QM[=S["I,/_LS>9@W.VK6DM6
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MZ(![\+,)FW^R]0K-^+--6DY(1&H$Z-T?PVO&^Z>SX;^F$WQ$U+.@\F]&YVG
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M,W^50Z:FRR<6D7)U,5S4Z[Y[](T=Q(NTQL.Y85T!@2:?R)+%<BG8)(^O# +
M0SOM><;L4Z3QZ%7J;3P=BJ@]G! :GU01?^JM3I!Y##=AJ5TA]1V-3\V=)YOZ
M87U.K-;_^5,^:3O;(I1X_=0-)4'QK&>^"9LZPK7KVFC@7-SVIYLORO@W<UQC
M:(!S9"8:X *9,7^5U8Y2;1.V)=1[,R^S[U+.(%M\R &AM"U&O/=#QM(?R8DY
M]B^)=#SU*.XOUR@.,B5+U8.ET@"/HYOW[QV8$J3IO!5H2P=-J=0A_1J2*[Q'
MFD[D-V]Q4J.SOL$Z:8#=:QM( BL=]>O9TU?Z&:R CIAN0017FA&@74M5,QH
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M($7:B%\!' DE9" /[] UTUUP<O!,"#M'MM_KBL/B0-#9%W25%I0[S;([V3:
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MPUAE0P-SWIRW/W.[P''12>"J5XNJ-$FHG3?++5HN229R<<[([G,</O7Q7#R
M[#79NIBMG_Y.IVS9\89^[LAGA"X1N-BZ.!"99AM/VBY.W33U2_K8PF149U"
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MA6'TCYE1@@F0:U ?2FHN[@>G\LZ;E/LEMTXDABF]#?8>+W16L]/)/HJR#^Z
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MK<ZYD8H*S+-K%TI3,>Q,FWQD]Y,IZ1<7PZ6F3T&DKHK"NZJ-^[,1;47+?]+
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M&8ANSH_,Q@+RAP#[V14ABNA\\REW\'E5>8G;M8E#_1PR1GZR%W8O*27J8$5
M=QCOG(;FD>Y#GWXG)OAZ?W$O.ZHW>[-L"ITX$RR??*3C L@R@CRE5!8-L%B+
MI54*4N"ZRYDW?N5/SRS]-'K5?.J%="SX7!67M,*$)VX]$>/SM4VF%_U 2%SJ
M65^BH:)J!DN2?> BDB%H>%[A[;4&:;FD(L<ILW+'QZEH6>+S.)47 O72$S0
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M]$EUG3JP?HD(P-SQA$<W\>7N3$ 9F7=G"I*D*DA^>P,JN=Z*H^.S6Y+;@Q9
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M*I[,XJPQ$7P=+BQ#?B&A&2[8J+M#+-' )M423NTE.2/C]D62.0RV,T56LM9
M??;K9ZHS7=JFQ51MO8>PPK81$P>+D44O'\EMV7%A8/P^O!+Z04382;1)VVU$
ME:D'*UDJ%VZL$V3+#>>V.Y<,I!PP&*EN=&+6K/E>&?&\NC;F1:3D)B,51=U
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MBVF_,I(\<T2Q$]29(XB 77Y/(B#/K%K>T@E%AC%N/\+DBC( J84T.&-$RNN
M-G1))$93O8=. M<NN[Z3,SKA+X[DK[JKV;9'8X@"[UU"F5"UP)9A]& ;/BYF
M%_PU"=UC0^U'8!@$0*#8 E\BL&\16$>]!M["6^ MLZ$-/YY+U:.7!&+[OOA/
MMD.1FB &C+@F)J)XRRSK0_<*.X86;54H\:XH1N75>V:@X"<IYXVW>M+= ^>&
M%I_3&@\]9.]VFF<47=PW!,N(R5B1ZHC2OH%Y?/ZKUY?*:Q(]4]#_)20Q)$4\
M].S!BL"U1ZR ?>G@UD6DQB)%:P$,QQLD/"%:<P=0A[X7.<,HOTI[GT=X%II:
MJ.5S IP!H<>0A3_ENH=OU4+H?;YS>8V6K=)UOR'K.QMYOL?S/ 20^3SS,OF9
MR!$:@UE#L>NDC[:9O2K+C'VL?"TBOV9U*_7,?=TWX_.JZ#P #1@-JTW2,[NE
M,<WO6"(?A\[&D(KN'J#X"'0'>U>*[4^-B@)?>0U_](I)2RIY]W2.E<5U[#DJ
MTW@!BM1:C#!>D,&PG6L5< ^Y(OK;K:D&W<SF<IL>0M%N?0I,1G!%@KQ/W7)<
MM+Q2X1S.,-@@V"1RLK_&4E_=4N$7^Q3R@\2<U(T-TE%)M"J.?I+PY( 3,HFO
M(T3YS50&=2_,#4)1$O*"!(K[1  ?[\6\/V_47AUW1POBXZMA<9\<@GA1"KN]
MB#W9C5U'Z]=8WA\9+^KG,&<ZI%:9"7[1[MK_<.%Q*HZ!E/ 4%@'9M4[\T\)A
M2UU+@D%)5Z]X5!QNKSTE^M,,TK;G8H7D3'/-V3%3*%F(\FA,61;\MD*2K\?[
M^E9M<$R^&Z!U($ 9"PK0:<" 4/[MV7?J,CM=2$:4_1K#384M0I+-"9?56#<-
MM1WPR:B=)]G74 Q:AM9L3KUN\Y?/-#,)3!AM%4ZM?+.4'-.[:M+0*E!-R35\
M.H'KDQNH$GI6%B3GX_ZH$64<[M%\H]405B/XK71O?-8AC>=M)/FNF*KD^096
M20*&!6*R"GD& V1#GYW,UXB?3ZY!_S'%S,2)J]O<E'M?E)P(:!4-$ 6&C0=H
M+L];K5B\[ WD46:J=HI]_U+%%K"26>[ZVS8N/$@:Q]>$X4.!S) A:VT+[,Q&
MH5O&=NG,.J@6L;?JWWN&KM*!ZSS/0!<NX^(NB6GC\)VV(2) F2)306W022VV
M1KI+2G7F8E&#XT1P[ECIS;;SUS_JAS=2U<3J>9+B'%5HL14-HL/* 718&YQ'
M"V8(Y6_PI/XU<B%*/D76L@&:Z) %DVJ4XY<A[ _/M'03 1\<TT"(+,E@YO/%
MO9TR*+AJ=AE^;ZY*CIFG7CYE!^K7H&LUH5TAR7-V.^[WXK0[FAP95(/<4$.I
M=@B:Q]CJ3 A/'')(.K^L"UU@9HV[(U8^:! JO_22ZJW:$L1I:&JC'4[6).RT
MHGV5!VVF-U=61DB3&!#KA"M:Q#<F3/7,*#&<)L6>#-DM7NQGCAE9G%U.4KJH
MYZ/Y'Z1JZ7RZ)![1Z>@[X+\]=^JZ)OVMZ1%6DC"^(#RR.BK9@U,NLQ]ALJT:
MDS>]BJP@Y4KRSZ4AN^HZ$^*I:"M!,U>KHZ!$($]$^:'75ZPPKH'BFO94I$:C
M=9EG(-G\X;@7EBPTW;[[CK0$BG@B@'OR/7R7'42(8:K',A#ZX R*##C;/_D-
MG0V7-QLL9#V0$=0G3>MJ-[]1W.!G.<_,I!'\QPL%4V<7N+W1#VQ[H30XDF5(
ME-7M[\C4T++78[ [WLG"[<MWW1CER[7)[I6D*$;*2#.A:5NA&+ZX.!PE2K\M
MB'>B!DJM5F@O^U%J5,G>_>T14#CX7<X70SXN"//&2!R&-R23MCQ N<'NTURW
MBPV]NNJOXH'[KTA_)STC AH$C^DW>X2_WH>437D%NG8*G!2P2C_Q*.K22(-^
M@M>"NC4.HHD YIHG&BDNU)M5O38%LT5G#XIFCORK*A.A^WL<)5MQ_YEIQ1VZ
M_=JU2%@]-"\/W-G>8U^"[[F[YTT-?-U6%&+S^*2";A-EZ0J_+4#A!*ZAHO[Q
MLYNI^>EAIXI811+'ZNKX8!AZ#A\;((>,:IM8D$ ^UGY5(-PWL[B5^&Q4R/QH
MK9>]7C@Z)O\^R/?I@:4QCH%O^61OH*L9N7S^.GV$A::LT$7F,,A3+8^SH^$>
M1^S1W&0J)ACMB"]I,B_H_>H8CXDR&\T7&++]YE-)CGA!\^CNZ9.;U\E6:OS"
M+H"( .X91AL%)="+WMBDS-UZNS7:QB,U<93&X_;EKDF^S;;;6^G2_)7=S%<\
MT_DN>PSJ/4>B&'[2J!H.QY69S<2>%<WA:HS1#! Q+W"6 !I;,P;M4NS!K1>G
M,Q#:7;1A=3/=D387-A-FI5$7JBFZ=_@(_;1K/EJ/STBN_BQB=HHJV*H>^R:H
M1S:L:ZLLP!)!RX/Y.CAGKFTM'IYRSJ6F6?[4,%Z#[NCY]8<\3JRX@XDFP15H
ML")7Q D'R!P95,80M(Y(,3?N.;@9S'I>5!QLR'^W<SI1L,U9SUAU4S0*M)1&
M (SCE&P#<W;84L..QS,5)E(@(PE/CQ+B>WYQBJFR?X:/M.0W#.\V@9:B8L0U
M:V+[M:N^^PCO(2QX7$M?"KS?!,!^$0'!(*1.7+CB%7AU#>I5*PH:UGXUR9*$
MN>*KBBDORT)[8H1X=AJ'ZI8IBB0LD@"LK2D8K#/SROF:4>*;FM>%<M8_8ULM
M8XNOS*@?UFQ=3 :&)&,Y4-#.F;#WD%?"CF8C^7:>[(&7>4-?8H?%<U6;_,OQ
MBR%!TI/[;!AM+=1BF[2\7(GRAGU#=@Q'_K:TG-5U<M(*UAZ%\&L-KL)\-W[=
M=1RP014B0&''8.: 9\B%N&5-#2R?4DM++'O_Q-MLBY='1U*4V1EQ5V0NT.G0
MGU83@0%,$]5,M=^'81)%TXQ?BUX5#?"$K2$JN.5MY3F9M]Z#:7 .^$@"-XYW
M7&1A5K4>I1IF&*548J_+JC5T[DB_ML)E(\,>R#))C=Q!?\#$($-?QK5G\X]Y
M8'W,LV1MCYS<YUA>]@7/<ETY,!N0K4V6H;N1D[\<E$ZX&,E*D6"L])PC,W);
M<YGC->[,'J+P/>1+'>EMWDL9"6]-*\7?_^ST7POHQ7(2)MO1'V-/'TV6+HT&
MF!?^%*&=CKB^H/3IZQ,]-2,C;L$$Q>>/MDE'/=<-UM=/3^5R^OOW=QEUE5^;
M_-^66_^/)-G8@&?XS[C[*W4IZ)^0-E )Z(ZC >>SF&T44GP_GW-#<M?#J'I;
M*W$]N(+AHX.@F@5&O!-8-=1!>\D2_W51.T,GEKM!;IXU_;$".EJ68'):?*ZZ
M=P7%WA:'MH%9:JQE2L@F:8@'DKLV!7F>SNN.56O*F3Y,#X4Z!@7GSK55TN)\
MV(Y3K'^5F5&H,K2Y-8XFJG9[$0&U4K%<FC#;W#G@@9K371!F]T.1 [BF+NX@
M^:/XUKFO3+NYV675T5_"(RVPC"4BX/V&TP""@_&FS6I%C.HJH,0+1!W 6_#=
M49MR$[V?=VFE(EQJHTZ"4!-B5OQHUY$(D$&.S=1UN$0E^MYQ<NRXV_TYE^:Y
ME5^R#EU0D_%7'U*TPH2G#/</E.&V_8TF!GN'-O-0M'"?Z.3ZN?%D!%O7>]W'
MMZ-)=-_QCS/\XG,VT]55BJ67:IH?=&\%TQX#PQILIZH5%.6D!^5[71M,G^[O
M^SH3VN5?-,C>A8GIN7DGCNVK*9M>T$2]>_\J%ZD<M!S6;BFU# U9&SZY_/N[
MRX.9=5#SU2_7V3FZ>:[[!4\MQ;9%]A5(&P47ZEHJ#"!/MA$.736L;GTB6WF(
M,IMV>Z20@Q4;*CDDNT4RZHX_98F1&,2VRB7FJV$\\P9"ZQ+K5--Q%VR7"$"Q
M@Y' &*%JN?[D9N1"F<"W'^E*JT7.-TSFCGO9U3/=6R^% ;5QFAAP7H#!;TA5
MC4F?&NN\D^]USC?4V_DGI W9M&.7Y;T-ZJKQ60%\11C;#K:W*%!PC>6!+9=
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MB3:E]BEN-QRB77U?(A@V#[*M,?GV! X10\MV!RPNH-7UAC?8;)2V-M;FTRE
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M='_4&\?\D=(F5"&;NLS:>F.MP=/G?J9X.72PHWL%N(,CN(QY:.WN!]_JXW_
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M%>8>;>S)7CR>Q _'BSY!HQ_,,XR6=<U3LI?1\/;2WYU\5D_$'$YDNQ&,%AO
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M&N,Z"6%'<CU/K2O_:O;4NS7=DPCYJX4DFJB94=H.JM*I=^!](#F4MLVO&^V
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MT,'&KZ;2))\6*<-%D[33-2BT)]L=2L.IC/?HJX_]J105QKD$>EGK1NQL#O;
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M>/DP<0WF8B;^ L,\,24IBF5;LF-RBS'4]0Q1LSOS*FUSN+_=NE^YS+_/N7%
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M:!ANCE,L"F/3C,"I'.:'&LS]I7P=#S2[?7"3]UOZC, .19QD[_["DI&^FYO
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M=*,L"6?VI[??$7\6;^_U-I87C_L<2?[08 9WVRJ[EI]DN+)$YXZ,PF9":;S
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M3\-<Q(;95;5V\(Z%_,DFF)7\TZX\3(<"6 1B0;^A$[]"=W==+KY!L0R5PF5
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M\EIK@-8-8+"D__8JGE=I5[171\.:<-H+KKL=6? $&V@Y;..X$R<^-'#'#;5
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M!RE! 5&J])[\%.D"(D@O*B " M)[(BB@]"*@M-"+E$B7&CH"TIMT D@O"35
MRHOGG#O>N>>>>]Y[]_WQQGU_[&2,/7:2O6;FFM_WS;7VG+!C4T0T$;!< CJ$
M^($([=6PS=E+J;]-)Y)\L=Y_^_38X%F%*XK0+STUL%4J8)+=5?./(+%P"EYL
M"^JW;:Q;U0XKYV+/*\$!@7?SL2J<3D<3ST%/_ Y"2=$+UZC[$<:U55??&/-A
M<]9N0,$GC&U]+IF/5XZ7:U5PJN4T\G#;_H?3%WBY-OAL&6^2JKIY=^/'-CM;
MZGAF3F#%3DO:#+AT\(SZ;FZ+ZL;_M$O-_XM$L<TC0G>CQJSR"\2VG9WY[S+
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MO=Z8)7^URL&)]7F#_*Z43>X2$$=7%*2$KBW\5"B^G\.9G_QN03KB0'-QXQA
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M;4V(T@<U:LG I.BD^41GZTCAC]O_TNE4>/D >]=D[]8*$4#N5Z^-AH1Y6R"
M'5,T,/_@E^O"G\P6)@WL0)+%#!M_>!-_[QG VL%$@*,-N]]XCPGA&L:XU'N%
MTZ<J<$YX9XNVGD%2,EP]'O>K# 21X&=9+?<*Y/#P_'+Y;+ _>$]-0WIT3I5_
MK+&7V<EJ(?;*.TDM&102B'0!AD.8E=V+L(;_()$_)MT6']4?B5C++[V42FIH
MI"L.B.Q6&S"*L22!A]-=Q"?8<@Z\QB$*?'/IM34=NC '_.'LU"4XL'BVKF^&
MIL:1RU5!SZ"/CV)_.=8#1?'4LOA?:D:Z&-AD$0'?!?=D5FV8<.K@JQAUA/^*
M+OAPRB+*HORAJDQW<[$<5__,*W7+: GY6^ZQ#_"414_I,QI,'SHY;9+ _=?W
M_]C".P%;CA'4P6J@B0!SC'7%LOD6FH-5M$WZD(?O$VSVU2T8US$+EA2Y!H'=
MH)J#GN[WHMX5?N&X85^/8FV+/%GKAQ0+,6S9?[=77%JIN>DAJO4&##G&-YP.
M5#G;"<SCS70H*^'.B\=@]?1""PWG*[ZS[P!:^WJ2^AY:Y6EWR^A"(X7_',PV
MG4Y582F@K3='I+$R2VS-#\V,43_K*HTY5'F?<LR$T[>9A%+Q\7+^MR:+X)Q<
M)+\XTFTXYBRUT*_9Y-IG#=#FB*-QH43(-J;:DW &E; I ET->E;BMXIB>X]3
M+9.4+?KF&&\US[[ZNR"3G$O\Q:#CT^B2TJI;!KHSW"TLJS:U&UUT,!2L39S!
M+ZF3C0B821O,3RFE&T[B:B*?5X\Y_%E6)-3EH32]X8"3B^O5O^"!'";8$@$]
M]\;SA"(W#;]E[PY/1PH?@@B<O:M%>"#H7//O*@,SK-,/YT4$Y*P2 ?=8(;B7
M-1=EE[G@2J;_-*1!OT*'""*30=YHC?990H/WZ9[%D^]F%:[*-7&_//3T)L@T
M]-J,G]WM3VN2#E.3LPN08?D#(X5-1R %8;A1VA=\J\'_1#CYSK!63:>EI6TK
M54>AG\A\@!V&)%5)&O09AL_FQ]<@N1<%?L:_PAD2V&;WV52H_,$/-?">Y!6>
M,P^CMYU"G_'1<5P$JT$U2.&N?KKG4OCG>GKW]Z6>AL&6GN37#(>4:_G:\][+
ML5D9)B.0Z[#EPAO;<J>S;EV9K-P*_+?H:_,I) 0A 9I:K\@+M9.6:+;ROY_<
M1C1(E%\/1JG9:B$LG*!,J:9CXB^::U,&*UPJ]N:U.&,^E-Y;8[#Y_!\#>MG6
M:++.7(YA<8XS',%LL@;Y[PTO7(R.P#'[K@R]EX;,'N1CTZ[]C+<VH^1_J^=Q
MD_O=#7G0/?9MJO7:B[)?^&;@)+5P%Q'@ )DM[5BJ,89+^S#TY?E%3EY-#9 9
MB+"W7 UR!1PQR7.T\:X*24KM)0_>_=$DE2,CX$6*_)K_U?; _YT.6A?Q]L;K
M$<7ZL,+- %=X,.1BKM1"<R5%CPB0$@J%W<1]PQ>*YJ2>3D_?\DM )5E4 CGO
M"K4GTK7%GO<-3R$M2@\M3DG4.&EQ"K*K0");V0^LOKA]NN":)+!L0S.(@(Y,
M-!!/2> DX:0ND@A@,)&&AQ,81L03CW30=5&%BX(+/VK&49%J%Y+%MQNUA1-W
M-ZNHUT_<P@F,TP>+ET:D:TJL6^7FK;;0 WRVA6:?DZP$F,,]+T"=1  -]N7.
MGB(D_#CFS@9GT XG94Y0@+T1EU% ?2>,$AM*T%DP[)@5*PB\\]\^'I)BSS^M
MI:94:<8%P]U; I!$2QP*B6.>(Q$+%C<=K .*COY4:5"N(^T.W)>CW])\:Z3[
M-I[#B,%*E-D3C+)C&79: @8)(YP@LS?AX37!ZI=QQZ5-E 6IL7"I>\HFJFKB
M#S((<7]3Q@1NY*5/,JJ%[W'S!O[V4,?=_ W$KV] !4BFG"G6&P5A6)+9+T?%
M<!HV/V>I$)?&%L:'C+#:WVD4NK<0^9,4%5!Z6 K"!Q@=$;!<N$0$?"Q5A'40
M =>WV!(6?F-U'E8U1N]K[1W_MO4&YX2NW=S:S#WX80:2@+6K(==F#V"[@J1Y
MFG/SR 9[9SI466$E+JQ5H&'*BT[<N"'"?(9K>LK@UV;K(PU 5>)U_Y4680*U
M*!%P9SJ0"'BAI(^GG+Y%!%QM(0(2-5:0E_0@O&!DXS0:5#)$!$0&FQ3@E- 5
M$<4T>+E.13 \B.KV^M2_#8[NYG3G$HU?RM%> ))DFZ<'G$&7<Y2%0?3O/>_)
MC(Q:ICJH)?3^C_Y@^!LGC+;^ZDLW"?\@S6E1G![DV5[X,#9FFUWL045AI +\
M;15UVU0S.2J.R9JFQ:8S3:_4)_MNUFG/O7R %^=7K6ZW44T'A2*< CHKKH3N
M86?'A6CR16+']I)^N,(#%;WEAN'5ISM99.CA2+&4#3/T>E*IY;<],T39RZ\=
M%U?Z]80#(GU?5LD3 5C#5A(_S0%UPK#W2&IV1<A"/PQ,];TA=F6N??9:2Y>#
MAPY]ZI5&^).':S>W-_.^GM'PEG'[MD%O8M0Z+)VMN<=J_4=]RNI/)?3Z5<CL
M^:D7<^.'?Q[,,NG7CL%<=(VG>F8YE4Q/!KCCYWKXU/K;])AI:1/U5VV^I9V%
M!,FME'[<F&I6*7!FZFEBM+B\6V1ON4'Z=ZY!S0AC\,/ V5Y\A CDF%+XI+!)
M&.G#$R$CNN9.!*"+@LB)@(>0\+\9/3<BH,LHA0B@"J)SE-2E>*\,H?WIRY^P
M]5;XWLE5098I \N,X891.Y8(A!^H,TLH3:$6 =P*:!Z-*1' ?_:LBOO'3.^:
MJX'F*]:(97TZOU=;^UXPH*/YLX&8<IF8Z"=-P(?/'L@T_6?U;RG^APJWFT1
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M@1-0:6C_QB;>]76Q^- /G!A5-INXX(GN8CO\-_Q^<4[#XI%@[+HB^THP(W.
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MQ]_Y'?&2#(B0RH$.G2^72- C\>57X1YGF\^+)4SYBR /!IU8G<YVGT'-E2L
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M>U!J=1!TI.2%TV>5UM<,S,')84H#$(FE)FH#W"[F4>"QW)?40(X]D@.)IA7
M=P:]@OAZ9EQG6<MH7E)A9)=S'KH$]YZ T0RQGVONQ-,LH>Y/[//N*>SS#*$G
MCBMOX:!H> ><K5I81KO_9VZ%(Y%4'#3 WZ=.*:AK"2N[)(]%Y$)$T8RMS6SQ
M@%%#HY_[RCF4G3!\P1IO6-F^SMAN50:;V Y*V\7TJCJS?IS(]S]4KJ^PV:M2
M=WNL6;>MJBN\"_.L<J</G5 K]-8E^79+X@QL#]/4QN;B J$O=;X&V0$' AK.
M?:;$^^P/FCF/OUG6:I?>I>'6*QN^#^_4"3("=G)4OF^T'UBCZ37+18'/@8V@
M_6_ IO?O@$W;;ZB/BR)%J9:!L<;3:NI?0BOE[\T5M>,EZU4-D0H99A^ZQ22_
M._C^Q85P,.U_A5%'' F.>C//1W,F)89^IG#\Z"\*UG"Y['3[]Y1)$Z()GKA/
MHB!^?NV#8.$%!B1M*5D8IZLUN+ M=U;),LS%L O4&>A*'2.\2A@O!OQ8[+:^
M-EH]9TFS;\/PC&O'L[V 0!7.V%:[W=*^M/DBN4#K_A08+#73M6Z:.>A<)@B9
M-+9*VOF@KPH<#_SW;5S^#DH3%LS"8P$IM1_M?!\#YAW,-%HI_2E->N&L2'L\
M47DKQ+ UVKW$-,U5/.-D^.3T,GY[]Z2>,;VY+J?^E:U05,J2G<%'YV(-0NNX
M]':3X.:NN^O+RI^Z/)S1??)$%7:@-5*WFINOVSA:/<3!/9C7OB[&GC?Q4B4(
M!<:!21%-_&0 P)8,6':9,LNI*2?H*2V!-7DSF$TV0011,H"6#!BNS8,NT8$)
M.KQH!$&"#'CT.Y$,"+L'Q<B 9Q-)#\_BD)\(TSE(33+@'V9\109$0%'0,Y8C
M&.'">S(@)A=O .KAU4\[_-?FEX8ZJY]2;$F2[ YM8XE"_SA;/JPEE#V^O2#*
MYZ.#'%W-O8L@S.S_6M$Q&AY&4%G):'7-WI25#]^@PWSCUSO))!3CTL_(@"7'
MG7TG])@;HKC1'!;]V:,D_)XYQ;A@4,7>]&;+GMZ/=CH_3(DG7S='G,C7%EX5
M Q,&?FZ#'VM:/9OY$?&ROX[_7D#TR>_?-YO[WS(@^Y@3K+,[J[5E0');/U=0
M%5QI,JN#;[[V9/C(1*D55;_*M?$G5M19ID#-$OW25[@K+] ^U-9Y5@D;$7(K
M-==1*7Y>G9&JPX$;2F$D>M1OB>Y*7';QO(3(GW7V2(CQO]A#7=>S1!1-@&.#
M<8$>^+DV[%<RH/S@!B'\@O6JE(;%XGO%WA?Y4%\X?-QD<1$]"&> _C&M)0.0
MHV0 Q@?:+@\Y)]S9MHLD,N"<1W=.D '.!B03'/0SR*!P@1<P H;^TV]&R "Z
M3?0&*>(]%$\\ES:K.C9?8@T:=1HU7N2OWB+]K_S/"+%0^Q2,(MD<BWP90=,#
M3TX(4@7M\#,6<3)@_PA)L.+]IRG^GW5]"M$J\(%0#'J(SH8RD :"AA+*2H_I
MO2Y7P1A7Y23ID^=A3PQ[J/'=4W%3D_6,[;R7 U[:W$]#+<B/^LI=SZ__3#T2
M+1#J.VXB_KJWUSRI]G.3(H?NH;_PIKG1MZAO<TY8EDT7!U>VV-MV;$;ZPU=^
MJ@*7 RM'__U9P'^E%(7G5_5IJQ7@$K,1L1Q=K_OGJA(Q-2<G1>_EOFW1XUE1
MR],-+-7YXZ;H-*+OW\K!S^+?QSKWZ1VU&\?VTD)*YR4HBS,=V+7*"3'%/L9>
M:=*9[V-_:!"L<2B\7$#_DDD,HO28^\Z!%8NPZ<SVAP[SWZ]JZ>,L/>+[UG1I
MA)"4V*SKQ!SDN27'L-"B$ P!X1T<LRE7W<9V<ETBAOSJ30F=H-U*6&EHS8@5
MV+3^)-?/9N?UD1^(DP0*_14JCF/,P[D;8:1[ SW+Q!!>P]?Y9@=IE W[1S*+
MW8:\V.A6A/86<4*,A(QW4"QK/1DP([HE+R)D-1XEJJJ6]*[L\S]_8HI\ GH!
M/I6!789.62P21=.;(W-B)C?>1M1P"1_T]FWTP]'Z^Z>RET$[$BY_;ZOL I<+
M$;Z WI$!VRG[I"1M<!FS/L=\N4>Y%EQZO RB1 904>(D,";++POSG8.HTLXY
M^+NJ!N]*[3%-E^_KBKVBJI./'AI9?;Y!T=(KM&;%B,W%+:#3!WQH($9%FXDM
M7\6S2AVY#IXT+C%6J?TJ_D/-%6RR8\6,LDA5_!$_G*^U_UF!-R'T,NXZQA'[
M"1/NG.1TEC+GS"2Z@(.9F23,"^M''K)!<%9USWN[Y@&BQU"47GN(+(JW?>%Z
MF[FF8^78C0/"!D!Z4-,Q,6SOUZ_IW4P3"U55K<%O7ZY$R- 'P2.@_R%C5IG1
M#F5IIL%!=::DMQ%7<5"5R9WL\9OC1]J].36I<D9FCQOM 2LB5VH8U-G9A.+^
MN5B"K/0G9.RWP_"L)="C1R;9Q@65L7X_NW6Y=N$?>-C1L@G*4@$QR(JC)HM.
M\])?GU*W&>^)O_E5*4O;)>='42!S%H^_&?K+,W20Q%"7K)^D,,2RU<K[+%W9
M &BY^U9JGBY)SWN'*N2"JL=XV9;H+7O?1TGAS3N8H5EOK/>YD;X:HBC+D.XO
MV*ZA&W,*BK&,SKMQ29W[J7L8@QRE\ 8;*(U'^7P?)99"J_:+_\A_^S29UQC4
M%.98VT*2SE*FYHZAD^H!XHU417SS=2Q\Y$8-IPIQ@2$K$M%0X&J45N.4HLX*
MJV&S OO>GD3TZD6CRV[X($:MLURL/C'<MTF[@P/Z7EE@<S?O#S9)O+,YR@LT
M>F=!UV10[]21[8:#Q?KK%V$,>G\6@'D5],6JIM$CF@L-69[X1P'N73QW<:K+
M]*PM4WXUYL0C9:U^KUT>6] VD"MDRJ$O4I'NF%M]S3=SD?V<'80XKV7#P&C+
MN;"/5;=*-I1B>EXY'%&O[RFY8&UC^[Z 7_XTK[_C<[JP;X>!=RPR-=\CC5^?
MV?0_,>^.(PW<N&>ZB;W"KWZS?)?K6M%>%QGP.?+APJ 4V#>T??''N2A;\)S[
MS &E_+#.H#R^!;$5#S+ MK;'MJ3][4Y?WM*'BV^R=$*L5)]ORZFGBO3HY_>=
M9C2 %/]>M+AX</>O(2#.[8F! W'.F*O)@,3N;O@QRI4,R.5!JM[.G0O=GYD.
M'5K<^+D!JA)JJ\ 4HQBC&P62NMW] VF"-?,&Q[/N,_)X#K,\RSN[MS2U,A3;
MR+C"&$ZZI2'3)&6 'D2XW/_STN%5PO&-J%B5=KNW[)>W&%Q.)&.?%\L[3]9?
M^3A^#+H'M85?A8";<&L.RX+E&-98'U>#:X[%6^8?DQ1?SH=T'ZZ[YN<J%JTF
MR0+D$'KG*%H [6E"'Y*:$: C&I>]>F&\>XCN'.T,/D$6)(7\A]PN.)#@AI/-
M(?CA0D)0KNX^PL+7S7^K?>UUD0__841=)JG"/?')WE%F45]?/L%[PYR5S:L[
M!1X/!2(=H#%PJN,HO%MX8(@-YU[M9%7T[V _P.K]-?8XS$A;UH.>];IM1 SH
M*L35D>6-]S*<:7L2%@'33M.O^QE?4PB@>7_50VHN/W1YQ(J6>7=?]!.>X1>A
MBI@)>D$&L! T)DME]#@V3ZQ9T9FZ/*9EXYV! 1>H^S6&?H4EE+5XA#X+#LUV
M.@NI22Z8,YUIY:[^4J5-=_=)ML&#<4!1;CD H)SR,G:]T,"(>Z9*^+LX8QLR
M>O'@6>/YYMAH(X@<$WA.O"RTMYGPX&^VLYL,>'(K2 F8;_Y[Y):MT]BJZSS.
MGW0EA0S@\P\[AT?2!AF@FA\81;A.3=(VB8'N6">3 5JNVT==L4 70ZP?M>[A
M1MV_G5\*V-B5P\MM0JL<WTSII#N,'<]=<JIJ>E+VQ. J!7_"-]D6:JZWS(=Q
MO/TP7LAE7!H:9.X_<<1M^-3%P%K)ND5J;@G*H<=+D= 1R;YZA5B44R\\F2+C
M.A*W*;P]3E!LQJ1U@&(/'N=;NV0)8MX7+G+'G?BS=GA=$'E7&])$G1^BC[]-
M:JW_G;],#^J$,_E@1WV"-5F6%Q__Y-UD=2L0W1 B5,9=E2P]O'_W(;70D5OL
MJ&GD1$[)DU=Y>PMMR*O*_YAL-MDE E-$FGMK7=*?%^RR;"3_QY1S3FR7[F[E
MDY*2<Y9X$_YY\;]*'Y\)J_K@W1?P"FS!(&C6WY-F]WYB%G>M\#2M&#V#>HS_
M&_O:48*.W&)@P:"?!5C6WYCBQ(N'X&K7.^NE=RZ!>!)]P :J::!#^1;Z6W%>
MM#+AT.)>6(*<V7-FFZ1+1M&]G:'+^E;/,4QO*\<WOK#U+KP*O>Q4;[5>X5-3
MPY*\:%E^RZ8F/L_[37($("OE2*(5-&VR+-LI_FC6U4X'WMK,,T\W55^B)C?C
MW1-+$2F %0-Z>"</DZKTS;6!@E7&@@]\:AV!J,6H,XFVQ0CHWWM/%DJK2I6[
M3%=,7 =7BUG\W79^:2IOA%VB"N4UV:\^W[G?@V?6ZRG"AW,6IDL@Q\73&W!Z
MZ([Y&.@H57Z5#'#1"_,@0' FO@5S7>$=Z6[; X(OETZ_0D:N$V< <YM?"G N
MLW]* M/3)*77=+PJT;%=AY:XX.6Z.]EXXQC$IJRHB/MCKLF#[)Z^Q \J.RY8
M!:PO;K$ $H1S+,#%CG<RY.3VC._8N;F6/3R-E-\%!>IE<[<B]')JBLV,+)P=
M=#.^_;VJ]6?\_]VMV X89],Y76 17K<F:WPT!N9-7>.6EU!(GT>';R47T5=P
M^]HC/J;[N78K;#MW.8E\"@IO^P_@JM19\'C(H$UF([VOJJ'!B,NOM*6AIMX
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M>@/'.[!*5!DG::;]<+ R(DU#R\I\474LUW&3'GC:4/AJ5CI9%<:F'D1Y+_[
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M+4N,7AZ /8WB6G\/4_-^;V]I/RQ&./!6RMNBVUN:BA? [*017FZ]CO>MJ 7
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M*W&G Q&%C21[0ND)'@ZD(,AB0'NR*(UA1O_X<PTQ 8\GGL6?W/VCKRI>M=Q
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M;,U$&#L0@FK[XJ'725,+HB.OC7U*131#6$BF\'/%GJF4JU#,3.5*PHQS)QG
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M#WS5C\^TK5@G%H%BUXG'/LHDG!]&I /,U/3P6N.RB^E-,ZVTT!%.1<UXW;]
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MS,YRQH\,X0ZFV 3<W?. E@-0QWZMHG6G5X; NU:M4Q(?<H:T&Z0"43@H39/
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M?M;D5ZC!T/2=3SZ7(O1/N0+?FVY]+%S_.!E+2)C,GIDE:<)10&+HXEDY1),
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M+GIF0"]8&YAR#\:)HRX?AVZZ>((9KA=9:+ORQ!DI7&<T#V4S[.6ME(\>/\J
MZ1&ZD=490ZWS_E#P"N5:'4HD6_2 \5=TEB!X)Q9.:A+L,:>AO+3G1=;^KE]-
MS1=,A[C&\SN=)"7:ET<>/D^R?=YV\9HR=_6&<63NO46#FL2$J+@7X;?+W)_]
M&TX")*?K7A"J08'?'VN_.?CX*EO\U:!TK>I]?],/P"B8FU/:^.*'ZHAY?8*!
MU*^Y <DROTK.3[YTRC,MG_"5"J^?UXPH"+C>HD%NG3[7104:22EU'OS9(48;
MVI;OD,(^4>!0,-W]LJ$AZ5FX&$ZG$P"6@&BGZ#W=\E-OQ,6PL!BD02.RCP1V
M0U&]GLYFJ]TL:)>:<NM+\=^6O_"NPS%4L12-OJ7^;B9*EU$9B "H0/ZFT3.?
M>Z_?BT;ZQ(S/82OIX>P+"#H&T\G"C='LK>&"W<\YC'JJ;]+_5>>#U-BC?!.;
MZT$Z.>]DTS]H-PVQ;7])'7#8>;(<_T0.5W!N9"?U%;#>U+BJWET,#CEWFC&M
M\H+=2'5C9/O13H>K@F_*XT&CLV]':P^L(X\0P3A3O@4V3&[A/"9&2ZZRY%"S
M9E+'2%97R?0%1?^[52&QC#P;XZ&-CS_J[HA*"7-F('"U.P3U*529J8ID3]T+
MJ2<1*:*F9C-.+N=$@+:&BV[(<P@S)H)P2^DF\I:_7#?*5?@32=#UTQE2[ MB
M.^WV(Z5]4)#EYNZ"KZ*1"H_8#WWX)&8[?%(<.#^=#64V'4H<'Y6 0V'4S9B
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M>@\\'69<^92F59A>T4CR L,K->B43A)_<KQQVG:27!O$I5!'4.7=9O%:<6K
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MB-'L9BM:Z5XP^>#*S45;LXAF/]H/_1W3+QA8V>BVC1:%K\WWSE1M(4M#C".
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MHH<S4;0X)J(QUUD*@%PJ"J:%A6?SD!L2"P,(5 'AJ!P:Q5H@RI>FUF,%".S
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M0R,28_E@?6> 26"JW<67$C8HV/IH#(SP&>\N+LVWF2.MMMVY:,Q[<V;*>O0
M6;R:4,""W1]JL \BEFET"5@BXR@G+ %E;GC"F1G<L0(RV2%&(&' @"[."CT6
MY2T^M_O,[0?OG&N.O<OSBB5[\98C9N,PS$V2ITAM0'_&)D1DF2(RHAF-\MQ$
MF1H:R7_D8OT,IAM:\LOWJB[G^.AA85?#HH<#6]-3O;^:^K@1HY-"76'#3V+Y
M*C"?H\&/5>"56Q\E,6D>264449(A#P% SHU( 0)Q1N,DCF(]6 CTP(-8#.ZI
MJ^4ST0(/]4Q.<TU!A>5"6C1,-!$:3/U$9 *@*F5T30P3%X%X4I=Z]W34U&=F
M^7ZE!5))Y$J M%-$I,IBE&%,I#&,A(DP)@YIR+/!\L[ W0>'\/&)=Q\LTGV0
M*&E-DBH2"9H0!O\C@H8&!+]5J>$L$O%@3S ?)%-ZI[F0=2.ZNKF8W;,JEBQ+
M(Y,IF@-%% /+"8,%<D6)ICH)1:9C.EP"H<E:5,?74.<)0,YW(. UJF;XBCNY
MZ(W>1E0PT,/S>GG'9C<DV9+U"MAD8;H02"/2.,8#K3RS8$+'J24\B0W :6M2
M)D669OE0-\)@(,T"]7P8)Z$!4$F,X9RP7,6$JX@3&2HJ6)B$*<V&2H^#L6P+
M78CFXD"@B\$M_%4V_=(49Z!40+8JLWS/$,@W"K1Y",ZY?NMCM)](<ALG64YD
M)$,,?]=$:@S@CS.J,Y7DJ1H<#0<!2Y_'D1?'-)2,8VZ%C E+$0#%>01\IRGC
MFEJ6#$X7.GK,3NNOR<"O&*UQWA1.2T[O63KI@'TB_D#2S=_Z*(]"R!@UH2+6
MXFF[E!Q0++6$)DD4\C0+T^&=MC^W:W0 '$=-(E6N)0DC ? @%1&0#7ZE$0\%
M9[%*HZ4?5SV;T]*$&=>AVZ2:8980"![!!(FR. 1P%*5A/LAS@^MG=>+[ \[J
M'HZZ &U=BR<!@_WPI!ZWHM*'YZ8\,[WK;;=2.)$S-")6)C@[CV2B8LN(87A$
MI!4G@N6<Z%0+%DE R7JPP=E8B$(T"G.?Y\[TYN+(,(<1DPL/ZR^FP:R^#W7C
M$D7;&Y!Y>W_K_=;3Z:3G$&Y)&%- U1')5 :(*DD9R5/&B:4TBT+-;28&2^HA
MIALMTHEJPRRC*B>9=$GU(-9EQC*2B=B$E@L=J^&29@C@:BXT[AI>>@Q95)HH
MSKDE&0_! *<J)'EB.;"N%B;1)HSL8$\@5E8X/D\43 9"T%(5$QES,-@CEN.Q
M4TILSF(92C#@\\%!XX>F2!^<R<EGRQ:("_/^<9HSL$83(BP-@1PJ(U*#?%2A
M#8W**5>Q&"PYGOUDY0H9[CU#O[SU,0RD(IHEH<U(+(0[6:$@*UE*#)4*\(2-
MJ!E<I-\S4FPY;).E"0T-6'<@MBP&?"5$1CDCH8QL9D'[*C%8MEFDPKHL"C'3
M6G#A'S4,Y1S&.DDJ6;*/-T%%1N.'^'BOW?HHIR%+="8C2;2)%4C.6),\,Y9H
M;:(\C<,LR0;+AX.Q\@> UD*;)'G()5$TQ+0,#< \DZ !4YJ%4N1:98-S_BXE
MKF(UU:'A,8L9Y227EA(6)AD1:%F&N6*<JRQ*\\$Z@'^ Z'KW?G=X8CZ)YIOI
M]JPUR\E'&( 3/XHH3;G"T"8@'\M83/(X5X2K7%@3QS13X5!I.-3"!<_DUU<F
MUEDJ"; @)C^">N12:9+%,;=:IVDB!@OD[\B.O0SL+,L^W*<X,W-W+<K_O6]*
M3'3\ G2ZP("5MB_6!C;7_"=SN^P_0#5WQ6ZEUG(G<1G%(E.2&&D F$H0##P1
MBJ2I99F,TR@=KA-U"YZ@"ZSK?&8.,)/,I:[N?%?E6!O]H:E/T>(:=RY":<].
MS2NPMOL@IHO;'_#RC@DM55ISGH!*QX-YD><DQ^C7-$VQJAO+5&R'M@E\984_
M6O2&4\DXBT@J<E=AQ6 I34YD1G.N>62M&!RQ?\_AY9PU\("#RV$)FULLFK7T
M3HLL2<(TU0 !4]B#DH)-RDU"-$;>:4.3+!M<=8^'!&[]#39B5U>]R%DNX;"P
MYL.\,==O?10,! 1A.8\)MXIBH5PL^Z-3PJ*<Y4)*E0\OA^79\I^?29ESFX=:
M)"1.F;/H*)&)SDD8 4@W2:JCX9:G^U'E'*Q#,ICJ.1./+;[/Q<(_L'K.PU[Y
M?FR0^O.OJ]NN=U!@I.$(LZK$?;5?'N7$QX(LR8+*PD;2Q"H&3&&L5H2%D2!Y
ME %B393!*A>4#M?M\+O1XF[5->8[F)EU,ZHG_0R6'!T0+JAPCN*":F-SD!E&
M@F&()*)2D!  82ZMR6,V6 _MK>XAYW1_7R!^DZ[YSWK'0\4ZI8HE*8F$PJX#
M%E.-;$*4432,6*KR=+"'9<]>S7( ].,T3S.M$Y(K#G*26DX$90E)# ]C :14
M;+!R\B$YH ^[=Z]ZM-Y^GG38/QRZNYJ[5:8T#K'JG@PM _L?'IRKQ! AC(@E
MSYFB@\UGN^=<MC\4TKKHK<HOHM"[U;88%1V8F,NL.S  9)[;D&54<NQ5 \@\
M"17),9R:YUD:@^G&J1F<$!H6,N][:M#D 82[?NNC"!?+-,1"!3RF& UMP7HS
M+"-4TEP*$9H\'5RVPR "_@9PN)Z%.E96NCKD<=\[#;L!D<SH-!(F#G5FADJ[
M0<5&/)/'14D6TR0"N(2IW3F(2R%T2!+*K,A2T(ILL#7+W?'66'5CC'K8KMNN
M/T''AJAWN*;-F<$\_R5'FST3*4'!Q6EN0L*S'$@)-@[FZVO"XC"F#/UG;+#1
M9OYP9#WV('-'([#I>([%UM C(T+X*\E2F65IFH;#;:0U5,MZ.1FF6L0ARS-!
MC,$PG!3KPJHL)W$4@=$L!0^CP7K,AE!G;0!X1]O8&O1W4A9B4U&6$J'2!)YN
M,ZM"RVTT6!C[ [/YDLH/E94/WSACV;H*S]W.V96#D3MN6,B1R) J,,1NHSX$
MWUV_]5'Y*"GG81HK8D.7060HD2IG1,7<\EB$N1+##< =OE988/(K8V&N<\6)
ME"''<Q2-;1 M$9HS:BFU-AFL'_YY*ST-P/AZ6,?JY1)O-58J25(C3)2#\6-A
MFZM0D]P*,%A%&N54IB&-!E>C^;F*+RVGUH6*J$*?'TD3+&&F!=@N2<H)S3(:
MYUFLDFAP453#+_ZX0$V@$IKP7%B2AS(#QHA#(F2DB4QHR//0)N'*-\1=0=26
M1QHL?)N2+.4@XE, ;()S!1*?QE0QFF3AX+RM+^QP,38YBWE"T7!*") $=$MJ
M(F)8GB06J_OIP3'.L$ZA>H9YT"G4]5L?13AI6,93;(NKX"^)[>"!N4@B8R&8
MIJ$:7K;N\Q/NBIP+&0FSA<BY&%@HBP4)%58PX$*"X@D3DEIM9<Z49'1P1[G+
M39Z?AH^ZM(\[7K'6(6))ENI0)IQDD;,864IXE$C0?UI&!H"KC0:;^_&TWJ[!
M>9V>)V4X-U9(@P>:"N%P@GT15)RA+R.3!N PHX,#>;_3@IULJ+7T;DMK,R'R
ME$0AGDS3F/4AO8FR,E2IX-0.%B$.+J0W![H\C/VNW/HXIZ^,;1PQ$J>1(HQI
M4.$<V$]B&2DKF5%T55R)+^T4-V4A=LS2A(H$+.%$")*'*B*)Y3G@ETB#,!T:
MZ8:@]*ZZRN;UV.-.:E,I+8N(3#4Z*TU*9)Y*$B4J5\*D*EQ^5Y_?-_F8A/!?
MM(C)YSQC,F3 !&D&4L2F" 1@/UK))9,T-ID=K!098N.I 4B7R-!0BLP2D>,9
MDP@QY Q(FC&0-E2G>1X.SD'RAW.J)OW.U?W]SA])3,RF B(]I(G3]5L?%8-@
M\HB#<@?HGX"5QCA8:6DD2!I*J;.8IGJX822#!^KWSN2Y7*M8) \V4?:0S7;M
MUD?%&JN,FBC-2"QCC5E&E'"#I5],2D,E9!*KP<81K&'!E^?!A8:G+#74D"2*
M4M@$7)&<Q3GHD!@,H3#!;J%#W03/'7"^G$JG*K=Y&)F$I#Q%BE@!.@"+[ F3
MT8@I+>2+<-8^:6GN^.',Y\SQ!<7W1JFP+*; ?&!%L%#E)(\4<+>,8A5IV C1
M8$G=Y^G./&L?:]6W_[LB0?]J*M.($K;#ECXM*O36N&IN.]]'RR]3^TP2%70T
M,*UE1"4I=MJ!OW*K8_A5YC)/J.7#:R>'I@[@*SU6W5YS8)HSL+JNZ<+Z0I3=
M?>G6][YH#6IU/<^N4E$6QCGF\\78PBBU,<:.,&*S/%1A#NIZ^0T;?J]9^SSI
MCW%BP'3-.<DPWI)1@^D3(%XCP53,LUS%=+">[N>V:*YM].?H8PP(),Z-BH@(
ME2(LUY1(K@0)K:"1%+$4:G#>TOMJ5S@2?C!ZH@N=TEQ+9Y3-;0:$ K%D#18>
M89S(R"A,(5=Q:DV:R<'F/SY/R_3?[0)[5PKU[4"=U*5I/]7:+-D1]DSJ#J"/
M84DL22Z2'+NX6H)'E,1&"<LHMY;+P6:^/4&EJ$<8=+VQA1[4?:/,J*N;90+C
M15:ETJF).+9U2V #$*:Q?:R&IPO.,YOJG$7+/[D9A'!YK*MB<7TU<PM0-8E(
M$F+EQX1G))<<BX48&;',"KAA:!2Y&X',U1N?BR; PH('=2G:0GPY$<VI^/MZ
MIKOD*E/*&$M"'J+$#8&6<8)187&B%<_3R"[]Z.'W;618IY3$X4)\;C+)39I&
MQ#(&Z,HDF/L)+Y#,<I,;'JILL(=H@PIN>B:S,PLSRT1"!!9L8)1B1B2+"+;G
M$EC)6LC!0K[[*MY\-N</K'CS\!TSL+Z6'&3.7)C4HS22BJA.L#%YB+4ZC,V(
M#).09"JWJ>+:L.&!_Q_&VER>37T9-^I$S)6\7?X)^'RWT7M.P.=O?50]<$E5
MDDH4[+'%!@2<Y"P4)$JITC9,)1MNU^8/HFC D!N;=Q>S'_\&3\03D8N/>!YR
ME<EF-^U6HW'7NCOHHIA\;C"?C&C'C=LS'QJ7CZ\N[AC)W*WM/FZ]Y;1 6E+'
M;QGK.-6,)$ID6(A<$&&T(B%3D8)]14T^6-?1[P:-_X"+S6E1HD-IOX:G=O_
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MA"0\5F#;9'E,1)A88.7(LBSCAJ:##:2YSPMQZ6QZDJ38ZX'<]]9!BA;B$.#
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M?=#[T,4X>>.E,^L ]J2 M?[2F+,"7EA>[)M1W71&KXI+/V5 %2Q<*$!2@1%
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M)+8F2DC"8U<6(B0B-"E1*I1A1)6,LT=OU"F;7N[4#W"E7?&]B.$(]QE[=]J
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MMS=AOVT&_X0?)KT1GC"Z3><L#!,N2*Y50E@6<_@I9$1*PQ4U4112O9BDEW_
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M_?S7X,/>_C_@1_)Q;^_O^/O!X=;ASJ>=SX<' Y%#SQ9QO]CE/SPIVF"KJL:
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MV^&55N 97 !\VL3D*TH%H/PEG[0[PEB[YS?(L[%V#[_<_=J]0P;6:%W]ZU\
M0'>1E-^L\P6MZU]K;]TG.^M@\\*8A QA%*59R*2,OD7K$#H0BGB$7DI(=G)Q
M840]"4E)7.5WH"[ R#-5YRB9BA5817R9P-K J^(@&L/>/&>*/4-HS90>PPKH
M$4-2%H"I?TA*(1Q-PRY]K_#1D[=IT7Q>7E7%%==K+7V': TKL(IG/<Z-2L /
MA'%J,',JD*$9WM6TNDR+$<GS6<_SH(UG[+EE\-3Q&958CZTQ:?FS'6CB-OKK
MH[]^#_3([87 *\]F<FEH1T,!W1.!T-.%@\0O0QPM@[WNB@QL7\VD8&JX9@_"
M:K!3I8$J\J7@9 /JM.WQ8FOL,F@](Y,/W&[&*Z_!253@61./15>S3D^H/*_
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M4 &)9@+F"E-I4"&'%:.M6^H"Q&'1'#OKFHWHUE>,Y(V"215X"+!3PZZ+X7[
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MN4A/T\2"@J7+=I,5.<EM$!NC+_*)ZZ/8UW;U!MYM"X +Y/\5?2[^Q!:8Z/5
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MG+EZE;2.F&J+"(U%O.GJE2,)_2T-%X*WM0/!SFY/@$+@8F<:&?18PG6LNOU
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M+HR5@+?STN,2!LT8X8Y>Q)</E-?$2'9ZV%4F.UJ.?A,7[60F1<.V\1 <;[#
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MMFU7ET<_[=&5=D8BMEPNLN=;<.3@,L]K<=KH%UUR_;_1<<@^RTD]E2Y?6U/
MYPLRG^ */WU-_[7'FWJ.12N,MM!2H+RWR%Z0%G@W6/0+5^/#Y*^XB3#A><Q
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M?)O1=4"WXZ"/[URS[MR:>UL=H^B>Q'%A)VQ*A<3.8"S@;Z2(6_%829@.UNM
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MS_OAI.)W?HTSKL^'U#D0BNDIP@!3<$!8WB\(=/-ZZV(,R5:P@&2JFCO-E+Q
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MU] KA]?)%HQ_BEM1 &0@FP*5B+X[)%9P1[8P'6/)^DA#B/>F HM12#$)2';
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M_OGLU9N7C(0 !(BV",HW@NA12(SH"@7/GY(BJ;)_]708F<"$I]U>.TR? ^-
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M?'$HD%05TU(QQ:VLB&EH#Z_N.P/[I*!N4U\!.5KA <_)[-17!AB=+J[3QQ:
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M0I?!FUI;0/35 WKE>VYZE6B3J;_P4[G; /'L\+N"A? /P4O$=]D8-DX1A"W
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MQSGA7N0NW:B'?%1_D6(^/HH\!<W'+%*123WO5;Z3TUR,/0WKRO K)-/@WNV
M"HP>0-7OC#/J%&1$DT,,14+O0=IN8P&T1KF8Q84[# 6,I.Q<4PEX:_KPW(?0
MN);D;&4KQ9^P'K*>.@U6R?0@MQ.V1=?;/7F"S)H*#=?AL.Y(UQSC'TLKR5C2
M!21@\MWM?9^##& Z]Y8KL_9.DJZ#=*^X0_B]&HYQXAHRH'7#,'%]U\*H<Q,C
MV!SI^FA*#D,7TBQX_3/R2.OD8X8',TQ@='\$%Z+JMTOI08P:;)0O0 [-E;PV
MZ3"GH^B46KJPQS%N:#Z!Y!SASG8)@TQ.6T[B%UOM;_QJ6VO,F?2T(]AK]&%&
M.!X"ZS;$M"[.T41.]N(7PEOSD3C8AW/0N<*Z?1\N<.IXY9XT78%9QV(L"X6'
MBJVNM_Q6(TCL@X?)93]7_(K/.JF5"B*T##AR:].5D)5FW'6@C[VF)Z]GQ^Z.
M6KX[T8J:2 9='53P./?TL%< S&I591A=WU"\(]F)[9DY>^+DK8NVZ7?"/1)B
MH-E#^S3.Z<>>913<_O4ESY4?T+D>.+O@D2[S@.A)+S:+L4]F@^F5-OU/'^!%
M='H7J7.VB(T1M#H;J<1CB["))CVKVL?XVE,#?(3H MK#*);BO*CH\=E>2\M+
M;M1?OSK\K]6TN\12\;8(#SD;(2QW81-5"2\%JP)8=%VB:H3H8N2$^"_RX)1\
M14QP3WY.M.VTLUXUY/V%C.;%Z@#.<M@%S5/GZA;)M)\\V ;M0?R$#;H\(Q?N
MWSWM"L/%[A@LH'*EO!GV5+N"<<4.9W&2&5H=RAX=BP@52P^/8<TRR$#/(>N$
M2_-A<"EFXW9-YC#J,Z8S;F@KO5<>H!H1L@S?$USF!4Y5V]8KAND)LT3*P;/)
M_R]OUG7?>H <#18W;HM#,QNQ3^0\_@Z9:V\-#H,_^ ("NV)"U>+B^=(2).<W
M/7K928F&^@L>[%5$)XGH.;6;GZ-A,N(?.6=N*59C:%SF_Z# ?5V:E4-!1Z9B
M)>AH771OX9H3"3EW:TP!XSJYP7W7T*%E?M7&?J$F_OSHA/6TTH4<HE:/R63"
M2:%=@:/'D_W_ZIN]V=E  &/3'?'J..W .*R7-O3-P%"5OZ"L@MU1<G\WKERS
M(E"0 -BYP,VUSK=D>31DQD>1RN K*'QK!)JE>4PUCV90327%I@VY)$4!5+X]
MNJL4#X)K/$8+_$5;KF;*YIY[('<%0^;D_=,C3K[_O$R/'^!,\G6A ZB#TWB5
MMYT+:2H<:VOAK2.9 +$20TH TS?F,.(#4;"W@Q$?S4C)+H^WUZ>)W[^[UVSN
M;(I_ASAS_*I-B$*ZD[,T'O.+S@<GLJ[AH/79T,I@/IPZVNP"!S&%4/3%/&'Q
MJ9S1WP6&O(U:8"RXHY,%]+^D&@#S4R XH'.&/!M\?35/HY/FTZKL=')&%0B8
MF/6[  8),ZC3;V58+P$G;H4#9"\+@";SJ&H0#74<+.EJLX=I)O/<27Q%UP*:
M8WY!(5';30B$N+H^.WJ]= )$]E<)IN0W->NI(X]Y7$3D%0/G-@$TC <!#\:
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M*H3<4>T&B+@"K:2M7ES6RQL7M3'ET0]2\@$N;2MW@%"C2(*S(T$$ B[*!+E
MBOM6E7+/0%2N\:T/G,G4/&B2M9VE^*X<J5F*;P7DC1/V\:C']8F9Q10]8*AG
M2!_F5,6DG2P62(U.F_&NM;<1PZ\IBH@,S%7N',AF==_QQC',F99<T70\R_F=
M.72SG-\.F./U<CM=-FR'1E[LJ';#YA6^MB[RBZINF792FA6*;LR6FM!"#W&>
M9NF\,T=EELZ[XDNGI17('/,?[( A8/(9?.LI[HW19,LL9W?FI<]R=E?DC&-6
M%C3OB+)8P>V5K!0+V"BM=&W'G@3!4JUI8N#>E'M\T".89T]^/%ED+[X_06^B
MD]8[GS)F3_W53R>+0$ 6_SQJ:)INR3O0L^3*UG%<'373#O<(W9&M3W\+>=FY
MDHE9I_^L@#XI:9@5T%U10-[0D]3FC>\U17>P^L>AR1DB^B<ET$1['5>F//_N
MM$*:9>ZN'(!9YFY!YGS/N ; %]Q2#1;A<L]&#*4A$R(_1QS18H.O$5.3.FPJ
M0X=72K>8,Q.MP!.S9$:SRS&U=L+EQ5'S8*B@;V<DKSMS:F9!O2O&\9S> L/I
MPWU>1433*=:#SFMPTSI)FOQ[W3<Z_#(TE4U29#K7:N\!\GH1:1UT=;\L7<Y$
M*1C_E>GJ.',=I@R,['6VU'?F-,X*X%: R<(@%\_9C:>])E+2T!*IM98!,('/
M$ YL,K]HS>219NE!CD0X(!S<K!.9LP. ?O)!?=+815>?Q?B.G*E9C.^*'8\Z
M0_(X;26<QRD/EA^YD9E0OJX"QVSS+D8N#!>:D9H^SLP50'9<==%M]A/#L7G+
M0XGX7[R-OJ(U4BS5V9BL'ZGWF)*CF<44F(*!5O+"<(FNR6;2IY8>C33Y!+A)
M#%"2FHD1C_TB7FG$FLPSB4TM7-8#7"7,@"O=]#6KO69]!P;7&(^#?^ZN?T(V
M/N?NRK%92P+506!;89%(X<)!-@P9S>S&H2K_7'^FSC8DCR&@\J:IK^(+TP;G
M3:6\=>#B>PV(MZ>,(>-CVY\*!FW"/\^XWGPAG-6OG_YT-D\V?TB!?2H87$W.
M" <9OVLYP\S[+C7^<^5*-)9V$21TU!;U#E)!J^^Y^[T]#!R3(W71MY";N!O>
M,#QNC#/0N,O",0) 18\ZT92[Y/O1T9&%+] ^1&M;[4,9)+HZH$% P!Z);OH(
M\4E?>_2<:]$, #Q (LC?3KZ\D ;%$?ST@M-"= ]LP=0%51\9#$G?_B*75 M2
MT92Z.;8SVLWOC';S#\?9PDL'OK&\$0 OO(D8BH@.;-W <@ ;9UM#^PIHT?I0
M^9!SDXQC)E<]8BBP ^!;9*+E_@G@!H!RCCQ0SG%&*Z6;P U;.B_Y5QO'5H%!
M[); MY"^'?:K.JE'6F^02;<P@18ECB5/4ZM41 !44Z"-!ZR7@$2-3/',0?QI
MB-OO@!1Z0$3HQ('V%T,D 2<O8<"N B)=0,T)1Q.6$8)Q8Z%4R;Z6L#@&K9+,
M8+F/^+RQIG7=QM3>Q]E?>MJ/,?:95RN)6'N"9>G@@S4#- &94X,)\6/7"R%@
M;CJ/<DABO!\""C7%1=W(Z)RW4W&=_SA[47?(@'+'O1D:2WL.F4W+O!)Q=SGM
M@EHS]ZYH.\W2'O+/Z1W1=[:"B0+$Q_PM+1,H.'19P0H29!;H&,<(*Q961GK+
M (3BQH0P!M0ZEPX("NJ<1Z %_[+ RT6@84SZ#)UTG#U3K0=0B7JUPA<E_!#M
MS T<0Q4MP"W\D\#V3OM "]YJN4FAREJ/*F0##@U&%N@22[J(='@T;N?RX:X#
M/Q4(?4K/K#N*W2F!*<OX*UY+CV&6F@&A]=0,E6!?N#];^##J_JCJ:F+@PQ\I
M>L\]X*YHNYTY<B0C;8\3H )A_RQ)36$=ODN<7<RUY/E'\:.7A[T1[2ANX;:N
M@-4:BQJ[:]$/TA*"O[2>TC9-2NCNSN S]](0G;2B/!GN@=%9FVFSLSCDZ%S0
M.6YX-$F=+4;5C!0QA^XH"E<7C@O&D^IXB$A&7EF8C!CU9P%@%X7F_0 U3\,T
MAI(ZB*G-SXHOBXU[/%8[;W@<"W!E=< J\\XB/V<.?#=5;EX['[C@H85(.QDC
MQ,,;+L:PX+-4WDNI?!Z S=:U:R7)S ?N@! RMOI @J<A EB06BTEM18#13U9
M IKKR\37).B4H$!/_S4"M1ABVY[W#=L>U2\+=6+>AL0B77EQ$*%-&U[@5#4R
M%4F^88Z6UN/LI.6?+=0YP<YI\E;*W7!K-$J$J3YG6#>-%K=XMVF,>%XWUR0^
M[Y=TSJA"?D,??SFC"N$OGSZJT&RH?LL.3]/.D#[5+GX43%F/^D0<ETJAJ)]H
M[$YZ=UV+A?/1J3J5G>2M*5*B (H"K1(!DR!K=$6)7ZJN9J80+1+1W3R3 TDA
M1#!4L,CZ@7-"<GZ6M%XDR/!B[K#F4(25"[(YIB"]H2]J&CYT-H<"'FY+5Q&.
M'S*VJRY@O!?G$CBKP>&)"@WQ]9&=?^![YOO-J?A?EBN,P>"1+Y.Z5((M0R*Q
MR8$DQ=*(055 A-NTJV2H)8&20L<7DSZ/(8WZ3(OT^-&'YX6H6=IV+>VNI;$_
MH%(-*U2><X>Y2__=(WR*4;/AIH5BD0<M]XN9\^B?AJQ\_/0%>_6,:)N6> 4<
M?@3/#&UO)$!A O6 ?,F?KY<P \VGBZY\%ZY01L4YC7"8[0?)A0P;"MF$?5>_
M):\(?T--^CA[?AW'FV$[V?-ET[D&=K:2.@(7MXMF+6!3])5X;KZOHDF_E C+
MYZB7$6X<K7N3EUTHG%F(-T5U< V'21:A(6M^\CU R*S%Z@9/I]D8)@P:A)C^
MMA,PR=?TGW#IND'LG74D4&[0?<*O)N<SRJ!?"7_"%4/ZU)I1OUF1Q:)^/GQE
MCH1_MJE+;A,8LQ3-+28?&H=;C\$T5)L<-?7D#.Q!D_-6<HC)%)#K-Q)(SXH5
M%7O$[>3Z4F(G(V8R/95E8==<E7FQ'?9J2;EG!"MG-:0 45'R:>;*#Y<5:C+(
M_X<F%$[Y4##H 2!91T)O;9$[X=%7>O"% M.1(*(EH.X[OJFVPX'LK^CZ:. H
M='?HM'\OS75=_0X\>Y!?>6S<R4-;5C7@*CW)7MQI28\CIX"KCUIVD@PJ5J"Y
MZ DD#J,*L<<A3ZBMJ\J5W$ 0*/;87T)2K.$&HN&W%6+O<!:.U2Q7%-61BMZ*
MN4JT!R1*F] ],$TW)9'.KA;6M[@KQL,DL-6;4*+/*T^PP _"9:C*OW&K).&5
M6[X]'+K4P!U4CRNE1K-3ZY6?_I+I%ZT^%>S@FL[59LA6AS1<%,(=OBES&EWR
M@1AZA+XD:9:CU62HQVHY:,79C>;C$6<<TV5;>6&?E75U<80H4-W5HWY' 2;I
MEDMY+P!RK->\V4B,KD6^O*7D6D#,H*C/%+DEUQTR>LR8BC%"AGN_>QV_LBG<
M_T\MT)SG#N:Y@WLP=W!-)S6,ZKK)KU*>]EB+?9?-0SMWY$W.PG.WA&>"UM5Z
M_BW>4B$*G0B<UIIEZLZ\X%FF;D&FIO,_F*! JR;CDF8NG939ADF95B=E..Y)
M.76U'0_CK<Z2+-E%SS%FWY42R/#D%:!/O:E+G/ES[H6+0"B20"3G0*JO[.)8
M _]DX_*RVS#B,BPI1BU:@[Z01)0KM0$)C8=MVQM-'  N9H5P5T[GK!!N1R&(
M "]1D@7L.7/>TQ^0N5+&=9Z%T% [DLGO^,NS_-R1ESG+SRW(#U(]C=OU7>#Y
M!@J#:XX/"<:<ZO]-9</*SW"CO'11<Y_\<'11F&I7F\)=^HQI4=D\I4UI2YD,
MW;]ZQ9 BGZ*$10>(ULB/LV=2I$+2<V%CDI+,YZ)1(VD['(>)F>[SHJ+;(F,+
MNHG"NUI^HCL="Y_;2>[H6;^%=I*5*TL^H,),@/Y9\HGKH[K"$UQ,%150C=Y;
M6)Q?YD49E;G(\[\0_YH!J9A?>ITA-@@C:PH=)Y_SD(IT[TJ=HZC.FYR<]IZ;
MCA?1K(]5L>26TBO5<X >5:B1CI=J/#=*DV2A,HY!!"]188WINOPZ%@(C(#4R
MR0_($[<U"@8D?"M,KE5KS"(Q)(#A$81\O'X\B&JVN[QHACW0<8^UX-,RXEZ4
M]9^'13\1"?[("O&G9,+E8&5,._N-W%D/>R E4C9V6!3VP;4CX0#>'([H4FI>
MC+# $S<K*55'736^ZV5Q R'W@K?PLAF6%\G#6K"E&3M.RG*H^!HU@].>'Y,^
M>FB63;V')U*+(:FC?K4 P*"[") =GB+W<ZUKMW,5]UQ<(^,RA^21)B:?TV]T
M"NQW384SKCE^_^($^8EV6ZR3%\D756B:2X?I/::DJ.@4==9D@M%&E+-Y!/<-
M*WP;I_0:47>X">5UJ7ZCSR2GTZZ*:F(/?:]1\M*DQ<@F:"_J>CTZ7#@L>%/T
M3D>8'.30J!+'<O@D716T3%+^15D>\:;N)':T)7&W@'/KEE\@;7]MO<3\)*I2
M#:I0STU[8!,,4F,P>JN]P]/7HFMLWV>*3E:KFGN$4>G6U%ET2@-6AQ2"L5%O
MW4'12=Z(-0S(K*N]G633[YG;-]L,V<T;^3^+@=MUR!_RF$H*FO3_V'O7Y;B-
M+%OX52KFFS[''0%R='%?%7$B:$D]K1G9<DCR<<SW#U7(*L)" =6XD*IY^I-K
M7S)W BA*<DLF-<2/;E-D%9!(Y+ZOO393M_QZ]PBT,RF]#!9>U@/K;+Z4ZD:.
MPFQL%$26^\;2CS>U$05".8%S+4IFZIIY.9\C:D/#_&[$817!G4DW*L/!-"^M
M2\L"'"9&:7&X 2? RXT%)W;C$:"YN1B!J)#5/@R*^KST"@!MNEDR9M3Y P)C
MH=KJ$JJ+&]#QK7\,.>VXMJ0+HHV7&KL41IXJ#T\ZRM5O(#U)]]9<UARKDW>1
MF8G3WD%[S0\0G2W*[EXJNP0,:;1>T'F:%V&G1<%>0^@D[;R(\[!.+W6PU*K)
M&(]<-1T5FZ))KII-WL]^(U,4:* 24FI7^< X]AO3,Q"6CEP&2BH%B'I*]9P)
MTQ8WOIZ2):_1&DE=W00RC-H7,V).XK2[D+ :=]VWCL#*]!W=)#O9.-*\A)I[
M E?SNG?@VP&;:J-_A7&;Y[0;MFOS_7V3^J4--VSHXS\N;;A+&^YB -$&Y1(G
M6K0X9Q:]LG2G<SWDYRL"7J9_4/,J(FL3 1N85(N'8B"$9BZ%Q?Q#"1%DE6(&
MX\!44'Q;60Z%\C-QN-9>S,W)KL8[?=CU#U$Y9ZN8WI92*F%X:%Y1PS!;/:R'
MZ=:3"U]Q45LHV/&EJZ8LF"JXBQ;?K*SE>0]Y'")*V3AT2Z FU(LUIZQ%'DUH
MBJG' R;>[NIY).FUK<339^@:;KO@]9%%359G,W/LK C7_ FVK<0.C\CI_BW)
M1FBW C&H4;]4>@,J=$FSU<QX93H9I3]%E7^;!?,QC@,$2EC%Y:J+P=U@/J8B
MDE_JN'#O_;N[:@*1*SM,.M6-FC8:G8]GS[L91ZG(_4-;LB]'ZK//WU%-L"$X
MH=#MW6\NGZ4 =V)[#?$!A):3S21Z_JBCX[-7?L.,VW_".0+-7-Z"A=%V6L6\
M^]/7K[IT'HN00:I8,IN-7(18%ZWH@I2.T+'9F-U\CCHOS%2,%PP7P(-EK#+4
M(!!3I7^BM3LV6#"-6B:>KJ7*]76(R6\QR3ODB"BY2*<?^R@2XG^^PH'>,5LT
MAZZ&/UJ-%[J=2UA..8Q(/TDGGY6<+ F59XXX%S1HAB&GZ*2'<=1^Z07Y$@:'
MQ ]%%U<=.+E0S]!P9<' D%5AYN&\.OZW^627HT.4NZ&[,4DVE 9\(V(@]9]K
MCLYUEI 3?Q39XFJ]1->MX3B)13,=#HO\WE7#(]/%=>#H6A:1[GT8?=$ACL>6
M[P#_)1M> F1_'%^'DA#>U'.:88^O%-[^[KCD1A,7-*=!#@VU3UOCJETM<K4!
MN<4KUTE[/'>BCNC$\[(29Q@/9J?5^A,J^8BP#TV2U;2:46_*M.A;Z>P4SX*R
M-&6GY=4B;PO6G^,6<^&<J6(*A]A@CE(YY3G8H21)4PF\!)EF1/FT4NF0,P84
MD;X?8Q-HR@+*8? H>=G*GIMF\;,X@TAR9#I>C,Y%8/PHD_R2N#BSYR1]!<E"
MF.4 "[PL#YV=*&BJ5^AG9",4:\3>\2*Z$^^VN=A*'(@11O+ACV0G DU?*.G7
M\GX+Y\4P$EKJ)Y"?.C0=HZBNM3: !+/?X<5QNYL6Z;?GQ*=3K'4M4\1E*54"
M4JZ^W#"[0$/<M8T\:<)#U[,^3, ")[O-(<>U0X0'-HGI,$ OZO\8<A$H\TEJ
M<(>Z#N',.*;[W"'+XII]W:[9J8/OS\T4R)$"$. L/7KPZ"$Y2FNWR^M1'NK4
MN/E>C.+998-XZ6. )63J-O_^_8_C"H6,Q3SJ52N>]G+I\L)+2-L# .*?Y>_^
M3CU\NK?N?2Z#+4Y@]DZLFIW53G,U2/NH6FB=8H<CGX2B2"Q+QRH>$<Y)*(4#
M4EZ@X6"'X<!T<5QKDJ<CR%+AW9XCQLN4@/Q<DC&CK3?*AM)1% U2=-:+"U'X
M *X8M/A/3IXD 9D0P^1$XC/0Y:I*M)$#X8%W/;GB[.H=?&!Z3(2 ;<UX90+1
M$!2 N99SK@D1SBOB!<R"]!+VY '5%""L0KD1+7K#C5V31X.S=NG%9F'/^9PZ
MXHT:'R+TP(L(@\9D@(!_66?ZLDX()Q)]0H_S?H68+[\*> O"1=7-=>6*G:-C
MG)R.RT8Q7QM8N>U0$92?>)E&I\;+?MTVWJ=T]579-K6,@WAJ3U,<HPO:NW>:
M-#7(1ZHLSS](R?//I-)I!!MN+C-*JD[P\0$4!V'W8_J$8I9(QA5#-!5Z!$\T
M(X,HCQ,N%1I0,9OH7^V]<H,:H/8#"+T_8CM6/S:8 :^(?,,LKQUJ6ICE0^=E
MA?>71:60H(Q"9-%A0%3[;K3\JK^D=5R+F9'0RW%0U%R/[47$J#)12EY'(]&[
M?)\Q!R=.DP2\U)'JXX)F4U+9GG1)G/D5OJWZW.CY>^;\+^HLDH%]' LZ)N*(
MQC( AZ3YAA50#S KY:SR ]Q7R:@H$,\./QAA,$)%(94#8L@J,;<DD3 =?W"^
M^CZ9]DW5.:/B(F'@UC^TF>(2)HG()+N(DQ[Q?P$6ZU4A^W!]HL^(<*JT)&;:
MGN3J3I9/5&F=$Y6#9>?*K!N3&MP0GBR)I-=<==-T O$YEJX"_$UQ;K(5=GN[
M\1!/N5#\$O5VDR*4['DF:A?N3-L2,;VB[W 1^MX62'6C_<P$43H=903SH#5]
MP^.3O,K%:]TZ#/;SW_*+DV%'(]9#)AM,VL5*LV4$<4(MH>PV7K6W$=VO727;
M$^R1LTT UHQ-1]*;"?/60<3TM:KIA.$JEXQ_P=L"0BS"J&L.4;-O>U<<PSA<
M\_I?4-7OT'AC21XK3(UY=0JE%&@CYY780_YHJ+U21RH]8TR*47P.-#:G)I7$
M:Q(?KU[\\$R+JIOVZ*V\"S1@9SS>$<@RF:$TF<.#0UYVL<[<4<)/\K@CE/CX
M%1"VK$OF_N"%Q#R$27::%,"XEA-T0 [/2\C<2#!*G1&QN,F?TZZ<('..O2<Y
MMX(6G.:UD(ZULT&MD_X4R>"<K8]GRGHHD=^ST%@PF@<U0N<*M"ZP/JK5(4=2
MKZD0<-(P QUI-@7@:R^I3)/,3T.Q<4CQC3I<1[,)*!\<73]ZIJF0S2DNZLP!
M(:N 6T[T;G#SKDL^.KKZ#:T3UJJ2C:N#0VI0T0%\?>.%!9D=265/,^#^? DZ
M;0K8*UH]*3^[N3>NDN(-_^!<A4W"CU'GS.P$SIGZ1Q8\\_D$4,(CR;U&B/M+
M;QE2G)'6.:(#KY-<FM;8^, #&:&C-.793*]C7.ZIL$"J8A;DBX-A&%9GLJF$
M?)+2"O&ZD+.BL]JHUC !"UD[8Q1N3& PW2]U7]V(FS\Q6356(J38DX[]G@7N
M*SIH--U[T>*?68N/<IAFJOIH#B7-@>:S3S5IS!B*@Z6Y<RW]BL*VV7$J-SAQ
M=>UW:$..';U1Z-QX%?;3GK7#;O6<O4HZ1A>%?X*2L@CJ?F\:KT.Z0U.K-PQ7
M;(?Y34[&2#&S$3FI$]\5J54#.-GAB2A_DCJJV)^J]/Y3-Q&3^0C*/+R:O"*=
M%(=-O"LSG__GX*?_M."G%_STHL]_#C.(X)!*'CF8\[*FU*B2R?E@$_C?8QSL
MR_%KUW,:XR.=R9M'(.!K5"GI^CFR"(T93Y?.S#K$[R67P;;AU3,>Q&BXRU5I
MLB6GUGL18T=3-KI"NCRZX@&0/@NEELLN7LIG/M4$O:$^*H%""2:MIZZV'<97
M;S@SR)BT@&"X+ \',V(X0M(%1I.>;9JIE7S/9-8,FAN;J#D:N?+YZJ6L0T:V
MX!+D44ACO!QWFBN=A=%B34OB&IG;!TJ&8&F!@R4E= J323C!6I4TA'P^,6;H
MZ>Z*S_$_%U/#]%97SDZP-FGDDWTK@AG\B)J\M)!KQ8>H&/S=N+=B9E:$1FJG
MT#"+=OH,VNE9!'^,RAW3E'/((,01.I1EF'G74D$,Q=,BXJHV1SX)54,VM6HX
MK46_*YJ:VSGHA_/5WYMK6#"^(\-Q5]@$"E8(I:!X R(S9$(X49&DD@J+;7&S
MO3)4"MWDF'"/)3 #[9%7P&:5(+'^0Q1[T0M;K2O 7SBCT.?O7!WGIDQ/<N0;
M"<4=,ZX^R1P70KZ@3R-CM>21XAYQJ5TQR+)F6V#97/K=<31<N*Q1AV7(Z67>
M7DDSPO1!Z/)#K3OP>77O(G#2)&CJ[)I:/)U5-%4)^(^!Q?6FSJ]IVY>BEF^H
MPH0DY17S/MEK4,)K?(*3 S:V%+IL.<X0T$N,[&PP&FA:]9M*KQ%]I/OB2%)*
M$!:Q=$G94\R<ZV;J*M) H)V4-B5=Y(<^62KEJ>GA#%X)LNF8_S$S,Y*H%Y%R
MH]XC IK#-DT*]'\$T*#=OZE8-KL_4ZW&+:'^^J<H!XQ7_S'XOL6Q^J*.U5L9
MAP7@7MWYLR1485VT%V\JY\A9_\[E _H@C]Y*[E=*T/P1CA63 E%*D2K:^Z;
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M^9$;C04YWZ-^0@#U>H/U1XT7Q I.#PLD:QB')".U+AE4;83\6E<Z37&8W!X
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M]SPR=I:PYFNBG-=JBA?$F#^SX*M3TYJS6&KXD-#:?DT*]@_\3:K2-K-RK 0
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M@7TT<)<<PQP3L$C3P"L5&G.]\]7/3@)U(3&5:64DJM&.2G /VSMX#ZW\;^8
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M?@.1W5>HTQD8Q>-@-HZZ,/Q%H[?*N8,(OQ6;G>!CL35BI%/3;7!C";Q@$S6
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MK*6]4O-Z])&*,*X,49%$]F:606EU[>7@7Q^<_^%/B7J:,1HVNZ;L3BI!'#]
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M4*\/79.,>CIG[ZCC0R7D3)<%H F,WD+P*]37)P2S2D4J^(]P/'D%6J+="L(
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M"4FSVAV]"G\J1BH/XG20C57PW,2N7SRT4<U.$[=!ALCJ31X:4Z>U5[T$MJF
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MS</#3:=9X]"PY'( ?QNI,!K P2AXS/;1PB&!++I,"IS?;8.5\#1-O=!QI)#
MU_% X;2OX=^YIJ6$V']A\<R'X0#!OF/%3V:P+[E/;\1NM\#O]$WJGV V"T9)
M J4+6#(\FA5 +#@M,"J> VKC !^Q7].," ^D+^(P 6IDPZ%6!1Z2,,A2=5#
MF<7&#M5$S3QPS;^_"UYC8P<-O^8.#S@CL!#&VL[F-]/NX;5K[I KNX7#/!O;
M-@__J1^]L8-(%)8HGTK,DD'H^:MX@.0H<CA!W$H VXL4J_8$,:2$/U')&U,^
M3D-[&L,)G/CO("H*!2?KI!,,RR3A$V5Y$U@8M@.D6U))@)5XN!W\J8)!F><P
M7Y1#69!F!7 +V#CQ!(^^CF&?<.ZX(FUG."QAH=(HY+$;A?RJ4I6#&$+I]3J"
MIV(Z</&UDE8AC\'2_GZ']?V69B'2+$2:A4BS$&D6LG79U8T#-Q!TS*W+C1?\
MH'W$#Y)F(7O*Z2*!FTD7J>QK/HV$+D(7H8O(M%VBD="E<701=XBX0_:0>LU@
M/D&OWT=WB#0+V0>V%G';3+J(N-T_<2O-0G:>K47<-I,N$NS;,W$KS4)VGK$;
MZS.29B'2+&0_65)"(%M"(Z&+T$7H(C)MEV@D=!&Z"%U$INT2C80N0A>AB\BT
M7:*1T*5Q=)%F(9ORI&Z^!KX9>&H-([4 "3:!"LU&/A-8W'DJ[@H28?>PU3UZ
M:'KD+K/D3LA T47-H,,V'7S11:*+-M2ZZK1U?'(D+"FZ:/-;+KJH"500722Z
M:$,([=VCUM&#Z\:$)Z5=2)-H)MJL"538B0T79;2)=B&BB+9.$4F[$&D7TL H
MZ$,:AG2/O(X8H;Y7NY#6HGXAS[J])3TVEK?M@.^&IN= U>QB<?N.4WNH?'(V
MD5Y!0UH1/%TIY"-OZ/')S(Z.7)K')+Q2K/P.PB&L]F68W(13_>JGX)<F -J'
MP2A7P[_^])<B&USB7'^(&#:K:*7Z-IH-,&&64_..E]3,)8E3Y:W\?)U4^DIP
M^<#$;_E756I&*(I@+3M\S_9%278#(CM15Z [N%\3:I"9AD;F_3 MO!9&AT_=
MPDCLA34>$VD&),V 'G2@^'V<YIW-@$+8;S@$"=%QG$7Q$&Z6>"Z$D]=I^2_=
MY@?U_@FUM/[9[=8_W?;Q^0J]7(Y[:^@:T^W=MVO,(\[EY,?[X*QG+F?ML_/>
MN?>?'QZQTSY;H9W3W7O4.SR6+C_K%E]-+HL0NC28+@+IU4 _EO3O$8POD<![
M0A<IMFT^C80N0A>AB\BT7:*1T*5Q=!%'QU:33^C28+I(JX@]<W1(9YY]8&L1
MM\VDBXC;_1.WTIEGY]E:Q&TSZ2)AO#T3M]*99^<9N['>(.G,(YUY]I,E);BQ
M)302N@A=A"XBTW:)1D(7H8O0163:+M%(Z")T$;J(3-LE&@E=&D<7Z<RS*4_J
MQBK3FX%8V# *"U1G$ZC0;&Q! 9Z>I^+.8'UV#P^%(;>,(05U6E194ZG0;,X1
M5;:[JNP__O*]U^D>"5/N)Q1\P[9<M%$3J"#:2+217*R$(>5B):ILRSEG)S9<
M--$&>FYW.L).6Z:('KF;SPZJB89MQA;*B>61TQ5A^7L$Y/VLT^XNZ][SK+,J
MPG\[>%UOP!/6&C7</D>M8%51\*\RS$&'X-LXNQ;]+=0Z&\2$Z,^#)''(*-;<
MA )W^B ;'F 7"GA6%<&-RK%MQ!B>+G$=?6I4E*6FG<1UK-U8DW ZALW4+3-Q
MG!!L:AA<T=X.:YLCO0 >='SY?9SF7;T /L+!BW,BB(#_KU%0>/OZ$+!_9*=U
MH_WO:'NZ[47[[YYV[\1T[W;NB_N^"#V^T_MQ)/MUS:5W=K)6A/WUS.NL?7YX
M-S7N1OL_/5H'VO]Q][[[<DNNWOG]4O4:DFIYWHQ4R[4V6=N%%-@]I,O.PH0\
M%2V? &Q@K>?A?Q=?NIK!N$^&&[*'G"X2N)ETV9@$%AH)[VPO7>12L-7D$[HT
MF"X"U=K\2X$@8__8#6"_REVW1]SN(5U$W.Z?N!5D[)UGZZT0M_MLW8K+N['B
M=JWG82^1L?>+L9OG#;H/FLOZ:;4A6.RU4GNW8+'WBQ^W$YIL#VDD=!&Z"%U$
MINT2C80N0A>AB\BT7:*1T$7H(G01F;9+-!*Z-(XNZX3%/FKU#D^>UI$JQ=W+
M2/XYSR:PKUSDK/Y5QA.LWUQ2\JR#V)5X/A0Z8DW4;R9XQ!8AXMR3#@+AL2ZR
M/1C<;;V<(Y Z#80:W6&FW DI*-JH&738IH,OVDBTT6:TT>G1@P'>=I@?=T(
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MUCMNG9Z>; &'BBZ3ZM)]N9=C=:E%U[\57+\9;M:&$7Q[+)RU>D/K\K/7[J$
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M<FV/N4819H$GC18 VTR\8C51-3'O*'PBI*&J'..V0PIV RO4! LN\4R@E+&
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ME^'0Y1<%@%9?OJNX*1!\P+@?;%C&."W8<\/$9C0 W+=5OJL-3,7\0K))G)(
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MIR*MN;JX[3\[/9X4@<Z2. KJN[=@PS=Z*'K']5/P=![QQ_7IA5=JT_Q^YZ%
M9[7]+_+GBXV?AET1$5NBOH%PVT)R%Z9A7(++;'@9NZR5XDEB-N;0K!*U6>]Q
MLGVGAEZB3H%%KK$&6:FBX'/93^*!W]OX0YR/9X([8G-LL4"YR^80<FX5.9M!
MS85F5Y/I2\_M0 #EP\&.0&!T-WV$&WY@=T @B<'Z@P9K/TRP*O92CY0J?JSM
M?>,MU3>\UN""UKH,KI\BOO!#5RS4W9$@#;%IA)QBH8J%*A:J7<CAIH]PPP_L
M#@@DL5!_T$*MT.?1K6J:/V7ICMNJ7MXB&*F?W*JIQQC6H?RO"G,=O%^"R"LV
M[.[)F(98/4).L6'%AA4;UB[D:--'N.$'=@<$DMBP/VS#5E7 EUB&4DSWR7SU
MF@'Y]="V$VOPGG9$3-N]%3T-,8:$G&+:BFDKIJU=R/&FCW###^P.""0Q;7_0
MM!V$>G0YQ +HO;)H8=7!!URU6*U[*U4:8N<(.<5J%:M5K%:'=K;I(]SP [L#
M DFLUA^T6M.L4/JRR"Y=2]G+*L]@MPW9/W#IB(&T""1)S-/=$1\-,6B$G&*>
MBGDJYJE=R.FFCW###^P.""1KGL+_(ZJA8(X^%>9H;R'F:(4#^VC@H\?MHW70
MQ$=./MT>"BWU&=M])ZC0;!P7B/C>5X.PU J=QE/Z UQ&@G R <HBM[2"+'>_
MMIBE]$OOQ1KF/4/*.U1[_+.[U@35M89\T"E;_X@Z7V1+@>:%1Q^/1P]?.-3F
MI>SX]%CFO9/SG^_:_[M0R;KKY)TY[;+-F+KM3N=NN-SS\],[GCFG62]!PIWQ
M YUNP@WT4/RNTXU86AOL;W&Z3E8QXB3XHR;0G]:VWH034$ 4A?DVSGSOE![D
M\80,,803R 8E6EMW>>T;RIF-8,P=XTO9?-G\1FV^1 ]_W"/7X+OH[0=B_G][
M[<T!98G9N#T2LAFA^U%13/3+7WZY^?_9>QNNN'5D7?BO>+$G9Y)S6R#)\A>Y
M^ZQ%")EA)@F<P)Y]SWW7NUBR)8-G-W:/[4Y@?OV59'?30/,1<(/LKKUF G3[
MLQY5U5.E4NG'C\U*)INGQ?>MG3(YR[[+:DN*4UYN"5[S+4)PP"C9PEC=@9(@
M)-C3OT=LJ]T>C. BEYMG]?FPY_MW3DMYM87\X9@;GOI%EJ>R=/AYD9^:C&'3
ML+7DZKBW.K6HGNK2:59H)>_W>'7YNXQ'SGZ>;#8?BO?O1L[_W3]P=I)_3;,J
M,P1XMR@GF^8^ZIO#O^Y\^]*<,G*$V>QR9WHZK6K'U46QV'/>7ML)<W$+3%V?
M, MKE3B(_OOZ4\X6CU7.)_6T3HC^/C)[<W[*QE)'PHX"&[G4]=3-FOV;VIM'
MS<W?;=Y5ZP TW2:R L('X:^G\(&F TU?^-<%F@XTW7KE>P9-QY&'28"I8F<L
M"NA6G90UDA?N"3$D??;R2%U.?:Q(8%)OMU1^X S^7)I599I7?Y-F0E\XNWJ(
MI&J0U++9>V'&I-4S-;N6\O%8\7MU:C/[W\[Y/Y)TN_=S[FN;I#J*^1L23O 2
M%DZ0ZV(WG+'P+UR- L?%S;HX8.%=>#D[^,I0 0+A@W8 F[<!R4&Q>=H/-08V
M/P3QOT;2G3&*&?8PC:B'M[YCZH4A/5&$'I'A9]UOT/,VW=YDP8_DI&[:0Y V
M$SY2)'S,S=YH+>D^;TY0IR[/L?_(ZC/#\K-<G7$]V]X-Q7]L6GWA;2"U/CC:
M,E2 0/B@'4#J;4!R4*3^]3;T %+?'RLZ&%*OR3Q=.S)_\".797663?0?3ZR=
M:4.!9@^Z!0K-;@<$-Z.!1:9_/0RX_BS-+$"B>R]GMXI\KGC^/%)P<GXNG;0L
MSIUKS^PL!!C.0:[!.[W\R4B#0J0!7*IO9MH*)PG"!^V 2 ,BC9N1QNMMNP*1
M1G^L:(\CC<@EU".^S["/W2VARX(B*E3$L0:S!X^I^/DH*R7KMM[G<,Z[FS8?
MW_3SM[%%F:D/27M(J7FTWH-EI&./AE>;($*3\X\JYOBA6X\<R:24-2\OS15J
M<\?<^=M4A36FH37QNYECV)VJ!U)1TXTZ(A4+;.T\5$BT^#00!PR'Z0P5(! ^
M: ?$ 38@.:@XX/7VJ($XH#]6M.]Q ,74PP$A6X)1[))U#@,^7"J27MV>>AC=
M,:5 FRUH\*H9^T-\?>&):/-$P-J'PTN&"A ('[0#6+L-2 Z(M3-8R@NLW7KE
MZZ1.R"4!]73QO^_[Y$1>L'4H_C^:R$2=ESM)<7Y>Z+<LDC^<9"%__S@NSN[G
MXK//S+* JV[O,TY^] '1&Z3<=5U$:*2X]XR5'R1UL5AX!)Q\.*QCJ "!\$$[
M@)/;@.2@.#DLR 5.;KOR=<#)?:P^"XCBY&Z(6T[N#Y^3&TJLB_>;5NVS7=L/
MITIJO#(5-4=GO)0F>WZ-MU]O76D:UV#6%-U7U51]I2CZL;K4;[F2?EEEM:F:
M.987O'*^;#H?-YT=_7:57KO+%<,OG5W3^_[108#_M$X\1Q\>*JAO>O'0YI6@
MB&9 Y&:H ('P03N ^MN Y*"H/RS;!>ION_*MB/H'PZ?^LVTXG4SCFJ67>CGL
M%T6Z2[U!YK$LSZNKR*!Z(#38;4(#4T/_: 8? (,'CM)W\V>%\P'A@W8 @P<&
M?Y/!PW)88/"V*U\'RV%#E[*(D2VAJ'Q F% ,?@WJ:6:Y^]]Y:9KL*#(])^=/
MXN-/+'&_H\*]Y>)?B^^+73U)"'1\.(1CJ "!\$$[@([;@.2@Z+CW2S_T&/CX
M$,3_BLM2L1>&OKLE0I\$OJ_Y^!HDU!_DX2]4&//$M/KCMJB"1:J#HRE#!0B$
M#]H!)-X&) =%XOU^J#%P^"&(_^4Y_!W[S;(3?\WWF[TOW7Y'(<P5X3_ZQX>F
M[[P:4CS+]9%9K=AXJKAUIOA\->M3\U$F;3N8T#!M\IQZ^#_#EK1 :?I@+:WP
M52!\T X@_$#X;Q+^H!]J#(1_".*WB/ ':T[X/\HJ*;-F8:SI'9E,RZS6;>,;
MABUUUW@5 E33-AQ01YB#"9WUH5PX9^_"[#DEG9VDUE^3R&6FVSQOVUD^([T/
M/!^83"^,I!4N"H0/V@$\'W@^?J^N[/ZO?B@OL/LAB/\52^1I2"AQMX1/ ]?3
M.T81O 8U\G?MT$JQ(NE[_YKJZAOU@5X ^UTZAV.>/X&3JT=>2>G\0F]X!K7S
M0^,?0P4(A _:T1T[5S]Y/);FU[L$^>9>3TWH<X=Q8NHO!\!]_<54MI;HV3SR
MF?!3V8QRQ%/UMMM\_(-?5N\WG*UGR+XS"S)C0+_417*BG_5%:$M<C,6C2$O4
M)4K'>L WM03FH^J&S]=P&*68O7PK0RVK;3ZMB_>QLE"R-&^6Y:?;^+TY'(WY
M93&MU=TNI#)@YLX$&PS;$Y28QGQ2R>U*3KCF/-?MB;GVQLV8^7M6*18T5DQJ
M>W;^DLBYN5VXB;'[1@.ZS!"WC[091<$#QT3FJ3<@F(=@?C&89Q#,0S!ON\H]
MOV,5H=CU/4*VOKO$#[%[HH-Y1(<?S<]*\/2N;V66U+-=FYV=TU(VVSS\18?>
MZO/?],.8B/SG4P"/#_OI*L+^OTUSZ5#?1/PP'S>@F&:H ('P03O6>#XNL@;(
M%V'PG<:Z-PB\!P0>"/RZ$GAW?0A\N]W$:]%V%V@[$),>VS\KO \('[2CS[0=
M,N\=$O< B#L0=]M5KHO.5D01=QQMB8CZ01@)>1%%:\3;]W,Q31K&OO.#EZ+A
M[8H.JQ$AS0+W.XZX8OJ/(^E1=#])?VB39Q0NV>.9NB&.\-6ZETLGA&Y60^,C
M0P4(A _: 6S=!B3[S]9#8.O UFU7N4[8>LA\-])]:-5?!!:]4/S<U/E*%KK\
M;3J^= AP\:&QC:$"!,('[0 N;@.2_>?B$7!QX.*VJUP'7)Q@WW7#8$M0S)AO
MJ'@T?"K><<7Z\_E[M,K-(4C;LA8X_'!8RE ! N&#=@"'MP')_G-X@H'$ XFW
M7>=60^+52ZT-BV^H^[.*USO(P&.@\$!2^FT(K7!#('S0#J#P0.$;"D^ P@.%
MMUWG.EAZZF+L$<JVOKOJ/\Q.= 4[6H.BF(42=GF>:P)^1>#3HG1$5LJD+LK*
ME+'+"YE,#3DOTC1+I/KXT87K3RR1>8B?_XTK9E]>.JZAZ,0%ACX<#C)4@$#X
MH!W T&U <@ ,W0>&#@S==IWK(LE.?1QZT990WV&\+D7K>^>3<7'9+!R=$?/9
MIL@[T]-I5;>[(%#%?Q7[UBP]EO4/*?,;9-M\]7?Y/<N=HTWG0Z&DY1R5FRNO
M<7^(P+=OT>ZT1H"_#X>A#!4@$#YH!_!W&Y#L/W^G[B_]T%[@[T,0OU5%,G2-
MBF2^2?V!KI#Y4.33ZJ=;OVA3\1(E+L"_A\,PA@H0"!^T _BW#4@.@'\SX-_
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MI>EZ+,_X.#6'WG'RE\V/F\Z.%D:E%R,T4<6NU'O6VM*9E#1-EB"$& X!&BI
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M]7;)W=,3ZDT=XF\ZG]2K.@2COSM'S;MV@HJ_BB':0[OVM<CEIB7C/)%Z:><
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M_%U^SW+G:-/Y4*C7&#E'Y8-Q)[AR,.@ $\ $, %,0W6-X!9!D0$F@ E@ IC
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M_;CW?YSC ^?3_M>=K[O[.Y^=H^.=X[TO>U^/CU:$U--,VP- +?.['3D2TJ7
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M.S!VVYT2]-K=NGHJ:W^E)!CXNE>9LP.#:E?.&*"Q%AJP9&#)0%T &HM9^_7
M"UA[+UB[[K\S;\2C=U7XSL?75I5"KLHZG5T!#GG1'Q2>H&8OJ%%_LD-S['>
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MMQ89/25/N<?+/,M/JT-9'FGW9USD37)=C,>\^7I.L_$BS::/8]G+WY0+FLH
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M\["OPVX4A8E$3*8AXEC]XP5^' 2^[V,W>B%W'8;!*/1#<-G@LBT4.;AL&U
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M&<D]#/ P8%P"XF' P<$ DXA<Y'E(,DISPB2&BT([T"WF14$3D7$S2(CIOF&
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MF&MM=\0+S5?M^=1>]*K7.M$+#1N8+QJ#&Q-V(X8B;8$-<GE1@23TV_9LY3!
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MMJOM?.Y=HR9=%<]1\-; 4@ )HON]O:85OA9^'<-,_ LOYW8A-K)0(W*L,:R
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MZN1H[R4O71G*P';)EU5AJFQ:>-_6F4&\F4O#7RF:3G643K]:1;G1>E<$K#9
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MB0@+DX3P*,R(8"+6.><B+ 9JO'?1C..%>K6)9;S^ML34E9L?XL>&W'?KPU9
M:8L)(*2-GQ$R('1K;*1][;#7%>HNI^RPWFI_O.-FF&Z#$Z(OR6]OS2O=*7>P
M$V&E!'FY)F"HG939,*TK*[ +*A=?,%=O Q.EML'\:HF5)^NZ/!L[[,N4[11[
M6!86_*PP>&CU]'I,%VBXIEHL]-S62/>M!ALKA1&3S4CJ3EL[18M?%_J4S\UV
MZKTGTSK?V$=J-M_MBWVW;*0-CF+@=67+@_L>JO4ZUJG$S>3JQJ:]ST%CVZ4A
M6>!2&\.WQ;Y?,8P*E[B0<F^6796U?9PS=6?\'U7=Y:EWV;M>N*L\K)O^&;LL
MMFUA=D2 V;;OZ]>=.:.$A2N;>NY&GFJUFMLDCZL;ZKBWVB[(:OKLS//@M$\R
M\?^?O7=M;B.WUH6_GU_1-<GLS%01"JX-P,Z;*HWMV?$^,[9K["1U/J70N%B]
MAV(K;-*V\NO?!32;(D52EBU*;E)()8XD-KO16+=G+:Q+$8"O^Y"\<1^BZ73+
M\^!KV43F]Y4&OVW?&+1GO9[#8GRN/Y>OS#@9X_;,P]:ZQ*T=K;>Q^U4H,2Q9
M;[UM\>^3YF,ZT(A=UQ>I(QW0>/')1+S2/7H9/[^U6%R%Z6,F^H6IHX@]6=6'
M*V9XH<*BJ@*%5Y;R^Z<;2M+5[<787#X)8_]I4T%&\P^BT2N,=!4H<- 83Y,:
M1*"]SMLG<3^2_[Y-:5ZI'GXB6+^&(]*B:WNZW-!Z$G<$I7V]\;G7#<\->[ZZ
ME:HD6"FI=(FIHM_WTT0H70Y=6.&$]44=_(Y_]U<+[Y'.A)82TTS?F\FBR+0K
MBGSVV^N41Q+5S*1+!^Y,P$)+=5G_BZ\O5=BFCE\^:Q;SK]NKH18)]FZ WRQU
M6>J.5.H "D2;]7Z1(E(GZSJ]*C-:(H8-D<LR-$2*9AEZ>!GZX">NV2XDL)RE
MG*P9GK5DXWCVG)(CGL:+LB -@:Q9D+Z=(*V4/O=9OG"/>73-4FQ[M%X2E#RK
MN@4[5,VO&I+L$+QV?G$Q7NNAMB)F.?*TKZ36J#P6R>V]G[M&U2OJM+.YJQ?U
MZ=<P18_<UQS_M7C*,O4Y16X6&9SIB3&*?C&?MG/39?>EF6:+IS3K?5? J>C\
M>?@@,5N\"-[:O/>[5M3Y$EV0XBJ>L)IR&G/?KGH'I&2=>4JTC(N9^/=-&H\2
MJX$^F.EEEXN]FOFZUH<B9O-U\TRBD9G'64N394YK&A/4CUV+5Z8BD:MQ2XO#
M@F6F_;EQUXOX_]06O>RE"AW_R7KOML:_VAX5NL4Y1[\JT\47E]5_Z22GW[T%
M$YP4;_I5='T9NHSY?L.N"-,5C_3QF+BNJ^*2Y0'10M372;02=>H&7\0X3.I=
ML@B#Q3#+39.44EEZ?V#R85G'>A7"6U1BK03&_&3:C,?]BU\ 7;L0ZF2>>FS&
MS4O .AGZ+CHTN;:['>_V2;$] _<)I-UREIT8%O$U6&E7;;N9F;5"KKY,Y]J3
M8OXQ?)KX;E7&UK=F];0K[20\-N;!+7/M$LWK90ANT=(I54F>%*?C6*'\_FSM
MEJ[Q7<BS2P2^)N#=!O25T;%/:!V+B1.?QZ6:1=5;MP5=[6F*M8[2C1)7I:39
ME9V)8;YY7_/8;]EF@/,J4W[9ES1M\VV_'D4OR?*FQ-:SE;/%_A6667RSIBG.
M0$$G4L'/(,]=?Z++:SGSB0=BTZ -.O5AY"3;7<1T45N^>L28HI=1@.N8/;RJ
M5&\?Q!_"J6%@"CNE+#(8*\1M"$CQ4B-C*U5Y@:G=G,#R-:>&+R>@:?P[\RE/
M&'C0H\)NWPO8>)\/!O<&SQ:[.HN[VI7MK'5DZ QR5]'9USSVQ:+/?=_OQGQ:
M#LL!#;$Z7+7/7UCI39:J/JY/98RWB%4BJ6C7]@4!YZ =H^[LU7W\H/*SCWYQ
M7K;ET.9J+N/2*'16M9ZNIG3'YR4T>OO76.1UN$4EK9^ )5A\JVNOV)FN#LL:
M\">Z(AWS*24EUMT^+U(O4BOZ)0CK"I.VO6SJ(+)RVT6GMP^I$C8=R,VZNN_=
M>2U3GWHR7M6K=O.+MK\ST 566[=GJ17)U43>F![_L6O)&,_SNE+P5+^UJ",&
MLS5)MJ:S7^,.$!3)NG6 ;-LCEX7?5;_.W!+MONH)^YG0G53WU7R1&&D^=%=T
MU'9%"5VK#U#%0&'441A%"B.@5?>9>PJ4!GE*<[3B+5=;+"U<@&;\(?ZVXV$=
MSUX-<(T\LFM=];6CV"ZNMJ@;'A7@X"<N&@,0ZP1EM#9!$NXU-A]'J]E92W]D
M[3DS\WM7TG%-YKJ_+VXU]:"Q^GFS/J59I2AY$L5ENWHSF_GDH"S=.P.KG0'\
M!QJF'_L(WZ)ER=5ZN\/FV'1N[:QYQ5,V:^O>+?VQ+]G*A>FL/OYW$A'LHL!S
MO>BT;1:H;]%$JXFLU$U4AO>)0V=3_@4HOZX[R,JBYI,519_T:]?2++U3O30S
M2Z?@A_6I:(0><8?7;=CE0%YRURO]>#O0OP.K$^*K$#"R , 1QSR@2N& 0B#8
M>ZVM4ALS1+\&J[\] POZ4U0=D<6![9*J>9UJ+$\G#L@2V?N#?S,VDS9G_#V$
M*)QVABA:AJAAWL[ =4*)1,4JC3(*V)>@=CO<V4^[LL/=<.:(XWI@NV@3_'X:
MHZ,I.6JMEG(%M&_.%4]YVJFAR5HQIEF&>A=9V/$^YQ?CYM+[JX9B*>$K1L-6
M\^E27&/GXON[KD*#>/.KZ%I:$F":\:R?8+MJU3_TMBRMU\WMPCN!_P5?SU*7
MJBZP>-DU_EATVUBIF.\B)FF SK66F^T">_\T!G9!;RV@I.C27"P+3U.[D\;Y
M<9^TO4AYVQ+5OEJTCUV^NGM$V.7[N.S4=Y I^3A].[/*QP+OON1ZD;=XO@PQ
M7M'R0Q/C6^/-),'51K7GYTT4 :#%HF[VBIBKR\LC:'(EY<V5E#174N9*RL.0
MZ%Q)>>";_"I74@ZC"W\'.<(<L$H-']E9'X9LHWNV0'<]*ER>8%]$GZP/F+Z]
M2LJ'[[Z^6/02:J]:WBS R^WF&2ZR0[H&RN#M)9_E/]TA63I3[DHV%ICRIT75
MP-M8-;!KAHW+4T-OG!K**ELJI2525GG$":Z0H9PCH940K!+8"'7=Y;=EQ0*C
M'+&26L2YJU"EF02."02'BGM+S.U<_KT,!F4G^-@'@QY:"&[7^Z2F8UO<Q95X
M9>?.]/[2D;SWK6: 1^67E=5-RLII9R63!!$!&HL3XY"FSJ-0"L:L+,N*;N02
MV%*6FE&'E%("\1(3I)TH4565I:T<(XS*!U16\OBG&!^+T&9EM7LP>T9;7Z7
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M'A]$*AG#3&&,%+%Q8!_V2!FCXP2^RBI25@KOI<_BMX=(BBA;J5*CT@H?X4Y
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MS,8WL'$I-9/&!^0Q-XCC$%E26N2]IA@84BBW$9T XU)*!\9%V0B52(C##[A
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M+XK3@J1M_!T<70M@TA<_U#\NTF*R/;II7%XPK"R-C.4%)'I='FDE'7+64:U
M3[C-9DM>E[ST8+0$I;%D%>"@XDPA8QB6X*<I;S;*\Y]%G^%U^&='JM?3W^(K
MOYI'!_IU6) ;9/(9J"OO?KI\8>S9^K5K9JL] YW7KMJKEZ]^OME@,3H" WNT
M1JO;D9V:WC;GYTU\P<;^/NICE<MB@@["_5 O16:]UT46H)M"?YA0#9R/..7@
M%F%"D"J91!5S1C)!P#O:' /T!0*40G^G2V+T(K,0CO9ETH1[$0[Z"(3C<W*P
M^$L7GUBU.-TI0(QQ+*(16]I>I*^G1!P;+5"L,8??/_FIK>%7 (6VJS)/R\F=
M8SX;$#1*!,PJQ&*>,^=8(F4)1Q3\FM(Y8=QF/<G>3-.+!=G>1*I=B=OBTY9<
M]Z*B7SU]&PF[]*?PJ@C2SP0EZ-%*W\FV]QCB0HL,]Q\6[M^ZH<Q2"2^^T+G-
MX.2F$#!<L/0 UAR#=%*S[3NC]2]%;1R=W.PNW*( A3ME >TP',!=T%J!3I8<
M:>D%-<%09S8F#3'A*\&41E*#8\&)=^!B$(6HX99IJ2PCU;8:OV?-Y(.?MO#P
M[B<@W%7JY)5"?IVZV"R $+DC$BJY'I7D>"/$6]V$/]W"/\A8YDYRHP)7N,04
MF=BN@VL!,B!C]0?\R @O=:DW&M_ WP5EI43!X9A*(#U\6S D6$E%98U3>"/L
M.P L0TY(>:SR,XJ)._U!8K^/5W'=_B\@*!=U%(O)0Y:MRE+&LB.)J'8!W%'C
MD'$ @ D+RDC)5.4W.HE]B6Y.GFC_BB_B&Z:8:BR\/OYJZ]4FO(P<>;%U1NR/
M#K%'%58OS@E!1[2@Q,)"U]T(S^M)S#OMS\1NA>A3<U!S<3%M/H'%F/GQ908/
M-P="0N6DL"4H:481K\IX9HQ+9(VMB#->2[Z174@4H0XP!U*5!* >A$:5YQAA
MSFD@(5C']";H#CXFX,0L0F"#9Y$+7OG]'!B3DZ,-<%RU&HV=5Z;POE.XX_44
MI>TN:I]5U9\UF_-8K/2?OO?MLI0) (6? /!N/BQ.4?M60O?CK^Y &)01Z9@
M'A2< XIU&FDN-<",4)4\4 ZP=+-$#K"M=!X1;2O$F<.H,IS!=Y@IA;?2^W6$
MT3>J>M&]\FF_(X\*9SR2IBXOK_'W=7NR$(>$,Z.3N6ZA1BD[/MN.&\]WI?1&
M<85*2VP<RZ>1PI8@5JE X1_O-CNN?HG(]K;CFM3N+=&(/0*[T0.MJ,.*#D!M
M))<GXY)9_<9) Y4403B+**[*R+8<*6,I$HX%;04#EY9O^+^22%&:@%Q)P*)5
M%4%&4?">G9.8!.$-W8BQW!>K/P:(= M6)]G]?)SN9S#UM/A@QG/_!1,'8D'!
MMF*<50>S38=/ =ZMN_U:7M_6H57_IRC^ O]_WP$[[[FUV""K/(Y]YBI4E88@
MRI51NHSV>6-D[M?8YC>+7,TW8Y/:R;WX][R^2%, ZC;.N)E/_3MXPD_CQO[^
M7>%!=5U$/I[.8X7XRC9L<+:KVXNQN7P2QO[3EC+I_P4D6X?+GLSI,M3&]HQ/
M$_,BX+GS]DEE6I]JP;>Q^A7#\!/!Y/??@O>O%?GND_/7MG2YG_4D[@=*VWKC
M<Z\KBQMV?&,C8VU?+P@K1%Y?PX%O[W=_[7D_J8\EXX^*B9\MM4 :4]?]>_]"
M;SP1VBB&J) *<:L5,@0+%"S#)5;:8;RES<P>A7ZWJ&<3MC=.\VN<-DJ]E^MV
MMCQY7982/+D[AKASCYGAC9+L9VRF$9O]DA9O$5?[Q,QG33_&-"XR[B1^FBY'
MH+V:.>B^^I-W3[O'$9QV<?&%5 1UT?HGK;\P<6I%OT&I!J*[]W=70S]GR_8N
M'^JVKE+EQI/^'BL7KDYQ[1Y;EB><)%6[<]SK8GTG9<EN=1V^S57T1,AR;[>C
M)YS?[B5NN3BEU5?>;G4 ZRIASCH)[]IO;*?(CKFZ*X-N'W+XNQZ"$.^U6\F=
M1[]G2CP<)6#?XZ<I/O&@5%F?/(U/XN#IMAG7;O>X]GX[OQ$UCZ.7T*I_/!P9
M_0PW;$XA'SI;#$?,LZ7\YO[&?<KS#W_LDC2;>0ON1OOC<&1Z6'0=CD"NVUV:
M[>ZCL+LQ%#T<V<SV]H@<G$R;K'JSZKU1]9+A2&M6O0?DZF YHCRVN*9'"(D/
MK^?ZZQ!BN5G7F^?\8AZGK2\/6.X@XD=-YN'(YSU08M(<#!V^0MP>3K+^.!SI
MV6IP;D7'>S@130>!UREY1QH<GM[=,28JE$1P)Q$C+B8C,(>4+PDREDL1:%5Y
MMU%F2#FA/+B 9*Q\Y:7T2#/MD-&>"E(Z53E\ZP2&_YXV;;LSXY*M95S>/*<>
M.%>QG3F768_MD?L'8SJR$1\*)0Z(^;,1ST;\J(PX+SVOL"P1,95'W%<!::4U
M*@VSE1?$.KLQ2+A2S@7F+;*L#(A74B EL4%4"%Y:[I6.9:C?P(@+MKNO8]9C
MW]R(YZ/H(X_/O&W"[*.9^N%$6X=%T8-"<5]*B:S]!GPPF$'8,#3DSJEAS@=?
MHH"#6TQ'D<PB5@K.F>*XTAL354J.)6<8(V.P13P0@Y10@-YH<")H0HC<:'#Z
M "",C*@F^P1A60T=NAH:UJ9G&SP,.AS+EF<;?!PV6)="46(=$B).-9/P4Z5)
M0*63SE 1J,)NHQQ3E@R7T>A6CB,N#$9:!8N,#R)UQ]6&?QL;S'9WWLQJZ)NK
MH9RH<N2!D%_BG+"S9NR*^OQBVGQ('2K:X83GAT7?@X)D.2@\^"W/D.S0].4.
M2%89+ PQR&&B$0\AMCME!%D5)#:EP<YNC"2+W4Y=4 )IP23BE:5(,Z(08#B"
MG6=<ZVTC,N\;DNF1*/<:%LEJZ-#5T+ V/=O@8=#A6+8\V^#CL,%8&R>%$4AX
M'T=.&Q);CBM46?B9A9C_N=%+TRNB')$.*5.%.!LHSI_@! DC#:\XX41OM!Q_
M$!O,9<X/&; :RODAQQX6,54S-;-F>KF7LIVCINY! ;*]!HAO6R<[+'H="VGV
M7\2< =XPM.^.((L+HI2T0E+'=N?:*J3BX"_)F8;?J.5F8RZ L%7PHK2(&B(0
MA__$UJ4>P9]MZ36GAKEO /" R]GNSND#5VN;A=]9OV40D$% !@'#$Y(, HX,
M!)@0J!0L(.^"1EP)@XR1'A%;8F&4%8IN@ !+XZ?>HU)H^(XS)3*BU(A(29B2
MS IZ^U[D^P0!A. , HY(O^5LF>/%#)D2ATJ)',P>&O-GM'4@:"MP)X0-##$7
M..*D$D@;XU%%/%>,F9+H:N-,C5(<C+1(4U$B[CG\A*E&03/&A>4!4->W2#56
M(UK*?*B6]=!0-ST;X6'0X5BV/!OAXS#"+DBOA"J1K9A%W,@2&<L(8EXZYSPO
M"=EL?$*4(-H;)(P3B%O!4%5*CBKE Z.E-Y)]B\8G8(29R)DM ]9#.;/EV#-;
M?-L^*8RU\_/YV,R\ ^F%9=@Z3:P?3N1^6'0^*&R6C[<&B^'R\=8.K'=XBO2'
M;3/?,V1-D%556E+I8W4ZB\USL4+&$15#0J*TWGNE-\:$?TW<Z/3*C#U?L6+P
M\]C''P#%GIXW(#G_27_?B7#WE+6M\%X#3/D\[T#:F>999ADV9=@T(-)DV#18
MP)!ATPVP26&'N;9(E#C.*2 4P9\ 196BHB4M"7$;L.EK(GV#@DURQ,E>)QID
MV'3HL"GG41UY$++7*&E UK+ ;E1,?!Z.=0Q0>J^G,NLJF)[0J(-=,Z_&?M!@
M>M"Z=T 3.&Y/W^'C\0QD$Y"U@4FFN$9*Z@! %L-/OJ)(ZZH203!G[4:;Z+WF
MC;WR^P&G:L3+O>;H/ZQF'#H\/1;[E9'$4"B1D41&$AE)' ^2*+W05K@*$5])
MQ$L'2,(%A4KF+1=!24[TO2:_[0M)$#S2?+B-%3.4N&NV'/QL8+=V;\KW]ZM%
MOL+4D\V'[G>K.F9_-3^'+UKXW=4?!K4_#Z(E][O+JP'[PG^Z\)/61[U3S,Y\
M<>G-M/"PHZYX[JT_K_RT8&144$QI\=&TQ1]O/GWYNJ4>X"[N<%NY-(ZX$H7
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M-2;.WV,WQA,""DGFC"M-(+F7&:AGQXDT/B>F9%06-H2RZ'6QED5.,U]Z$J0
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MDSNS"O?1%HK.:]IT#S#B]^:">:?7\I'UL4#7KUY^\A<C?GY%K2"\3@4+(-V
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MWBG-*=,KS+$=='*?XAZS2"?+#-?+S- 97-=8;QZ#Z<NVUG:<V;G]9'% T&)
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MS<8Y/$[L7YB/7)BKQOG0FBV#-)9T=@K+W#LL$T";%4$3*TQ)1 #5)TO."./
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M(DNMB<MIX40AI2M[7F8HLQ(, H0^\2!%*:7$6,&(S9W0RBD&ED3R,I\V"+P
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M!Q?- ^VBH/,53?T6&"UX'X1W5!V67E$1$L;3I;JL%<-^%=HHK6?J!^IE3K5
MR7OTZO..:#''I'I@G'J/3'X:>?\;J8!^4%JFVS:2PV^Q#^&6OUXL*-XCR1X
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M(/-0QD>&Z04&+XKW@E6_=<]"UHC#.*OINX'9WB-YK?*9,-72/)BOJ+H3^UD
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M187M/W<R48K.WB0':"S0>I.2@&S;_@ FVZ,[VSUBFANDF@4%D=LL*\R0J&=
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MN/0?O]^AYR"^3G*J=G  Y(T8':3J6UR1MO=G2,"XC.C^1JTJEF,HYK'N"'<
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MM4N7?P%(%_/<4[LT^2M@FO FR))6[5+F9X"4T4J'M6S60\[,T,FJM4P.R$[
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M72J7"_AC'0!]8&?A 3JFJTS50X:!(.JYT_YM2F"$73>Z?W7 !GHMPB0,;;"
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M3MNV.JM#:BKJS'2 T*]4<),@IE#-(BK,<<8D-7Y!.BCIS?U#FIA6)3!,_?
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MI)1":A\8^&HO[;VX(U J: DI7EB:M]_ I8M2"Y&&9)M+VY@SP%.#]PYF+')
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MZG^D=/=^HVA0C@/6AZ]XRG"$67HLJ6C^">6KE%*UW%^TIQD-0P/:\]WFDRK
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M0LO&NWV<>,F!OS-]\7X[NUE_N>\ [N%A&T>8ARO4/-Q'32:CZI41+);9#0[
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MN*$/&!55C@"X[MJB%4\E,6_!L"T_^C$F1*2?V)<<^T[$B>:F\18%$L-=N+K
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M;@JPZ82$N/'K*&/Q@7Z<0+ 5+!@+K[H$TWARN(R#L\MQ,\JH1%I458$@+C$
M@A%L>[\5BL/ SR.<WQHHA/W"!:]A\/''X0891@A]_'&*\R3E*5HO@!=%N4?
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M%!]AT*'8*8R(-7200=.4*P[W>IJ%/E4V=! *6W,NE*W"X;7:K/WD06@X)L2
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M<^2KY.JH!O2>9Q.5\XV:&;7H-[F+HQ<P#$.ZXV O(1![S\S,0 ZJ%\G4..'
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MB?X->\D-U<P'H51O,=7S@-K,F1([FX^U0&W.BRQ&SQB!:WF!&.L(!D4PJOW
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MY.X0YSY+MI2^<?J4R\#M*4]?=UXP^)Y43CM@.5,J2#7D<1<67;&#F9$[2GV
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M2R^V?O4-N1.E>ZZ*-#T?]Z+V:%YXDNZ%QRG/A:/J6Z"F9$> 4AXP.9B(C76
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M4P[L_X=."5.&L>A8L\85;F/HPF/4O;_Q/^TCFCPQ^R'D1QX4F?8)1;O7@GR
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M:Z"<#1( 4&*=2?KB>%L$F+7#&?[^6#('!'3ATB( 6:=CV!..J_L)' &#JQK
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MPWJ.*C1'U/G@84(G[[JCIH>(DIT\'ZT&A]MY\*"*56V,6!>EKLGU\NXS;X<
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M"( 993X0SY:*&=%:T?3)AM)"Y.\!F9-7@!X2Q<JK[LO96 2EF<*B8>UZR<F
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MB.7:#PR#,(E_11F9RA-4/(P ^)!G0/6-%GF)WREAKZ1<M=);#OT?EC/^W1X
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MDF1YD;P+ 4>ZLLD46$'NDL#'C]LD1@P*]=R=!F0\2H=CJH[MZZ^ZX1?Y$H4
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M6XS_FOW4STH@X!7*$'A[L$2CLLD_HQ%'XJ(>]9\H-Z)H-#9@QM"+4$DXX0N
M!-L6 :B4=(!=$C-4(Q_C52H87"*?R#EG6^X976:V)T>4D(9/)C^HH#XCQJJA
M3^(+6<2<$H@_29P5&$+5EV@H\**2I@=$+0:@#,Z)"5RJY&A#.1H)6VH(EII%
M3A5N,I2^DSUFT]LC_:\-87T1JW'9U#,ZB/E(34<$GTX2PP-.H30:,O[L&1=^
M+,4)K6&3VIQ4SP9S1-LU-C%#J/^:I'Z>L"KAU.35'V.]).JALIZB98/[4(S@
M!@\WL^.A;I >EQ<9522";I5JHIG\QY\CE/IIL#WT-VDJ(;.2Z@@6&JO\X1;6
MX+9X6/PZ HN\1!Q<B?31\W'?O#!!D3(A:(ZBOND^UY)!V@>#;L(+3RV?*X=P
MM"-[LL@_V]@<\2#->KY8!=KGC&RQJG;-2C5;+21OB8_2P,X2W@1E[S;F!:BM
M)O19XDH32AO)E+Y0IO2%S 0/(;,,!1V2_."_ J)#'^ G!N%,9"U<_\)>BO9)
M"A%_?J;^NRU5 331**<O [E#9840P-VXCK( )W"J[H8 >!'*D,"[FB5#B@&!
M#T+?B<HP7CG.&+ M=AFN;?D_#^/5FWBDS?M<O-(;88W2'0_Y0%!# 8(^%N2_
MPMT9&GR5$S&$1\[FSO,%T3DQA&N< '%/4O<(>1J:XRWFR%P#)DG]7(%DDE"G
MH3KE%[08M-,"@W'E[Z/<QX/X>;80,0MO92+Q+_S2_* \AFX0/WJR6A>)3) ?
M?)AQ,#\P3@+(+] '5?.<P >4KS9K_UO?3&OJ+?!8&48D4'?&P78=AV%Q,>F"
MO<MX\ N1:WGA^1MR ,#.9G-#OZ.,OI*7?OP54E?"]RA+TL-EFGRE^%7D\7R)
M0Y1^0$02LQ73]Y2\KAG4>.@'ZT>V<([>HL#S^;C2: RV\.^*;WG"Q<@>'_K"
M$X-?>'+X"WJKJ3.@[@XN5LE)?%<K5 5#&7*9K%>_Y8E8CWZ:'];D+&?D9B8#
M#Z(:B20O2MQ3J(\$?3@T;]@M6U 2XX9H _D 5C-&QW+]CCZ3Q2/-L]PKVC3(
M!?FP[U0X*W6OODXI<S9D.5I%YQPE]GF,!:A>#LIX5F,AR9D,%:A%T*C3Z+6@
MZ6F7!XZ3V,OQQ@>!U',*M;@GPX _N1P'DN6X;&BQQITU9G&53Q52DH7OEZ@:
M=:YOK'$-5\Q5\H[2GJH+I6%5+\EH-3-61AJ2\[BDV.MFY/0XC@8E:-LO\->"
MO'@HQ0<NZ!.=#X(O>D5T2II"20+3,Z4Z<29P??X":>9V'O.O&63,W\%:-(\F
MZ.,&1[LHAG?G99_ Y94E. I9)O29A[P).4].3H!02!2U--E51/!Y<\IWI"&T
MI1R08:%4AK2?QSO2&M0CU::V%N>43EE&[[TR5S__Y?/_FB\G?%>?504&QIL@
M8@/+G2]!>C(:@+C>^C$'38#B,"B\C1^IF[5?Y3)&ZT^T"H,C67"H V6F'$DN
M)W,M<2[8=,'HS29LZ2(MU;#5AM=DJ91D(5?L->1C$M6MWSNB:*"KC<>'*A,A
M6,T<>K7R\>P_(O9YK[T?)Z_!>$E]_6U S8!8!^F5/8O2.N! $20L9(.-XPX<
MC@?Q/*L8WV,DA]'[@".P/OL894_H'<4%6L6_;:-@6P<8S'C\8\_[@ _H93"B
ME[(A/?*:?,"@3>A!J+%)Q[6E1-E? ?Z!!>=T)(\/Y:UBCP[F-3 D,X^/-UO&
MU=-Y]G>W%@-(9D?D#0&<NTO2//H#A3T@801):<>01&T"P@S)2.VL2H:$0<.7
M#%D"@QF<HRHL12L[=HR6]_XWV/?]4U,X(8O9#[VGBV<STZI)BY.R)RR(?%MP
M"M&$6P71#V+$SEQHF59,/6"4<+4@&=">#U>:I.+,VQ08'[QWIAE24Y.H(6Y+
M0RH0#=,['SR&4& 1>.-!T(I29=R-8; HL! G\C= F0F2MQCN/J9J,[#:09(D
M3>8"Q;J/BY#I^<_DJ6'91Q#SSBU35F-;)K-F&NM*6TA8R.):6 @@S.&" ]>/
MDG$I5N\!Y5=^MGU,$T"T#2\/+QG8EUC$#GB]I:^[;TA@0(;QBHQMDTC0]WPY
MP!R9Q"5_,((GA@#SV0\OC-D?/3F0$LU@Z;(39^!,G$I=04CK )4]YXSG-=V:
M2#[&M,4Y^.)'\5V29:L87G/P]M!KD'H-^EG4@3+H?BR ?9>$-*L>R$^<&\V^
MGSLO6&'CASM:0YQ"S4JZ\#)3RF,\RGJ,Q9MO3&18I@GD4^R+G'-<+ZE^%MQ^
M17I1X X,P(R>F WS?BOS@4YB1M3$3>=D'YO?[?+A.:\< .TP4+5K&D;')#N&
M5$]_7(F26PPZIZ<K49*9)4MMD$+D \K,#5;((6'#C%/&P3[7PWE#5V5A-#:7
MS*;+4ZP0$2_)@2=RY8[LQUY!Z2_L<TM:4YTSUD]W7&!DE@^(\AS3K0%:9!E2
M3_\.>V$;[<]6)&M9G'(H8#IE@^UIG'VJC#9'1G&#P]7&JZ82J..,4:C=*K_U
MA,^.?#NZ9&DT>@1U'FDS>M=]28D\V3O$G1+ECXH/9*?PI@S&KMC5E#TVFL>&
MXT^"*!ITX2FKP9KS!X6.:VF'\[=KF:0_1^03D.%]3 U?J\UZBWC!@/ Q3=Y2
MOU^NDW@EH:+P5H[E!;2^%2\TA_EXWIX/.$NN<9/A<AA>T(LS+(;R'N?,<.TF
M.^M+V_(V*N$T,A"2NC-6&R(YT)"8?C(_)09L%>!R!'HSX*0E2DC2]B1G(&(M
MYL59/4RM*X=SV(8:DWIG_JRGRU;+X4+X7_:\3Y$?KN)?_30"A1^*0Y^+R]RH
M\4M'\-@08-D2@] 2U/-CLUI0*::J34 ^;$2N4S_@8=R1B'1(+?.81N\^&'DD
M?!N DHI_E-OL5!X9-M9S3D1;SNDE>HMB&CEZZ6,[SM]QF+J)I2F(U?.;+3_R
MO E*:A[!<_'Z=Q3DD$]P[V< 9?% M!?JTE)]FZ^(B  0&+RQ\G;87H+J!:M;
M!Q5:D4KIZH^6+]IJ0LGM;D_F LM^=[Z2TD@=*:EZ=U9T$!O,5("KJQR-QU"K
M<LG^G0CC(L^U5]@;CY>A+P7#MV>Z--&AF91-'>NRY)M[W;HW^R?HU/Q74$6>
MK6&6R]0+"-A X5.4?5V$?R\@INGI',NF)L>"4?920MKS.6WZ_-M3G(;C1[PE
M)1] TA,TJ:@V@\]220VI\O+)5WD9_5S1)\B!\V?&C':X0_C#SIKP\;PQ7'S%
M:Q:%D9\>5BE+K;M'^38)6> 0Z@UB6M*GU4]8\AX;PA-CC 1 ](S>X*)[HMBW
M\)6IRV; DJ"E ,"'LKEG;3 CO2*4MB>).W!S7:-WA),]*TN;0=I(=.ZQ4TAQ
M@R@0F_"\&_:D<O[,KDGD2FM $$,P4,UKU,W>TN1%C;NR,AV[2A?O?H1I"9-D
MO4429 *EZ^21T-KVC-MZD%7]_+(D'GNV/%\,#0HL6*.+<G3XIST??_XK@BN+
ML=IX2GU -J@G1R4*JP?(YLK \$^/W\UBU,[P$#O$(O;N=4%87VPV$8Z(2"F2
M4./P(8F#_A6=GE"T>RW(?XM0 IXTE7EA8=-:-3A3XD$IZ*>2I"U6'C$5_7[)
MT*; =]&FU[U5J6%>%BDJ*'&BT&_FQ1JN<F4H9<[H>W=6N6.F)5KYN9=5GAJ2
M(DIGDI/%ZCQOISM/U;RJ3M::Y92^-R+S[.;;/F+92 -DTLITMI*JS9S@87C@
M^V26<]?F$J*2 3L)OTQ@07EIK4ZR[ IJNVR2E$8N]<^S@>0AQ6H-/H7*"//A
M"G=CR':"C@7.ZH*D8PXOL1]\?0ZV9&K9?1(BW'\74I*?.$V/$IT)%UAAP)LC
M [7-U?8E;&H?]=JC9),/ S I0U5R_YO]TNY#\H%K#)1E4B_ _ST*+&(U[N2*
MUQ5CJ<+G"HI)_/:)EM(!XM;"36UPH(J05&CT0D)])G-7=8K$CSE.,4VF.G@+
MX:^=!S/5(S[&IU JJ3-?[Z+(MTD*J?.]4,84#_H%]Y-[OB0]"WYPA15>[)X1
M]18660&X\77J0]S3\V'WFN S)\YI>(R(K8AH1'X@K^P;6FU6:?06Q3Y^3(E:
M'^U]?%V@1;98TG]CP<R]3#IR*#"T)7PP;R]& Y,;5'WTO0W[@0TY3\:QCF<Q
MCB<'\JX%STOVPYQYKL>_G_>]+4AS *2TCG)(';Z-P^@]"@L?_Q;EVTH"4S)4
MS91*>E:>>-9KDXS G[B38!3XG.4X(R!I@J>>EC3.;][)_ZU)GW. BRH9\)*D
M1VEZ0-0^E-$PC&"7/#14"8IQW"LX 0A,?<)M6H]E!GCP]/,6H?R.XS3UW?^<
MID>)>H*J]<TS%"O8"1?L$<5^0%62Q1NDDK&:<'0'\&15#F75L^*N',;SWV@6
MF2CZEE!(<>&GG!N3N,X='8"5M"-#<,!TD?9[,U,NZY)0^[?DZ>ORFUJT9YT-
MPB]3"LB=5^Q8$"!$?"Z)?BX01Y_.][X,@#=1)B%XRAPO6(PM3-.3R*B6@U.G
MML85V12B=#>P&B-E3TUN-:K7[.CK(8H* 4H1@%*O-L9P@Y[Q$TKM(@C= 4AJ
MD-SWVLB*63*,=;P^<SYKL187U6"+6?*KVGG/8=IN2 ''%QX!8IXC+T\&8MXZ
MX_7J M-9 %E8/*!Y((+!J_ZA>8*B/83\8>>.:]/FU&25BZG/7[U<C$Q83^>$
M:^O!W_6V[]!:HT#(NDK;9\9X[,F6&(J&FM?9Y:'RRY!(D\9ZV$1*?SW4?AX1
M3M+B4N"IKH+69-SWT&FMPY9V]& ,M%FV+9_&=8K\K$@/JKLS(,+:^55F!<6J
MN_/"$V0M24!73XOKA?35]XI8HJ1*O[_M:*4A9EZ3SFH<V-GZU^1K!GF2]H]Q
M$Y0L%S+I-V$\VER/)@& DZ6_C_!()@#SY%AWK%E@DG\I&DUU%[U33TG\%D$.
MT5B%]Y08$O**KE):?H/E3 L(Z'X%EJ(\ E]]\8JC &!=$,V7)F^'&FLR*_[$
MY5N)E2'$(3.:D>>F58E:/2OVJC:_:G#3GG#Y#L3M1OKWS7SF9,: >^T[X]I[
M",F4Y+_(U>V%99E4N'?(-0 'A^<6?K!A;64/]^6JNH=$MH6=\#$6J?$;POB7
M./F(GXE0E\0HI/@,9Y<"85$H0/335Z#J";(,]\&" YM)6-C/LM6&+]@JI6!\
M[ WH]<)0NI#+*T[&*N5 ?XRLQ8?&#E]U,=+$GZT#PN%/N<^S'V(?I23<MY.<
M+Y[/5&L;@Q?$*I.5I0.97*2"'U%?=(J^Y*,%W;_0J_7<@NXUI'CJ,7ZE'F.^
M* Q>VWN#4>99\;[? E7J^OQ9%P&KVZ-7X %'#E)FRJ-8<C+7L@P&F^X8-3",
M6EU9I7X04*%*CKZBO,8V42YM,H>K?&EU<Z\<Q[(L?I1C4>LC%+@$[_W W"0]
MQS +0_#5Y5->>"7'$GKAW6:EEZ.786:Z#;5WWF\(Y$$4+LB3Y[\A@<GVF!(A
MH.>K6:EMQ%]*(F]P)+P]C/"G7*9IO9WNUN&$YS/K6BBJ_D)>>&+&'I^RA!WT
M'NWLP#I(/8OPIAC=+WMR1SVFZ(JTAT(.SWD1GE,!5G6. MU/Q9Y>2WNR/@&G
M[66,^!P9%*;Z9J"\1X?Q7O8TTI>,Y(FAO.?Y\FLJL5#F=9.O"7R7W]FK?V>K
M&>QJ>NM=3\S,6MV!D> Q>]9[[)^87*GTF)65'E&ETF-0K?2(1*5'(H&P%-H+
MSZ=3^<Y6"FL6Z?QRF*+BMT4'@Y]MR=&'/T 6?/<QO%(RWK@4\'ME4$/E:U22
MGR$[6.&$E64G?U&&J,3<E\/8XQ1&DO7J/R#SY_)0O]O[QK#(,3PY",@OS>?,
M>G2(+6[QU!B]C0,(6T'7B/UY&U/[20F&R![M?O6IF$DFEC3YVSP?KJI?3U#W
M?A#T?P3!F7%9CL$EKU8N%VE0X<M/ S$A\M<C<^(M_B4@0Z)]_HE-CW>'"Y^+
M8"6N*8!\9.""C7+R=>22)D<:TG7ZE]$G7WKCR,3(%\^NR%]7Z3KYB-6IMS1S
M-'&ZF$L4$KT)D]>!.M%9T$QCR;6M'$U;G)X;#K3_C$#S(\V;<S_2U#$#U(+R
MA 1";A.^7\?*T4XN-Q.#I23/ LIH5&IC']4;./X"FEIS1!Q5@*]T7^!H)]?;
M2D8MWVPV* !96RX[9,,](2!"P7_))4H_@S2':W=<#WHN-Z,*9<+M2:L-=WXN
M47-O'FGO^*MJA/6L;9>VM7?Y5>XCC+(\B1%?XL9GJ#=P_<K4]=^6-3>UG<K6
MN8V)7IW=04V#G\R/94OSR=QLBR!("R*XE_?O*??8L=ZN7R5RMV9Y%%R!C2,]
MF+^4MJ'K;]12CN@!?=!?,J-@<ZRCRYMK$<<%43GD@Y UKJY&"\??X@EEB#0'
MTX]2R(2'&+%B.+HOT:&;8\:(L 66IL<T>8]"%%X>7H@D?!L#,AF11.*W!4@I
M]&"W7=>G4W%]MH8$2H#O&1"M^1I2F5!,"[UISZ7M05V>:3$?N@_8W'D^:^-P
MFYLZWA7\OI'91 !0FYD?C9;F+K]$PP%WY>^CW,< P$E3TS)J\Z%5G1K?YI3.
M#JU$"[+>(:SY$OMO==M0Y4?'6XHO'[WRPR@'W>&6V0O#RR)_2/+?40ZEM73[
MJVO?N=ZEH@Q3'7MVT+O3-(CK16N"$[) =BWSIL;.[\N8Z !7M%3\DE>*5]&"
M5.E3?X%V[^_R1A7Y)[6RBHW+T]#.J:B=K[?HWD^_HESDSAD,T\:6+J?/G]B0
M2)9A$>2:Q[BEF>/34:TO3K-)5ALB&--W57<<6CNX_ K4T<4LE5QW,7P'4\-)
M?0EAK#A0!PPS3G)-Q<>/"1-P;K[E4,6<R*1W4=;A:YU!U/6BP+=B'C\:. A^
M9RV?FG8N-V-KF7=^ XO(Q<8&/:6SX^]#-DW.*F!3\0;%:!/EK5IX>P^7W^PJ
MB86C61JE6>"124<\VL.UZ(.R+$FK=X   %LGE^#*09"0O]X2Y?!WY*?:LW4Z
M%=<&U4J 8\,SV=+,]6GBJ[I,TM+E2V3/,OU=>Z*.]G)YJH1J<^T?,A;7S:XN
M[8%J:^S4B\7@]=C97FV>DH./\X/I6FAM[?QLU*'/C27@B.Y.=+J_HR!?)V51
MPB,N\O.(.HV(T=@M :&3\]0X=IT[N5;>I?_K(8G?R>.$F 3!S=R'4SQH72A,
MX*U#R"#OOL2 ,P''$1"\ ]*4'4[3<W<RH8EYK5ML !V[.!6>R5*3-N1\872X
M]..O!D7.T,ZM63L+TFC/8NG9"[9.P.1.M*P<K;>E'?YEG\3D,KQ'"';9%<,^
MD5*DSN8]$&67R[,.$,8@+^XE[E>#44T;UZ>+IG/?HWR;A+?T(J3REO94Z9NZ
M?@J$NF^4A:LM'(=Q$5EA1X/;%3.YR:C6WGQ*D4_W?HA6L49:U+=SOF7((\"N
M&;-OL='(Z:MQKO.%9YLNWL@%"OD!MW&>1G$6!4S T]@RQAC/M>%-J^X?-S&*
MEFX](3F\BQCBUY\2LBWSW\#JM/,-=\B1]E,):B5Z$W,AD+5FYFNN4JX3%958
M=T6>2L.U/[HT77#W,K-]0J12^H["99(N"W U@Y$4KGZM8_I4(BXC!8HP(M+.
M,DIWMQ4G9.-'U\^"->P>J6+6, DH!, UV9E2Y1[4\S[@O+[;3_,KY=^ &>'Z
M^YPX.<<?:8UV^R3UTP/CRX1FJEO"CEV=^O&%2,.=($D.*)]$/3\\H6CW6J09
M@K>F:7LYO;=+-E_B$*4?D,L>O]6 PAM,M;1U;3#3Q+7<"3"(KH$P=Q7T"'?,
MR PE'CLEBMKJ^#"U=<P"&+!@D\3@2(LVN8@Q:G.F'NOC-![#Z ,0 >>E_1^N
MZ*;)ZV0*CM@%,'L>U$.N9")<$@F['JA@:C,AKU:99UT:"SNZN%JZ.C4)%&0"
M1*)8I,AOZN_*CTY5//'.F4J#-16Z8SU<ORP:#TK6ZHQH[^':_"NRR;N8Q(R-
M)V7/J8G)3VC'@-?IC^!4^.FXI><XC4GE%U3]>!KW2FM[UR>J3%VDF QD;VT3
M3"3+C"D#>G&MO8_K6!=>),TLIU5;N,^M(QIHD--X/+ 3,FL9I)B(3"$1O"("
M*;,;'#'OG#:NO!]%MVJ>R"4B8X 04Q=VS*VFDAJ]"/]>,-^<Q.O7ZCRM'=S*
M;@:%\]ZMU;I\T>$)ER]&FQ)C:.H<W@?TQ!1,+G#TJ*6%)UY?)6%%*.O891(J
MLG3TMGT10U.WP;GO4?C3OQLV?>57]TGC8,5\TH%=5']V;3"6X5V0NA6%D9\>
M5FDS@@$A<]C :21<W_XTU0%5)3M>QE9[^;>T=_WM:!EQ*M2!B+3:*%5#6U+T
MCO9R_6J4,FO+=VFV<CWMMI!!H9M?%S0XGD;)=]6!6XFX/DU"-+JG!489L/<3
M@+SJ\_=.Z>?\J61F5)X>IG\B*TU<7P=Z]QK82N&(DUMZ_9&TQ/%T[^[R<=4#
ME0ACJE W_EKX*?DV6)R9QB-\'AG'7[A6T9W,O8EJI*EWHOO:9Y)R?B:YUZ9#
M;+.IK7L6:OBO5TE,)>O?HGQ[1?1+,NM4:Z,ZD\0$4R#IU7]F!J2NK^M\&HYL
MDYD31HXT=6V'JTRF"\I%>P^76^X+D6#!5[B*[Y,PVD0!![6GLE1CD[6V=KVM
MM*"CVEVE;>E:'BDQ1"44+WU>#9(&)K<S7WV %WV+82>Q,T]!?#HHH ,.-&57
MS35//P+D$1[8>;*K1D/#H>=<9RW0.P:.MW9^ER8!0F$&535$5.DJ95JWV5%S
MO)?CK/@\C5X+.#1<8EQ!L!V8LG;D@&DL_\>[.+?M/N]\C"^++(J)UJVWY5::
MN Z(]K-MK9H'=1]% J&.^H_4?U!:ZO9<+X*N8R@)]=5&B1TU@8)H&T[%:L*\
MS&29E5>;6T3"52SM(:3!0Q*GXC_IZ9%U.M8HV,;1/PH-_/H8XTW3)=L-#+1S
MYTD%,5RC/?DT42,1_WAKY_*LBK7QA$+$DN:9Z&6V6'?IY]HRPQ HS>;J2@/W
M$HJ^PNI=6^3O\5Y.DXK)1+9"$1#) Z;D8G-;IQ@4$H-8*9)YQ)QW4D>GH0KA
M H+@LR2^ M$VO4)@.S>%+[0T=GQV:EI4%;-S5>19[L<A?S,#W3$ZB8#[QU5C
M)%=VF=F;T+&K:Q-%&\A:*?K29@S?.DDW*#($<YU/S:$J!!6I(/I9%\^B_C8I
M>PA9S"@L?$R%6FZL"[NB51K[NMZ,/7/)E<NCFDU^@K>O_V"N%U': D%J/ 7>
MJ-E^,JS487JNH9PJ%"]@Z<U7V,_:0^O/).4Z&8K;7134&_*<4&V4PFQEB)=7
M;N7]="JNOWO/H\E?%0;";H:TMC",TPR:BD.J5!*%G?N:S/#=AT)F35OE"7U=
MJ]!2JJ?8CO*S*7'C&?UJKRH.3FMENUX47<=<M;O%IN,+>Z0;"!'=.3@B..M;
M.A00KWDA>W;$;X@\7RL:8VSD7GM1)>Y67:79T'6^F1Y#K&-T3_?>KGT:2<Q,
ML.3&(:](FKQ!E5SSIVIK[]9!)G%FA/<.;DZ-5TS;SFFT.L1]^3@C%T^2KI-E
ME&8Y*ZX %J7]/DW>?=Q@I%,OI_* #_FQD!0/_HH$)V^'>A4D$YI<UYZN;<Z-
M@#UN7F;NFZ#%&-VII],:72&*+Z,$4" -7ZG18N92.T6IR=S@ZYPWA6DNN!*O
MO(I;RH.?T-UA7,P3?#H=C(3\P?G342H%J\TZ2$5A&_V+86@\.2 ?"*3]3T2+
M"R$3ZFC7CJXMIX"51>V;M[L].;LPRRNR^=_T.E-+<^?R?(E-J.0L99<']1=3
M'$CWWJZ?=>HI-ON079Z5OQ*1+]I$*"1[@TAX=,<+O[#AE!SOXOI\".\ -76
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M6X;DPX[]7++V*WER\XC(&H:[I/:[<YF#YCY"UKM QP"?ZE61Y41D3V^^!;B
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MHZ;P]+GV:*8S<P4O#Q.Q E/'8>)[C@@H*GX=QP&2NCKKS,-"\U3PN6_[S.K
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MQ);"?A.;3+YA>LRFZ#@=65*P4"]UH-77V*8AXY%TY8M5[?Y,]>4R'N N8JZ
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MM)+%4^QM95_A"QM(4A(ACI>"NXN:K<X9[+1VQ5WTBL$SL"M$ ]DX2KU]^=3
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M!^WT#_IH)C20QU(X'F3:+_ZB#J)":(/C&*K$0[3>5FN[W5R'4"] H<E_K1
MQZ'J'[HB?]_O;@['_J$-C0-#(V+ **133%(R9'Q!(R]3PRGO^.[6=N^+C^*&
M^]QYCM3WO(O1XT+O.!,:TJY%@0)&WU?,C!>/4:P[<0JG4B_H.-U:>,Z[#F%_
MW5H]KL1Q#,THW<-H3*<)O:[FKA-&Y#BB8RGNO,@FQ^$UK,*KA56=LCYUG&[/
MU,8<9U'SYG-Q&217BS/T5_*5(_6&0'!2ECE#&KZ0=QUG0V,F8>58RT$ C;$0
MGS2@FCJG3G2GXX".IG(*(TX=%P.&%4].H*M1$*>H:0X96] (KG.\N.L0%E!1
M6*_C<.KJ26,'# \"_^F=8/H!R$, /ZD;@EEWE"C<V6B9Z"F>;:,*D6'*;N=I
M__%$4#H-3(>6#*HAX,XSKQDYP ]!-UKL?(H CKK[__C3,.7C)U8692R]0!QW
M[SSKFMG[.I'_!:1&2_I,2)_5E07*402#X#:=:]CX^UW\BL,HW%/<^6,!KN-@
M+$ ?M CM6,E?%VCM187)M,)EXCE?BQ<FI)1?'$)?(4$9OX.%%UJ760(CD"37
M(/$1I/R"-2E\PX<)V>@'T)<8X\N0_Q*WQT#6M[-TZ>J;L@]28P3GCK4Y*\UD
M-NF8JX60[,AN.V//I0_J'$GIOLXS6U_#Q _C)$. MZGT^MK>1UR<*Y.!.@PN
M[9CG;+OUT'ZQ>H;K"*Z@3Z+[.C)G+KMIY@>=< UDAYMB9]L;4>] 4T7$I2UY
MD#GU5 ]3WWJ$U@/EDFW':6PEA6V=$MD>X[6VO:G$X#=?!W+FZ](.*B__]3#U
M6KKSJ6\E;JB]9%?)^]E)G,8F2GW7:0UA>RLJ+UXK^D4#))>V:O%&KPC3GXVB
M6>3J(.$&= 9>*-,T13ULY)IL)ATIJ6J\EE3?H7U'L[Y9Y<O8")?L"YI+._8)
MA,3:_>AA>;7$-^4$@T6>,<QEZ_+HE^Q?:3<KZ>'8-*EO7)T1;&]6U85K1B]H
M(.32+GT&:1H6#LN+.@KTSP2"#=R=MZPA$VH=;1[80CNJW@!SVHE]\!DGO=)8
M6Y'&G,SF>,RI/3B#Q5N,U]K"87@/D@2 0\P\I4QV_DDZV=YHDL6HGW2RZ;MT
MN)$@9)C'.& =_"JF5F$0S<E3(9B"LA55;PP;.8!5")1M4<U!;&_97@O;B"+5
M!,VEC5U4%1]K%W.TN9(*Z4:4M3:F7Q;?$*J0G3:V=H(BAI5RV)V<6_K? 0(:
M_)WY:4:*HG^8RU'5H)J&L%,%GA\FV+F&J?:W8D*1$*=C2^DQE.WC2GMQF]:5
M/N"Y=&#E0;5+[VT^FF=%LK*>*>IAIWI1FQS9UA1VL;T%%1:D%7@MF+Y+F^NQ
MI)(^-R4O>\E_-W&(IY@0%VFZOP8KZ,/9>/9SHB7;K=7(BL^^#KS</<]N;7M?
ML<%NNMTY\W1I%UT#!%_Q(*^@B'#UPKN(G-M;,-Y-RT"<5CF+&O%8)/P-!.O&
MFQ6-&+3^(UH)5-,F5Q[-=L20MG>W 89HQL4= Z]+\J*6FI"$(\U&0%3K0I-4
M5'D_BCL)36E%,X.\D,P@978+F8PX;E!S_L5:NLC&(_)<,_KJH>!@ZQ<[&ON-
M9'VW&UG=@S^R)YXN[?-6YIPY[?5'O-R DD^6N4K](PG $W>RXQZI&)D$?787
M1.J_U!K"]B966[:6+T0#(9=VY]]C&*6_X8&PR)O+MLPO7)] NB&YT$C6SE*+
MJL]&MD]U1[%1]9A-HKKFK3& [4W;<U$;.=HTX'++]:/VNO+\RG+<= +Y<_@6
M4?O\_TM3"*AUMC"MSR0]WTV2PBW6B'FE>%N-;+QQS5X2\,\,,_;-*Y$".N"K
M]35VZZJG^O#"*YK",Q%3JM[/4DEN$E+2REVJ!+U:7RM*=.1C4E!^'83)ERM\
M+,"4_(FK,_-[3.F!G-K"*'>WX:FKBMDL$#[M=W'BA7D6P7OX"H(\1;;:-'L-
M94.\@34A\@GL2&9UO;-%K:_IH"(5B<9K:@'@6\P&OWEA!CX!C^B.!U97 UF]
MOY5H%'RN98"D[<+Z(C7!*DU*WL].: W ]PQR;%QC^L*8BJ7BI6=.'S^21MK3
M9N"!HLCB-;<AEI@YL1=EAJ@[>B)B04I-*L*UZ3.2C2NZAR*2!^H1($JQVI+)
M>EF8R /X6KML('RYS##$6UW567L8VW8'S<1GBG<ZQRL1ZX'6OC$Z7L5-,_.0
MVCW5\1HY:IAIW)8=KSJBQV.*%_(AR@+,%S/1?7^(!.JS14K=L.!Z#FHMV/H9
M+<9(<3P;"!6-( 5F/Y\T9F)33 '1+\X6*])C+ WC3ZG,GE5]1<-2"=A9_5<V
M7I60G;;V+S>/E3B=M?[>MK@2PO,E0,FZ5\)UO@GTLR&6^ UZ)9A6%,Z29@(\
MQ^",XX_P-R#(2*&>2J4K:BY']62*A9H7+"*LN62(/#.FEEZZ5E)WJM%O6 5)
ML(&)_2BWM=U%]38P\N$N5$@;;_8C5F$JXX.? 7J%/F ?M!<A)8,<N:M"'_X7
M"/(*OO0=@3IBIK]G%3R\-[)M_B2"%(32W&+BWG:YHJ4L7,,P2TG=J[R6[57H
M)3IKKC6:W17%NS0@Y&%E\IG(-BKO;MY(56H0D$KKA$^SM&#.]LPT%M_4A^:E
M5AD^Q,Z^22:V9LZ^(7R;,S:D#7AFGCVB3)PEQ^O9+\KF3KVS>PA/J1.[W)PJ
M,(:+U4ZEI7D9 &9:;^G DA7DZGHFHXOM#:E>>4D\<Y?>KG+*+\UK?YU&$:;>
MKTNFLP/-%EQR=$NVRBS-;"O.O=A230_KU O2M;/)!K"^'?5**NE X]*&+/+S
MSVH?SK@T!":%V"F4-ANO]41J6I0;9/_)(XEWT[WBI/1'LBU*M*I?<%;8<:/J
MD05"I+PTQI,0RWG8YR6#G4[&?E &.&1J^F?51K&]AX]*P:X-F4M*5"W[^KQV
M\>QSL->-63FC8-)8SD]M"Y_.:';#"E8KX.<)8XNE><+[C7C'(A^32YE.<_8]
MAK0MO#23U_?F&\?UN-XP]N%"IY0Z87;S>9T*SY@F&MA R>9)BV8C&R*PI(!Z
M7Q>K/&?N&^3E'..WGT<:=;?RR-<7X3K>>C#BS(O1T":SX9T*[O ?I5QV:&A9
M+RK9HG:J7:15I)BV8J0UG,W$3(HQ<+C!0QRA1D@<Z9\?6<#?1/"?F:(".<ZW
M;2L)[/.AH1?P1;/C"I3A<A!MJ!U'3WJD-S(P,$Z04\&G<PKQ+C=ZPO]4X),+
MKAK CJ<C4N.ID4Y5EZZ$K0(V,[L$NE''QJ BS8Y(;U1PR0]W-4>H@8'M/@6,
M:09]$%#R>TY=:1#; M)<S1^33.7X43TDZ&JLZ])15,^)=Q$$,*?^+EK%:$O_
M\1JD'@SG<C;-Q4#93-VXQ)\2F2<YK2T1#@/HH?VS1Z64S++*;6^#^ ,)#]X6
M_W&)L/*%A0)A<Y&A4:&C3<-C7KV&R,(XHK).P=+-[&.M4%%%AW 9V&W/)E^5
MJAJM#)Z'>H)%AL_F/]1:\FSO1XUIIY3=MM"?/H'M"T"\B77:62!V[KE3N@>6
M6+YRVULI"H 5G@@$Y0M##&VVS:ANV:KEW@E<DW:T4^.@M@E%,7>'1G:W)]6]
MDXLLW6#=^E\@D&_43H\I3&"1I4GJ10%F!=49U+O8G<*5MX.I%^9DD4R#Z!4$
MMS&ZS4@MO;LDR;S(Y^G7^N/8OE,JF']Y&OL0M^UP$A=MJ:[?P$=!MW88*A55
MO%MPLJ/VG@!"0E_"D9JJXY8OX5VI592XK>LZ#HUFUHD1?.<3V79B0Y/DA#LA
ML20\^#FGX!!VX(G!(I36*C>E4W&1R^,&V*K!$+FHYL5#S>NIX[FYCHHS,9IZ
M:TY,(C0..)Z7K"="#>N#X^69M"%2M6ZXE$FL>'Q"CFD'W+QS-C"WB!%Z(]AM
M+1!]Z45?\N"]Y0;!57H784;&9[?$+R'M9C=PBPB#RWV>HU$4,"#H<?)^;$[M
M[HMTN0&?//0%I(L5EH^8"YB<+FEL"MX$I35HDX)D2B[^RQ]/)$<OPV_>_&U,
M8IA@M7\=B:!/WAO<9ELN2<W?3SDL)0'^=^OX]7T 8$XW_L.!7/R7/^[!V@MO
M(GS"[AD$LEH,3E+^+:;DZ/QL87%_P^<%.4/XRUEO88] H>AMMK'WJK*HX[=
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M?4HK=+DG48."Y$\J/:<T(4E>,'F_*4V&("Q,-Z?2T]C3SL5JA>]G^"MY33N
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M"D@5/0P.P  ("WO-QA/<+58I]/GQV]MP_36)858*$;>U5=JA4R6:;:YC-9T
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M/H"O(%A$-3.EW.^A,(8Q?GK,7D+HEPZ-!Y!2?N7(/94>T^&I7$;D_WX;HV>
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M>1,?2W+$W9^B'K8=]FQ3?A4!HN/B=#RNV(Q'M/&"R9QST5'L3_[%4Z^X3-=
M&,-YV2S.Q#1'.8XNTV78*<1D''['437GXS23_-A9G$T'ZC32)C><E8XB>83[
MLY;]L>6#=!0KD1>;Q3B."SNID[?45[3YRU' >MV^Q![K(9Z6S/?QN:M/DX96
M@04>_E-'MI>B-D#P@>OK,*0BU[KC. KED9H<*R;$4:3LB%6Q?<'5EW3#"%B%
M^)LA<)V$9C2HR!3H](XRJHD+,"/6RE&TIJTWJ46"C?&VTT6YT$U0XBR$@W"W
MQ:"\(2HN3&F]AKP]F& &U_&?UW[AQ%$6BS1H043G%FF\*,QB>7YR5Z&?URZJ
M5N3/YPTSQH;AAX<6Z_"S>XEEIKT$W:#38B5^.>\(G>50"&0=I-R\^\C68FI=
MK3L_+(+"L-]!BM77!._X]>M:J:)J?RWJ >X_1WC.K6:C)H_BU0DZTG1TL5XC
M6OVR:2WBI#8:Y9-S>H[1=5R.\OZ2_[US\BP'>.@I#DF-2_+C\ Q4_YBY\F5'
MTE=5 \4W56\-G@#Q/V!BK^*(+G#FA4N MD.**5T2;+'<BWR*+W(N4)SM1Q$_
MCDS)O/=X:YJE"X=JK61+KL;:_ZJ$N NW78QG#NQ,L\2,*&6+U286DZ:RQLMA
M,. '9\AKM=D,RFO=[\R;UQ3/T1&84)F2*7(GUW'*=-<,<<P8I&"* &O-;J"]
M;S_UR'"V>;. 33$AQ+$;J!,^96,7ZQ%A*^\&>6')\E3H)(/K,= <N0IOB16
MY%FJ5;[2)6.*4.M/<:!S@O6E&0(VBWOQ'S_.'-IQ;\;SA(M_2QB#$U6_;LO'
M.Z:';Z!W?)P@=%?C&09(FS206\G1A;#I?>HLV]BN&4?7U+[W9: -*3[RAEC-
M77[52CV4.K>F#*_Y.(_3W5PAJ\K'0.X6QQ]V3T_[8#AO'%T#5Q2/7AXD1]=T
M9HJ'25?5>44GHG9PGH.YNC 3.L)47[V<<QU,6NII>O?.BVI*\/7P%QH%_Y<<
M_(C>/X)IP#\A\7;$+CVGP9B#X--V0)^7=2(Z'].A;71UW):-=N[BYV0G4Y"*
MQH(/!EG/W+I[$TUDR\U')++B'4YAA28F%*7V_',RH1D(0>6HFS%6T_YK_VR[
M]=!^L:JR ;52UH[ZSO_\'-M09)KIW'CMV#-CX\\I;$^:O:S:0RW!0DVFUYA7
M;CV(Z)DQX"/W@:@\T86:\.HXNB23V!KN<_XP =K:WY\BN$=4 ##V@$7P*6-Y
M2F15"AI34NEA83&9I0Q;J]!L,T6.4TY39FJ?'@:>$QR:Z6.G=[CKTN?PXEC&
MWBUH<Z$\7;[7I<_AQ;&,O5O0UGR%TV-Z+>)<7!:+3-^EP"F G;!?S.S1[MRN
MUFUX9^V_&\"P?7XO:,/*/4X9$1WYZ/0[-KMVVY$7^R1>)HYAQ=2M8^JJ#&4:
M%\V$J8H6P7%4S5E#1Y8OIY!"8K ( GEM;F>AG(":8^UPUK;(._[$SV5%[,1>
M:\[V'-.3%JZOXDS*R#J+_]3X?<PMJ>VW.S_0G>WIV'8#.O_<]Z1WMIYG\OSX
M=+;;FN'K=/ZQZDGO;"T'YRF\TG-Y=W=]JJ.MZ%A/P\I:\9<@ BN8$F/T11#
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MY$)&&A;L;[W=@L,@6,;O A:S!>]V\3R7N5[$PD5,O-UN%S$DS;\C((P"[ZX
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MGDHE_9CJE&73$OT%;@BPC\QU1W2NRQ%2K]MF055M*Z0=%^JJ+#-6! -"OV,
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MW11(%K+(R)C.N>R2V%#E$SXA,UT(I%VW/U\Z?M>N%S][^@=02P$"% ,4
M" #;.V=66$_18*)P  !_IP  $@              @ $     :6UG,34Y.3$R
M.#4W7S N:G!G4$L! A0#%     @ VSMG5O;<<V2PF 0 GX(% !(
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M+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #;.V=6P)[=!14#  "G$0
M#P              @ &>O0H =&-R="UE>#(S7S$N:'1M4$L! A0#%     @
MVSMG5KLDP;5."   ?40   \              ( !X, * '1C<G0M97@S,5\Q
M+FAT;5!+ 0(4 Q0    ( -L[9U9P ,_[#04  /TD   /              "
J 5O)"@!T8W)T+65X,S)?,2YH=&U02P4&      L "P#! @  E<X*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
